start-ver=1.4
cd-journal=joma
no-vol=16
cd-vols=
no-issue=
article-no=
start-page=191
end-page=203
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260328
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Examining a Practical Case of Learning for Community Development ?Focusing on the Changes in Awareness of Junior High School Students During Integrated Studies?
kn-title=町づくりを考える実践事例の検討 ―総合的な学習の時間を通じた中学生の意識変化に着目して―
en-subtitle=
kn-subtitle=
en-abstract= This study aims to clarify the effects of junior high school students planning community development through collaboration and interaction with others, and the changes in learners that arise from the results of such practice. It also examines how interactions with others, which are emphasized in dialogic learning, can be applied to junior high school practice and what form this should take. The goal of this practice is to foster a change in students' awareness of their town by having them interpret the future and nature of the town from various perspectives in relation to their interactions with others, and consider sustainable ways of living in the town and forming relationships as their own concern. As a result of the practice, students experienced changes in their perspectives and awareness regarding the town and were able to think about the regional issues involved in town development as their own concern.
kn-abstract=　本研究は，中学校総合的な学習の時間における町づくりにおいて，他者との協働や相互作用を通じて町づくりを構想し，実践の結果生じた学習者の変化からその効果を明らかにすることを目的としている。また，対話的な学びで重視される他者との相互作用を，中学校の実践に落とし込み，そのあり方についても検討する。本実践のねらいは，多様な視点から町の将来の姿やあり方を人との関わりについて読み解き，持続可能な町のあり方について自分事に引き寄せて考えることで，町に対する意識の変化を促すことにある。実践の結果，学習者の町に対する見方や考え方の意識変化が引き起こされ，町づくりの持つ地域課題について自分事に引き寄せて思考することができた。
en-copyright=
kn-copyright=

en-aut-name=KAMADAAkemi
en-aut-sei=KAMADA
en-aut-mei=Akemi
kn-aut-name=鎌田明美
kn-aut-sei=鎌田
kn-aut-mei=明美
aut-affil-num=1
ORCID=

en-aut-name=KAJIIKazuaki
en-aut-sei=KAJII
en-aut-mei=Kazuaki
kn-aut-name=梶井一暁
kn-aut-sei=梶井
kn-aut-mei=一暁
aut-affil-num=2
ORCID=

affil-num=1
en-affil=Anan City Anan First Junior High School
kn-affil=阿南市立阿南第一中学校

affil-num=2
en-affil=Faculty of Education, Okayama University
kn-affil=岡山大学学術研究院教育学域
en-keyword=総合的な学習の時間 (the period for integrated studies)
kn-keyword=総合的な学習の時間 (the period for integrated studies)
en-keyword=中学生 (junior high school student) 
kn-keyword=中学生 (junior high school student) 
en-keyword=町づくり (community development)
kn-keyword=町づくり (community development)
en-keyword=対話的な学び (int eractive lea rning)
kn-keyword=対話的な学び (int eractive lea rning)
END

start-ver=1.4
cd-journal=joma
no-vol=16
cd-vols=
no-issue=
article-no=
start-page=91
end-page=105
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260328
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Practical Research on Nurturing the Next Generation of Classical Japanese Instrument Music that Connects the Local and the Global Community (3) . The Potential for Developing Intercultural Competence through Questionnaire Surveys of Elementary and Junior High School Student.
kn-title=地域社会とグローバルをつなぐ和楽器音楽次世代育成の実践研究（３） 小中学生の質問紙調査に見る「異文化間能力」育成の可能性
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=　本研究は，「おかやま国際和楽器学生フェスティバル」の実践における，異文化間能力育成の可能性について，参加した小中学生の質問紙調査結果から検討した。<br>
　その結果，１）体験を通して形成された新たな認識により，和楽器音楽文化と自己との関係性を再認識・再構築し，和楽器音楽文化への積極的な関与を示す価値づけ・意味づけが行われ，内在化が促されたこと，２）越境文化としての和楽器音楽文化に対して，開放的・尊重的態度を示していたが，自己の文化的アイデンティティを意識する契機となったこと，３）和楽器音楽の共有を通して生じた共感の上に，相互理解や協働関係が構築されていたこと，４）「文化の共有の可能性についての認識」が形成されるなど，フェスティバルでの経験が，文化観の形成に影響を与える契機となっていたこと，が明らかになった。
en-copyright=
kn-copyright=

en-aut-name=HAYAKAWARinko
en-aut-sei=HAYAKAWA
en-aut-mei=Rinko
kn-aut-name=早川倫子
kn-aut-sei=早川
kn-aut-mei=倫子
aut-affil-num=1
ORCID=

en-aut-name=BEPPUYuko
en-aut-sei=BEPPU
en-aut-mei=Yuko
kn-aut-name=別府祐子
kn-aut-sei=別府
kn-aut-mei=祐子
aut-affil-num=2
ORCID=

en-aut-name=YAMAJIMiho
en-aut-sei=YAMAJI
en-aut-mei=Miho
kn-aut-name=山路みほ
kn-aut-sei=山路
kn-aut-mei=みほ
aut-affil-num=3
ORCID=

en-aut-name=HANAKUSAYoko
en-aut-sei=HANAKUSA
en-aut-mei=Yoko
kn-aut-name=花草容子
kn-aut-sei=花草
kn-aut-mei=容子
aut-affil-num=4
ORCID=

en-aut-name=TAKESHITANoriko
en-aut-sei=TAKESHITA
en-aut-mei=Noriko
kn-aut-name=竹下則子
kn-aut-sei=竹下
kn-aut-mei=則子
aut-affil-num=5
ORCID=

en-aut-name=TAKASUHiromi
en-aut-sei=TAKASU
en-aut-mei=Hiromi
kn-aut-name=��須裕美
kn-aut-sei=��須
kn-aut-mei=裕美
aut-affil-num=6
ORCID=

en-aut-name=MIYOSHIKeiko
en-aut-sei=MIYOSHI
en-aut-mei=Keiko
kn-aut-name=三好啓子
kn-aut-sei=三好
kn-aut-mei=啓子
aut-affil-num=7
ORCID=

en-aut-name=SHIMIZUNaoko
en-aut-sei=SHIMIZU
en-aut-mei=Naoko
kn-aut-name=清水尚子
kn-aut-sei=清水
kn-aut-mei=尚子
aut-affil-num=8
ORCID=

en-aut-name=TOSAChihiro
en-aut-sei=TOSA
en-aut-mei=Chihiro
kn-aut-name=土佐千紘
kn-aut-sei=土佐
kn-aut-mei=千紘
aut-affil-num=9
ORCID=

en-aut-name=NAKAMURA Ai
en-aut-sei=NAKAMURA 
en-aut-mei=Ai
kn-aut-name=中村愛
kn-aut-sei=中村
kn-aut-mei=愛
aut-affil-num=10
ORCID=

en-aut-name=HIGUCHIAki
en-aut-sei=HIGUCHI
en-aut-mei=Aki
kn-aut-name=樋口亜希
kn-aut-sei=樋口
kn-aut-mei=亜希
aut-affil-num=11
ORCID=

affil-num=1
en-affil=Okayama University
kn-affil=岡山大学学術研究院教育学域

affil-num=2
en-affil=Kurashiki City College
kn-affil=倉敷市立短期大学

affil-num=3
en-affil=Part-time Lecturer at Okayama University
kn-affil=岡山大学非常勤講師

affil-num=4
en-affil=Research Student at the Joint Graduate School in Science of School Education Hyogo University of Teacher Education
kn-affil=兵庫教育大学大学院連合学校教育学研究科

affil-num=5
en-affil=Biwako-Gakuin University
kn-affil=びわこ学院大学短期大学部

affil-num=6
en-affil=Okayama University
kn-affil=岡山大学学術研究院教育学域

affil-num=7
en-affil=Research Student at the Joint Graduate School in Science of School Education Hyogo University of Teacher Education
kn-affil=兵庫教育大学大学院連合学校教育学研究科

affil-num=8
en-affil=Doctoral Student at the Joint Graduate School in Science of School Education Hyogo University of Teacher Education
kn-affil=兵庫教育大学大学院連合学校教育学研究科

affil-num=9
en-affil=Yamaha Corporation
kn-affil=ヤマハ株式会社楽器事業本部

affil-num=10
en-affil=Doctoral Student at the Joint Graduate School in Science of School Education Hyogo University of Teacher Education
kn-affil=兵庫教育大学大学院連合学校教育学研究科

affil-num=11
en-affil=Okayama Prefectural School for the Deaf
kn-affil=岡山県立岡山聾学校
en-keyword=和楽器音楽 (Classical Japanese instrument)
kn-keyword=和楽器音楽 (Classical Japanese instrument)
en-keyword=異文化間能力 (‘Intercultural Competence’)
kn-keyword=異文化間能力 (‘Intercultural Competence’)
en-keyword=次世代育成 (the next generation)
kn-keyword=次世代育成 (the next generation)
en-keyword=質問紙調査 (questionnaire survey)
kn-keyword=質問紙調査 (questionnaire survey)
en-keyword=小学生・中学生 (elementary and junior high school students)
kn-keyword=小学生・中学生 (elementary and junior high school students)
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260325
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Clinicopathological and transcriptomic profiles of 101 patients with diffuse large B-cell lymphoma/high-grade B-cell lymphoma with double-hit MYC and BCL2 or BCL6 and triple hit
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Aims: Diffuse large B-cell lymphoma/high-grade B-cell lymphoma (DLBCL/HGBCL) with MYC and BCL2 rearrangements (double-hit lymphoma with BCL2, DHL-BCL2) is a mature aggressive B-cell lymphoma that also includes concurrent triple hit with BCL6 translocation (TH). DHL with MYC and BCL6 (DH-BCL6) can also occur. The differences among these three DLBCL/HGBCL subtypes have not yet been definitively determined.<br>
Methods and Results: This study characterized the clinicopathological features and transcriptomic profiles of a series of 101 cases of DLBCL/HGBCL that were subclassified according to MYC, BCL2 and BCL6 FISH data, including cell-of-origin (COO)-like, molecular high-grade (MHG)-like and double-hit/dark-zone (DHIT/DZsig)-like signatures. DLBCL/HGBCL-DH-BCL2 was characterized by higher HGBCL morphology, CD10 positivity, GCB Hans's, GCB COO and MHG molecular subtype. DLBCL/HGBCL-TH had higher LDH levels and worse overall survival. DLBCL/HGBCL-DH-BCL6 had higher MUM1 expression, non-GCB Hans', ABC/Unclassified COO, non-MHG and low DHIT/DZ signatures. Transcriptomic analysis showed that DLBCL/HGBCL-DH-BCL2 and DLBCL/HGBCL-TH were close but separated from DLBCL/HGBCL-DH-BCL6. Gene set enrichment analysis (GSEA) revealed different levels of enrichment between the subtypes.<br>
Conclusions: DLBCL/HGBCL-DH-BCL6 differs from the DLBCL/HGBCL-DH-BCL2, and the DLBCL/HGBCL-TH is associated with the worst survival. Analysis of all three genes of MYC, BCL2 and BCL6 is recommended in the context of DLBCL/HGBCL diagnosis.
en-copyright=
kn-copyright=

en-aut-name=MiyaokaMasashi
en-aut-sei=Miyaoka
en-aut-mei=Masashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=CarrerasJoaquim
en-aut-sei=Carreras
en-aut-mei=Joaquim
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KikutiYara Yukie
en-aut-sei=Kikuti
en-aut-mei=Yara Yukie
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=IkomaHaruka
en-aut-sei=Ikoma
en-aut-mei=Haruka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=NagaseShunsuke
en-aut-sei=Nagase
en-aut-mei=Shunsuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=ItoAtsushi
en-aut-sei=Ito
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=OritaMakoto
en-aut-sei=Orita
en-aut-mei=Makoto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KawadaHiroshi
en-aut-sei=Kawada
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=SakaiRika
en-aut-sei=Sakai
en-aut-mei=Rika
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=SatoYasuharu
en-aut-sei=Sato
en-aut-mei=Yasuharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=NishimuraMidori Filiz
en-aut-sei=Nishimura
en-aut-mei=Midori Filiz
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=TsukasakiKunihiro
en-aut-sei=Tsukasaki
en-aut-mei=Kunihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=MomoseShuji
en-aut-sei=Momose
en-aut-mei=Shuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=KameokaYoshihiro
en-aut-sei=Kameoka
en-aut-mei=Yoshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=YoshidaMasahiro
en-aut-sei=Yoshida
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=SatouAkira
en-aut-sei=Satou
en-aut-mei=Akira
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=KatoSeiichi
en-aut-sei=Kato
en-aut-mei=Seiichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=OishiNaoki
en-aut-sei=Oishi
en-aut-mei=Naoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=SaitoAkio
en-aut-sei=Saito
en-aut-mei=Akio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=SadahiraKen
en-aut-sei=Sadahira
en-aut-mei=Ken
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=MasugiYohei
en-aut-sei=Masugi
en-aut-mei=Yohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=NakamuraNaoya
en-aut-sei=Nakamura
en-aut-mei=Naoya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

affil-num=1
en-affil=Department of Pathology, School of Medicine, Tokai University
kn-affil=

affil-num=2
en-affil=Department of Pathology, School of Medicine, Tokai University
kn-affil=

affil-num=3
en-affil=Department of Pathology, School of Medicine, Tokai University
kn-affil=

affil-num=4
en-affil=Department of Pathology, School of Medicine, Tokai University
kn-affil=

affil-num=5
en-affil=Department of Pathology, School of Medicine, Tokai University
kn-affil=

affil-num=6
en-affil=Department of Pathology, School of Medicine Tokai University  Isehara Japan
kn-affil=

affil-num=7
en-affil=Department of Pathology, School of Medicine, Tokai University
kn-affil=

affil-num=8
en-affil=Department of Hematology, School of Medicine, Tokai University
kn-affil=

affil-num=9
en-affil=Department of Medical Oncology, Kanagawa Cancer Center
kn-affil=

affil-num=10
en-affil=Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences
kn-affil=

affil-num=11
en-affil=Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences
kn-affil=

affil-num=12
en-affil=Department of Hematology, International Medical Center, Saitama Medical University
kn-affil=

affil-num=13
en-affil=Department of Pathology, Saitama Medical Center, Saitama Medical University
kn-affil=

affil-num=14
en-affil=Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine
kn-affil=

affil-num=15
en-affil=Department of Hematology, Osaka City General Hospital
kn-affil=

affil-num=16
en-affil=Department of Surgical Pathology, Aichi Medical University Hospital
kn-affil=

affil-num=17
en-affil=Center for Clinical Pathology, Fujita Health University Hospital
kn-affil=

affil-num=18
en-affil=Department of Pathology, University of Yamanashi
kn-affil=

affil-num=19
en-affil=Department of Hematology, NHO Shibukawa Medical Center
kn-affil=

affil-num=20
en-affil=Division of Hematology, Kawasaki Municipal Kawasaki Hospital
kn-affil=

affil-num=21
en-affil=Department of Pathology, School of Medicine, Tokai University
kn-affil=

affil-num=22
en-affil=Department of Pathology, School of Medicine, Tokai University
kn-affil=
en-keyword=BCL2
kn-keyword=BCL2
en-keyword=BCL6
kn-keyword=BCL6
en-keyword=high-grade B-cell lymphoma
kn-keyword=high-grade B-cell lymphoma
en-keyword=molecular profile
kn-keyword=molecular profile
en-keyword=MYC
kn-keyword=MYC
en-keyword=rearrangements
kn-keyword=rearrangements
END

start-ver=1.4
cd-journal=joma
no-vol=57
cd-vols=
no-issue=3
article-no=
start-page=11
end-page=40
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260318
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Network Analysis of Interregional Information Exchange: A Study in the Takahashi River Basin Area
kn-title=地域間での情報交流に関するネットワーク分析：高梁川流域圏での調査による
en-subtitle=
kn-subtitle=
en-abstract=　This paper conducted network analysis focusing on information exchange among participating entities in the "Takahashi River Basin Economic Growth Strategy Council," operating within Okayama Prefecture's "Takahashi River Basin Core City Area." The Takahashi River Basin Collaborative Core City Area（ Takahashi River Basin Area）is a collaborative core city area encompassing ten municipalities located around the Takahashi River in Okayama Prefecture: Niimi City, Takahashi City, Soja City, Hayashima Town, Kurashiki City, Yakage Town, Ibara City, Asakuchi City, Satosho Town, and Kasaoka City. For the network analysis within the Takahashi River Basin Area, projects implemented within the area were classified into eight categories. A questionnaire survey was conducted regarding information exchange among participating entities for each project. Network metrics included calculating centrality indices（ degree centrality and betweenness centrality） for each project, along with density, transitivity, and reciprocity. By project type, tourism projects exhibited the densest network structure for information exchange. From a network perspective, tourism projects can be considered the most actively pursued initiative within the Takahashi River Basin area. Furthermore, across all projects, centrality indicators for specific administrative bodies and regional economic organizations, such as chambers of commerce and industry, generally showed high values. This clearly indicates their function as hubs for information exchange and as entities concentrating or dispersing information within the network. Based on the results of network analysis, two recommendations for future regional development in the Takahashi River Basin were proposed from a network perspective. The first is to aim for dense networks across all businesses by sharing the roles of information exchange hubs and information concentration/distribution entities among the entities involved, depending on the business. The second is to aim for a dense network overall by eliminating entities that are not participating at all in the Takahashi River Basin's information exchange network.
kn-abstract=　本稿では，岡山県の「高梁川流域連携中枢都市圏」で2014年から開催されている「高梁川流域経済成長戦略会議」における参加主体間の情報交流についてのネットワーク分析を行った。高梁川流域連携中枢都市圏（高梁川流域圏）とは，岡山県高梁川周辺に位置する現在の新見市，高梁市，総社市，早島町，倉敷市，矢掛町，井原市，浅口市，里庄町，笠岡市の10自治体が参加している連携中枢都市圏である。高梁川流域圏におけるネットワーク分析に際しては，同圏域内で展開されている事業を８つに分類し，それぞれの事業に関する参加主体間の情報交流についてアンケート調査を行った。ネットワーク指標については事業ごとに次数中心性と媒介中心性の中心性指標を，また事業別に密度，推移性，相互性を算出した。事業別にみると，観光事業についての情報交流が最も密なネットワーク構造をしており，ネットワークの視点では観光事業が高梁川流域圏内で最も勢力的に行われている事業といえる。また全事業において特定の行政主体や商工会議所をはじめとする地域経済団体等の中心性指標が全体的に大きな値をとっており，ネットワークにおいて情報交流のハブや情報の集中・分散主体として機能していることが明らかになった。分析結果を踏まえ，ネットワークの視点から高梁川流域圏の今度の地域振興について２点提言した。１つは事業によって情報交流のハブや情報の集中・分散主体を主体間で分担することによって，すべての事業で密なネットワークを築くことを目指すことである。もう１つは高梁川流域圏の情報交流ネットワークに全く参加していない主体をなくすことで，全体的に密なネットワークを目指すことである。
en-copyright=
kn-copyright=

en-aut-name=NakamuraRyohei
en-aut-sei=Nakamura
en-aut-mei=Ryohei
kn-aut-name=中村良平
kn-aut-sei=中村
kn-aut-mei=良平
aut-affil-num=1
ORCID=

en-aut-name=YokotaNatsumi
en-aut-sei=Yokota
en-aut-mei=Natsumi
kn-aut-name=横田夏実
kn-aut-sei=横田
kn-aut-mei=夏実
aut-affil-num=2
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学

affil-num=2
en-affil=
kn-affil=下関市役所
END

start-ver=1.4
cd-journal=joma
no-vol=22
cd-vols=
no-issue=9
article-no=
start-page=e772
end-page=e780
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202509
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Aging of the tricuspid valve annulus detected by photon-counting detector computed tomography: Importance of aortic root compression on occurrence of arrhythmias
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background The aortic root compresses the heart in elderly patients, potentially influencing the conduction system and causing atrial tachyarrhythmias. However, actual anatomic alterations in the right side of the heart because of aortic root compression have not yet been fully evaluated.<br>
Objective This study aimed to elucidate the alterations in the tricuspid valve annulus (TVA) caused by aortic root compression using a 3-dimensional endoscopic view of the heart constructed by photon-counting detector computed tomography, an emerging medical technology.<br>
Methods We analyzed 147 consecutive patients who underwent photon-counting detector computed tomography at our institute after excluding those with diseases that directly influenced the right side of the heart.<br>
Results Aortic root compression caused significant TVA deformation. We defined severe TVA compression as the length of the TVA compressed by the aortic root ?80% of the major axis of the TVA. Severe compression was more prevalent in elderly patients (age ?75 years [44%]; P < .01). The distance between the membranous septum and ostium of the coronary sinus was shortened, whereas the cavotricuspid isthmus was elongated in older patients. The regression analysis identified aging as a significant contributor to TVA compression. The short minor and long major axes of the TVA, incidence of atrial tachyarrhythmias (74% vs 45%; P < .01), and atrioventricular conduction disturbances (35% vs 15%; P < .01) were more frequently observed in patients with severe compression.<br>
Conclusion Aortic root compression deforms the TVA and alters the anatomic relationship between the atrioventricular conduction system and the cavotricuspid isthmus. Therefore, aortic root compression may contribute to the occurrence of atrial tachyarrhythmias and conduction disturbances in older patients.
en-copyright=
kn-copyright=

en-aut-name=MoritaHiroshi
en-aut-sei=Morita
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NakagawaKoji
en-aut-sei=Nakagawa
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NagaseSatoshi
en-aut-sei=Nagase
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MorimotoYoshihisa
en-aut-sei=Morimoto
en-aut-mei=Yoshihisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MasudaTakuro
en-aut-sei=Masuda
en-aut-mei=Takuro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=UeokaAkira
en-aut-sei=Ueoka
en-aut-mei=Akira
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=AsadaSaori
en-aut-sei=Asada
en-aut-mei=Saori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=MiyamotoMasakazu
en-aut-sei=Miyamoto
en-aut-mei=Masakazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=TohNorihisa
en-aut-sei=Toh
en-aut-mei=Norihisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=MiyoshiToru
en-aut-sei=Miyoshi
en-aut-mei=Toru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=NishiiNobuhiro
en-aut-sei=Nishii
en-aut-mei=Nobuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=YuasaShinsuke
en-aut-sei=Yuasa
en-aut-mei=Shinsuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

affil-num=1
en-affil=Department of Cardiovascular Therapeutics, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry
kn-affil=

affil-num=3
en-affil=Department of General Internal Medicine 3, Kawasaki Medical School General Medical Center
kn-affil=

affil-num=4
en-affil=Department of Cardiovascular Medicine, Fukuyama City Hospital
kn-affil=

affil-num=5
en-affil=Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry
kn-affil=

affil-num=6
en-affil=Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry
kn-affil=

affil-num=7
en-affil=Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry
kn-affil=

affil-num=8
en-affil=Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry
kn-affil=

affil-num=9
en-affil=Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry
kn-affil=

affil-num=10
en-affil=Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry
kn-affil=

affil-num=11
en-affil=Department of Cardiovascular Therapeutics, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=12
en-affil=Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry
kn-affil=
en-keyword=Tricuspid valve annulus
kn-keyword=Tricuspid valve annulus
en-keyword=Aortic root
kn-keyword=Aortic root
en-keyword=Photon-counting detector computed tomography
kn-keyword=Photon-counting detector computed tomography
en-keyword=Atrial tachyarrhythmia
kn-keyword=Atrial tachyarrhythmia
en-keyword=Conduction abnormality
kn-keyword=Conduction abnormality
END

start-ver=1.4
cd-journal=joma
no-vol=28
cd-vols=
no-issue=1
article-no=
start-page=32
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260102
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Real-world comparative effectiveness of sarilumab versus Janus kinase inhibitors as monotherapy in rheumatoid arthritis
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Sarilumab (SAR), an interleukin-6 receptor inhibitor (IL-6Ri), and Janus kinase inhibitors (JAKi) are approved options for rheumatoid arthritis (RA) when methotrexate (MTX) cannot be used. Real-world evidence for MTX-free monotherapy remains limited.<br>
Methods: We conducted a multicenter retrospective cohort study of RA patients receiving SAR or JAKi as MTX-free monotherapy. To reduce confounding, 1:1 propensity score matching was performed in the overall cohort (n?=?252, 126 per group) and separately within treatment-line strata: Phase 2 first-line biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs: 45 per group), Phase 3 second-line b/tsDMARDs (53 per group), and Phase 3???third-line b/tsDMARDs (47 per group). Outcomes over 12 months included drug retention, change in Clinical Disease Activity Index (CDAI), glucocorticoid (GC) tapering and discontinuation, low disease activity (LDA, CDAI???10), and safety profiles. Predictors of LDA were evaluated with logistic regression. This multicenter real-world.<br>
Results: Across matched strata by prior b/tsDMARDs, retention and CDAI change did not differ significantly between SAR and JAKi through 12 months. When classified by cause, adverse events (AEs)-related discontinuation was higher with JAKi, yielding lower AE-specific retention. Both groups demonstrated GC sparing overtime, with a greater increase in GC discontinuation for SAR than for JAKi in Phase 2. Baseline predictors of achieving LDA at 12 months included higher C-reactive protein (CRP) and platelet count (Plt) in both groups, with additional associations of younger age and lower hemoglobin (Hb) in the SAR. In safety analyses, overall AEs were less frequent with SAR than with JAKi, driven by lower risks of infection including herpes zoster, while other categories were similarly infrequent.<br>
Conclusion: SAR and JAKi showed no statistically significant differences in 12-month retention or disease control in MTX-free monotherapy settings. Higher CRP and Plt with lower Hb, particularly in younger patients, identified better response to SAR and support biomarker guided selection between IL-6Ri and JAKi. In Phase 2, GC discontinuation with SAR suggests a practical strategy to reduce AEs while maintaining efficacy. Prospective studies should validate these findings and define actionable thresholds.
en-copyright=
kn-copyright=

en-aut-name=NozakiYuji
en-aut-sei=Nozaki
en-aut-mei=Yuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KishimotoKazuya
en-aut-sei=Kishimoto
en-aut-mei=Kazuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=ItamiTetsu
en-aut-sei=Itami
en-aut-mei=Tetsu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TomitaDaisuke
en-aut-sei=Tomita
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=WadaYumiko
en-aut-sei=Wada
en-aut-mei=Yumiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KotaniTakuya
en-aut-sei=Kotani
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TakeuchiTohru
en-aut-sei=Takeuchi
en-aut-mei=Tohru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=HidakaToshihiko
en-aut-sei=Hidaka
en-aut-mei=Toshihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=HinoShoichi
en-aut-sei=Hino
en-aut-mei=Shoichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=MiyamotoToshiaki
en-aut-sei=Miyamoto
en-aut-mei=Toshiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=MiyakeHirofumi
en-aut-sei=Miyake
en-aut-mei=Hirofumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=HattaKazunari
en-aut-sei=Hatta
en-aut-mei=Kazunari
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=MamotoKenji
en-aut-sei=Mamoto
en-aut-mei=Kenji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=YamadaYutaro
en-aut-sei=Yamada
en-aut-mei=Yutaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=OkanoTadashi
en-aut-sei=Okano
en-aut-mei=Tadashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=OkanoTakaichi
en-aut-sei=Okano
en-aut-mei=Takaichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=SaegusaJun
en-aut-sei=Saegusa
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=HoritaMasahiro
en-aut-sei=Horita
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=NishidaKeiichiro
en-aut-sei=Nishida
en-aut-mei=Keiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=KinoshitaKoji
en-aut-sei=Kinoshita
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=RaiShinya
en-aut-sei=Rai
en-aut-mei=Shinya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

affil-num=1
en-affil=Department of Hematology and Rheumatology, Kindai University Faculty of Medicine
kn-affil=

affil-num=2
en-affil=Department of Hematology and Rheumatology, Kindai University Faculty of Medicine
kn-affil=

affil-num=3
en-affil=Department of Hematology and Rheumatology, Kindai University Faculty of Medicine
kn-affil=

affil-num=4
en-affil=Department of Hematology and Rheumatology, Kindai University Faculty of Medicine
kn-affil=

affil-num=5
en-affil=Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University
kn-affil=

affil-num=6
en-affil=Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University
kn-affil=

affil-num=7
en-affil=Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University
kn-affil=

affil-num=8
en-affil=Rheumatology Center, Miyazaki Zenjinkai Hospital
kn-affil=

affil-num=9
en-affil=Department of Rheumatology and Clinical Immunology, Izumi City General Medical Center
kn-affil=

affil-num=10
en-affil=Miyamoto Internal Medicine and Rheumatology Clinic
kn-affil=

affil-num=11
en-affil=Department of General Internal Medicine, Tenri Hospital
kn-affil=

affil-num=12
en-affil=Department of General Internal Medicine, Tenri Hospital
kn-affil=

affil-num=13
en-affil=Department of Orthopaedic Surgery, Graduate School of Medicine, Osaka Metropolitan University
kn-affil=

affil-num=14
en-affil=Center for Senile Degenerative Disorders (CSDD), Osaka Metropolitan University Graduate School of Medicine
kn-affil=

affil-num=15
en-affil=Center for Senile Degenerative Disorders (CSDD), Osaka Metropolitan University Graduate School of Medicine
kn-affil=

affil-num=16
en-affil=Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine
kn-affil=

affil-num=17
en-affil=Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine
kn-affil=

affil-num=18
en-affil=Department of Orthopaedic Surgery, Faculty of Medical Development Field, Okayama University
kn-affil=

affil-num=19
en-affil=Locomotive Pain Center, Faculty of Medical Development Field, Okayama University
kn-affil=

affil-num=20
en-affil=Department of Hematology and Rheumatology, Kindai University Faculty of Medicine
kn-affil=

affil-num=21
en-affil=Department of Hematology and Rheumatology, Kindai University Faculty of Medicine
kn-affil=
en-keyword=Rheumatoid arthritis
kn-keyword=Rheumatoid arthritis
en-keyword=Methotrexate
kn-keyword=Methotrexate
en-keyword=Biological DMARDs
kn-keyword=Biological DMARDs
END

start-ver=1.4
cd-journal=joma
no-vol=165
cd-vols=
no-issue=
article-no=
start-page=105344
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202503
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Local immune response induced by intra-fin antigen injection in Japanese medaka (Oryzias latipes) is a useful model for immunological studies
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Teleost fishes play a pivotal role in advancing our understanding of immune system evolution because they retain the ancient characteristics of vertebrate immunity, encompassing both innate and adaptive immune systems. Among these, innate immunity plays a critical role in fish as the first line of defense, coordinating rapid responses to pathogen infections. However, the lack of fish-specific immunological methodologies has limited progress in elucidating fish immune mechanisms. To better understand how the innate immune response develops and resolves in fish, detailed observation and integrative analysis of leukocytes at multiple time points is necessary. In the present study, an intra-fin injection method for observing local immune responses in Japanese medaka (Oryzias latipes) was tested and optimized to analyze the progression of zymosan-induced innate immune responses. Zymosan-injected medaka showed a rapid immune response characterized by leukocyte recruitment and phagocytosis. Using TG(FmpxP:mCherry) transgenic medaka with mCherry fluorescence driven by myeloperoxidase (mpx) promoter, granulocyte chemotaxis towards the site of zymosan entry was successfully visualized. The rapid increase in tumor necrosis factor α (tnfa), interleukin-1β (il1b), interleukin-6 (il6), and CXC motif chemokine ligand 8 (cxcl8) expressions in zymosan-injected anal fins provided a molecular basis for the visualized tissue-specific cellular response. Our study underscores the dynamic orchestration of immune components during the innate immune response in Japanese medaka and highlights their potential as a promising model for immunological research.
en-copyright=
kn-copyright=

en-aut-name=RyuTsukasa
en-aut-sei=Ryu
en-aut-mei=Tsukasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YoshinoMizuki
en-aut-sei=Yoshino
en-aut-mei=Mizuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TseWilliam Ka Fai
en-aut-sei=Tse
en-aut-mei=William Ka Fai
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=AnsaiSatoshi
en-aut-sei=Ansai
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=IguchiTaisen
en-aut-sei=Iguchi
en-aut-mei=Taisen
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KumarAnu
en-aut-sei=Kumar
en-aut-mei=Anu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=SomamotoTomonori
en-aut-sei=Somamoto
en-aut-mei=Tomonori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=NakaoMiki
en-aut-sei=Nakao
en-aut-mei=Miki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=OginoYukiko
en-aut-sei=Ogino
en-aut-mei=Yukiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Graduate School of Bioresource and Bioenvironmental Sciences, Laboratory of Marine Biochemistry, Kyushu University
kn-affil=

affil-num=2
en-affil=Graduate School of Bioresource and Bioenvironmental Sciences, Laboratory of Marine Biology, Kyushu University
kn-affil=

affil-num=3
en-affil=Graduate School of Bioresource and Bioenvironmental Sciences, Laboratory of Developmental Disorders and Toxicology, Kyushu University
kn-affil=

affil-num=4
en-affil=Ushimado Marine Institute, Faculty of Science, Okayama University
kn-affil=

affil-num=5
en-affil=Graduate School of Nanobioscience, Yokohama City University
kn-affil=

affil-num=6
en-affil=Commonwealth Scientific and Industrial Research Organisation, CSIRO Environment
kn-affil=

affil-num=7
en-affil=Graduate School of Bioresource and Bioenvironmental Sciences, Laboratory of Marine Biochemistry, Kyushu University
kn-affil=

affil-num=8
en-affil=Graduate School of Bioresource and Bioenvironmental Sciences, Laboratory of Marine Biochemistry, Kyushu University
kn-affil=

affil-num=9
en-affil=Center for Promotion of International Education and Research, Faculty of Agriculture, Kyushu University
kn-affil=
en-keyword=Chemotaxis
kn-keyword=Chemotaxis
en-keyword=Local immunity
kn-keyword=Local immunity
en-keyword=Inflammation
kn-keyword=Inflammation
en-keyword=Innate immunity
kn-keyword=Innate immunity
en-keyword=Phagocytosis
kn-keyword=Phagocytosis
en-keyword=Zymosan
kn-keyword=Zymosan
END

start-ver=1.4
cd-journal=joma
no-vol=411
cd-vols=
no-issue=1
article-no=
start-page=21
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251127
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Surgical outcomes and patient selection in nonagenarians with colon cancer: a comparative multi-institutional study of laparoscopic and open approaches
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Purpose The appropriate surgical approach for colon cancer (CC) in nonagenarian patients remains a subject of clinical debate. This study aimed to compare the short-term outcomes of laparoscopic (Lap) versus open (Open) surgery in patients aged???90 years with resectable colon cancer.<br>
Methods This multi-institutional retrospective cohort study included oldest-old patientswith pathological Stage II/III CC who underwent elective surgery at 15 hospitals between 2011 and 2022. Patients with rectal cancer, Stage 0/I/IV disease, or emergency surgery were excluded. To address selection bias, inverse-probability-weighted regression adjustment and stabilized inverse probability of treatment weighting (sIPTW) were applied. The primary outcome was postoperative complications; secondary outcomes included overall survival (OS).<br>
Results Median age was 92 years in both groups. Before adjustment, the Lap group had a higher proportion of female patients (p?=?0.038) and lower ASA scores (p?=?0.01). Laparoscopic surgery was associated with a significantly longer operative time (220 vs. 171 min, p?=?0.046) but less intraoperative blood loss (10 vs. 78 mL, p?<?0.01). Postoperative complication rates were comparable (Lap: 31.8%, Open: 33.8%), while the Lap group had a significantly shorter hospital stay (13 vs. 17 days, p?<?0.01). D3 lymph node dissection was more frequently performed in the Lap group (p?<?0.01). After sIPTW, overall survival did not differ significantly between groups (p?=?0.61).<br>
Conclusion Both laparoscopic and open surgery are feasible options for selected nonagenarians with colon cancer. Laparoscopic surgery may offer benefits in terms of reduced blood loss and shorter hospitalization, despite longer operative times. Careful patient selection considering frailty and comorbidities is essential in determining the most appropriate surgical approach.
en-copyright=
kn-copyright=

en-aut-name=ShojiRyohei
en-aut-sei=Shoji
en-aut-mei=Ryohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TeraishiFuminori
en-aut-sei=Teraishi
en-aut-mei=Fuminori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TakanagaSatoe
en-aut-sei=Takanaga
en-aut-mei=Satoe
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MitsuhashiToshiharu
en-aut-sei=Mitsuhashi
en-aut-mei=Toshiharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=InadaRyo
en-aut-sei=Inada
en-aut-mei=Ryo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=ToshimaToshiaki
en-aut-sei=Toshima
en-aut-mei=Toshiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=OhtaniTsuyoshi
en-aut-sei=Ohtani
en-aut-mei=Tsuyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=YoshidaRyosuke
en-aut-sei=Yoshida
en-aut-mei=Ryosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=HoriNaoto
en-aut-sei=Hori
en-aut-mei=Naoto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=ShigemitsuKaoru
en-aut-sei=Shigemitsu
en-aut-mei=Kaoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=YamamotoSumiharu
en-aut-sei=Yamamoto
en-aut-mei=Sumiharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=KubotaTetsushi
en-aut-sei=Kubota
en-aut-mei=Tetsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=OkanoYuka
en-aut-sei=Okano
en-aut-mei=Yuka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=NobuhisaTetsuji
en-aut-sei=Nobuhisa
en-aut-mei=Tetsuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=TaniguchiFumitaka
en-aut-sei=Taniguchi
en-aut-mei=Fumitaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=IshikawaWataru
en-aut-sei=Ishikawa
en-aut-mei=Wataru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=MatsudaTatsuo
en-aut-sei=Matsuda
en-aut-mei=Tatsuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=UmeokaTatsuo
en-aut-sei=Umeoka
en-aut-mei=Tatsuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=FujiwaraToshiyoshi
en-aut-sei=Fujiwara
en-aut-mei=Toshiyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=Setouchi Colorectal Neoplasm Registration study group collaborators
en-aut-sei=Setouchi Colorectal Neoplasm Registration study group collaborators
en-aut-mei=
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

affil-num=1
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of Surgery, Kochi Health Sciences Center
kn-affil=

affil-num=6
en-affil=Department of Surgery, Kagawa Rosai Hospital
kn-affil=

affil-num=7
en-affil=Department of Surgery, Saiseikai Okayama Hospital
kn-affil=

affil-num=8
en-affil=Department of Surgery, Okayama Rosai Hospital
kn-affil=

affil-num=9
en-affil=Department of Surgery, Tottori Municipal Hospital
kn-affil=

affil-num=10
en-affil=Department of Surgery, Tsuyama Chuo Hospital
kn-affil=

affil-num=11
en-affil=Department of Surgery, Okayama City Hospital
kn-affil=

affil-num=12
en-affil=Department of Surgery, Kobe Red Cross Hospital
kn-affil=

affil-num=13
en-affil=Department of Surgery, Onomichi City Hospital
kn-affil=

affil-num=14
en-affil=Department of Surgery, Himeji Red Cross Hospital
kn-affil=

affil-num=15
en-affil=Department of Surgery, National Hospital Organization Iwakuni Clinical Center
kn-affil=

affil-num=16
en-affil=Department of Surgery, Fukuyama City Hospital
kn-affil=

affil-num=17
en-affil=Department of Surgery, Matsuda Hospital
kn-affil=

affil-num=18
en-affil=Department of Surgery, Matsuyama City Hospital
kn-affil=

affil-num=19
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=20
en-affil=
kn-affil=
en-keyword=Oldest-old patients
kn-keyword=Oldest-old patients
en-keyword=Colon cancer
kn-keyword=Colon cancer
en-keyword=Laparoscopic surgery
kn-keyword=Laparoscopic surgery
en-keyword=Surgical outcome
kn-keyword=Surgical outcome
en-keyword=Overall survival
kn-keyword=Overall survival
END

start-ver=1.4
cd-journal=joma
no-vol=23
cd-vols=
no-issue=1
article-no=
start-page=120
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251124
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Comparison of clinical practices during the transitional and young adult phases between patients with oligoarticular/polyarticular juvenile idiopathic arthritis and those with rheumatoid arthritis in Japan
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background Juvenile idiopathic arthritis (JIA) is a chronic inflammatory condition that frequently persists into adulthood, posing long-term challenges in disease control and quality of life. However, clinical management during the transitional and young adult phases remains insufficiently characterized, especially in comparison with adult-onset rheumatoid arthritis (RA). This study aimed to compare disease activity, medication use, and treatment practices between patients with oligoarticular/polyarticular JIA and those with RA, focusing on individuals aged 16?30 years.<br>
Methods Data were derived from two nationwide multicenter databases in Japan?NinJa (National Database of Rheumatic Diseases in Japan) for RA and CoNinJa (a pediatric counterpart of NinJa) for JIA. A total of 176 JIA and 152 RA patients, all aged 16?30 years, were analyzed. Clinical parameters, disease activity indices, and medication profiles were compared using the Mann?Whitney U test and Fisher’s exact test.<br>
Results Compared to RA patients, JIA patients demonstrated significantly lower disease activity (median SDAI 0.6 vs. 2.4) and higher remission rates, particularly Boolean remission (70% vs. 44%) (p?<?0.001). MTX usage was less frequent in JIA (49% vs. 68%, p?<?0.001), whereas biologic use was notably more common (69% vs. 38%, p?<?0.001), with 31% involving off-label prescriptions. Among patients in CDAI remission, biologic monotherapy was observed more frequently in JIA (29% vs. 7%, p?<?0.001). Discontinuation of MTX was most commonly attributed to disease improvement (58%) or gastrointestinal intolerance (nausea, 29%). Subcutaneous tocilizumab, though unapproved for JIA in Japan, had the lowest discontinuation rate (4%), suggesting favorable tolerability.<br>
Conclusions Despite an overlap in age, patients with JIA and RA exhibit distinct disease characteristics and therapeutic patterns. These differences underscore the need to expand approved treatment options for JIA, promote equitable access to biologics, and strengthen transitional care frameworks. Further research is warranted to explore long-term outcomes, reproductive health considerations, and socioeconomic barriers that influence treatment continuity in young adults with childhood-onset arthritis.
en-copyright=
kn-copyright=

en-aut-name=MoriSho
en-aut-sei=Mori
en-aut-mei=Sho
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ShabanaKosuke
en-aut-sei=Shabana
en-aut-mei=Kosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MatsuiToshihiro
en-aut-sei=Matsui
en-aut-mei=Toshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NozawaTomo
en-aut-sei=Nozawa
en-aut-mei=Tomo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SugitaYuko
en-aut-sei=Sugita
en-aut-mei=Yuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TomiitaMinako
en-aut-sei=Tomiita
en-aut-mei=Minako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NakagishiYasuo
en-aut-sei=Nakagishi
en-aut-mei=Yasuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=YamasakiYuichi
en-aut-sei=Yamasaki
en-aut-mei=Yuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=UmebayashiHiroaki
en-aut-sei=Umebayashi
en-aut-mei=Hiroaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=YashiroMasato
en-aut-sei=Yashiro
en-aut-mei=Masato
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=IwataNaomi
en-aut-sei=Iwata
en-aut-mei=Naomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=YasumuraJunko
en-aut-sei=Yasumura
en-aut-mei=Junko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=WakiguchiHiroyuki
en-aut-sei=Wakiguchi
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=YamamotoTakeshi
en-aut-sei=Yamamoto
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=TakezakiShunichiro
en-aut-sei=Takezaki
en-aut-mei=Shunichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=OkuraYuka
en-aut-sei=Okura
en-aut-mei=Yuka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=YokoyamaTadafumi
en-aut-sei=Yokoyama
en-aut-mei=Tadafumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=ShimizuMasaki
en-aut-sei=Shimizu
en-aut-mei=Masaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=HirayamaMasahiro
en-aut-sei=Hirayama
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=TohmaShigeto
en-aut-sei=Tohma
en-aut-mei=Shigeto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=OkamotoNami
en-aut-sei=Okamoto
en-aut-mei=Nami
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=MoriMasaaki
en-aut-sei=Mori
en-aut-mei=Masaaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

affil-num=1
en-affil=Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine
kn-affil=

affil-num=2
en-affil=Department of Pediatrics, Osaka Medical and Pharmaceutical University
kn-affil=

affil-num=3
en-affil=Department of Rheumatology Research, Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital
kn-affil=

affil-num=4
en-affil=Department of Pediatrics, Graduate School of Medicine, Yokohama City University
kn-affil=

affil-num=5
en-affil=Department of Pediatrics, Osaka Medical and Pharmaceutical University
kn-affil=

affil-num=6
en-affil=Department of Allergy and Rheumatology, Chiba Children’s Hospital
kn-affil=

affil-num=7
en-affil=Department of Pediatric Rheumatology, Hyogo Prefectural Kobe Children’s Hospital
kn-affil=

affil-num=8
en-affil=Department of Pediatrics, Kagoshima University Hospital
kn-affil=

affil-num=9
en-affil=Department of General Pediatrics, Miyagi Children’s Hospital
kn-affil=

affil-num=10
en-affil=Department of Pediatrics, Okayama University Hospital
kn-affil=

affil-num=11
en-affil=Department of Infection and Immunology, Allergy and Immunology Center, Aichi Children’s Health and Medical Center
kn-affil=

affil-num=12
en-affil=Department of Pediatrics, Hiroshima University Graduate School of Biomedical and Health Sciences
kn-affil=

affil-num=13
en-affil=Department of Pediatrics, Yamaguchi University Graduate School of Medicine
kn-affil=

affil-num=14
en-affil=Department of Pediatrics, Chiba University Graduate School of Medicine
kn-affil=

affil-num=15
en-affil=Department of Pediatrics, Faculty of Medicinea and Graduate School of Medicine, Hokkaido University
kn-affil=

affil-num=16
en-affil=Center for Pediatric Allergy and Rheumatology, KKR Sapporo Medical Center
kn-affil=

affil-num=17
en-affil=Department of Pediatrics, Kanazawa University
kn-affil=

affil-num=18
en-affil=Department of Pediatrics, Perinatal and Maternal Medicine, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo
kn-affil=

affil-num=19
en-affil=Department of Pediatrics, Mie University Graduate School of Medicine
kn-affil=

affil-num=20
en-affil=Department of Rheumatology, National Hospital Organization Tokyo National Hospital
kn-affil=

affil-num=21
en-affil=Department of Pediatrics, Osaka Medical and Pharmaceutical University
kn-affil=

affil-num=22
en-affil=Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine
kn-affil=
en-keyword=Juvenile idiopathic arthritis
kn-keyword=Juvenile idiopathic arthritis
en-keyword=Rheumatoid arthritis
kn-keyword=Rheumatoid arthritis
en-keyword=Disease activity
kn-keyword=Disease activity
en-keyword=Biologics
kn-keyword=Biologics
en-keyword=Methotrexate
kn-keyword=Methotrexate
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=
article-no=
start-page=39
end-page=50
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251212
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Inheritance and Changes of Accents in the Hiroshima City Dialect（1）: Generational Variation in One-, Two-, and Three-Mora Nouns
kn-title=広島市方言におけるアクセントの継承と変容（1）─ 1 拍・2 拍・3 拍名詞のアクセントの世代的動態 ─
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=NAKATOYasue
en-aut-sei=NAKATO
en-aut-mei=Yasue
kn-aut-name=中東靖恵
kn-aut-sei=中東
kn-aut-mei=靖恵
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=6
cd-vols=
no-issue=2
article-no=
start-page=284
end-page=293
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260201
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Clinical Characteristics and Spatial Transcriptome Analysis of Non?Small Cell Lung Cancers Exhibiting Early Alectinib Resistance: A Retrospective OLCSG Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Some anaplastic lymphoma kinase (ALK) gene rearrangement?positive lung cancers show early resistance, within 3 months, to alectinib. This study investigated the clinical and molecular characteristics of these patients. We analyzed patients with unresectable stage III/IV disease without indications for radical radiotherapy and recurrent ALK-positive lung cancer who received alectinib as the primary ALK tyrosine kinase inhibitor between 2013 and 2021 at nine hospitals. In total, 103 patients were included. The median age was 65 years; 44 were male and 22 had brain metastases. The median progression-free survival and overall survival (OS) were 28.7 and 80.6 months. Nineteen patients treated for ?3 months and 84 treated for >3 months were categorized into the early resistance and responder groups, respectively. The early resistance group had significantly shorter OS (8.4 months vs. not estimable, P < 0.001) and was significantly more likely to have brain metastases (42% vs. 17%, P = 0.027). They also showed elevated inflammatory markers, including neutrophil-to-lymphocyte ratio (NLR). Univariate analysis identified brain metastases and high NLR as significant predictors of early resistance. Spatial transcriptome analysis and immunohistochemical staining revealed upregulation of annexin A1 (ANXA1), a calcium-dependent phospholipid-binding protein involved in inflammation and cancer progression, in the early resistance group. Interleukin 6 stimulation, prompted by elevated inflammatory markers, increased ANXA1 expression and reduced alectinib sensitivity. Knockdown of ANXA1 improved alectinib sensitivity in alectinib-resistant cells. In conclusion, brain metastases and high NLR are associated with early resistance. ANXA1 may play an important role in mediating early resistance. New treatment options for the early resistance group are required.
en-copyright=
kn-copyright=

en-aut-name=KuribayashiTadahiro
en-aut-sei=Kuribayashi
en-aut-mei=Tadahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MakimotoGo
en-aut-sei=Makimoto
en-aut-mei=Go
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=OhashiKadoaki
en-aut-sei=Ohashi
en-aut-mei=Kadoaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TomidaShuta
en-aut-sei=Tomida
en-aut-mei=Shuta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=InoueHirofumi
en-aut-sei=Inoue
en-aut-mei=Hirofumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=YokoyamaToshihide
en-aut-sei=Yokoyama
en-aut-mei=Toshihide
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KuyamaShoichi
en-aut-sei=Kuyama
en-aut-mei=Shoichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KatoYuka
en-aut-sei=Kato
en-aut-mei=Yuka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=KudoKenichiro
en-aut-sei=Kudo
en-aut-mei=Kenichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=HoritaNaokatsu
en-aut-sei=Horita
en-aut-mei=Naokatsu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=KayataniHiroe
en-aut-sei=Kayatani
en-aut-mei=Hiroe
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=InoueMasaaki
en-aut-sei=Inoue
en-aut-mei=Masaaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=SugimotoKeisuke
en-aut-sei=Sugimoto
en-aut-mei=Keisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=NinomiyaKiichiro
en-aut-sei=Ninomiya
en-aut-mei=Kiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=MaedaYoshinobu
en-aut-sei=Maeda
en-aut-mei=Yoshinobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=TogashiYosuke
en-aut-sei=Togashi
en-aut-mei=Yosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=HottaKatsuyuki
en-aut-sei=Hotta
en-aut-mei=Katsuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

affil-num=1
en-affil=Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Respiratory Medicine, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Respiratory Medicine, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Center for Comprehensive Genomic Medicine, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Center for Comprehensive Genomic Medicine, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Department of Respiratory Medicine, Ohara Healthcare Foundation, Kurashiki Central Hospital
kn-affil=

affil-num=7
en-affil=Department of Respiratory Medicine, NHO Iwakuni Clinical Center
kn-affil=

affil-num=8
en-affil=Department of Thoracic Oncology and Medicine, National Hospital Organization, Shikoku Cancer Center
kn-affil=

affil-num=9
en-affil=Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center
kn-affil=

affil-num=10
en-affil=Department of Respiratory Medicine, Kure Kyosai Hospital
kn-affil=

affil-num=11
en-affil=Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital
kn-affil=

affil-num=12
en-affil=Department of Chest Surgery, Shimonoseki City Hospital
kn-affil=

affil-num=13
en-affil=Department of Respiratory Medicine, Japanese Red Cross Kobe Hospital
kn-affil=

affil-num=14
en-affil=Center for Comprehensive Genomic Medicine, Okayama University Hospital
kn-affil=

affil-num=15
en-affil=Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=16
en-affil=Department of Respiratory Medicine, Okayama University Hospital
kn-affil=

affil-num=17
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=29
cd-vols=
no-issue=1
article-no=
start-page=146
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250719
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Safety and feasibility of D3 lymph node dissection in oldest-old patients undergoing colorectal cancer surgery: a multi-institutional, retrospective analysis
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background Colorectal cancer (CRC) is a significant health burden, with lymph node dissection (LND) playing a critical role in staging and guiding treatment. However, the optimal extent of LND for the oldest-old population (aged???90 years) remains undefined because of insufficient targeted clinical data. This study aimed to compare the short-term outcomes of D3 versus non-D3 LND in Stage II?III CRC in oldest-old patients.<br>
Methods This retrospective cohort study utilized data from the Setouchi Colorectal Neoplasm Registration database, including 282 oldest-old patients with CRC treated between 2011 and 2022. Patients were stratified into D3 and non-D3 LND groups, with inverse-probability-weighted regression adjustment implemented to address potential confounding factors. Postoperative complications and hospital stays were analyzed using regression models and descriptive statistics.<br>
Results D3 LND resulted in significantly higher lymph node harvests in both Stage II and Stage III patients (p?<?0.01). There were no significant differences in overall or major postoperative complications between D3 and non-D3 groups. Hospital stays were comparable for Stage II patients but shorter for Stage III patients in the D3 group (p?<?0.01). Complication rates ranged from 28% to 47.7%, with surgical site infections and pneumonia being the most common.<br>
Conclusions D3 LND can be safely performed in oldest-old patients with CRC without increasing postoperative complications or extending hospital stays. These findings support the feasibility of extensive LND in this age gr
en-copyright=
kn-copyright=

en-aut-name=InadaR.
en-aut-sei=Inada
en-aut-mei=R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TeraishiF.
en-aut-sei=Teraishi
en-aut-mei=F.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MitsuhashiT.
en-aut-sei=Mitsuhashi
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TakanagaS.
en-aut-sei=Takanaga
en-aut-mei=S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=ToshimaT.
en-aut-sei=Toshima
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=OhtaniT.
en-aut-sei=Ohtani
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=YoshidaR.
en-aut-sei=Yoshida
en-aut-mei=R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=HoriN.
en-aut-sei=Hori
en-aut-mei=N.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=ShigemitsuK.
en-aut-sei=Shigemitsu
en-aut-mei=K.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=YamamotoS.
en-aut-sei=Yamamoto
en-aut-mei=S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=KubotaT.
en-aut-sei=Kubota
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=OkanoY.
en-aut-sei=Okano
en-aut-mei=Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=NobuhisaT.
en-aut-sei=Nobuhisa
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=TaniguchiF.
en-aut-sei=Taniguchi
en-aut-mei=F.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=IshikawaW.
en-aut-sei=Ishikawa
en-aut-mei=W.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=ShojiR.
en-aut-sei=Shoji
en-aut-mei=R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=MatsudaT.
en-aut-sei=Matsuda
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=UmeokaT.
en-aut-sei=Umeoka
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=FujiwaraT.
en-aut-sei=Fujiwara
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=Setouchi Colorectal Neoplasm Registration Study Group Collaborators
en-aut-sei=Setouchi Colorectal Neoplasm Registration Study Group Collaborators
en-aut-mei=
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

affil-num=1
en-affil=Department of Surgery, Kochi Health Sciences Center
kn-affil=

affil-num=2
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Surgery, Kagawa Rosai Hospital
kn-affil=

affil-num=6
en-affil=Department of Surgery, Saiseikai Okayama Hospital
kn-affil=

affil-num=7
en-affil=Department of Surgery, Okayama Rosai Hospital
kn-affil=

affil-num=8
en-affil=Department of Surgery, Tottori Municipal Hospital
kn-affil=

affil-num=9
en-affil=Department of Surgery, Tsuyama Chuo Hospital
kn-affil=

affil-num=10
en-affil=Department of Surgery, Okayama City Hospital
kn-affil=

affil-num=11
en-affil=Department of Surgery, Kobe Red Cross Hospital
kn-affil=

affil-num=12
en-affil=Department of Surgery, Onomichi City Hospital
kn-affil=

affil-num=13
en-affil=Department of Surgery, Himeji Red Cross Hospital
kn-affil=

affil-num=14
en-affil=Department of Surgery, National Hospital Organization Iwakuni Clinical Center
kn-affil=

affil-num=15
en-affil=Department of Surgery, Fukuyama City Hospital
kn-affil=

affil-num=16
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=17
en-affil=Department of Surgery, Matsuda Hospital
kn-affil=

affil-num=18
en-affil=Department of Surgery, Matsuyama City Hospital
kn-affil=

affil-num=19
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=20
en-affil=
kn-affil=
en-keyword=Lymph node dissection
kn-keyword=Lymph node dissection
en-keyword=Colorectal cancer
kn-keyword=Colorectal cancer
en-keyword=Oldest-old patients
kn-keyword=Oldest-old patients
en-keyword=Postoperative complication
kn-keyword=Postoperative complication
END

start-ver=1.4
cd-journal=joma
no-vol=18
cd-vols=
no-issue=1
article-no=
start-page=123
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260119
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Streamlined Radiosynthesis of [18F]Fluproxadine (AF78): An Unprotected Guanidine Precursor Enables Efficient One-Step, Automation-Ready Labeling for Clinical Use
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background/Objectives: [18F]Fluproxadine (formerly [18F]AF78) is a PET radiotracer targeting the norepinephrine transporter (NET) with potential applications in cardiac, neurological, and oncological imaging. Its guanidine moiety, while essential for NET binding, presents major radiosynthetic challenges due to high basicity and the harsh deprotection conditions required for protected precursors. Previous methods relied on multistep procedures, strong acids, and complex purification, limiting clinical translation. This study aimed to develop a practical one-step radiosynthesis suitable for routine and automated production. Methods: A direct SN2-type nucleophilic [18F]fluorination was performed using an unprotected guanidine precursor to eliminate deprotection steps. Reaction parameters, including the base system, solvent composition, precursor concentration, and temperature, were optimized under conventional and microwave heating. Radiochemical conversion (RCC) and operational robustness were evaluated, and purification strategies were assessed for automation compatibility. Results: Direct [18F]fluorination using the unprotected precursor reduced the total synthesis time to 60?70 min. Optimal conditions employed a tert-butanol/acetonitrile (4:1) solvent system with K2CO3/Kryptofix222, affording RCC up to 33% under conventional heating. Microwave irradiation further improved efficiency, achieving RCC of up to 64% within 1.5 min at 140 °C. The method showed broad tolerance to variations in the base molar ratio and precursor concentration and enabled isocratic HPLC purification. Conclusions: This one-step radiosynthesis overcomes longstanding challenges in [18F]fluproxadine production by eliminating harsh deprotection and enabling high-yield, automation-ready synthesis, thereby improving clinical feasibility.
en-copyright=
kn-copyright=

en-aut-name=ChenXinyu
en-aut-sei=Chen
en-aut-mei=Xinyu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=OhtaKaito
en-aut-sei=Ohta
en-aut-mei=Kaito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KimuraHiroyuki
en-aut-sei=Kimura
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YagiYusuke
en-aut-sei=Yagi
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SasakiTakanori
en-aut-sei=Sasaki
en-aut-mei=Takanori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NoseNaoko
en-aut-sei=Nose
en-aut-mei=Naoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=AkehiMasaru
en-aut-sei=Akehi
en-aut-mei=Masaru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=YamaneTomohiko
en-aut-sei=Yamane
en-aut-mei=Tomohiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=WernerRudolf A.
en-aut-sei=Werner
en-aut-mei=Rudolf A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=HiguchiTakahiro
en-aut-sei=Higuchi
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Nuclear Medicine, Faculty of Medicine, University of Augsburg
kn-affil=

affil-num=2
en-affil=Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Agency for Health, Safety and Environment, Kyoto University
kn-affil=

affil-num=4
en-affil=Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=5
en-affil=Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=6
en-affil=Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=7
en-affil=Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=8
en-affil=Department of Molecular Imaging Research, Kobe City Medical Center General Hospital
kn-affil=

affil-num=9
en-affil=Department of Nuclear Medicine, LMU Hospital, and German Cancer Consortium (DKTK), Partner Site Munich, Ludwig-Maximilians-University of Munich
kn-affil=

affil-num=10
en-affil=Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=norepinephrine transporter
kn-keyword=norepinephrine transporter
en-keyword=positron emission tomography
kn-keyword=positron emission tomography
en-keyword=[18F]AF78
kn-keyword=[18F]AF78
en-keyword=[18F]fluproxadine
kn-keyword=[18F]fluproxadine
en-keyword=radiolabeling
kn-keyword=radiolabeling
END

start-ver=1.4
cd-journal=joma
no-vol=24
cd-vols=
no-issue=1
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260124
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=TeMPRA: advancing continuing professional development in pediatric rheumatology in Japan
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background In the context of the global shortage of pediatric rheumatologists, mid-career specialists who can play key roles in regional education, research, and clinical practice have become increasingly important. In Japan, the Team of Mid-career Pediatric Rheumatologists Alliance (TeMPRA) was founded in 2014 to support continuing professional development (CPD) and foster collaboration among mid-career pediatric rheumatologists. The aim of this study was to characterize the current status and future perspectives of the TeMPRA members.<br>
Methods In 2024, a cross-sectional, web-based survey was conducted among all 37 active members of the TeMPRA across Japan. Data were collected on career trajectories, educational roles, research activities, clinical practices, and international engagement. Categorical variables were compared using appropriate statistical tests, with a significance level of 0.05.<br>
Results Responses were obtained from 35 members (response rate: 95%). Most respondents (71%) were affiliated with university hospitals, and 60% had?>?10 years of experience in pediatric rheumatology. Compared with those working in community hospitals, respondents affiliated with university hospitals were significantly more likely to be involved in research activities (50% vs. 0%, P?=?0.0261) and global professional contributions (88% vs. 0%, P?<?0.0001). Overall, 54% of respondents were engaged in teaching students or early-career pediatric rheumatologists, while 43% were involved in clinical or basic research, most commonly focusing on juvenile idiopathic arthritis and systemic lupus erythematosus. Collectively, respondents were responsible for the care of 1,677 children with pediatric rheumatic diseases. While all respondents reported willingness to contribute to pediatric rheumatology at the regional level, 94% and 71% reported willingness to contribute at the national and global levels, respectively.<br>
Conclusions This nationwide survey highlights the substantial educational roles, research activities, and clinical practices of mid-career pediatric rheumatologists in Japan and suggests that the TeMPRA framework can serve as a valuable model for supporting CPD and workforce sustainability. Similar alliance-based approaches may be applicable in other countries facing comparable challenges in pediatric rheumatology.
en-copyright=
kn-copyright=

en-aut-name=WakiguchiHiroyuki
en-aut-sei=Wakiguchi
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HashimotoKunio
en-aut-sei=Hashimoto
en-aut-mei=Kunio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YashiroMasato
en-aut-sei=Yashiro
en-aut-mei=Masato
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NishimuraKenichi
en-aut-sei=Nishimura
en-aut-mei=Kenichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=EbatoTakasuke
en-aut-sei=Ebato
en-aut-mei=Takasuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=AkamineKeiji
en-aut-sei=Akamine
en-aut-mei=Keiji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=UejimaYoji
en-aut-sei=Uejima
en-aut-mei=Yoji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=SatoTomomi
en-aut-sei=Sato
en-aut-mei=Tomomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=YamasakiYuichi
en-aut-sei=Yamasaki
en-aut-mei=Yuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=YasumuraJunko
en-aut-sei=Yasumura
en-aut-mei=Junko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=OkazakiFumiko
en-aut-sei=Okazaki
en-aut-mei=Fumiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=KizawaToshitaka
en-aut-sei=Kizawa
en-aut-mei=Toshitaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=YasuokaRyuhei
en-aut-sei=Yasuoka
en-aut-mei=Ryuhei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=IshikawaTomoaki
en-aut-sei=Ishikawa
en-aut-mei=Tomoaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=YamamotoTakeshi
en-aut-sei=Yamamoto
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=FujitaYuji
en-aut-sei=Fujita
en-aut-mei=Yuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=ItohNaohiro
en-aut-sei=Itoh
en-aut-mei=Naohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=TakasakiAsami
en-aut-sei=Takasaki
en-aut-mei=Asami
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=SakuraiNodoka
en-aut-sei=Sakurai
en-aut-mei=Nodoka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=SuzukiKazuo
en-aut-sei=Suzuki
en-aut-mei=Kazuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=TamaiTasuku
en-aut-sei=Tamai
en-aut-mei=Tasuku
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=HiranoNaoki
en-aut-sei=Hirano
en-aut-mei=Naoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=OkamotoNami
en-aut-sei=Okamoto
en-aut-mei=Nami
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=ShimizuMasaki
en-aut-sei=Shimizu
en-aut-mei=Masaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

affil-num=1
en-affil=Division of General Pediatrics and Emergency Medicine, Department of Pediatrics, Oita University Faculty of Medicine
kn-affil=

affil-num=2
en-affil=Department of Pediatrics, Nagasaki University Graduate School of Biomedical Sciences
kn-affil=

affil-num=3
en-affil=Department of Pediatrics, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Pediatrics, Yokohama City University Graduate School of Medicine
kn-affil=

affil-num=5
en-affil=Department of Pediatrics, Kitasato University
kn-affil=

affil-num=6
en-affil=Department of Nephrology and Rheumatology, Tokyo Metropolitan Children’s Medical Center
kn-affil=

affil-num=7
en-affil=Division of Infectious Diseases and Immunology, Saitama Children’s Medical Center
kn-affil=

affil-num=8
en-affil=Clinical Education Center for Physicians, Shiga University of Medical Science
kn-affil=

affil-num=9
en-affil=Department of Pediatrics, Kagoshima University Hospital
kn-affil=

affil-num=10
en-affil=Department of Pediatrics, Hiroshima Prefectural Hospital Organization Futabanosato Prefectural Hospital
kn-affil=

affil-num=11
en-affil=Department of Pediatrics, Yamaguchi University Graduate School of Medicine
kn-affil=

affil-num=12
en-affil=Department of Pediatrics, Japan Community Health Care Organization Sapporo Hokushin Hospital
kn-affil=

affil-num=13
en-affil=Department of Pediatrics, Hamamatsu University School of Medicine
kn-affil=

affil-num=14
en-affil=Department of Pediatrics, Nara Medical University
kn-affil=

affil-num=15
en-affil=Department of Pediatrics, Chiba University Graduate School of Medicine
kn-affil=

affil-num=16
en-affil=Department of Pediatrics, Dokkyo Medical University
kn-affil=

affil-num=17
en-affil=Department of Pediatrics, Faculty of Medical Sciences, University of Fukui
kn-affil=

affil-num=18
en-affil=Department of Pediatrics, School of Medicine, University of Toyama
kn-affil=

affil-num=19
en-affil=Department of Pediatrics, NTT East Medical Center Sapporo
kn-affil=

affil-num=20
en-affil=Suzuki Kids Clinic
kn-affil=

affil-num=21
en-affil=Division of General Pediatrics and Emergency Medicine, Department of Pediatrics, Oita University Faculty of Medicine
kn-affil=

affil-num=22
en-affil=Department of Public Health and Epidemiology, Faculty of Medicine, Oita University
kn-affil=

affil-num=23
en-affil=Department of Pediatrics, Osaka Rosai Hospital, Japan Organization of Occupational Health and Safety
kn-affil=

affil-num=24
en-affil=Department of Pediatrics, Perinatal and Maternal Medicine, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo
kn-affil=
en-keyword=Child
kn-keyword=Child
en-keyword=Education
kn-keyword=Education
en-keyword=Juvenile idiopathic arthritis
kn-keyword=Juvenile idiopathic arthritis
en-keyword=Practice
kn-keyword=Practice
en-keyword=Rheumatic diseases
kn-keyword=Rheumatic diseases
en-keyword=Systemic lupus erythematosus
kn-keyword=Systemic lupus erythematosus
en-keyword=Team of mid-career pediatric rheumatologists alliance
kn-keyword=Team of mid-career pediatric rheumatologists alliance
END

start-ver=1.4
cd-journal=joma
no-vol=9
cd-vols=
no-issue=6
article-no=
start-page=1128
end-page=1136
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250531
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Surgery for Older Cancer Patients: Cross‐Organ Review and Good Practice Statement by the Japanese Geriatric Oncology Guideline Committee
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Although the number of older people is increasing, there is a lack of evidence and insufficient consensus regarding postoperative complications and survival in older cancer patients. In this study, we conducted a literature search and systematic review focusing on the outcomes after surgery for older cancer patients.<br>
Methods: Literature focusing on surgical treatment for older cancer patients was extracted from Japanese clinical practice guidelines for gastric cancer, lung cancer, colorectal cancer, liver cancer, and gynecological cancers (uterine body, uterine cervix, ovary, and external genitalia and vagina). Outcomes were reviewed, and committee members determined the strength of evidence on a four-point scale (A to D), with A being the highest and D being the lowest.<br>
Results: Older cancer patients tend to have a higher incidence of postoperative complications and postoperative syndromes, and their expected survival is generally shorter compared to non-older patients. When extensive surgeries such as para-aortic lymph node dissection and/or resection with other organs are performed for older cancer patients, the postoperative mortality rates tend to increase compared to non-older patients.<br>
Conclusion: Surgical treatments for older cancer patients tend to result in higher morbidity even when the patients are in good health status. Nevertheless, there is still a possibility that a certain fraction of the patients achieve treatment outcomes comparable to those of non-older patients. Therefore, surgical indication and procedure for older cancer patients should be carefully determined based on surgical invasiveness and patient tolerability.
en-copyright=
kn-copyright=

en-aut-name=TanakaChie
en-aut-sei=Tanaka
en-aut-mei=Chie
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=OfuchiTakashi
en-aut-sei=Ofuchi
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NinomiyaKiichiro
en-aut-sei=Ninomiya
en-aut-mei=Kiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=InoueDaisuke
en-aut-sei=Inoue
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SugimotoKen
en-aut-sei=Sugimoto
en-aut-mei=Ken
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MurofushiKeiko
en-aut-sei=Murofushi
en-aut-mei=Keiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=OkuyamaToru
en-aut-sei=Okuyama
en-aut-mei=Toru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=WatanukiShigeaki
en-aut-sei=Watanuki
en-aut-mei=Shigeaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=ImamuraChiyo
en-aut-sei=Imamura
en-aut-mei=Chiyo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=SakaiDaisuke
en-aut-sei=Sakai
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=SakuraiNaomi
en-aut-sei=Sakurai
en-aut-mei=Naomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=WatanabeKiyotaka
en-aut-sei=Watanabe
en-aut-mei=Kiyotaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=TamuraKazuo
en-aut-sei=Tamura
en-aut-mei=Kazuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=SaekiToshiaki
en-aut-sei=Saeki
en-aut-mei=Toshiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=IshiguroHiroshi
en-aut-sei=Ishiguro
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

affil-num=1
en-affil=Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine
kn-affil=

affil-num=2
en-affil=Department of Surgery, Kyushu University Beppu Hospital
kn-affil=

affil-num=3
en-affil=Center for Comprehensive Genomic Medicine, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Obstetrics and Gynecology, University of Fukui
kn-affil=

affil-num=5
en-affil=Department of General Geriatric Medicine, Kawasaki Medical School
kn-affil=

affil-num=6
en-affil=Division of Radiation Oncology, Department of Radiology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
kn-affil=

affil-num=7
en-affil=Department of Psychiatry/Palliative Care Center, Nagoya City University West Medical Center
kn-affil=

affil-num=8
en-affil=National Center for Global Health and Medicine, National College of Nursing
kn-affil=

affil-num=9
en-affil=Advanced Cancer Translational Research Institute, Showa University
kn-affil=

affil-num=10
en-affil=Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine
kn-affil=

affil-num=11
en-affil=Cancer Solutions Co. Ltd
kn-affil=

affil-num=12
en-affil=Division of Medical Oncology, Department of Medicine, School of Medicine, Teikyo University
kn-affil=

affil-num=13
en-affil=NPO Clinical Hematology/Oncology Treatment Study Group
kn-affil=

affil-num=14
en-affil=Breast Oncology Service, Saitama Medical University International Medical Center
kn-affil=

affil-num=15
en-affil=Breast Oncology Service, Saitama Medical University International Medical Center
kn-affil=
en-keyword=cancer
kn-keyword=cancer
en-keyword=older patients
kn-keyword=older patients
en-keyword=surgery
kn-keyword=surgery
END

start-ver=1.4
cd-journal=joma
no-vol=27
cd-vols=
no-issue=
article-no=
start-page=53
end-page=64
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202601
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Sixteen-Year Chronicle of Service as Mayor of Setouchi City
kn-title=瀬戸内市長としての16年間のあゆみ ― 市長の意思決定 ―
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=TAKEHISAAkinari
en-aut-sei=TAKEHISA
en-aut-mei=Akinari
kn-aut-name=武久顕也
kn-aut-sei=武久
kn-aut-mei=顕也
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=前瀬戸内市長
END

start-ver=1.4
cd-journal=joma
no-vol=27
cd-vols=
no-issue=
article-no=
start-page=1
end-page=51
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202601
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Current situation and issues of core organization in Adult Gurdianship System
kn-title=成年後見制度　〜中核機関の現状と課題〜
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=NISHIDAKazuhiro
en-aut-sei=NISHIDA
en-aut-mei=Kazuhiro
kn-aut-name=西田和弘
kn-aut-sei=西田
kn-aut-mei=和弘
aut-affil-num=1
ORCID=

en-aut-name=NISHIYAMAMika
en-aut-sei=NISHIYAMA
en-aut-mei=Mika
kn-aut-name=西山三佳
kn-aut-sei=西山
kn-aut-mei=三佳
aut-affil-num=2
ORCID=

en-aut-name=NAGASHIOAyaka
en-aut-sei=NAGASHIO
en-aut-mei=Ayaka
kn-aut-name=長塩彩香
kn-aut-sei=長塩
kn-aut-mei=彩香
aut-affil-num=3
ORCID=

en-aut-name=YOSHIOKAKyosuke
en-aut-sei=YOSHIOKA
en-aut-mei=Kyosuke
kn-aut-name=吉岡亨祐
kn-aut-sei=吉岡
kn-aut-mei=亨祐
aut-affil-num=4
ORCID=

en-aut-name=IMAITomono
en-aut-sei=IMAI
en-aut-mei=Tomono
kn-aut-name=今井友乃
kn-aut-sei=今井
kn-aut-mei=友乃
aut-affil-num=5
ORCID=

en-aut-name=MIZUTAYuji
en-aut-sei=MIZUTA
en-aut-mei=Yuji
kn-aut-name=水田雄二
kn-aut-sei=水田
kn-aut-mei=雄二
aut-affil-num=6
ORCID=

en-aut-name=UCHIDADaisuke
en-aut-sei=UCHIDA
en-aut-mei=Daisuke
kn-aut-name=内田大介
kn-aut-sei=内田
kn-aut-mei=大介
aut-affil-num=7
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学大学院法務研究科

affil-num=2
en-affil=Okayama City Adult Gurdianship Center Case
kn-affil=岡山市社会福祉協議会岡山市成年後見センター

affil-num=3
en-affil=Okayama City Adult Gurdianship Center Case
kn-affil=岡山市社会福祉協議会岡山市成年後見センター

affil-num=4
en-affil=Soja City Case
kn-affil=総社市社会福祉協議会

affil-num=5
en-affil=Chita Area Avocacy Center Case
kn-affil=知多地域権利擁護支援センター

affil-num=6
en-affil=Oda City Case
kn-affil=大田市社会福祉協議会大田市成年後見センター

affil-num=7
en-affil=Oda City Case
kn-affil=大田市介護保険課
END

start-ver=1.4
cd-journal=joma
no-vol=59
cd-vols=
no-issue=
article-no=
start-page=101740
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202506
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Evaluation of platinum-free interval and chemotherapeutic effect of subsequent platinum-containing chemotherapy in patients with recurrent ovarian cancer initially treated with bevacizumab: SGSG018/Intergroup study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Objective: The effect of bevacizumab on platinum sensitivity in recurrent ovarian cancer remains poorly understood. This study examined the association between platinum-free interval (PFI) and sensitivity to subsequent platinum-containing chemotherapy in patients with first relapsed ovarian cancer after bevacizumab chemotherapy.<br>
Methods: We retrospectively analyzed patients who received platinum-based chemotherapy for platinum-sensitive recurrence between November 2013, and December 2019, and who were initially treated by platinum-based chemotherapy with concurrent and maintenance bevacizumab. The primary endpoint was response rate to subsequent chemotherapy after various periods of PFI. The relevance between response rate and PFI was assessed for each PFI of 6?12, 12?24 and ≧24 months using Cochran-Armitage test. The secondary endpoint was progression-free survival (PFS) defined as time from chemotherapy for first recurrence to subsequent progression and response rate to subsequent chemotherapy for each treatment-free interval since last administration of bevacizumab (Bev-TFI).<br>
Results: A total of 77 patients were eligible. The median PFI until first recurrence was 12 months (range: 6?43). The response rates of subsequent chemotherapy for patients with PFI of 6?12, ?12-24, and 24 months were 42 %, 65 %, and 80 %, showing a linear trend (p < 0.05). Median PFS among the three groups was 8 (95 %CI: 6.7?9.2), 11 (95 %CI: 8.4?13.5) and 13 months (95 % CI: 5.4?20.5) (p = 0.107, log-rank test), respectively. By contrast, no linear trend was observed between Bev-TFI and response rate (p = 0.225)<br>
Conclusion: In patients with first relapse of primary ovarian cancer and bevacizumab beyond progression, the prolonged PFS effect of bevacizumab does not seem to affect sensitivity to subsequent platinum-based chemotherapy.
en-copyright=
kn-copyright=

en-aut-name=TanakaTamaki
en-aut-sei=Tanaka
en-aut-mei=Tamaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TakeharaKazuhiro
en-aut-sei=Takehara
en-aut-mei=Kazuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=UsamiTomoka
en-aut-sei=Usami
en-aut-mei=Tomoka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=IshikawaMasako
en-aut-sei=Ishikawa
en-aut-mei=Masako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KondoEiji
en-aut-sei=Kondo
en-aut-mei=Eiji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KagabuMasahiro
en-aut-sei=Kagabu
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=HirabayashiKei
en-aut-sei=Hirabayashi
en-aut-mei=Kei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=MatsumuraNoriomi
en-aut-sei=Matsumura
en-aut-mei=Noriomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=SatoShinya
en-aut-sei=Sato
en-aut-mei=Shinya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=NishimuraMasato
en-aut-sei=Nishimura
en-aut-mei=Masato
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=ArakawaAtsushi
en-aut-sei=Arakawa
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=NakamuraKeiichiro
en-aut-sei=Nakamura
en-aut-mei=Keiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=KonnoYosuke
en-aut-sei=Konno
en-aut-mei=Yosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=FujiwaraSatoe
en-aut-sei=Fujiwara
en-aut-mei=Satoe
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=SueokaKotaro
en-aut-sei=Sueoka
en-aut-mei=Kotaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=NakamuraHiroko
en-aut-sei=Nakamura
en-aut-mei=Hiroko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=KohIemasa
en-aut-sei=Koh
en-aut-mei=Iemasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=ItoKimihiko
en-aut-sei=Ito
en-aut-mei=Kimihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=HongoAtsushi
en-aut-sei=Hongo
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

affil-num=1
en-affil=Department of Perinatology and Gynecology, Kagawa University Graduate School of Medicine
kn-affil=

affil-num=2
en-affil=Department of Gynecologic Oncology, NHO Shikoku Cancer Center
kn-affil=

affil-num=3
en-affil=Department of Obstetrics and Gynecology, Ehime University Graduate School of Medicine
kn-affil=

affil-num=4
en-affil=Department of Obstetrics and Gynecology, Shimane University Faculty of Medicine
kn-affil=

affil-num=5
en-affil=Department of Obstetrics and Gynecology, Mie University Graduate School of Medicine
kn-affil=

affil-num=6
en-affil=Department of Obstetrics and Gynecology, Iwate Medical University
kn-affil=

affil-num=7
en-affil=Department of Obstetrics and Gynecology, JCHO Tokuyama Central Hospital
kn-affil=

affil-num=8
en-affil=Department of Obstetrics and Gynecology, Kindai University Faculty of Medicine
kn-affil=

affil-num=9
en-affil=Department of Obstetrics and Gynecology, Faculty of Medicine Tottori University
kn-affil=

affil-num=10
en-affil=Department of Obstetrics and Gynecology, Tokushima Prefectural Central Hospital
kn-affil=

affil-num=11
en-affil=Department of Obstetrics and Gynecology, Nagoya City University West Medical Center
kn-affil=

affil-num=12
en-affil=Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=13
en-affil=Department of Obstetrics and Gynecology, Hokkaido University Hospital
kn-affil=

affil-num=14
en-affil=Department of Obstetrics and Gynecology, Osaka Medical and Pharmaceutical University
kn-affil=

affil-num=15
en-affil=Department of Obstetrics and Gynecology, Yamaguchi University Graduate School of Medicine
kn-affil=

affil-num=16
en-affil=Department of Obstetrics and Gynecology, NHO Kure Medical Center and Chugoku Cancer Center
kn-affil=

affil-num=17
en-affil=Department of Obstetrics and Gynecology, Graduate School of Biomedical Sciences, Hiroshima University
kn-affil=

affil-num=18
en-affil=Department of Obstetrics and Gynecology, Kansai Rosai Hospital
kn-affil=

affil-num=19
en-affil=Department of Obstetrics and Gynecology, Kansai Rosai Hospital
kn-affil=
en-keyword=Ovarian cancer
kn-keyword=Ovarian cancer
en-keyword=Bevacizumab
kn-keyword=Bevacizumab
en-keyword=Chemotherapy
kn-keyword=Chemotherapy
en-keyword=Platinum-sensitive relapse
kn-keyword=Platinum-sensitive relapse
en-keyword=Platinum-free interval
kn-keyword=Platinum-free interval
END

start-ver=1.4
cd-journal=joma
no-vol=8
cd-vols=
no-issue=2
article-no=
start-page=606
end-page=608
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=2025
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A Case of Hepatocellular Carcinoma Associated with Hepatic Sarcoidosis
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=NagaiYasuo
en-aut-sei=Nagai
en-aut-mei=Yasuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TakagiKosei
en-aut-sei=Takagi
en-aut-mei=Kosei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YasuiKazuya
en-aut-sei=Yasui
en-aut-mei=Kazuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KariyamaKazuya
en-aut-sei=Kariyama
en-aut-mei=Kazuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=FujiTomokazu
en-aut-sei=Fuji
en-aut-mei=Tomokazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=FujiwaraToshiyoshi
en-aut-sei=Fujiwara
en-aut-mei=Toshiyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Gastroenterology, Okayama City Hospital
kn-affil=

affil-num=5
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=
en-keyword=hepatocellular carcinoma
kn-keyword=hepatocellular carcinoma
en-keyword=hepatic sarcoidosis
kn-keyword=hepatic sarcoidosis
en-keyword=peritoneal sarcoidosis
kn-keyword=peritoneal sarcoidosis
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=
article-no=
start-page=103078
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202502
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): long-term results of a multicentre, single-arm, phase 2 trial
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background Intravascular large B-cell lymphoma (IVLBCL) is a rare type of extranodal large B-cell lymphoma for which prognosis is typically poor without a timely diagnosis. To explore the safety and efficacy of standard chemotherapy combined with central nervous system (CNS)-directed therapy, we conducted a multicentre, single-arm, phase 2 trial in untreated IVLBCL patients without CNS involvement at diagnosis (PRIMEUR-IVL). In the primary analysis, the PRIMEUR-IVL study demonstrated 2-year progression-free survival (PFS) of 76% and 2-year overall survival (OS) of 92% with a low incidence (3%) of secondary CNS involvement (sCNSi).<br>
Methods We present a prespecified final analysis of the PRIMEUR-IVL study including 5-year PFS, OS and cumulative incidence of sCNSi. Participants were enrolled between June 2011 and July 2016, and the data cutoff date for the final analysis was 16 November 2021. The trial was registered in the UMIN Clinical Trial Registry (UMIN000005707) and the Japan Registry of Clinical Trials (jRCTs041180165).<br>
Findings With a median follow-up of 7.1 years (interquartile range 5.6?8.7), 5-year PFS in all 37 eligible patients was 68% (95% confidence interval [CI] 50%?80%) and OS was 78% (95% CI 61%?89%). No additional sCNSi was observed after the primary analysis. Severe adverse events after the primary analysis were grade 4 neutropenia (n = 1) and grade 4 myelodysplastic syndrome that did not require specific treatment (n = 1). Eight deaths occurred during the observation period after enrolment, due to primary disease (n = 6), sepsis (n = 1) and unknown sudden death (n = 1).<br>
Interpretation Long-term follow-up data demonstrated durable response for PFS and OS, and low cumulative incidence of sCNSi, indicating the efficacy of standard chemotherapy combined with CNS-directed therapy for untreated IVLBCL patients.<br>
Funding This study received financial support from the Japan Agency for Medical Research and Development, Center for Supporting Hematology-Oncology Studies, and National Cancer Center.
en-copyright=
kn-copyright=

en-aut-name=ShimadaKazuyuki
en-aut-sei=Shimada
en-aut-mei=Kazuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YamaguchiMotoko
en-aut-sei=Yamaguchi
en-aut-mei=Motoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KuwatsukaYachiyo
en-aut-sei=Kuwatsuka
en-aut-mei=Yachiyo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MatsueKosei
en-aut-sei=Matsue
en-aut-mei=Kosei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SatoKeijiro
en-aut-sei=Sato
en-aut-mei=Keijiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KusumotoShigeru
en-aut-sei=Kusumoto
en-aut-mei=Shigeru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NagaiHirokazu
en-aut-sei=Nagai
en-aut-mei=Hirokazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=TakizawaJun
en-aut-sei=Takizawa
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=FukuharaNoriko
en-aut-sei=Fukuhara
en-aut-mei=Noriko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=NagafujiKoji
en-aut-sei=Nagafuji
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=MiyazakiKana
en-aut-sei=Miyazaki
en-aut-mei=Kana
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=OhtsukaEiichi
en-aut-sei=Ohtsuka
en-aut-mei=Eiichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=OkamotoAkinao
en-aut-sei=Okamoto
en-aut-mei=Akinao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=SugitaYasumasa
en-aut-sei=Sugita
en-aut-mei=Yasumasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=UchidaToshiki
en-aut-sei=Uchida
en-aut-mei=Toshiki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=KayukawaSatoshi
en-aut-sei=Kayukawa
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=WakeAtsushi
en-aut-sei=Wake
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=EnnishiDaisuke
en-aut-sei=Ennishi
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=KondoYukio
en-aut-sei=Kondo
en-aut-mei=Yukio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=MeguroAkiko
en-aut-sei=Meguro
en-aut-mei=Akiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=KinYoshihiro
en-aut-sei=Kin
en-aut-mei=Yoshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=MinamiYosuke
en-aut-sei=Minami
en-aut-mei=Yosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=HashimotoDaigo
en-aut-sei=Hashimoto
en-aut-mei=Daigo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=NishiyamaTakahiro
en-aut-sei=Nishiyama
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=ShimadaSatoko
en-aut-sei=Shimada
en-aut-mei=Satoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=MasakiYasufumi
en-aut-sei=Masaki
en-aut-mei=Yasufumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

en-aut-name=OkamotoMasataka
en-aut-sei=Okamoto
en-aut-mei=Masataka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=27
ORCID=

en-aut-name=AtsutaYoshiko
en-aut-sei=Atsuta
en-aut-mei=Yoshiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=28
ORCID=

en-aut-name=KiyoiHitoshi
en-aut-sei=Kiyoi
en-aut-mei=Hitoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=29
ORCID=

en-aut-name=SuzukiRitsuro
en-aut-sei=Suzuki
en-aut-mei=Ritsuro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=30
ORCID=

en-aut-name=NakamuraShigeo
en-aut-sei=Nakamura
en-aut-mei=Shigeo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=31
ORCID=

en-aut-name=KinoshitaTomohiro
en-aut-sei=Kinoshita
en-aut-mei=Tomohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=32
ORCID=

affil-num=1
en-affil=Department of Hematology and Oncology, Nagoya University Graduate School of Medicine
kn-affil=

affil-num=2
en-affil=Department of Hematological Malignancies, Mie University Graduate School of Medicine
kn-affil=

affil-num=3
en-affil=Department of Advanced Medicine, Nagoya University Hospital
kn-affil=

affil-num=4
en-affil=Division of Hematology/Oncology, Internal Medicine, Kameda Medical Center
kn-affil=

affil-num=5
en-affil=Department of Hematology, Nagano Red Cross Hospital
kn-affil=

affil-num=6
en-affil=Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences
kn-affil=

affil-num=7
en-affil=Department of Hematology, National Hospital Organization Nagoya Medical Center
kn-affil=

affil-num=8
en-affil=Department of Hematology, Endocrinology and Metabolism, Niigata University Faculty of Medicine
kn-affil=

affil-num=9
en-affil=Department of Hematology and Rheumatology, Tohoku University Hospital
kn-affil=

affil-num=10
en-affil=Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine
kn-affil=

affil-num=11
en-affil=Department of Hematology and Oncology, Mie University Graduate School of Medicine
kn-affil=

affil-num=12
en-affil=Department of Hematology, Oita Prefectural Hospital
kn-affil=

affil-num=13
en-affil=Department of Hematology, Fujita Health University School of Medicine
kn-affil=

affil-num=14
en-affil=Department of Hematology, Oami Municipal Hospital
kn-affil=

affil-num=15
en-affil=Department of Hematology and Oncology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital
kn-affil=

affil-num=16
en-affil=Department of Clinical Oncology, Nagoya Memorial Hospital
kn-affil=

affil-num=17
en-affil=Department of Hematology, Toranomon Hospital Kajigaya
kn-affil=

affil-num=18
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=19
en-affil=Department of Internal Medicine, Toyama Prefectural Central Hospital
kn-affil=

affil-num=20
en-affil=Division of Hematology, Tochigi Cancer Center
kn-affil=

affil-num=21
en-affil=Department of Hematology, Daini Osaka Police Hospital
kn-affil=

affil-num=22
en-affil=Department of Hematology, National Cancer Center Hospital East
kn-affil=

affil-num=23
en-affil=Department of Hematology, Hokkaido University Faculty of Medicine, Graduate School of Medicine
kn-affil=

affil-num=24
en-affil=Division of Hematology, Ichinomiya Municipal Hospital
kn-affil=

affil-num=25
en-affil=Department of Pathology and Clinical Laboratories, Nagoya University Hospital
kn-affil=

affil-num=26
en-affil=Department of Hematology and Immunology, Kanazawa Medical University
kn-affil=

affil-num=27
en-affil=Department of Hematology, Fujita Health University School of Medicine
kn-affil=

affil-num=28
en-affil=Japanese Data Center for Hematopoietic Cell Transplantation
kn-affil=

affil-num=29
en-affil=Department of Hematology and Oncology, Nagoya University Graduate School of Medicine
kn-affil=

affil-num=30
en-affil=Department of HSCT Data Management and Biostatistics, Nagoya University School of Medicine
kn-affil=

affil-num=31
en-affil=Department of Pathology and Clinical Laboratories, Nagoya University Hospital
kn-affil=

affil-num=32
en-affil=Department of Hematology and Cell Therapy, Aichi Cancer Center
kn-affil=
en-keyword=Central nervous system-directed therapy
kn-keyword=Central nervous system-directed therapy
en-keyword=Intravascular large B-Cell lymphoma
kn-keyword=Intravascular large B-Cell lymphoma
en-keyword=R-CHOP
kn-keyword=R-CHOP
en-keyword=Secondary central nervous system involvement
kn-keyword=Secondary central nervous system involvement
END

start-ver=1.4
cd-journal=joma
no-vol=15
cd-vols=
no-issue=5
article-no=
start-page=1877
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260228
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Effect of Surgical Procedures for Rheumatoid Forefoot Deformities on Radiographic Foot Length and Width Variations
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: The number of patients with rheumatoid arthritis (RA) undergoing forefoot arthroplasty has increased to better control the disease. Despite patients frequently expressing concerns regarding postoperative foot appearance and footwear-related expectations, no study has investigated postoperative changes in foot length and width in patients with RA. The aim of this study was to evaluate the effect of surgical procedures for rheumatoid forefoot deformities on variations in radiologically determined foot length and width. Methods: In total, 72 feet of 50 women and 3 men (average age: 66.7 years) underwent joint-preserving arthroplasty (n = 33) and arthrodesis of the first metatarsophalangeal joint with shortening osteotomy of the lesser metatarsals or resection arthroplasty of the lesser metatarsal heads (n = 39); procedures were carried out in our institute from August 2013 to February 2020. The mean disease duration was 23.5 years, and the average follow-up period was 17.5 months. Pre- and postoperative hallux valgus angle (HVA), intermetatarsal angle (IMA) of the first and second metatarsals (M1M2A), and IMA of the first and fifth metatarsals (M1M5A) were measured on weightbearing radiographs as well as foot length and width. We also evaluated the correlation between changes in radiographic parameters and variations in radiologically determined foot length and width. Results: Radiologically determined foot width changed significantly from 10.1 cm to 9.7 cm (p < 0.01), while no significant difference was found between pre- and postoperative radiologically determined foot length. HVA, M1M2A, and M1M5A were significantly improved after the surgery (p < 0.01, p < 0.01, and p < 0.01, respectively). A significant negative correlation was found between the variation in radiologically determined foot length and changes in HVA (r = ?0.29, p = 0.02) and M1M5A (r = ?0.23, p < 0.05), while a significant positive correlation was found between the variation in the foot width and changes in HVA (r = 0.34, p < 0.01), M1M2A (r = 0.55, p < 0.01), and M1M5A (r = 0.45, p < 0.01). There were no significant differences between operative procedures regarding variation in radiologically determined foot length and width. Conclusions: Surgical procedure for rheumatoid forefoot deformity improved radiographic parameters and reduced radiographic foot width while maintaining foot length.
en-copyright=
kn-copyright=

en-aut-name=HoritaMasahiro
en-aut-sei=Horita
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KisoYohei
en-aut-sei=Kiso
en-aut-mei=Yohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NasuYoshihisa
en-aut-sei=Nasu
en-aut-mei=Yoshihisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NakaharaRyuichi
en-aut-sei=Nakahara
en-aut-mei=Ryuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SaigaKenta
en-aut-sei=Saiga
en-aut-mei=Kenta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=OzakiToshifumi
en-aut-sei=Ozaki
en-aut-mei=Toshifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NishidaKeiichiro
en-aut-sei=Nishida
en-aut-mei=Keiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Department of Orthopaedic Surgery, Faculty of Medical Development Field, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Orthopaedic Surgery, Kurashiki Sweet Hospital
kn-affil=

affil-num=3
en-affil=Department of Orthopaedic Surgery, Okayama City Hospital
kn-affil=

affil-num=4
en-affil=Department of Musculoskeletal Health Promotion, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=5
en-affil=Department of Sports Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=6
en-affil=Department of Orthopaedic Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=7
en-affil=Locomotive Pain Center, Faculty of Medical Development Field, Okayama University
kn-affil=
en-keyword=forefoot surgery
kn-keyword=forefoot surgery
en-keyword=foot length
kn-keyword=foot length
en-keyword=foot width
kn-keyword=foot width
en-keyword=rheumatoid arthritis
kn-keyword=rheumatoid arthritis
END

start-ver=1.4
cd-journal=joma
no-vol=6
cd-vols=
no-issue=1
article-no=
start-page=96
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260109
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Effects of an oral exercise intervention on pre-frailty or frailty in older people: a randomized clinical trial
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Frailty is often experienced by older adults, which can lead to long-term health problems. We aimed to examine associations with improvements in nutritional status, sarcopenia (age-related loss of skeletal muscle mass and strength), and frailty in four groups with different oral exercise frequencies.<br>
Methods: We conducted a prospective, parallel multi-arm randomized controlled trial (Japan Registry of Clinical Trials (jRCT) 1062210063) to test the effects of oral exercise on frailty in older adults. Each intervention consisted of a standardized oral exercise protocol including neck exercises, lip exercises, and tongue movements, designed to improve oral function and reduce frailty. The primary outcome was the change in the number of frailty criteria from baseline to follow-up. Individuals aged ?60 years were screened for frailty status using standardized criteria at the Department of Preventive Dentistry at Okayama University Hospital between October 2022 and December 2023. Those identified as pre-frailty or frailty were eligible and enrolled in the study. After screening 60 individuals, 58 eligible participants were randomly assigned using block randomization to one of four oral exercise frequency groups: 3 times/day & everyday, 3 times/day & 3 days/week, once/day & everyday, and once/day & 3 days/week. A two-way repeated measures analysis of variance was used to evaluate the impact of the four frequencies of oral exercise methods on frailty in older adults. Outcome assessors were blinded; participants were not.<br>
Results: Here we show the results of the 58 participants. Group sizes are: 3 times/day & everyday (n?=?14), 3 times/day & 3 days/week (n?=?15), once/day & everyday (n?=?14), once/day & 3 days/week (n?=?15). The trial is completed as planned, and all randomized participants are analyzed. The main effect of time is significant for the number of frailty criteria (F?=?14.803, p?<?0.001, partial eta squared = 0.215). The mean changes from baseline to follow-up are ?0.357 (95% Confidence Interval ?0.787 to 0.073) in the 3 times/day & everyday group, ?0.600 (95% Confidence Interval ?1.255 to 0.055) in the 3 times/day & 3 days/week group, ?0.571 (95% Confidence Interval ?1.379 to 0.236) in the once/day & everyday group, and ?0.600 (95% Confidence Interval ?1.008 to ?0.192) in the once/day & 3 days/week group. The main effect of time is also significant for the number of oral hypofunction criteria (F?=?16.456, p?<?0.001, partial eta squared = 0.234). No important adverse events or side effects related to the intervention were observed.<br>
Conclusions: After conducting oral exercises for 3 months on older adults with pre-frailty or frailty, improvements in frailty are observed. Overall, these exercises could be a simple, low-cost way to support healthy aging in the community.
en-copyright=
kn-copyright=

en-aut-name=TakeuchiNoriko
en-aut-sei=Takeuchi
en-aut-mei=Noriko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SawadaNanami
en-aut-sei=Sawada
en-aut-mei=Nanami
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=InadaSakura
en-aut-sei=Inada
en-aut-mei=Sakura
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MoritaManabu
en-aut-sei=Morita
en-aut-mei=Manabu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=EkuniDaisuke
en-aut-sei=Ekuni
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

affil-num=1
en-affil=Department of Preventive Dentistry, Division of Dentistry, Medical Development Field, Okayama University
kn-affil=

affil-num=2
en-affil=Section of Preventive and Public Health Dentistry, Division of Oral Health, Growth and Development, Faculty of Dental Science, Kyushu University
kn-affil=

affil-num=3
en-affil=Division of Health Promotion, Okayama-City Health Center
kn-affil=

affil-num=4
en-affil=Department of Oral Health Sciences, Faculty of Health Care Sciences, Takarazuka University of Medical and Health Care
kn-affil=

affil-num=5
en-affil=Department of Preventive Dentistry, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=18
cd-vols=
no-issue=1
article-no=
start-page=e100872
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260105
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Saliva as a Reliable and Non-invasive Sample for Detecting Influenza A in Severe Acute Respiratory Infection Cases
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background<br>
Nasopharyngeal swab sampling remains the gold standard for influenza diagnosis; however, it has several limitations, including dependence on medical staff, invasiveness, potential for nosocomial transmission, and occupational exposure risk. Non-invasive alternatives, such as saliva and nasal vestibular swabs, may improve patient comfort and participation in clinical studies. In addition, diagnosis with reverse transcription real-time quantitative polymerase chain reaction (RT-qPCR) is often delayed because it requires trained laboratory technicians and facilities with appropriate laboratory settings. Although rapid diagnostic devices such as the GenPad? offer potential alternatives to RT-qPCR, their performance with non-invasive samples remains insufficiently explored. This study addresses the two key questions for influenza detection in severe acute respiratory infection (SARI) cases: (i) whether saliva or nasal vestibular swab samples serve as suitable alternatives to nasopharyngeal swab samples, and (ii) whether the GenPad? provides a reliable option for detecting influenza using saliva samples.<br>
Methodology<br>
A prospective observational study was conducted with 16 inpatients classified as having SARIs and diagnosed with influenza between December 2024 and March 2025 in Japan. Paired saliva and nasal vestibular swab samples were collected 1-9 (median = 3.5) days after symptom onset. RT-qPCR testing was performed according to the National Institute of Infectious Diseases protocol. Saliva samples were also tested using the GenPad? system. Comparisons between sample types and diagnostic methods were analyzed using the exact McNemar's test.<br>
Results<br>
Among the 16 influenza-positive patients, saliva samples demonstrated higher sensitivity (87.5%) than nasal vestibular swabs (31.3%) in RT-qPCR when compared with the diagnostic results obtained from nasopharyngeal swabs. A comparison of RT-qPCR results between saliva and nasal vestibular swabs revealed a total agreement of 43.8%, with exact McNemar's test showing a significant difference (p = 0.0039). While nasal vestibular swabs showed inconsistent results, saliva samples consistently tested positive, particularly within seven days of symptom onset (100% positive agreement). The GenPad?, a rapid diagnostic device, showed promising performance (92.9%) using saliva samples compared to RT-qPCR.<br>
Conclusions<br>
Saliva is a reliable non-invasive alternative to nasopharyngeal swabs for influenza detection in SARI cases, particularly within seven days of symptom onset, whereas nasal vestibular swabs show lower sensitivity. Additionally, the GenPad? provides comparable performance to RT-qPCR using saliva samples, offering a rapid, portable diagnostic option. These approaches may mitigate discomfort, minimize infection risk for healthcare workers, and improve testing capacity. However, the absence of influenza-negative controls and the small sample size (n = 16) substantially limit the assessment of diagnostic accuracy and specificity. As a result, the broader applicability of our findings should be interpreted with caution, and further studies are required to validate these observations.
en-copyright=
kn-copyright=

en-aut-name=TakeuchiJunko S
en-aut-sei=Takeuchi
en-aut-mei=Junko S
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MatsunagaNobuaki
en-aut-sei=Matsunaga
en-aut-mei=Nobuaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TsukadaAi
en-aut-sei=Tsukada
en-aut-mei=Ai
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=IwamotoNoriko
en-aut-sei=Iwamoto
en-aut-mei=Noriko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=FuwaNoriko
en-aut-sei=Fuwa
en-aut-mei=Noriko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=IchikawaTakahiro
en-aut-sei=Ichikawa
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KatoYasuyuki
en-aut-sei=Kato
en-aut-mei=Yasuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=TomitaYuka
en-aut-sei=Tomita
en-aut-mei=Yuka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=KitagawaHiroki
en-aut-sei=Kitagawa
en-aut-mei=Hiroki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=YamatoMasaya
en-aut-sei=Yamato
en-aut-mei=Masaya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=AoyagiTetsuji
en-aut-sei=Aoyagi
en-aut-mei=Tetsuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=HagiyaHideharu
en-aut-sei=Hagiya
en-aut-mei=Hideharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=HaseRyota
en-aut-sei=Hase
en-aut-mei=Ryota
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=HatakeyamaShuji
en-aut-sei=Hatakeyama
en-aut-mei=Shuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=InabaTohru
en-aut-sei=Inaba
en-aut-mei=Tohru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=IzumikawaKoichi
en-aut-sei=Izumikawa
en-aut-mei=Koichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=TakesueYoshio
en-aut-sei=Takesue
en-aut-mei=Yoshio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=KimuraMoto
en-aut-sei=Kimura
en-aut-mei=Moto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=OhmagariNorio
en-aut-sei=Ohmagari
en-aut-mei=Norio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

affil-num=1
en-affil=Department of Academic-Industrial Partnerships Promotion, Center for Clinical Sciences, Japan Institute for Health Security
kn-affil=

affil-num=2
en-affil=Antimicrobial Resistance (AMR) Clinical Reference Center, Japan Institute for Health Security
kn-affil=

affil-num=3
en-affil=Antimicrobial Resistance (AMR) Clinical Reference Center, Japan Institute for Health Security
kn-affil=

affil-num=4
en-affil=Disease Control and Prevention Center, Japan Institute for Health Security
kn-affil=

affil-num=5
en-affil=Disease Control and Prevention Center, Japan Institute for Health Security
kn-affil=

affil-num=6
en-affil=Department of Infectious Diseases, Sapporo City General Hospital
kn-affil=

affil-num=7
en-affil=Department of Infectious Diseases, International University of Health and Welfare (IUHW) Narita Hospital
kn-affil=

affil-num=8
en-affil=Department of Infectious Diseases, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital
kn-affil=

affil-num=9
en-affil=Department of Infectious Diseases, Hiroshima University Hospital
kn-affil=

affil-num=10
en-affil=Department of General Internal Medicine and Infectious Diseases, Rinku General Medical Center
kn-affil=

affil-num=11
en-affil=Department of Clinical Infectious Diseases, Tohoku University Graduate School of Medicine
kn-affil=

affil-num=12
en-affil=Department of Infectious Diseases, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=13
en-affil=Department of Infectious Diseases, Japanese Red Cross Narita Hospital
kn-affil=

affil-num=14
en-affil=Division of Infectious Diseases, Jichi Medical University Hospital
kn-affil=

affil-num=15
en-affil=Department of Infection Control and Laboratory Medicine, Kyoto Prefectural University of Medicine
kn-affil=

affil-num=16
en-affil=
kn-affil=

affil-num=17
en-affil=Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences
kn-affil=

affil-num=18
en-affil=Department of Academic-Industrial Partnerships Promotion, Center for Clinical Sciences, Japan Institute for Health Security
kn-affil=

affil-num=19
en-affil=Disease Control and Prevention Center, Japan Institute for Health Security
kn-affil=
en-keyword=influenza a
kn-keyword=influenza a
en-keyword=nasal vestibular swab
kn-keyword=nasal vestibular swab
en-keyword=nasopharyngeal swab
kn-keyword=nasopharyngeal swab
en-keyword=rapid diagnostics
kn-keyword=rapid diagnostics
en-keyword=rt-qpcr
kn-keyword=rt-qpcr
en-keyword=saliva
kn-keyword=saliva
en-keyword=sari
kn-keyword=sari
END

start-ver=1.4
cd-journal=joma
no-vol=26
cd-vols=
no-issue=4
article-no=
start-page=1081
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260207
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A Generative AI?Based Technical Data Extraction Tool for IoT Application Systems
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Nowadays, Internet of Things (IoT) application systems play an essential role in smart cities, industry, healthcare, agriculture, and smart homes. For non-expert users, designing and implementing IoT application systems remains challenging, especially when configuring sensors, edge devices, and server platforms. To support configuration tasks of IoT application systems, we have developed an AI-based setup assistance tool. However, AI models still fail to reliably support newly released or previously unseen devices, sometimes producing incomplete or erroneous outputs that may lead to configuration failures. Incorporating their technical-document information into Retrieval-Augmented Generation (RAG) is an effective way to supplement AI knowledge and improve reliability. In this paper, we propose a generative AI-based technical data extraction tool to address the challenges. It extracts essential technical information using the schema-based extraction from given PDF or HTML datasheets and converts it into a structured format suitable for AI-supported configurations. A local vector database is used to enable semantic similarity retrieval and provide document-grounded evidence for RAG-based answering, ensuring consistent support for previously unseen IoT devices. For evaluations, we applied the proposal to several sensor and device datasheets and compared extracted specifications with ground-truth values to measure accuracy and completeness. Then, we compared end-to-end configuration QA reliability against a commercial baseline (ChatPDF) using the golden benchmark. The results show that the proposed tool reliably acquires key specifications and significantly improves end-to-end configuration QA reliability. Across 960 golden QA pairs, the proposed method improves Recall from 0.636 to 0.926 and Accuracy from 0.595 to 0.807 compared with ChatPDF.
en-copyright=
kn-copyright=

en-aut-name=KongDezheng
en-aut-sei=Kong
en-aut-mei=Dezheng
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=FunabikiNobuo
en-aut-sei=Funabiki
en-aut-mei=Nobuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KyawHtoo Htoo Sandi
en-aut-sei=Kyaw
en-aut-mei=Htoo Htoo Sandi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KotamaI Nyoman Darma
en-aut-sei=Kotama
en-aut-mei=I Nyoman Darma
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=ZhuZihao
en-aut-sei=Zhu
en-aut-mei=Zihao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=RahmadaniAlfiandi Aulia
en-aut-sei=Rahmadani
en-aut-mei=Alfiandi Aulia
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Department of Information and Communication Systems, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Information and Communication Systems, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Information and Communication Systems, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Information and Communication Systems, Okayama University
kn-affil=

affil-num=5
en-affil=Department of Information and Communication Systems, Okayama University
kn-affil=

affil-num=6
en-affil=Department of Information and Communication Systems, Okayama University
kn-affil=
en-keyword=internet of things
kn-keyword=internet of things
en-keyword=AI
kn-keyword=AI
en-keyword=retrieval-augmented generation
kn-keyword=retrieval-augmented generation
en-keyword=vector database
kn-keyword=vector database
en-keyword=schema-based extraction
kn-keyword=schema-based extraction
en-keyword=data sheet
kn-keyword=data sheet
en-keyword=technical information
kn-keyword=technical information
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=1
article-no=
start-page=31
end-page=37
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202602
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=The Preoperative Anterior Pelvic Plane Angle Predicts Cup Anteversion Changes at 1 Year after Total Hip Arthroplasty
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=We investigated global alignment changes following total hip arthroplasty (THA) and predictive alignment parameters for increased cup anteversion (CA) by retrospectively analyzing the primary THA data of 75 patients treated at our hospital (49 women, 26 men; age 65.1±5.7 years, BMI 28.3±3.4 kg/m2). Global alignment parameters, i.e., the anterior pelvic plane angle (APPa) and proximal femoral shaft angle (PFSa) and other alignment parameters were measured. CA was evaluated based on the patients’ standing coronal radiographs. ΔCA was defined as the difference in CA from 2 weeks before to 1 year after each THA. We classified the cases as stable (S) (CA < 10°; n=63) and pelvic retroversion (R) (CA ? 10°; n=12) groups. Associations between ΔCA and alignment parameters were evaluated by linear regression and a receiver operating characteristic (ROC) analysis. A significant decrease in the PFSa occurred between the 2-week and 1-year post-THA timepoints (7.8±4.3° vs. 4.2±3.6°, p<0.001), with no notable change in other alignment parameters. At 1-year post-THA, the CA of 12 (16%) patients had increased to 4.5±4.4°. Only the preoperative APPa was positively associated with ΔCA (β=0.165, p=0.020). The ROC analysis revealed that the optimal cut-off value for increased CA in the APPa is 2.1° (area under the curve, 0.700; p=0.020; odds ratio, 4.80). The APPa change predicted increased CA, which emphasizes the importance of the use of preoperative standing radiography for identifying the optimal cup positioning for post-THA changes in CA.
en-copyright=
kn-copyright=

en-aut-name=IshibashiKyota
en-aut-sei=Ishibashi
en-aut-mei=Kyota
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=OishiHirotaka
en-aut-sei=Oishi
en-aut-mei=Hirotaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=ArakiRyo
en-aut-sei=Araki
en-aut-mei=Ryo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KawamuraKosuke
en-aut-sei=Kawamura
en-aut-mei=Kosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SasakiIsamu
en-aut-sei=Sasaki
en-aut-mei=Isamu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=SasakiEiji
en-aut-sei=Sasaki
en-aut-mei=Eiji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KamadaHikaru
en-aut-sei=Kamada
en-aut-mei=Hikaru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KogawaMasakazu
en-aut-sei=Kogawa
en-aut-mei=Masakazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=TanakaSunao
en-aut-sei=Tanaka
en-aut-mei=Sunao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=NumasawaTakuya
en-aut-sei=Numasawa
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=IshibashiYasuyuki
en-aut-sei=Ishibashi
en-aut-mei=Yasuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

affil-num=1
en-affil=Department of Orthopedic Surgery, Hachinohe City Hospital
kn-affil=

affil-num=2
en-affil=Department of Orthopedic Surgery, Hachinohe City Hospital
kn-affil=

affil-num=3
en-affil=Department of Orthopedic Surgery, Hachinohe City Hospital
kn-affil=

affil-num=4
en-affil=Department of Orthopedic Surgery, Hachinohe City Hospital
kn-affil=

affil-num=5
en-affil=Department of Orthopedic Surgery, Hachinohe City Hospital
kn-affil=

affil-num=6
en-affil=Department of Orthopedic Surgery, Hirosaki University Graduate School of Medicine
kn-affil=

affil-num=7
en-affil=Department of Orthopedic Surgery, Hachinohe City Hospital
kn-affil=

affil-num=8
en-affil=Department of Orthopedic Surgery, Hachinohe City Hospital
kn-affil=

affil-num=9
en-affil=Department of Orthopedic Surgery, Hachinohe City Hospital
kn-affil=

affil-num=10
en-affil=Department of Orthopedic Surgery, Hachinohe City Hospital
kn-affil=

affil-num=11
en-affil=Department of Orthopedic Surgery, Hirosaki University Graduate School of Medicine
kn-affil=
en-keyword=total hip arthroplasty
kn-keyword=total hip arthroplasty
en-keyword=global alignment
kn-keyword=global alignment
en-keyword=anterior pelvic plane
kn-keyword=anterior pelvic plane
en-keyword=cup anteversion
kn-keyword=cup anteversion
en-keyword=pelvic tilt
kn-keyword=pelvic tilt
END

start-ver=1.4
cd-journal=joma
no-vol=5
cd-vols=
no-issue=
article-no=
start-page=40
end-page=53
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202603
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Proposed locations of villages recorded in the Silla Village Register
kn-title=「新羅村落文書」に記された村の比定地 ―西原京所属の村（いわゆるＤ村）の検討―
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The Silla Village Register is a fragmentary record from the Unified Silla period that details the economic conditions of villages under the jurisdiction of small capitals (小京) and local counties (郡 / 県). In analyzing this register, it is essential to consider the geographical conditions of the locations; however, the exact locations of the villages have long remained unidentified in previous studies. Therefore, this study builds on the readings proposed by Choi Ky?ng-s?n ( ? ? ? ) and examines official histories and geographical texts from the Chos?n dynasty, as well as topographic maps from the early 20th century. As a result, this paper proposes a concrete candidate for the location of one of the four villages under the jurisdiction of S?w?n-gy?ng (西原京), commonly referred to as Village D. It has been clarified that Village D can be read as " 西原京□椒子村" and it is highly likely to correspond to present-day Choj?ng-ri, Naesu-?p, Heungdeok-gu, Cheongju City (清州市清原区内秀邑椒井里). It was also found that Village D’s characteristic of having few rice paddies and a high proportion of upland field cultivation closely matches the actual local geographical conditions, which are characterized by limited water resources.
en-copyright=
kn-copyright=

en-aut-name=MURAKAMINana
en-aut-sei=MURAKAMI
en-aut-mei=Nana
kn-aut-name=村上菜菜
kn-aut-sei=村上
kn-aut-mei=菜菜
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Research Institute for the Dynamics of Civilizations, Okayama University
kn-affil=
en-keyword=Silla Village Register
kn-keyword=Silla Village Register
en-keyword=Unified Silla
kn-keyword=Unified Silla
en-keyword=village history
kn-keyword=village history
en-keyword=S?w?n-gy?ng
kn-keyword=S?w?n-gy?ng
END

start-ver=1.4
cd-journal=joma
no-vol=5
cd-vols=
no-issue=
article-no=
start-page=20
end-page=39
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202603
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Radiocarbon dating, dietary habits, and genetic characteristics of ancient skeletal remains excavated from the Inome Cave Site in Shimane Prefecture
kn-title=島根県猪目洞窟遺跡出土人骨の年代・食性・遺伝的特徴
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=This paper reports on the integrative research findings of the human bones excavated from the Inome Cave Site in Shimane Prefecture, based on dietary estimation using carbon and nitrogen isotope analysis, radiocarbon dating, and whole genome analysis. The dates of the analyzed human bones span a wide range, from the Middle to Late Kofun period, the Nara period to the Early Heian period, and the Middle to Late Heian period, indicating that the Inome Cave Site was continuously used as a burial place. Dietary habits were a mixture of C3 resources (C3 plants and terrestrial animals that consumed C3 plants) and marine resources, with individual variations in the intake of marine and terrestrial resources. A correlation was observed between differences in dietary habits and individual variations in the Jomon ratio in the nuclear genome, with individuals who consumed higher amounts of marine resources tending to have a higher Jomon ratio. This suggests that individuals with different backgrounds were buried in the same site due to interactions with surrounding settlements.
en-copyright=
kn-copyright=

en-aut-name=KANZAWA-KIRIYAMAHideaki
en-aut-sei=KANZAWA-KIRIYAMA
en-aut-mei=Hideaki
kn-aut-name=神澤秀明
kn-aut-sei=神澤
kn-aut-mei=秀明
aut-affil-num=1
ORCID=

en-aut-name=TAKIGAMIMai
en-aut-sei=TAKIGAMI
en-aut-mei=Mai
kn-aut-name=瀧上舞
kn-aut-sei=瀧上
kn-aut-mei=舞
aut-affil-num=2
ORCID=

en-aut-name=KAKUDATsuneo
en-aut-sei=KAKUDA
en-aut-mei=Tsuneo
kn-aut-name=角田恒雄
kn-aut-sei=角田
kn-aut-mei=恒雄
aut-affil-num=3
ORCID=

en-aut-name=SPEIDELLeo
en-aut-sei=SPEIDEL
en-aut-mei=Leo
kn-aut-name=シュパイデルレオ
kn-aut-sei=シュパイデル
kn-aut-mei=レオ
aut-affil-num=4
ORCID=

en-aut-name=HELLENTHALGarrett
en-aut-sei=HELLENTHAL
en-aut-mei=Garrett
kn-aut-name=ヘレンタールガレット
kn-aut-sei=ヘレンタール
kn-aut-mei=ガレット
aut-affil-num=5
ORCID=

en-aut-name=BIRDNancy
en-aut-sei=BIRD
en-aut-mei=Nancy
kn-aut-name=バードナンシー
kn-aut-sei=バード
kn-aut-mei=ナンシー
aut-affil-num=6
ORCID=

en-aut-name=KAWAIYousuke
en-aut-sei=KAWAI
en-aut-mei=Yousuke
kn-aut-name=河合洋介
kn-aut-sei=河合
kn-aut-mei=洋介
aut-affil-num=7
ORCID=

en-aut-name=NCBN Controls WGS Consortium
en-aut-sei=NCBN Controls WGS Consortium
en-aut-mei=
kn-aut-name=NCBN コントロール WGS コンソーシアム
kn-aut-sei=NCBN コントロール WGS コンソーシアム
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=SAKAMOTOMinoru
en-aut-sei=SAKAMOTO
en-aut-mei=Minoru
kn-aut-name=坂本稔
kn-aut-sei=坂本
kn-aut-mei=稔
aut-affil-num=9
ORCID=

en-aut-name=KAMEDAYuichi
en-aut-sei=KAMEDA
en-aut-mei=Yuichi
kn-aut-name=亀田勇一
kn-aut-sei=亀田
kn-aut-mei=勇一
aut-affil-num=10
ORCID=

en-aut-name=ADACHINoboru
en-aut-sei=ADACHI
en-aut-mei=Noboru
kn-aut-name=安達登
kn-aut-sei=安達
kn-aut-mei=登
aut-affil-num=11
ORCID=

en-aut-name=SHINODAKen-ichi
en-aut-sei=SHINODA
en-aut-mei=Ken-ichi
kn-aut-name=篠田謙一
kn-aut-sei=篠田
kn-aut-mei=謙一
aut-affil-num=12
ORCID=

en-aut-name=SAITOUNaruya
en-aut-sei=SAITOU
en-aut-mei=Naruya
kn-aut-name=斎藤成也
kn-aut-sei=斎藤
kn-aut-mei=成也
aut-affil-num=13
ORCID=

en-aut-name=HAMADATatsuhiko
en-aut-sei=HAMADA
en-aut-mei=Tatsuhiko
kn-aut-name=�M田竜彦
kn-aut-sei=�M田
kn-aut-mei=竜彦
aut-affil-num=14
ORCID=

affil-num=1
en-affil=Division of Human Evolution, Paleontology and Anthropology, National Museum of Nature and Science, Tsukuba City, Ibaraki Prefecture
kn-affil=

affil-num=2
en-affil=Division of Human Evolution, Paleontology and Anthropology, National Museum of Nature and Science, Tsukuba City, Ibaraki Prefecture
kn-affil=

affil-num=3
en-affil=Department of Legal Medicine, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi
kn-affil=

affil-num=4
en-affil=Center for Interdisciplinary Theoretical and Mathematical Sciences, RIKEN
kn-affil=

affil-num=5
en-affil=Department of Genetics, Evolution and Environment, University College London Genetics Institute (UGI), University College London
kn-affil=

affil-num=6
en-affil=Department of Genetics, Evolution and Environment, University College London Genetics Institute (UGI), University College London
kn-affil=

affil-num=7
en-affil=Genome Medical Science Project, National Institute of Global Health and Medicine, National Institute for Health Security
kn-affil=

affil-num=8
en-affil=
kn-affil=

affil-num=9
en-affil=National Museum of Japanese History
kn-affil=

affil-num=10
en-affil=Division of Human Evolution, Paleontology and Anthropology, National Museum of Nature and Science, Tsukuba City, Ibaraki Prefecture
kn-affil=

affil-num=11
en-affil=Department of Legal Medicine, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi
kn-affil=

affil-num=12
en-affil=National Museum of Nature and Science
kn-affil=

affil-num=13
en-affil=National Institute of Genetics
kn-affil=

affil-num=14
en-affil=Research Institute for the Dynamics of Civilizations, Okayama University
kn-affil=
en-keyword=Inome Cave Site
kn-keyword=Inome Cave Site
en-keyword=human bone
kn-keyword=human bone
en-keyword=radiocarbon dating
kn-keyword=radiocarbon dating
en-keyword=dietary habits
kn-keyword=dietary habits
en-keyword=ancient genome
kn-keyword=ancient genome
END

start-ver=1.4
cd-journal=joma
no-vol=15
cd-vols=
no-issue=4
article-no=
start-page=1422
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260211
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Perioperative Ozoralizumab Management for Patients with Rheumatoid Arthritis Who Underwent Orthopaedic Surgery: A Retrospective Case Series
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background/Objectives: Launched in Japan in 2022, ozoralizumab (OZR) is a novel, anti-tumour necrosis factor (TNF)-α inhibitor for treating rheumatoid arthritis (RA) that is refractory to conventional therapies. However, there is a lack of evidence regarding its perioperative management. Methods: This retrospective case series included nine patients with RA who underwent a total of 12 either RA-related (n = 9) or unrelated (n = 3) orthopaedic procedures. We reviewed patient demographics, surgical procedures, perioperative OZR discontinuation periods, and postoperative complications. Results: The mean preoperative OZR discontinuation period was 15.8 days (range, 2?25 days). Sutures were removed at a mean of 12.8 days postoperatively (range, 11?14 days) after adequate wound healing had been confirmed. The mean total discontinuation period was 34.9 days (range, 27?43 days). No cases of surgical site infection (SSI) or delayed wound healing (DWH) were observed during a minimum follow-up period of three months. One patient experienced a disease flare before OZR was restarted. Conclusions: Preoperative OZR discontinuation for up to four weeks appeared to be safe in this cohort. These findings may assist orthopaedic surgeons in determining an appropriate perioperative discontinuation strategy for OZR that minimises SSI and DWH risk while reducing the likelihood of RA flare.
en-copyright=
kn-copyright=

en-aut-name=NishidaKeiichiro
en-aut-sei=Nishida
en-aut-mei=Keiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NasuYoshihisa
en-aut-sei=Nasu
en-aut-mei=Yoshihisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HaradaRyozo
en-aut-sei=Harada
en-aut-mei=Ryozo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NakaharaRyuichi
en-aut-sei=Nakahara
en-aut-mei=Ryuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HoritaMasahiro
en-aut-sei=Horita
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NatsumedaMasamitsu
en-aut-sei=Natsumeda
en-aut-mei=Masamitsu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NaniwaShuichi
en-aut-sei=Naniwa
en-aut-mei=Shuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=OzakiToshifumi
en-aut-sei=Ozaki
en-aut-mei=Toshifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Locomotive Pain Center, Faculty of Medical Development Field, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Orthopaedic Surgery, Okayama City Hospital
kn-affil=

affil-num=3
en-affil=Department of Orthopaedic Surgery, Kurashiki Sweet Hospital
kn-affil=

affil-num=4
en-affil=Locomotive Pain Center, Faculty of Medical Development Field, Okayama University
kn-affil=

affil-num=5
en-affil=Locomotive Pain Center, Faculty of Medical Development Field, Okayama University
kn-affil=

affil-num=6
en-affil=Rheumatic Disease Center, Mabi Memorial Hospital
kn-affil=

affil-num=7
en-affil=Department of Orthopaedic Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=8
en-affil=Department of Orthopaedic Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=delayed wound healing
kn-keyword=delayed wound healing
en-keyword=discontinuation
kn-keyword=discontinuation
en-keyword=ozoralizumab
kn-keyword=ozoralizumab
en-keyword=orthopaedic surgery
kn-keyword=orthopaedic surgery
en-keyword=perioperative management
kn-keyword=perioperative management
en-keyword=rheumatoid arthritis
kn-keyword=rheumatoid arthritis
en-keyword=surgical site infection
kn-keyword=surgical site infection
END

start-ver=1.4
cd-journal=joma
no-vol=16
cd-vols=
no-issue=3
article-no=
start-page=369
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260123
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Impact of the July 2018 Heavy Rain Disaster on the Endangered Nagoya Daruma Pond Frog (Pelophylax porosus brevipodus) in Rice Fields of Mabi Town, Kurashiki City, Western Japan: Changes in Population Structure over Five Years
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Rice paddy fields (referred to below as rice fields) are important not only for food production, but also as habitats for various species. The Nagoya Daruma Pond Frog (Pelophylax porosus brevipodus) is an endangered frog species endemic to Japan, mainly living in and around rice field areas. In July 2018, heavy rainfall caused severe flooding in Mabi Town of Okayama Prefecture, western Japan, submerging numerous rice fields and affecting local frog populations, including P. porosus brevipodus. To clarify whether the population structure of P. porosus brevipodus changed following the flood disaster in the rice fields of Mabi Town, we conducted quantitative field surveys in a rice fallow field in mid-October before (2017) and after (2018, 2020?2022, excluding 2019) the flood. The number of frogs declined sharply after the 2018 flood, reaching only a few individuals by 2020, but showed a substantial recovery in 2021 following the resumption of rice cultivation, although numbers decreased again in 2022. This recovery, despite fluctuations, indicates that habitat restoration through rice farming played a key role in enabling the population to rebound. Our findings underscore the importance of maintaining and restoring rice field environments after natural disasters for the survival and long-term recovery of P. porosus brevipodus.
en-copyright=
kn-copyright=

en-aut-name=NakajimaRyo
en-aut-sei=Nakajima
en-aut-mei=Ryo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=AzumiDaisuke
en-aut-sei=Azumi
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TadaMasakazu
en-aut-sei=Tada
en-aut-mei=Masakazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NakaichiJunya
en-aut-sei=Nakaichi
en-aut-mei=Junya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KatsuharaKoki R.
en-aut-sei=Katsuhara
en-aut-mei=Koki R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NakataKazuyoshi
en-aut-sei=Nakata
en-aut-mei=Kazuyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=2
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=3
en-affil=Okayama Prefectural Public Interest Incorporated Foundation for Environmental Conservation
kn-affil=

affil-num=4
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=5
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=6
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=
en-keyword=agroecosystem
kn-keyword=agroecosystem
en-keyword=conservation ecology
kn-keyword=conservation ecology
en-keyword=endangered amphibian
kn-keyword=endangered amphibian
en-keyword=paddy field
kn-keyword=paddy field
en-keyword=post-disaster habitat recovery
kn-keyword=post-disaster habitat recovery
END

start-ver=1.4
cd-journal=joma
no-vol=31
cd-vols=
no-issue=7
article-no=
start-page=102730
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202507
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Impact of full-time equivalent allocation on the effectiveness of antimicrobial stewardship activities: A multicenter study in Okayama, Japan
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Optimized administration of antimicrobial agents is critical for mitigating the emergence of antimicrobial resistance. This study aimed to elucidate the relationship between antimicrobial stewardship (AS) activities and antimicrobial prescription trends and patterns.<br>
Methods: This retrospective, multicenter, longitudinal study was conducted between April 2014 and March 2023 (9-year fiscal period). A structured, questionnaire survey, regarding institutional infrastructure and environmental parameters, service modalities provided by AS activities, resource allocation and systemic support, and data on the use of broad-spectrum antimicrobial agents, was distributed to co-investigators working at seven hospitals in Okayama, Japan. Full-time equivalent (FTE) allocation for each healthcare facility were calculated and subsequently compared among the hospitals. Temporal variations in the proportional distribution of broad-spectrum antimicrobial agents were statistically evaluated using joinpoint regression analysis.<br>
Results: Two hospitals where pharmacists were exclusively dedicated to AS activities and met the recommended FTE allocation showed a statistically significant reduction in the proportion of broad-spectrum antibiotic administration, with average annual percentage changes of ?8.0 % (95 % confidence interval [CI]: ?10.5 to ?5.8) and ?3.1 % (95 % CI: ?5.5 to ?0.7), respectively. In contrast, two other hospitals with full-time AS members but insufficient FTE allocation exhibited inconsistent and statistically nonuniform trends. The remaining three healthcare institutions with poorly resourced AS teams demonstrated no statistically significant trends in their broad-spectrum antimicrobial prescriptions.<br>
Conclusion: Our findings uncovered that hospitals with adequate FTE staffing metrics for AS activities exhibited statistically significant downward trends in the consumption of broad-spectrum antimicrobial agents.
en-copyright=
kn-copyright=

en-aut-name=KajitaShiho
en-aut-sei=Kajita
en-aut-mei=Shiho
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HagiyaHideharu
en-aut-sei=Hagiya
en-aut-mei=Hideharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=OkitaAtsushi
en-aut-sei=Okita
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=HarukiYuto
en-aut-sei=Haruki
en-aut-mei=Yuto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=YamadaHaruto
en-aut-sei=Yamada
en-aut-mei=Haruto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=InoueYasurou
en-aut-sei=Inoue
en-aut-mei=Yasurou
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=HigashionnaTsukasa
en-aut-sei=Higashionna
en-aut-mei=Tsukasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=SatouKana
en-aut-sei=Satou
en-aut-mei=Kana
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=TorigoeFumihiro
en-aut-sei=Torigoe
en-aut-mei=Fumihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=IwamotoShinobu
en-aut-sei=Iwamoto
en-aut-mei=Shinobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=YoshidaMika
en-aut-sei=Yoshida
en-aut-mei=Mika
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=YamaneYumiko
en-aut-sei=Yamane
en-aut-mei=Yumiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=KenmotsuHiroki
en-aut-sei=Kenmotsu
en-aut-mei=Hiroki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=SugimuraSatoru
en-aut-sei=Sugimura
en-aut-mei=Satoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=FujiwaraYutaka
en-aut-sei=Fujiwara
en-aut-mei=Yutaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=IkedaFusao
en-aut-sei=Ikeda
en-aut-mei=Fusao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=KoyamaToshihiro
en-aut-sei=Koyama
en-aut-mei=Toshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=YoshidaChikamasa
en-aut-sei=Yoshida
en-aut-mei=Chikamasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=AndouShinichirou
en-aut-sei=Andou
en-aut-mei=Shinichirou
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=SuwakiToshimitsu
en-aut-sei=Suwaki
en-aut-mei=Toshimitsu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

affil-num=1
en-affil=Antimicrobial Stewardship Team, Okayama City Hospital
kn-affil=

affil-num=2
en-affil=Department of Infectious Diseases, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Surgery, Setouchi City Hospital
kn-affil=

affil-num=4
en-affil=Department of Pharmacy, Tsuyama Chuo Hospital
kn-affil=

affil-num=5
en-affil=Antimicrobial Stewardship Team, Okayama City Hospital
kn-affil=

affil-num=6
en-affil=Antimicrobial Stewardship Team, Okayama City Hospital
kn-affil=

affil-num=7
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=

affil-num=8
en-affil=Division of Pharmacy, Kurashiki Central Hospital
kn-affil=

affil-num=9
en-affil=Division of Pharmacy, Kurashiki Central Hospital
kn-affil=

affil-num=10
en-affil=Division of Pharmacy, Okayama Kyoritsu Hospital
kn-affil=

affil-num=11
en-affil=Infection Control Team, National Hospital Organization Minami-Okayama Medical Center
kn-affil=

affil-num=12
en-affil=Infection Control Team, National Hospital Organization Minami-Okayama Medical Center
kn-affil=

affil-num=13
en-affil=Division of Pharmacy, Okayama Saiseikai Hospital
kn-affil=

affil-num=14
en-affil=Department of Internal Medicine, Okayama Kyoritsu Hospital
kn-affil=

affil-num=15
en-affil=Infection Control Team, National Hospital Organization Minami-Okayama Medical Center
kn-affil=

affil-num=16
en-affil=Department of Hepatology, Okayama Saiseikai Hospital
kn-affil=

affil-num=17
en-affil=Department of Health Data Science, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=18
en-affil=Infection Control Team, Okayama City Hospital
kn-affil=

affil-num=19
en-affil=Infection Control Team, Okayama City Hospital
kn-affil=

affil-num=20
en-affil=Infection Control Team, Okayama City Hospital
kn-affil=
en-keyword=Antimicrobial resistance
kn-keyword=Antimicrobial resistance
en-keyword=Antimicrobial stewardship
kn-keyword=Antimicrobial stewardship
en-keyword=Full-time equivalent
kn-keyword=Full-time equivalent
en-keyword=Infection prevention and control
kn-keyword=Infection prevention and control
en-keyword=Trend analysis
kn-keyword=Trend analysis
END

start-ver=1.4
cd-journal=joma
no-vol=5
cd-vols=
no-issue=4
article-no=
start-page=74
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251201
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=An Integrated QGIS-Based Evacuation Route Optimization Approach for Disaster Preparedness Against Urban Flood in Japan
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Urban inland flooding has become a serious problem in many cities because heavy rain often exceeds the capacity of drainage systems. In Japan, GIS-based evacuation maps are commonly used to support disaster preparedness, but they still have several limitations. In particular, they do not avoid flooded road segments and cannot generate multiple evacuation options at the same time. This study proposes an improved evacuation route method using the free and open-source software QGIS. The method combines flood-depth data with road network processing to remove roads where the predicted water depth is higher than 0.5 m. It also provides several evacuation paths to different shelters at the same time. A case study in Kurashiki City, Okayama Prefecture, demonstrates that about 1.37% of the road network becomes unusable during an inland-flood scenario. Several existing evacuation routes also pass through hazardous areas, but the QGIS-based method avoids these areas in most cases. Since the workflow uses only built-in QGIS functions and does not require programming or plug-ins, it is easy to reproduce and apply in other regions. This study offers a practical and low-cost method to support inland-flood evacuation planning for local governments.
en-copyright=
kn-copyright=

en-aut-name=PanWenliang
en-aut-sei=Pan
en-aut-mei=Wenliang
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=PanShijun
en-aut-sei=Pan
en-aut-mei=Shijun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KanetoJunko
en-aut-sei=Kaneto
en-aut-mei=Junko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YoshidaKeisuke
en-aut-sei=Yoshida
en-aut-mei=Keisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=NishiyamaSatoshi
en-aut-sei=Nishiyama
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

affil-num=1
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=

affil-num=2
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=

affil-num=3
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=

affil-num=4
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=

affil-num=5
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=
en-keyword=evacuation route
kn-keyword=evacuation route
en-keyword=hazard mapping
kn-keyword=hazard mapping
en-keyword=inland flood
kn-keyword=inland flood
en-keyword=land use analysis
kn-keyword=land use analysis
en-keyword=QGIS
kn-keyword=QGIS
END

start-ver=1.4
cd-journal=joma
no-vol=15
cd-vols=
no-issue=1
article-no=
start-page=376
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260104
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Oral Health-Related Quality of Life and Self-Reported Oral Health Status Are Associated with Change in Self-Reported Depression Status: A Cohort Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background/Objectives: Oral health-related quality of life (OHRQoL) may influence mental health outcomes, yet longitudinal evidence on its association with depression remains limited. This study aimed to examine whether oral health status and OHRQoL are associated with a change in self-reported depression status among adults in Japan. Methods: We analyzed data from the Japan COVID-19 and Society Internet Survey (JACSIS), conducted in 2022 and 2023. A total of 15,068 participants aged ?20 years without depression at baseline were included. Depression status was identified by self-reported measures between the two survey waves. Logistic regression models estimated odds ratios (ORs) and 95% confidence intervals (CIs) for change in self-reported depression status in relation to OHRQoL and oral health status, adjusting for sociodemographic and behavioral factors. Results: During follow-up, 218 participants (1.45%) reported a change in self-reported depression status. Poorer OHRQoL was significantly associated with a change in self-reported depression status (OR: 1.018; 95% CI: 1.001?1.036; p = 0.039). Additional risk factors included younger age (OR: 0.974; 95% CI: 0.964?0.985), participation in hobbies and cultural activities (OR: 2.224; 95% CI: 1.498?3.302), habitual use of sleeping pills or anxiolytics (current use OR: 3.512; 95% CI: 2.267?5.442), increased loneliness (OR: 1.217; 95% CI: 1.140?1.299), lower life satisfaction (OR: 0.900; 95% CI: 0.836?0.969), and poor self-rated health (OR: 2.921; 95% CI: 1.810?4.715). Conclusions: Impaired OHRQoL was associated with a change in self-reported depression status, potentially through psychosocial mechanisms. These findings suggest that oral health and OHRQoL may be relevant factors to consider in integrated oral and mental health approaches in clinical practice.
en-copyright=
kn-copyright=

en-aut-name=TakeuchiNoriko
en-aut-sei=Takeuchi
en-aut-mei=Noriko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MaruyamaTakayuki
en-aut-sei=Maruyama
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=ToyamaNaoki
en-aut-sei=Toyama
en-aut-mei=Naoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KatsubeYuzuki
en-aut-sei=Katsube
en-aut-mei=Yuzuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TabuchiTakahiro
en-aut-sei=Tabuchi
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=EkuniDaisuke
en-aut-sei=Ekuni
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Department of Preventive Dentistry, Division of Dentistry, Medical Development Field, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Preventive Dentistry, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Preventive Dentistry, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Dental School, Okayama University
kn-affil=

affil-num=5
en-affil=Division of Epidemiology, School of Public Health, Tohoku University Graduate School of Medicine
kn-affil=

affil-num=6
en-affil=Department of Preventive Dentistry, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=oral health-related quality of life
kn-keyword=oral health-related quality of life
en-keyword=depression status
kn-keyword=depression status
en-keyword=cohort study
kn-keyword=cohort study
END

start-ver=1.4
cd-journal=joma
no-vol=137
cd-vols=
no-issue=3
article-no=
start-page=118
end-page=125
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251201
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=The results of COVID-19 antibody testing studies in Bizen, Japan
kn-title=備前市における新型コロナウイルス感染症の抗体検査に関する研究の成果報告
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=　We conducted two prospective cohort studies (June 2022?March 2023 and Nov 2023?Jan 2024) of 1,899 and 445 residents and other individuals who are affiliated with institutions in the city of Bizen in Japan's Okayama prefecture (population 32,320 as of 2020). We measured the subjects' titers of antibodies against SARS-CoV-2, evaluated changes in their antibody titers, and assessed the associations of the titers with the subjects' vaccination status, infection, and COVID-19 status/severity. This report summarizes the two studies' findings. These prospective studies based on a wide age range in a general population provide information that can be used to determine the appropriate timing of vaccination during a pandemic.
en-copyright=
kn-copyright=

en-aut-name=YorifujiTakashi
en-aut-sei=Yorifuji
en-aut-mei=Takashi
kn-aut-name=頼藤貴志
kn-aut-sei=頼藤
kn-aut-mei=貴志
aut-affil-num=1
ORCID=

en-aut-name=SasakiAyako
en-aut-sei=Sasaki
en-aut-mei=Ayako
kn-aut-name=佐々木綾子
kn-aut-sei=佐々木
kn-aut-mei=綾子
aut-affil-num=2
ORCID=

en-aut-name=MatsumotoNaomi
en-aut-sei=Matsumoto
en-aut-mei=Naomi
kn-aut-name=松本尚美
kn-aut-sei=松本
kn-aut-mei=尚美
aut-affil-num=3
ORCID=

en-aut-name=KadowakiTomoka
en-aut-sei=Kadowaki
en-aut-mei=Tomoka
kn-aut-name=門脇知花
kn-aut-sei=門脇
kn-aut-mei=知花
aut-affil-num=4
ORCID=

en-aut-name=MitsuhashiToshiharu
en-aut-sei=Mitsuhashi
en-aut-mei=Toshiharu
kn-aut-name=三橋利晴
kn-aut-sei=三橋
kn-aut-mei=利晴
aut-affil-num=5
ORCID=

en-aut-name=TakaoSoshi
en-aut-sei=Takao
en-aut-mei=Soshi
kn-aut-name=高尾総司
kn-aut-sei=高尾
kn-aut-mei=総司
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Department of Epidemiology, Faculty of Medicine, Dentistry and Pharmaceutical Science, Okayama University
kn-affil=岡山大学学術研究院医歯薬学域　疫学・衛生学

affil-num=2
en-affil=Kurashiki City Public Health Center
kn-affil=倉敷市保健所

affil-num=3
en-affil=Department of Epidemiology, Faculty of Medicine, Dentistry and Pharmaceutical Science, Okayama University
kn-affil=岡山大学学術研究院医歯薬学域　疫学・衛生学

affil-num=4
en-affil=Center for Public Health Action in Applied Epidemiology, National Institute of Infectious Diseases
kn-affil=国立感染症研究所　応用疫学研究センター

affil-num=5
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=岡山大学病院　新医療研究開発センター

affil-num=6
en-affil=Department of Epidemiology, Faculty of Medicine, Dentistry and Pharmaceutical Science, Okayama University
kn-affil=岡山大学学術研究院医歯薬学域　疫学・衛生学
en-keyword=COVID-19
kn-keyword=COVID-19
en-keyword=ワクチン (vaccination)
kn-keyword=ワクチン (vaccination)
en-keyword=抗体価 (antibody titer)
kn-keyword=抗体価 (antibody titer)
en-keyword=感染 (infection)
kn-keyword=感染 (infection)
END

start-ver=1.4
cd-journal=joma
no-vol=10
cd-vols=
no-issue=11
article-no=
start-page=105889
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202511
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Association between adjuvant chemotherapy and outcomes in resected locoregional recurrence of hormone receptor-positive HER2-negative breast cancer: a multi-institutional retrospective study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: To evaluate the association of adjuvant chemotherapy and prognosis for locoregional recurrence (LRR) in hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative subtype breast cancer.<br>
Patients and methods: We carried out a multi-institutional retrospective cohort study in patients with breast cancer who developed HR-positive HER2-negative LRR. Patients who underwent curative surgery for LRR between 2014 and 2018 were categorized based on whether they received adjuvant chemotherapy for LRR (CTx versus no-CTx). Invasive disease-free survival (iDFS) was evaluated between the groups by Cox proportional hazards analysis. The primary analysis used a double-robust Cox model incorporating inverse probability of treatment weighting, and a sensitivity analysis using propensity score matching was also carried out.<br>
Results: A total of 958 patients were included. The median time from the primary surgery to LRR diagnosis was 9.5 years (interquartile range 3.1-10.1 years). There were 235 patients (25%) in the CTx group and 722 (75%) in the no-CTx group. Among all patients, the 5-year iDFS rate was 75.4% [95% confidence interval (CI) 72.4% to 78.2%]. Multivariate analysis showed better iDFS in the CTx group (hazard ratio 0.70, 95% CI 0.49-0.99, P = 0.045). Sensitivity analysis supported these findings. Subgroup analyses showed that the CTx group had better iDFS in cases with non-ipsilateral breast tumor recurrence (IBTR), recurrences during adjuvant endocrine therapy for primary breast cancer, and without perioperative chemotherapy for primary breast cancer. Secondary analysis showed no significant difference with a worse trend toward overall survival in the CTx group with multivariate Cox proportional hazards analysis.<br>
Conclusion: Adjuvant chemotherapy for HR-positive HER2-negative LRR was associated with better iDFS, particularly in cases of non-IBTR, recurrences during adjuvant endocrine therapy, and no prior perioperative chemotherapy for their primary tumor. However, the retrospective design and inability to distinguish true recurrences from new primary tumors in IBTR warrant cautious interpretation.
en-copyright=
kn-copyright=

en-aut-name=OzakiY.
en-aut-sei=Ozaki
en-aut-mei=Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TokudaE.
en-aut-sei=Tokuda
en-aut-mei=E.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=SagaraY.
en-aut-sei=Sagara
en-aut-mei=Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=HaraF.
en-aut-sei=Hara
en-aut-mei=F.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SasadaS.
en-aut-sei=Sasada
en-aut-mei=S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=SawakiM.
en-aut-sei=Sawaki
en-aut-mei=M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KanbayashiC.
en-aut-sei=Kanbayashi
en-aut-mei=C.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=YamanakaT.
en-aut-sei=Yamanaka
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=OnishiT.
en-aut-sei=Onishi
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=FujikiY.
en-aut-sei=Fujiki
en-aut-mei=Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=SutoA.
en-aut-sei=Suto
en-aut-mei=A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=TakahashiY.
en-aut-sei=Takahashi
en-aut-mei=Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=TokunagaE.
en-aut-sei=Tokunaga
en-aut-mei=E.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=ArugaT.
en-aut-sei=Aruga
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=NakamuraR.
en-aut-sei=Nakamura
en-aut-mei=R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=FujisawaT.
en-aut-sei=Fujisawa
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=SajiS.
en-aut-sei=Saji
en-aut-mei=S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=IwataH.
en-aut-sei=Iwata
en-aut-mei=H.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=ShienT.
en-aut-sei=Shien
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

affil-num=1
en-affil=Department of Breast Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research
kn-affil=

affil-num=2
en-affil=Department of Medical Oncology, Fukushima Medical University
kn-affil=

affil-num=3
en-affil=Department of Breast Surgery, Social Medical Corporation Hakuaikai Sagara Hospital
kn-affil=

affil-num=4
en-affil=Department of Breast Oncology, Aichi Cancer Center Hospital
kn-affil=

affil-num=5
en-affil=Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University
kn-affil=

affil-num=6
en-affil=Department of Breast Oncology, Aichi Cancer Center Hospital
kn-affil=

affil-num=7
en-affil=Department of Breast Oncology, Niigata Cancer Center Hospital
kn-affil=

affil-num=8
en-affil=Department of Breast Surgery and Oncology, Kanagawa Cancer Center
kn-affil=

affil-num=9
en-affil=Department of Breast Oncology, National Cancer Center Hospital East
kn-affil=

affil-num=10
en-affil=Department of Breast Surgery, Social Medical Corporation Hakuaikai Sagara Hospital
kn-affil=

affil-num=11
en-affil=Department of Breast Oncology, National Cancer Center Hospital
kn-affil=

affil-num=12
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=13
en-affil=Department of Breast Oncology, National Hospital Organization Kyushu Cancer Center
kn-affil=

affil-num=14
en-affil=Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital
kn-affil=

affil-num=15
en-affil=Division of Breast Surgery, Chiba Cancer Center
kn-affil=

affil-num=16
en-affil=Department of Breast Oncology, Gunma Prefectural Cancer Center
kn-affil=

affil-num=17
en-affil=Department of Medical Oncology, Fukushima Medical University
kn-affil=

affil-num=18
en-affil=Department of Advanced Clinical Research and Development, Nagoya City University
kn-affil=

affil-num=19
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=
en-keyword=breast cancer
kn-keyword=breast cancer
en-keyword=locoregional recurrence
kn-keyword=locoregional recurrence
en-keyword=adjuvant chemotherapy
kn-keyword=adjuvant chemotherapy
en-keyword=inverse probability of treatment weighting
kn-keyword=inverse probability of treatment weighting
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251117
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Genomic Profiling of Pediatric Solid Tumors With a Dual DNA/RNA Panel: JCCG-TOP2 Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=To develop an optimized genomic medicine platform for pediatric cancers, a nationwide cancer genome profiling project was conducted from January 2022 to February 2023 in collaboration with the Japan Children's Cancer Group. This prospective observational study analyzed matched blood and FFPE tumor samples from patients aged 0?29?years with solid tumors. Genomic analysis used the TOP2 hybrid capture?enrichment system, targeting 737 and 455 genes in the DNA and RNA panels, along with allele-specific genome copy number alterations. A total of 210 patients from 50 institutions were enrolled across Japan (median age, 8?years; range, 0?25). Of these, 154 (77%) were enrolled at diagnosis or during/after initial treatment and 56 (27%) at disease progression or relapse. The TOP2 findings had great benefits in clarifying the diagnosis of pediatric solid tumors. Among the 204 patients with genomic results, 147 (72%) had potentially actionable findings, including diagnostic, prognostic, and therapeutic findings in 111 (54%), 61 (30%), and 64 (31%), respectively. Oncogenic fusions were noted in 45 (23%) patients. A copy number alteration was identified in at least one genomic region in 170 (83%) patients. Two patients exhibited a high tumor mutation burden. Seventeen (8%) patients harbored a germline pathogenic/likely pathogenic variant in cancer-predisposing genes. This study highlighted the feasibility of implementing a nationwide precision medicine platform and the clinical utility of the TOP2 system for pediatric cancers. The results support the integration of genomic data into the standard clinical care of pediatric patients with cancer, both at diagnosis and at relapse.
en-copyright=
kn-copyright=

en-aut-name=TaoKayoko
en-aut-sei=Tao
en-aut-mei=Kayoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YoshiokaTakako
en-aut-sei=Yoshioka
en-aut-mei=Takako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KatoMiho
en-aut-sei=Kato
en-aut-mei=Miho
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KomatsuKazuyuki
en-aut-sei=Komatsu
en-aut-mei=Kazuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TsujimotoShinichi
en-aut-sei=Tsujimoto
en-aut-mei=Shinichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=SakamotoKenichi
en-aut-sei=Sakamoto
en-aut-mei=Kenichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TanimuraKazuki
en-aut-sei=Tanimura
en-aut-mei=Kazuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=SugiyamaMinako
en-aut-sei=Sugiyama
en-aut-mei=Minako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=SekiguchiMasahiro
en-aut-sei=Sekiguchi
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=NakanoYoshiko
en-aut-sei=Nakano
en-aut-mei=Yoshiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=OtaniYoshihiro
en-aut-sei=Otani
en-aut-mei=Yoshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=YatabeYasushi
en-aut-sei=Yatabe
en-aut-mei=Yasushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=YoshidaAkihiko
en-aut-sei=Yoshida
en-aut-mei=Akihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=OkitaHajime
en-aut-sei=Okita
en-aut-mei=Hajime
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=HiratoJunko
en-aut-sei=Hirato
en-aut-mei=Junko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=KohashiKenichi
en-aut-sei=Kohashi
en-aut-mei=Kenichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=TanakaYukichi
en-aut-sei=Tanaka
en-aut-mei=Yukichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=KohsakaShinji
en-aut-sei=Kohsaka
en-aut-mei=Shinji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=KuboTakashi
en-aut-sei=Kubo
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=SunamiKuniko
en-aut-sei=Sunami
en-aut-mei=Kuniko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=HirataMakoto
en-aut-sei=Hirata
en-aut-mei=Makoto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=TsutsumiShuichi
en-aut-sei=Tsutsumi
en-aut-mei=Shuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=AburataniHiroyuki
en-aut-sei=Aburatani
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=KohKatsuyoshi
en-aut-sei=Koh
en-aut-mei=Katsuyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=HirayamaMasahiro
en-aut-sei=Hirayama
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=KarakawaShuhei
en-aut-sei=Karakawa
en-aut-mei=Shuhei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

en-aut-name=TerashitaYukayo
en-aut-sei=Terashita
en-aut-mei=Yukayo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=27
ORCID=

en-aut-name=FujisakiHiroyuki
en-aut-sei=Fujisaki
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=28
ORCID=

en-aut-name=YagiTakeshi
en-aut-sei=Yagi
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=29
ORCID=

en-aut-name=YonedaAkihiro
en-aut-sei=Yoneda
en-aut-mei=Akihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=30
ORCID=

en-aut-name=MochizukiShinji
en-aut-sei=Mochizuki
en-aut-mei=Shinji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=31
ORCID=

en-aut-name=ShichinoHiroyuki
en-aut-sei=Shichino
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=32
ORCID=

en-aut-name=SuzukiTatsuya
en-aut-sei=Suzuki
en-aut-mei=Tatsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=33
ORCID=

en-aut-name=TakimotoTetsuya
en-aut-sei=Takimoto
en-aut-mei=Tetsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=34
ORCID=

en-aut-name=IchimuraKoichi
en-aut-sei=Ichimura
en-aut-mei=Koichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=35
ORCID=

en-aut-name=OgawaChitose
en-aut-sei=Ogawa
en-aut-mei=Chitose
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=36
ORCID=

en-aut-name=MatsumotoKimikazu
en-aut-sei=Matsumoto
en-aut-mei=Kimikazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=37
ORCID=

en-aut-name=IchikawaHitoshi
en-aut-sei=Ichikawa
en-aut-mei=Hitoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=38
ORCID=

en-aut-name=KatoMotohiro
en-aut-sei=Kato
en-aut-mei=Motohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=39
ORCID=

affil-num=1
en-affil=Department of Pediatrics, National Cancer Center Hospital
kn-affil=

affil-num=2
en-affil=Department of Pathology, National Center for Child Health and Development
kn-affil=

affil-num=3
en-affil=Department of Childhood Cancer Data Management, National Center for Child Health and Development
kn-affil=

affil-num=4
en-affil=Department of Pediatrics, Hamamatsu University School of Medicine
kn-affil=

affil-num=5
en-affil=Department of Pediatrics, Yokohama City University
kn-affil=

affil-num=6
en-affil=Department of Pediatrics, Shinshu University School of Medicine
kn-affil=

affil-num=7
en-affil=Department of Pediatrics, National Cancer Center Hospital
kn-affil=

affil-num=8
en-affil=Department of Pediatrics, National Cancer Center Hospital
kn-affil=

affil-num=9
en-affil=Department of Pediatrics, The University of Tokyo
kn-affil=

affil-num=10
en-affil=Department of Pediatrics, The University of Tokyo
kn-affil=

affil-num=11
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=12
en-affil=Department of Diagnostic Pathology, National Cancer Center Hospital
kn-affil=

affil-num=13
en-affil=Department of Diagnostic Pathology, National Cancer Center Hospital
kn-affil=

affil-num=14
en-affil=Department of Pathology, Keio University School of Medicine
kn-affil=

affil-num=15
en-affil=Department of Pathology, Public Tomioka General Hospital
kn-affil=

affil-num=16
en-affil=Department of Pathology, Graduate School of Medicine, Osaka Metropolitan University
kn-affil=

affil-num=17
en-affil=Department of Pathology, Kanagawa Children's Medical Center
kn-affil=

affil-num=18
en-affil=Division of Cellular Signaling, National Cancer Center Research Institute
kn-affil=

affil-num=19
en-affil=Department of Clinical Genomics, National Cancer Center Research Institute
kn-affil=

affil-num=20
en-affil=Department of Laboratory Medicine, National Cancer Center Hospital
kn-affil=

affil-num=21
en-affil=Department of Genetic Medicine and Services, National Cancer Center Hospital
kn-affil=

affil-num=22
en-affil=Genome Science & Medicine Division, Research Center of Advanced Science and Technology, The University of Tokyo
kn-affil=

affil-num=23
en-affil=Genome Science & Medicine Division, Research Center of Advanced Science and Technology, The University of Tokyo
kn-affil=

affil-num=24
en-affil=Department of Hematology and Oncology, Saitama Children's Medical Center
kn-affil=

affil-num=25
en-affil=Department of Pediatrics, Mie University Graduate School of Medicine
kn-affil=

affil-num=26
en-affil=Department of Pediatrics, Hiroshima University Hospital
kn-affil=

affil-num=27
en-affil=Department of Pediatrics, Hokkaido University Hospital
kn-affil=

affil-num=28
en-affil=Department of Pediatric Hematology and Oncology, Osaka City General Hospital
kn-affil=

affil-num=29
en-affil=Okinawa Prefectural Nanbu Medical Center & Children's Medical Center
kn-affil=

affil-num=30
en-affil=Department of Pediatric Surgery, National Center for Child Health and Development
kn-affil=

affil-num=31
en-affil=Department of Pediatrics, National Center for Global Health and Medicine, Japan Institute for Health Security
kn-affil=

affil-num=32
en-affil=Department of Pediatrics, National Center for Global Health and Medicine, Japan Institute for Health Security
kn-affil=

affil-num=33
en-affil=Department of Hematology, National Cancer Center Hospital
kn-affil=

affil-num=34
en-affil=Department of Childhood Cancer Data Management, National Center for Child Health and Development
kn-affil=

affil-num=35
en-affil=Department of Pathology, Kyorin University Faculty of Medicine
kn-affil=

affil-num=36
en-affil=Department of Pediatrics, National Cancer Center Hospital
kn-affil=

affil-num=37
en-affil=Children's Cancer Center National Center for Child Health and Development
kn-affil=

affil-num=38
en-affil=Department of Clinical Genomics, National Cancer Center Research Institute
kn-affil=

affil-num=39
en-affil=Department of Pediatrics, The University of Tokyo
kn-affil=
en-keyword=genomic medicine
kn-keyword=genomic medicine
en-keyword=integrative diagnosis
kn-keyword=integrative diagnosis
en-keyword=molecularly targeted therapy
kn-keyword=molecularly targeted therapy
en-keyword=multigene panel
kn-keyword=multigene panel
en-keyword=pediatric cancers
kn-keyword=pediatric cancers
END

start-ver=1.4
cd-journal=joma
no-vol=25
cd-vols=
no-issue=1
article-no=
start-page=1908
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251125
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Evaluation of Streptococcus mutans strains possessing genes encoding collagen-binding proteins in the Japanese population
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background Streptococcus mutans harbors collagen-binding protein genes, namely cnm and cbm, which are implicated in its virulence and pathogenicity in both oral and extraoral infections. Although both genes were initially identified in S. mutans isolated from Japanese populations, their geographical prevalence, distribution, and genetic relatedness within Japan remain largely unexplored. This study investigates the prevalence of S. mutans strains carrying cnm and cbm genes across Japan, correlates these findings with clinical data, and analyzes the genetic relatedness of cnm-positive and cnm-negative strains using multilocus sequence typing (MLST).<br>
Methods Dental plaque specimens were collected from 1248 individuals from eight Japanese cities (Hiroshima, Fukuoka, Nagasaki, Niigata, Okayama, Osaka, Tokushima, and Tokyo) and plated on selective medium for S. mutans isolation. S. mutans was confirmed in 523 subjects by colony morphology and PCR using species-specific primers, and the presence of the cnm and cbm genes was determined by PCR with gene-specific primers. Demographic (age, sex) and oral examination (caries prevalence, caries experience, number of teeth) data were recorded. MLST was employed to genotype selected cnm-positive and cnm-negative S. mutans strains to assess their clonal relationships.<br>
Results Among 523 subjects possessing S. mutans (aged 3?90 years), we detected cnm-positive strains in all cities; specifically, the prevalence ranged from 5.5% in Okayama to 25.0% in Tokushima. In contrast, cbm-positive strains were less common and undetectable in some regions. Furthermore, subjects harboring cnm-positive S. mutans were significantly older (p?=?0.002) and had higher caries prevalence and experience (p?<?0.001). MLST revealed evolutionary relationships among cnm-positive strains across the cities but no discernible region-specific clustering. Clonal relationships partially reflected cnm gene distribution, particularly for exclusively cnm-positive or cnm-negative clonal complexes, but inconsistencies involving serotypes and cnm presence within some clonal complexes and sequence types were also noted.<br>
Conclusions The cnm-positive S. mutans strains are widely distributed throughout Japan and are associated with increased age and caries burden. Although core genome analysis revealed some clonal patterns, the non-uniform distribution of the non-core cnm gene is likely influenced by horizontal gene transfer, providing S. mutans with adaptive advantages irrespective of its core genetic background or serotype.
en-copyright=
kn-copyright=

en-aut-name=OkudaMakoto
en-aut-sei=Okuda
en-aut-mei=Makoto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SuehiroYuto
en-aut-sei=Suehiro
en-aut-mei=Yuto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=LapirattanakulJinthana
en-aut-sei=Lapirattanakul
en-aut-mei=Jinthana
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NakaShuhei
en-aut-sei=Naka
en-aut-mei=Shuhei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=Matsumoto-NakanoMichiyo
en-aut-sei=Matsumoto-Nakano
en-aut-mei=Michiyo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NomuraRyota
en-aut-sei=Nomura
en-aut-mei=Ryota
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=OkawaRena
en-aut-sei=Okawa
en-aut-mei=Rena
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=NakanoKazuhiko
en-aut-sei=Nakano
en-aut-mei=Kazuhiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Pediatric Dentistry, Graduate School of Dentistry, The University of Osaka
kn-affil=

affil-num=2
en-affil=Department of Pediatric Dentistry, Graduate School of Dentistry, The University of Osaka
kn-affil=

affil-num=3
en-affil=Department of Oral Microbiology, Faculty of Dentistry, Mahidol University
kn-affil=

affil-num=4
en-affil=Department of Pediatric Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Pediatric Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Pediatric Dentistry, Graduate School of Biomedical and Health Sciences, Hiroshima University
kn-affil=

affil-num=7
en-affil=Department of Pediatric Dentistry, Graduate School of Dentistry, The University of Osaka
kn-affil=

affil-num=8
en-affil=Department of Pediatric Dentistry, Graduate School of Dentistry, The University of Osaka
kn-affil=
en-keyword=Collagen-binding protein gene
kn-keyword=Collagen-binding protein gene
en-keyword=cnm gene
kn-keyword=cnm gene
en-keyword=cbm gene
kn-keyword=cbm gene
en-keyword=Japan
kn-keyword=Japan
en-keyword=Multilocus sequence typing
kn-keyword=Multilocus sequence typing
en-keyword=Serotype
kn-keyword=Serotype
en-keyword=Streptococcus mutans
kn-keyword=Streptococcus mutans
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251015
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=German Chamomile (Matricaria chamomilla) Induces Cytochrome P450 Expression Through Increased BMAL1 Protein Expression in Liver Nuclei
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=German chamomile (Matricaria chamomilla) is a medicinal herb that promotes improved digestion and reduces insomnia. Although it is widely used worldwide, the mechanism of induction of drug-metabolizing enzymes is unknown. We found that German chamomile extracts induced cytochrome P450 expression at the transcriptional stage. Cyp3a11 expression is decreased at night in wild-type mice, but German chamomile extract induced nocturnal Cyp3a11 and Cyp1a2 expression. German chamomile extract increased the nuclear protein expression of the clock gene BMAL1, which drives and abolishes the rhythm of Cyp3a11 expression. By contrast, German chamomile extract did not significantly alter clock gene expression in the suprachiasmatic nucleus (SCN). Similarly, it did not affect the mRNA expression of the clock genes in the kidneys. Because it did not induce the mRNA expression of ATP-binding cassette (ABC) transporters (Abcb1a, Abcc2, Abcc4, and Abcg2) in the kidney, German chamomile extract had no effect on the transcription of pharmacokinetics-related molecules other than CYPs. German chamomile extract promoted liver-selective nuclear transfer rhythm changes in clock genes and induced the expression of CYPs. This study may help to explain the mechanism of drug interactions associated with chronic German chamomile extract consumption.
en-copyright=
kn-copyright=

en-aut-name=IkedaMoka
en-aut-sei=Ikeda
en-aut-mei=Moka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TsurudomeYuya
en-aut-sei=Tsurudome
en-aut-mei=Yuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=EnrinMai
en-aut-sei=Enrin
en-aut-mei=Mai
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=WadaYukiyo
en-aut-sei=Wada
en-aut-mei=Yukiyo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HoriguchiMichiko
en-aut-sei=Horiguchi
en-aut-mei=Michiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=UshijimaKentaro
en-aut-sei=Ushijima
en-aut-mei=Kentaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Division of Pharmaceutics, Faculty of Pharmaceutical Sciences, Sanyo-Onoda City University
kn-affil=

affil-num=2
en-affil=Division of Pharmaceutics, Faculty of Pharmaceutical Sciences, Sanyo-Onoda City University
kn-affil=

affil-num=3
en-affil=Division of Pharmaceutics, Faculty of Pharmaceutical Sciences, Sanyo-Onoda City University
kn-affil=

affil-num=4
en-affil=Division of Pharmaceutics, Faculty of Pharmaceutical Sciences, Sanyo-Onoda City University
kn-affil=

affil-num=5
en-affil=Department of Regenerative and Therapeutic Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=6
en-affil=Division of Pharmaceutics, Faculty of Pharmaceutical Sciences, Sanyo-Onoda City University
kn-affil=
en-keyword=Circadian clock
kn-keyword=Circadian clock
en-keyword=German chamomile
kn-keyword=German chamomile
en-keyword=Xenobiotic transporter
kn-keyword=Xenobiotic transporter
en-keyword=Metabolic enzyme
kn-keyword=Metabolic enzyme
en-keyword=Clock gene
kn-keyword=Clock gene
END

start-ver=1.4
cd-journal=joma
no-vol=8
cd-vols=
no-issue=1
article-no=
start-page=1720
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251205
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A genome-wide association study identifies the GPM6A locus associated with age at onset in ALS
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Amyotrophic lateral sclerosis (ALS) exhibits considerable clinical variability, such as differences in age at onset (AAO). Multiple factors, including genetic factors, may underlie this variability; however, the specific determinants remain unclear. To identify genes affecting AAO, we have conducted a genome-wide association study in Japanese patients with ALS (discovery cohort: n?=?1808; replication cohort: n?=?207). Here, we show that the minor A allele of rs113161727 at the ADAM29-GPM6A locus is associated with a younger AAO in the discovery cohort (effect, -4.27 years; p?=?4.60 × 10-8); this finding has been confirmed in the replication cohort (p?=?0.0068) and meta-analysis (p?=?1.08 × 10?9). Among 65 ALS patients with a SOD1 mutation, the AAO has been found to be 10.2 years younger in those with the A allele than in those without it (p?=?0.002). This variant correlates with GPM6A upregulation in iPSC-derived motor neurons, suggesting GPM6A as a candidate AAO modifier. Overall, our study highlights the impact of genetic modifiers on ALS heterogeneity and provides a potential target for delaying disease onset.
en-copyright=
kn-copyright=

en-aut-name=NakamuraRyoichi
en-aut-sei=Nakamura
en-aut-mei=Ryoichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TohnaiGenki
en-aut-sei=Tohnai
en-aut-mei=Genki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=AtsutaNaoki
en-aut-sei=Atsuta
en-aut-mei=Naoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MatsudaYumi
en-aut-sei=Matsuda
en-aut-mei=Yumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MorimotoSatoru
en-aut-sei=Morimoto
en-aut-mei=Satoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=ItoDaisuke
en-aut-sei=Ito
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KatsunoMasahisa
en-aut-sei=Katsuno
en-aut-mei=Masahisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=IzumiYuishin
en-aut-sei=Izumi
en-aut-mei=Yuishin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MoritaMitsuya
en-aut-sei=Morita
en-aut-mei=Mitsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=IwataIkuko
en-aut-sei=Iwata
en-aut-mei=Ikuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=YabeIchiro
en-aut-sei=Yabe
en-aut-mei=Ichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=NakazatoTomoko
en-aut-sei=Nakazato
en-aut-mei=Tomoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=HattoriNobutaka
en-aut-sei=Hattori
en-aut-mei=Nobutaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=HirayamaTakehisa
en-aut-sei=Hirayama
en-aut-mei=Takehisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=KanoOsamu
en-aut-sei=Kano
en-aut-mei=Osamu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=TamuraAsako
en-aut-sei=Tamura
en-aut-mei=Asako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=SuzukiNaoki
en-aut-sei=Suzuki
en-aut-mei=Naoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=AokiMasashi
en-aut-sei=Aoki
en-aut-mei=Masashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=ShibuyaKazumoto
en-aut-sei=Shibuya
en-aut-mei=Kazumoto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=KuwabaraSatoshi
en-aut-sei=Kuwabara
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=OdaMasaya
en-aut-sei=Oda
en-aut-mei=Masaya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=HashimotoRina
en-aut-sei=Hashimoto
en-aut-mei=Rina
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=AibaIkuko
en-aut-sei=Aiba
en-aut-mei=Ikuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=IshiharaTomohiko
en-aut-sei=Ishihara
en-aut-mei=Tomohiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=OnoderaOsamu
en-aut-sei=Onodera
en-aut-mei=Osamu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=YamashitaToru
en-aut-sei=Yamashita
en-aut-mei=Toru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

en-aut-name=IshiuraHiroyuki
en-aut-sei=Ishiura
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=27
ORCID=

en-aut-name=BokudaKota
en-aut-sei=Bokuda
en-aut-mei=Kota
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=28
ORCID=

en-aut-name=ShimizuToshio
en-aut-sei=Shimizu
en-aut-mei=Toshio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=29
ORCID=

en-aut-name=IkedaYoshio
en-aut-sei=Ikeda
en-aut-mei=Yoshio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=30
ORCID=

en-aut-name=HasegawaKazuko
en-aut-sei=Hasegawa
en-aut-mei=Kazuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=31
ORCID=

en-aut-name=TanakaFumiaki
en-aut-sei=Tanaka
en-aut-mei=Fumiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=32
ORCID=

en-aut-name=YokotaTakanori
en-aut-sei=Yokota
en-aut-mei=Takanori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=33
ORCID=

en-aut-name=KanaiKazuaki
en-aut-sei=Kanai
en-aut-mei=Kazuaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=34
ORCID=

en-aut-name=NotoYu-ichi
en-aut-sei=Noto
en-aut-mei=Yu-ichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=35
ORCID=

en-aut-name=KajiRyuji
en-aut-sei=Kaji
en-aut-mei=Ryuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=36
ORCID=

en-aut-name=WatanabeHirohisa
en-aut-sei=Watanabe
en-aut-mei=Hirohisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=37
ORCID=

en-aut-name=KonishiTomoko
en-aut-sei=Konishi
en-aut-mei=Tomoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=38
ORCID=

en-aut-name=HasegawaMikiko
en-aut-sei=Hasegawa
en-aut-mei=Mikiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=39
ORCID=

en-aut-name=FukayaHozuki
en-aut-sei=Fukaya
en-aut-mei=Hozuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=40
ORCID=

en-aut-name=NiwaJun-ichi
en-aut-sei=Niwa
en-aut-mei=Jun-ichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=41
ORCID=

en-aut-name=DoyuManabu
en-aut-sei=Doyu
en-aut-mei=Manabu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=42
ORCID=

en-aut-name=OkadaYohei
en-aut-sei=Okada
en-aut-mei=Yohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=43
ORCID=

en-aut-name=NakamuraShiho
en-aut-sei=Nakamura
en-aut-mei=Shiho
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=44
ORCID=

en-aut-name=OzawaFumiko
en-aut-sei=Ozawa
en-aut-mei=Fumiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=45
ORCID=

en-aut-name=OkanoHideyuki
en-aut-sei=Okano
en-aut-mei=Hideyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=46
ORCID=

en-aut-name=NakatochiMasahiro
en-aut-sei=Nakatochi
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=47
ORCID=

en-aut-name=SobueGen
en-aut-sei=Sobue
en-aut-mei=Gen
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=48
ORCID=

affil-num=1
en-affil=Department of Neurology, Aichi Medical University School of Medicine
kn-affil=

affil-num=2
en-affil=Division of ALS Research, Aichi Medical University School of Medicine
kn-affil=

affil-num=3
en-affil=Department of Neurology, Aichi Medical University School of Medicine
kn-affil=

affil-num=4
en-affil=Public Health Informatics Unit, Department of Integrated Health Sciences, Nagoya University Graduate School of Medicine
kn-affil=

affil-num=5
en-affil=Keio University Regenerative Medicine Research Center, Kawasaki
kn-affil=

affil-num=6
en-affil=Department of Neurology, Nagoya University Graduate School of Medicine
kn-affil=

affil-num=7
en-affil=Department of Neurology, Nagoya University Graduate School of Medicine
kn-affil=

affil-num=8
en-affil=Department of Neurology, Tokushima University Graduate School of Biomedical Sciences
kn-affil=

affil-num=9
en-affil=Division of Neurology, Department of Internal Medicine, Jichi Medical University
kn-affil=

affil-num=10
en-affil=Department of Neurology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University
kn-affil=

affil-num=11
en-affil=Department of Neurology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University
kn-affil=

affil-num=12
en-affil=Department of Neurology, Juntendo University School of Medicine
kn-affil=

affil-num=13
en-affil=Department of Neurology, Juntendo University School of Medicine
kn-affil=

affil-num=14
en-affil=Department of Neurology, Toho University Faculty of Medicine
kn-affil=

affil-num=15
en-affil=Department of Neurology, Toho University Faculty of Medicine
kn-affil=

affil-num=16
en-affil=Department of Neurology, Mie University Graduate School of Medicine
kn-affil=

affil-num=17
en-affil=Department of Neurology, Tohoku University Graduate School of Medicine
kn-affil=

affil-num=18
en-affil=Department of Neurology, Tohoku University Graduate School of Medicine
kn-affil=

affil-num=19
en-affil=Department of Neurology, Graduate School of Medicine, Chiba University
kn-affil=

affil-num=20
en-affil=Department of Neurology, Graduate School of Medicine, Chiba University
kn-affil=

affil-num=21
en-affil=Department of Neurology, Vihara Hananosato Hospital
kn-affil=

affil-num=22
en-affil=Department of Neurology, NHO Higashinagoya National Hospital
kn-affil=

affil-num=23
en-affil=Department of Neurology, NHO Higashinagoya National Hospital
kn-affil=

affil-num=24
en-affil=Department of Neurology, Brain Research Institute, Niigata University
kn-affil=

affil-num=25
en-affil=Department of Neurology, Brain Research Institute, Niigata University
kn-affil=

affil-num=26
en-affil=Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=27
en-affil=Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=28
en-affil=Department of Neurology, Tokyo Metropolitan Neurological Hospital
kn-affil=

affil-num=29
en-affil=Department of Neurology, Tokyo Metropolitan Neurological Hospital
kn-affil=

affil-num=30
en-affil=Department of Neurology, Gunma University Graduate School of Medicine
kn-affil=

affil-num=31
en-affil=Division of Neurology, NHO Sagamihara National Hospital
kn-affil=

affil-num=32
en-affil=Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine
kn-affil=

affil-num=33
en-affil=Department of Neurology and Neurological Science, NucleoTIDE and PepTIDE Drug Discovery Center (TIDE), Institute of Science Tokyo
kn-affil=

affil-num=34
en-affil=Department of Neurology, Fukushima Medical University School of Medicine
kn-affil=

affil-num=35
en-affil=Department of Neurology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine
kn-affil=

affil-num=36
en-affil=Department of Neurology, Tokushima University Graduate School of Biomedical Sciences
kn-affil=

affil-num=37
en-affil=Department of Neurology, Fujita Health University
kn-affil=

affil-num=38
en-affil=Division of ALS Research, Aichi Medical University School of Medicine
kn-affil=

affil-num=39
en-affil=Division of ALS Research, Aichi Medical University School of Medicine
kn-affil=

affil-num=40
en-affil=Division of ALS Research, Aichi Medical University School of Medicine
kn-affil=

affil-num=41
en-affil=Department of Neurology, Aichi Medical University School of Medicine
kn-affil=

affil-num=42
en-affil=Department of Neurology, Aichi Medical University School of Medicine
kn-affil=

affil-num=43
en-affil=Department of Neurology, Aichi Medical University School of Medicine
kn-affil=

affil-num=44
en-affil=Keio University Regenerative Medicine Research Center, Kawasaki
kn-affil=

affil-num=45
en-affil=Keio University Regenerative Medicine Research Center, Kawasaki
kn-affil=

affil-num=46
en-affil=Keio University Regenerative Medicine Research Center, Kawasaki
kn-affil=

affil-num=47
en-affil=Public Health Informatics Unit, Department of Integrated Health Sciences, Nagoya University Graduate School of Medicine
kn-affil=

affil-num=48
en-affil=Division of ALS Research, Aichi Medical University School of Medicine
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=30
cd-vols=
no-issue=4
article-no=
start-page=e70082
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202512
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A Case of Retinopathy?Sensory Neuropathy Syndrome With a Novel Compound Heterozygous FLVCR1 Variant
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background and Aims: Retinopathy?sensory neuropathy syndrome (RETSNS), also known as posterior column ataxia with retinitis pigmentosa (PCARP), is a rare neurodegenerative disorder that is caused by biallelic pathogenic variants in FLVCR1. Here, we report a case of a Japanese patient with RETSNS.<br>
Methods: Clinical, neuroradiological, and electrophysiological findings were documented. Whole-genome sequencing was performed. Subcloning was carried out to confirm compound heterozygosity. A functional assay was performed to assess the pathogenicity of the variants.<br>
Results: The patient showed retinitis pigmentosa and sensory ataxia. Over the course of the disease, autonomic dysfunction has become increasingly evident. Despite consanguinity in the family, whole-genome sequencing identified two heterozygous variants in FLVCR1 (c.369T>G, p.Phe123Leu and c.733A>G, p.Asn245Asp). Cloning of the PCR product followed by Sanger sequencing indicated compound heterozygosity of the variants. Immunocytochemistry of HEK293FT cells transfected with plasmids containing wild-type or variant FLVCR1 cDNA demonstrated altered subcellular localization of the variant FLVCR1 proteins, characterized by reduced membrane localization.<br>
Interpretation: We report a novel variant in FLVCR1 causing RETSNS. The functional assay supports the pathogenicity of the variants.
en-copyright=
kn-copyright=

en-aut-name=NakanoYumiko
en-aut-sei=Nakano
en-aut-mei=Yumiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=FukuiYusuke
en-aut-sei=Fukui
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=DeguchiKentaro
en-aut-sei=Deguchi
en-aut-mei=Kentaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MatsuokaChika
en-aut-sei=Matsuoka
en-aut-mei=Chika
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KawanoTomohito
en-aut-sei=Kawano
en-aut-mei=Tomohito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TairaYuki
en-aut-sei=Taira
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MatsuoAyaka
en-aut-sei=Matsuo
en-aut-mei=Ayaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=OsakadaYosuke
en-aut-sei=Osakada
en-aut-mei=Yosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=YunokiTaijun
en-aut-sei=Yunoki
en-aut-mei=Taijun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=NomuraEmi
en-aut-sei=Nomura
en-aut-mei=Emi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=TakemotoMami
en-aut-sei=Takemoto
en-aut-mei=Mami
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=MoriharaRyuta
en-aut-sei=Morihara
en-aut-mei=Ryuta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=YamashitaToru
en-aut-sei=Yamashita
en-aut-mei=Toru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=IshiuraHiroyuki
en-aut-sei=Ishiura
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

affil-num=1
en-affil=Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Neurology, Okayama City General Medical Center
kn-affil=

affil-num=4
en-affil=Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=11
en-affil=Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=12
en-affil=Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=13
en-affil=Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=14
en-affil=Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=FLCVR1
kn-keyword=FLCVR1
en-keyword=functional analysis 
kn-keyword=functional analysis 
en-keyword=posterior column ataxia with retinitis pigmentosa
kn-keyword=posterior column ataxia with retinitis pigmentosa
en-keyword=subcellular localization
kn-keyword=subcellular localization
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=6
article-no=
start-page=431
end-page=436
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202512
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Association of Weekend Admission and In-Hospital Mortality in Adult Patients with Acute Myeloid Leukemia in Japan
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The effect of weekend admission on patient mortality has been investigated in several therapeutic areas, including acute myeloid leukemia (AML), but the investigations’ results are controversial. We evaluated the relationship between in-hospital mortality and weekend admission in adult patients with AML in Japan by conducting a retrospective observational study using administrative data from 144 acute care hospitals from which patients were discharged between April 2014 and March 2019. The primary endpoint was in-hospital mortality, compared between weekend and weekday admissions. Among the 1,340 eligible patients, 11% (150) were admitted during a weekend. The in-hospital mortality rates of the patients admitted during weekends and those admitted on a weekday were 28% (42/150) and 17% (204/1190), respectively. After an adjustment for covariates, weekend admission was associated with a significantly higher risk of in-hospital mortality than weekday admission (HR 1.70, 95%CI: 1.20-2.40; p=0.003). However, such an association was not observed in patients treated in a bio-clean room (HR 1.26, 95%CI: 0.65-2.42). Our results demonstrate that for patients with AML, weekend admission was independently associated with a higher risk of death during hospitalization. An appropriate system is necessary for these patients.
en-copyright=
kn-copyright=

en-aut-name=InoueTakahiro
en-aut-sei=Inoue
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KuwabaraHiroyo
en-aut-sei=Kuwabara
en-aut-mei=Hiroyo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YamamotoKoh
en-aut-sei=Yamamoto
en-aut-mei=Koh
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

affil-num=1
en-affil=Healthcare Management Research Center, Chiba University Hospital
kn-affil=

affil-num=2
en-affil=Healthcare Management Research Center, Chiba University Hospital
kn-affil=

affil-num=3
en-affil=Department of Hematology, Yokohama City Minato Red Cross Hospital
kn-affil=
en-keyword=acute leukemia
kn-keyword=acute leukemia
en-keyword=weekend admission
kn-keyword=weekend admission
en-keyword=in-hospital mortality
kn-keyword=in-hospital mortality
en-keyword=bio-clean room
kn-keyword=bio-clean room
END

start-ver=1.4
cd-journal=joma
no-vol=22
cd-vols=
no-issue=12
article-no=
start-page=3199
end-page=3207
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202512
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Virtual endoscopic imaging of the heart using photon-counting detector computed tomography for electrophysiologists
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=MoritaHiroshi
en-aut-sei=Morita
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=AsadaSaori
en-aut-sei=Asada
en-aut-mei=Saori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MiyamotoMasakazu
en-aut-sei=Miyamoto
en-aut-mei=Masakazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NakagawaKoji
en-aut-sei=Nakagawa
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=NagaseSatoshi
en-aut-sei=Nagase
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MorimotoYoshimasa
en-aut-sei=Morimoto
en-aut-mei=Yoshimasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KawadaSatoshi
en-aut-sei=Kawada
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=WadaTadashi
en-aut-sei=Wada
en-aut-mei=Tadashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MasudaTakuro
en-aut-sei=Masuda
en-aut-mei=Takuro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=UeokaAkira
en-aut-sei=Ueoka
en-aut-mei=Akira
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=TohNorihisa
en-aut-sei=Toh
en-aut-mei=Norihisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=MiyoshiToru
en-aut-sei=Miyoshi
en-aut-mei=Toru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=NishiiNobuhiro
en-aut-sei=Nishii
en-aut-mei=Nobuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=YuasaShinsuke
en-aut-sei=Yuasa
en-aut-mei=Shinsuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

affil-num=1
en-affil=Department of Cardiovascular Therapeutics, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry
kn-affil=

affil-num=3
en-affil=Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry
kn-affil=

affil-num=4
en-affil=Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry
kn-affil=

affil-num=5
en-affil=Department of General Internal Medicine 3, Kawasaki Medical School General Medical Center
kn-affil=

affil-num=6
en-affil=Department of Cardiovascular Medicine, Fukuyama City Hospital
kn-affil=

affil-num=7
en-affil=Department of Cardiovascular Medicine, Kochi Health Science Center
kn-affil=

affil-num=8
en-affil=Department of Cardiology, National Hospital Organization Iwakuni Clinical Center
kn-affil=

affil-num=9
en-affil=Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry
kn-affil=

affil-num=10
en-affil=Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry
kn-affil=

affil-num=11
en-affil=Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry
kn-affil=

affil-num=12
en-affil=Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry
kn-affil=

affil-num=13
en-affil=Department of Cardiovascular Therapeutics, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=14
en-affil=Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry
kn-affil=
en-keyword=Photon-counting detector computed tomography
kn-keyword=Photon-counting detector computed tomography
en-keyword=Endoscopic view
kn-keyword=Endoscopic view
en-keyword=False tendon
kn-keyword=False tendon
en-keyword=Ablation
kn-keyword=Ablation
en-keyword=Anatomy
kn-keyword=Anatomy
END

start-ver=1.4
cd-journal=joma
no-vol=114
cd-vols=
no-issue=3
article-no=
start-page=117209
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202603
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Molecular epidemiological investigation of the carbapenemase-producing Enterobacterales isolates in Okayama prefecture, Japan
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=We investigated the genetic characteristics of non-IMP type carbapenemase-producing Enterobacterales isolates detected in Japan. The isolates were found to carry diverse plasmids with high sequence similarity to those previously reported in other countries, underscoring the critical imperative for comprehensive nationwide epidemiological surveillance for the silent pandemic of the nightmare pathogen.
en-copyright=
kn-copyright=

en-aut-name=TsujiShuma
en-aut-sei=Tsuji
en-aut-mei=Shuma
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=FukushimaShinnosuke
en-aut-sei=Fukushima
en-aut-mei=Shinnosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=GotohKazuyoshi
en-aut-sei=Gotoh
en-aut-mei=Kazuyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=IioKoji
en-aut-sei=Iio
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SatoMayu
en-aut-sei=Sato
en-aut-mei=Mayu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=InoueYasurou
en-aut-sei=Inoue
en-aut-mei=Yasurou
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=SakitaSayaka
en-aut-sei=Sakita
en-aut-mei=Sayaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=FudeyasuTomoko
en-aut-sei=Fudeyasu
en-aut-mei=Tomoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=OtsukaFumio
en-aut-sei=Otsuka
en-aut-mei=Fumio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=HagiyaHideharu
en-aut-sei=Hagiya
en-aut-mei=Hideharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Department of Medical Laboratory Science, Okayama University Graduate School of Health Sciences
kn-affil=

affil-num=2
en-affil=Department of Bacteriology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Medical Laboratory Science, Okayama University Graduate School of Health Sciences
kn-affil=

affil-num=4
en-affil=Microbiology Division, Clinical Laboratory, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of Clinical Laboratory, Okayama City Hospital
kn-affil=

affil-num=6
en-affil=Department of Clinical Laboratory, Okayama City Hospital
kn-affil=

affil-num=7
en-affil=Department of Clinical Laboratory, Okayama Rosai Hospital
kn-affil=

affil-num=8
en-affil=Department of Clinical Laboratory, Microbiology Division, Tsuyama Chuo Hospital
kn-affil=

affil-num=9
en-affil=Department of Infectious Diseases, Okayama University Hospital
kn-affil=

affil-num=10
en-affil=Department of Infectious Diseases, Okayama University Hospital
kn-affil=
en-keyword=Antimicrobial resistance
kn-keyword=Antimicrobial resistance
en-keyword=Carbapenemase-producing Enterobacterales
kn-keyword=Carbapenemase-producing Enterobacterales
en-keyword=New Delhi metallo-β-lactamase
kn-keyword=New Delhi metallo-β-lactamase
en-keyword=Klebsiella pneumoniae carbapenemase
kn-keyword=Klebsiella pneumoniae carbapenemase
en-keyword=Genomic surveillance
kn-keyword=Genomic surveillance
END

start-ver=1.4
cd-journal=joma
no-vol=55
cd-vols=
no-issue=5
article-no=
start-page=547
end-page=555
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250223
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Multicenter, open-label, randomized, controlled study to test the utility of electronic patient-reported outcome monitoring in patients with unresectable advanced cancers or metastatic/recurrent solid tumors
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Electronic patient-reported outcome (ePRO) monitoring for patients undergoing cancer chemotherapy may provide qualified and early detection of adverse events or disease-related symptoms, leading to improved patient care. The aim of this study is to examine whether addition of ePRO monitoring to routine medical care contributes to improved overall survival and quality of life of cancer patients undergoing chemotherapy. Patients with unresectable advanced cancers or metastatic/recurrent solid tumors receiving systemic chemotherapy will be randomized to an ePRO monitoring group and a usual care group. The ePRO group will conduct weekly symptom monitoring using an electronic device after study enrollment until the end of the study. Monitoring results will be returned to medical personnel and used as information for patient care. The primary endpoints are overall survival and health related quality of life. The initial target sample size for the study was 1500 patients. However, due to delays in enrollment, the target was readjusted to 500 patients. Enrollment has been completed, and the study is now in the follow-up phase.
en-copyright=
kn-copyright=

en-aut-name=TairaNaruto
en-aut-sei=Taira
en-aut-mei=Naruto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KiyotaNaomi
en-aut-sei=Kiyota
en-aut-mei=Naomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KikawaYuichiro
en-aut-sei=Kikawa
en-aut-mei=Yuichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=IchiharaEiki
en-aut-sei=Ichihara
en-aut-mei=Eiki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KatoKyoko
en-aut-sei=Kato
en-aut-mei=Kyoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KubotaKaoru
en-aut-sei=Kubota
en-aut-mei=Kaoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TateishiRyosuke
en-aut-sei=Tateishi
en-aut-mei=Ryosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=NakataAkinobu
en-aut-sei=Nakata
en-aut-mei=Akinobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=NakamuraKeiichiro
en-aut-sei=Nakamura
en-aut-mei=Keiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=NaritaYukiya
en-aut-sei=Narita
en-aut-mei=Yukiya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=HottaKatsuyuki
en-aut-sei=Hotta
en-aut-mei=Katsuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=IwataHiroji
en-aut-sei=Iwata
en-aut-mei=Hiroji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=GemmaAkihiko
en-aut-sei=Gemma
en-aut-mei=Akihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=ShimozumaKojiro
en-aut-sei=Shimozuma
en-aut-mei=Kojiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=MuroKei
en-aut-sei=Muro
en-aut-mei=Kei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=IwamotoTetsuya
en-aut-sei=Iwamoto
en-aut-mei=Tetsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=TakumotoYuki
en-aut-sei=Takumoto
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=ShiroiwaTakeru
en-aut-sei=Shiroiwa
en-aut-mei=Takeru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=FukudaTakashi
en-aut-sei=Fukuda
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=YamaguchiTakuhiro
en-aut-sei=Yamaguchi
en-aut-mei=Takuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=HagiwaraYasuhiro
en-aut-sei=Hagiwara
en-aut-mei=Yasuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=MinamiHironobu
en-aut-sei=Minami
en-aut-mei=Hironobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

affil-num=1
en-affil=Department of Breast and Thyroid Surgery, Kawasaki Medical School
kn-affil=

affil-num=2
en-affil=Department of Medical Oncology and Hematology, Cancer Center, Kobe University Hospital
kn-affil=

affil-num=3
en-affil=Department of Breast Surgery, Kansai Medical University
kn-affil=

affil-num=4
en-affil=Center for Clinical Oncology, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of Medical Oncology, National Hospital Organization Nagoya Medical Center 
kn-affil=

affil-num=6
en-affil=Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School
kn-affil=

affil-num=7
en-affil=Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo
kn-affil=

affil-num=8
en-affil=Department of Gastroenterology, Osaka Metropolitan University Graduate School of Medicine
kn-affil=

affil-num=9
en-affil=Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Department of Gastroenterology, Osaka Metropolitan University Graduate School of Medicine
kn-affil=

affil-num=11
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=

affil-num=12
en-affil=Department of Advanced Clinical Research and Development, Nagoya City University
kn-affil=

affil-num=13
en-affil=Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School
kn-affil=

affil-num=14
en-affil=Department of Biomed Sciences, College of Life Sciences, Ritsumeikan University
kn-affil=

affil-num=15
en-affil=Department of Gastroenterology, Osaka Metropolitan University Graduate School of Medicine
kn-affil=

affil-num=16
en-affil=Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health
kn-affil=

affil-num=17
en-affil=Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health
kn-affil=

affil-num=18
en-affil=Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health
kn-affil=

affil-num=19
en-affil=Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health
kn-affil=

affil-num=20
en-affil=Division of Biostatistics, Tohoku University Graduate School of Medicine
kn-affil=

affil-num=21
en-affil=Department of Biostatistics, Division of Health Sciences and Nursing, The University of Tokyo Graduate School of Medicine
kn-affil=

affil-num=22
en-affil=Division of Medical Oncology and Hematology, Department of Medicine, Kobe University Graduate School of Medicine
kn-affil=
en-keyword=electronic patient-reported outcomes monitoring
kn-keyword=electronic patient-reported outcomes monitoring
en-keyword=advanced cancers
kn-keyword=advanced cancers
en-keyword=systemic chemotherapy
kn-keyword=systemic chemotherapy
en-keyword=randomized controlled study
kn-keyword=randomized controlled study
en-keyword=quality of life
kn-keyword=quality of life
en-keyword=overall survival
kn-keyword=overall survival
END

start-ver=1.4
cd-journal=joma
no-vol=60
cd-vols=
no-issue=12
article-no=
start-page=1584
end-page=1595
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250906
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Combination chemotherapy for older patients with unresectable biliary tract cancer: a prospective observational study using propensity-score matched analysis (JON2104-B)
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Systemic chemotherapy with gemcitabine plus S-1 (GEM?+?S-1), GEM?+?CDDP plus S-1 (GEM?+?CDDP?+?S-1), or gemcitabine plus cisplatin (GEM?+?CDDP) is standard treatment for advanced biliary tract cancer (aBTC). We aimed to evaluate the efficacy and safety of combination chemotherapy in older patients with aBTC.<br>
Methods: This multicenter prospective observational study (JON2104-B, UMIN000045156) included patients aged???70 years with aBTC. Inverse-probability weighting propensity-score analyses (IPW) were used to compare overall survival (OS) as the primary endpoint and progression-free survival (PFS) across treatment groups.<br>
Results: This study included 305 patients between August 2021 and January 2023. Of them, 75, 131, 26, 52, and 10 received GEM?+?CDDP?+?S-1, GEM?+?CDDP, GEM?+?S-1, gemcitabine, and S-1; their median ages were 74, 75, 77.5, 80, and 80 years, and approximately 24%, 16.8%, 23.1%, 9.6%, and 0% had G-8 scores of?>?14, respectively. GEM?+?CDDP had a safety profile comparable to that of GEM?+?CDDP?+?S-1 but was more toxic than gemcitabine. Per IPW, the hazard ratio (HR) for GEM?+?CDDP?+?S-1 versus GEM?+?CDDP was 0.80 for OS (95% confidence interval [CI], 0.55?1.17) and 0.55 for PFS (95% CI 0.38?0.80). The HR for GEM?+?CDDP versus gemcitabine was 0.74 for OS (95% CI 0.42?1.29) and 0.79 for PFS (95% CI 0.42?1.49).<br>
Conclusions: GEM?+?CDDP?+?S-1 was associated with longer PFS without additional toxicity than GEM?+?CDDP for fit older patients. However, the OS for both were not statistically different. The efficacies of GEM?+?CDDP and gemcitabine for vulnerable older patients did not also differ significantly. These findings highlight the importance of vulnerability in patients with aBTC.
en-copyright=
kn-copyright=

en-aut-name=KobayashiSatoshi
en-aut-sei=Kobayashi
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NakachiKohei
en-aut-sei=Nakachi
en-aut-mei=Kohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YamamotoKouji
en-aut-sei=Yamamoto
en-aut-mei=Kouji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=UenoMakoto
en-aut-sei=Ueno
en-aut-mei=Makoto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MarukiYuta
en-aut-sei=Maruki
en-aut-mei=Yuta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=IkezawaKenji
en-aut-sei=Ikezawa
en-aut-mei=Kenji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TerashimaTakeshi
en-aut-sei=Terashima
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=ShimizuSatoshi
en-aut-sei=Shimizu
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=OshimaKotoe
en-aut-sei=Oshima
en-aut-mei=Kotoe
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=TsujiKunihiro
en-aut-sei=Tsuji
en-aut-mei=Kunihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=MasakiYoshiharu
en-aut-sei=Masaki
en-aut-mei=Yoshiharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=TsumuraHidetaka
en-aut-sei=Tsumura
en-aut-mei=Hidetaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=ShibukiTaro
en-aut-sei=Shibuki
en-aut-mei=Taro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=OzakaMasato
en-aut-sei=Ozaka
en-aut-mei=Masato
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=OkanoNaohiro
en-aut-sei=Okano
en-aut-mei=Naohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=OkamuraYukiyasu
en-aut-sei=Okamura
en-aut-mei=Yukiyasu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=UmemotoKumiko
en-aut-sei=Umemoto
en-aut-mei=Kumiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=SatohTatsunori
en-aut-sei=Satoh
en-aut-mei=Tatsunori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=KojimaYasushi
en-aut-sei=Kojima
en-aut-mei=Yasushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=ShiojiKazuhiko
en-aut-sei=Shioji
en-aut-mei=Kazuhiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=NebikiHiroko
en-aut-sei=Nebiki
en-aut-mei=Hiroko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=DoiToshifumi
en-aut-sei=Doi
en-aut-mei=Toshifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=NaganumaAtsushi
en-aut-sei=Naganuma
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=KataokaShigeki
en-aut-sei=Kataoka
en-aut-mei=Shigeki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=KitaEmiri
en-aut-sei=Kita
en-aut-mei=Emiri
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=AsamaHiroyuki
en-aut-sei=Asama
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

en-aut-name=TsuchiyaKaoru
en-aut-sei=Tsuchiya
en-aut-mei=Kaoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=27
ORCID=

en-aut-name=UnnoMichiaki
en-aut-sei=Unno
en-aut-mei=Michiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=28
ORCID=

en-aut-name=AshidaReiko
en-aut-sei=Ashida
en-aut-mei=Reiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=29
ORCID=

en-aut-name=MatsumotoKazuyuki
en-aut-sei=Matsumoto
en-aut-mei=Kazuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=30
ORCID=

en-aut-name=OhnoIzumi
en-aut-sei=Ohno
en-aut-mei=Izumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=31
ORCID=

en-aut-name=ItoiTakao
en-aut-sei=Itoi
en-aut-mei=Takao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=32
ORCID=

en-aut-name=NegoroYuji
en-aut-sei=Negoro
en-aut-mei=Yuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=33
ORCID=

en-aut-name=SakamotoYasunari
en-aut-sei=Sakamoto
en-aut-mei=Yasunari
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=34
ORCID=

en-aut-name=ArimaShiho
en-aut-sei=Arima
en-aut-mei=Shiho
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=35
ORCID=

en-aut-name=AsagiAkinori
en-aut-sei=Asagi
en-aut-mei=Akinori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=36
ORCID=

en-aut-name=OkuyamaHiroyuki
en-aut-sei=Okuyama
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=37
ORCID=

en-aut-name=KomatsuYoshito
en-aut-sei=Komatsu
en-aut-mei=Yoshito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=38
ORCID=

en-aut-name=KobayashiNoritoshi
en-aut-sei=Kobayashi
en-aut-mei=Noritoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=39
ORCID=

en-aut-name=NaganoHiroaki
en-aut-sei=Nagano
en-aut-mei=Hiroaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=40
ORCID=

en-aut-name=FuruseJunji
en-aut-sei=Furuse
en-aut-mei=Junji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=41
ORCID=

affil-num=1
en-affil=Department of Gastroenterology, Kanagawa Cancer Center
kn-affil=

affil-num=2
en-affil=Department of Medical Oncology, Tochigi Cancer Center
kn-affil=

affil-num=3
en-affil=Department of Biostatistics, Yokohama City University School of Medicine
kn-affil=

affil-num=4
en-affil=Department of Gastroenterology, Kanagawa Cancer Center
kn-affil=

affil-num=5
en-affil=
kn-affil=

affil-num=6
en-affil=Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute
kn-affil=

affil-num=7
en-affil=Department of Gastroenterology, Kanazawa University Hospital
kn-affil=

affil-num=8
en-affil=Department of Gastroenterology, Kanazawa University Hospital
kn-affil=

affil-num=9
en-affil=Division of Gastrointestinal Oncology, Shizuoka Cancer Center
kn-affil=

affil-num=10
en-affil=Department of Gastroenterology, Ishikawa Prefectural Central Hospital
kn-affil=

affil-num=11
en-affil=Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine
kn-affil=

affil-num=12
en-affil=Department of Gastroenterological Oncology, Hyogo Cancer Center
kn-affil=

affil-num=13
en-affil=Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East
kn-affil=

affil-num=14
en-affil=Hepato-Biliary-Pancreatic Medicine Department, Cancer Institute Hospital of Japanese Foundation for Cancer Research
kn-affil=

affil-num=15
en-affil=Department of Medical Oncology, Kyorin University Faculty of Medicine
kn-affil=

affil-num=16
en-affil=Division of Digestive Surgery, Department of Surgery, Nihon University School of Medicine
kn-affil=

affil-num=17
en-affil=Department of Clinical Oncology, St. Marianna University School of Medicine
kn-affil=

affil-num=18
en-affil=Department of Gastroenterology, Shizuoka General Hospital
kn-affil=

affil-num=19
en-affil=Department of Gastroenterology, National Center for Global Health and Medicine
kn-affil=

affil-num=20
en-affil=Department of Gastroenterology, Niigata Cancer Center Hospital
kn-affil=

affil-num=21
en-affil=Department of Gastroenterology, Osaka City General Hospital
kn-affil=

affil-num=22
en-affil=Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine
kn-affil=

affil-num=23
en-affil=Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center
kn-affil=

affil-num=24
en-affil=Department of Clinical Oncology, Graduate School of Medicine Faculty of Medicine, Kyoto University
kn-affil=

affil-num=25
en-affil=Department of Gastroenterology, Chiba Cancer Center
kn-affil=

affil-num=26
en-affil=Department of Gastroenterology, Fukushima Medical University
kn-affil=

affil-num=27
en-affil=Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital
kn-affil=

affil-num=28
en-affil=Department of Surgery, Tohoku University Graduate School of Medicine
kn-affil=

affil-num=29
en-affil=Second Department of Internal Medicine, Wakayama Medical University
kn-affil=

affil-num=30
en-affil=Department of Gastroenterology, Okayama University Graduate School of Medicine
kn-affil=

affil-num=31
en-affil=Department of Gastroenterology, Chiba University Graduate School of Medicine
kn-affil=

affil-num=32
en-affil=Department of Gastroenterology, Tokyo Medical University
kn-affil=

affil-num=33
en-affil=Department of Oncologial Medicine, Kochi Health Sciences Center
kn-affil=

affil-num=34
en-affil=Department of Gastroenterology and Hepatology, International University of Health and Welfare Atami Hospital
kn-affil=

affil-num=35
en-affil=Digestive and Lifestyle Diseases, Kagoshima University Graduate School of Medical and Dental Sciences
kn-affil=

affil-num=36
en-affil=Department of Gastroenterology, National Hospital Organization Shikoku Cancer Center
kn-affil=

affil-num=37
en-affil=Department of Medical Oncology, Kagawa University Hospital
kn-affil=

affil-num=38
en-affil=Department of Cancer Chemotherapy, Hokkaido University Hospital Cancer Center
kn-affil=

affil-num=39
en-affil=Department of Oncology, School of Medicine Graduate School of Medicine, Yokohama City University
kn-affil=

affil-num=40
en-affil=Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine
kn-affil=

affil-num=41
en-affil=Department of Gastroenterology, Kanagawa Cancer Center
kn-affil=
en-keyword=Biliary tract cancer
kn-keyword=Biliary tract cancer
en-keyword=Unresectable
kn-keyword=Unresectable
en-keyword=Chemotherapy
kn-keyword=Chemotherapy
en-keyword=Older
kn-keyword=Older
en-keyword=Survival
kn-keyword=Survival
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251118
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Mortality and cancer risk in patients with chronic pancreatitis in japan: insights into the importance of surveillance for pancreatic cancer
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background/Objective: Since the 2010s, Japan’s national health insurance system has covered key management for chronic pancreatitis (CP), including pancreatic enzyme replacement therapy. These therapies are expected to improve long-term prognosis; however, recent data are lacking. This study aimed to clarify the updated cancer risk and mortality among patients with CP in Japan.<br>
Methods: We conducted a multicenter, retrospective cohort study on 1,110 patients with CP treated at 28 institutions in 2011. Standardized incidence ratios (SIRs) and standardized mortality ratios (SMRs) were calculated for comorbidities. Factors associated with the development of malignancy and overall survival were analyzed.<br>
Results: Patients with CP had an elevated SIR of 1.62 (95% confidence interval [CI], 1.43?1.83) for malignancy, with the highest risk observed for pancreatic cancer (SIR?=?6.44 [95% CI, 4.64?8.90]). During follow-up, 143 patients (12.9%) died, most frequently from malignancy (47.5%). The SMR was elevated in all patients with CP (SMR?=?1.20 [95% CI, 1.01?1.42]) and in those with alcohol-related CP (SMR?=?1.49 [95% CI, 1.23?1.81]) but not in those with alcohol-unrelated CP. Pancreatic cancer was identified as the strongest factor associated with overall survival (hazard ratio, 48.92 in multivariate analysis). Overall survival of the patients with pancreatic cancer was significantly longer in those who underwent regular examinations for CP at least every three months (P?=?0.011).<br>
Conclusions: Patients with alcohol-related CP have higher mortality than the general population in Japan. Pancreatic cancer remains a crucial prognostic factor in patients with CP. Regular surveillance for pancreatic cancer is important to improve their prognosis.
en-copyright=
kn-copyright=

en-aut-name=MatsumotoRyotaro
en-aut-sei=Matsumoto
en-aut-mei=Ryotaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KikutaKazuhiro
en-aut-sei=Kikuta
en-aut-mei=Kazuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TakikawaTetsuya
en-aut-sei=Takikawa
en-aut-mei=Tetsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NakaiYousuke
en-aut-sei=Nakai
en-aut-mei=Yousuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TakenakaMamoru
en-aut-sei=Takenaka
en-aut-mei=Mamoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=OkiKentaro
en-aut-sei=Oki
en-aut-mei=Kentaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=OhnoEizaburo
en-aut-sei=Ohno
en-aut-mei=Eizaburo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=ItoKen
en-aut-sei=Ito
en-aut-mei=Ken
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=FujimoriNao
en-aut-sei=Fujimori
en-aut-mei=Nao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=KatanumaAkio
en-aut-sei=Katanuma
en-aut-mei=Akio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=MasudaAtsuhiro
en-aut-sei=Masuda
en-aut-mei=Atsuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=HoriYasuki
en-aut-sei=Hori
en-aut-mei=Yasuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=IkeuraTsukasa
en-aut-sei=Ikeura
en-aut-mei=Tsukasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=SuzukiRei
en-aut-sei=Suzuki
en-aut-mei=Rei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=YamamotoSatoshi
en-aut-sei=Yamamoto
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=SogameYoshio
en-aut-sei=Sogame
en-aut-mei=Yoshio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=KawashimaHiroki
en-aut-sei=Kawashima
en-aut-mei=Hiroki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=ItoTetsuhide
en-aut-sei=Ito
en-aut-mei=Tetsuhide
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=OkuwakiKosuke
en-aut-sei=Okuwaki
en-aut-mei=Kosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=ItoiTakao
en-aut-sei=Itoi
en-aut-mei=Takao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=TakayamaYukiko
en-aut-sei=Takayama
en-aut-mei=Yukiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=NakamuraAkira
en-aut-sei=Nakamura
en-aut-mei=Akira
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=TeraiShuji
en-aut-sei=Terai
en-aut-mei=Shuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=MatsumotoKazuyuki
en-aut-sei=Matsumoto
en-aut-mei=Kazuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=KuwataniMasaki
en-aut-sei=Kuwatani
en-aut-mei=Masaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=KishiwadaMasashi
en-aut-sei=Kishiwada
en-aut-mei=Masashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

en-aut-name=ShigekawaMinoru
en-aut-sei=Shigekawa
en-aut-mei=Minoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=27
ORCID=

en-aut-name=MatsumoriTomoaki
en-aut-sei=Matsumori
en-aut-mei=Tomoaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=28
ORCID=

en-aut-name=InatomiOsamu
en-aut-sei=Inatomi
en-aut-mei=Osamu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=29
ORCID=

en-aut-name=HattaWaku
en-aut-sei=Hatta
en-aut-mei=Waku
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=30
ORCID=

en-aut-name=IrisawaAtsushi
en-aut-sei=Irisawa
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=31
ORCID=

en-aut-name=UnnoMichiaki
en-aut-sei=Unno
en-aut-mei=Michiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=32
ORCID=

en-aut-name=TakeyamaYoshifumi
en-aut-sei=Takeyama
en-aut-mei=Yoshifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=33
ORCID=

en-aut-name=MasamuneAtsushi
en-aut-sei=Masamune
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=34
ORCID=

en-aut-name=Japan Pancreatitis Study Group for Chronic Pancreatitis
en-aut-sei=Japan Pancreatitis Study Group for Chronic Pancreatitis
en-aut-mei=
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=35
ORCID=

affil-num=1
en-affil=Division of Gastroenterology, Tohoku University Graduate School of Medicine
kn-affil=

affil-num=2
en-affil=Division of Gastroenterology, Tohoku University Graduate School of Medicine
kn-affil=

affil-num=3
en-affil=Division of Gastroenterology, Tohoku University Graduate School of Medicine
kn-affil=

affil-num=4
en-affil=Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo
kn-affil=

affil-num=5
en-affil=Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine
kn-affil=

affil-num=6
en-affil=Department of Gastroenterology and Hepatology, Kurashiki Central Hospital
kn-affil=

affil-num=7
en-affil=Department of Gastroenterology and Hepatology, Fujita Health University School of Medicine
kn-affil=

affil-num=8
en-affil=Division of Gastroenterology and Hepatology, Toho University Omori Medical Center
kn-affil=

affil-num=9
en-affil=Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University
kn-affil=

affil-num=10
en-affil=Center for Gastroenterology, Teine-Keijinkai Hospital
kn-affil=

affil-num=11
en-affil=Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine
kn-affil=

affil-num=12
en-affil=Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences
kn-affil=

affil-num=13
en-affil=Department of Gastroenterology and Hepatology, Kansai Medical University
kn-affil=

affil-num=14
en-affil=Department of Gastroenterology, Fukushima Medical University School of Medicine
kn-affil=

affil-num=15
en-affil=Department of Gastroenterology, Fujita Health University Bantane Hospital
kn-affil=

affil-num=16
en-affil=Department of Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine
kn-affil=

affil-num=17
en-affil=Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine
kn-affil=

affil-num=18
en-affil=Neuroendocrine Tumor Centre, Fukuoka Sanno Hospital, International University of Health and Welfare
kn-affil=

affil-num=19
en-affil=Department of Gastroenterology, Kitasato University School of Medicine
kn-affil=

affil-num=20
en-affil=Department of Gastroenterology and Hepatology, Tokyo Medical University
kn-affil=

affil-num=21
en-affil=Department of Internal Medicine, Institute of Gastroenterology, Tokyo Women’s Medical University
kn-affil=

affil-num=22
en-affil=Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine
kn-affil=

affil-num=23
en-affil=Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University
kn-affil=

affil-num=24
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=25
en-affil=Department of Gastroenterology and Hepatology, Hokkaido University Hospital
kn-affil=

affil-num=26
en-affil=Department of Hepatobiliary Pancreatic and Transplant Surgery, Mie University Graduate School of Medicine
kn-affil=

affil-num=27
en-affil=Department of Gastroenterology and Hepatology, The University of Osaka Graduate School of Medicine
kn-affil=

affil-num=28
en-affil=Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine
kn-affil=

affil-num=29
en-affil=Department of Medicine, Shiga University of Medical Science
kn-affil=

affil-num=30
en-affil=Division of Gastroenterology, Tohoku University Graduate School of Medicine
kn-affil=

affil-num=31
en-affil=Department of Gastroenterology, Dokkyo Medical University School of Medicine
kn-affil=

affil-num=32
en-affil=Department of Surgery, Tohoku University Graduate School of Medicine
kn-affil=

affil-num=33
en-affil=Department of Surgery, Kindai University Faculty of Medicine
kn-affil=

affil-num=34
en-affil=Division of Gastroenterology, Tohoku University Graduate School of Medicine
kn-affil=

affil-num=35
en-affil=
kn-affil=
en-keyword=Alcohol
kn-keyword=Alcohol
en-keyword=Chronic pancreatitis
kn-keyword=Chronic pancreatitis
en-keyword=Pancreatic cancer
kn-keyword=Pancreatic cancer
en-keyword=Pancreatitis
kn-keyword=Pancreatitis
en-keyword=Smoking
kn-keyword=Smoking
END

start-ver=1.4
cd-journal=joma
no-vol=25
cd-vols=
no-issue=7
article-no=
start-page=1103
end-page=1108
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202511
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Efficacy of diagnosing intraductal papillary mucinous neoplasm with mural nodules by contrast-enhanced endoscopic ultrasound using time?intensity curve analysis with a new support program: A multicenter retrospective study (with video)
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background/objectives: Preoperative diagnosis of the pathological grade of intraductal papillary mucinous neoplasms (IPMN) is challenging. This study aimed to evaluate the accuracy of contrast-enhanced endoscopic ultrasound (CE-EUS) using time?intensity curve (TIC) analysis with a newly developed support program to differentiate between low-grade dysplasia (LGD) and high-grade dysplasia (HGD)/invasive carcinoma (IC) in IPMN.<br>
Methods: This study retrospectively analyzed 32 patients who underwent CE-EUS using the support program for TIC analysis and IPMN resection (LGD: 17, HGD/IC: 15) at two medical centers. The TIC parameters of mural nodules (MN) were compared between the LGD and HGD/IC groups, and the diagnostic accuracies of the TIC parameters were evaluated.<br>
Results: The MN/pancreatic parenchyma contrast ratio was significantly higher in the HGD/IC group than in the LGD group (1.53 vs. 0.99; P < 0.0001), and the diagnostic abilities of the contrast ratio were as follows: sensitivity, 67 %; specificity, 100 %; and accuracy, 84 %. There were no differences in the echo intensity reduction rate of the MNs between the two groups (HGD/IC, 61.6 vs. 61.2, 0.99; P = 0.421), and the diagnostic abilities of the reduction rate were as follows: sensitivity, 93 %; specificity, 41 %; and accuracy, 66 %.<br>
Conclusions: The contrast ratio calculated using TIC analysis with the support program is potentially useful for differentiating between IPMNs with LGD and those with HGD/IC.
en-copyright=
kn-copyright=

en-aut-name=MiyamotoKazuya
en-aut-sei=Miyamoto
en-aut-mei=Kazuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=UchidaDaisuke
en-aut-sei=Uchida
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MatsumotoKazuyuki
en-aut-sei=Matsumoto
en-aut-mei=Kazuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SaragaiYosuke
en-aut-sei=Saragai
en-aut-mei=Yosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=OgawaTsuneyoshi
en-aut-sei=Ogawa
en-aut-mei=Tsuneyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=UekiToru
en-aut-sei=Ueki
en-aut-mei=Toru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=HaradaKei
en-aut-sei=Harada
en-aut-mei=Kei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=HattoriNao
en-aut-sei=Hattori
en-aut-mei=Nao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=ObataTaisuke
en-aut-sei=Obata
en-aut-mei=Taisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=SatoRyosuke
en-aut-sei=Sato
en-aut-mei=Ryosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=MatsumiAkihiro
en-aut-sei=Matsumi
en-aut-mei=Akihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=TerasawaHiroyuki
en-aut-sei=Terasawa
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=FujiiYuki
en-aut-sei=Fujii
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=HoriguchiShigeru
en-aut-sei=Horiguchi
en-aut-mei=Shigeru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=TsutsumiKoichiro
en-aut-sei=Tsutsumi
en-aut-mei=Koichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=UemotoSoichiro
en-aut-sei=Uemoto
en-aut-mei=Soichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=TanimotoTakayoshi
en-aut-sei=Tanimoto
en-aut-mei=Takayoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=OhtoAkimitsu
en-aut-sei=Ohto
en-aut-mei=Akimitsu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=OtsukaMotoyuki
en-aut-sei=Otsuka
en-aut-mei=Motoyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

affil-num=1
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Internal Medicine, Fukuyama City Hospital
kn-affil=

affil-num=5
en-affil=Department of Internal Medicine, Fukuyama City Hospital
kn-affil=

affil-num=6
en-affil=Department of Internal Medicine, Fukuyama City Hospital
kn-affil=

affil-num=7
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=8
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=9
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=10
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=11
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=12
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=13
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=14
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=15
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=16
en-affil=Business Strategy Division, Ryobi Systems Co., Ltd.
kn-affil=

affil-num=17
en-affil=Business Strategy Division, Ryobi Systems Co., Ltd.
kn-affil=

affil-num=18
en-affil=Business Strategy Division, Ryobi Systems Co., Ltd.
kn-affil=

affil-num=19
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=
en-keyword=Endoscopic ultrasonography
kn-keyword=Endoscopic ultrasonography
en-keyword=Pancreatic intraductal papillary mucinous neoplasm
kn-keyword=Pancreatic intraductal papillary mucinous neoplasm
en-keyword=Neoplasm grading
kn-keyword=Neoplasm grading
en-keyword=Contrast agent
kn-keyword=Contrast agent
END

start-ver=1.4
cd-journal=joma
no-vol=51
cd-vols=
no-issue=11
article-no=
start-page=e70112
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202511
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=The Short‐Term Impacts of Japan's 2024 Physician Working‐Hour Limits on Labor Conditions, Self‐Directed Professional Development, and Happiness Among Obstetrician‐Gynecologists
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Objective: To examine the short-term impacts of Japan's newly implemented physician working-hour limits (April 2024) on working conditions, self-directed professional development (SDPD), defined as activities undertaken outside working hours to enhance one's professional skills, and work-related happiness among obstetrician-gynecologists (OB-GYNs).<br>
Methods: An online survey was conducted between July 8 and July 31, 2024, targeting 867 Japan Society of Obstetrics and Gynecology members. Five hundred and fourteen full-time practitioners who had not changed workplaces around April 2024 and had no missing data were analyzed. Participants were stratified by regulation levels (A, B, C, discretionary labor system, those who don't know their own level), and their working hours, anticipated income, SDPD satisfaction, and happiness (0?10 scale) were assessed. We used multivariate linear regression to evaluate the influence of labor condition changes on happiness and explored interactions involving unpaid overtime, income changes, and SDPD satisfaction.<br>
Results: Compared with level A (up to 960?h of overtime per year), participants at levels B and C (up to 1860?h of overtime per year) reported significantly lower happiness (p?<?0.001). Most respondents observed no major shifts in working conditions since March 2024, yet about 40% did not record SDPD hours that meet the working hour requirement as official work time. Adjusted analyses revealed that decreased income and unsatisfactory SDPD significantly lowered happiness, whereas higher SDPD satisfaction increased it (β: ?0.64 [?1.07, ?0.21], ?0.98 [?1.46, ?0.50], and 0.90 [0.44, 1.35], respectively). Subgroup analysis indicated that rising unpaid overtime further reduced happiness among those dissatisfied with SDPD (?1.43 [?2.41, ?0.45]).<br>
Conclusions: The new working-hour limits had minimal impact on labor conditions in the short run. However, satisfaction with SDPD was positively associated with happiness, whereas anticipated decreases in income were correlated with lower happiness.
en-copyright=
kn-copyright=

en-aut-name=MaedaYuto
en-aut-sei=Maeda
en-aut-mei=Yuto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NakagawaSatoru
en-aut-sei=Nakagawa
en-aut-mei=Satoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NakanishiKentaro
en-aut-sei=Nakanishi
en-aut-mei=Kentaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=InoueEri
en-aut-sei=Inoue
en-aut-mei=Eri
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=InoueDaisuke
en-aut-sei=Inoue
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KidoSaki
en-aut-sei=Kido
en-aut-mei=Saki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KidoMichiko
en-aut-sei=Kido
en-aut-mei=Michiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KogaKaori
en-aut-sei=Koga
en-aut-mei=Kaori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=SuzukiShunji
en-aut-sei=Suzuki
en-aut-mei=Shunji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=SuzukiYukio
en-aut-sei=Suzuki
en-aut-mei=Yukio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=HaragaJunko
en-aut-sei=Haraga
en-aut-mei=Junko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=MasuyamaHisashi
en-aut-sei=Masuyama
en-aut-mei=Hisashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=YamamotoEiko
en-aut-sei=Yamamoto
en-aut-mei=Eiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=UmazumeTakeshi
en-aut-sei=Umazume
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=YokoyamaYoshihito
en-aut-sei=Yokoyama
en-aut-mei=Yoshihito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=IwaseAkira
en-aut-sei=Iwase
en-aut-mei=Akira
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=IkedaTomoaki
en-aut-sei=Ikeda
en-aut-mei=Tomoaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=YoshidaYoshio
en-aut-sei=Yoshida
en-aut-mei=Yoshio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=KudoYoshiki
en-aut-sei=Kudo
en-aut-mei=Yoshiki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=SugiyamaTakashi
en-aut-sei=Sugiyama
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=MiuraKiyonori
en-aut-sei=Miura
en-aut-mei=Kiyonori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=YahataHideaki
en-aut-sei=Yahata
en-aut-mei=Hideaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=UnnoNobuya
en-aut-sei=Unno
en-aut-mei=Nobuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=KurasawaKentaro
en-aut-sei=Kurasawa
en-aut-mei=Kentaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=MaenakaTakahide
en-aut-sei=Maenaka
en-aut-mei=Takahide
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=MiyagiEtsuko
en-aut-sei=Miyagi
en-aut-mei=Etsuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

en-aut-name=KatoKiyoko
en-aut-sei=Kato
en-aut-mei=Kiyoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=27
ORCID=

en-aut-name=KatoYasuhito
en-aut-sei=Kato
en-aut-mei=Yasuhito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=28
ORCID=

affil-num=1
en-affil=Department of Public Health, Institute of Science Tokyo
kn-affil=

affil-num=2
en-affil=Department of Obstetrics and Gynecology, Osaka University
kn-affil=

affil-num=3
en-affil=Department of Obstetrics and Gynecology, Asahikawa Medical University
kn-affil=

affil-num=4
en-affil=Aiiku Maternal and Child Health Center, Aiiku Hospital
kn-affil=

affil-num=5
en-affil=Department of Obstetrics and Gynecology, University of Fukui
kn-affil=

affil-num=6
en-affil=Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Kyushu University
kn-affil=

affil-num=7
en-affil=Department of Obstetrics and Gynecology, Japanese Red Cross Medical Center
kn-affil=

affil-num=8
en-affil=Department of Obstetrics and Gynecology, Reproductive Medicine Chiba University
kn-affil=

affil-num=9
en-affil=Department of Obstetrics and Gynecology, Nippon Medical School
kn-affil=

affil-num=10
en-affil=Department of Gynecology, Kanagawa Cancer Center
kn-affil=

affil-num=11
en-affil=Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=12
en-affil=Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=13
en-affil=Department of Healthcare Administration, Nagoya University Graduate School of Medicine
kn-affil=

affil-num=14
en-affil=Department of Obstetrics and Gynecology, Hokkaido University
kn-affil=

affil-num=15
en-affil=Department of Obstetrics and Gynecology, Hirosaki University Graduate School of Medicine
kn-affil=

affil-num=16
en-affil=Department of Obstetrics and Gynecology, Gunma University Graduate School of Medicine
kn-affil=

affil-num=17
en-affil=Saiseikai Matsusaka General Hospital
kn-affil=

affil-num=18
en-affil=Department of Obstetrics and Gynecology, University of Fukui
kn-affil=

affil-num=19
en-affil=Department of Obstetrics and Gynecology, Hiroshima University
kn-affil=

affil-num=20
en-affil=Department of Obstetrics and Gynecology, Ehime University Graduate School of Medicine
kn-affil=

affil-num=21
en-affil=Department of Obstetrics and Gynecology, Nagasaki University
kn-affil=

affil-num=22
en-affil=Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Kyushu University
kn-affil=

affil-num=23
en-affil=Center for Perinatal Medicine, JCHO Sagamino Hospital
kn-affil=

affil-num=24
en-affil=Department of Obstetrics and Gynecology, Yokohama City University Graduate School of Medicine
kn-affil=

affil-num=25
en-affil=Department of Obstetrics and Gynecology, Higashiosaka City Medical Center
kn-affil=

affil-num=26
en-affil=Department of Obstetrics and Gynecology, Yokohama City University Graduate School of Medicine
kn-affil=

affil-num=27
en-affil=Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Kyushu University
kn-affil=

affil-num=28
en-affil=Department of Obstetrics and Gynecology, Asahikawa Medical University
kn-affil=
en-keyword=gynecologists
kn-keyword=gynecologists
en-keyword=happiness
kn-keyword=happiness
en-keyword=obstetrician
kn-keyword=obstetrician
en-keyword=work style reform
kn-keyword=work style reform
en-keyword=working-hour limits
kn-keyword=working-hour limits
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=e00463-25
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251128
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Analysis of the drug target of the anti-tuberculosis compound OCT313: phosphotransacetylase is a potential drug target for anti-mycobacterial agents
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Tuberculosis (TB) is one of the most common infectious diseases caused by bacteria worldwide. The increasing prevalence of multidrug-resistant TB (MDR-TB) and latent TB infection (LTBI) has intensified the global TB burden. Therefore, the development of new drugs for MDR-TB and LTBI is urgently required. We have reported that the derivative of dithiocarbamate sugar derivative, 2-acetamido-2-deoxy-β-D-glucopyranosyl N,N-dimethyldithiocarbamate (OCT313), exhibits anti-mycobacterial activity against MDR-MTB. Here, we identified the target of OCT313. In experimentally generated OCT313-resistant bacteria, adenine at position 1,092 in the metabolic enzyme phosphotransacetylase (PTA) gene was replaced with cytosine. This mutation is a nonsynonymous mutation that converts methionine to leucine at position 365 in the PTA protein. OCT313 inhibited the enzymatic activity of recombinant wild-type PTA, but not of the mutant PTA (M365L). PTA is an enzyme that produces acetyl-coenzyme A (acetyl-CoA) from acetyl phosphate and CoA and is involved in metabolic pathways; therefore, it was expected to also be active against dormant Mycobacterium tuberculosis bacilli. OCT313 exhibits antibacterial activity in the Wayne model of dormancy using Mycobacterium bovis BCG, and overexpression of PTA in OCT313-resistant bacilli restored sensitivity to OCT313. Collectively, the target of OCT313 is PTA, and OCT313 is a promising antimicrobial candidate for MDR-TB and LTBI.
en-copyright=
kn-copyright=

en-aut-name=TakiiTakemasa
en-aut-sei=Takii
en-aut-mei=Takemasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HasegawaTomohiro
en-aut-sei=Hasegawa
en-aut-mei=Tomohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=ItohSaotomo
en-aut-sei=Itoh
en-aut-mei=Saotomo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MaedaShinji
en-aut-sei=Maeda
en-aut-mei=Shinji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=WadaTakayuki
en-aut-sei=Wada
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=HoritaYasuhiro
en-aut-sei=Horita
en-aut-mei=Yasuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NishiyamaAkihito
en-aut-sei=Nishiyama
en-aut-mei=Akihito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=MatsumotoSohkichi
en-aut-sei=Matsumoto
en-aut-mei=Sohkichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=OharaNaoya
en-aut-sei=Ohara
en-aut-mei=Naoya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=KimishimaAoi
en-aut-sei=Kimishima
en-aut-mei=Aoi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=AsamiYukihiro
en-aut-sei=Asami
en-aut-mei=Yukihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=HidaShigeaki
en-aut-sei=Hida
en-aut-mei=Shigeaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=OnozakiKikuo
en-aut-sei=Onozaki
en-aut-mei=Kikuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

affil-num=1
en-affil=Department of Mycobacterium Reference and Research, the Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association
kn-affil=

affil-num=2
en-affil=Department of Hygienic Chemistry, Graduate School of Pharmaceutical Sciences, Nagoya City University
kn-affil=

affil-num=3
en-affil=Department of Hygienic Chemistry, Graduate School of Pharmaceutical Sciences, Nagoya City University
kn-affil=

affil-num=4
en-affil=Graduate School of Pharmaceutical Sciences, Hokkaido University of Sciences
kn-affil=

affil-num=5
en-affil=Department of Microbiology, Graduate School of Human Life and Ecology, Osaka Metropolitan University
kn-affil=

affil-num=6
en-affil=Department of Clinical Pharmaceutics, Graduate School of Medical Sciences, Nagoya City University
kn-affil=

affil-num=7
en-affil=Department of Bacteriology, Niigata University School of Medicine
kn-affil=

affil-num=8
en-affil=Department of Bacteriology, Niigata University School of Medicine
kn-affil=

affil-num=9
en-affil=Department of Oral Microbiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=10
en-affil=Laboratory of Applied Microbial Chemistry, ?mura Satoshi Memorial Institute, Kitasato University
kn-affil=

affil-num=11
en-affil=Laboratory of Applied Microbial Chemistry, ?mura Satoshi Memorial Institute, Kitasato University
kn-affil=

affil-num=12
en-affil=Department of Hygienic Chemistry, Graduate School of Pharmaceutical Sciences, Nagoya City University
kn-affil=

affil-num=13
en-affil=Department of Hygienic Chemistry, Graduate School of Pharmaceutical Sciences, Nagoya City University
kn-affil=
en-keyword=phosphotransacetylase
kn-keyword=phosphotransacetylase
en-keyword=acetyl coenzyme A
kn-keyword=acetyl coenzyme A
en-keyword=dithiocarbamate
kn-keyword=dithiocarbamate
en-keyword=N-acetyl glucosamine
kn-keyword=N-acetyl glucosamine
en-keyword=anti-mycobacterial agents
kn-keyword=anti-mycobacterial agents
en-keyword=latent tuberculosis infection
kn-keyword=latent tuberculosis infection
END

start-ver=1.4
cd-journal=joma
no-vol=27
cd-vols=
no-issue=1
article-no=
start-page=219
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251121
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Does perioperative discontinuation of anti-rheumatic drugs increase postoperative complications in orthopedic surgery for rheumatoid arthritis?
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Objective This study aimed to investigate whether discontinuation of biological or targeted synthetic antirheumatic disease-modifying drugs (bDMARDs or tsDMARDs) influences the incidence of postoperative complications in patients with rheumatoid arthritis (RA) undergoing orthopedic surgery.<br>
Methods A retrospective multicenter cohort study including patients receiving bDMARDs or tsDMARDs who underwent orthopedic surgery was conducted. Data collected encompassed the duration of drug discontinuation and postoperative adverse events, such as delayed wound healing, surgical site infection (SSI), disease flare-ups, and mortality. The association between drug discontinuation and these outcomes was analyzed. Multivariate analyses were conducted to identify potential risk factors for these events.<br>
Results A total of 2,060 cases were initially enrolled. After applying inclusion and exclusion criteria, data from 1,953 patients were analyzed. No significant differences were observed between the groups regarding delayed wound healing, SSI, or mortality. However, the incidence of disease flare-ups was substantially higher in the drug discontinuation group and in the interleukin (IL)-6 inhibitor group. Multivariate analysis identified that tumor necrosis factor α and IL-6 inhibitor use was associated with a higher risk of delayed wound healing relative to T-cell function modifiers.<br>
Conclusion In orthopedic surgery for patients with RA, maintaining the standard or the half of administration interval of bDMARD appears safe in the preoperative period. However, the drug discontinuation may increase the risk of postoperative flare-ups, particularly with IL-6 inhibitors. In addition, T-cell function modifiers may be associated with a lower risk of delayed wound healing, suggesting their safety profile in this context.
en-copyright=
kn-copyright=

en-aut-name=ItoHiromu
en-aut-sei=Ito
en-aut-mei=Hiromu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=IshikawaHajime
en-aut-sei=Ishikawa
en-aut-mei=Hajime
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TsujiShigeyoshi
en-aut-sei=Tsuji
en-aut-mei=Shigeyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NakayamaMasanori
en-aut-sei=Nakayama
en-aut-mei=Masanori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=NishidaKeiichiro
en-aut-sei=Nishida
en-aut-mei=Keiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MochizukiTakeshi
en-aut-sei=Mochizuki
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=EbinaKosuke
en-aut-sei=Ebina
en-aut-mei=Kosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KojimaToshihisa
en-aut-sei=Kojima
en-aut-mei=Toshihisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MatsumotoTakumi
en-aut-sei=Matsumoto
en-aut-mei=Takumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=KubotaAyako
en-aut-sei=Kubota
en-aut-mei=Ayako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=NakajimaArata
en-aut-sei=Nakajima
en-aut-mei=Arata
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=KanekoAtsushi
en-aut-sei=Kaneko
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=MatsushitaIsao
en-aut-sei=Matsushita
en-aut-mei=Isao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=HaraRyota
en-aut-sei=Hara
en-aut-mei=Ryota
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=SakurabaKoji
en-aut-sei=Sakuraba
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=AkasakiYukio
en-aut-sei=Akasaki
en-aut-mei=Yukio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=MatsubaraTsukasa
en-aut-sei=Matsubara
en-aut-mei=Tsukasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=MochidaYuichi
en-aut-sei=Mochida
en-aut-mei=Yuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=KanbeKatsuaki
en-aut-sei=Kanbe
en-aut-mei=Katsuaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=NakagawaNatsuko
en-aut-sei=Nakagawa
en-aut-mei=Natsuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=MurataKoichi
en-aut-sei=Murata
en-aut-mei=Koichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=MomoharaShigeki
en-aut-sei=Momohara
en-aut-mei=Shigeki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

affil-num=1
en-affil=Department of Orthopaedic Surgery, Kurashiki Central Hospital
kn-affil=

affil-num=2
en-affil=Department of Rheumatology, Niigata Rheumatic Center
kn-affil=

affil-num=3
en-affil=Department of Orthopaedic Surgery, Osaka Minami Medical Center
kn-affil=

affil-num=4
en-affil=Department of Orthopaedic Surgery, International University of Health and Welfare
kn-affil=

affil-num=5
en-affil=Locomotive Pain Center, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Department of Orthopaedic Surgery, Kamagaya General Hospital
kn-affil=

affil-num=7
en-affil=Department of Orthopaedic Surgery, Osaka University Faculty of Medicine Graduate School of Medicine
kn-affil=

affil-num=8
en-affil=Department of Orthopaedic Surgery, Nagoya University Hospital
kn-affil=

affil-num=9
en-affil=Department of Orthopaedic Surgery, University of Tokyo
kn-affil=

affil-num=10
en-affil=Department of Orthopaedic Surgery, Toho University Omori Medical Center
kn-affil=

affil-num=11
en-affil=Department of Orthopaedic Surgery and Rehabilitation, Toho University Sakura Medical Center
kn-affil=

affil-num=12
en-affil=Department of Orthopaedic Surgery, Nagoya Medical Center
kn-affil=

affil-num=13
en-affil=Department of Rehabilitation Medicine, Kanazawa Medical University
kn-affil=

affil-num=14
en-affil=The Center for Rheumatic Diseases, Nara Medical University
kn-affil=

affil-num=15
en-affil=Department of Orthopaedic Surgery, Kyushu Medical Center
kn-affil=

affil-num=16
en-affil=Department of Orthopaedic Surgery, Kyushu University
kn-affil=

affil-num=17
en-affil=Department of Orthopaedic Surgery, Matsubara Mayflower Hospital
kn-affil=

affil-num=18
en-affil=Department of Orthopaedic Surgery, Yokohama City University Medical Center
kn-affil=

affil-num=19
en-affil=Department of Orthopaedic Surgery, Nippori Orthopaedics and Rheumatic Clinic
kn-affil=

affil-num=20
en-affil=Department of Orthopaedic Surgery, Kakogawa Medical Center
kn-affil=

affil-num=21
en-affil=Department of Orthopaedic Surgery, Kyoto University Graduate School of Medicine
kn-affil=

affil-num=22
en-affil=Endowed Course for Advanced Therapy for Musculoskeletal Disorders, Keio University School of Medicine
kn-affil=
en-keyword=Rheumatoid arthritis
kn-keyword=Rheumatoid arthritis
en-keyword=Orthopaedic surgery
kn-keyword=Orthopaedic surgery
en-keyword=DMARD
kn-keyword=DMARD
en-keyword=Perioperative complications
kn-keyword=Perioperative complications
END

start-ver=1.4
cd-journal=joma
no-vol=68
cd-vols=
no-issue=1
article-no=
start-page=100718
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202602
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Evaluation of Mycobacterium-derived plasmids for application in oral Actinomyces species
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Objectives: Genetic manipulation tools are essential for elucidating the pathogenic mechanisms of microorganisms. Several species of Actinomyces, including A. israelii, are present in the oral cavity and they are the causative agents of actinomycosis. However, efficient gene-editing tools for these species have not yet been developed. In this study, the aim was to evaluate the introduction of foreign genes into Actinomyces using plasmids derived from Mycobacterium, which belong to the same class as Actinomycetes.<br>
Methods: A truncated derivative of pYT923, pYT923S, which contains the replication origin of the M. scrofulaceum plasmid pMSC262 was constructed and introduced into A. israelii by electrotransformation.<br>
Results: pYT923S was successfully introduced into A. israelii. The transformation efficiency of A. israelii was approximately 7?66 CFU/μg of DNA, and all transformed colonies harbored pYT923S. The plasmid recovered from A. israelii replicated in Escherichia coli.<br>
Conclusions: pYT923S was introduced into and maintained within A. israelii. Therefore, the pYT923S vector represents a useful genetic tool for Actinomyces and it is expected to facilitate future studies on the biology and pathogenicity of Actinomyces.
en-copyright=
kn-copyright=

en-aut-name=OharaSakiko
en-aut-sei=Ohara
en-aut-mei=Sakiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ShengYijuan
en-aut-sei=Sheng
en-aut-mei=Yijuan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NishiyaYuki
en-aut-sei=Nishiya
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TosaIkue
en-aut-sei=Tosa
en-aut-mei=Ikue
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TakebeKatsuki
en-aut-sei=Takebe
en-aut-mei=Katsuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=ArimuraYuki
en-aut-sei=Arimura
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MeseHiroshi
en-aut-sei=Mese
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=OharaNaoko
en-aut-sei=Ohara
en-aut-mei=Naoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=OharaNaoya
en-aut-sei=Ohara
en-aut-mei=Naoya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Oral Microbiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Oral Microbiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Oral Microbiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Oral Microbiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Dental Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=6
en-affil=Department of Oral and Maxillofacial Reconstructive Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Dentistry and Oral Surgery, Fukuyama City Hospital
kn-affil=

affil-num=8
en-affil=Department of Operative Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=9
en-affil=Department of Oral Microbiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=Actinomyces
kn-keyword=Actinomyces
en-keyword=Plasmid
kn-keyword=Plasmid
en-keyword=Shuttle vector
kn-keyword=Shuttle vector
en-keyword=Transformation
kn-keyword=Transformation
END

start-ver=1.4
cd-journal=joma
no-vol=14
cd-vols=
no-issue=1
article-no=
start-page=27481
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20241111
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Association between proteinuria and mineral metabolism disorders in chronic kidney disease: the Japan chronic kidney disease database extension (J-CKD-DB-Ex)
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Chronic kidney disease-mineral and bone disorder (CKD-MBD) are recognized as a systemic disease affecting the prognosis of patients with CKD. Proper management of CKD-MBD is important to improve the prognosis of patients with CKD. Although proteinuria is recognized as a poor prognostic factor in these patients, few reports have examined its association with CKD-MBD. We examined the association between proteinuria and CKD-MBD using data from the Japan Chronic Kidney Disease Database Extension (J-CKD-DB-Ex). Among the patients registered in the J-CKD-DB-Ex, 30,977 with CKD stages G2?G5 who had serum creatinine, albumin, calcium, and phosphate concentrations measured at least once and urinalysis performed were included. The patients were divided into four groups (negative, 1+, 2+, and 3+) according to the degree of proteinuria. The association between proteinuria and CKD-MBD was examined by a logistic regression analysis. In a model adjusted for age, sex, diabetes, and the estimated glomerular filtration rate (eGFR), the odds ratio of the 3?+?group compared with the negative group significantly increased to 2.67 (95% confidence interval, 2.29?3.13) for hyperphosphatemia, 2.68 (1.94?3.71) for hypocalcemia, and 1.56 (1.24?1.98) for hypomagnesemia. Proteinuria is associated with hyperphosphatemia, hypocalcemia, and hypomagnesemia in patients with CKD independently of eGFR.
en-copyright=
kn-copyright=

en-aut-name=ShimamotoSho
en-aut-sei=Shimamoto
en-aut-mei=Sho
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NakaharaTakako
en-aut-sei=Nakahara
en-aut-mei=Takako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YamadaShunsuke
en-aut-sei=Yamada
en-aut-mei=Shunsuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NagasuHajime
en-aut-sei=Nagasu
en-aut-mei=Hajime
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KishiSeiji
en-aut-sei=Kishi
en-aut-mei=Seiji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NakashimaNaoki
en-aut-sei=Nakashima
en-aut-mei=Naoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TsuruyaKazuhiko
en-aut-sei=Tsuruya
en-aut-mei=Kazuhiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=OkadaHirokazu
en-aut-sei=Okada
en-aut-mei=Hirokazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=TamuraKouichi
en-aut-sei=Tamura
en-aut-mei=Kouichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=NaritaIchiei
en-aut-sei=Narita
en-aut-mei=Ichiei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=MaruyamaShoichi
en-aut-sei=Maruyama
en-aut-mei=Shoichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=YanoYuichiro
en-aut-sei=Yano
en-aut-mei=Yuichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=YokooTakashi
en-aut-sei=Yokoo
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=WadaTakashi
en-aut-sei=Wada
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=WadaJun
en-aut-sei=Wada
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=KandaEiichiro
en-aut-sei=Kanda
en-aut-mei=Eiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=KataokaHiromi
en-aut-sei=Kataoka
en-aut-mei=Hiromi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=NangakuMasaomi
en-aut-sei=Nangaku
en-aut-mei=Masaomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=KashiharaNaoki
en-aut-sei=Kashihara
en-aut-mei=Naoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=NakanoToshiaki
en-aut-sei=Nakano
en-aut-mei=Toshiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

affil-num=1
en-affil=Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University
kn-affil=

affil-num=2
en-affil=Department of Medical Technology, Faculty of Health Science and Technology, Kawasaki University of Medical Welfare
kn-affil=

affil-num=3
en-affil=Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University
kn-affil=

affil-num=4
en-affil=Department of Nephrology and Hypertension, Kawasaki Medical School
kn-affil=

affil-num=5
en-affil=Department of Nephrology and Hypertension, Kawasaki Medical School
kn-affil=

affil-num=6
en-affil=Department of Medical Informatics, Graduate School of Medical Science, Kyushu University
kn-affil=

affil-num=7
en-affil=Department of Nephrology, Nara Medical University
kn-affil=

affil-num=8
en-affil=Department of Nephrology, Faculty of Medicine, Saitama Medical University
kn-affil=

affil-num=9
en-affil=Department of Medical Science and Cardiorenal Medicine, Graduate School of Medicine, Yokohama City University
kn-affil=

affil-num=10
en-affil=Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences
kn-affil=

affil-num=11
en-affil=Department of Nephrology, Nagoya University Graduate School of Medicine
kn-affil=

affil-num=12
en-affil=Department of General Medicine, Juntendo University Faculty of Medicine
kn-affil=

affil-num=13
en-affil=Division of Kidney and Hypertension, Department of Internal Medicine, Jikei University School of Medicine
kn-affil=

affil-num=14
en-affil=Department of Nephrology and Rheumatology, Kanazawa University
kn-affil=

affil-num=15
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=

affil-num=16
en-affil=Department of Health Data Science, Kawasaki Medical School
kn-affil=

affil-num=17
en-affil=Department of Medical Technology, Faculty of Health Science and Technology, Kawasaki University of Medical Welfare
kn-affil=

affil-num=18
en-affil=Division of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine
kn-affil=

affil-num=19
en-affil=Department of Nephrology and Hypertension, Kawasaki Medical School
kn-affil=

affil-num=20
en-affil=Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University
kn-affil=
en-keyword=CKD-MBD
kn-keyword=CKD-MBD
en-keyword=Proteinuria
kn-keyword=Proteinuria
en-keyword=Hyperphosphatemia
kn-keyword=Hyperphosphatemia
en-keyword=Hypocalcemia
kn-keyword=Hypocalcemia
en-keyword=Hypomagnesemia
kn-keyword=Hypomagnesemia
en-keyword=J-CKD-DB-Ex
kn-keyword=J-CKD-DB-Ex
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251019
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Impact of methotrexate-dosing regimens for GVHD prophylaxis on clinical outcomes of HLA-matched allogeneic HSCT
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Severe graft-versus-host disease (GVHD) remains a major complication of allogeneic haematopoietic stem cell transplantation (allo-HSCT), necessitating optimal immunosuppressive strategies. This retrospective study used data from the Japanese Transplant Registry Unified Management Program to compare three methotrexate (MTX)-dosing regimens for GVHD prophylaxis in patients undergoing human leucocyte antigen (HLA)-matched allo-HSCT: a low-dose 3-day regimen (Ld3:10?mg/m2 on day 1, 7?mg/m2 on days 3 and 6), a low-dose 4-day regimen (Ld4: Ld3 with an additional 7?mg/m2 on day 11) and an original-dose 3-day regimen (Od3: 15?mg/m2 on day 1, 10?mg/m2 on days 3 and 6). Among 2537 analysed patients, Ld3 was the most commonly used regimen. Multivariate analyses showed no significant differences in the cumulative incidence of grade II?IV acute GVHD among regimens. However, Od3 was associated with an increased risk of grade III?IV acute GVHD, and Ld4 was linked to delayed neutrophil engraftment. This study is the first large-scale retrospective analysis of the impact of different MTX-dosing regimens on the outcomes of HLA-matched allo-HSCT, providing valuable insights into optimal MTX-dosing strategies in clinical practice.
en-copyright=
kn-copyright=

en-aut-name=SuzukiTomotaka
en-aut-sei=Suzuki
en-aut-mei=Tomotaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=JoTomoyasu
en-aut-sei=Jo
en-aut-mei=Tomoyasu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YoshifujiKota
en-aut-sei=Yoshifuji
en-aut-mei=Kota
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KondoTadakazu
en-aut-sei=Kondo
en-aut-mei=Tadakazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=DokiNoriko
en-aut-sei=Doki
en-aut-mei=Noriko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KandaYoshinobu
en-aut-sei=Kanda
en-aut-mei=Yoshinobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NishidaTetsuya
en-aut-sei=Nishida
en-aut-mei=Tetsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=OnishiYasushi
en-aut-sei=Onishi
en-aut-mei=Yasushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=AsadaNoboru
en-aut-sei=Asada
en-aut-mei=Noboru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=FukudaTakahiro
en-aut-sei=Fukuda
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=SawaMasashi
en-aut-sei=Sawa
en-aut-mei=Masashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=HasegawaYuta
en-aut-sei=Hasegawa
en-aut-mei=Yuta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=SerizawaKentaro
en-aut-sei=Serizawa
en-aut-mei=Kentaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=OtaShuichi
en-aut-sei=Ota
en-aut-mei=Shuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=TanakaMasatsugu
en-aut-sei=Tanaka
en-aut-mei=Masatsugu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=YoshimitsuMakoto
en-aut-sei=Yoshimitsu
en-aut-mei=Makoto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=AtsutaYoshiko
en-aut-sei=Atsuta
en-aut-mei=Yoshiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=KandaJunya
en-aut-sei=Kanda
en-aut-mei=Junya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

affil-num=1
en-affil=Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences
kn-affil=

affil-num=2
en-affil=Department of Hematology, Graduate School of Medicine, Kyoto University
kn-affil=

affil-num=3
en-affil=Department of Hematology, Institute of Science Tokyo
kn-affil=

affil-num=4
en-affil=Department of Hematology, Graduate School of Medicine, Kyoto University
kn-affil=

affil-num=5
en-affil=Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital
kn-affil=

affil-num=6
en-affil=Division of Hematology, Jichi Medical University Saitama Medical Centre
kn-affil=

affil-num=7
en-affil=Department of Hematology, Japanese Red Cross Aichi Medical Centre Nagoya Daiichi Hospital
kn-affil=

affil-num=8
en-affil=Department of Hematology, Tohoku University Hospital
kn-affil=

affil-num=9
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=10
en-affil=Department of Haematopoietic Stem Cell Transplantation, National Cancer Centre Hospital
kn-affil=

affil-num=11
en-affil=Department of Hematology and Oncology, Anjo Kosei Hospital
kn-affil=

affil-num=12
en-affil=Department of Hematology, Hokkaido University Hospital
kn-affil=

affil-num=13
en-affil=Department of Hematology and Rheumatology, Kindai University Faculty of Medicine
kn-affil=

affil-num=14
en-affil=Department of Hematology, Sapporo Hokuyu Hospital
kn-affil=

affil-num=15
en-affil=Department of Hematology, Kanagawa Cancer Centre
kn-affil=

affil-num=16
en-affil=Department of Hematology and Rheumatology, Graduate School of Medical and Dental Sciences, Kagoshima University
kn-affil=

affil-num=17
en-affil=Japanese Data Centre for Haematopoietic Cell Transplantation
kn-affil=

affil-num=18
en-affil=Department of Hematology, Graduate School of Medicine, Kyoto University
kn-affil=
en-keyword=allo-HSCT
kn-keyword=allo-HSCT
en-keyword=dosing regimens
kn-keyword=dosing regimens
en-keyword=graft-versus-host disease
kn-keyword=graft-versus-host disease
en-keyword=GVHD prophylaxis
kn-keyword=GVHD prophylaxis
en-keyword=methotrexate
kn-keyword=methotrexate
END

start-ver=1.4
cd-journal=joma
no-vol=9
cd-vols=
no-issue=18
article-no=
start-page=4640
end-page=4653
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250912
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Refinement of day 28 treatment response criteria for acute GVHD: a collaboration study of the JSTCT and MAGIC
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Overall response (OR) that combines complete (CR) and partial responses (PR) is the conventional end point for acute graft-versus-host disease (GVHD) trials. Because PR includes heterogeneous clinical presentations, reclassifying PR could produce a better end point. Patients in the primary treatment cohort from the Japanese Society for Transplantation and Cellular Therapy (JSTCT) were randomly divided into training and validation sets. In the training set, a classification and regression tree algorithm generated day 28 refined response (RR) criteria based on symptoms at treatment and day 28. We then evaluated RR for primary and second-line treatments, using the area under the receiver operating characteristic curve (AUC) and negative predictive value (NPV) for 6-month nonrelapse mortality as performance measures. RR considered patients with grade 0/1 at day 28 without additional treatment as responders. RR for primary treatment produced higher AUCs than OR with small improvement of NPVs in both validation sets: JSTCT (AUC, 0.73 vs 0.69 [P < .001]; NPV, 92.0% vs 89.6% [P < .001]) and the Mount Sinai Acute GVHD International Consortium (MAGIC; AUC, 0.71 vs 0.68 [P = .032]; NPV, 90.9% vs 89.8% [P = .009]). RR for second-line treatment produced similar AUCs but much higher NPVs than OR in both validation sets of JSTCT (AUC, 0.64 vs 0.63 [P = .775]; NPV, 74.5% vs 66.0% [P < .001]) and MAGIC (AUC, 0.67 vs 0.64 [P = .105]; NPV, 86.8% vs 76.1% [P = .004]). Classifying persistent but mild skin symptoms as responses and residual lower gastrointestinal GVHD as nonresponses were major drivers in improving the prognostic performance of RR. Our externally validated day 28 RR would serve as a better end point than conventional criteria in future first- and second-line treatment trials.
en-copyright=
kn-copyright=

en-aut-name=AkahoshiYu
en-aut-sei=Akahoshi
en-aut-mei=Yu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=InamotoYoshihiro
en-aut-sei=Inamoto
en-aut-mei=Yoshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=SpyrouNikolaos
en-aut-sei=Spyrou
en-aut-mei=Nikolaos
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NakasoneHideki
en-aut-sei=Nakasone
en-aut-mei=Hideki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=DinizMarcio A.
en-aut-sei=Diniz
en-aut-mei=Marcio A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=AsadaNoboru
en-aut-sei=Asada
en-aut-mei=Noboru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=AyukFrancis
en-aut-sei=Ayuk
en-aut-mei=Francis
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=ChoeHannah K.
en-aut-sei=Choe
en-aut-mei=Hannah K.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=DokiNoriko
en-aut-sei=Doki
en-aut-mei=Noriko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=EtoTetsuya
en-aut-sei=Eto
en-aut-mei=Tetsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=EtraAaron M.
en-aut-sei=Etra
en-aut-mei=Aaron M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=HexnerElizabeth O.
en-aut-sei=Hexner
en-aut-mei=Elizabeth O.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=HiramotoNobuhiro
en-aut-sei=Hiramoto
en-aut-mei=Nobuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=HoganWilliam J.
en-aut-sei=Hogan
en-aut-mei=William J.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=HollerErnst
en-aut-sei=Holler
en-aut-mei=Ernst
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=KataokaKeisuke
en-aut-sei=Kataoka
en-aut-mei=Keisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=KawakitaToshiro
en-aut-sei=Kawakita
en-aut-mei=Toshiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=TanakaMasatsugu
en-aut-sei=Tanaka
en-aut-mei=Masatsugu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=TanakaTakashi
en-aut-sei=Tanaka
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=UchidaNaoyuki
en-aut-sei=Uchida
en-aut-mei=Naoyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=VasovaIngrid
en-aut-sei=Vasova
en-aut-mei=Ingrid
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=YoshiharaSatoshi
en-aut-sei=Yoshihara
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=IshimaruFumihiko
en-aut-sei=Ishimaru
en-aut-mei=Fumihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=FukudaTakahiro
en-aut-sei=Fukuda
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=ChenYi-Bin
en-aut-sei=Chen
en-aut-mei=Yi-Bin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=KandaJunya
en-aut-sei=Kanda
en-aut-mei=Junya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

en-aut-name=NakamuraRyotaro
en-aut-sei=Nakamura
en-aut-mei=Ryotaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=27
ORCID=

en-aut-name=AtsutaYoshiko
en-aut-sei=Atsuta
en-aut-mei=Yoshiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=28
ORCID=

en-aut-name=FerraraJames L. M.
en-aut-sei=Ferrara
en-aut-mei=James L. M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=29
ORCID=

en-aut-name=KandaYoshinobu
en-aut-sei=Kanda
en-aut-mei=Yoshinobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=30
ORCID=

en-aut-name=LevineJohn E.
en-aut-sei=Levine
en-aut-mei=John E.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=31
ORCID=

en-aut-name=TeshimaTakanori
en-aut-sei=Teshima
en-aut-mei=Takanori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=32
ORCID=

affil-num=1
en-affil=Division of Hematology/Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
kn-affil=

affil-num=2
en-affil=Department of Blood and Marrow Transplantation and Cellular Therapy, Fujita Health University School of Medicine
kn-affil=

affil-num=3
en-affil=Division of Hematology/Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
kn-affil=

affil-num=4
en-affil=Division of Hematology, Jichi Medical University Saitama Medical Center
kn-affil=

affil-num=5
en-affil=Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai
kn-affil=

affil-num=6
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=7
en-affil=Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf
kn-affil=

affil-num=8
en-affil=Division of Hematology, Blood and Marrow Transplantation Program, The Ohio State University Comprehensive Cancer Center
kn-affil=

affil-num=9
en-affil=Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital
kn-affil=

affil-num=10
en-affil=Department of Hematology, Hamanomachi Hospital
kn-affil=

affil-num=11
en-affil=Division of Hematology/Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
kn-affil=

affil-num=12
en-affil=Department of Medicine and Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania
kn-affil=

affil-num=13
en-affil=Department of Hematology, Kobe City Medical Center General Hospital
kn-affil=

affil-num=14
en-affil=Division of Hematology, Mayo Clinic
kn-affil=

affil-num=15
en-affil=Department of Hematology and Oncology, Internal Medicine III, University of Regensburg
kn-affil=

affil-num=16
en-affil=Division of Molecular Oncology, National Cancer Center Research Institute
kn-affil=

affil-num=17
en-affil=Department of Hematology, National Hospital Organization Kumamoto Medical Center
kn-affil=

affil-num=18
en-affil=Department of Hematology, Kanagawa Cancer Center
kn-affil=

affil-num=19
en-affil=Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital
kn-affil=

affil-num=20
en-affil=Department of Hematology, Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital
kn-affil=

affil-num=21
en-affil=Department of Internal Medicine 5, Hematology and Oncology, Friedrich-Alexander-Universit?t Erlangen-N?rnberg and University Hospital Erlangen
kn-affil=

affil-num=22
en-affil=Department of Hematology, Hyogo Medical University Hospital
kn-affil=

affil-num=23
en-affil=Technical Department, Japanese Red Cross Blood Service Headquarters
kn-affil=

affil-num=24
en-affil=Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital
kn-affil=

affil-num=25
en-affil=Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital
kn-affil=

affil-num=26
en-affil=Department of Hematology, Graduate School of Medicine, Kyoto University
kn-affil=

affil-num=27
en-affil=Department of Hematology and Hematopoietic Cell Transplantation, City of Hope
kn-affil=

affil-num=28
en-affil=Japanese Data Center for Hematopoietic Cell Transplantation
kn-affil=

affil-num=29
en-affil=Division of Hematology/Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
kn-affil=

affil-num=30
en-affil=Division of Hematology, Jichi Medical University Saitama Medical Center
kn-affil=

affil-num=31
en-affil=Division of Hematology/Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
kn-affil=

affil-num=32
en-affil=Department of Hematology, Hokkaido University Faculty of Medicine and Graduate School of Medicine
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250908
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Efficacy of ciclosporin monotherapy in non-severe aplastic anaemia not requiring transfusions: Results from a multicentre phase II study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The efficacy of ciclosporin (CsA) to treat transfusion-independent non-severe aplastic anaemia (TI-NSAA) has not yet been systematically evaluated. We conducted a prospective trial in patients with TI-NSAA treated with CsA monotherapy. CsA (3.5?mg/kg/day) was administered to patients with TI-NSAA aged ?16. The CsA dose was adjusted to maintain a blood CsA level of ?600?ng/mL at 2?h post-administration. Blood cell counts were assessed after 8, 16 and 52?weeks of therapy. Thirty-two evaluable patients from 21 institutions were enrolled. The median age was 63.5 (range: 16?83) years. At 8?weeks, haematological improvement, with increases in haemoglobin (Hb) ?1.5?g/dL (haematological improvement in erythrocytes [HI-E]) and platelet count ?30?×?109/L (haematological improvement in platelets [HI-P]), was observed in 0/25 (0%) and 6/32 (19%) evaluable cases respectively. HI-E and HI-P occurred in 1/25 (4%) and 10/32 (31%) patients at 16?weeks, respectively, and at 52?weeks in 5/25 (20%) and 16/32 (50%) patients respectively. Nine grade 3 adverse events (AEs) occurred in six patients, but there were no grade ?4 AEs. Ten of the 32 patients experienced grade 2 renal toxicity. Low-dose CsA is effective in TI-NSAA patients and demonstrates minimal renal toxicity. However, at least 16?weeks are necessary to adequately evaluate its efficacy.
en-copyright=
kn-copyright=

en-aut-name=IshiyamaKen
en-aut-sei=Ishiyama
en-aut-mei=Ken
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YamazakiMasahide
en-aut-sei=Yamazaki
en-aut-mei=Masahide
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MaruyamaHiroyuki
en-aut-sei=Maruyama
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=HosonoNaoko
en-aut-sei=Hosono
en-aut-mei=Naoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=YamaguchiHiroki
en-aut-sei=Yamaguchi
en-aut-mei=Hiroki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=AsadaNoboru
en-aut-sei=Asada
en-aut-mei=Noboru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TanimotoKazuki
en-aut-sei=Tanimoto
en-aut-mei=Kazuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=SugiuraHiroyuki
en-aut-sei=Sugiura
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=UsukiKensuke
en-aut-sei=Usuki
en-aut-mei=Kensuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=YoshimuraKenichi
en-aut-sei=Yoshimura
en-aut-mei=Kenichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=OgawaSeishi
en-aut-sei=Ogawa
en-aut-mei=Seishi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=KanakuraYuzuru
en-aut-sei=Kanakura
en-aut-mei=Yuzuru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=MatsumuraItaru
en-aut-sei=Matsumura
en-aut-mei=Itaru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=AkashiKoichi
en-aut-sei=Akashi
en-aut-mei=Koichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=NakaoShinji
en-aut-sei=Nakao
en-aut-mei=Shinji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

affil-num=1
en-affil=Department of Hematology, Kanazawa University Hospital
kn-affil=

affil-num=2
en-affil=Department of Internal Medicine, Keiju Medical Center
kn-affil=

affil-num=3
en-affil=Department of Hematology, Kanazawa University Hospital
kn-affil=

affil-num=4
en-affil=Department of Hematology and Oncology, University of Fukui Hospital
kn-affil=

affil-num=5
en-affil=Department of Hematology, Nippon Medical School
kn-affil=

affil-num=6
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=7
en-affil=Department of Hematology and Oncology, Japanese Red Cross Fukuoka Hospital
kn-affil=

affil-num=8
en-affil=Department of Hematology, Chugoku Central Hospital of Japan Mutual Aid Association of Public School Teachers
kn-affil=

affil-num=9
en-affil=Department of Hematology, NTT Medical Center Tokyo
kn-affil=

affil-num=10
en-affil=Department of Biostatistics and Health Data Science, Graduate School of Medical Science, Nagoya City University
kn-affil=

affil-num=11
en-affil=Department of Pathology and Tumor Biology, Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University
kn-affil=

affil-num=12
en-affil=Sumitomo Hospital
kn-affil=

affil-num=13
en-affil=Department of Hematology and Rheumatology, Kindai University Faculty of Medicine
kn-affil=

affil-num=14
en-affil=Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences
kn-affil=

affil-num=15
en-affil=Department of Hematology, Kanazawa University Hospital
kn-affil=
en-keyword=ciclosporin
kn-keyword=ciclosporin
en-keyword=prospective study
kn-keyword=prospective study
en-keyword=renal toxicity
kn-keyword=renal toxicity
en-keyword=transfusion-independent non-severe aplastic anaemia
kn-keyword=transfusion-independent non-severe aplastic anaemia
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251110
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2024 for the clinical practice of hereditary colorectal cancer
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Approximately 5% of all colorectal cancers have a strong genetic component and are classified as hereditary colorectal cancer (HCRC). Some of the unique features commonly seen in HCRC cases include early age of onset, synchronous/metachronous cancer occurrence, and multiple cancers in other organs. These characteristics require different management approaches, including diagnosis, treatment or surveillance, from those used in the management of sporadic colorectal cancer. Accurate diagnosis of HCRC is essential because it enables targeted surveillance and risk reduction strategies that improve patient outcomes. Recent genetic advances revealed several causative genes for polyposis and non-polyposis syndromes. The Japanese Society for Cancer of the Colon and Rectum (JSCCR) first published guidelines for the management of HCRC in 2012, with subsequent revisions every 4 years. The 2024 update to the JSCCR guidelines for HCRC was developed by meticulously reviewing evidence from systematic reviews and the consensus of the JSCCR HCRC Guidelines Committee, which includes representatives from patient advocacy groups for FAP and Lynch syndrome. These guidelines provide an up-to-date summary of HCRC, along with clinical recommendations for managing FAP and Lynch syndrome.
en-copyright=
kn-copyright=

en-aut-name=TanakayaKohji
en-aut-sei=Tanakaya
en-aut-mei=Kohji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YamaguchiTatsuro
en-aut-sei=Yamaguchi
en-aut-mei=Tatsuro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HirataKeiji
en-aut-sei=Hirata
en-aut-mei=Keiji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YamadaMasayoshi
en-aut-sei=Yamada
en-aut-mei=Masayoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KumamotoKensuke
en-aut-sei=Kumamoto
en-aut-mei=Kensuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=AkiyamaYasuki
en-aut-sei=Akiyama
en-aut-mei=Yasuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=IshimaruKei
en-aut-sei=Ishimaru
en-aut-mei=Kei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=OkamotoKoichi
en-aut-sei=Okamoto
en-aut-mei=Koichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=KawasakiYuko
en-aut-sei=Kawasaki
en-aut-mei=Yuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=KomineKeigo
en-aut-sei=Komine
en-aut-mei=Keigo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=SakamotoAkira
en-aut-sei=Sakamoto
en-aut-mei=Akira
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=ShigeyasuKunitoshi
en-aut-sei=Shigeyasu
en-aut-mei=Kunitoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=ShibataYoshiko
en-aut-sei=Shibata
en-aut-mei=Yoshiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=ShimamotoYusaku
en-aut-sei=Shimamoto
en-aut-mei=Yusaku
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=ShimodairaHideki
en-aut-sei=Shimodaira
en-aut-mei=Hideki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=SekineShigeki
en-aut-sei=Sekine
en-aut-mei=Shigeki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=TakaoAkinari
en-aut-sei=Takao
en-aut-mei=Akinari
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=TakaoMisato
en-aut-sei=Takao
en-aut-mei=Misato
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=TakamizawaYasuyuki
en-aut-sei=Takamizawa
en-aut-mei=Yasuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=TakeuchiYoji
en-aut-sei=Takeuchi
en-aut-mei=Yoji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=TanabeNoriko
en-aut-sei=Tanabe
en-aut-mei=Noriko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=TaniguchiFumitaka
en-aut-sei=Taniguchi
en-aut-mei=Fumitaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=ChinoAkiko
en-aut-sei=Chino
en-aut-mei=Akiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=ChoHourin
en-aut-sei=Cho
en-aut-mei=Hourin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=DoiSatoru
en-aut-sei=Doi
en-aut-mei=Satoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=NakajimaTakeshi
en-aut-sei=Nakajima
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

en-aut-name=NakamoriSakiko
en-aut-sei=Nakamori
en-aut-mei=Sakiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=27
ORCID=

en-aut-name=NakayamaYoshiko
en-aut-sei=Nakayama
en-aut-mei=Yoshiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=28
ORCID=

en-aut-name=NagasakiToshiya
en-aut-sei=Nagasaki
en-aut-mei=Toshiya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=29
ORCID=

en-aut-name=HasumiHisashi
en-aut-sei=Hasumi
en-aut-mei=Hisashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=30
ORCID=

en-aut-name=BannoKouji
en-aut-sei=Banno
en-aut-mei=Kouji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=31
ORCID=

en-aut-name=HinoiTakao
en-aut-sei=Hinoi
en-aut-mei=Takao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=32
ORCID=

en-aut-name=FujiyoshiKenji
en-aut-sei=Fujiyoshi
en-aut-mei=Kenji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=33
ORCID=

en-aut-name=HorimatsuTakahiro
en-aut-sei=Horimatsu
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=34
ORCID=

en-aut-name=MasudaKenta
en-aut-sei=Masuda
en-aut-mei=Kenta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=35
ORCID=

en-aut-name=MiguchiMasashi
en-aut-sei=Miguchi
en-aut-mei=Masashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=36
ORCID=

en-aut-name=MizuuchiYusuke
en-aut-sei=Mizuuchi
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=37
ORCID=

en-aut-name=MiyakuraYasuyuki
en-aut-sei=Miyakura
en-aut-mei=Yasuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=38
ORCID=

en-aut-name=MutohMichihiro
en-aut-sei=Mutoh
en-aut-mei=Michihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=39
ORCID=

en-aut-name=YoshiokaTakahiro
en-aut-sei=Yoshioka
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=40
ORCID=

en-aut-name=TanakaShinji
en-aut-sei=Tanaka
en-aut-mei=Shinji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=41
ORCID=

en-aut-name=SakamotoKazuhiro
en-aut-sei=Sakamoto
en-aut-mei=Kazuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=42
ORCID=

en-aut-name=SakamakiKentaro
en-aut-sei=Sakamaki
en-aut-mei=Kentaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=43
ORCID=

en-aut-name=ItabashiMichio
en-aut-sei=Itabashi
en-aut-mei=Michio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=44
ORCID=

en-aut-name=IshidaHideyuki
en-aut-sei=Ishida
en-aut-mei=Hideyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=45
ORCID=

en-aut-name=TomitaNaohiro
en-aut-sei=Tomita
en-aut-mei=Naohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=46
ORCID=

en-aut-name=SugiharaKenichi
en-aut-sei=Sugihara
en-aut-mei=Kenichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=47
ORCID=

en-aut-name=AjiokaYoichi
en-aut-sei=Ajioka
en-aut-mei=Yoichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=48
ORCID=

affil-num=1
en-affil=Department of Surgery, National Hospital Organization Iwakuni Clinical Center
kn-affil=

affil-num=2
en-affil=Department of Clinical Genetics, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
kn-affil=

affil-num=3
en-affil=Department of Surgery 1, University of Occupational and Environmental Health
kn-affil=

affil-num=4
en-affil=Endoscopy Division, National Cancer Center Hospital
kn-affil=

affil-num=5
en-affil=Department of Genome Medical Science and Medical Genetics, Faculty of Medicine, Kagawa University
kn-affil=

affil-num=6
en-affil=Department of Surgery 1, University of Occupational and Environmental Health
kn-affil=

affil-num=7
en-affil=Division of Gastrointestinal Surgery and Surgical Oncology, Graduate School of Medicine, Ehime University
kn-affil=

affil-num=8
en-affil=Department of Gastroenterology and Oncology, Tokushima University Graduate School of Medical Science
kn-affil=

affil-num=9
en-affil=College of Nursing, University of Hyogo
kn-affil=

affil-num=10
en-affil=Department of Medical Oncology, Tohoku University Hospital
kn-affil=

affil-num=11
en-affil=Department of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
kn-affil=

affil-num=12
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=13
en-affil=Himawari-No-Kai (Sunflower Association), a Patient Advocacy Group for Individuals and Families Affected By Lynch Syndrome
kn-affil=

affil-num=14
en-affil=Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine
kn-affil=

affil-num=15
en-affil=Division of Medical Oncology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University
kn-affil=

affil-num=16
en-affil=Department of Pathology, Keio University School of Medicine
kn-affil=

affil-num=17
en-affil=Department of Gastroenterology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
kn-affil=

affil-num=18
en-affil=Department of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
kn-affil=

affil-num=19
en-affil=Department of Colorectal Surgery, National Cancer Center Hospital
kn-affil=

affil-num=20
en-affil=Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine
kn-affil=

affil-num=21
en-affil=Department of Clinical Genetics, Saitama Medical Center, Saitama Medical University
kn-affil=

affil-num=22
en-affil=Department of Surgery, Hiroshima City Hospital Organization Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=23
en-affil=Department of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research
kn-affil=

affil-num=24
en-affil=Endoscopy Center, Tokyo Medical University Hospital
kn-affil=

affil-num=25
en-affil=Harmony Line (Association for Patients and Families With Familial Adenomatous Polyposis)
kn-affil=

affil-num=26
en-affil=Division of Hereditary Tumors, Department of Genetic Oncology, Osaka International Cancer Institute
kn-affil=

affil-num=27
en-affil=Department of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
kn-affil=

affil-num=28
en-affil=Department of Pediatrics, Shinshu University School of Medicine
kn-affil=

affil-num=29
en-affil=Department of Gastroenterological Surgery, Saitama Cancer Center
kn-affil=

affil-num=30
en-affil=Department of Urology, Yokohama City University
kn-affil=

affil-num=31
en-affil=Center of Maternal -Fetal/Neonatal Medicine, Hiroshima University Hospital
kn-affil=

affil-num=32
en-affil=Department of Clinical and Molecular Genetics, Hiroshima University Hospital
kn-affil=

affil-num=33
en-affil=Department of Surgery, Kurume University School of Medicine
kn-affil=

affil-num=34
en-affil=Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital
kn-affil=

affil-num=35
en-affil=Department of Obstetrics and Gynecology, Keio University School of Medicine
kn-affil=

affil-num=36
en-affil=Department of Gastroenterological Surgery, Hiroshima Prefectural Hospital
kn-affil=

affil-num=37
en-affil=Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University
kn-affil=

affil-num=38
en-affil=Department of Colon and Pelvic Surgery, Cancer Prevention and Genetic Counseling, Tochigi Cancer Center
kn-affil=

affil-num=39
en-affil=Department of Molecular-Targeting Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine
kn-affil=

affil-num=40
en-affil=Department of Gastroenterological Surgery, Kochi Health Sciences Center
kn-affil=

affil-num=41
en-affil=JA Onomichi General Hospital
kn-affil=

affil-num=42
en-affil=Koshigaya Municipal Hospital
kn-affil=

affil-num=43
en-affil=Faculty of Health Data Science, Juntendo University
kn-affil=

affil-num=44
en-affil=Saiseikai Kazo Hospital
kn-affil=

affil-num=45
en-affil=Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University
kn-affil=

affil-num=46
en-affil=Division of Cancer Treatment , Toyonaka Municipal Hospital
kn-affil=

affil-num=47
en-affil=Institute of Science Tokyo
kn-affil=

affil-num=48
en-affil=Division of Molecular and Diagnostic Pathology, Graduate School of Medical and Dental Sciences, Niigata University
kn-affil=
en-keyword=Hereditary colorectal cancer
kn-keyword=Hereditary colorectal cancer
en-keyword=Guidelines
kn-keyword=Guidelines
en-keyword=Familial adenomatous polyposis
kn-keyword=Familial adenomatous polyposis
en-keyword=Lynch syndrome
kn-keyword=Lynch syndrome
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251119
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=The Role of the Mylohyoid Line in the Spread of Mandibular Odontogenic Deep Neck Infection
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Introduction: Although mandibular odontogenic deep neck infections are occasionally fatal, the transmission pathway has not been elucidated.<br>
Materials and Methods: This multicenter retrospective study was comprised of the patients of both sexes who were over 18?years of age and who had mandibular odontogenic deep neck abscesses. The patients' characteristics, laboratory tests, and radiographic findings were analyzed.<br>
Results: One hundred eighteen patients with mandibular odontogenic deep neck abscesses were included. Bone resorption superior to the mylohyoid line and the related abscess formation in submandibular space or submental space were both significantly associated with the presence of sublingual space abscess. In addition, the type of causative tooth was not a risk factor for abscess formation in both the sublingual space and “submandibular or submental” space.<br>
Conclusions: When an odontogenic lesion is located superior to the mylohyoid line, the abscess tends to initially form in the sublingual space and subsequently spread to the submandibular or submental space. Since any mandibular tooth can lead to abscess formation in these regions, oral and maxillofacial surgeons should carefully assess the anatomical position of the lesion and accurately identify the causative tooth.
en-copyright=
kn-copyright=

en-aut-name=IwataEiji
en-aut-sei=Iwata
en-aut-mei=Eiji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ObataKyoichi
en-aut-sei=Obata
en-aut-mei=Kyoichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KikutaShogo
en-aut-sei=Kikuta
en-aut-mei=Shogo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KanekoNaoki
en-aut-sei=Kaneko
en-aut-mei=Naoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SatoKotaro
en-aut-sei=Sato
en-aut-mei=Kotaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KitagawaNorio
en-aut-sei=Kitagawa
en-aut-mei=Norio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TakeshitaYohei
en-aut-sei=Takeshita
en-aut-mei=Yohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=MatsuoKatsuhisa
en-aut-sei=Matsuo
en-aut-mei=Katsuhisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=SameshimaJunsei
en-aut-sei=Sameshima
en-aut-mei=Junsei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=TachibanaAkira
en-aut-sei=Tachibana
en-aut-mei=Akira
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=KawanoShintaro
en-aut-sei=Kawano
en-aut-mei=Shintaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=KusukawaJingo
en-aut-sei=Kusukawa
en-aut-mei=Jingo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=AkashiMasaya
en-aut-sei=Akashi
en-aut-mei=Masaya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=IbaragiSoichiro
en-aut-sei=Ibaragi
en-aut-mei=Soichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=IwanagaJoe
en-aut-sei=Iwanaga
en-aut-mei=Joe
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

affil-num=1
en-affil=Department of Oral and Maxillofacial Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Oral and Maxillofacial Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Dental and Oral Medical Center, Kurume University School of Medicine
kn-affil=

affil-num=4
en-affil=Section of Oral and Maxillofacial Oncology, Division of Maxillofacial Diagnostic and Surgical Sciences, Faculty of Dental Science, Kyushu University
kn-affil=

affil-num=5
en-affil=Department of Oral and Maxillofacial Surgery, Nagoya University, Graduate School of Medicine
kn-affil=

affil-num=6
en-affil=Department of Oral and Maxillofacial Anatomy, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo
kn-affil=

affil-num=7
en-affil=Department of Oral and Maxillofacial Radiology, Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Dental and Oral Medical Center, Kurume University School of Medicine
kn-affil=

affil-num=9
en-affil=Section of Oral and Maxillofacial Oncology, Division of Maxillofacial Diagnostic and Surgical Sciences, Faculty of Dental Science, Kyushu University
kn-affil=

affil-num=10
en-affil=Department of Oral and Maxillofacial Surgery, Kakogawa Central City Hospital
kn-affil=

affil-num=11
en-affil=Section of Oral and Maxillofacial Oncology, Division of Maxillofacial Diagnostic and Surgical Sciences, Faculty of Dental Science, Kyushu University
kn-affil=

affil-num=12
en-affil=Dental and Oral Medical Center, Kurume University School of Medicine
kn-affil=

affil-num=13
en-affil=Department of Oral and Maxillofacial Surgery, Kobe University
kn-affil=

affil-num=14
en-affil=Department of Oral and Maxillofacial Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=15
en-affil=Dental and Oral Medical Center, Kurume University School of Medicine
kn-affil=
en-keyword=causative tooth
kn-keyword=causative tooth
en-keyword=mylohyoid line
kn-keyword=mylohyoid line
en-keyword=odontogenic deep neck abscesses
kn-keyword=odontogenic deep neck abscesses
en-keyword=odontogenic deep neck infections
kn-keyword=odontogenic deep neck infections
en-keyword=transmission pathway
kn-keyword=transmission pathway
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250917
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Impact of CT-assessed sarcopenia on the severity of odontogenic deep neck infections: a retrospective cohort study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Sarcopenia is increasingly recognized as a key predictor of adverse health outcomes. This study aimed to evaluate the impact of computed tomography-assessed sarcopenia (CT?SP) on the clinical severity and hospitalization duration of odontogenic deep neck infections (DNIs). Total of 119 patients admitted for odontogenic DNI treatment were included. Patients were divided into two groups by DNI clinical severity (severe or mild) and the patients' characteristics, including CT?SP based on skeletal muscle index (SMI), were compared between two groups. Multivariable logistic regression analysis was performed to identify independent risk factors for severe DNI. The correlation between SMI and hospitalization duration was assessed using Spearman’s rank correlation coefficient. Of the 119 patients, 60 (50.4%) presented with severe DNIs, including deep neck abscesses and necrotizing soft tissue infections. After adjusting for potential confounders, multivariable analysis identified CT?SP as the sole independent risk factor associated with severe DNI (Odds Ratio?=?3.04; 95% Confidence Interval, 1.20?7.71; p?=?0.019). Furthermore, SMI demonstrated a significant, weak negative correlation with the hospitalization duration (r?=?? 0.331, p?<?0.001). CT?SP is a powerful, independent risk factor associated with severity in patients with odontogenic DNIs. This finding underscores the critical role of systemic host factors in the clinical course of maxillofacial infections and highlights the potential of opportunistic CT screening as a factor to consider in risk stratification in this vulnerable population.
en-copyright=
kn-copyright=

en-aut-name=KikutaShogo
en-aut-sei=Kikuta
en-aut-mei=Shogo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=IwataEiji
en-aut-sei=Iwata
en-aut-mei=Eiji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TakeshitaYohei
en-aut-sei=Takeshita
en-aut-mei=Yohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KobayashiChizuru
en-aut-sei=Kobayashi
en-aut-mei=Chizuru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KimuraHiroki
en-aut-sei=Kimura
en-aut-mei=Hiroki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KinisadaYuki
en-aut-sei=Kinisada
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TachibanaAkira
en-aut-sei=Tachibana
en-aut-mei=Akira
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KusukawaJingo
en-aut-sei=Kusukawa
en-aut-mei=Jingo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=AkashiMasaya
en-aut-sei=Akashi
en-aut-mei=Masaya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=IbaragiSoichiro
en-aut-sei=Ibaragi
en-aut-mei=Soichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Dental and Oral Medical Center, Kurume University School of Medicine
kn-affil=

affil-num=2
en-affil=Department of Oral and Maxillofacial Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=

affil-num=3
en-affil=Department of Oral and Maxillofacial Radiology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=

affil-num=4
en-affil=Department of Oral and Maxillofacial Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=

affil-num=5
en-affil=Department of Oral and Maxillofacial Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=

affil-num=6
en-affil=Department of Oral and Maxillofacial Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=

affil-num=7
en-affil=Department of Oral and Maxillofacial Surgery, Kakogawa Central City Hospital
kn-affil=

affil-num=8
en-affil=Dental and Oral Medical Center, Kurume University School of Medicine
kn-affil=

affil-num=9
en-affil=Department of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine
kn-affil=

affil-num=10
en-affil=Department of Oral and Maxillofacial Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=
en-keyword=CT-assessed sarcopenia
kn-keyword=CT-assessed sarcopenia
en-keyword=Odontogenic deep neck infections
kn-keyword=Odontogenic deep neck infections
en-keyword=Severity
kn-keyword=Severity
en-keyword=Hospitalization duration
kn-keyword=Hospitalization duration
en-keyword=Skeletal muscle index
kn-keyword=Skeletal muscle index
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250909
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Current Status of Continuous Renal Replacement Therapy in Japanese Intensive Care Units: A Multicenter Retrospective Observational Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Introduction: Continuous renal replacement therapy (CRRT) is often performed for critically ill patients in intensive care units (ICUs), but its optimal indication and settings have yet to be determined. Thus, we aimed to describe the current status of CRRT in Japan through a multicenter retrospective observational study. Methods: Adult ICU patients receiving CRRT at 18 tertiary hospitals in Japan (up to 100 patients from each hospital over the past year) were retrospectively enrolled. Patients receiving CRRT for <24 h or intermittent renal replacement therapy together with CRRT were excluded. The primary outcomes were the temporal changes in the electrolyte levels, acid-base balance, and uremia-related small solute concentrations. The secondary outcomes included potassium (K) and phosphate (P) supplementations during CRRT. Results: Altogether, 1,045 patients were enrolled. The median CRRT duration and dose were 4.4 days and 17.3 mL/kg/h, respectively. The electrolyte levels, acid-base balance, and uremia-related small solute concentrations returned to normal by day 4 of treatment. A total of 732 (70.0%) patients received K supplementation, and only a few patients had hypokalemia until day 5. Moreover, 414 (39.6%) patients received P supplementation, and approximately 30%?50% of the patients had hypophosphatemia until day 5. Conclusion: The CRRT dose in Japan was lower than that was recommended by the Kidney Disease: Improving Global Outcomes guideline. The electrolyte level abnormalities and acid-base imbalances of the studied patients were improved within 72?96 h of CRRT. Contrarily, K and P supplementations were common, indicating that the current CRRT solutions need to be modified.
en-copyright=
kn-copyright=

en-aut-name=NakanoHidehiko
en-aut-sei=Nakano
en-aut-mei=Hidehiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=InokuchiRyota
en-aut-sei=Inokuchi
en-aut-mei=Ryota
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=InoueYutaro
en-aut-sei=Inoue
en-aut-mei=Yutaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SekinoMotohiro
en-aut-sei=Sekino
en-aut-mei=Motohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KakihanaYasuyuki
en-aut-sei=Kakihana
en-aut-mei=Yasuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=HattoriNoriyuki
en-aut-sei=Hattori
en-aut-mei=Noriyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MiyazakiMariko
en-aut-sei=Miyazaki
en-aut-mei=Mariko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=TokuhiraNatsuko
en-aut-sei=Tokuhira
en-aut-mei=Natsuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=FujitaniShigeki
en-aut-sei=Fujitani
en-aut-mei=Shigeki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=TodaYuichiro
en-aut-sei=Toda
en-aut-mei=Yuichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=OhchiYoshifumi
en-aut-sei=Ohchi
en-aut-mei=Yoshifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=MorimatsuHiroshi
en-aut-sei=Morimatsu
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=IchibaShingo
en-aut-sei=Ichiba
en-aut-mei=Shingo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=MasudaYoshiki
en-aut-sei=Masuda
en-aut-mei=Yoshiki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=NishidaOsamu
en-aut-sei=Nishida
en-aut-mei=Osamu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=AbeTakaya
en-aut-sei=Abe
en-aut-mei=Takaya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=MoriguchiTakeshi
en-aut-sei=Moriguchi
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=SatohKasumi
en-aut-sei=Satoh
en-aut-mei=Kasumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=IdeiMasafumi
en-aut-sei=Idei
en-aut-mei=Masafumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=NagataHiromasa
en-aut-sei=Nagata
en-aut-mei=Hiromasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=DoiKent
en-aut-sei=Doi
en-aut-mei=Kent
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

affil-num=1
en-affil=Department of Emergency and Critical Care Medicine, The University of Tokyo Hospital
kn-affil=

affil-num=2
en-affil=Department of Emergency and Critical Care Medicine, The University of Tokyo Hospital
kn-affil=

affil-num=3
en-affil=Department of Emergency and Critical Care Medicine, The University of Tokyo Hospital
kn-affil=

affil-num=4
en-affil=Department of Anesthesiology and Intensive Care Medicine, Nagasaki University Graduate School of Biomedical Sciences
kn-affil=

affil-num=5
en-affil=Department of Emergency and Intensive Care Medicine, Kagoshima University Graduate School of Medical and Dental Sciences
kn-affil=

affil-num=6
en-affil=Department of Emergency and Critical Care Medicine, Chiba University Graduate School of Medicine
kn-affil=

affil-num=7
en-affil=Department of Nephrology, Tohoku University Hospital
kn-affil=

affil-num=8
en-affil=Department of Intensive Care, Osaka University Hospital
kn-affil=

affil-num=9
en-affil=Department of Emergency and Critical Care Medicine, St. Marianna University School of Medicine
kn-affil=

affil-num=10
en-affil=Department of Anesthesiology and Intensive Care Medicine, Kawasaki Medical School
kn-affil=

affil-num=11
en-affil=Department of Anesthesiology and Intensive Care, Oita University Faculty of Medicine
kn-affil=

affil-num=12
en-affil=Department of Anesthesiology and Resuscitology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=13
en-affil=Department of Intensive Care Medicine, Tokyo Women’s Medical University
kn-affil=

affil-num=14
en-affil=Department of Intensive Care Medicine, Sapporo Medical University School of Medicine
kn-affil=

affil-num=15
en-affil=Department of Anesthesiology and Critical Care Medicine, School of Medicine, Fujita Health University
kn-affil=

affil-num=16
en-affil=Department of Urology, Iwate Medical University
kn-affil=

affil-num=17
en-affil=Department of Emergency and Critical Care Medicine, University of Yamanashi Graduate School of Medicine
kn-affil=

affil-num=18
en-affil=Department of Emergency and Critical Care Medicine, Akita University Graduate School of Medicine
kn-affil=

affil-num=19
en-affil=Department of Intensive Care Medicine, Yokohama City University
kn-affil=

affil-num=20
en-affil=Department of Anesthesiology, Keio University School of Medicine
kn-affil=

affil-num=21
en-affil=Department of Emergency and Critical Care Medicine, The University of Tokyo Hospital
kn-affil=
en-keyword=Acute kidney injury
kn-keyword=Acute kidney injury
en-keyword=Renal failure
kn-keyword=Renal failure
en-keyword=Continuous renal replacement therapy
kn-keyword=Continuous renal replacement therapy
en-keyword=Electrolytes
kn-keyword=Electrolytes
END

start-ver=1.4
cd-journal=joma
no-vol=14
cd-vols=
no-issue=17
article-no=
start-page=6122
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250829
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Potential of Kidney Exchange Programs (KEPs) in Japan for Donor-Specific Antibody-Positive Kidney Transplants: A Questionnaire Survey on KEPs and a Multi-Institutional Study Conducting Virtual Cross-Matching Simulations
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Objectives: To clarify the need for a kidney exchange program (KEP) in Japan by conducting a questionnaire survey on KEPs and simulated KEPs by virtual cross-matching based on past cases of transplantation avoidance. Methods: In addition to the content regarding KEPs, an electronic survey was conducted to investigate the number of cases of kidney transplant abandonment due to “immunological” reasons over the past 10 years (2012?2021). Virtual cross-matching was conducted to simulate the feasibility of avoiding immunological risks and enabling kidney transplantation in patients who were previously unable to undergo the procedure. Results: The survey received responses from 107 facilities (response rate: 81.7%). In response to the question about the necessity of a KEP in Japan, 71 facilities (66.4%) indicated that KEPs are necessary. In addition, 251 living-donor kidney transplants were abandoned for “immunological” reasons over the past decade (2012?2021). Among the 80 pairs for which detailed information was available, virtual cross-matching simulations showed that 37/80 pairs (46.3%) were donor-specific antibody (DSA)-negative for blood type-matched combinations, and 41/80 pairs (51.3%) were DSA-negative for blood type-incompatible transplants. Conclusions: The need for a KEP in Japan and its potential usefulness were demonstrated.
en-copyright=
kn-copyright=

en-aut-name=ItoTaihei
en-aut-sei=Ito
en-aut-mei=Taihei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ItoMiki
en-aut-sei=Ito
en-aut-mei=Miki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=AidaNaohiro
en-aut-sei=Aida
en-aut-mei=Naohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KuriharaKei
en-aut-sei=Kurihara
en-aut-mei=Kei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TeraoAkihiro
en-aut-sei=Terao
en-aut-mei=Akihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=WataraiYoshihiko
en-aut-sei=Watarai
en-aut-mei=Yoshihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=SaitoMitsuru
en-aut-sei=Saito
en-aut-mei=Mitsuru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KakuKeizo
en-aut-sei=Kaku
en-aut-mei=Keizo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=IshiiDaisuke
en-aut-sei=Ishii
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=SekiguchiSatoshi
en-aut-sei=Sekiguchi
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=YonedaTatsuo
en-aut-sei=Yoneda
en-aut-mei=Tatsuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=UnagamiKohei
en-aut-sei=Unagami
en-aut-mei=Kohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=TasakiMasayuki
en-aut-sei=Tasaki
en-aut-mei=Masayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=IwamotoHitoshi
en-aut-sei=Iwamoto
en-aut-mei=Hitoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=ArakiMotoo
en-aut-sei=Araki
en-aut-mei=Motoo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=TakahashiKazuhiro
en-aut-sei=Takahashi
en-aut-mei=Kazuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=YamanakaKazuaki
en-aut-sei=Yamanaka
en-aut-mei=Kazuaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=SugimotoMikio
en-aut-sei=Sugimoto
en-aut-mei=Mikio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=NishikawaKouhei
en-aut-sei=Nishikawa
en-aut-mei=Kouhei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=SetoChikashi
en-aut-sei=Seto
en-aut-mei=Chikashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=MuramatsuMasaki
en-aut-sei=Muramatsu
en-aut-mei=Masaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=AsaiToshihiro
en-aut-sei=Asai
en-aut-mei=Toshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=IwamiDaiki
en-aut-sei=Iwami
en-aut-mei=Daiki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=YamadaYasutoshi
en-aut-sei=Yamada
en-aut-mei=Yasutoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=YamanagaShigeyoshi
en-aut-sei=Yamanaga
en-aut-mei=Shigeyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=KomatsuTomonori
en-aut-sei=Komatsu
en-aut-mei=Tomonori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

en-aut-name=MiuraMasayoshi
en-aut-sei=Miura
en-aut-mei=Masayoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=27
ORCID=

en-aut-name=NoharaTakahiro
en-aut-sei=Nohara
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=28
ORCID=

en-aut-name=MaruyamaMichihiro
en-aut-sei=Maruyama
en-aut-mei=Michihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=29
ORCID=

en-aut-name=MiyauchiYuki
en-aut-sei=Miyauchi
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=30
ORCID=

en-aut-name=TanakaToshiaki
en-aut-sei=Tanaka
en-aut-mei=Toshiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=31
ORCID=

en-aut-name=NakamuraMichio
en-aut-sei=Nakamura
en-aut-mei=Michio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=32
ORCID=

en-aut-name=HottaKiyohiko
en-aut-sei=Hotta
en-aut-mei=Kiyohiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=33
ORCID=

en-aut-name=KenmochiTakashi
en-aut-sei=Kenmochi
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=34
ORCID=

affil-num=1
en-affil=Department of Transplantation and Regenerative Medicine, School of Medicine, Fujita Health University
kn-affil=

affil-num=2
en-affil=Department of Transplantation and Regenerative Medicine, School of Medicine, Fujita Health University
kn-affil=

affil-num=3
en-affil=Department of Transplantation and Regenerative Medicine, School of Medicine, Fujita Health University
kn-affil=

affil-num=4
en-affil=Department of Transplantation and Regenerative Medicine, School of Medicine, Fujita Health University
kn-affil=

affil-num=5
en-affil=Department of Transplantation and Regenerative Medicine, School of Medicine, Fujita Health University
kn-affil=

affil-num=6
en-affil=Department of Transplant Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital
kn-affil=

affil-num=7
en-affil=Division of Blood Purification, Akita University Hospital
kn-affil=

affil-num=8
en-affil=Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University
kn-affil=

affil-num=9
en-affil=Department of Urology, Kitasato University of Medicine
kn-affil=

affil-num=10
en-affil=Transplantation Surgery, Japan Community Healthcare Organization Sendai Hospital
kn-affil=

affil-num=11
en-affil=Unit of Dialysis, Department of Urology, Nara Medical University
kn-affil=

affil-num=12
en-affil=Organ Transplant Medicine, Tokyo Women’s Medical University
kn-affil=

affil-num=13
en-affil=Division of Urology, Department of Regenerative & Transplant Medicine, Graduate School of Medical and Dental Sciences, Niigata University
kn-affil=

affil-num=14
en-affil=Department of Kidney Transplantation Surgery, Tokyo Medical University Hachioji Medical Center
kn-affil=

affil-num=15
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=16
en-affil=Department of Gastrointestinal and Hepatobiliary Pancreatic Surgery, University of Tsukuba
kn-affil=

affil-num=17
en-affil=Department of Urology, Osaka University Graduate School of Medicine
kn-affil=

affil-num=18
en-affil=Department of Urology, Faculty of Medicine, Adrenal Surgery and Renal Transplantation, Kagawa University
kn-affil=

affil-num=19
en-affil=Department of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine
kn-affil=

affil-num=20
en-affil=Department of Urology, Toyama Prefectural Central Hospital
kn-affil=

affil-num=21
en-affil=Department of Nephrology, Toho University Faculty of Medicine
kn-affil=

affil-num=22
en-affil=Department of Kidney Transplant and Dialysis, Osaka City General Hospital
kn-affil=

affil-num=23
en-affil=Division of Renal Surgery and Transplantation, Department of Urology, Jichi Medical University
kn-affil=

affil-num=24
en-affil=Department of Blood Purification, Kagoshima University Hospital
kn-affil=

affil-num=25
en-affil=Department of Transplant Surgery, Japanese Red Cross Kumamoto Hospital
kn-affil=

affil-num=26
en-affil=Department of Urology, Chukyo Hospital, Japan Community Healthcare Organization
kn-affil=

affil-num=27
en-affil=Department of Renal Transplantation Surgery and Urology, Sapporo Hokuyu Hospital
kn-affil=

affil-num=28
en-affil=Department of Urology, Kanazawa University Hospital
kn-affil=

affil-num=29
en-affil=Department of Frontier Surgery, Chiba University School of Medicine
kn-affil=

affil-num=30
en-affil=Department of Urology, Ehime University
kn-affil=

affil-num=31
en-affil=Department of Urology, Sapporo Medical University
kn-affil=

affil-num=32
en-affil=Department of Transplant Surgery, Tokai University School of Medicine
kn-affil=

affil-num=33
en-affil=Department of Renal and Genitourinary Surgery, Faculty of Medicine, Hokkaido University
kn-affil=

affil-num=34
en-affil=Department of Transplantation and Regenerative Medicine, School of Medicine, Fujita Health University
kn-affil=
en-keyword=kidney transplantation
kn-keyword=kidney transplantation
en-keyword=donor-specific antibodies
kn-keyword=donor-specific antibodies
en-keyword=kidney exchange program
kn-keyword=kidney exchange program
en-keyword=virtual cross-matching
kn-keyword=virtual cross-matching
END

start-ver=1.4
cd-journal=joma
no-vol=65
cd-vols=
no-issue=3
article-no=
start-page=101624
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202506
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Spatial distribution estimation by considering the cross-correlation between components with indirect data using Gaussian process regression
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Generally, soil properties are measured only at limited locations. To rationally estimate the spatial distribution of soil properties, it is preferable to effectively use all available measurement data, including indirect data. We propose a Gaussian process regression with multiple random fields that considers the cross-correlation between one of the random fields of direct data and indirect data, and show the application to simulated data and actual measured data. In the application, the direct data are of CPT tip resistance (qc), which was obtained within a narrow area, and the indirect data are of shear wave velocity (Vs) obtained by surface wave exploration, which were obtained over a wide area. We estimate the spatial distribution of qc from the limited qc and wide area Vs data. The estimation accuracy of the proposed method is evaluated by cross-validation, and its effectiveness is discussed.
en-copyright=
kn-copyright=

en-aut-name=TsudaYuto
en-aut-sei=Tsuda
en-aut-mei=Yuto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YoshidaIkumasa
en-aut-sei=Yoshida
en-aut-mei=Ikumasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NishimuraShinichi
en-aut-sei=Nishimura
en-aut-mei=Shinichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

affil-num=1
en-affil=Postdoctoral Researcher, School of Integrative Science and Engineering, Tokyo City University
kn-affil=

affil-num=2
en-affil=Professor Emeritus, Department of Urban and Civil Engineering, Tokyo City University
kn-affil=

affil-num=3
en-affil=Department of Civil Environmental Engineering, Okayama University
kn-affil=
en-keyword=Shear wave velocity
kn-keyword=Shear wave velocity
en-keyword=Gaussian process regression
kn-keyword=Gaussian process regression
en-keyword=Random field
kn-keyword=Random field
en-keyword=CPT tip resistance
kn-keyword=CPT tip resistance
en-keyword=Indirect data
kn-keyword=Indirect data
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250704
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Admission prognostic nutritional index predicts prolonged hospitalization in severe odontogenic deep neck infections
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Objectives Severe odontogenic deep neck infections (DNIs) can be life threatening. This study investigated the nutritional status of affected patients and evaluated the usefulness of the Prognostic Nutritional Index (PNI) at admission in helping maxillofacial surgeons identify, at presentation, those likely to require extended hospitalization.<br>
Methods A total of 112 patients treated for odontogenic deep neck abscesses and necrotizing soft tissue infections at five hospitals in Japan. Patients were included. Patients were categorized by length of hospitalization duration and factors associated with prolonged hospitalization were analyzed using propensity score matching to minimize bias. Spearman’s rank correlation analysis was also performed to assess the relationship between PNI and hospitalization duration.<br>
Results Fifty patients (44.6%) required hospitalization for more than 14 days. Multivariate analysis identified PNI???41.2 (odds ratio [OR]?=?2.79) and the presence of abscesses in multiple deep neck spaces (OR?=?2.76) as significant predictors of prolonged hospitalization. Propensity score analysis confirmed the significant association between PNI and length of hospitalization duration (P?=?0.048). In addition, Spearman’s rank correlation coefficient was r?=???0.471 (P?<?0.001), indicating a moderate negative correlation.<br>
Conclusion The admission PNI may serve as a useful adjunctive indicator for predicting prolonged hospitalization in patients with severe odontogenic DNIs, as it reflects both nutritional status and systemic inflammation.
en-copyright=
kn-copyright=

en-aut-name=IwataEiji
en-aut-sei=Iwata
en-aut-mei=Eiji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ObataKyoichi
en-aut-sei=Obata
en-aut-mei=Kyoichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KikutaShogo
en-aut-sei=Kikuta
en-aut-mei=Shogo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KanekoNaoki
en-aut-sei=Kaneko
en-aut-mei=Naoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SatoKotaro
en-aut-sei=Sato
en-aut-mei=Kotaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KitagawaNorio
en-aut-sei=Kitagawa
en-aut-mei=Norio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TakeshitaYohei
en-aut-sei=Takeshita
en-aut-mei=Yohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=MatsuoKatsuhisa
en-aut-sei=Matsuo
en-aut-mei=Katsuhisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=SameshimaJunsei
en-aut-sei=Sameshima
en-aut-mei=Junsei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=TachibanaAkira
en-aut-sei=Tachibana
en-aut-mei=Akira
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=KawanoShintaro
en-aut-sei=Kawano
en-aut-mei=Shintaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=KusukawaJingo
en-aut-sei=Kusukawa
en-aut-mei=Jingo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=AkashiMasaya
en-aut-sei=Akashi
en-aut-mei=Masaya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=IwanagaJoe
en-aut-sei=Iwanaga
en-aut-mei=Joe
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=IbaragiSoichiro
en-aut-sei=Ibaragi
en-aut-mei=Soichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

affil-num=1
en-affil=Department of Oral and Maxillofacial Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Oral and Maxillofacial Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Dental and Oral Medical Center, Kurume University School of Medicine
kn-affil=

affil-num=4
en-affil=Section of Oral and Maxillofacial Oncology, Division of Maxillofacial Diagnostic and Surgical Sciences, Faculty of Dental Science, Kyushu University
kn-affil=

affil-num=5
en-affil=Department of Oral and Maxillofacial Surgery, Nagoya University Graduate School of Medicine
kn-affil=

affil-num=6
en-affil=Department of Oral and Maxillofacial Anatomy, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo
kn-affil=

affil-num=7
en-affil=Department of Oral and Maxillofacial Radiology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=

affil-num=8
en-affil=Dental and Oral Medical Center, Kurume University School of Medicine
kn-affil=

affil-num=9
en-affil=Section of Oral and Maxillofacial Oncology, Division of Maxillofacial Diagnostic and Surgical Sciences, Faculty of Dental Science, Kyushu University
kn-affil=

affil-num=10
en-affil=Department of Oral and Maxillofacial Surgery, Kakogawa Central City Hospital
kn-affil=

affil-num=11
en-affil=Section of Oral and Maxillofacial Oncology, Division of Maxillofacial Diagnostic and Surgical Sciences, Faculty of Dental Science, Kyushu University
kn-affil=

affil-num=12
en-affil=Dental and Oral Medical Center, Kurume University School of Medicine
kn-affil=

affil-num=13
en-affil=Department of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine
kn-affil=

affil-num=14
en-affil=Dental and Oral Medical Center, Kurume University School of Medicine
kn-affil=

affil-num=15
en-affil=Department of Oral and Maxillofacial Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=Odontogenic deep neck infections
kn-keyword=Odontogenic deep neck infections
en-keyword=Nutrition status
kn-keyword=Nutrition status
en-keyword=Prognostic nutritional index
kn-keyword=Prognostic nutritional index
en-keyword=Prolonged hospitalization
kn-keyword=Prolonged hospitalization
en-keyword=Multiple spaces with abscess
kn-keyword=Multiple spaces with abscess
END

start-ver=1.4
cd-journal=joma
no-vol=81
cd-vols=
no-issue=
article-no=
start-page=102548
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202601
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Does innovation-driven policy optimize urban energy consumption? Evidence from China’s innovation-driven city pilot policies
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Restructuring energy consumption is essential for promoting green, low-carbon economic and societal development. Innovation-driven policies, particularly those implemented in pilot cities, play a crucial role in this transformation. This study conducts a theoretical analysis to examine how such policies influence urban energy-consumption structures. Using a multitime-point difference-in-differences model, it treats China’s national innovation-driven city pilot policies as a quasi-natural experiment. The results indicate that these policies significantly improve urban energy structures. Mechanism analyses reveal that the improvements occur mainly through green innovation and industrial upgrading. Heterogeneity analysis further indicates that the effects are more pronounced in cities with lower administrative tiers, more challenging geographical conditions, and stronger environmental priorities. These findings provide valuable policy insights for refining innovation-driven strategies, enhancing urban energy-consumption structures, and promoting sustainable economic development in China.
en-copyright=
kn-copyright=

en-aut-name=CongYingnan
en-aut-sei=Cong
en-aut-mei=Yingnan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HouYufei
en-aut-sei=Hou
en-aut-mei=Yufei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=JiYuan
en-aut-sei=Ji
en-aut-mei=Yuan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=CaiXiaojing
en-aut-sei=Cai
en-aut-mei=Xiaojing
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

affil-num=1
en-affil=Business School, China University of Political Science and Law
kn-affil=

affil-num=2
en-affil=School of Economics, Renmin University of China
kn-affil=

affil-num=3
en-affil=Business School, China University of Political Science and Law
kn-affil=

affil-num=4
en-affil=Graduate School of Humanities and Social Sciences, Okayama University
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=15
cd-vols=
no-issue=1
article-no=
start-page=27684
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250729
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=The significance of adding posterior decompression to spine stabilization in metastatic spinal surgery: a multicenter prospective study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The usefulness of spine stabilization for treating metastatic spinal tumors with tumor-induced instability has been reported. However, no reports have prospectively evaluated the effectiveness of adding posterior decompression to stabilization surgery for improving symptoms. This multicenter prospective study aimed to determine whether adding posterior decompression to spine stabilization surgery for metastatic spinal tumors affects postoperative outcomes and complications. A total of 263 patients who underwent spine stabilization with (n?=?189) or without (n?=?74) decompression were analyzed. Patient demographics, the Spinal Instability Neoplastic Score (SINS), and the Epidural Spinal Cord Compression (ESCC) score were recorded. The outcomes were assessed preoperatively and at 1 and 6 months postoperatively in terms of neurological status, the Barthel Index, the EQ-5D-5 L, and the visual analog scale (VAS). Decompression was primarily performed in patients with severe neurological deficits and high-grade ESCC. Both groups showed postoperative improvement. Propensity score matching was applied to adjust for baseline differences. After matching, there were no significant differences in functional improvement between the decompression and nondecompression groups, and the complication rates were comparable. In matched patients presenting primarily with spinal instability and pain, the addition of decompression did not appear to confer a significant functional benefit within 6 months postoperatively.
en-copyright=
kn-copyright=

en-aut-name=TominagaHiroyuki
en-aut-sei=Tominaga
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KawamuraIchiro
en-aut-sei=Kawamura
en-aut-mei=Ichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=ShimadaHirofumi
en-aut-sei=Shimada
en-aut-mei=Hirofumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SasakiHiromi
en-aut-sei=Sasaki
en-aut-mei=Hiromi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TaniguchiNoboru
en-aut-sei=Taniguchi
en-aut-mei=Noboru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=ShirataniYuki
en-aut-sei=Shiratani
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=SuzukiAkinobu
en-aut-sei=Suzuki
en-aut-mei=Akinobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=TeraiHidetomi
en-aut-sei=Terai
en-aut-mei=Hidetomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=ShimizuTakaki
en-aut-sei=Shimizu
en-aut-mei=Takaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=KakutaniKenichiro
en-aut-sei=Kakutani
en-aut-mei=Kenichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=KandaYutaro
en-aut-sei=Kanda
en-aut-mei=Yutaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=IshiharaMasayuki
en-aut-sei=Ishihara
en-aut-mei=Masayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=PakuMasaaki
en-aut-sei=Paku
en-aut-mei=Masaaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=TakahashiYohei
en-aut-sei=Takahashi
en-aut-mei=Yohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=FunayamaToru
en-aut-sei=Funayama
en-aut-mei=Toru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=MiuraKousei
en-aut-sei=Miura
en-aut-mei=Kousei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=ShirasawaEiki
en-aut-sei=Shirasawa
en-aut-mei=Eiki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=InoueHirokazu
en-aut-sei=Inoue
en-aut-mei=Hirokazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=KimuraAtsushi
en-aut-sei=Kimura
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=IimuraTakuya
en-aut-sei=Iimura
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=MoridairaHiroshi
en-aut-sei=Moridaira
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=NakajimaHideaki
en-aut-sei=Nakajima
en-aut-mei=Hideaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=WatanabeShuji
en-aut-sei=Watanabe
en-aut-mei=Shuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=AkedaKoji
en-aut-sei=Akeda
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=TakegamiNorihiko
en-aut-sei=Takegami
en-aut-mei=Norihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=NakanishiKazuo
en-aut-sei=Nakanishi
en-aut-mei=Kazuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

en-aut-name=SawadaHirokatsu
en-aut-sei=Sawada
en-aut-mei=Hirokatsu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=27
ORCID=

en-aut-name=MatsumotoKoji
en-aut-sei=Matsumoto
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=28
ORCID=

en-aut-name=FunabaMasahiro
en-aut-sei=Funaba
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=29
ORCID=

en-aut-name=SuzukiHidenori
en-aut-sei=Suzuki
en-aut-mei=Hidenori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=30
ORCID=

en-aut-name=FunaoHaruki
en-aut-sei=Funao
en-aut-mei=Haruki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=31
ORCID=

en-aut-name=OshigiriTsutomu
en-aut-sei=Oshigiri
en-aut-mei=Tsutomu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=32
ORCID=

en-aut-name=HiraiTakashi
en-aut-sei=Hirai
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=33
ORCID=

en-aut-name=OtsukiBungo
en-aut-sei=Otsuki
en-aut-mei=Bungo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=34
ORCID=

en-aut-name=KobayakawaKazu
en-aut-sei=Kobayakawa
en-aut-mei=Kazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=35
ORCID=

en-aut-name=UotaniKoji
en-aut-sei=Uotani
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=36
ORCID=

en-aut-name=ManabeHiroaki
en-aut-sei=Manabe
en-aut-mei=Hiroaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=37
ORCID=

en-aut-name=TanishimaShinji
en-aut-sei=Tanishima
en-aut-mei=Shinji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=38
ORCID=

en-aut-name=HashimotoKo
en-aut-sei=Hashimoto
en-aut-mei=Ko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=39
ORCID=

en-aut-name=IwaiChizuo
en-aut-sei=Iwai
en-aut-mei=Chizuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=40
ORCID=

en-aut-name=YamabeDaisuke
en-aut-sei=Yamabe
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=41
ORCID=

en-aut-name=HiyamaAkihiko
en-aut-sei=Hiyama
en-aut-mei=Akihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=42
ORCID=

en-aut-name=SekiShoji
en-aut-sei=Seki
en-aut-mei=Shoji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=43
ORCID=

en-aut-name=GotoYuta
en-aut-sei=Goto
en-aut-mei=Yuta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=44
ORCID=

en-aut-name=MiyazakiMasashi
en-aut-sei=Miyazaki
en-aut-mei=Masashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=45
ORCID=

en-aut-name=WatanabeKazuyuki
en-aut-sei=Watanabe
en-aut-mei=Kazuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=46
ORCID=

en-aut-name=NakamaeToshio
en-aut-sei=Nakamae
en-aut-mei=Toshio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=47
ORCID=

en-aut-name=KaitoTakashi
en-aut-sei=Kaito
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=48
ORCID=

en-aut-name=NakashimaHiroaki
en-aut-sei=Nakashima
en-aut-mei=Hiroaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=49
ORCID=

en-aut-name=NagoshiNarihito
en-aut-sei=Nagoshi
en-aut-mei=Narihito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=50
ORCID=

en-aut-name=KatoSatoshi
en-aut-sei=Kato
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=51
ORCID=

en-aut-name=ImagamaShiro
en-aut-sei=Imagama
en-aut-mei=Shiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=52
ORCID=

en-aut-name=WatanabeKota
en-aut-sei=Watanabe
en-aut-mei=Kota
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=53
ORCID=

en-aut-name=InoueGen
en-aut-sei=Inoue
en-aut-mei=Gen
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=54
ORCID=

en-aut-name=FuruyaTakeo
en-aut-sei=Furuya
en-aut-mei=Takeo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=55
ORCID=

affil-num=1
en-affil=Department of Orthopaedic Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University
kn-affil=

affil-num=2
en-affil=Department of Orthopaedic Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University
kn-affil=

affil-num=3
en-affil=Department of Orthopaedic Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University
kn-affil=

affil-num=4
en-affil=Department of Orthopaedic Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University
kn-affil=

affil-num=5
en-affil=Department of Orthopaedic Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University
kn-affil=

affil-num=6
en-affil=Department of Orthopaedic Surgery, Graduate School of Medicine, Chiba University
kn-affil=

affil-num=7
en-affil=Department of Orthopaedic Surgery, Osaka Metropolitan University
kn-affil=

affil-num=8
en-affil=Department of Orthopaedic Surgery, Osaka Metropolitan University
kn-affil=

affil-num=9
en-affil=Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University
kn-affil=

affil-num=10
en-affil=Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine
kn-affil=

affil-num=11
en-affil=Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine
kn-affil=

affil-num=12
en-affil=Department of Orthopaedic Surgery, Kansai Medical University Hospital
kn-affil=

affil-num=13
en-affil=Department of Orthopaedic Surgery, Kansai Medical University Hospital
kn-affil=

affil-num=14
en-affil=Department of Orthopaedic Surgery, Keio University
kn-affil=

affil-num=15
en-affil=Department of Orthopaedic Surgery, Institute of Medicine, University of Tsukuba
kn-affil=

affil-num=16
en-affil=Department of Orthopaedic Surgery, Institute of Medicine, University of Tsukuba
kn-affil=

affil-num=17
en-affil=Department of Orthopaedic Surgery, Kitasato University School of Medicine
kn-affil=

affil-num=18
en-affil=Rehabilitation Center, Jichi Medical University Hospital
kn-affil=

affil-num=19
en-affil=Department of Orthopaedics, Jichi Medical University
kn-affil=

affil-num=20
en-affil=Department of Orthopaedic Surgery, Dokkyo Medical University
kn-affil=

affil-num=21
en-affil=Department of Orthopaedic Surgery, Dokkyo Medical University
kn-affil=

affil-num=22
en-affil=Department of Orthopaedics and Rehabilitation Medicine, Faculty of Medical Sciences, University of Fukui
kn-affil=

affil-num=23
en-affil=Department of Orthopaedics and Rehabilitation Medicine, Faculty of Medical Sciences, University of Fukui
kn-affil=

affil-num=24
en-affil=Department of Orthopaedic Surgery, Mie University Graduate School of Medicine
kn-affil=

affil-num=25
en-affil=Department of Orthopaedic Surgery, Mie University Graduate School of Medicine
kn-affil=

affil-num=26
en-affil=Department of Orthopaedic Surgery, Kawasaki Medical School
kn-affil=

affil-num=27
en-affil=Department of Orthopaedic Surgery, Nihon University School of Medicine
kn-affil=

affil-num=28
en-affil=Department of Orthopaedic Surgery, Nihon University School of Medicine
kn-affil=

affil-num=29
en-affil=Department of Orthopaedics Surgery, Yamaguchi University Graduate school of Medicine
kn-affil=

affil-num=30
en-affil=Department of Orthopaedics Surgery, Yamaguchi University Graduate school of Medicine
kn-affil=

affil-num=31
en-affil=Department of Orthopaedic Surgery, International University of Health and Welfare Narita Hospital
kn-affil=

affil-num=32
en-affil=Department of Orthopaedic Surgery, Sapporo Medical University School of Medicine
kn-affil=

affil-num=33
en-affil=Department of Orthopedic Surgery, Institute of Science Tokyo
kn-affil=

affil-num=34
en-affil=Department of Orthopaedic Surgery, Kyoto University Hospital
kn-affil=

affil-num=35
en-affil=Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University
kn-affil=

affil-num=36
en-affil=Department of Orthopaedic Surgery, Okayama University Hospital
kn-affil=

affil-num=37
en-affil=Department of Orthopedics, Tokushima University
kn-affil=

affil-num=38
en-affil=Division of Orthopedic Surgery, Department of Sensory and Motor Organs, School of Medicine, Faculty of Medicine, Tottori University
kn-affil=

affil-num=39
en-affil=Department of Orthopaedic Surgery, Tohoku University Graduate School of Medicine
kn-affil=

affil-num=40
en-affil=Department of Orthopaedic Surgery, Gifu University Hospital
kn-affil=

affil-num=41
en-affil=Department of Orthopaedic Surgery, Iwate Medical University
kn-affil=

affil-num=42
en-affil=Department of Orthopaedic Surgery, Tokai University School of Medicine
kn-affil=

affil-num=43
en-affil=Department of Orthopaedic Surgery, University of Toyama
kn-affil=

affil-num=44
en-affil=Department of Orthopaedic Surgery, Nagoya City University
kn-affil=

affil-num=45
en-affil=Department of Orthopaedic Surgery, Faculty of Medicine, Oita University
kn-affil=

affil-num=46
en-affil=Department of Orthopaedic Surgery, Fukushima Medical University School of Medicine
kn-affil=

affil-num=47
en-affil=Department of Orthopaedic Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University
kn-affil=

affil-num=48
en-affil=Department of Orthopedic Surgery, Osaka University Graduate School of Medicine
kn-affil=

affil-num=49
en-affil=Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine
kn-affil=

affil-num=50
en-affil=Department of Orthopaedic Surgery, Keio University
kn-affil=

affil-num=51
en-affil=Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University
kn-affil=

affil-num=52
en-affil=Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine
kn-affil=

affil-num=53
en-affil=Department of Orthopaedic Surgery, Keio University
kn-affil=

affil-num=54
en-affil=Department of Orthopaedic Surgery, Kitasato University School of Medicine
kn-affil=

affil-num=55
en-affil=Department of Orthopaedic Surgery, Graduate School of Medicine, Chiba University
kn-affil=
en-keyword=Metastatic spinal tumors
kn-keyword=Metastatic spinal tumors
en-keyword=Spine stabilization
kn-keyword=Spine stabilization
en-keyword=Decompression
kn-keyword=Decompression
en-keyword=Propensity score matching
kn-keyword=Propensity score matching
en-keyword=Multicenter prospective study
kn-keyword=Multicenter prospective study
en-keyword=The epidural spinal cord compression (ESCC) score
kn-keyword=The epidural spinal cord compression (ESCC) score
END

start-ver=1.4
cd-journal=joma
no-vol=18
cd-vols=
no-issue=10
article-no=
start-page=e70318
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250929
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Effectiveness of Statins for Oxaliplatin‐Induced Peripheral Neuropathy: A Multicenter Retrospective Observational Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Chemotherapy-induced peripheral neuropathy, including oxaliplatin-induced peripheral neuropathy (OIPN), can have a negative impact on patient quality of life for months or even years after discontinuation of chemotherapy. Statins are commonly used for lowering cholesterol; however, evidence indicates that statins have multiple pleiotropic effects. Although statins are anticipated to exert neuroprotective actions against OIPN, no large-scale investigations have been conducted in real-world clinical settings. Our investigation aimed to determine if statins protected against OIPN. This multicentre retrospective study enrolled Japanese patients with cancer, including those with colorectal cancer (CRC), who received oxaliplatin-containing chemotherapy between April 2009 and December 2019. Propensity score matching between groups was performed to assess the relationship between the occurrence of OIPN and statin use. Among the examined 2657 patients receiving oxaliplatin, 24.7% had Grade ??2 OIPN. There was no significant difference in the incidence of OIPN between the statin and non-statin groups, even after propensity score matching. However, among the matched patients with CRC (n?=?510), statin use was associated with a significantly lower incidence of Grade ??2 OIPN than no statin use (19.8% vs. 28.3%, respectively; p?=?0.029). Our findings indicate that statins may protect against OIPN in patients with CRC.
en-copyright=
kn-copyright=

en-aut-name=TakechiKenshi
en-aut-sei=Takechi
en-aut-mei=Kenshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KawashiriTakehiro
en-aut-sei=Kawashiri
en-aut-mei=Takehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MineKeisuke
en-aut-sei=Mine
en-aut-mei=Keisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=UshioSoichiro
en-aut-sei=Ushio
en-aut-mei=Soichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HamanoHirofumi
en-aut-sei=Hamano
en-aut-mei=Hirofumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=HidaNoriko
en-aut-sei=Hida
en-aut-mei=Noriko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MomoKenji
en-aut-sei=Momo
en-aut-mei=Kenji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=UchiyamaMasanobu
en-aut-sei=Uchiyama
en-aut-mei=Masanobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=UchidaMami
en-aut-sei=Uchida
en-aut-mei=Mami
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=TanakaMamoru
en-aut-sei=Tanaka
en-aut-mei=Mamoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=HidakaNoriaki
en-aut-sei=Hidaka
en-aut-mei=Noriaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=YasuiHideki
en-aut-sei=Yasui
en-aut-mei=Hideki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=UedaMasahiro
en-aut-sei=Ueda
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=FujiiRyohei
en-aut-sei=Fujii
en-aut-mei=Ryohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=HashimotoMisaki
en-aut-sei=Hashimoto
en-aut-mei=Misaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=SakamotoYasutaka
en-aut-sei=Sakamoto
en-aut-mei=Yasutaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=UyamaKana
en-aut-sei=Uyama
en-aut-mei=Kana
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=NiimuraTakahiro
en-aut-sei=Niimura
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=HanaiYuki
en-aut-sei=Hanai
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=TsuboyaAyaka
en-aut-sei=Tsuboya
en-aut-mei=Ayaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=SuzukiKeisuke
en-aut-sei=Suzuki
en-aut-mei=Keisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=KamiyamaNaoya
en-aut-sei=Kamiyama
en-aut-mei=Naoya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=HagiwaraHiromi
en-aut-sei=Hagiwara
en-aut-mei=Hiromi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=OkadaNaoto
en-aut-sei=Okada
en-aut-mei=Naoto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=ZamamiYoshito
en-aut-sei=Zamami
en-aut-mei=Yoshito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=IshizawaKeisuke
en-aut-sei=Ishizawa
en-aut-mei=Keisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

affil-num=1
en-affil=Department of Drug Information Analysis, College of Pharmaceutical Sciences, Matsuyama University
kn-affil=

affil-num=2
en-affil=Department of Clinical Pharmacy and Pharmaceutical Care, Graduate School of Pharmaceutical Sciences, Kyushu University
kn-affil=

affil-num=3
en-affil=Department of Clinical Pharmacy and Pharmaceutical Care, Graduate School of Pharmaceutical Sciences, Kyushu University
kn-affil=

affil-num=4
en-affil=Department of Emergency and Disaster Medical Pharmacy, Faculty of Pharmaceutical Sciences, Fukuoka University
kn-affil=

affil-num=5
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Department of Clinical Research and Development, Graduate School of Pharmacy, SHOWA Medical University 
kn-affil=

affil-num=7
en-affil=Department of Hospital Pharmaceutics, Graduate School of Pharmacy, SHOWA Medical University
kn-affil=

affil-num=8
en-affil=Department of Oncology and Infectious Disease Pharmacy, Faculty of Pharmaceutical Sciences, Fukuoka University
kn-affil=

affil-num=9
en-affil=Department of Pharmacy, Fukuoka University Hospital
kn-affil=

affil-num=10
en-affil=Division of Pharmacy, Ehime University Hospital
kn-affil=

affil-num=11
en-affil=Division of Pharmacy, Ehime University Hospital
kn-affil=

affil-num=12
en-affil=Center for Clinical Research, Hamamatsu University Hospital
kn-affil=

affil-num=13
en-affil=Faculty of Pharmaceutical Sciences, Setsunan University
kn-affil=

affil-num=14
en-affil=Department of Pharmacy, Kansai Medical University Hospital
kn-affil=

affil-num=15
en-affil=Department of Pharmacy, Kansai Medical University Hospital
kn-affil=

affil-num=16
en-affil=Department of Pharmacy, Yokohama City University Hospital
kn-affil=

affil-num=17
en-affil=Department of Pharmacy, Yokohama City University Hospital
kn-affil=

affil-num=18
en-affil=Department of Clinical Pharmacology and Therapeutics, University of Tokushima Graduate School of Biomedical Sciences
kn-affil=

affil-num=19
en-affil=Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University
kn-affil=

affil-num=20
en-affil=Department of Pharmacy, Kawasaki Municipal Tama Hospital
kn-affil=

affil-num=21
en-affil=Innovation Center for Translational Research, National Center for Geriatrics and Gerontology
kn-affil=

affil-num=22
en-affil=Asahikawa Medical University Hospital
kn-affil=

affil-num=23
en-affil=Nagoya City University Hospital
kn-affil=

affil-num=24
en-affil=Pharmacy Department, Yamaguchi University Hospital 
kn-affil=

affil-num=25
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=

affil-num=26
en-affil=Department of Clinical Pharmacology and Therapeutics, University of Tokushima Graduate School of Biomedical Sciences
kn-affil=
en-keyword=cancer
kn-keyword=cancer
en-keyword=colorectal cancer
kn-keyword=colorectal cancer
en-keyword=oxaliplatin
kn-keyword=oxaliplatin
en-keyword=peripheral neuropathy
kn-keyword=peripheral neuropathy
en-keyword=statins
kn-keyword=statins
END

start-ver=1.4
cd-journal=joma
no-vol=19
cd-vols=
no-issue=1
article-no=
start-page=468
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250929
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=The safety and efficacy of finasteride for transgender men with androgenetic alopecia: a case series
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background Testosterone replacement therapy is commonly used in transgender men for masculinization. One of the most common adverse effects of testosterone replacement therapy is androgenetic alopecia. In Japan, finasteride is approved exclusively for cisgender men and is not indicated for transgender men. The aim of this clinical trial was to evaluate the safety and efficacy of finasteride in transgender men with androgenetic alopecia.<br>
Case presentation This study included three transgender men (assigned female at birth, identifying as male), aged 44, 43, and 29 years. All participants were of Asian ethnicity. A clinical trial was conducted from October 2021 to December 2023. Transgender men aged 20?60 years who had not undergone hysterectomy, were undergoing testosterone replacement therapy, and who had been diagnosed with stage???II androgenetic alopecia on the basis of the Norwood?Hamilton scale were recruited. The participants initiated treatment with 0.2 mg of finasteride per day for 3 months (phase 1). If no adverse events above grade 2 occurred, the dose was increased to 1.0 mg per day for an additional 3 months (phase 2). The primary endpoints were the incidence of treatment-related adverse events at 1 week, 1 month, and 3 months, as well as the rate of participants continuing treatment at 3 months. None of the patients experienced serious adverse events at 3 months, and all the patients extended their treatment to a total of 6 months. Improvements of at least one stage on the N?H scale were observed, but two participants experienced resumption of menstruation.<br>
Conclusion Finasteride appears to be a safe and effective treatment for androgenetic alopecia in transgender men undergoing testosterone replacement therapy. However, its potential for reducing some of the effects of testosterone replacement therapy warrants further investigation. Trial registration: jRCT, jRCTs061210040, registered 7 October 2021, https://jrct.mhlw.go.jp/latest-detail/jRCTs061210040.
en-copyright=
kn-copyright=

en-aut-name=TominagaYusuke
en-aut-sei=Tominaga
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KobayashiTomoko
en-aut-sei=Kobayashi
en-aut-mei=Tomoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MatsumotoYuko
en-aut-sei=Matsumoto
en-aut-mei=Yuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SakoTomoko
en-aut-sei=Sako
en-aut-mei=Tomoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MoriwakeTakatoshi
en-aut-sei=Moriwake
en-aut-mei=Takatoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=HoriiSatoshi
en-aut-sei=Horii
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=SadahiraTakuya
en-aut-sei=Sadahira
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KatayamaSatoshi
en-aut-sei=Katayama
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=IwataTakehiro
en-aut-sei=Iwata
en-aut-mei=Takehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=NishimuraShingo
en-aut-sei=Nishimura
en-aut-mei=Shingo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=BekkuKensuke
en-aut-sei=Bekku
en-aut-mei=Kensuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=EdamuraKohei
en-aut-sei=Edamura
en-aut-mei=Kohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=WatanabeMasami
en-aut-sei=Watanabe
en-aut-mei=Masami
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=ArakiMotoo
en-aut-sei=Araki
en-aut-mei=Motoo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

affil-num=1
en-affil=Department of Urology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=

affil-num=2
en-affil=Department of Urology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=

affil-num=3
en-affil=Department of Urology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=

affil-num=4
en-affil=Department of Urology, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=5
en-affil=Department of Urology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=

affil-num=6
en-affil=Department of Urology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=

affil-num=7
en-affil=Department of Urology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=

affil-num=8
en-affil=Department of Urology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=

affil-num=9
en-affil=Department of Urology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=

affil-num=10
en-affil=Department of Urology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=

affil-num=11
en-affil=Department of Urology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=

affil-num=12
en-affil=Department of Urology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=

affil-num=13
en-affil=Center for Innovative Clinical Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=

affil-num=14
en-affil=Department of Urology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=
en-keyword=Finasteride
kn-keyword=Finasteride
en-keyword=Dihydrotestosterone
kn-keyword=Dihydrotestosterone
en-keyword=Transgender men
kn-keyword=Transgender men
en-keyword= Androgenetic alopecia
kn-keyword= Androgenetic alopecia
en-keyword=Resumption of menstruation
kn-keyword=Resumption of menstruation
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=5
article-no=
start-page=329
end-page=337
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202510
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Current Status of Extracorporeal Membrane Oxygenation as a Treatment Strategy for Primary Graft Dysfunction after Lung Transplantation
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Primary graft dysfunction (PGD) is one of the major risk factors affecting patients’ short- and long-term survival after lung transplantation. No particular management strategy has been established for PGD; supportive care is the mainstay of PGD treatment. When a supportive strategy fails, the patient may require the introduction of extracorporeal membrane oxygenation (ECMO) as the last-resort measure for severe PGD. A variety of study of ECMO as a PGD treatment was reported and the management of PGD patients developed so far. Early recognition of a patient’s need for ECMO and its prompt initiation are critical to improved outcomes. The use of venovenous-ECMO became the preferred procedure for PGD rather than venoarterial-ECMO. However, the current ECMO strategy has limitations, and using ECMO to manage patients with PGD is not sufficiently effective. Further studies are required to develop this promising technology.
en-copyright=
kn-copyright=

en-aut-name=MatsubaraKei
en-aut-sei=Matsubara
en-aut-mei=Kei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MiyoshiKentaroh
en-aut-sei=Miyoshi
en-aut-mei=Kentaroh
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=ToyookaShinichi
en-aut-sei=Toyooka
en-aut-mei=Shinichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

affil-num=1
en-affil=Department of Thoracic Surgery, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=2
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=lung transplantation
kn-keyword=lung transplantation
en-keyword=primary graft dysfunction
kn-keyword=primary graft dysfunction
en-keyword=extracorporeal membrane oxygenation
kn-keyword=extracorporeal membrane oxygenation
en-keyword=ex vivo lung perfusion
kn-keyword=ex vivo lung perfusion
END

start-ver=1.4
cd-journal=joma
no-vol=14
cd-vols=
no-issue=17
article-no=
start-page=6102
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250828
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Risk Factors for Perioperative Urinary Tract Infection After Living Donor Kidney Transplantation Characterized by High Prevalence of Desensitization Therapy: A Single-Center Analysis
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background/Objectives: Limited research exists on risk factors for urinary tract infections (UTIs) in kidney transplant recipients, particularly in high-risk groups such as ABO-incompatible or donor-specific antibody (DSA)-positive cases. Early UTIs, especially within the first month post-transplant, impact on acute rejection and long-term graft outcomes, highlighting the need for risk factor identification and management. Methods: Among 157 living donor kidney transplant cases performed at our institution between 2009 and 2024, 128 patients were included after excluding cases with >72 h of perioperative prophylactic antibiotics or urological complications. UTI was defined as the presence of pyuria and a positive urine culture, accompanied by clinical symptoms requiring antibiotic treatment, occurring within one month post-transplantation. Results: The median onset of UTI was postoperative day 8 (interquartile range, IQR: 6.8?9.3). No subsequent acute rejection episodes were observed. The median serum creatinine at 1 month postoperatively was 1.3 mg/dL (IQR: 1.1?1.7), and this was not significantly different from those who did not develop UTI. In univariate analysis, low or high BMI (<20 or >25), longer dialysis duration (>2.5 years), desensitization therapy (plasmapheresis + rituximab), elevated preoperative neutrophil-to-lymphocyte ratio (NLR) (?3), and longer warm ischemic time (WIT) (?7.8 min) were significantly associated with an increased infection risk of UTI (p = 0.010, 0.036, 0.028, 0.015, and 0.038, respectively). Multivariate analyses revealed that abnormal BMI, longer dialysis duration, desensitization therapy, and longer WIT were independent risk factors for UTI (p = 0.012, 0.031, 0.008, and 0.033, respectively). The incidence of UTI increased with the number of risk factors: 0% (0/16) for zero, 10% (5/48) for one, 31% (16/51) for two, 45% (5/11) for three, and 100% (2/2) for four risk factors. Conclusions: Desensitization therapy, BMI, dialysis duration, and WIT were identified as independent risk factors for perioperative UTI. In patients with risk factors, additional preventive strategies should be considered, with extended antibiotic prophylaxis being one potential option.
en-copyright=
kn-copyright=

en-aut-name=NishimuraShingo
en-aut-sei=Nishimura
en-aut-mei=Shingo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=InoueShota
en-aut-sei=Inoue
en-aut-mei=Shota
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=SekitoTakanori
en-aut-sei=Sekito
en-aut-mei=Takanori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TsuboiIchiro
en-aut-sei=Tsuboi
en-aut-mei=Ichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TokunagaMoto
en-aut-sei=Tokunaga
en-aut-mei=Moto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=YoshinagaKasumi
en-aut-sei=Yoshinaga
en-aut-mei=Kasumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MaruyamaYuki
en-aut-sei=Maruyama
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=MitsuiYosuke
en-aut-sei=Mitsui
en-aut-mei=Yosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=YamanoiTomoaki
en-aut-sei=Yamanoi
en-aut-mei=Tomoaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=KawadaTatsushi
en-aut-sei=Kawada
en-aut-mei=Tatsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=KubotaRisa
en-aut-sei=Kubota
en-aut-mei=Risa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=SadahiraTakuya
en-aut-sei=Sadahira
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=TominagaYusuke
en-aut-sei=Tominaga
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=IwataTakehiro
en-aut-sei=Iwata
en-aut-mei=Takehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=KatayamaSatoshi
en-aut-sei=Katayama
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=BekkuKensuke
en-aut-sei=Bekku
en-aut-mei=Kensuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=EdamuraKohei
en-aut-sei=Edamura
en-aut-mei=Kohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=WadaKoichiro
en-aut-sei=Wada
en-aut-mei=Koichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=KobayashiYasuyuki
en-aut-sei=Kobayashi
en-aut-mei=Yasuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=ArakiMotoo
en-aut-sei=Araki
en-aut-mei=Motoo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

affil-num=1
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic
kn-affil=

affil-num=4
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Urology, NHO Okayama Medical Center
kn-affil=

affil-num=6
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic
kn-affil=

affil-num=8
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=11
en-affil=Department of Urology, NHO Okayama Medical Center
kn-affil=

affil-num=12
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=13
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=14
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=15
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=16
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=17
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=18
en-affil=Department of Urology, Shimane University Faculty of Medicine
kn-affil=

affil-num=19
en-affil=Department of Urology, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=20
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=living donor kidney transplantation
kn-keyword=living donor kidney transplantation
en-keyword=urinary tract infection
kn-keyword=urinary tract infection
en-keyword=perioperative
kn-keyword=perioperative
en-keyword=desensitization
kn-keyword=desensitization
en-keyword=rituximab
kn-keyword=rituximab
en-keyword=plasmapheresis
kn-keyword=plasmapheresis
en-keyword=body mass index
kn-keyword=body mass index
en-keyword=dialysis duration
kn-keyword=dialysis duration
en-keyword=warm ischemic time
kn-keyword=warm ischemic time
en-keyword=prophylactic antimicrobials
kn-keyword=prophylactic antimicrobials
END

start-ver=1.4
cd-journal=joma
no-vol=55
cd-vols=
no-issue=6
article-no=
start-page=643
end-page=649
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250202
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Real-world clinical usage and efficacy of apalutamide in men with nonmetastatic castration-resistant prostate cancer: a multi-institutional study in the CsJUC
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Objective: To evaluate the real-world clinical usage and effectiveness of apalutamide in men with nonmetastatic castration-resistant prostate cancer (nmCRPC).<br>
Methods: We retrospectively reviewed the data of 186 men who received apalutamide across 17 institutions. The primary outcomes were the clinical usage of apalutamide for nmCRPC: prior usage of other androgen receptor signaling inhibitors (ARSIs), prior radical treatment, and the distribution of the prostate-specific antigen (PSA) doubling time (PSA-DT) at the initial administration of apalutamide. The secondary outcomes were the efficacy of apalutamide: PSA response (50% or 90% decline), progression-free survival, and skin-adverse events (AEs).<br>
Results: We identified 75 patients with nmCRPC. A total of 31 (41.3%) patients received prior treatment with other ARSIs. A total of 42 men (56%) did not receive any prior radical treatment. The PSA-DT was <3.0, 3.0?5.9, 6.0?10, and > 10 months in 34.7%, 40%, 14.7%, and 10.6% of the patients, respectively. Patients receiving prior treatment with other ARSIs showed a significantly lower PSA response (PSA 50% decline, 88.4% vs. 18.8%; PSA 90% decline, 60.5% vs. 6.2%, P < .001, respectively) and significantly shorter progression-free survival (median: 37 months vs. 4 months; log-rank P < .001) than those without prior ARSI treatment, although cancer status did not differ between the groups. Skin-AEs were observed in 42.7%.<br>
Conclusions: This real-world study revealed that apalutamide was used for the treatment after other ARSIs in >40% of patients with nmCRPC and showed limited efficacy in this context, although the effectiveness of apalutamide without prior other ARSI treatment was comparable with that reported in clinical trial results.
en-copyright=
kn-copyright=

en-aut-name=TohiYoichiro
en-aut-sei=Tohi
en-aut-mei=Yoichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KobayashiKeita
en-aut-sei=Kobayashi
en-aut-mei=Keita
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=DaizumotoKei
en-aut-sei=Daizumoto
en-aut-mei=Kei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SekinoYohei
en-aut-sei=Sekino
en-aut-mei=Yohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=FukuharaHideo
en-aut-sei=Fukuhara
en-aut-mei=Hideo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NiigawaHeima
en-aut-sei=Niigawa
en-aut-mei=Heima
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KatayamaSatoshi
en-aut-sei=Katayama
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=ShimizuRyutaro
en-aut-sei=Shimizu
en-aut-mei=Ryutaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=TakamotoAtsushi
en-aut-sei=Takamoto
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=NishimuraKenichi
en-aut-sei=Nishimura
en-aut-mei=Kenichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=NagamiTaichi
en-aut-sei=Nagami
en-aut-mei=Taichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=HayashidaYushi
en-aut-sei=Hayashida
en-aut-mei=Yushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=HiramaHiromi
en-aut-sei=Hirama
en-aut-mei=Hiromi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=ShiraishiKoji
en-aut-sei=Shiraishi
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=TomidaRyotaro
en-aut-sei=Tomida
en-aut-mei=Ryotaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=KobatakeKohei
en-aut-sei=Kobatake
en-aut-mei=Kohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=InoueKeiji
en-aut-sei=Inoue
en-aut-mei=Keiji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=MiyajiYoshiyuki
en-aut-sei=Miyaji
en-aut-mei=Yoshiyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=BekkuKensuke
en-aut-sei=Bekku
en-aut-mei=Kensuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=MorizaneShuichi
en-aut-sei=Morizane
en-aut-mei=Shuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=MiuraNoriyoshi
en-aut-sei=Miura
en-aut-mei=Noriyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=WadaKoichiro
en-aut-sei=Wada
en-aut-mei=Koichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=SugimotoMikio
en-aut-sei=Sugimoto
en-aut-mei=Mikio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=Chu-shikoku Japan Urological Consortium
en-aut-sei=Chu-shikoku Japan Urological Consortium
en-aut-mei=
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

affil-num=1
en-affil=Department of Urology, Faculty of Medicine, Kagawa University 
kn-affil=

affil-num=2
en-affil=Department of Urology, Graduate School of Medicine, Yamaguchi University 
kn-affil=

affil-num=3
en-affil=Department of Urology, Tokushima University Graduate School of Biomedical Sciences
kn-affil=

affil-num=4
en-affil=Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University
kn-affil=

affil-num=5
en-affil=Department of Urology, Kochi Medical School
kn-affil=

affil-num=6
en-affil=Department of Urology, Kawasaki Medical School
kn-affil=

affil-num=7
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Division of Urology, Department of Surgery, Faculty of Medicine, Tottori University
kn-affil=

affil-num=9
en-affil=Department of Urology, Fukuyama City Hospital
kn-affil=

affil-num=10
en-affil=Department of Urology, Ehime University
kn-affil=

affil-num=11
en-affil=Department of Urology, Shimane University Faculty of Medicine
kn-affil=

affil-num=12
en-affil=Department of Urology, Sakaide City Hospital
kn-affil=

affil-num=13
en-affil=Department of Urology, KKR Takamatsu Hospital
kn-affil=

affil-num=14
en-affil=Department of Urology, Graduate School of Medicine, Yamaguchi University
kn-affil=

affil-num=15
en-affil=Department of Urology, Tokushima University Graduate School of Biomedical Sciences
kn-affil=

affil-num=16
en-affil=Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University
kn-affil=

affil-num=17
en-affil=Department of Urology, Kochi Medical School
kn-affil=

affil-num=18
en-affil=Department of Urology, Kawasaki Medical School 
kn-affil=

affil-num=19
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=20
en-affil=Division of Urology, Department of Surgery, Faculty of Medicine, Tottori University
kn-affil=

affil-num=21
en-affil=Department of Urology, Ehime University
kn-affil=

affil-num=22
en-affil=Department of Urology, Shimane University Faculty of Medicine
kn-affil=

affil-num=23
en-affil=Department of Urology, Faculty of Medicine, Kagawa University
kn-affil=

affil-num=24
en-affil=
kn-affil=
en-keyword=apalutamide
kn-keyword=apalutamide
en-keyword=nonmetastatic castration-resistant prostate cancer
kn-keyword=nonmetastatic castration-resistant prostate cancer
en-keyword=prostate cancer
kn-keyword=prostate cancer
en-keyword=prostate-specific antigen response
kn-keyword=prostate-specific antigen response
en-keyword=PSA-doubling time
kn-keyword=PSA-doubling time
END

start-ver=1.4
cd-journal=joma
no-vol=76
cd-vols=
no-issue=9
article-no=
start-page=4815
end-page=4837
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202511
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Spatiotemporal evolution of ecosystem carbon storage under land use/land cover dynamics in the coastal region of Central Vietnam
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Ecosystem carbon storage is a cost-effective strategy for global climate change mitigation, and its fluctuation is markedly shaped by land use/land cover (LULC) dynamics. Taking Danang city as an example of Central Coastal Vietnam, this study aims to assess LULC changes and analyze the spatiotemporal evolution of carbon storage from 2023 to 2050 under four LULC change scenarios, including natural trend scenario (NTS), ecological protection scenario (EPS), economic development scenario (EDS), and cropland protection scenario (CPS), by integrating the support vector machine-cellular automata-Markov (SVM-CA-Markov) model and the InVEST model. The Optimal Parameters-based Geographical Detector (OPGD) model was subsequently employed to elucidate the impacts of driving factors on the spatial distribution of carbon storage. The results showed that, from 2007 to 2023, Danang city experienced a dramatic back-and-forth transformation between LULC types, with the predominant transitions being from natural forest to acacia tree-dominated plantation forest (6492.31 ha), and from cropland to settlements, acacia tree-dominated plantation forest, and other land (5483.05 ha, 3763.66 ha, 2762.35 ha, respectively). Between 2023 and 2050, LULC transformations in Danang city are projected to yield varying degrees of carbon storage levels across different scenarios. Specifically, carbon storage is anticipated to dwindle by 0.221 Mt, 0.223 Mt, and 0.298 Mt under NTS, EDS, and CPS, respectively, while enhancing by 0.141 Mt under EPS. Regarding the spatial distribution of carbon storage, high values will be chiefly found in the western high-elevation mountainous region, while low values will be concentrated mostly in the eastern lower-lying areas of the city. Additionally, elevation and temperature acted as the two most significant driving factors influencing the spatial distribution of carbon storage, with Q values of 0.88 and 0.86 (p-value < 0.05), respectively. For interaction detection, the combination of elevation and soil exhibited a synergistic reinforcement effect on the spatial partitioning of carbon storage, with a high Q value of 0.9566 (p-value < 0.05). Our study highlights the necessity of ecological conservation measures in Danang city in the on-track pursuit of national net-zero carbon emissions by 2050.
en-copyright=
kn-copyright=

en-aut-name=HoViet Hoang
en-aut-sei=Ho
en-aut-mei=Viet Hoang
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MoritaHidenori
en-aut-sei=Morita
en-aut-mei=Hidenori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HoThanh Ha
en-aut-sei=Ho
en-aut-mei=Thanh Ha
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=BachoferFelix
en-aut-sei=Bachofer
en-aut-mei=Felix
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

affil-num=1
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=

affil-num=2
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=3
en-affil=University of Agriculture and Forestry, Hue University
kn-affil=

affil-num=4
en-affil=German Aerospace Center (DLR), Earth Observation Center
kn-affil=
en-keyword=Carbon sequestration
kn-keyword=Carbon sequestration
en-keyword=Scenario-based modeling
kn-keyword=Scenario-based modeling
en-keyword=Remote sensing
kn-keyword=Remote sensing
en-keyword=Spatial autocorrelation analysis
kn-keyword=Spatial autocorrelation analysis
END

start-ver=1.4
cd-journal=joma
no-vol=18
cd-vols=
no-issue=2
article-no=
start-page=22
end-page=32
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250805
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Data inventory, processing, and reporting on plant blindness among high school students in three schools in West Java
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Plant blindness is a problem related to a person's inability to realize, recognize, and know the benefits and roles of plants. After some research, there was a shift in the term, from Plant Blindness to Plant Awareness Disparity. This study aims to find out the prevalence of Plant Blindness in three high schools in West Java. The method used in this study is descriptive Cross sectional. The results of this study revealed that there were differences in the level of plant awareness in the three schools studied. One of the schools in the city of Bandung showed the highest plant awareness rate. In addition, it was also found that students who had a high level of plant awareness had a high perception of plant awareness. As a follow-up, further research can be carried out to collect more data so that it becomes a whole population. In addition, researchers can then use additional instruments so that more things can be revealed about plant blindness.
en-copyright=
kn-copyright=

en-aut-name=SorayaPuan Helwa Rezha
en-aut-sei=Soraya
en-aut-mei=Puan Helwa Rezha
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SolihatRini
en-aut-sei=Solihat
en-aut-mei=Rini
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=SanjayaYayan
en-aut-sei=Sanjaya
en-aut-mei=Yayan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=HaradaTaro
en-aut-sei=Harada
en-aut-mei=Taro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

affil-num=1
en-affil=Biology Education, Faculty of Mathematics and Science Education, Universitas Pendidikan Indonesia
kn-affil=

affil-num=2
en-affil=Biology Education, Faculty of Mathematics and Science Education, Universitas Pendidikan Indonesia
kn-affil=

affil-num=3
en-affil=Biology Education, Faculty of Mathematics and Science Education, Universitas Pendidikan Indonesia
kn-affil=

affil-num=4
en-affil=Graduate School of Education, Okayama University
kn-affil=
en-keyword=Descriptive statistics
kn-keyword=Descriptive statistics
en-keyword=Inferential statistics
kn-keyword=Inferential statistics
en-keyword=Plant Blindness
kn-keyword=Plant Blindness
END

start-ver=1.4
cd-journal=joma
no-vol=40
cd-vols=
no-issue=4
article-no=
start-page=463
end-page=474
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20241225
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Nationwide diversity of symbolic “city flowers” in Japan is increasing
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Recognizing and maintaining locally rooted human?nature interactions is essential for utilizing ecosystem services. Although the general public's awareness of biodiversity and ecosystem services has been examined using various proxies, it remains unclear how local governments?key sectors in creating conservation policies?appreciate them within a solid local context. Here, we focused on the “city flower,” an official symbolic species of Japanese cities, as a new proxy for measuring governmental attitudes toward biota and its services. We aimed to capture temporal changes in the awareness of species with locally relevant value at the city government level by examining the changes in city flowers over more than half a century. Data from the official websites of municipalities, including the names, the adoption years, and the reasons for adoption, revealed two major periods of adoption, with a notable increase in species diversity in and after 1993. This increase could be attributed to a recent reduction in bias toward popular flowers and growing interest in alternative, less popular flowers. Analysis of the reasons for adoption suggested that the temporal change in adopted flower species was related to the increasing emphasis on species with an explicit local context, especially those with instrumental value to the city. Our findings indicate the tendency for local governments to increasingly recognize their biocultural backgrounds and the ecosystem services of plants within their regions. The growing awareness of the local governments regarding their biocultural background is a positive sign for the conservation of biodiversity and ecosystem services.
en-copyright=
kn-copyright=

en-aut-name=TsuzukiYoichi
en-aut-sei=Tsuzuki
en-aut-mei=Yoichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=OhsakiHaruna
en-aut-sei=Ohsaki
en-aut-mei=Haruna
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KawaguchiYawako W.
en-aut-sei=Kawaguchi
en-aut-mei=Yawako W.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SuzukiSayaka
en-aut-sei=Suzuki
en-aut-mei=Sayaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HaradaShogo
en-aut-sei=Harada
en-aut-mei=Shogo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=OtakeYurie
en-aut-sei=Otake
en-aut-mei=Yurie
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=ShinoharaNaoto
en-aut-sei=Shinohara
en-aut-mei=Naoto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KatsuharaKoki R.
en-aut-sei=Katsuhara
en-aut-mei=Koki R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Health and Environmental Risk Division, National Institute for Environmental Studies
kn-affil=

affil-num=2
en-affil=Department of Biological Sciences, Tokyo Metropolitan University
kn-affil=

affil-num=3
en-affil=Department of Biological Sciences, Graduate School of Science, The University of Tokyo
kn-affil=

affil-num=4
en-affil=Center for Ecological Research, Kyoto University
kn-affil=

affil-num=5
en-affil=Department of Biology, Graduate School of Science, Osaka City University
kn-affil=

affil-num=6
en-affil=Center for Ecological Research, Kyoto University
kn-affil=

affil-num=7
en-affil=Center for Ecological Research, Kyoto University
kn-affil=

affil-num=8
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=
en-keyword=awareness of local governments
kn-keyword=awareness of local governments
en-keyword=biocultural diversity
kn-keyword=biocultural diversity
en-keyword=ecosystem services
kn-keyword=ecosystem services
en-keyword=manual web scraping
kn-keyword=manual web scraping
en-keyword=temporal trend
kn-keyword=temporal trend
END

start-ver=1.4
cd-journal=joma
no-vol=142
cd-vols=
no-issue=
article-no=
start-page=104967
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202506
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Cross-feeding between beneficial and pathogenic bacteria to utilize eukaryotic host cell-derived sialic acids and bacteriophages shape the pathogen-host interface milieu
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Under an inflamed-intestinal milieu, increased free sialic acids are associated with the overgrowth of some pathogenic bacterial strains. Recently, the protective immunomodulatory activity of gut bacteriophages (phages) has also been highlighted. However, the role of phages in triple reciprocal interactions between pathogenic bacteria, beneficial bacteria, and their host cell sialic acids has not been studied so far. We established a sialidase-explicit model in which beneficial and pathogenic bacteria interact through cross-feeding and competition for free sialic acid using a human triple co-culture cell model incorporating colonocytes (T84 cells), monocytes (THP-1 cells), and hepatocytes (Huh7 cells). Triple co-cultured cells were challenged with Gram-positive Bifidobacterium bifidum (B. bifidum) and Gram-negative Pseudomonas aeruginosa PAO1 (P. a PAO1) in the absence or presence of its KPP22 phage in two different cell culture mediums: 1) standard Dulbecco's Modified Eagle Medium (DMEM) and 2) DMEM with 2,3-dehydro-2-deoxy-N-acetylneuraminic acid (DANA). Changes in physiological, functional, and structural health markers of stimulated cocultured cells were evaluated. The concentrations of sialic acid and pro-inflammatory cytokines in the cell culture supernatants were quantified. P. a PAO1 triggered the release of interleukin 6 and 8 (IL-6 and IL-8), accompanied by increased levels of free sialic acid, reduced viability of co-cultured cells, and disrupted the integrity of the cellular monolayer. These disruptive effects were markedly attenuated by KPP22 phage and B. bifidum. In addition to well-documented differences in the structure and composition of the bacterial cell walls of Gram-negative pathogenic bacteria and bifidobacteria, two distinct factors seem to be pivotal in modulating the pathogen-host interface milieu: (i) the presence of phages and (ii) the utilization of free sialic acids secreted from host cells by bifidobacteria.
en-copyright=
kn-copyright=

en-aut-name=GhadimiDarab
en-aut-sei=Ghadimi
en-aut-mei=Darab
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=F?lster-HolstRegina
en-aut-sei=F?lster-Holst
en-aut-mei=Regina
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=Bl?merSophia
en-aut-sei=Bl?mer
en-aut-mei=Sophia
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=EbsenMichael
en-aut-sei=Ebsen
en-aut-mei=Michael
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=R?ckenChristoph
en-aut-sei=R?cken
en-aut-mei=Christoph
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=UchiyamaJumpei
en-aut-sei=Uchiyama
en-aut-mei=Jumpei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MatsuzakiShigenobu
en-aut-sei=Matsuzaki
en-aut-mei=Shigenobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=BockelmannWilhelm
en-aut-sei=Bockelmann
en-aut-mei=Wilhelm
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Microbiology and Biotechnology, Max Rubner-Institut
kn-affil=

affil-num=2
en-affil=Clinic of Dermatology, Venerology und Allergology, University Hospital Schleswig-Holstein
kn-affil=

affil-num=3
en-affil=Clinic of Dermatology, Venerology und Allergology, University Hospital Schleswig-Holstein
kn-affil=

affil-num=4
en-affil=St?dtisches MVZ Kiel GmbH (Kiel City Hospital), Department of Pathology
kn-affil=

affil-num=5
en-affil=Institute of Pathology, Kiel University, University Hospital, Schleswig-Holstein
kn-affil=

affil-num=6
en-affil=Department of Bacteriology, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=7
en-affil=Department of Medical Laboratory Science, Faculty of Health Sciences, Kochi Gakuen University
kn-affil=

affil-num=8
en-affil=Department of Microbiology and Biotechnology, Max Rubner-Institut
kn-affil=
en-keyword=Bacterial sialidase
kn-keyword=Bacterial sialidase
en-keyword=Inflammation
kn-keyword=Inflammation
en-keyword=Cytokines
kn-keyword=Cytokines
en-keyword=Infection
kn-keyword=Infection
en-keyword=Bifidobacteria
kn-keyword=Bifidobacteria
en-keyword=Phages
kn-keyword=Phages
END

start-ver=1.4
cd-journal=joma
no-vol=32
cd-vols=
no-issue=5
article-no=
start-page=1302
end-page=1309
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250718
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=X-ray fluorescence holography under high-pressure conditions
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=This study reports the first application of X-ray fluorescence holography (XFH) under high-pressure conditions. We integrated XFH with a diamond anvil cell to investigate the local structure around Sr atoms in single-crystal SrTiO3 under high pressure. By utilizing nano-polycrystalline diamond anvils and a yttrium filter, we effectively eliminated significant background noise from both the anvils and the gasket. This optimized experimental configuration enabled the measurement of Sr?Kα holograms of the SrTiO3 sample at pressures up to 13.3?GPa. The variation of lattice constants with pressure was calculated by the shifts of Kossel lines, and real-space images of the atomic structures were reconstructed from the Sr?Kα holograms at different pressures. This work successfully demonstrates the feasibility of employing XFH under high-pressure conditions as a novel method for visualizing pressure-induced changes in the three-dimensional local structure around the specified element.
en-copyright=
kn-copyright=

en-aut-name=ZhanXinhui
en-aut-sei=Zhan
en-aut-mei=Xinhui
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=IshimatsuNaoki
en-aut-sei=Ishimatsu
en-aut-mei=Naoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KimuraKoji
en-aut-sei=Kimura
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=HappoNaohisa
en-aut-sei=Happo
en-aut-mei=Naohisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SekharHalubai
en-aut-sei=Sekhar
en-aut-mei=Halubai
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=SatoTomoko
en-aut-sei=Sato
en-aut-mei=Tomoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NakajimaNobuo
en-aut-sei=Nakajima
en-aut-mei=Nobuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KawamuraNaomi
en-aut-sei=Kawamura
en-aut-mei=Naomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=HigashiKotaro
en-aut-sei=Higashi
en-aut-mei=Kotaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=SekizawaOki
en-aut-sei=Sekizawa
en-aut-mei=Oki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=KadobayashiHirokazu
en-aut-sei=Kadobayashi
en-aut-mei=Hirokazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=EguchiRitsuko
en-aut-sei=Eguchi
en-aut-mei=Ritsuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=KubozonoYoshihiro
en-aut-sei=Kubozono
en-aut-mei=Yoshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=TajiriHiroo
en-aut-sei=Tajiri
en-aut-mei=Hiroo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=HosokawaShinya
en-aut-sei=Hosokawa
en-aut-mei=Shinya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=MatsushitaTomohiro
en-aut-sei=Matsushita
en-aut-mei=Tomohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=ShinmeiToru
en-aut-sei=Shinmei
en-aut-mei=Toru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=IrifuneTetsuo
en-aut-sei=Irifune
en-aut-mei=Tetsuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=HayashiKoichi
en-aut-sei=Hayashi
en-aut-mei=Koichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

affil-num=1
en-affil=Graduate School of Advanced Science and Engineering, Hiroshima University
kn-affil=

affil-num=2
en-affil=Geodynamics Research Center, PIAS, Ehime University
kn-affil=

affil-num=3
en-affil=Department of Physical Science and Engineering, Nagoya Institute of Technology
kn-affil=

affil-num=4
en-affil=Graduate School of Information Sciences, Hiroshima City University
kn-affil=

affil-num=5
en-affil=Institute of Industrial Nanomaterials, Kumamoto University
kn-affil=

affil-num=6
en-affil=Institute of Materials Structure Science, High Energy Accelerator Research Organization, KEK
kn-affil=

affil-num=7
en-affil=Graduate School of Advanced Science and Engineering, Hiroshima University
kn-affil=

affil-num=8
en-affil=Japan Synchrotron Radiation Research Institute, SPring-8
kn-affil=

affil-num=9
en-affil=Japan Synchrotron Radiation Research Institute, SPring-8
kn-affil=

affil-num=10
en-affil=Japan Synchrotron Radiation Research Institute, SPring-8
kn-affil=

affil-num=11
en-affil=Japan Synchrotron Radiation Research Institute, SPring-8
kn-affil=

affil-num=12
en-affil=Graduate School of Science, University of Hyogo
kn-affil=

affil-num=13
en-affil=Research Institute for Interdisciplinary Science, Okayama University
kn-affil=

affil-num=14
en-affil=Japan Synchrotron Radiation Research Institute, SPring-8
kn-affil=

affil-num=15
en-affil=Faculty of Materials for Energy, Shimane University
kn-affil=

affil-num=16
en-affil=Graduate School of Science and Technology, Nara Institute of Science and Technology
kn-affil=

affil-num=17
en-affil=Geodynamics Research Center, PIAS, Ehime University
kn-affil=

affil-num=18
en-affil=Geodynamics Research Center, PIAS, Ehime University
kn-affil=

affil-num=19
en-affil=Department of Physical Science and Engineering, Nagoya Institute of Technology
kn-affil=
en-keyword=X-ray fluorescence holography
kn-keyword=X-ray fluorescence holography
en-keyword=high pressure
kn-keyword=high pressure
en-keyword=SrTiO3
kn-keyword=SrTiO3
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=roaf042
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250603
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Recommendations for the treatment of juvenile idiopathic arthritis with oligoarthritis or polyarthritis from the 2024 update of the Japan College of Rheumatology Clinical Practice Guidelines for the management of rheumatoid arthritis including juvenile idiopathic arthritis with oligoarthritis or polyarthritis ? secondary publication
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Objectives: To conduct systematic reviews (SRs) and develop clinical practice guidelines (CPGs) for managing juvenile idiopathic arthritis (JIA) with oligoarthritis or polyarthritis.<br>
Methods: The Grading of Recommendations, Assessment, Development, and Evaluation methodology was employed to carry out SRs and formulate the CPGs. An expert panel, including patients, paediatric and nonpaediatric rheumatologists, guideline specialists, and patient representatives, used the Delphi method to discuss and agree on the recommendations.<br>
Results: Six clinical questions (CQs) on the efficacy and safety of medical treatments were evaluated. These included CQ1 on methotrexate (MTX), CQ2 on non-MTX conventional synthetic disease-modifying antirheumatic drugs, CQ3 on glucocorticoids, CQ4 on tumour necrosis factor inhibitors, CQ5 on interleukin-6 inhibitors, and CQ6 on Janus kinase inhibitors. Two randomized controlled trials were identified for CQ1, three for CQ2, two for CQ3, eight for CQ4, two for CQ5, and two for CQ6. Based on these evaluations, three strong and three conditional recommendations were established. The CPGs have been endorsed by the Japan College of Rheumatology and the Pediatric Rheumatology Association of Japan.<br>
Conclusions: The SRs provided the necessary evidence to develop the CPGs, which are intended to guide not only paediatric but also nonpaediatric rheumatologists, caregivers, patients, and their families in treatment decision-making.
en-copyright=
kn-copyright=

en-aut-name=MiyamaeTakako
en-aut-sei=Miyamae
en-aut-mei=Takako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=OkamotoNami
en-aut-sei=Okamoto
en-aut-mei=Nami
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=InoueYuzaburo
en-aut-sei=Inoue
en-aut-mei=Yuzaburo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KubotaTomohiro
en-aut-sei=Kubota
en-aut-mei=Tomohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=EbatoTakasuke
en-aut-sei=Ebato
en-aut-mei=Takasuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=IrabuHitoshi
en-aut-sei=Irabu
en-aut-mei=Hitoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KamedaHideto
en-aut-sei=Kameda
en-aut-mei=Hideto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KanekoYuko
en-aut-sei=Kaneko
en-aut-mei=Yuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=KuboHiroshi
en-aut-sei=Kubo
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=MitsunagaKanako
en-aut-sei=Mitsunaga
en-aut-mei=Kanako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=MoriMasaaki
en-aut-sei=Mori
en-aut-mei=Masaaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=NakajimaAyako
en-aut-sei=Nakajima
en-aut-mei=Ayako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=NishimuraKenichi
en-aut-sei=Nishimura
en-aut-mei=Kenichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=OhkuboNaoaki
en-aut-sei=Ohkubo
en-aut-mei=Naoaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=SatoTomomi
en-aut-sei=Sato
en-aut-mei=Tomomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=SugitaYuko
en-aut-sei=Sugita
en-aut-mei=Yuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=TakanashiSatoshi
en-aut-sei=Takanashi
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=TanakaTakayuki
en-aut-sei=Tanaka
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=UmebayashiHiroaki
en-aut-sei=Umebayashi
en-aut-mei=Hiroaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=YashiroMasato
en-aut-sei=Yashiro
en-aut-mei=Masato
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=YamanishiShingo
en-aut-sei=Yamanishi
en-aut-mei=Shingo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=FusamaMie
en-aut-sei=Fusama
en-aut-mei=Mie
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=HirataShintaro
en-aut-sei=Hirata
en-aut-mei=Shintaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=KishimotoMitsumasa
en-aut-sei=Kishimoto
en-aut-mei=Mitsumasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=KohnoMasataka
en-aut-sei=Kohno
en-aut-mei=Masataka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=KojimaMasayo
en-aut-sei=Kojima
en-aut-mei=Masayo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

en-aut-name=KojimaToshihisa
en-aut-sei=Kojima
en-aut-mei=Toshihisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=27
ORCID=

en-aut-name=MorinobuAkio
en-aut-sei=Morinobu
en-aut-mei=Akio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=28
ORCID=

en-aut-name=SugiharaTakahiko
en-aut-sei=Sugihara
en-aut-mei=Takahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=29
ORCID=

en-aut-name=TanakaEiichi
en-aut-sei=Tanaka
en-aut-mei=Eiichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=30
ORCID=

en-aut-name=YajimaNobuyuki
en-aut-sei=Yajima
en-aut-mei=Nobuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=31
ORCID=

en-aut-name=YanaiRyo
en-aut-sei=Yanai
en-aut-mei=Ryo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=32
ORCID=

en-aut-name=KawahitoYutaka
en-aut-sei=Kawahito
en-aut-mei=Yutaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=33
ORCID=

en-aut-name=HarigaiMasayoshi
en-aut-sei=Harigai
en-aut-mei=Masayoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=34
ORCID=

affil-num=1
en-affil=Department of Pediatric Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University Hospital
kn-affil=

affil-num=2
en-affil=Department of Pediatrics, Osaka Rosai Hospital, Japan Organization of Occupational Health and Safety
kn-affil=

affil-num=3
en-affil=Department of General Medical Science, Graduate School of Medicine, Chiba University
kn-affil=

affil-num=4
en-affil=Department of Pediatrics, Kagoshima Prefectural Satsunan Hospital
kn-affil=

affil-num=5
en-affil=Department of Pediatrics, Kitasato University
kn-affil=

affil-num=6
en-affil=Department of Pediatrics and Development Biology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University
kn-affil=

affil-num=7
en-affil=Division of Rheumatology, Department of Internal Medicine, Toho University
kn-affil=

affil-num=8
en-affil=Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine
kn-affil=

affil-num=9
en-affil=Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine
kn-affil=

affil-num=10
en-affil=Department of Allergy and Rheumatology, Chiba Children's Hospital
kn-affil=

affil-num=11
en-affil=Department of Lifetime Clinical Immunology, Tokyo Medical and Dental University
kn-affil=

affil-num=12
en-affil=Center for Rheumatic Diseases, Mie University Hospital
kn-affil=

affil-num=13
en-affil=Department of Pediatrics, Yokohama City University Graduate School of Medicine
kn-affil=

affil-num=14
en-affil=Iizuka Hospital
kn-affil=

affil-num=15
en-affil=Clinical Education Center For Physicians, Shiga University of Medical Science
kn-affil=

affil-num=16
en-affil=Department of Pediatrics, School of Medicine, Osaka Medical and Pharmaceutical University
kn-affil=

affil-num=17
en-affil=Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine
kn-affil=

affil-num=18
en-affil=Department of Pediatrics, Japanese Red Cross Otsu Hospital
kn-affil=

affil-num=19
en-affil=Department of Rheumatology and Infectious Diseases, Miyagi Children’s Hospital
kn-affil=

affil-num=20
en-affil=Department of Pediatrics, Okayama University Hospital
kn-affil=

affil-num=21
en-affil=Department of Pediatrics, Nippon Medical School
kn-affil=

affil-num=22
en-affil=Health Sciences Department of Nursing, Kansai University of International Studies
kn-affil=

affil-num=23
en-affil=Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital
kn-affil=

affil-num=24
en-affil=Department of Nephrology and Rheumatology, Kyorin University School of Medicine
kn-affil=

affil-num=25
en-affil=Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine
kn-affil=

affil-num=26
en-affil=Graduate School of Medical Sciences, Nagoya City University
kn-affil=

affil-num=27
en-affil=Department of Orthopedic Surgery, National Hospital Organization Nagoya Medical Center
kn-affil=

affil-num=28
en-affil=Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University
kn-affil=

affil-num=29
en-affil=Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine
kn-affil=

affil-num=30
en-affil=Division of Rheumatology, Department of Internal Medicine, School of Medicine, Tokyo Women's Medical University
kn-affil=

affil-num=31
en-affil=Division of Rheumatology, Department of Medicine, Showa University School of Medicine
kn-affil=

affil-num=32
en-affil=Division of Rheumatology, Department of Medicine, Showa University School of Medicine
kn-affil=

affil-num=33
en-affil=Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine
kn-affil=

affil-num=34
en-affil=Division of Rheumatology, Department of Internal Medicine, School of Medicine, Tokyo Women's Medical University
kn-affil=
en-keyword=Clinical practice guidelines
kn-keyword=Clinical practice guidelines
en-keyword=baricitinib
kn-keyword=baricitinib
en-keyword=GRADE (Grading of Recommendations, Assessment, Development, and Evaluation)
kn-keyword=GRADE (Grading of Recommendations, Assessment, Development, and Evaluation)
en-keyword=juvenile idiopathic arthritis
kn-keyword=juvenile idiopathic arthritis
en-keyword=systematic review
kn-keyword=systematic review
END

start-ver=1.4
cd-journal=joma
no-vol=43
cd-vols=
no-issue=8
article-no=
start-page=1261
end-page=1268
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250505
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Overview of task shifting guidelines in Japan: from radiologists to radiological technologists
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=As one of the key pillars of work style reform for physicians, task shifting and sharing from radiologists to radiological technologists has been considered. In May 2021, the Radiological Technologists Act was amended, allowing for the expansion of several duties. Alongside these legal and regulatory changes, a notice from Ministry of Health, Labour and Welfare was issued, highlighting tasks to be particularly promoted under the current system prior to the amendment of the Radiological Technologists Act. These amendments authorize radiological technologists to perform advanced and specialized tasks, such as securing venous access for contrast agent administration, which require significantly higher skill levels than their traditional roles. However, the amended legislation did not include specific guidelines, rules, or considerations for the practical implementation of these new duties in daily medical practice, especially from the perspectives of patient safety and quality of care. To address this, the Japan Radiological Society, the Japanese College of Radiology, and the Japan Association of Radiological Technologists collaborated with other related societies to develop guidelines on five key topics:-Guidelines for Safe Conduct of CT/MRI Contrast-Enhanced Examinations: Considering the expanded scope of practice for radiological technologists. -Guidelines for Safe Conduct of Nuclear Medicine Examinations: Aligned with the expanded responsibilities of radiological technologists. -Guidelines for Clinical application of Image-Guided Radiation Therapy (IGRT). -Guidelines for Safe Conduct of Angiography and Interventional Radiology (IR): Adapted for the expanded roles of radiological technologists. -Guidelines for Reporting Findings of STAT Imaging: Addressing urgent conditions with potential impact on life prognosis.
en-copyright=
kn-copyright=

en-aut-name=KidoAki
en-aut-sei=Kido
en-aut-mei=Aki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=OhnoKazuko
en-aut-sei=Ohno
en-aut-mei=Kazuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YamadaKei
en-aut-sei=Yamada
en-aut-mei=Kei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YamakadoKoichiro
en-aut-sei=Yamakado
en-aut-mei=Koichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HirakiTakao
en-aut-sei=Hiraki
en-aut-mei=Takao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MizowakiTakashi
en-aut-sei=Mizowaki
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=AidaNoriko
en-aut-sei=Aida
en-aut-mei=Noriko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=Oyama-ManabeNoriko
en-aut-sei=Oyama-Manabe
en-aut-mei=Noriko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=KodamaNaoki
en-aut-sei=Kodama
en-aut-mei=Naoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=UedaKatsuhiko
en-aut-sei=Ueda
en-aut-mei=Katsuhiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=AokiShigeki
en-aut-sei=Aoki
en-aut-mei=Shigeki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=TomiyamaNoriyuki
en-aut-sei=Tomiyama
en-aut-mei=Noriyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

affil-num=1
en-affil=Department of Radiology, Toyama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Radiological Technology, Kyoto University of Medial Science
kn-affil=

affil-num=3
en-affil=Department of Radiology, Kyoto Prefectural University of Medicine
kn-affil=

affil-num=4
en-affil=Department of Radiology, The Hospital of Hyogo College of Medicine
kn-affil=

affil-num=5
en-affil=Department of Radiology, Okayama University
kn-affil=

affil-num=6
en-affil=Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University
kn-affil=

affil-num=7
en-affil=Department of Diagnostic Radiology, Yokohama City University Graduate School of Medicine
kn-affil=

affil-num=8
en-affil=Department of Radiology, Jichi Medical University Saitama Medical Center
kn-affil=

affil-num=9
en-affil=Department of Radiological Technology, Faculty of Medical Technology, Niigata University of Health and Welfare
kn-affil=

affil-num=10
en-affil=Department of Radiological Sciences, School of Health Sciences at Narita, International University of Health and Welfare
kn-affil=

affil-num=11
en-affil=Health Data Science, Department of Radiology/Data Science, Graduate School of Medicine, Juntendo University
kn-affil=

affil-num=12
en-affil=Department of Radiology, Osaka University Graduate School of Medicine
kn-affil=
en-keyword=Task shifting and sharing
kn-keyword=Task shifting and sharing
en-keyword=Radiological technologists
kn-keyword=Radiological technologists
en-keyword=Guideline
kn-keyword=Guideline
en-keyword=IGRT
kn-keyword=IGRT
en-keyword=STAT
kn-keyword=STAT
END

start-ver=1.4
cd-journal=joma
no-vol=30
cd-vols=
no-issue=1
article-no=
start-page=144
end-page=156
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20241109
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Lymphadenectomy and chemotherapy are effective treatments for patients with 2023 international federation of gynecology and obstetrics stage IIC-high risk endometrial cancer in Japan
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background In early-stage endometrial cancer (EC), the treatment of aggressive histological subtypes (endometrioid carcinoma grade 3, serous carcinoma, clear-cell carcinoma, undifferentiated carcinoma, mixed carcinoma, and carcinosarcoma) is controversial. We aimed to investigate the treatment of patients with International Federation of Gynecology and Obstetrics (FIGO) stage IC and stage IIC EC according to the 2023 classification.<br>
Methods We retrospectively identified patients with FIGO 2023 stage IC, IIC-intermediate risk (IIC-I), and IIC-high risk (IIC-H) EC who underwent adjuvant therapy or observation after surgery at eight medical institutions from 2004 to 2023. Progression-free survival (PFS) and overall survival (OS) were evaluated using Kaplan?Meier estimates and univariate and multivariate analyses.<br>
Results The PFS and OS were significantly worse in patients with FIGO 2023 stage IIC-H EC than in those with FIGO 2023 stage IIC-I EC (PFS: p?=?0.008 and OS: p?=?0.006). According to the FIGO 2023 stage IIC-H classification, lymphadenectomy and chemotherapy resulted in better prognoses regarding both PFS and OS (p?<?0.001 for both) than other treatments. Our findings suggest that lymphadenectomy and chemotherapy effectively reduced vaginal stump and lymph node metastases in FIGO 2023 stage IIC-H EC (p?<?0.001 and p?=?0.008, respectively). Furthermore, in the multivariate analysis, not undergoing lymphadenectomy or chemotherapy were independent predictors of recurrence and poor prognoses in patients with FIGO 2023 stage IIC-H EC (p?<?0.001 and p?=?0.031, respectively).<br>
Conclusion Lymphadenectomy and chemotherapy resulted in better prognoses regarding both recurrence and survival in patients with FIGO 2023 stage IIC high-risk EC.
en-copyright=
kn-copyright=

en-aut-name=TaniYoshinori
en-aut-sei=Tani
en-aut-mei=Yoshinori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NakamuraKeiichiro
en-aut-sei=Nakamura
en-aut-mei=Keiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YorimitsuMasae
en-aut-sei=Yorimitsu
en-aut-mei=Masae
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SekiNoriko
en-aut-sei=Seki
en-aut-mei=Noriko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=NakanishiMie
en-aut-sei=Nakanishi
en-aut-mei=Mie
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=ItouHironori
en-aut-sei=Itou
en-aut-mei=Hironori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=ShimizuMiyuki
en-aut-sei=Shimizu
en-aut-mei=Miyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=YamamotoDan
en-aut-sei=Yamamoto
en-aut-mei=Dan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=TakaharaEtsuko
en-aut-sei=Takahara
en-aut-mei=Etsuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=MasuyamaHisashi
en-aut-sei=Masuyama
en-aut-mei=Hisashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Obstetrics and Gynecology, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=4
en-affil=Department of Obstetrics and Gynecology, Japanese Red Cross Society Himeji Hospital
kn-affil=

affil-num=5
en-affil=Department of Obstetrics and Gynecology, Kagawa Prefectural Central Hospital
kn-affil=

affil-num=6
en-affil=Department of Obstetrics and Gynecology, National Hospital Organization Iwakuni Clinical Center
kn-affil=

affil-num=7
en-affil=Department of Obstetrics and Gynecology, Kagawa Rosai Hospital
kn-affil=

affil-num=8
en-affil=Department of Obstetrics and Gynecology, National Organization Fukuyama Medical Center
kn-affil=

affil-num=9
en-affil=Department of Obstetrics and Gynecology, Fukuyama City Hospital
kn-affil=

affil-num=10
en-affil=Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=Endometrial cancer
kn-keyword=Endometrial cancer
en-keyword=FIGO 2023
kn-keyword=FIGO 2023
en-keyword=Stage IIC high risk
kn-keyword=Stage IIC high risk
en-keyword=Lymphadenectomy
kn-keyword=Lymphadenectomy
en-keyword=Chemotherapy
kn-keyword=Chemotherapy
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250704
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Primary tumour resection plus systemic therapy versus systemic therapy alone in metastatic breast cancer (JCOG1017, PRIM-BC): a randomised clinical trial
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Several prospective studies have evaluated the benefit of primary tumour resection (PTR) in de novo Stage IV breast cancer (BC) patients, but it remains controversial. We aimed to investigate whether PTR improves the survival of de novo stage IV BC patients.<br>
Methods: De novo stage IV BC patients were enrolled in the first registration and received systemic therapies according to clinical subtypes. Patients without progression after primary systemic therapy for 3 months were randomly assigned 1:1 to systemic therapy alone (arm A) or PTR plus systemic therapy (arm B). The primary endpoint was overall survival (OS), and the secondary endpoints included local relapse-free survival (LRFS).<br>
Results: Five hundred seventy patients were enrolled between May 5, 2011, and May 31, 2018. Of these, 407 were randomised to arm A (N?=?205) or arm B (N?=?202). The median follow-up time of all randomised patients was 60 months. The difference in OS was not statistically significant (HR 0.86 90% CI 0.69?1.07, one-sided p?=?0.13). Median OS was 69 months (arm A) and 75 months (arm B). In the subgroup analysis, PTR was associated with improved OS in pre-menopausal patients, or those with single-organ metastasis. LRFS in arm B was significantly longer than that in arm A (median LRFS 20 vs. 63 months: HR 0.42, 95% CI 0.33?0.53, p?<?0.0001). There were no treatment-related deaths.<br>
Conclusions: PTR did not prolong OS. However, it improved local control and might benefit a subset of patients, such as those with premenopausal status or with single-organ metastasis. It also improved local relapse-free survival (LRFS), which is a clinically meaningful outcome in trials of systemic therapy.<br>
Clinical trial registration: UMIN Clinical Trials Registry (UMIN000005586); Japan Registry of Clinical Trials (jRCTs031180151).
en-copyright=
kn-copyright=

en-aut-name=ShienTadahiko
en-aut-sei=Shien
en-aut-mei=Tadahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HaraFumikata
en-aut-sei=Hara
en-aut-mei=Fumikata
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=AogiKenjiro
en-aut-sei=Aogi
en-aut-mei=Kenjiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YanagidaYasuhiro
en-aut-sei=Yanagida
en-aut-mei=Yasuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TsuneizumiMichiko
en-aut-sei=Tsuneizumi
en-aut-mei=Michiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=YamamotoNaohito
en-aut-sei=Yamamoto
en-aut-mei=Naohito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MatsumotoHiroshi
en-aut-sei=Matsumoto
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=SutoAkihiko
en-aut-sei=Suto
en-aut-mei=Akihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=WatanabeKenichi
en-aut-sei=Watanabe
en-aut-mei=Kenichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=HaraoMichiko
en-aut-sei=Harao
en-aut-mei=Michiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=KanbayashiChizuko
en-aut-sei=Kanbayashi
en-aut-mei=Chizuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=ItohMitsuya
en-aut-sei=Itoh
en-aut-mei=Mitsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=KadoyaTakayuki
en-aut-sei=Kadoya
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=AnanKeisei
en-aut-sei=Anan
en-aut-mei=Keisei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=MaedaShigeto
en-aut-sei=Maeda
en-aut-mei=Shigeto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=SasakiKeita
en-aut-sei=Sasaki
en-aut-mei=Keita
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=OgawaGakuto
en-aut-sei=Ogawa
en-aut-mei=Gakuto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=SajiShigehira
en-aut-sei=Saji
en-aut-mei=Shigehira
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=FukudaHaruhiko
en-aut-sei=Fukuda
en-aut-mei=Haruhiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=IwataHiroji
en-aut-sei=Iwata
en-aut-mei=Hiroji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

affil-num=1
en-affil=Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Cancer Institute Hospital
kn-affil=

affil-num=3
en-affil=National Hospital Organization Shikoku Cancer Center
kn-affil=

affil-num=4
en-affil=Shizuoka General Hospital
kn-affil=

affil-num=5
en-affil=Gunma Prefectural Cancer Center
kn-affil=

affil-num=6
en-affil=Chiba Prefectural Cancer Center
kn-affil=

affil-num=7
en-affil=Saitama Prefectural Cancer Center
kn-affil=

affil-num=8
en-affil=National Cancer Center Hospital
kn-affil=

affil-num=9
en-affil=Hokkaido Cancer Center
kn-affil=

affil-num=10
en-affil=Jichi Medical University Hospital
kn-affil=

affil-num=11
en-affil=Niigata Prefectural Cancer Center
kn-affil=

affil-num=12
en-affil=Hiroshima City Hiroshima Citizen’s Hospital
kn-affil=

affil-num=13
en-affil=Hiroshima University Hospital
kn-affil=

affil-num=14
en-affil=Kitakyushu Municipal Medical Center
kn-affil=

affil-num=15
en-affil=Nagasaki Municipal Medical Center
kn-affil=

affil-num=16
en-affil=National Cancer Center Hospital
kn-affil=

affil-num=17
en-affil=National Cancer Center Hospital
kn-affil=

affil-num=18
en-affil=Fukushima Medical University
kn-affil=

affil-num=19
en-affil=National Cancer Center Hospital
kn-affil=

affil-num=20
en-affil=Aichi Cancer Center Hospital
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=32
cd-vols=
no-issue=4
article-no=
start-page=630
end-page=637
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250526
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Immediate breast reconstruction surgery for breast cancer: current status and future directions
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background Immediate breast reconstruction (IBR) has become increasingly recognized in Japan as an important component of breast cancer care, improving patients’ quality of life after mastectomy. While the adoption of IBR is growing, the reconstruction rate in Japan remains lower than in Western countries. To clarify the current practice and challenges, the Japanese Breast Cancer Society (JBCS) conducted a nationwide survey.<br>
Methods We conducted a comprehensive web-based questionnaire survey among all JBCS-certified institutions between December 2020 and February 2021. The survey assessed institutional capabilities, surgical techniques, decision-making criteria for BR, and the integration of adjuvant therapy.<br>
Results A total of 429 institutions responded, with 72.5% offering BR and 61.7% capable of providing immediate reconstruction. Nipple-sparing mastectomy (NSM) was performed at 73.7% of institutions offering reconstruction. Multidisciplinary conferences with plastic surgeons were held at 70.5% of institutions. Approximately 30% of institutions discontinued IBR if sentinel lymph node metastases were detected intraoperatively, and 62.8% avoided recommending IBR for patients likely to require postoperative radiation therapy. In 94% of institutions, BR did not cause delays in the administration of adjuvant chemotherapy. However, 15% of institutions modified their radiation therapy approach in reconstructed patients. Additionally, 27% of physicians still believed that BR could negatively affect prognosis.<br>
Conclusions The survey confirmed that IBR is widely performed and feasible in Japan. However, institutional differences, limited access to plastic surgeons, and persistent misconceptions remain significant barriers. Strengthening multidisciplinary collaboration and establishing standardized guidelines will help improve BR rates and patient outcomes in Japan.
en-copyright=
kn-copyright=

en-aut-name=ShienTadahiko
en-aut-sei=Shien
en-aut-mei=Tadahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NogiHiroko
en-aut-sei=Nogi
en-aut-mei=Hiroko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=OgiyaAkiko
en-aut-sei=Ogiya
en-aut-mei=Akiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=IshitobiMakoto
en-aut-sei=Ishitobi
en-aut-mei=Makoto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=YamauchiChikako
en-aut-sei=Yamauchi
en-aut-mei=Chikako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=ShimoAyaka
en-aut-sei=Shimo
en-aut-mei=Ayaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NaruiKazutaka
en-aut-sei=Narui
en-aut-mei=Kazutaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=NaguraNaomi
en-aut-sei=Nagura
en-aut-mei=Naomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=SekiHirohito
en-aut-sei=Seki
en-aut-mei=Hirohito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=TerataKaori
en-aut-sei=Terata
en-aut-mei=Kaori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=SaigaMiho
en-aut-sei=Saiga
en-aut-mei=Miho
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=UchidaTatsuya
en-aut-sei=Uchida
en-aut-mei=Tatsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=SasadaShinsuke
en-aut-sei=Sasada
en-aut-mei=Shinsuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=SakuraiTeruhisa
en-aut-sei=Sakurai
en-aut-mei=Teruhisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=NiikuraNaoki
en-aut-sei=Niikura
en-aut-mei=Naoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=MoriHiroki
en-aut-sei=Mori
en-aut-mei=Hiroki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

affil-num=1
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Breast and Endocrine Surgery, The Jikei University School of Medicine
kn-affil=

affil-num=3
en-affil=Department of Breast Surgery, Japanese Red Cross Medical Center
kn-affil=

affil-num=4
en-affil=Department of Breast Surgery, Mie University School of Medicine
kn-affil=

affil-num=5
en-affil=Department of Radiation Oncology, Shiga General Hospital
kn-affil=

affil-num=6
en-affil=Department of Breast and Endocrine Surgery, St. Marianna University School of Medicine
kn-affil=

affil-num=7
en-affil=Department of Breast and Thyroid Surgery, Medical Center, Yokohama City University
kn-affil=

affil-num=8
en-affil=Department of Breast Surgical Oncology, St Luke’s International Hospital
kn-affil=

affil-num=9
en-affil=Department of Breast Surgery, Kyorin University School of Medicine
kn-affil=

affil-num=10
en-affil=Department of Breast and Endocrine Surgery, Akita University Hospital
kn-affil=

affil-num=11
en-affil=Department of Plastic Surgery, Okayama University Hospital
kn-affil=

affil-num=12
en-affil=Department of Plastic Surgery, Okayama University Hospital
kn-affil=

affil-num=13
en-affil=Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University
kn-affil=

affil-num=14
en-affil=Sakurai Breast Clinic
kn-affil=

affil-num=15
en-affil=Department of Breast Oncology, Tokai University School of Medicine
kn-affil=

affil-num=16
en-affil=Department of Plastic and Reconstructive Surgery, Tokyo Medical and Dental University
kn-affil=
en-keyword=Breast cancer
kn-keyword=Breast cancer
en-keyword=Immediate reconstruction surgery
kn-keyword=Immediate reconstruction surgery
en-keyword=Prognosis
kn-keyword=Prognosis
en-keyword=Complications
kn-keyword=Complications
END

start-ver=1.4
cd-journal=joma
no-vol=12
cd-vols=
no-issue=1
article-no=
start-page=e003250
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202501
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Clinical impact of combined assessment of myocardial inflammation and fibrosis using myocardial biopsy in patients with dilated cardiomyopathy: a multicentre, retrospective cohort study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background Among patients with dilated cardiomyopathy (DCM), myocardial inflammation and fibrosis are risk factors for poor clinical outcomes. Here, we investigated the combined prognostic value of these two factors, as evaluated using myocardial biopsy samples.<br>
Methods This retrospective and multicentre study included patients with DCM?defined as LVEF of ?45% and left diastolic diameter of >112% of predicted value, without evidence of secondary or ischaemic cardiomyopathy. In myocardial biopsy samples, inflammatory cells were counted using immunohistochemistry, and Masson’s Trichrome staining was performed to quantify the myocardial fibrosis as collagen area fraction (CAF). Higher myocardial inflammation was defined as leucocytes of ?14/mm?, including ?4 monocytes/mm?, with CD3+ T lymphocytes of?7/mm?. Greater myocardial fibrosis was defined as CAF of>5.9% by the Youden’s index. The primary endpoint was cardiac death or left ventricular assist device implantation.<br>
Results A total of 255 DCM patients were enrolled (average age, 53.1 years; 78% males). Within this cohort, the mean LVEF was 28.0%, mean CAF was 10.7% and median CD3+ cell count was 8.3/mm2. During the median follow-up period of 2688 days, 46 patients met the primary endpoint. Multivariable Cox proportional hazard analyses revealed that CD3+ cell count and CAF were independent determinants of the primary endpoint. Kaplan?Meier analysis showed that patients with both higher myocardial inflammation and greater fibrosis had the worst prognosis (log-rank p<0.001). When myocardial inflammation was graded as one of three degrees: T lymphocytes of <13/mm? (low); 13 of 13.1?23.9/mm? (moderate); and T lymphocytes of ?24?/mm? (high), patients with moderate inflammation exhibited a superior survival rate when CAF was ?5.9%, but a worse survival rate when CAF was >5.9%.<br>
Conclusions Having both biopsy-proven higher myocardial inflammation and greater fibrosis predicted the worst clinical prognosis in patients with DCM.
en-copyright=
kn-copyright=

en-aut-name=NakayamaTakafumi
en-aut-sei=Nakayama
en-aut-mei=Takafumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=OgoKeiko Ohta
en-aut-sei=Ogo
en-aut-mei=Keiko Ohta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=SuganoYasuo
en-aut-sei=Sugano
en-aut-mei=Yasuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YokokawaTetsuro
en-aut-sei=Yokokawa
en-aut-mei=Tetsuro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KanamoriHiromitsu
en-aut-sei=Kanamori
en-aut-mei=Hiromitsu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=IkedaYoshihiko
en-aut-sei=Ikeda
en-aut-mei=Yoshihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=HiroeMichiaki
en-aut-sei=Hiroe
en-aut-mei=Michiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=HatakeyamaKinta
en-aut-sei=Hatakeyama
en-aut-mei=Kinta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=Ishibashi-UedaHatsue
en-aut-sei=Ishibashi-Ueda
en-aut-mei=Hatsue
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=NakamuraKazufumi
en-aut-sei=Nakamura
en-aut-mei=Kazufumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=DohiKaoru
en-aut-sei=Dohi
en-aut-mei=Kaoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=AnzaiToshihisa
en-aut-sei=Anzai
en-aut-mei=Toshihisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=SeoYoshihiro
en-aut-sei=Seo
en-aut-mei=Yoshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=Imanaka-YoshidaKyoko
en-aut-sei=Imanaka-Yoshida
en-aut-mei=Kyoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

affil-num=1
en-affil=Department of Cardiology, Nagoya City University Graduate School of Medical Sciences
kn-affil=

affil-num=2
en-affil=Department of Pathology, National Cerebral and Cardiovascular Center
kn-affil=

affil-num=3
en-affil=Department of Cardiology, Keiyu Hospital
kn-affil=

affil-num=4
en-affil=Department of Cardiovascular Medicine, Fukushima Medical University
kn-affil=

affil-num=5
en-affil=Department of Cardiology, Gifu University Graduate School of Medicine
kn-affil=

affil-num=6
en-affil=Department of Pathology, National Cerebral and Cardiovascular Center
kn-affil=

affil-num=7
en-affil=Department of Cardiology, National Center for Global Health and Medicine
kn-affil=

affil-num=8
en-affil=Department of Pathology, National Cerebral and Cardiovascular Center
kn-affil=

affil-num=9
en-affil=Department of Pathology, National Cerebral and Cardiovascular Center
kn-affil=

affil-num=10
en-affil=Center for Advanced Heart Failure, Okayama University Hospital
kn-affil=

affil-num=11
en-affil=Department of Cardiology and Nephrology, Mie University Graduate School of Medicine
kn-affil=

affil-num=12
en-affil=Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine
kn-affil=

affil-num=13
en-affil=Department of Cardiology, Nagoya City University Graduate School of Medical Sciences
kn-affil=

affil-num=14
en-affil=Department of Pathology and Matrix Biology, Mie University Graduate School of Medicine
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=13
cd-vols=
no-issue=2
article-no=
start-page=373
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250205
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=The Asia-Pacific Body Mass Index Classification and New-Onset Chronic Kidney Disease in Non-Diabetic Japanese Adults: A Community-Based Longitudinal Study from 1998 to 2023
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background/Objectives: Obesity is a risk factor for chronic kidney disease (CKD) in Asians. The Asia-Pacific body mass index (BMI) classification sets lower obesity cutoffs than the conventional BMI classification for all races, generally reflecting the lower BMIs in Asians. This longitudinal study evaluated the association between BMI, as classified by the Asia-Pacific BMI system, and CKD development in non-diabetic Asian adults. Methods: A population-based longitudinal study (1998?2023) was conducted in non-diabetic Japanese adults (hemoglobin A1c < 6.5%) in Zentsuji City (Kagawa Prefecture, Japan). The generalized gamma model was used to assess the relationship between time-varying BMI categories and CKD development, stratified by sex. CKD was defined as an estimated glomerular filtration rate of <60 mL/min/1.73 m2. BMI was calculated as weight (kg) divided by the square of height (m2) and categorized per the Asia-Pacific classification as overweight (23.0?24.9 kg/m2), obesity class I (25.0?29.9 kg/m2), and obesity class II (?30.0 kg/m2). Results: CKD developed in 34.2% of 3098 men and 34.8% of 4391 women. The mean follow-up times were 7.41 years for men and 8.25 years for women. During follow-up, the BMI distributions for men were 5.0% underweight, 43.3% normal weight, 25.6% overweight, 24.1% obesity class I, and 2.0% obesity class II; those for women were 7.7%, 50.5%, 20.5%, 18.3%, and 2.9%, respectively. Compared with normal weight, obesity class I was associated with a 6% (95% confidence interval [CI]: 2?10%) shorter time to CKD onset in men and 5% (95% CI: 2?7%) in women. In both sexes, obesity class II showed shorter survival times than normal weight by point estimates, although all 95% CIs crossed the null value. Conclusions: Obesity, as classified by the Asia-Pacific BMI system, shortened the time to CKD onset in non-diabetic Asians. The conventional BMI cutoff for obesity (?30.0 kg/m2) may be too high to identify CKD risk in this population. The findings of this study may be useful for public health professionals in designing interventions to prevent CKD.
en-copyright=
kn-copyright=

en-aut-name=OkawaYukari
en-aut-sei=Okawa
en-aut-mei=Yukari
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MitsuhashiToshiharu
en-aut-sei=Mitsuhashi
en-aut-mei=Toshiharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TsudaToshihide
en-aut-sei=Tsuda
en-aut-mei=Toshihide
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

affil-num=1
en-affil=Department of Public Health and Welfare, Zentsuji City Hall
kn-affil=

affil-num=2
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=body mass index
kn-keyword=body mass index
en-keyword=chronic kidney disease
kn-keyword=chronic kidney disease
en-keyword=East Asian
kn-keyword=East Asian
en-keyword=longitudinal studies
kn-keyword=longitudinal studies
en-keyword=risk factors
kn-keyword=risk factors
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250714
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Week 2 remission with vedolizumab as a predictor of long-term remission in patients with ulcerative colitis: a multicenter, retrospective, observational study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background/Aims Vedolizumab (VDZ), a gut-selective monoclonal antibody for ulcerative colitis (UC) treatment, has no established biomarkers or clinical features that predict long-term remission. Week 2 remission, a potential predictor of long-term remission, could inform maintenance treatment strategy.<br>
Methods This retrospective, observational chart review included patients with UC in Japan who initiated VDZ between December 2018 and February 2020. Outcome measures included 14- and 54-week remission rates in patients with week 2 and non-week 2 remission (remission by week 14), 54-week remission rates in patients with week 14 remission and primary nonresponse, and predictive factors of week 2 and week 54 remission (logistic regression).<br>
Results Overall, 332 patients with UC (176 biologic-na?ve and 156 biologic-non-na?ve) were included. Significantly more biologic-na?ve than biologic-non-na?ve patients achieved week 2 remission (36.9% vs. 28.2%; odds ratio [OR], 1.43; 95% confidence interval [CI], 1.05?1.94; P=0.0224). Week 54 remission rates were significantly different between week 14 remission and primary nonresponse (both groups: P<0.0001), and between week 2 and non-week 2 remission (all patients: OR, 2.41; 95% CI, 1.30?4.48; P=0.0052; biologic-na?ve patients: OR, 2.40; 95% CI, 1.10?5.24; P=0.0280). Week 2 remission predictors were male sex, no anti-tumor necrosis factor alpha exposure, and normal/mild endoscopic findings. Week 54 remission was significantly associated with week 2 remission and no tacrolimus use.<br>
Conclusions Week 2 remission with VDZ is a predictor of week 54 remission in patients with UC. Week 2 may be used as an evaluation point for UC treatment decisions. (Japanese Registry of Clinical Trials: jRCT-1080225363)
en-copyright=
kn-copyright=

en-aut-name=KobayashiTaku
en-aut-sei=Kobayashi
en-aut-mei=Taku
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HisamatsuTadakazu
en-aut-sei=Hisamatsu
en-aut-mei=Tadakazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MotoyaSatoshi
en-aut-sei=Motoya
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=FujiiToshimitsu
en-aut-sei=Fujii
en-aut-mei=Toshimitsu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KunisakiReiko
en-aut-sei=Kunisaki
en-aut-mei=Reiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=ShibuyaTomoyoshi
en-aut-sei=Shibuya
en-aut-mei=Tomoyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MatsuuraMinoru
en-aut-sei=Matsuura
en-aut-mei=Minoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=TakeuchiKen
en-aut-sei=Takeuchi
en-aut-mei=Ken
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=HiraokaSakiko
en-aut-sei=Hiraoka
en-aut-mei=Sakiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=YasudaHiroshi
en-aut-sei=Yasuda
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=YokoyamaKaoru
en-aut-sei=Yokoyama
en-aut-mei=Kaoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=TakatsuNoritaka
en-aut-sei=Takatsu
en-aut-mei=Noritaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=MaemotoAtsuo
en-aut-sei=Maemoto
en-aut-mei=Atsuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=TaharaToshiyuki
en-aut-sei=Tahara
en-aut-mei=Toshiyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=TominagaKeiichi
en-aut-sei=Tominaga
en-aut-mei=Keiichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=ShimadaMasaaki
en-aut-sei=Shimada
en-aut-mei=Masaaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=KunoNobuaki
en-aut-sei=Kuno
en-aut-mei=Nobuaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=CavaliereMary
en-aut-sei=Cavaliere
en-aut-mei=Mary
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=IshiguroKaori
en-aut-sei=Ishiguro
en-aut-mei=Kaori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=FernandezJovelle L
en-aut-sei=Fernandez
en-aut-mei=Jovelle L
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=HibiToshifumi
en-aut-sei=Hibi
en-aut-mei=Toshifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

affil-num=1
en-affil=Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital
kn-affil=

affil-num=2
en-affil=Department of Gastroenterology and Hepatology, Kyorin University School of Medicine
kn-affil=

affil-num=3
en-affil=Inflammatory Bowel Disease Center, Sapporo-Kosei General Hospital
kn-affil=

affil-num=4
en-affil=Department of Gastroenterology and Hepatology, Institute of Science Tokyo
kn-affil=

affil-num=5
en-affil=Inflammatory Bowel Disease Center, Yokohama City University Medical Center
kn-affil=

affil-num=6
en-affil=Department of Gastroenterology, Juntendo University School of Medicine
kn-affil=

affil-num=7
en-affil=Department of Gastroenterology and Hepatology, Kyorin University School of Medicine
kn-affil=

affil-num=8
en-affil=Department of Gastroenterology and Hepatology, IBD Center, Tsujinaka Hospital Kashiwanoha
kn-affil=

affil-num=9
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=10
en-affil=Department of Gastroenterology, St. Marianna University School of Medicine
kn-affil=

affil-num=11
en-affil=Department of Gastroenterology, Kitasato University School of Medicine
kn-affil=

affil-num=12
en-affil=Inflammatory Bowel Disease Center, Fukuoka University Chikushi Hospital
kn-affil=

affil-num=13
en-affil=Inflammatory Bowel Disease Center, Sapporo Higashi Tokushukai Hospital
kn-affil=

affil-num=14
en-affil=Department of Gastroenterology, Saiseikai Utsunomiya Hospital
kn-affil=

affil-num=15
en-affil=Department of Gastroenterology, Dokkyo Medical University
kn-affil=

affil-num=16
en-affil=Department of Gastroenterology, NHO Nagoya Medical Center
kn-affil=

affil-num=17
en-affil=Department of Gastroenterology and Medicine, Fukuoka University Hospital
kn-affil=

affil-num=18
en-affil=Japan Medical Office, Takeda Pharmaceutical Company Limited
kn-affil=

affil-num=19
en-affil=Japan Medical Office, Takeda Pharmaceutical Company Limited
kn-affil=

affil-num=20
en-affil=Japan Medical Office, Takeda Pharmaceutical Company Limited
kn-affil=

affil-num=21
en-affil=Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital
kn-affil=
en-keyword=Colitis, ulcerative
kn-keyword=Colitis, ulcerative
en-keyword=Inflammatory bowel diseases
kn-keyword=Inflammatory bowel diseases
en-keyword=Japan
kn-keyword=Japan
en-keyword=Vedolizumab
kn-keyword=Vedolizumab
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250604
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=The duration of prior anti-tumor necrosis factor agents is associated with the effectiveness of vedolizumab in patients with ulcerative colitis: a real-world multicenter retrospective study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background/Aims Previous literature suggests that the response of patients with ulcerative colitis to vedolizumab may be affected by previous biologic therapy exposure. This real-world study evaluated vedolizumab treatment effectiveness in biologicnon-na?ve patients.<br>
Methods This was a multicenter, retrospective, observational chart review of records from 16 hospitals in Japan (December 1, 2018, to February 29, 2020). Included patients who had ulcerative colitis, were aged ? 20 years, and received at least 1 dose of vedolizumab. Outcomes included clinical remission rates from weeks 2 to 54 according to prior biologic exposure status and factors associated with clinical remission up to week 54.<br>
Results A total of 370 eligible patients were included. Clinical remission rates were significantly higher in biologic-na?ve (n=197) than in biologic-non-na?ve (n=173) patients for weeks 2 to 54 of vedolizumab treatment. Higher clinical remission rates up to week 54 were significantly associated with lower disease severity (partial Mayo score ? 4, P= 0.001; albumin ? 3.0, P= 0.019) and the duration of prior anti-tumor necrosis factor α (anti-TNFα) therapy (P= 0.026). Patients with anti-TNFα therapy durations of < 3 months, 3 to < 12 months, and ? 12 months had clinical remission rates of 28.1%, 32.7%, and 60.0%, respectively (P= 0.001 across groups).<br>
Conclusions The effectiveness of vedolizumab in biologic-non-na?ve patients was significantly influenced by duration of prior anti-TNFα therapy. (Japanese Registry of Clinical Trials: jRCT-1080225363)
en-copyright=
kn-copyright=

en-aut-name=KobayashiTaku
en-aut-sei=Kobayashi
en-aut-mei=Taku
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HisamatsuTadakazu
en-aut-sei=Hisamatsu
en-aut-mei=Tadakazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MotoyaSatoshi
en-aut-sei=Motoya
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MatsuuraMinoru
en-aut-sei=Matsuura
en-aut-mei=Minoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=FujiiToshimitsu
en-aut-sei=Fujii
en-aut-mei=Toshimitsu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KunisakiReiko
en-aut-sei=Kunisaki
en-aut-mei=Reiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=ShibuyaTomoyoshi
en-aut-sei=Shibuya
en-aut-mei=Tomoyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=TakeuchiKen
en-aut-sei=Takeuchi
en-aut-mei=Ken
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=HiraokaSakiko
en-aut-sei=Hiraoka
en-aut-mei=Sakiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=YasudaHiroshi
en-aut-sei=Yasuda
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=YokoyamaKaoru
en-aut-sei=Yokoyama
en-aut-mei=Kaoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=TakatsuNoritaka
en-aut-sei=Takatsu
en-aut-mei=Noritaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=MaemotoAtsuo
en-aut-sei=Maemoto
en-aut-mei=Atsuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=TaharaToshiyuki
en-aut-sei=Tahara
en-aut-mei=Toshiyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=TominagaKeiichi
en-aut-sei=Tominaga
en-aut-mei=Keiichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=ShimadaMasaaki
en-aut-sei=Shimada
en-aut-mei=Masaaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=KunoNobuaki
en-aut-sei=Kuno
en-aut-mei=Nobuaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=CavaliereMary
en-aut-sei=Cavaliere
en-aut-mei=Mary
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=IshiguroKaori
en-aut-sei=Ishiguro
en-aut-mei=Kaori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=FernandezJovelle L
en-aut-sei=Fernandez
en-aut-mei=Jovelle L
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=HibiToshifumi
en-aut-sei=Hibi
en-aut-mei=Toshifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

affil-num=1
en-affil=Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital
kn-affil=

affil-num=2
en-affil=Department of Gastroenterology and Hepatology, Kyorin University School of Medicine
kn-affil=

affil-num=3
en-affil=Inflammatory Bowel Disease Center, Sapporo-Kosei General Hospital
kn-affil=

affil-num=4
en-affil=Department of Gastroenterology and Hepatology, Kyorin University School of Medicine
kn-affil=

affil-num=5
en-affil=Department of Gastroenterology and Hepatology, Institute of Science Tokyo
kn-affil=

affil-num=6
en-affil=Inflammatory Bowel Disease Center, Yokohama City University Medical Center
kn-affil=

affil-num=7
en-affil=Department of Gastroenterology, Juntendo University School of Medicine
kn-affil=

affil-num=8
en-affil=Department of Gastroenterology and Hepatology, IBD Center, Tsujinaka Hospital Kashiwanoha
kn-affil=

affil-num=9
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=10
en-affil=Department of Gastroenterology, St. Marianna University School of Medicine
kn-affil=

affil-num=11
en-affil=Department of Gastroenterology, Kitasato University School of Medicine
kn-affil=

affil-num=12
en-affil=Inflammatory Bowel Disease Center, Fukuoka University Chikushi Hospital
kn-affil=

affil-num=13
en-affil=Inflammatory Bowel Disease Center, Sapporo Higashi Tokushukai Hospital
kn-affil=

affil-num=14
en-affil=Department of Gastroenterology, Saiseikai Utsunomiya Hospital
kn-affil=

affil-num=15
en-affil=Department of Gastroenterology, Dokkyo Medical University
kn-affil=

affil-num=16
en-affil=Department of Gastroenterology, NHO Nagoya Medical Center
kn-affil=

affil-num=17
en-affil=Department of Gastroenterology and Medicine, Fukuoka University Hospital
kn-affil=

affil-num=18
en-affil=Japan Medical Office, Takeda Pharmaceutical Company Limited
kn-affil=

affil-num=19
en-affil=Japan Medical Office, Takeda Pharmaceutical Company Limited
kn-affil=

affil-num=20
en-affil=Japan Medical Office, Takeda Pharmaceutical Company Limited
kn-affil=

affil-num=21
en-affil=Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital
kn-affil=
en-keyword=Tumor necrosis factor-alpha
kn-keyword=Tumor necrosis factor-alpha
en-keyword=Real-world evidence
kn-keyword=Real-world evidence
en-keyword=Colitis
kn-keyword=Colitis
en-keyword=ulcerative
kn-keyword=ulcerative
en-keyword=Vedolizumab
kn-keyword=Vedolizumab
en-keyword=Sequencing
kn-keyword=Sequencing
END

start-ver=1.4
cd-journal=joma
no-vol=40
cd-vols=
no-issue=6
article-no=
start-page=1435
end-page=1445
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250515
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Real-World Effectiveness and Safety of Vedolizumab in Patients ??70 Versus <?70?Years With Ulcerative Colitis: Multicenter Retrospective Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background and Aim: Vedolizumab (VDZ) is often used in older patients with ulcerative colitis (UC) in clinical practice; however, real-world evidence is still limited, including in those with late-onset UC.<br>
Methods: This post hoc analysis of a multicenter, retrospective, observational chart review, enrolling 370 patients with UC receiving VDZ between December 2018 and February 2020, compared effectiveness and safety of VDZ among patients ??70 (n?=?40) versus <?70?years (n?=?330), and among patients ??70?years with and without late-onset UC (age at disease onset: ??70 [n?=?13] versus <?70?years [n?=?26]).<br>
Results: There were no differences between patients ??70 and <?70?years in clinical remission rates (week 6: 57.5% vs. 47.6%, p?=?0.9174; week 14: 62.5% vs. 54.8%, p?=?0.1317; week 54: 47.5% vs. 46.4%, p?=?0.8149), primary nonresponse (10.0% vs. 15.5%, p?=?0.6248), loss of response (12.5% vs. 9.4%, p?=?0.5675), or overall safety. Among patients ??70?years, the incidence of adverse drug reactions was numerically greater in those with concomitant corticosteroids than in those without. For older patients with and without late-onset UC, week 54 remission rates were 23.1% versus 57.7% (p?=?0.0544); surgery was reported in 3/13 versus 2/26 patients and hospitalization in 5/13 versus 6/26 patients. One death was reported in patients with late-onset UC.<br>
Conclusions: VDZ effectiveness and safety were similar in patients ??70 and <?70?years; VDZ may be a suitable treatment option for patients ??70?years with UC. Patients with late-onset UC tended to have more frequent surgery/hospitalization and lower effectiveness than those without, possibly necessitating greater caution when using VDZ.<br>
Trial Registration: Japanese Registry of Clinical Trials registration number: jRCT-1080225363
en-copyright=
kn-copyright=

en-aut-name=HisamatsuTadakazu
en-aut-sei=Hisamatsu
en-aut-mei=Tadakazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KobayashiTaku
en-aut-sei=Kobayashi
en-aut-mei=Taku
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MotoyaSatoshi
en-aut-sei=Motoya
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=FujiiToshimitsu
en-aut-sei=Fujii
en-aut-mei=Toshimitsu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KunisakiReiko
en-aut-sei=Kunisaki
en-aut-mei=Reiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=ShibuyaTomoyoshi
en-aut-sei=Shibuya
en-aut-mei=Tomoyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MatsuuraMinoru
en-aut-sei=Matsuura
en-aut-mei=Minoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=HiraokaSakiko
en-aut-sei=Hiraoka
en-aut-mei=Sakiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=TakeuchiKen
en-aut-sei=Takeuchi
en-aut-mei=Ken
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=YasudaHiroshi
en-aut-sei=Yasuda
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=YokoyamaKaoru
en-aut-sei=Yokoyama
en-aut-mei=Kaoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=TakatsuNoritaka
en-aut-sei=Takatsu
en-aut-mei=Noritaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=MaemotoAtsuo
en-aut-sei=Maemoto
en-aut-mei=Atsuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=TaharaToshiyuki
en-aut-sei=Tahara
en-aut-mei=Toshiyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=TominagaKeiichi
en-aut-sei=Tominaga
en-aut-mei=Keiichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=ShimadaMasaaki
en-aut-sei=Shimada
en-aut-mei=Masaaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=KunoNobuaki
en-aut-sei=Kuno
en-aut-mei=Nobuaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=FernandezJovelle?L.
en-aut-sei=Fernandez
en-aut-mei=Jovelle?L.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=HiroseLisa
en-aut-sei=Hirose
en-aut-mei=Lisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=IshiguroKaori
en-aut-sei=Ishiguro
en-aut-mei=Kaori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=CavaliereMary
en-aut-sei=Cavaliere
en-aut-mei=Mary
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=HibiToshifumi
en-aut-sei=Hibi
en-aut-mei=Toshifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

affil-num=1
en-affil=Department of Gastroenterology and Hepatology, Kyorin University School of Medicine
kn-affil=

affil-num=2
en-affil=Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital
kn-affil=

affil-num=3
en-affil=Inflammatory Bowel Disease Center, Sapporo-Kosei General Hospital
kn-affil=

affil-num=4
en-affil=Department of Gastroenterology and Hepatology, Institute of Science Tokyo
kn-affil=

affil-num=5
en-affil=Inflammatory Bowel Disease Center, Yokohama City University Medical Center
kn-affil=

affil-num=6
en-affil=Department of Gastroenterology, Juntendo University School of Medicine
kn-affil=

affil-num=7
en-affil=Department of Gastroenterology and Hepatology, Kyorin University School of Medicine
kn-affil=

affil-num=8
en-affil=
kn-affil=

affil-num=9
en-affil=Department of Gastroenterology and Hepatology, IBD Center, Tsujinaka Hospital Kashiwanoha
kn-affil=

affil-num=10
en-affil=Department of Gastroenterology, St. Marianna University School of Medicine
kn-affil=

affil-num=11
en-affil=Department of Gastroenterology, Kitasato University School of Medicine
kn-affil=

affil-num=12
en-affil=Inflammatory Bowel Disease Center, Fukuoka University Chikushi Hospital
kn-affil=

affil-num=13
en-affil=Inflammatory Bowel Disease Center, Sapporo Higashi Tokushukai Hospital
kn-affil=

affil-num=14
en-affil=Department of Gastroenterology, Saiseikai Utsunomiya Hospital
kn-affil=

affil-num=15
en-affil=Department of Gastroenterology, Dokkyo Medical University
kn-affil=

affil-num=16
en-affil=Department of Gastroenterology, NHO Nagoya Medical Center
kn-affil=

affil-num=17
en-affil=Department of Gastroenterology and Medicine, Fukuoka University Hospital
kn-affil=

affil-num=18
en-affil=Japan Medical Office, Takeda Pharmaceutical Company Limited
kn-affil=

affil-num=19
en-affil=Japan Medical Office, Takeda Pharmaceutical Company Limited
kn-affil=

affil-num=20
en-affil=Japan Medical Office, Takeda Pharmaceutical Company Limited
kn-affil=

affil-num=21
en-affil=Japan Medical Office, Takeda Pharmaceutical Company Limited
kn-affil=

affil-num=22
en-affil=Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital
kn-affil=
en-keyword=elderly
kn-keyword=elderly
en-keyword=inflammatory bowel diseases
kn-keyword=inflammatory bowel diseases
en-keyword=onset age
kn-keyword=onset age
en-keyword=vedolizumab
kn-keyword=vedolizumab
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250116
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Factors affecting 1-year persistence with vedolizumab for ulcerative colitis: a multicenter, retrospective real-world study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background/Aims The objectives of this real-world study were to determine 1-year persistence with vedolizumab in patients with ulcerative colitis and to evaluate factors contributing to loss of response.<br>
Methods In this multicenter, retrospective, observational chart review, patients with moderately to severely active ulcerative colitis who received ? 1 dose of vedolizumab in clinical practice at 16 tertiary hospitals in Japan (from December 2018 through February 2020) were enrolled.<br>
Results Persistence with vedolizumab was 64.5% (n = 370); the median follow-up time was 53.2 weeks. Discontinuation due to loss of response among initial clinical remitters was reported in 12.5% (35/281) of patients. Multivariate analysis showed that concomitant use of tacrolimus (odds ratio [OR], 2.76; 95% confidence interval [CI], 1.00?7.62; P= 0.050) and shorter disease duration (OR for median duration ? 7.8 years vs. < 7.8 years, 0.33; 95% CI, 0.13?0.82; P= 0.017) were associated with discontinuation due to loss of response. Loss of response was not associated with prior use of anti-tumor necrosis factor alpha therapy, age at the time of treatment, disease severity, or concomitant corticosteroids or immunomodulators. Of the 25 patients with disease duration < 1 year, 32.0% discontinued due to loss of response.<br>
Conclusions Persistence with vedolizumab was consistent with previous reports. Use of tacrolimus and shorter disease duration were the main predictors of decreased persistence.
en-copyright=
kn-copyright=

en-aut-name=KobayashiTaku
en-aut-sei=Kobayashi
en-aut-mei=Taku
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HisamatsuTadakazu
en-aut-sei=Hisamatsu
en-aut-mei=Tadakazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MotoyaSatoshi
en-aut-sei=Motoya
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=FujiiToshimitsu
en-aut-sei=Fujii
en-aut-mei=Toshimitsu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KunisakiReiko
en-aut-sei=Kunisaki
en-aut-mei=Reiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=ShibuyaTomoyoshi
en-aut-sei=Shibuya
en-aut-mei=Tomoyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MatsuuraMinoru
en-aut-sei=Matsuura
en-aut-mei=Minoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=TakeuchiKen
en-aut-sei=Takeuchi
en-aut-mei=Ken
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=HiraokaSakiko
en-aut-sei=Hiraoka
en-aut-mei=Sakiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=YasudaHiroshi
en-aut-sei=Yasuda
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=YokoyamaKaoru
en-aut-sei=Yokoyama
en-aut-mei=Kaoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=TakatsuNoritaka
en-aut-sei=Takatsu
en-aut-mei=Noritaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=MaemotoAtsuo
en-aut-sei=Maemoto
en-aut-mei=Atsuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=TaharaToshiyuki
en-aut-sei=Tahara
en-aut-mei=Toshiyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=TominagaKeiichi
en-aut-sei=Tominaga
en-aut-mei=Keiichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=ShimadaMasaaki
en-aut-sei=Shimada
en-aut-mei=Masaaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=KunoNobuaki
en-aut-sei=Kuno
en-aut-mei=Nobuaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=FernandezJovelle L.
en-aut-sei=Fernandez
en-aut-mei=Jovelle L.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=IshiguroKaori
en-aut-sei=Ishiguro
en-aut-mei=Kaori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=CavaliereMary
en-aut-sei=Cavaliere
en-aut-mei=Mary
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=DeguchiHisato
en-aut-sei=Deguchi
en-aut-mei=Hisato
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=HibiToshifumi
en-aut-sei=Hibi
en-aut-mei=Toshifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

affil-num=1
en-affil=Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital
kn-affil=

affil-num=2
en-affil=Department of Gastroenterology and Hepatology, Kyorin University School of Medicine
kn-affil=

affil-num=3
en-affil=Inflammatory Bowel Disease Center, Sapporo-Kosei General Hospital
kn-affil=

affil-num=4
en-affil=Department of Gastroenterology and Hepatology, Institute of Science Tokyo
kn-affil=

affil-num=5
en-affil=Inflammatory Bowel Disease Center, Yokohama City University Medical Center
kn-affil=

affil-num=6
en-affil=Department of Gastroenterology, Juntendo University School of Medicine
kn-affil=

affil-num=7
en-affil=Department of Gastroenterology and Hepatology, Kyorin University School of Medicine
kn-affil=

affil-num=8
en-affil=Department of Gastroenterology and Hepatology, IBD Center
kn-affil=

affil-num=9
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=10
en-affil=Department of Gastroenterology, St. Marianna University School of Medicine
kn-affil=

affil-num=11
en-affil=Department of Gastroenterology, Kitasato University School of Medicine
kn-affil=

affil-num=12
en-affil=Inflammatory Bowel Disease Center, Fukuoka University Chikushi Hospital
kn-affil=

affil-num=13
en-affil=Inflammatory Bowel Disease Center, Sapporo Higashi Tokushukai Hospital
kn-affil=

affil-num=14
en-affil=Department of Gastroenterology, Saiseikai Utsunomiya Hospital
kn-affil=

affil-num=15
en-affil=Department of Gastroenterology, Dokkyo Medical University
kn-affil=

affil-num=16
en-affil=Department of Gastroenterology, NHO Nagoya Medical Center
kn-affil=

affil-num=17
en-affil=Department of Gastroenterology and Medicine, Fukuoka University Hospital
kn-affil=

affil-num=18
en-affil=Japan Medical Office, Takeda Pharmaceutical Company Limited
kn-affil=

affil-num=19
en-affil=Japan Medical Office, Takeda Pharmaceutical Company Limited
kn-affil=

affil-num=20
en-affil=Japan Medical Office, Takeda Pharmaceutical Company Limited
kn-affil=

affil-num=21
en-affil=Japan Medical Office, Takeda Pharmaceutical Company Limited
kn-affil=

affil-num=22
en-affil=Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital
kn-affil=
en-keyword=Colitis, ulcerative
kn-keyword=Colitis, ulcerative
en-keyword=Inflammatory bowel diseases
kn-keyword=Inflammatory bowel diseases
en-keyword=Japan
kn-keyword=Japan
en-keyword=Vedolizumab
kn-keyword=Vedolizumab
en-keyword=Medication persistence
kn-keyword=Medication persistence
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=4
article-no=
start-page=311
end-page=315
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202508
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Mimicking Contralateral Pneumothorax during Thoracoscopic Bullectomy Associated with Intraoperative Hyperinflation of a Large Bulla in an Obese Patient
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=A 55-year-old obese Japanese male with left pneumothorax presented to our hospital. Bilateral pulmonary emphysema was confirmed. Persistent air leakage was observed, and a thoracoscopic bullectomy was performed. Although the thoracoscopic bullectomy was completed uneventfully, pre-extubation chest X-ray imaging indicated hyper-lucency occupying the right upper part of the thoracic cavity, suggesting right-sided pneumothorax. CT imaging indicated a right-upper-lobe expanded bulla. Extubation was performed, and the hyperinflated bulla gradually deflated. Careful management of bulla expansion and respiratory status may be necessary for patients with obesity and large bullae, especially in one-lung ventilation cases.
en-copyright=
kn-copyright=

en-aut-name=MatsubaraKei
en-aut-sei=Matsubara
en-aut-mei=Kei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MatsubaraKei
en-aut-sei=Matsubara
en-aut-mei=Kei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HiranoYutaka
en-aut-sei=Hirano
en-aut-mei=Yutaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=FujiwaraToshiya
en-aut-sei=Fujiwara
en-aut-mei=Toshiya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

affil-num=1
en-affil=Department of Thoracic Surgery, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=2
en-affil=Department of Thoracic Surgery, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=3
en-affil=Department of Thoracic Surgery, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=4
en-affil=Department of Thoracic Surgery, Hiroshima City Hiroshima Citizens Hospital
kn-affil=
en-keyword=giant bulla
kn-keyword=giant bulla
en-keyword=pneumothorax
kn-keyword=pneumothorax
en-keyword=obesity
kn-keyword=obesity
en-keyword=positive pressure ventilation
kn-keyword=positive pressure ventilation
en-keyword=one lung ventilation
kn-keyword=one lung ventilation
END

start-ver=1.4
cd-journal=joma
no-vol=23
cd-vols=
no-issue=3
article-no=
start-page=79
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250703
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Association of the expression of 5?FU biomarkers with aging and prognosis in elderly patients with lung cancer treated with S?1 adjuvant chemotherapy: Follow?up results of the Setouchi Lung Cancer Group Study 1201
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Managing elderly patients presents several challenges because of age?related declines; however, age should not be the sole determinant for adjuvant treatment decisions in patients with non?small cell lung cancer (NSCLC). Moreover, age may affect the expression of 5?fluorouracil (5?FU) biomarkers. The present study assessed: i) The effect of age on the expression levels of 5?FU biomarkers by analyzing a public database; and ii) the ability of these biomarkers to predict clinical outcomes in elderly patients with NSCLC who underwent complete resection in the Setouchi Lung Cancer Group Study 1201 (SCLG1201) followed by S?1 adjuvant chemotherapy. Changes in gene expression levels across age groups were assessed by analyzing The Cancer Genome Atlas (TCGA) database. The expression of 5?FU biomarkers, including thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyltransferase, epidermal growth factor receptor (EGFR) and excision repair cross?complementation group 1 (ERCC1), were assessed via quantitative reverse?transcription PCR assays in 89 elderly patients (?75 years) with NSCLC who received adjuvant chemotherapy with oral fluoropyrimidine prodrug S?1 in the SLCG1201 trial. TCGA database analysis (n=955) showed that TS expression decreased significantly with aging, especially in the age group ?75. In the SCLG1201 trial, univariate analysis revealed that EGFR upregulation and TS downregulation were correlated with favorable recurrence?free survival (RFS) and overall survival (OS), respectively. Multivariate analysis demonstrated that pathological stage was an independent prognostic factor for both RFS and OS. EGFR mutations were associated with upregulation of DPD and EGFR, and downregulation of TS and ERCC1. In conclusion, although pathological stage is an independent prognostic factor for survival, EGFR upregulation and TS downregulation may be a greater predictor of clinical outcomes in elderly patients with NSCLC treated with S?1 adjuvant chemotherapy. The age?related decrease in TS expression supports the potential benefit of 5?FU therapies in elderly patients. Nonetheless, further research is warranted to validate these results.
en-copyright=
kn-copyright=

en-aut-name=SohJunichi
en-aut-sei=Soh
en-aut-mei=Junichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YamamotoHiromasa
en-aut-sei=Yamamoto
en-aut-mei=Hiromasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=OkumuraNorihito
en-aut-sei=Okumura
en-aut-mei=Norihito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SuzukiHiroyuki
en-aut-sei=Suzuki
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=NakataMasao
en-aut-sei=Nakata
en-aut-mei=Masao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=FujiwaraToshiya
en-aut-sei=Fujiwara
en-aut-mei=Toshiya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=GembaKenicehi
en-aut-sei=Gemba
en-aut-mei=Kenicehi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=SanoIsao
en-aut-sei=Sano
en-aut-mei=Isao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=FujinagaTakuji
en-aut-sei=Fujinaga
en-aut-mei=Takuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=KataokaMasafumi
en-aut-sei=Kataoka
en-aut-mei=Masafumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=TerasakiYasuhiro
en-aut-sei=Terasaki
en-aut-mei=Yasuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=FujimotoNobukazu
en-aut-sei=Fujimoto
en-aut-mei=Nobukazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=KataokaKazuhiko
en-aut-sei=Kataoka
en-aut-mei=Kazuhiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=KosakaShinji
en-aut-sei=Kosaka
en-aut-mei=Shinji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=YamashitaMotohiro
en-aut-sei=Yamashita
en-aut-mei=Motohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=InokawaHidetoshi
en-aut-sei=Inokawa
en-aut-mei=Hidetoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=InoueMasaaki
en-aut-sei=Inoue
en-aut-mei=Masaaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=NakamuraHiroshige
en-aut-sei=Nakamura
en-aut-mei=Hiroshige
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=YamashitaYoshinori
en-aut-sei=Yamashita
en-aut-mei=Yoshinori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=TakahashiYuta
en-aut-sei=Takahashi
en-aut-mei=Yuta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=TorigoeHidejiro
en-aut-sei=Torigoe
en-aut-mei=Hidejiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=SatoHiroki
en-aut-sei=Sato
en-aut-mei=Hiroki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=TomidaShuta
en-aut-sei=Tomida
en-aut-mei=Shuta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=HottaKatsuyuki
en-aut-sei=Hotta
en-aut-mei=Katsuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=YoshiokaHiroshige
en-aut-sei=Yoshioka
en-aut-mei=Hiroshige
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=MoritaSatoshi
en-aut-sei=Morita
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

en-aut-name=MatsuoKeitaro
en-aut-sei=Matsuo
en-aut-mei=Keitaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=27
ORCID=

en-aut-name=SakamotoJunichi
en-aut-sei=Sakamoto
en-aut-mei=Junichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=28
ORCID=

en-aut-name=DateHiroshi
en-aut-sei=Date
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=29
ORCID=

en-aut-name=ToyookaShinichi
en-aut-sei=Toyooka
en-aut-mei=Shinichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=30
ORCID=

affil-num=1
en-affil=Department of Thoracic Surgery, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Thoracic Surgery, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Thoracic Surgery, Kurashiki Central Hospital
kn-affil=

affil-num=4
en-affil=Department of Chest Surgery, Fukushima Medical University Hospital
kn-affil=

affil-num=5
en-affil=Department of General Thoracic Surgery, Kawasaki Medical School Hospital
kn-affil=

affil-num=6
en-affil=Department of Thoracic Surgery, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=7
en-affil=Department of Respiratory Medicine, Chugoku Central Hospital, Fukuyama, Hiroshima 720?0001, Japan; 8Department of Respiratory Surgery, Japanese Red Cross Nagasaki Genbaku Hospital
kn-affil=

affil-num=8
en-affil=Department of Respiratory Surgery, Japanese Red Cross Nagasaki Genbaku Hospital
kn-affil=

affil-num=9
en-affil=Department of General Thoracic Surgery, National Hospital Organization Nagara Medical Center
kn-affil=

affil-num=10
en-affil=Department of Surgery and Respiratory Center, Okayama Saiseikai General Hospital
kn-affil=

affil-num=11
en-affil=Department of Respiratory Surgery, Saga Medical Center Koseikan
kn-affil=

affil-num=12
en-affil=Department of Medical Oncology and Respiratory Medicine, Okayama Rosai Hospital
kn-affil=

affil-num=13
en-affil=Department of Thoracic Surgery, National Hospital Organization Iwakuni Clinical Center
kn-affil=

affil-num=14
en-affil=Department of Thoracic Surgery, Shimane Prefectural Central Hospital
kn-affil=

affil-num=15
en-affil=Department of Thoracic Surgery, National Hospital Organization Shikoku Cancer Center
kn-affil=

affil-num=16
en-affil=Department of Thoracic Surgery, National Hospital Organization Yamaguchi?Ube Medical Center
kn-affil=

affil-num=17
en-affil=Department of Thoracic Surgery, Shimonoseki City Hospital
kn-affil=

affil-num=18
en-affil=Division of General Thoracic Surgery, Tottori University Hospital
kn-affil=

affil-num=19
en-affil=Department of Thoracic Surgery, National Hospital Organization Kure Medical Center and Chugoku Cancer Center
kn-affil=

affil-num=20
en-affil=Department of Thoracic Surgery, Okayama University Hospital
kn-affil=

affil-num=21
en-affil=Department of Thoracic Surgery, Okayama University Hospital
kn-affil=

affil-num=22
en-affil=Department of Thoracic Surgery, Okayama University Hospital
kn-affil=

affil-num=23
en-affil=Center for Comprehensive Genomic Medicine, Okayama University Hospital
kn-affil=

affil-num=24
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=

affil-num=25
en-affil=Department of Thoracic Oncology, Kansai Medical University Hospital
kn-affil=

affil-num=26
en-affil=Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine
kn-affil=

affil-num=27
en-affil=Division of Cancer Epidemiology and Prevention, Aichi Cancer Center Research Institute
kn-affil=

affil-num=28
en-affil=Tokai Central Hospital
kn-affil=

affil-num=29
en-affil=Department of Thoracic Surgery, Kyoto University Hospital
kn-affil=

affil-num=30
en-affil=Department of Thoracic Surgery, Okayama University Hospital
kn-affil=
en-keyword=non?small cell lung cancer
kn-keyword=non?small cell lung cancer
en-keyword=elderly patients
kn-keyword=elderly patients
en-keyword=adjuvant chemotherapy
kn-keyword=adjuvant chemotherapy
en-keyword=S?1
kn-keyword=S?1
en-keyword=EGFR
kn-keyword=EGFR
en-keyword=TP
kn-keyword=TP
en-keyword=TS
kn-keyword=TS
en-keyword=OPRT
kn-keyword=OPRT
en-keyword=ERCC1
kn-keyword=ERCC1
en-keyword=DPD
kn-keyword=DPD
END

start-ver=1.4
cd-journal=joma
no-vol=10
cd-vols=
no-issue=6
article-no=
start-page=e00110-25
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250519
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Mycobacterium tuberculosis bacillus induces pyroptosis in human lung fibroblasts
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=We previously reported that live, but not dead, virulent Mycobacterium tuberculosis (Mtb) H37Rv bacilli induce cell death in human lung fibroblast cell lines, MRC-5, MRC-9, and TIG-1. Here, using two distinct Mtb strains from two different lineages (HN878 lineage 2 and H37Rv lineage 4), we confirmed cell death at day 2 after infection with a device that measures cell growth/cytotoxicity in real time (Maestro-Z [AXION]). Mtb bacilli uptake by the fibroblast was confirmed with a transmission electron microscope on day 2. Expressions of inflammatory cytokines and interleukin (IL)?1β, IL-6, and IL-8 were observed when exposed to live, but not dead bacteria. The cell death of fibroblasts induced by both Mtb strains tested was prevented by caspase-1/4 and NLRP3 inflammasome inhibitors, but not by caspase-3 and caspase-9 inhibitors. Therefore, we classified the fibroblast cell death by Mtb infection as pyroptosis. To investigate the biological and pathological relevance of fibroblast cell death by Mtb infection, we performed dual RNA-Seq analysis on Mtb within fibroblasts and Mtb-infected fibroblasts at day 2. In Mtb bacilli tcrR, secE2, ahpD, and mazF8 genes were highly induced during infection. These genes play roles in survival in a hypoxic environment, production of a calcium-binding protein-inducing cytokine, and regulation of transcription in a toxin-antitoxin system. The gene expressions of IL-1β, IL-6, and IL-8, caspase-4, and NLRP3, but not of caspase-3 and caspase-9, were augmented in Mtb bacilli-infected fibroblasts. Taken together, our study suggests that Mtb bacilli attempt to survive in lung fibroblasts and that pyroptosis of the host fibroblasts activates the immune system against the infection.
en-copyright=
kn-copyright=

en-aut-name=TakiiTakemasa
en-aut-sei=Takii
en-aut-mei=Takemasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YamadaHiroyuki
en-aut-sei=Yamada
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MotozonoChihiro
en-aut-sei=Motozono
en-aut-mei=Chihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YamasakiSho
en-aut-sei=Yamasaki
en-aut-mei=Sho
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TorrellesJordi B.
en-aut-sei=Torrelles
en-aut-mei=Jordi B.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TurnerJoanne
en-aut-sei=Turner
en-aut-mei=Joanne
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KimishimaAoi
en-aut-sei=Kimishima
en-aut-mei=Aoi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=AsamiYukihiro
en-aut-sei=Asami
en-aut-mei=Yukihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=OharaNaoya
en-aut-sei=Ohara
en-aut-mei=Naoya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=HidaShigeaki
en-aut-sei=Hida
en-aut-mei=Shigeaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=HayashiHidetoshi
en-aut-sei=Hayashi
en-aut-mei=Hidetoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=OnozakiKikuo
en-aut-sei=Onozaki
en-aut-mei=Kikuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

affil-num=1
en-affil=Department of Mycobacterium Reference and Research, the Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association
kn-affil=

affil-num=2
en-affil=Department of Mycobacterium Reference and Research, the Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association
kn-affil=

affil-num=3
en-affil=Department of Molecular Immunology, Research Institute for Microbial Diseases, The University of Osaka
kn-affil=

affil-num=4
en-affil=Department of Molecular Immunology, Research Institute for Microbial Diseases, The University of Osaka
kn-affil=

affil-num=5
en-affil=Texas Biomedical Research Institute and International Center for the Advancement of Research & Education (I?CARE)
kn-affil=

affil-num=6
en-affil=Texas Biomedical Research Institute and International Center for the Advancement of Research & Education (I?CARE)
kn-affil=

affil-num=7
en-affil=Laboratory of Applied Microbial Chemistry, ?mura Satoshi Memorial Institute, Kitasato University
kn-affil=

affil-num=8
en-affil=Laboratory of Applied Microbial Chemistry, ?mura Satoshi Memorial Institute, Kitasato University
kn-affil=

affil-num=9
en-affil=Department of Oral Microbiology, Graduate School of Medicine, Density and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=10
en-affil=Department of Hygienic Chemistry, Graduate School of Pharmaceutical Sciences, Nagoya City University
kn-affil=

affil-num=11
en-affil=Department of Cell Signaling, Graduate School of Pharmaceutical Sciences, Nagoya City University
kn-affil=

affil-num=12
en-affil=Department of Hygienic Chemistry, Graduate School of Pharmaceutical Sciences, Nagoya City University
kn-affil=
en-keyword=Mycobacterium tuberculosis
kn-keyword=Mycobacterium tuberculosis
en-keyword=pyroptosis
kn-keyword=pyroptosis
en-keyword=caspase
kn-keyword=caspase
en-keyword=RNA-Seq
kn-keyword=RNA-Seq
en-keyword=cytokine
kn-keyword=cytokine
en-keyword=fibroblasts
kn-keyword=fibroblasts
END

start-ver=1.4
cd-journal=joma
no-vol=63
cd-vols=
no-issue=24
article-no=
start-page=3299
end-page=3306
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20241215
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A Preliminary Survey of Rheumatologists on the Management of Late-onset Rheumatoid Arthritis in Japan
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Objective We investigated the current perspectives regarding the management of late-onset rheumatoid arthritis (LORA) among rheumatologists in clinical practice.<br>
Methods This study was performed in October 2021, and included 65 rheumatologists certified by the Japan College of Rheumatology, who were administered questionnaires (including multiple choice and descriptive formulae) regarding the management of LORA. We aggregated and analyzed the responses.<br>
Results All 65 rheumatologists responded to the survey; 47 (72%) answered that >50% of newly diagnosed patients were aged ?65 years, 42 (65%) answered that achievement of remission or low disease activity was the treatment goal, and 40 (62%) considered patient safety to be the highest priority. Most rheumatologists are concerned about the management of conditions other than RA, such as comorbidities, financial constraints, and life circumstances that interfere with standard or recommended treatment implementation.<br>
Conclusion This preliminary survey highlighted various rheumatologists' perspectives regarding the management of LORA.
en-copyright=
kn-copyright=

en-aut-name=TakanashiSatoshi
en-aut-sei=Takanashi
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KanekoYuko
en-aut-sei=Kaneko
en-aut-mei=Yuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KawahitoYutaka
en-aut-sei=Kawahito
en-aut-mei=Yutaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KidaTakashi
en-aut-sei=Kida
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SugiharaTakahiko
en-aut-sei=Sugihara
en-aut-mei=Takahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KojimaToshihisa
en-aut-sei=Kojima
en-aut-mei=Toshihisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=HaradaRyozo
en-aut-sei=Harada
en-aut-mei=Ryozo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=IshitokuMichinori
en-aut-sei=Ishitoku
en-aut-mei=Michinori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=HirataShintaro
en-aut-sei=Hirata
en-aut-mei=Shintaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=HashimotoMotomu
en-aut-sei=Hashimoto
en-aut-mei=Motomu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=HidakaToshihiko
en-aut-sei=Hidaka
en-aut-mei=Toshihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=AbeAsami
en-aut-sei=Abe
en-aut-mei=Asami
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=IshikawaHajime
en-aut-sei=Ishikawa
en-aut-mei=Hajime
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=ItoHiromu
en-aut-sei=Ito
en-aut-mei=Hiromu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=KishimotoMitsumasa
en-aut-sei=Kishimoto
en-aut-mei=Mitsumasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=MatsuiKazuo
en-aut-sei=Matsui
en-aut-mei=Kazuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=MatsuiToshihiro
en-aut-sei=Matsui
en-aut-mei=Toshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=MatsushitaIsao
en-aut-sei=Matsushita
en-aut-mei=Isao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=OnishiAkira
en-aut-sei=Onishi
en-aut-mei=Akira
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=MorinobuAkio
en-aut-sei=Morinobu
en-aut-mei=Akio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=NishidaKeiichiro
en-aut-sei=Nishida
en-aut-mei=Keiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=AsaiShuji
en-aut-sei=Asai
en-aut-mei=Shuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=TanakaEiichi
en-aut-sei=Tanaka
en-aut-mei=Eiichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=HarigaiMasayoshi
en-aut-sei=Harigai
en-aut-mei=Masayoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=KojimaMasayo
en-aut-sei=Kojima
en-aut-mei=Masayo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

affil-num=1
en-affil=Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine
kn-affil=

affil-num=2
en-affil=Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine
kn-affil=

affil-num=3
en-affil=Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine
kn-affil=

affil-num=4
en-affil=Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine
kn-affil=

affil-num=5
en-affil=Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine
kn-affil=

affil-num=6
en-affil=National Hospital Organization Nagoya Medical Center, Orthopaedic Surgery and Rheumatology
kn-affil=

affil-num=7
en-affil=Department of Orthopaedic Surgery, Kurashiki Sweet Hospital
kn-affil=

affil-num=8
en-affil=Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital
kn-affil=

affil-num=9
en-affil=Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital
kn-affil=

affil-num=10
en-affil=Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine
kn-affil=

affil-num=11
en-affil=Miyazaki-Zenjinkai Hospital
kn-affil=

affil-num=12
en-affil=Department of Rheumatology, Niigata Rheumatic Center
kn-affil=

affil-num=13
en-affil=Department of Rheumatology, Niigata Rheumatic Center
kn-affil=

affil-num=14
en-affil=Kurashiki Central Hospital
kn-affil=

affil-num=15
en-affil=Department of Nephrology and Rheumatology, Kyorin University School of Medicine
kn-affil=

affil-num=16
en-affil=Department of Rheumatology, Teine Keijinkai Hospital
kn-affil=

affil-num=17
en-affil=Department of Rheumatology Research, Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital
kn-affil=

affil-num=18
en-affil=Department of Rehabilitation Medicine, Kanazawa Medical University
kn-affil=

affil-num=19
en-affil=Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University
kn-affil=

affil-num=20
en-affil=Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University
kn-affil=

affil-num=21
en-affil=Department of Orthopaedic Surgery, Science of Functional Recovery and Reconstruction, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=22
en-affil=Department of Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine
kn-affil=

affil-num=23
en-affil=Division of Rheumatology, Department of Internal Medicine, Tokyo Women&apos;s Medical University School of Medicine
kn-affil=

affil-num=24
en-affil=Division of Rheumatology, Department of Internal Medicine, Tokyo Women&apos;s Medical University School of Medicine
kn-affil=

affil-num=25
en-affil=Department of Public Health, Nagoya City University Graduate School of Medical Sciences
kn-affil=
en-keyword=late-onset rheumatoid arthritis
kn-keyword=late-onset rheumatoid arthritis
en-keyword=ageing society
kn-keyword=ageing society
en-keyword=questionnaire
kn-keyword=questionnaire
END

start-ver=1.4
cd-journal=joma
no-vol=15
cd-vols=
no-issue=4
article-no=
start-page=2286
end-page=2299
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202411
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Effects of Palliative Surgical Treatment for Spinal Metastases on the Patient’s Quality of Life With a Focus on the Segment of the Metastasis: A Prospective Multicenter Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Study Design: Prospective multicenter study.<br>
Objectives: Palliative surgery is crucial for maintaining the quality of life (QOL) in patients with spinal metastases. This study aimed to compare the short-term outcomes of QOL after palliative surgery between patients with metastatic spinal tumors at different segments.<br>
Methods: We prospectively compared the data of 203 patients with spinal metastases at 2-3 consecutive segments who were divided into the following three groups: cervical, patients with cervical spine lesions; thoracic, patients with upper?middle thoracic spine lesions; and TL/L/S, patients with lesions at the thoracolumbar junction and lumbar and sacral regions. Preoperative and postoperative EuroQol 5-dimension (EQ5D) 5-level were compared.<br>
Results: All groups exhibited improvement in the Frankel grade, performance status, pain, Barthel index, EQ5D health state utility value (HSUV), and EQ5D visual analog scale (VAS) postoperatively. Although preoperative EQ5D HSUVs did not significantly differ between the groups (cervical, 0.461 ± 0.291; thoracic, 0.321 ± 0.292; and TL/L/S, 0.376 ± 0.272), the thoracic group exhibited significantly lower postoperative EQ5D HSUVs than the other two groups (cervical, 0.653 ± 0.233; thoracic, 0.513 ± 0.252; and TL/L/S, 0.624 ± 0.232). However, postoperative EQ5D VAS was not significantly different between the groups (cervical, 63.4 ± 25.8; thoracic, 54.7 ± 24.5; and TL/L/S, 61.7 ± 21.9).<br>
Conclusions: Palliative surgery for metastatic spinal tumors provided comparable QOL improvement, irrespective of the spinal segment involved. Patients with upper and middle thoracic spinal metastases had poorer QOL outcomes than those with metastases in other segments; however, sufficient QOL improvement was achieved.
en-copyright=
kn-copyright=

en-aut-name=SegiNaoki
en-aut-sei=Segi
en-aut-mei=Naoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NakashimaHiroaki
en-aut-sei=Nakashima
en-aut-mei=Hiroaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=ItoSadayuki
en-aut-sei=Ito
en-aut-mei=Sadayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=OuchidaJun
en-aut-sei=Ouchida
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=ShirataniYuki
en-aut-sei=Shiratani
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=ShimizuTakaki
en-aut-sei=Shimizu
en-aut-mei=Takaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=SuzukiAkinobu
en-aut-sei=Suzuki
en-aut-mei=Akinobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=TeraiHidetomi
en-aut-sei=Terai
en-aut-mei=Hidetomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=KakutaniKenichiro
en-aut-sei=Kakutani
en-aut-mei=Kenichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=KandaYutaro
en-aut-sei=Kanda
en-aut-mei=Yutaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=TominagaHiroyuki
en-aut-sei=Tominaga
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=KawamuraIchiro
en-aut-sei=Kawamura
en-aut-mei=Ichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=IshiharaMasayuki
en-aut-sei=Ishihara
en-aut-mei=Masayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=PakuMasaaki
en-aut-sei=Paku
en-aut-mei=Masaaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=TakahashiYohei
en-aut-sei=Takahashi
en-aut-mei=Yohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=FunabaMasahiro
en-aut-sei=Funaba
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=FunayamaToru
en-aut-sei=Funayama
en-aut-mei=Toru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=NakajimaHideaki
en-aut-sei=Nakajima
en-aut-mei=Hideaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=AkedaKoji
en-aut-sei=Akeda
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=HiraiTakashi
en-aut-sei=Hirai
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=InoueHirokazu
en-aut-sei=Inoue
en-aut-mei=Hirokazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=NakanishiKazuo
en-aut-sei=Nakanishi
en-aut-mei=Kazuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=FunaoHaruki
en-aut-sei=Funao
en-aut-mei=Haruki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=OshigiriTsutomu
en-aut-sei=Oshigiri
en-aut-mei=Tsutomu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=OtsukiBungo
en-aut-sei=Otsuki
en-aut-mei=Bungo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=KobayakawaKazu
en-aut-sei=Kobayakawa
en-aut-mei=Kazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

en-aut-name=TanishimaShinji
en-aut-sei=Tanishima
en-aut-mei=Shinji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=27
ORCID=

en-aut-name=HashimotoKo
en-aut-sei=Hashimoto
en-aut-mei=Ko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=28
ORCID=

en-aut-name=IimuraTakuya
en-aut-sei=Iimura
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=29
ORCID=

en-aut-name=SawadaHirokatsu
en-aut-sei=Sawada
en-aut-mei=Hirokatsu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=30
ORCID=

en-aut-name=UotaniKoji
en-aut-sei=Uotani
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=31
ORCID=

en-aut-name=ManabeHiroaki
en-aut-sei=Manabe
en-aut-mei=Hiroaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=32
ORCID=

en-aut-name=IwaiChizuo
en-aut-sei=Iwai
en-aut-mei=Chizuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=33
ORCID=

en-aut-name=YamabeDaisuke
en-aut-sei=Yamabe
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=34
ORCID=

en-aut-name=HiyamaAkihiko
en-aut-sei=Hiyama
en-aut-mei=Akihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=35
ORCID=

en-aut-name=SekiShoji
en-aut-sei=Seki
en-aut-mei=Shoji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=36
ORCID=

en-aut-name=GotoYuta
en-aut-sei=Goto
en-aut-mei=Yuta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=37
ORCID=

en-aut-name=MiyazakiMasashi
en-aut-sei=Miyazaki
en-aut-mei=Masashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=38
ORCID=

en-aut-name=WatanabeKazuyuki
en-aut-sei=Watanabe
en-aut-mei=Kazuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=39
ORCID=

en-aut-name=NakamaeToshio
en-aut-sei=Nakamae
en-aut-mei=Toshio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=40
ORCID=

en-aut-name=KaitoTakashi
en-aut-sei=Kaito
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=41
ORCID=

en-aut-name=NagoshiNarihito
en-aut-sei=Nagoshi
en-aut-mei=Narihito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=42
ORCID=

en-aut-name=KatoSatoshi
en-aut-sei=Kato
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=43
ORCID=

en-aut-name=WatanabeKota
en-aut-sei=Watanabe
en-aut-mei=Kota
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=44
ORCID=

en-aut-name=ImagamaShiro
en-aut-sei=Imagama
en-aut-mei=Shiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=45
ORCID=

en-aut-name=InoueGen
en-aut-sei=Inoue
en-aut-mei=Gen
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=46
ORCID=

en-aut-name=FuruyaTakeo
en-aut-sei=Furuya
en-aut-mei=Takeo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=47
ORCID=

affil-num=1
en-affil=Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine
kn-affil=

affil-num=2
en-affil=Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine
kn-affil=

affil-num=3
en-affil=Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine
kn-affil=

affil-num=4
en-affil=Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine
kn-affil=

affil-num=5
en-affil=Department of Orthopaedic Surgery, Chiba University Hospital
kn-affil=

affil-num=6
en-affil=Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University
kn-affil=

affil-num=7
en-affil=Department of Orthopaedic Surgery, Osaka Metropolitan University
kn-affil=

affil-num=8
en-affil=Department of Orthopaedic Surgery, Osaka Metropolitan University
kn-affil=

affil-num=9
en-affil=Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine
kn-affil=

affil-num=10
en-affil=Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine
kn-affil=

affil-num=11
en-affil=Department of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University
kn-affil=

affil-num=12
en-affil=Department of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University
kn-affil=

affil-num=13
en-affil=Department of Orthopaedic Surgery, Kansai Medial University Hospital
kn-affil=

affil-num=14
en-affil=Department of Orthopaedic Surgery, Kansai Medial University Hospital
kn-affil=

affil-num=15
en-affil=Department of Orthopaedic Surgery, Keio University
kn-affil=

affil-num=16
en-affil=Department of Orthopaedics Surgery, Yamaguchi University Graduate school of Medicine
kn-affil=

affil-num=17
en-affil=Department of Orthopaedic Surgery, Institute of Medicine, University of Tsukuba
kn-affil=

affil-num=18
en-affil=Department of Orthopaedics and Rehabilitation Medicine, University of Fukui Faculty of Medical Sciences
kn-affil=

affil-num=19
en-affil=Department of Orthopaedic Surgery, Mie University Graduate School of Medicine
kn-affil=

affil-num=20
en-affil=Department of Orthopedic Surgery, Tokyo Medical and Dental University
kn-affil=

affil-num=21
en-affil=Rehabilitation Center, Jichi Medical University Hospital
kn-affil=

affil-num=22
en-affil=Department of Orthopaedic Surgery, Kawasaki Medical School
kn-affil=

affil-num=23
en-affil=Department of Orthopaedic Surgery, International University of Health and Welfare Narita Hospital
kn-affil=

affil-num=24
en-affil=Department of Orthopaedic Surgery, Sapporo Medical University School of Medicine
kn-affil=

affil-num=25
en-affil=Department of Orthopaedic Surgery, Kyoto University Hospital
kn-affil=

affil-num=26
en-affil=Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University
kn-affil=

affil-num=27
en-affil=Division of Orthopedic Surgery, Department of Sensory and Motor Organs, School of Medicine, Faculty of Medicine, Tottori University
kn-affil=

affil-num=28
en-affil=Department of Orthopaedic Surgery, Tohoku University Graduate School of Medicine
kn-affil=

affil-num=29
en-affil=Department of Orthopaedic Surgery, Dokkyo Medical University
kn-affil=

affil-num=30
en-affil=Department of Orthopaedic Surgery, Nihon University School of Medicine
kn-affil=

affil-num=31
en-affil=Department of Orthopaedic Surgery, Okayama University Hospital
kn-affil=

affil-num=32
en-affil=Department of Orthopedics, Tokushima University
kn-affil=

affil-num=33
en-affil=Department of Orthopaedic Surgery, Gifu University Hospital
kn-affil=

affil-num=34
en-affil=Department of Orthopaedic Surgery, Iwate Medical University
kn-affil=

affil-num=35
en-affil=Department of Orthopaedic Surgery, Tokai University School of Medicine
kn-affil=

affil-num=36
en-affil=Department of Orthopaedic Surgery, University of Toyama
kn-affil=

affil-num=37
en-affil=Department of Orthopaedic Surgery, Nagoya City University
kn-affil=

affil-num=38
en-affil=Department of Orthopaedic Surgery, Faculty of Medicine, Oita University
kn-affil=

affil-num=39
en-affil=Department of Orthopaedic Surgery, Fukushima Medical University School of Medicine
kn-affil=

affil-num=40
en-affil=Department of Orthopaedic Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University
kn-affil=

affil-num=41
en-affil=Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine
kn-affil=

affil-num=42
en-affil=Department of Orthopaedic Surgery, Keio University
kn-affil=

affil-num=43
en-affil=Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University
kn-affil=

affil-num=44
en-affil=Department of Orthopaedic Surgery, Keio University
kn-affil=

affil-num=45
en-affil=Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine
kn-affil=

affil-num=46
en-affil=Department of Orthopaedic Surgery, Kitasato University School of Medicine
kn-affil=

affil-num=47
en-affil=Department of Orthopaedic Surgery, Chiba University Hospital
kn-affil=
en-keyword=spinal metastasis
kn-keyword=spinal metastasis
en-keyword=metastasis segment
kn-keyword=metastasis segment
en-keyword=palliative surgery
kn-keyword=palliative surgery
en-keyword=quality of life
kn-keyword=quality of life
en-keyword=activities of daily living
kn-keyword=activities of daily living
en-keyword=pain
kn-keyword=pain
en-keyword=anxiety
kn-keyword=anxiety
END

start-ver=1.4
cd-journal=joma
no-vol=27
cd-vols=
no-issue=2
article-no=
start-page=euaf024
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202502
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=SCN5A variant type-dependent risk prediction in Brugada syndrome
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Aims The variant in SCN5A with the loss of function (LOF) effect in the cardiac Na+ channel (Nav1.5) is the definitive cause for Brugada syndrome (BrS), and the functional analysis data revealed that LOF variants are associated with poor prognosis. However, which variant types (e.g. missense or non-missense) affect the prognoses of those variant carriers remain unelucidated.<br>
Methods and results We defined SCN5A LOF variants as all non-missense and missense variants that produce peak INa < 65% of wild-type previously confirmed by patch-clamp studies. The study population consisted of 76 Japanese BrS patients (74% patients were male and the median age [IQR] at diagnosis was 28 [14?45] years) with LOF type of SCN5A variants: 40 with missense and 36 with non-missense variants. Non-missense variant carriers presented significantly more severe cardiac conduction disorder compared to the missense variant carriers. During follow-up periods of 9.0 [5.0?14.0] years, compared to missense variants, non-missense variants were significant risk factors of lifetime lethal arrhythmia events (LAEs) (P = 0.023). When focusing only on the missense variants that produce no peak INa, these missense variant carriers exhibited the same clinical outcomes as those with non-missense (log-rank P = 0.325). After diagnosis, however, both variant types were comparable in risk of LAEs (P = 0.155).<br>
Conclusion We identified, for the first time, that SCN5A non-missense variants were associated with higher probability of LAE than missense variants in BrS patients though it did not change significantly after diagnosis.
en-copyright=
kn-copyright=

en-aut-name=AizawaTakanori
en-aut-sei=Aizawa
en-aut-mei=Takanori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MakiyamaTakeru
en-aut-sei=Makiyama
en-aut-mei=Takeru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HuangHai
en-aut-sei=Huang
en-aut-mei=Hai
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=ImamuraTomohiko
en-aut-sei=Imamura
en-aut-mei=Tomohiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=FukuyamaMegumi
en-aut-sei=Fukuyama
en-aut-mei=Megumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=SonodaKeiko
en-aut-sei=Sonoda
en-aut-mei=Keiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KatoKoichi
en-aut-sei=Kato
en-aut-mei=Koichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=HisamatsuTakashi
en-aut-sei=Hisamatsu
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=NakamuraYuko
en-aut-sei=Nakamura
en-aut-mei=Yuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=HoshinoKenji
en-aut-sei=Hoshino
en-aut-mei=Kenji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=OzawaJunichi
en-aut-sei=Ozawa
en-aut-mei=Junichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=SuzukiHiroshi
en-aut-sei=Suzuki
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=YasudaKazushi
en-aut-sei=Yasuda
en-aut-mei=Kazushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=AokiHisaaki
en-aut-sei=Aoki
en-aut-mei=Hisaaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=KuritaTakashi
en-aut-sei=Kurita
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=YoshidaYoko
en-aut-sei=Yoshida
en-aut-mei=Yoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=SuzukiTsugutoshi
en-aut-sei=Suzuki
en-aut-mei=Tsugutoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=NakamuraYoshihide
en-aut-sei=Nakamura
en-aut-mei=Yoshihide
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=OgawaYoshiharu
en-aut-sei=Ogawa
en-aut-mei=Yoshiharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=YamagamiShintaro
en-aut-sei=Yamagami
en-aut-mei=Shintaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=MoritaHiroshi
en-aut-sei=Morita
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=YuasaShinsuke
en-aut-sei=Yuasa
en-aut-mei=Shinsuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=FukudaMasakazu
en-aut-sei=Fukuda
en-aut-mei=Masakazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=OnoMakoto
en-aut-sei=Ono
en-aut-mei=Makoto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=KondoHidekazu
en-aut-sei=Kondo
en-aut-mei=Hidekazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=TakahashiNaohiko
en-aut-sei=Takahashi
en-aut-mei=Naohiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

en-aut-name=OhnoSeiko
en-aut-sei=Ohno
en-aut-mei=Seiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=27
ORCID=

en-aut-name=NakagawaYoshihisa
en-aut-sei=Nakagawa
en-aut-mei=Yoshihisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=28
ORCID=

en-aut-name=OnoKoh
en-aut-sei=Ono
en-aut-mei=Koh
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=29
ORCID=

en-aut-name=HorieMinoru
en-aut-sei=Horie
en-aut-mei=Minoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=30
ORCID=

affil-num=1
en-affil=Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine
kn-affil=

affil-num=2
en-affil=Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine
kn-affil=

affil-num=3
en-affil=Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine , 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507 ,
kn-affil=

affil-num=4
en-affil=Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine
kn-affil=

affil-num=5
en-affil=Department of Cardiovascular Medicine, Shiga University of Medical Science
kn-affil=

affil-num=6
en-affil=Medical Genome Center, National Cerebral and Cardiovascular Center
kn-affil=

affil-num=7
en-affil=Department of Cardiovascular Medicine, Shiga University of Medical Science
kn-affil=

affil-num=8
en-affil=Department of Public Health, Dentistry and Pharmaceutical Science, Okayama University Graduate School of Medicine
kn-affil=

affil-num=9
en-affil=Department of Pediatrics, Tsuchiura Kyodo General Hospital
kn-affil=

affil-num=10
en-affil=Department of Cardiology, Saitama Children’s Medical Center
kn-affil=

affil-num=11
en-affil=Department of Pediatrics, Niigata University Graduate School of Medical and Dental Sciences
kn-affil=

affil-num=12
en-affil=Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital
kn-affil=

affil-num=13
en-affil=Department of Pediatric Cardiology, Aichi Children’s Health and Medical Center
kn-affil=

affil-num=14
en-affil=Department of Pediatric Cardiology, Osaka Women’s and Children’s Hospital
kn-affil=

affil-num=15
en-affil=Division of Cardiovascular Center, Kindai University School of Medicine
kn-affil=

affil-num=16
en-affil=Division of Pediatric Cardiology and Electrophysiology, Osaka City General Hospital
kn-affil=

affil-num=17
en-affil=Division of Pediatric Cardiology and Electrophysiology, Osaka City General Hospital
kn-affil=

affil-num=18
en-affil=Division of Pediatric Cardiology and Electrophysiology, Osaka City General Hospital
kn-affil=

affil-num=19
en-affil=Division of Cardiology, Hyogo Prefectural Kobe Children’s Hospital
kn-affil=

affil-num=20
en-affil=Department of Cardiology, Tenri Hospital
kn-affil=

affil-num=21
en-affil=Department of Cardiovascular Therapeutics, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=22
en-affil=Department of Cardiovascular Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=23
en-affil=Division of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine
kn-affil=

affil-num=24
en-affil=Division of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine
kn-affil=

affil-num=25
en-affil=Department of Cardiology and Clinical Examination, Faculty of Medicine, Oita University
kn-affil=

affil-num=26
en-affil=Department of Cardiology and Clinical Examination, Faculty of Medicine, Oita University
kn-affil=

affil-num=27
en-affil=Medical Genome Center, National Cerebral and Cardiovascular Center
kn-affil=

affil-num=28
en-affil=Department of Cardiovascular Medicine, Shiga University of Medical Science
kn-affil=

affil-num=29
en-affil=Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine
kn-affil=

affil-num=30
en-affil=Department of Cardiovascular Medicine, Shiga University of Medical Science
kn-affil=
en-keyword=Brugada syndrome
kn-keyword=Brugada syndrome
en-keyword=SCN5A
kn-keyword=SCN5A
en-keyword=Lethal arrhythmia event
kn-keyword=Lethal arrhythmia event
en-keyword=Variant type
kn-keyword=Variant type
en-keyword=Loss of function
kn-keyword=Loss of function
END

start-ver=1.4
cd-journal=joma
no-vol=37
cd-vols=
no-issue=2
article-no=
start-page=395
end-page=412.e6
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202502
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Maternal circadian rhythms during pregnancy dictate metabolic plasticity in offspring
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Tissue-level oscillation is achieved by tissue-intrinsic clocks along with network-dependent signals originating from distal organs and organismal behavior. Yet, it remains unexplored whether maternal circadian rhythms during pregnancy influence fetal rhythms and impact long-term susceptibility to dietary challenges in offspring. Here, we demonstrate that circadian disruption during pregnancy decreased placental and neonatal weight yet retained transcriptional and structural maturation. Intriguingly, diet-induced obesity was exacerbated in parallel with arrhythmic feeding behavior, hypothalamic leptin resistance, and hepatic circadian reprogramming in offspring of chronodisrupted mothers. In utero circadian desynchrony altered the phase-relationship between the mother and fetus and impacted placental efficiency. Temporal feeding restriction in offspring failed to fully prevent obesity, whereas the circadian alignment of caloric restriction with the onset of the active phase virtually ameliorated the phenotype. Thus, maternal circadian rhythms during pregnancy confer adaptive properties to metabolic functions in offspring and provide insights into the developmental origins of health and disease.
en-copyright=
kn-copyright=

en-aut-name=YaoNa
en-aut-sei=Yao
en-aut-mei=Na
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KinouchiKenichiro
en-aut-sei=Kinouchi
en-aut-mei=Kenichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KatohManami
en-aut-sei=Katoh
en-aut-mei=Manami
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=AshtianiKousha Changizi
en-aut-sei=Ashtiani
en-aut-mei=Kousha Changizi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=AbdelkarimSherif
en-aut-sei=Abdelkarim
en-aut-mei=Sherif
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MorimotoHiroyuki
en-aut-sei=Morimoto
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TorimitsuTakuto
en-aut-sei=Torimitsu
en-aut-mei=Takuto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KozumaTakahide
en-aut-sei=Kozuma
en-aut-mei=Takahide
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=IwaharaAkihide
en-aut-sei=Iwahara
en-aut-mei=Akihide
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=KosugiShotaro
en-aut-sei=Kosugi
en-aut-mei=Shotaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=KomuroJin
en-aut-sei=Komuro
en-aut-mei=Jin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=KatoKyosuke
en-aut-sei=Kato
en-aut-mei=Kyosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=TonomuraShun
en-aut-sei=Tonomura
en-aut-mei=Shun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=NakamuraToshifumi
en-aut-sei=Nakamura
en-aut-mei=Toshifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=ItohArata
en-aut-sei=Itoh
en-aut-mei=Arata
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=YamaguchiShintaro
en-aut-sei=Yamaguchi
en-aut-mei=Shintaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=YoshinoJun
en-aut-sei=Yoshino
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=IrieJunichiro
en-aut-sei=Irie
en-aut-mei=Junichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=HashimotoHisayuki
en-aut-sei=Hashimoto
en-aut-mei=Hisayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=YuasaShinsuke
en-aut-sei=Yuasa
en-aut-mei=Shinsuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=SatohAkiko
en-aut-sei=Satoh
en-aut-mei=Akiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=MikamiYohei
en-aut-sei=Mikami
en-aut-mei=Yohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=UchidaShusaku
en-aut-sei=Uchida
en-aut-mei=Shusaku
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=UekiTakatoshi
en-aut-sei=Ueki
en-aut-mei=Takatoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=NomuraSeitaro
en-aut-sei=Nomura
en-aut-mei=Seitaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=BaldiPierre
en-aut-sei=Baldi
en-aut-mei=Pierre
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

en-aut-name=HayashiKaori
en-aut-sei=Hayashi
en-aut-mei=Kaori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=27
ORCID=

en-aut-name=ItohHiroshi
en-aut-sei=Itoh
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=28
ORCID=

affil-num=1
en-affil=Division of Endocrinology, Metabolism, and Nephrology, Department of Internal Medicine, Keio University School of Medicine
kn-affil=

affil-num=2
en-affil=Division of Endocrinology, Metabolism, and Nephrology, Department of Internal Medicine, Keio University School of Medicine
kn-affil=

affil-num=3
en-affil=Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo
kn-affil=

affil-num=4
en-affil=Department of Computer Science, University of California
kn-affil=

affil-num=5
en-affil=Department of Computer Science, University of California
kn-affil=

affil-num=6
en-affil=Department of Integrative Anatomy, Nagoya City University Graduate School of Medical Sciences
kn-affil=

affil-num=7
en-affil=Division of Endocrinology, Metabolism, and Nephrology, Department of Internal Medicine, Keio University School of Medicine
kn-affil=

affil-num=8
en-affil=Division of Endocrinology, Metabolism, and Nephrology, Department of Internal Medicine, Keio University School of Medicine
kn-affil=

affil-num=9
en-affil=Division of Endocrinology, Metabolism, and Nephrology, Department of Internal Medicine, Keio University School of Medicine
kn-affil=

affil-num=10
en-affil=Division of Endocrinology, Metabolism, and Nephrology, Department of Internal Medicine, Keio University School of Medicine
kn-affil=

affil-num=11
en-affil=Department of Cardiology, Keio University School of Medicine
kn-affil=

affil-num=12
en-affil=Division of Endocrinology, Metabolism, and Nephrology, Department of Internal Medicine, Keio University School of Medicine
kn-affil=

affil-num=13
en-affil=Division of Endocrinology, Metabolism, and Nephrology, Department of Internal Medicine, Keio University School of Medicine
kn-affil=

affil-num=14
en-affil=Division of Endocrinology, Metabolism, and Nephrology, Department of Internal Medicine, Keio University School of Medicine
kn-affil=

affil-num=15
en-affil=Division of Endocrinology, Metabolism, and Nephrology, Department of Internal Medicine, Keio University School of Medicine
kn-affil=

affil-num=16
en-affil=Division of Endocrinology, Metabolism, and Nephrology, Department of Internal Medicine, Keio University School of Medicine
kn-affil=

affil-num=17
en-affil=Division of Endocrinology, Metabolism, and Nephrology, Department of Internal Medicine, Keio University School of Medicine
kn-affil=

affil-num=18
en-affil=Division of Endocrinology, Metabolism, and Nephrology, Department of Internal Medicine, Keio University School of Medicine
kn-affil=

affil-num=19
en-affil=Department of Cardiology, Keio University School of Medicine
kn-affil=

affil-num=20
en-affil=Department of Cardiovascular Medicine, Academic Field, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=21
en-affil=Department of Integrative Physiology, Institute of Development, Aging and Cancer, Tohoku University
kn-affil=

affil-num=22
en-affil=Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine
kn-affil=

affil-num=23
en-affil=Department of Integrative Anatomy, Nagoya City University Graduate School of Medical Sciences
kn-affil=

affil-num=24
en-affil=Department of Integrative Anatomy, Nagoya City University Graduate School of Medical Sciences
kn-affil=

affil-num=25
en-affil=Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo
kn-affil=

affil-num=26
en-affil=Department of Computer Science, University of California
kn-affil=

affil-num=27
en-affil=Division of Endocrinology, Metabolism, and Nephrology, Department of Internal Medicine, Keio University School of Medicine
kn-affil=

affil-num=28
en-affil=Division of Endocrinology, Metabolism, and Nephrology, Department of Internal Medicine, Keio University School of Medicine
kn-affil=
en-keyword=circadian rhythm
kn-keyword=circadian rhythm
en-keyword=metabolism
kn-keyword=metabolism
en-keyword=circadian clock
kn-keyword=circadian clock
en-keyword=pregnancy
kn-keyword=pregnancy
en-keyword=developmental origins of health and disease
kn-keyword=developmental origins of health and disease
en-keyword=obesity
kn-keyword=obesity
en-keyword=leptin
kn-keyword=leptin
en-keyword=time-restricted feeding
kn-keyword=time-restricted feeding
en-keyword=caloric restriction
kn-keyword=caloric restriction
en-keyword=eating behavior
kn-keyword=eating behavior
END

start-ver=1.4
cd-journal=joma
no-vol=106
cd-vols=
no-issue=7
article-no=
start-page=002114
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250725
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Summary of taxonomy changes ratified by the International Committee on Taxonomy of Viruses from the Plant Viruses Subcommittee, 2025
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=In March 2025, following the annual International Committee on Taxonomy of Viruses (ICTV) ratification vote, newly proposed taxa were added to those under the mandate of the Plant Viruses Subcommittee. In brief, 1 new order, 3 new families, 6 new genera, 2 new subgenera and 206 new species were created. Some taxa were reorganized. Genus Cytorhabdovirus in the family Rhabdoviridae was abolished and its taxa were redistributed into three new genera Alphacytorhabdovirus, Betacytorhabdovirus and Gammacytorhabdovirus. Genus Waikavirus in the family Secoviridae was reorganized into two subgenera (Actinidivirus and Ritunrivirus). One family and four previously unaffiliated genera were moved to the newly established order Tombendovirales. Twelve species not assigned to a genus were abolished. To comply with the ICTV mandate of a binomial format for virus species, eight species were renamed. Demarcation criteria in the absence of biological information were defined in the genus Ilarvirus (family Bromoviridae). This article presents the updated taxonomy put forth by the Plant Viruses Subcommittee and ratified by the ICTV.
en-copyright=
kn-copyright=

en-aut-name=RubinoLuisa
en-aut-sei=Rubino
en-aut-mei=Luisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=AbrahamianPeter
en-aut-sei=Abrahamian
en-aut-mei=Peter
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=AnWenxia
en-aut-sei=An
en-aut-mei=Wenxia
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=ArandaMiguel A.
en-aut-sei=Aranda
en-aut-mei=Miguel A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=Ascencio-Iba?ezJos? T.
en-aut-sei=Ascencio-Iba?ez
en-aut-mei=Jos? T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=BejermanNicolas
en-aut-sei=Bejerman
en-aut-mei=Nicolas
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=BlouinArnaud G.
en-aut-sei=Blouin
en-aut-mei=Arnaud G.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=CandresseThierry
en-aut-sei=Candresse
en-aut-mei=Thierry
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=CantoTomas
en-aut-sei=Canto
en-aut-mei=Tomas
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=CaoMengji
en-aut-sei=Cao
en-aut-mei=Mengji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=CarrJohn P.
en-aut-sei=Carr
en-aut-mei=John P.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=ChoWon Kyong
en-aut-sei=Cho
en-aut-mei=Won Kyong
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=ConstableFiona
en-aut-sei=Constable
en-aut-mei=Fiona
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=DasguptaIndranil
en-aut-sei=Dasgupta
en-aut-mei=Indranil
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=DebatHumberto
en-aut-sei=Debat
en-aut-mei=Humberto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=DietzgenRalf G.
en-aut-sei=Dietzgen
en-aut-mei=Ralf G.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=DigiaroMichele
en-aut-sei=Digiaro
en-aut-mei=Michele
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=DonaireLivia
en-aut-sei=Donaire
en-aut-mei=Livia
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=ElbeainoToufic
en-aut-sei=Elbeaino
en-aut-mei=Toufic
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=FargetteDenis
en-aut-sei=Fargette
en-aut-mei=Denis
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=FilardoFiona
en-aut-sei=Filardo
en-aut-mei=Fiona
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=FischerMatthias G.
en-aut-sei=Fischer
en-aut-mei=Matthias G.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=FontdevilaNuria
en-aut-sei=Fontdevila
en-aut-mei=Nuria
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=FoxAdrian
en-aut-sei=Fox
en-aut-mei=Adrian
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=Freitas-AstuaJuliana
en-aut-sei=Freitas-Astua
en-aut-mei=Juliana
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=FuchsMarc
en-aut-sei=Fuchs
en-aut-mei=Marc
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

en-aut-name=GeeringAndrew D.W.
en-aut-sei=Geering
en-aut-mei=Andrew D.W.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=27
ORCID=

en-aut-name=GhafariMahan
en-aut-sei=Ghafari
en-aut-mei=Mahan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=28
ORCID=

en-aut-name=Hafr?nAnders
en-aut-sei=Hafr?n
en-aut-mei=Anders
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=29
ORCID=

en-aut-name=HammondJohn
en-aut-sei=Hammond
en-aut-mei=John
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=30
ORCID=

en-aut-name=HammondRosemarie
en-aut-sei=Hammond
en-aut-mei=Rosemarie
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=31
ORCID=

en-aut-name=Hasi?w-JaroszewskaBeata
en-aut-sei=Hasi?w-Jaroszewska
en-aut-mei=Beata
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=32
ORCID=

en-aut-name=HebrardEugenie
en-aut-sei=Hebrard
en-aut-mei=Eugenie
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=33
ORCID=

en-aut-name=Hern?ndezCarmen
en-aut-sei=Hern?ndez
en-aut-mei=Carmen
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=34
ORCID=

en-aut-name=HilyJean-Michel
en-aut-sei=Hily
en-aut-mei=Jean-Michel
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=35
ORCID=

en-aut-name=HosseiniAhmed
en-aut-sei=Hosseini
en-aut-mei=Ahmed
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=36
ORCID=

en-aut-name=HullRoger
en-aut-sei=Hull
en-aut-mei=Roger
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=37
ORCID=

en-aut-name=Inoue-NagataAlice K.
en-aut-sei=Inoue-Nagata
en-aut-mei=Alice K.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=38
ORCID=

en-aut-name=JordanRamon
en-aut-sei=Jordan
en-aut-mei=Ramon
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=39
ORCID=

en-aut-name=KondoHideki
en-aut-sei=Kondo
en-aut-mei=Hideki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=40
ORCID=

en-aut-name=KreuzeJan F.
en-aut-sei=Kreuze
en-aut-mei=Jan F.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=41
ORCID=

en-aut-name=KrupovicMart
en-aut-sei=Krupovic
en-aut-mei=Mart
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=42
ORCID=

en-aut-name=KubotaKenji
en-aut-sei=Kubota
en-aut-mei=Kenji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=43
ORCID=

en-aut-name=KuhnJens H.
en-aut-sei=Kuhn
en-aut-mei=Jens H.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=44
ORCID=

en-aut-name=LeisnerScott
en-aut-sei=Leisner
en-aut-mei=Scott
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=45
ORCID=

en-aut-name=LettJean-Michel
en-aut-sei=Lett
en-aut-mei=Jean-Michel
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=46
ORCID=

en-aut-name=LiChengyu
en-aut-sei=Li
en-aut-mei=Chengyu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=47
ORCID=

en-aut-name=LiFan
en-aut-sei=Li
en-aut-mei=Fan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=48
ORCID=

en-aut-name=LiJun Min
en-aut-sei=Li
en-aut-mei=Jun Min
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=49
ORCID=

en-aut-name=L?pez-LambertiniPaola M.
en-aut-sei=L?pez-Lambertini
en-aut-mei=Paola M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=50
ORCID=

en-aut-name=Lopez-MoyaJuan J.
en-aut-sei=Lopez-Moya
en-aut-mei=Juan J.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=51
ORCID=

en-aut-name=MaclotFrancois
en-aut-sei=Maclot
en-aut-mei=Francois
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=52
ORCID=

en-aut-name=M?kinenKristiina
en-aut-sei=M?kinen
en-aut-mei=Kristiina
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=53
ORCID=

en-aut-name=MartinDarren
en-aut-sei=Martin
en-aut-mei=Darren
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=54
ORCID=

en-aut-name=MassartSebastien
en-aut-sei=Massart
en-aut-mei=Sebastien
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=55
ORCID=

en-aut-name=MillerW. Allen
en-aut-sei=Miller
en-aut-mei=W. Allen
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=56
ORCID=

en-aut-name=MohammadiMusa
en-aut-sei=Mohammadi
en-aut-mei=Musa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=57
ORCID=

en-aut-name=MollovDimitre
en-aut-sei=Mollov
en-aut-mei=Dimitre
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=58
ORCID=

en-aut-name=MullerEmmanuelle
en-aut-sei=Muller
en-aut-mei=Emmanuelle
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=59
ORCID=

en-aut-name=NagataTatsuya
en-aut-sei=Nagata
en-aut-mei=Tatsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=60
ORCID=

en-aut-name=Navas-CastilloJes?s
en-aut-sei=Navas-Castillo
en-aut-mei=Jes?s
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=61
ORCID=

en-aut-name=NeriyaYutaro
en-aut-sei=Neriya
en-aut-mei=Yutaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=62
ORCID=

en-aut-name=Ochoa-CoronaFrancisco M.
en-aut-sei=Ochoa-Corona
en-aut-mei=Francisco M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=63
ORCID=

en-aut-name=OhshimaKazusato
en-aut-sei=Ohshima
en-aut-mei=Kazusato
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=64
ORCID=

en-aut-name=Pall?sVicente
en-aut-sei=Pall?s
en-aut-mei=Vicente
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=65
ORCID=

en-aut-name=PappuHanu
en-aut-sei=Pappu
en-aut-mei=Hanu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=66
ORCID=

en-aut-name=PetrzikKarel
en-aut-sei=Petrzik
en-aut-mei=Karel
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=67
ORCID=

en-aut-name=PoogginMikhail
en-aut-sei=Pooggin
en-aut-mei=Mikhail
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=68
ORCID=

en-aut-name=PrigigalloMaria Isabella
en-aut-sei=Prigigallo
en-aut-mei=Maria Isabella
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=69
ORCID=

en-aut-name=Ramos-Gonz?lezPedro L.
en-aut-sei=Ramos-Gonz?lez
en-aut-mei=Pedro L.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=70
ORCID=

en-aut-name=RibeiroSimone
en-aut-sei=Ribeiro
en-aut-mei=Simone
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=71
ORCID=

en-aut-name=Richert-P?ggelerKatja R.
en-aut-sei=Richert-P?ggeler
en-aut-mei=Katja R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=72
ORCID=

en-aut-name=RoumagnacPhilippe
en-aut-sei=Roumagnac
en-aut-mei=Philippe
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=73
ORCID=

en-aut-name=RoyAvijit
en-aut-sei=Roy
en-aut-mei=Avijit
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=74
ORCID=

en-aut-name=SabanadzovicSead
en-aut-sei=Sabanadzovic
en-aut-mei=Sead
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=75
ORCID=

en-aut-name=?af??ov?Dana
en-aut-sei=?af??ov?
en-aut-mei=Dana
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=76
ORCID=

en-aut-name=SaldarelliPasquale
en-aut-sei=Saldarelli
en-aut-mei=Pasquale
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=77
ORCID=

en-aut-name=Sanfa?onH?l?ne
en-aut-sei=Sanfa?on
en-aut-mei=H?l?ne
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=78
ORCID=

en-aut-name=SarmientoCecilia
en-aut-sei=Sarmiento
en-aut-mei=Cecilia
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=79
ORCID=

en-aut-name=SasayaTakahide
en-aut-sei=Sasaya
en-aut-mei=Takahide
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=80
ORCID=

en-aut-name=ScheetsKay
en-aut-sei=Scheets
en-aut-mei=Kay
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=81
ORCID=

en-aut-name=SchravesandeWillem E.W.
en-aut-sei=Schravesande
en-aut-mei=Willem E.W.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=82
ORCID=

en-aut-name=SealSusan
en-aut-sei=Seal
en-aut-mei=Susan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=83
ORCID=

en-aut-name=ShimomotoYoshifumi
en-aut-sei=Shimomoto
en-aut-mei=Yoshifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=84
ORCID=

en-aut-name=S?meraMerike
en-aut-sei=S?mera
en-aut-mei=Merike
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=85
ORCID=

en-aut-name=StavoloneLivia
en-aut-sei=Stavolone
en-aut-mei=Livia
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=86
ORCID=

en-aut-name=StewartLucy R.
en-aut-sei=Stewart
en-aut-mei=Lucy R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=87
ORCID=

en-aut-name=TeycheneyPierre-Yves
en-aut-sei=Teycheney
en-aut-mei=Pierre-Yves
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=88
ORCID=

en-aut-name=ThomasJohn E.
en-aut-sei=Thomas
en-aut-mei=John E.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=89
ORCID=

en-aut-name=ThompsonJeremy R.
en-aut-sei=Thompson
en-aut-mei=Jeremy R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=90
ORCID=

en-aut-name=TiberiniAntonio
en-aut-sei=Tiberini
en-aut-mei=Antonio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=91
ORCID=

en-aut-name=TomitakaYasuhiro
en-aut-sei=Tomitaka
en-aut-mei=Yasuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=92
ORCID=

en-aut-name=TzanetakisIoannis
en-aut-sei=Tzanetakis
en-aut-mei=Ioannis
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=93
ORCID=

en-aut-name=UmberMarie
en-aut-sei=Umber
en-aut-mei=Marie
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=94
ORCID=

en-aut-name=UrbinoCica
en-aut-sei=Urbino
en-aut-mei=Cica
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=95
ORCID=

en-aut-name=van den BurgHarrold A.
en-aut-sei=van den Burg
en-aut-mei=Harrold A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=96
ORCID=

en-aut-name=Van der VlugtRen? A.A.
en-aut-sei=Van der Vlugt
en-aut-mei=Ren? A.A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=97
ORCID=

en-aut-name=VarsaniArvind
en-aut-sei=Varsani
en-aut-mei=Arvind
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=98
ORCID=

en-aut-name=VerhageAdriaan
en-aut-sei=Verhage
en-aut-mei=Adriaan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=99
ORCID=

en-aut-name=VillamorDan
en-aut-sei=Villamor
en-aut-mei=Dan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=100
ORCID=

en-aut-name=von BargenSusanne
en-aut-sei=von Bargen
en-aut-mei=Susanne
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=101
ORCID=

en-aut-name=WalkerPeter J.
en-aut-sei=Walker
en-aut-mei=Peter J.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=102
ORCID=

en-aut-name=WetzelThierry
en-aut-sei=Wetzel
en-aut-mei=Thierry
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=103
ORCID=

en-aut-name=WhitfieldAnna E.
en-aut-sei=Whitfield
en-aut-mei=Anna E.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=104
ORCID=

en-aut-name=WylieStephen J.
en-aut-sei=Wylie
en-aut-mei=Stephen J.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=105
ORCID=

en-aut-name=YangCaixia
en-aut-sei=Yang
en-aut-mei=Caixia
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=106
ORCID=

en-aut-name=ZerbiniF. Murilo
en-aut-sei=Zerbini
en-aut-mei=F. Murilo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=107
ORCID=

en-aut-name=ZhangSong
en-aut-sei=Zhang
en-aut-mei=Song
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=108
ORCID=

affil-num=1
en-affil=Istituto per la Protezione Sostenibile delle Piante, CNR
kn-affil=

affil-num=2
en-affil=USDA-ARS, BARC, National Germplasm Resources Laboratory
kn-affil=

affil-num=3
en-affil=Liaoning Key Laboratory of Urban Integrated Pest Management and Ecological Security, Shenyang University
kn-affil=

affil-num=4
en-affil=Centro de Edafolog?a y Biolog?a Aplicada del Segura-CSIC
kn-affil=

affil-num=5
en-affil=Department of Molecular and Structural Biochemistry, North Carolina State University
kn-affil=

affil-num=6
en-affil=Unidad de Fitopatolog?a y Modelizaci?n Agr?cola (UFYMA) INTA-CONICET
kn-affil=

affil-num=7
en-affil=Plant Protection Department
kn-affil=

affil-num=8
en-affil=UMR 1332 Biologie du Fruit et Pathologie, University of Bordeaux, INRAE
kn-affil=

affil-num=9
en-affil=Margarita Salas Center for Biological Research (CIB-CSIC) Spanish Council for Scientific Research (CSIC)
kn-affil=

affil-num=10
en-affil=National Citrus Engineering and Technology Research Center, Integrative Science Center of Germplasm Creation in Western China (CHONGQING) Science City, Citrus Research Institute, Southwest University
kn-affil=

affil-num=11
en-affil=Department of Plant Sciences, University of Cambridge
kn-affil=

affil-num=12
en-affil=Agriculture and Life Sciences Research Institute, Kangwon National University
kn-affil=

affil-num=13
en-affil=Agriculture Victoria Research, Department of Energy, Environment and Climate Action and School of Applied Systems Biology, La Trobe University
kn-affil=

affil-num=14
en-affil=University of Delhi South Campu
kn-affil=

affil-num=15
en-affil=Unidad de Fitopatolog?a y Modelizaci?n Agr?cola (UFYMA) INTA-CONICET
kn-affil=

affil-num=16
en-affil=Queensland Alliance for Agriculture and Food Innovation, The University of Queensland
kn-affil=

affil-num=17
en-affil=CIHEAM, Istituto Agronomico Mediterraneo of Bari
kn-affil=

affil-num=18
en-affil=Centro de Edafolog?a y Biolog?a Aplicada del Segura-CSIC
kn-affil=

affil-num=19
en-affil=CIHEAM, Istituto Agronomico Mediterraneo of Bari
kn-affil=

affil-num=20
en-affil=Virus South Data
kn-affil=

affil-num=21
en-affil=Queensland Department of Primary Industries
kn-affil=

affil-num=22
en-affil=Max Planck Institute for Marine Microbiology
kn-affil=

affil-num=23
en-affil=Plant Protection Department
kn-affil=

affil-num=24
en-affil=Fera Science Ltd (Fera), York Biotech Campus
kn-affil=

affil-num=25
en-affil=Embrapa Cassava and Fruits, Brazilian Agricultural Research Corporation
kn-affil=

affil-num=26
en-affil=Plant Pathology, Cornell University
kn-affil=

affil-num=27
en-affil=Queensland Alliance for Agriculture and Food Innovation, The University of Queensland
kn-affil=

affil-num=28
en-affil=Department of Biology, University of Oxford
kn-affil=

affil-num=29
en-affil=Swedish University of Agriculture
kn-affil=

affil-num=30
en-affil=USDA-ARS, USNA, Floral and Nursery Plants Research Unit
kn-affil=

affil-num=31
en-affil=USDA-ARS, BARC, Molecular Plant Pathology Laboratory
kn-affil=

affil-num=32
en-affil=Institute of Plant Protection-NRI
kn-affil=

affil-num=33
en-affil=PHIM Plant Health Institute, University of Montpellier, INRAE, CIRAD, IRD, Institute Agro
kn-affil=

affil-num=34
en-affil=Instituto de Biolog?a Molecular y Celular de Plantas (IBMCP), Universitat Polit?cnica de Valencia-CSIC
kn-affil=

affil-num=35
en-affil=Institut Fran?ais de la Vigne et du Vin
kn-affil=

affil-num=36
en-affil=Vali-e-Asr University of Rafsanjan, Department of Plant Protection
kn-affil=

affil-num=37
en-affil=Retired from John Innes Centre
kn-affil=

affil-num=38
en-affil=Embrapa Hortali?as
kn-affil=

affil-num=39
en-affil=USDA-ARS, USNA, Floral and Nursery Plants Research Unit
kn-affil=

affil-num=40
en-affil=Institute of Plant Science and Resources, Okayama University
kn-affil=

affil-num=41
en-affil=International Potato Center (CIP)
kn-affil=

affil-num=42
en-affil=Institut Pasteur, Universit? Paris Cit?, CNRS UMR6047, Archaeal Virology Unit
kn-affil=

affil-num=43
en-affil=Institute for Plant Protection, NARO
kn-affil=

affil-num=44
en-affil=Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health
kn-affil=

affil-num=45
en-affil=Department of Biological Sciences, University of Toledo
kn-affil=

affil-num=46
en-affil=CIRAD, UMR PVBMT
kn-affil=

affil-num=47
en-affil=Liaoning Key Laboratory of Urban Integrated Pest Management and Ecological Security, Shenyang University
kn-affil=

affil-num=48
en-affil=State Key Laboratory for Conservation and Utilization of Bio-Resources in Yunnan, Yunnan Agricultural University
kn-affil=

affil-num=49
en-affil=Institute of Plant Virology, Ningbo University
kn-affil=

affil-num=50
en-affil=Instituto de Patolog?a Vegetal (IPAVE), INTA, Unidad de Fitopatolog?a y Modelizaci?n Agr?cola (UFYMA) INTA-CONICET
kn-affil=

affil-num=51
en-affil=Centre for Research in Agricultural Genomics, CRAG (CSIC-IRTA-UAB-UB)
kn-affil=

affil-num=52
en-affil=UMR 1332 Biologie du Fruit et Pathologie, University of Bordeaux, INRAE
kn-affil=

affil-num=53
en-affil=Department of Agricultural Sciences, University of Helsinki
kn-affil=

affil-num=54
en-affil=Institute of Infectious Disease and Molecular Medicine, University of Cape Town
kn-affil=

affil-num=55
en-affil=Plant Pathology Laboratory, TERRA Gembloux Agro-Bio Tech, University of Liege
kn-affil=

affil-num=56
en-affil=Department of Plant Pathology, Entomology and Microbiology, Iowa State University
kn-affil=

affil-num=57
en-affil=Department of Plant Protection, Gorgan University of Agricultural Sciences and Natural Resources
kn-affil=

affil-num=58
en-affil=USDA-APHIS, Plant Protection and Quarantine
kn-affil=

affil-num=59
en-affil=CIRAD, AGAP Institut; AGAP Institut, University of Montpellier; CIRAD, INRAE
kn-affil=

affil-num=60
en-affil=Instituto de Ci?ncias Biol?gicas, Universidade de Bras?lia
kn-affil=

affil-num=61
en-affil=Instituto de Hortofruticultura Subtropical y Mediterr?nea “La Mayora” (IHSM-UMA-CSIC), Consejo Superior de Investigaciones Cient?ficas
kn-affil=

affil-num=62
en-affil=Utsunomiya University
kn-affil=

affil-num=63
en-affil=Oklahoma State University, Institute for Biosecurity & Microbial Forensics
kn-affil=

affil-num=64
en-affil=Saga University
kn-affil=

affil-num=65
en-affil=Instituto de Biolog?a Molecular y Celular de Plantas (IBMCP), Universitat Polit?cnica de Valencia-CSIC
kn-affil=

affil-num=66
en-affil=Department of Plant Pathology, Washington State University
kn-affil=

affil-num=67
en-affil=Institute of Plant Molecular Biology
kn-affil=

affil-num=68
en-affil=PHIM Plant Health Institute, University of Montpellier, INRAE, CIRAD, IRD
kn-affil=

affil-num=69
en-affil=Istituto per la Protezione Sostenibile delle Piante, CNR
kn-affil=

affil-num=70
en-affil=Applied Molecular Biology Laboratory, Instituto Biol?gico de S?o Paulo
kn-affil=

affil-num=71
en-affil=Embrapa Recursos Gen?ticos e Biotecnologia
kn-affil=

affil-num=72
en-affil=Julius K?hn Institute, Federal Research Centre for Cultivated Plants, Institute for Epidemiology and Pathogen Diagnostics
kn-affil=

affil-num=73
en-affil=CIRAD, UMR PHIM
kn-affil=

affil-num=74
en-affil=USDA-ARS, BARC, Molecular Plant Pathology Laboratory, Beltsville, MD, USA
kn-affil=

affil-num=75
en-affil=Department of Agricultural Science and Plant Protection, Mississippi State University
kn-affil=

affil-num=76
en-affil=Department of Cell Biology and Genetics, Faculty of Science, Palack? University Olomouc
kn-affil=

affil-num=77
en-affil=Istituto per la Protezione Sostenibile delle Piante, CNR
kn-affil=

affil-num=78
en-affil=Summerland Research and Development Centre, Agriculture and Agri-Food Canada
kn-affil=

affil-num=79
en-affil=Department of Chemistry and Biotechnology, Tallinn University of Technology
kn-affil=

affil-num=80
en-affil=Strategic Planning Headquarters, NARO
kn-affil=

affil-num=81
en-affil=Department of Plant Pathology, Ecology and Evolution, Oklahoma State University
kn-affil=

affil-num=82
en-affil=Molecular Plant Pathology, University of Amsterdam
kn-affil=

affil-num=83
en-affil=Natural Resources Institute, University of Greenwich
kn-affil=

affil-num=84
en-affil=Kochi Agricultural Research Center
kn-affil=

affil-num=85
en-affil=Department of Chemistry and Biotechnology, Tallinn University of Technology
kn-affil=

affil-num=86
en-affil=Istituto per la Protezione Sostenibile delle Piante, CNR
kn-affil=

affil-num=87
en-affil=Currently unaffiliated
kn-affil=

affil-num=88
en-affil=CIRAD, UMR PVBMT & UMR PVBMT, Universit? de la R?union
kn-affil=

affil-num=89
en-affil=Queensland Alliance for Agriculture and Food Innovation, The University of Queensland
kn-affil=

affil-num=90
en-affil=Plant Health and Environment Laboratory
kn-affil=

affil-num=91
en-affil=Council for Agricultural Research and Economics, Research Centre for Plant Protection and Certification
kn-affil=

affil-num=92
en-affil=Institute for Plant Protection, NARO
kn-affil=

affil-num=93
en-affil=Department of Entomology and Plant Pathology, Division of Agriculture, University of Arkansas System
kn-affil=

affil-num=94
en-affil=INRAE, UR ASTRO
kn-affil=

affil-num=95
en-affil=PHIM Plant Health Institute, University of Montpellier, INRAE, CIRAD, IRD, Institute Agro
kn-affil=

affil-num=96
en-affil=Molecular Plant Pathology, University of Amsterdam
kn-affil=

affil-num=97
en-affil=Wageningen University and Research
kn-affil=

affil-num=98
en-affil=The Biodesign Center for Fundamental and Applied Microbiomics, Center for Evolution and Medicine, School of Life Sciences, Arizona State University
kn-affil=

affil-num=99
en-affil=Rijk Zwaan Breeding B.V.
kn-affil=

affil-num=100
en-affil=Department of Entomology and Plant Pathology, Division of Agriculture, University of Arkansas System
kn-affil=

affil-num=101
en-affil=Humboldt-Universit?t zu Berlin, Thaer-Institute of Agricultural and Horticultural Sciences
kn-affil=

affil-num=102
en-affil=The University of Queensland
kn-affil=

affil-num=103
en-affil=Dienstleistungszentrum L?ndlicher Raum Rheinpfalz
kn-affil=

affil-num=104
en-affil=North Carolina State University
kn-affil=

affil-num=105
en-affil=Food Futures Institute, Murdoch University
kn-affil=

affil-num=106
en-affil=Liaoning Key Laboratory of Urban Integrated Pest Management and Ecological Security, Shenyang University
kn-affil=

affil-num=107
en-affil=Dep. de Fitopatologia/BIOAGRO, Universidade Federal de Vi?osa
kn-affil=

affil-num=108
en-affil=National Citrus Engineering and Technology Research Center, Integrative Science Center of Germplasm Creation in Western China (CHONGQING) Science City, Citrus Research Institute, Southwest University
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=24
cd-vols=
no-issue=1
article-no=
start-page=551
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240827
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Body weight and eating attitudes influence improvement of depressive symptoms in children and pre-adolescents with eating disorders: a prospective multicenter cohort study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background Pediatric patients with eating disorders in a multicenter joint study on 11 facilities were enrolled and prospectively investigated to determine whether improvement in body weight, eating attitudes, and psychosocial factors in children with eating disorders would also improve depressive symptoms.<br>
Methods In this study, 91 patients were enrolled between April 2014 and March 2016. The severity of underweight was assessed using the body mass index-standard deviation score (BMI-SDS), eating behavior was assessed using the children's eating attitude test (ChEAT26), the outcome of childhood eating disorders was assessed using the childhood eating disorder outcome scale, and depressive symptoms were assessed using the Children's Depression Inventory (CDI) score.<br>
Results After 12 months of treatment, depressive symptoms were evaluated in 62 of the 91 cases where it was evaluated at the initial phase. There was no difference in background characteristics between the included patients and the 29 patients who dropped out. A paired-sample t-test revealed a significant decrease in CDI scores after 12 months of treatment (p?<?0.001, 95% CI: 2.401?7.373) and a significant increase in the BMI-SDS (p?<?0.001, 95% CI:???2.41973?1.45321). Multiple regression analysis revealed that BMI-SDS and ChEAT26 scores at the initial phase were beneficial in CDI recovery. In addition, BMI-SDS at the initial phase was useful for predicting BMI-SDS recovery after 12 months of treatment.<br>
Conclusions Depressive symptoms in children with eating disorders improved with therapeutic intervention on body weight and eating attitudes.<br>
Trial registration The Clinical Trial Number for this study is UMIN000055004.
en-copyright=
kn-copyright=

en-aut-name=SuzukiYuichi
en-aut-sei=Suzuki
en-aut-mei=Yuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NagamitsuShinichiro
en-aut-sei=Nagamitsu
en-aut-mei=Shinichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=EshimaNobuoki
en-aut-sei=Eshima
en-aut-mei=Nobuoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=InoueTakeshi
en-aut-sei=Inoue
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=OtaniRyoko
en-aut-sei=Otani
en-aut-mei=Ryoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=SakutaRyoichi
en-aut-sei=Sakuta
en-aut-mei=Ryoichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=IguchiToshiyuki
en-aut-sei=Iguchi
en-aut-mei=Toshiyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=IshiiRyuta
en-aut-sei=Ishii
en-aut-mei=Ryuta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=UchidaSoh
en-aut-sei=Uchida
en-aut-mei=Soh
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=OkadaAyumi
en-aut-sei=Okada
en-aut-mei=Ayumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=KitayamaShinji
en-aut-sei=Kitayama
en-aut-mei=Shinji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=KoyanagiKenshi
en-aut-sei=Koyanagi
en-aut-mei=Kenshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=SuzukiYuki
en-aut-sei=Suzuki
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=SumiYoshino
en-aut-sei=Sumi
en-aut-mei=Yoshino
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=TakamiyaShizuo
en-aut-sei=Takamiya
en-aut-mei=Shizuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=FujiiChikako
en-aut-sei=Fujii
en-aut-mei=Chikako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=FukaiYoshimitsu
en-aut-sei=Fukai
en-aut-mei=Yoshimitsu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

affil-num=1
en-affil=Department of Pediatrics, Fukushima Medical University School of Medicine
kn-affil=

affil-num=2
en-affil=Department of Pediatrics, Fukuoka University Faculty of Medicine
kn-affil=

affil-num=3
en-affil=Department of Pediatrics, Kurume University School of Medicine
kn-affil=

affil-num=4
en-affil=Child Development and Psychosomatic Medicine Center, Dokkyo Medical University Saitama Medical Center
kn-affil=

affil-num=5
en-affil=Child Development and Psychosomatic Medicine Center, Dokkyo Medical University Saitama Medical Center
kn-affil=

affil-num=6
en-affil=Child Development and Psychosomatic Medicine Center, Dokkyo Medical University Saitama Medical Center
kn-affil=

affil-num=7
en-affil=Department of Pediatrics, Hoshigaoka Maternity Hospital
kn-affil=

affil-num=8
en-affil=Department of Pediatrics and Child Health, Kurume University School of Medicine
kn-affil=

affil-num=9
en-affil=Karamun`S Forest Children`S Clinic
kn-affil=

affil-num=10
en-affil=Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=11
en-affil=Himeji City Center for the Disabled
kn-affil=

affil-num=12
en-affil=Nagasaki Prefectural Center of Medicine and Welfare for Children
kn-affil=

affil-num=13
en-affil=Department of Pediatrics, National Hospital Organization Mie National Hospital
kn-affil=

affil-num=14
en-affil=Mental and Developmental Clinic for Children “Elm Tree”
kn-affil=

affil-num=15
en-affil=Takamiya Psychiatry Clinic
kn-affil=

affil-num=16
en-affil=Department of Pediatrics/Child Psychosomatic Medicine, Okayama University Hospital
kn-affil=

affil-num=17
en-affil=Department of Pediatrics, St. Luke’s International Hospital
kn-affil=
en-keyword=Eating disorders
kn-keyword=Eating disorders
en-keyword=Anorexia nervosa
kn-keyword=Anorexia nervosa
en-keyword=Body mass index-standard deviation score
kn-keyword=Body mass index-standard deviation score
en-keyword=Eating attitudes
kn-keyword=Eating attitudes
en-keyword=Children’s depression inventory
kn-keyword=Children’s depression inventory
END

start-ver=1.4
cd-journal=joma
no-vol=7
cd-vols=
no-issue=1
article-no=
start-page=e000923
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250427
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Reversible cerebral vasoconstriction syndrome in idiopathic multicentric Castleman disease under treatment with tocilizumab
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background Idiopathic multicentric Castleman disease (iMCD) is a rare polyclonal lymphoproliferative disorder characterised by systemic inflammation resulting from overproduction of interleukin 6 (IL-6). While iMCD primarily affects the lymph nodes and related tissues, it can also rarely involve the central nervous system.<br>
Case presentation We report the case of a 58-year-old female patient with at least a 3-year history of iMCD, who experienced acute thunderclap headaches due to reversible cerebral vasoconstriction syndrome (RCVS). RCVS occurred 3?months after initiating treatment with tocilizumab, a humanised anti-IL-6 receptor monoclonal antibody, and was accompanied by focal cortical subarachnoid haemorrhage (SAH). Elevated IL-6 levels were found in both serum and cerebrospinal fluid. MR angiography revealed multiple diffuse stenotic lesions in the bilateral middle and posterior cerebral arteries, which, along with bilateral cerebral oedema, resolved within 3?months. The diffuse nature of the cerebral vasospasm and the presence of bilateral brain oedema suggested that cerebral vasospasm was due to RCVS rather than SAH.<br>
Conclusions In patients with Castleman disease, RCVS may occur due to IL-6-dependent chronic cerebral vascular inflammation, either as a primary condition or as a complication of tocilizumab treatment.
en-copyright=
kn-copyright=

en-aut-name=KamimuraNaoya
en-aut-sei=Kamimura
en-aut-mei=Naoya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=UedaNaohisa
en-aut-sei=Ueda
en-aut-mei=Naohisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KimuraKatsuo
en-aut-sei=Kimura
en-aut-mei=Katsuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NishikoriAsami
en-aut-sei=Nishikori
en-aut-mei=Asami
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SatoYasuharu
en-aut-sei=Sato
en-aut-mei=Yasuharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KishidaHitaru
en-aut-sei=Kishida
en-aut-mei=Hitaru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TanakaFumiaki
en-aut-sei=Tanaka
en-aut-mei=Fumiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Department of Neurology, Yokohama City University Medical Center
kn-affil=

affil-num=2
en-affil=Department of Neurology, Yokohama City University Medical Center
kn-affil=

affil-num=3
en-affil=Department of Neurology, Yokohama City University Medical Center
kn-affil=

affil-num=4
en-affil=
kn-affil=

affil-num=5
en-affil=
kn-affil=

affil-num=6
en-affil=Department of Neurology, Yokohama City University Medical Center
kn-affil=

affil-num=7
en-affil=Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=31
cd-vols=
no-issue=6
article-no=
start-page=388.e1
end-page=388.e14
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202506
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Clinical effects of granulocyte colony-stimulating factor administration and the timing of its initiation on allogeneic hematopoietic cell transplantation outcomes for myelodysplastic syndrome
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Granulocyte colony-stimulating factor (G-CSF) accelerates neutrophil recovery after allogeneic hematopoietic cell transplantation (HCT). However, the optimal use of G-CSF and the timing of its initiation after allogeneic HCT for myelodysplastic syndrome (MDS) according to graft type have not been determined. This retrospective study aimed to investigate the effects of using G-CSF administration and the timing of its initiation on transplant outcomes in adult patients with MDS undergoing allogeneic HCT. Using Japanese registry data, we retrospectively investigated the effects of G-CSF administration and the timing of its initiation on transplant outcomes among 4140 adults with MDS after bone marrow transplantation (BMT), peripheral blood stem cell transplantation (PBSCT), or single-unit cord blood transplantation (CBT) between 2013 and 2022. Multivariate analysis showed that early (days 0 to 4) and late (days 5 to 10) G-CSF administration significantly accelerated neutrophil recovery compared with no G-CSF administration following BMT, PBSCT, and CBT, but there was no benefit of early G-CSF initiation for early neutrophilic recovery regardless of graft type. Late G-CSF initiation was significantly associated with a higher risk of overall chronic GVHD following PBSCT (hazard ratio [HR], 1.63; 95% confidence interval [CI], 1.18 to 2.24; P = .002) and CBT (HR, 2.09; 95% CI, 1.21 to 3.60; P = .007) compared with no G-CSF administration. Late G-CSF initiation significantly improved OS compared with no G-CSF administration only following PBSCT (HR, 0.74; 95% CI, 0.58 to 0.94; P = .015). However, G-CSF administration and the timing of its initiation did not affect acute GVHD, relapse, or non-relapse mortality, irrespective of graft type. These results suggest that G-CSF administration significantly accelerated neutrophil recovery after BMT, PBSCT, and CBT, but increased risk of overall chronic GVHD after PBSCT and CBT. However, the effect of early and late G-CSF initiation on transplant outcomes needs further study in adult patients with MDS.

en-copyright=
kn-copyright=

en-aut-name=KonumaTakaaki
en-aut-sei=Konuma
en-aut-mei=Takaaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=FujiokaMachiko
en-aut-sei=Fujioka
en-aut-mei=Machiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=FuseKyoko
en-aut-sei=Fuse
en-aut-mei=Kyoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=HosoiHiroki
en-aut-sei=Hosoi
en-aut-mei=Hiroki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MasamotoYosuke
en-aut-sei=Masamoto
en-aut-mei=Yosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=DokiNoriko
en-aut-sei=Doki
en-aut-mei=Noriko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=UchidaNaoyuki
en-aut-sei=Uchida
en-aut-mei=Naoyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=TanakaMasatsugu
en-aut-sei=Tanaka
en-aut-mei=Masatsugu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=SawaMasashi
en-aut-sei=Sawa
en-aut-mei=Masashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=NishidaTetsuya
en-aut-sei=Nishida
en-aut-mei=Tetsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=IshikawaJun
en-aut-sei=Ishikawa
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=AsadaNoboru
en-aut-sei=Asada
en-aut-mei=Noboru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=NakamaeHirohisa
en-aut-sei=Nakamae
en-aut-mei=Hirohisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=HasegawaYuta
en-aut-sei=Hasegawa
en-aut-mei=Yuta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=OnizukaMakoto
en-aut-sei=Onizuka
en-aut-mei=Makoto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=MaedaTakeshi
en-aut-sei=Maeda
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=FukudaTakahiro
en-aut-sei=Fukuda
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=KawamuraKoji
en-aut-sei=Kawamura
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=KandaYoshinobu
en-aut-sei=Kanda
en-aut-mei=Yoshinobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=OhbikiMarie
en-aut-sei=Ohbiki
en-aut-mei=Marie
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=AtsutaYoshiko
en-aut-sei=Atsuta
en-aut-mei=Yoshiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=ItonagaHidehiro
en-aut-sei=Itonaga
en-aut-mei=Hidehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

affil-num=1
en-affil=Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo
kn-affil=

affil-num=2
en-affil=Department of Hematology, Sasebo City General Hospital
kn-affil=

affil-num=3
en-affil=Faculty of Medicine, Department of Hematology, Endocrinology and Metabolism, Niigata University
kn-affil=

affil-num=4
en-affil=Department of Hematology/Oncology, Wakayama Medical University
kn-affil=

affil-num=5
en-affil=Department of Cell Therapy and Transplantation Medicine, The University of Tokyo Hospital
kn-affil=

affil-num=6
en-affil=Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital
kn-affil=

affil-num=7
en-affil=Department of Hematology, Toranomon Hospital
kn-affil=

affil-num=8
en-affil=Department of Hematology, Kanagawa Cancer Center
kn-affil=

affil-num=9
en-affil=Department of Hematology and Oncology, Anjo Kosei Hospital
kn-affil=

affil-num=10
en-affil=Department of Hematology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital
kn-affil=

affil-num=11
en-affil=Department of Hematology, Osaka International Cancer Institute
kn-affil=

affil-num=12
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=13
en-affil=Department of Hematology, Osaka Metropolitan University Graduate School of Medicine
kn-affil=

affil-num=14
en-affil=Department of Hematology, Hokkaido University Hospital
kn-affil=

affil-num=15
en-affil=Department of Hematology and Oncology, Tokai University School of Medicine
kn-affil=

affil-num=16
en-affil=Department of Hematology and oncology, Kurashiki Central Hospital
kn-affil=

affil-num=17
en-affil=Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital
kn-affil=

affil-num=18
en-affil=Department of Hematology, Tottori University Hospital
kn-affil=

affil-num=19
en-affil=Division of Hematology, Jichi Medical University
kn-affil=

affil-num=20
en-affil=Japanese Data Center for Hematopoietic Cell Transplantation
kn-affil=

affil-num=21
en-affil=Japanese Data Center for Hematopoietic Cell Transplantation
kn-affil=

affil-num=22
en-affil=Transfusion and Cell Therapy Unit, Nagasaki University Hospital
kn-affil=
en-keyword=Granulocyte colony-stimulating factor
kn-keyword=Granulocyte colony-stimulating factor
en-keyword=Graft-versus-host disease
kn-keyword=Graft-versus-host disease
en-keyword=Bone marrow transplantation
kn-keyword=Bone marrow transplantation
en-keyword=Peripheral blood stem cell transplantation
kn-keyword=Peripheral blood stem cell transplantation
en-keyword=Cord blood transplantation
kn-keyword=Cord blood transplantation
en-keyword=Myelodysplastic syndrome
kn-keyword=Myelodysplastic syndrome
END

start-ver=1.4
cd-journal=joma
no-vol=7
cd-vols=
no-issue=1
article-no=
start-page=vdaf036
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250209
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Evaluating short-term survivors of glioblastoma: A proposal based on SEER registry data
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Glioblastomas (GBMs) are central nervous system tumors with a poor prognosis and limited treatment options. Although small subsets of GBM patients survive longer than 3 years, there is little evidence regarding the prognostic factors of GBM. Therefore, we conducted a thorough characterization of GBM in the United States.<br>
Methods: We queried the Surveillance, Epidemiology, and End Results database between 2000 and 2021 to extract age-adjusted incidence rates (AAIRs), age-adjusted mortality rates (AAMRs), and survival data for GBM. We compared trends in AAIR, AAMR, and survival time across age groups 0?14, 15?39, 40?69, and 70+ years. Also, we employed the Fine?Gray competing risk model among short-term survivors (STSs), defined as those with a survival time of 6 months or less, and long-term survivors (LTSs), defined as those with a survival time of 3 years or more.<br>
Results: This study included 60 615 incident GBM cases, 54 998 GBM-specific deaths, and 47 207 GBM patients with available survival time between 2000 and 2021. The mortality-to-incidence ratio was constant among STSs, whereas it increased with age among LTSs. Higher age and male sex were significantly associated with GBM-specific death among LTSs, whereas non-Hispanic White and less intensive treatments were associated with GBM-specific deaths among STSs. Interestingly, higher age was significantly associated with other causes of death among STSs.<br>
Conclusions: STSs partially consist of populations who died from causes other than GBM. It is important to include only GBM-specific deaths in STS groups to conduct reproducible research comparing STSs and LTSs.
en-copyright=
kn-copyright=

en-aut-name=TomitaYusuke
en-aut-sei=Tomita
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=OtaniYoshihiro
en-aut-sei=Otani
en-aut-mei=Yoshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=OmaeRyo
en-aut-sei=Omae
en-aut-mei=Ryo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MizutaRyo
en-aut-sei=Mizuta
en-aut-mei=Ryo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=IshidaJoji
en-aut-sei=Ishida
en-aut-mei=Joji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=HirotsuneNobuyuki
en-aut-sei=Hirotsune
en-aut-mei=Nobuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TanakaShota
en-aut-sei=Tanaka
en-aut-mei=Shota
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Department of Neurological Surgery, Okayama University Medical School
kn-affil=

affil-num=2
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Neurosurgery and Neuroendovascular Surgery, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=7
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=glioblastoma
kn-keyword=glioblastoma
en-keyword=long-term survivor
kn-keyword=long-term survivor
en-keyword=SEER
kn-keyword=SEER
en-keyword=short-term survivor
kn-keyword=short-term survivor
en-keyword=United States
kn-keyword=United States
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=3
article-no=
start-page=167
end-page=176
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202506
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Promising Effectiveness of Combined Chemotherapy and Immunotherapy in Patients with Advanced Non-small Cell Lung Cancer: A Real-World Prospective Observational Study (CS-Lung-003)
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=This prospective observational study investigated the clinical status of patients with advanced non-small cell lung cancer (NSCLC) treated with cytotoxic chemotherapy+an immune checkpoint inhibitor (chemo + IO) as first-line treatment in a real-world setting. The cases of 98 patients treated with chemo + IO were prospectively collected and analyzed for effectiveness and safety. The response rate to chemo + IO was 46.9%, and the disease control rate was 76.5%. The median progression-free survival and overall survival (OS) in the total population were 5.2 and 22.3 months, respectively. The patients positive for PD-L1 (? 1%) showed significantly longer OS than the negative group (<1%) (median 26.7 vs. 18.7 months, p=0.04). Pre-existing interstitial lung disease (ILD) was associated with shorter OS than the absence of ILD (median 9.0 vs. 22.6 months, p<0.01). Immunerelated adverse events (irAEs) were observed in 28 patients (28.6%). The most frequent irAE was ILD (n=11); Grade 1 (n=1 patient), G2 (n=5), G3 (n=4), and only a single patient with a G5 irAE. In this CS-Lung-003 study, first-line chemo + IO in a real-world setting showed good effectiveness, comparable to that observed in international clinical trials. In real-world practice, chemo + IO is a promising and steadfast strategy.
en-copyright=
kn-copyright=

en-aut-name=KanajiNobuhiro
en-aut-sei=Kanaji
en-aut-mei=Nobuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NishiiKazuya
en-aut-sei=Nishii
en-aut-mei=Kazuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TsubataYukari
en-aut-sei=Tsubata
en-aut-mei=Yukari
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NakaoMika
en-aut-sei=Nakao
en-aut-mei=Mika
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=OkunoTakae
en-aut-sei=Okuno
en-aut-mei=Takae
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=OkawaSachi
en-aut-sei=Okawa
en-aut-mei=Sachi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TakataKenji
en-aut-sei=Takata
en-aut-mei=Kenji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KodaniMasahiro
en-aut-sei=Kodani
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=YamasakiMasahiro
en-aut-sei=Yamasaki
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=FujitakaKazunori
en-aut-sei=Fujitaka
en-aut-mei=Kazunori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=KubotaTetsuya
en-aut-sei=Kubota
en-aut-mei=Tetsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=InoueMasaaki
en-aut-sei=Inoue
en-aut-mei=Masaaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=WatanabeNaoki
en-aut-sei=Watanabe
en-aut-mei=Naoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=HottaKatsuyuki
en-aut-sei=Hotta
en-aut-mei=Katsuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=CS-Lung-003 Investigator
en-aut-sei=CS-Lung-003 Investigator
en-aut-mei=
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

affil-num=1
en-affil=Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University
kn-affil=

affil-num=2
en-affil=Department of Respiratory Medicine, National Hospital Organization Iwakuni Clinical Center
kn-affil=

affil-num=3
en-affil=Department of Internal Medicine, Division of Medical Oncology and Respiratory Medicine, Shimane University Faculty of Medicine
kn-affil=

affil-num=4
en-affil=Department of Internal Medicine, Division of Medical Oncology and Respiratory Medicine, Shimane University Faculty of Medicine
kn-affil=

affil-num=5
en-affil=Department of Internal Medicine, Division of Medical Oncology and Respiratory Medicine, Shimane University Faculty of Medicine
kn-affil=

affil-num=6
en-affil=Department of Allergy and Respiratory Medicine, Okayama University Hospital
kn-affil=

affil-num=7
en-affil=Department of Allergy and Respiratory Medicine, Okayama University Hospital
kn-affil=

affil-num=8
en-affil=Division of Medical Oncology and Molecular Respirology, Faculty of Medicine, Tottori University
kn-affil=

affil-num=9
en-affil=Department of Respiratory Disease, Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital
kn-affil=

affil-num=10
en-affil=Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University
kn-affil=

affil-num=11
en-affil=Department of Respiratory Medicine and Allergology, Kochi University
kn-affil=

affil-num=12
en-affil=Department of Chest Surgery, Shimonoseki City Hospital
kn-affil=

affil-num=13
en-affil=Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University
kn-affil=

affil-num=14
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=

affil-num=15
en-affil=
kn-affil=
en-keyword=non-small cell lung cancer
kn-keyword=non-small cell lung cancer
en-keyword=real-world
kn-keyword=real-world
en-keyword=first-line
kn-keyword=first-line
en-keyword=immune checkpoint inhibitor
kn-keyword=immune checkpoint inhibitor
en-keyword=combined immunotherapy
kn-keyword=combined immunotherapy
END

start-ver=1.4
cd-journal=joma
no-vol=20
cd-vols=
no-issue=5
article-no=
start-page=1617
end-page=1618
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250312
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Iatrogenic fever of unknown origin
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=FukushimaShinnosuke
en-aut-sei=Fukushima
en-aut-mei=Shinnosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HagiyaHideharu
en-aut-sei=Hagiya
en-aut-mei=Hideharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YunokiKeiji
en-aut-sei=Yunoki
en-aut-mei=Keiji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KatoGentaro
en-aut-sei=Kato
en-aut-mei=Gentaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MukaiShinichi
en-aut-sei=Mukai
en-aut-mei=Shinichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

affil-num=1
en-affil=Department of General Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=

affil-num=2
en-affil=Department of Infectious Diseases, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Cardiovascular Surgery, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Cardiovascular Surgery, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of General Medicine, Okayama City Hospital
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=23
cd-vols=
no-issue=1
article-no=
start-page=36
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250416
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Anticoagulant effects of edoxaban in cancer and noncancer patients with venous thromboembolism
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background Edoxaban, a direct oral anticoagulant (DOAC), is a first-line treatment for venous thromboembolism (VTE) and the suppression of VTE recurrence. In patients with cancer, however, recurrent VTE after DOAC treatment may be more common than in noncancer patients. To evaluate our hypothesis that the anticoagulation effect of edoxaban is lower in VTE patients with cancer than in noncancer patients.<br>
Methods This study was a prospective, multicenter, observational study including patients treated with edoxaban for VTE in Japan. The primary outcome was the difference in the prothrombin time (PT), activated partial thromboplastin time (APTT), and D-dimer level at 5 h after initial edoxaban administration between the cancer and noncancer groups. An additional outcome was the longitudinal change in PT and APTT from 5 h to overnight after edoxaban administration. The incidence of adverse events was further investigated.<br>
Results PT and APTT at 5 h after initial edoxaban administration were not significantly different between the cancer (n = 84) and noncancer groups (n = 138) (e.g., log-transformed APTT 3.55 vs. 3.55, p = 0.45). However, D-dimer in the cancer groups was significantly greater than that in the noncancer groups (log-transformed 1.83 vs. 1.79, p = 0.009). PT and APTT significantly decreased from 5 h to overnight after edoxaban, but a similar pattern was observed in each group. All adverse events after edoxaban administration were also similar between patients with cancer and noncancer.<br>
Conclusion PT and APTT after edoxaban administration were similar between VTE patients with cancer and noncancer groups, suggesting that edoxaban has anticoagulation effects on cancer-associated VTE similar to those of noncancer patients.<br>
Trial registration UMIN000041973; Registration Date: 2020.10.5.
en-copyright=
kn-copyright=

en-aut-name=YoshidaMasashi
en-aut-sei=Yoshida
en-aut-mei=Masashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=EjiriKentaro
en-aut-sei=Ejiri
en-aut-mei=Kentaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MatsuoNaoaki
en-aut-sei=Matsuo
en-aut-mei=Naoaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NaitoTakanori
en-aut-sei=Naito
en-aut-mei=Takanori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KurodaKazuhiro
en-aut-sei=Kuroda
en-aut-mei=Kazuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TokiokaKoji
en-aut-sei=Tokioka
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=HatanakaKunihiko
en-aut-sei=Hatanaka
en-aut-mei=Kunihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=FujimotoRyohei
en-aut-sei=Fujimoto
en-aut-mei=Ryohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=YamaokaHidenaru
en-aut-sei=Yamaoka
en-aut-mei=Hidenaru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=KajikawaYutaka
en-aut-sei=Kajikawa
en-aut-mei=Yutaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=SurugaKazuki
en-aut-sei=Suruga
en-aut-mei=Kazuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=SugiyamaHiroki
en-aut-sei=Sugiyama
en-aut-mei=Hiroki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=MiyajiTsuyoshi
en-aut-sei=Miyaji
en-aut-mei=Tsuyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=MorimotoYoshimasa
en-aut-sei=Morimoto
en-aut-mei=Yoshimasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=OkamuraNobuhiro
en-aut-sei=Okamura
en-aut-mei=Nobuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=SarashinaToshihiro
en-aut-sei=Sarashina
en-aut-mei=Toshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=AkagiSatoshi
en-aut-sei=Akagi
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=MiyoshiToru
en-aut-sei=Miyoshi
en-aut-mei=Toru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=NakamuraKazufumi
en-aut-sei=Nakamura
en-aut-mei=Kazufumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=ItoHiroshi
en-aut-sei=Ito
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=YuasaShinsuke
en-aut-sei=Yuasa
en-aut-mei=Shinsuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

affil-num=1
en-affil=Department of Cardiovascular Medicine, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Cardiovascular Medicine, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of General Internal Medicine 3, Kawasaki Medical School
kn-affil=

affil-num=4
en-affil=Department of Cardiovascular Medicine, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Cardiovascular Medicine, Japanese Red Cross Okayama Hospital
kn-affil=

affil-num=6
en-affil=Department of Cardiovascular Medicine, Okayama City Hospital
kn-affil=

affil-num=7
en-affil=Department of Cardiovascular Medicine, Japanese Red Cross Society Himeji Hospital
kn-affil=

affil-num=8
en-affil=Department of Cardiovascular Medicine, Tsuyama Chuo Hospital
kn-affil=

affil-num=9
en-affil=Department of Cardiovascular Medicine, Okayama Rosai Hospital
kn-affil=

affil-num=10
en-affil=Department of Cardiovascular Medicine, NHO Fukuyama Medical Center
kn-affil=

affil-num=11
en-affil=Department of Cardiovascular Medicine, Okayama Medical Center
kn-affil=

affil-num=12
en-affil=Department of Cardiovascular Medicine, Okayama Saiseikai General Hospital
kn-affil=

affil-num=13
en-affil=Hosogi Hospital
kn-affil=

affil-num=14
en-affil=Department of Cardiovascular Medicine, Fukuyama City Hospital
kn-affil=

affil-num=15
en-affil=Okamura Isshindow Hospital
kn-affil=

affil-num=16
en-affil=Kuroda Clinic
kn-affil=

affil-num=17
en-affil=Department of Cardiovascular Medicine, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=18
en-affil=Department of Cardiovascular Medicine, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=19
en-affil=Department of Cardiovascular Medicine, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=20
en-affil=Department of General Internal Medicine 3, Kawasaki Medical School
kn-affil=

affil-num=21
en-affil=Department of Cardiovascular Medicine, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=Factor Xa inhibitors
kn-keyword=Factor Xa inhibitors
en-keyword=Anticoagulation effects
kn-keyword=Anticoagulation effects
en-keyword=Cancer
kn-keyword=Cancer
en-keyword=Venous thromboembolism
kn-keyword=Venous thromboembolism
END

start-ver=1.4
cd-journal=joma
no-vol=24
cd-vols=
no-issue=1
article-no=
start-page=116
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250416
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=ADAR1-high tumor-associated macrophages induce drug resistance and are therapeutic targets in colorectal cancer
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background Colorectal cancer (CRC) is considered the third most common type of cancer worldwide. Tumor-associated macrophages (TAMs) have been shown to promote drug resistance. Adenosine-to-inosine RNA-editing, as regulated by adenosine deaminase acting on RNA (ADAR), is a process that induces the posttranscriptional modification of critical oncogenes. The aim of this study is to determine whether the signals from cancer cells would induce RNA-editing in macrophages.<br>
Methods The effects of RNA-editing on phenotypes in macrophages were analyzed using clinical samples and in vitro and in vivo models.<br>
Results The intensity of the RNA-editing enzyme ADAR1 (Adenosine deaminase acting on RNA 1) in cancer and mononuclear cells indicated a strong positive correlation between the nucleus and cytoplasm. The ADAR1-positive mononuclear cells were positive for CD68 and CD163, a marker for M2 macrophages. Cancer cells transport pro-inflammatory cytokines or ADAR1 protein directly to macrophages via the exosomes, promoting RNA-editing in AZIN1 (Antizyme Inhibitor 1) and GLI1 (Glioma-Associated Oncogene Homolog 1) and resulting in M2 macrophage polarization. GLI1 RNA-editing in the macrophages induced by cancer cells promotes the secretion of SPP1, which is supplied to the cancer cells. This activates the NF kappa B pathway in cancer cells, promoting oxaliplatin resistance. When the JAK inhibitors were administered, oncogenic RNA-editing in the macrophages was suppressed. This altered the macrophage polarization from M2 to M1 and decreased oxaliplatin resistance in cancer cells.<br>
Conclusions This study revealed that ADAR1-high TAMs are crucial in regulating drug resistance in CRC and that targeting ADAR1 in TAMs could be a promising treatment approach for overcoming drug resistance in CRC.
en-copyright=
kn-copyright=

en-aut-name=UmedaHibiki
en-aut-sei=Umeda
en-aut-mei=Hibiki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ShigeyasuKunitoshi
en-aut-sei=Shigeyasu
en-aut-mei=Kunitoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TakahashiToshiaki
en-aut-sei=Takahashi
en-aut-mei=Toshiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MoriwakeKazuya
en-aut-sei=Moriwake
en-aut-mei=Kazuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KondoYoshitaka
en-aut-sei=Kondo
en-aut-mei=Yoshitaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=YoshidaKazuhiro
en-aut-sei=Yoshida
en-aut-mei=Kazuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TakedaSho
en-aut-sei=Takeda
en-aut-mei=Sho
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=YanoShuya
en-aut-sei=Yano
en-aut-mei=Shuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MatsumiYuki
en-aut-sei=Matsumi
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=KishimotoHiroyuki
en-aut-sei=Kishimoto
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=FujiTomokazu
en-aut-sei=Fuji
en-aut-mei=Tomokazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=YasuiKazuya
en-aut-sei=Yasui
en-aut-mei=Kazuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=YamamotoHideki
en-aut-sei=Yamamoto
en-aut-mei=Hideki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=TakagiKosei
en-aut-sei=Takagi
en-aut-mei=Kosei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=KayanoMasashi
en-aut-sei=Kayano
en-aut-mei=Masashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=MichiueHiroyuki
en-aut-sei=Michiue
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=NakamuraKeiichiro
en-aut-sei=Nakamura
en-aut-mei=Keiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=MoriYoshiko
en-aut-sei=Mori
en-aut-mei=Yoshiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=TeraishiFuminori
en-aut-sei=Teraishi
en-aut-mei=Fuminori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=TazawaHiroshi
en-aut-sei=Tazawa
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=UmedaYuzo
en-aut-sei=Umeda
en-aut-mei=Yuzo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=KagawaShunsuke
en-aut-sei=Kagawa
en-aut-mei=Shunsuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=GoelAjay
en-aut-sei=Goel
en-aut-mei=Ajay
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=FujiwaraToshiyoshi
en-aut-sei=Fujiwara
en-aut-mei=Toshiyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

affil-num=1
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=11
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=12
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=13
en-affil=Department of Clinical Genomic Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=14
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=15
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=16
en-affil=Neutron Therapy Research Center, Okayama University
kn-affil=

affil-num=17
en-affil=Department of Obstetrics and Gynecology, Okayama University Gradu?ate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=18
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=19
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=20
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=21
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=22
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=23
en-affil=Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute, City of Hope Comprehensive Cancer Center
kn-affil=

affil-num=24
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=
en-keyword=RNA-editing
kn-keyword=RNA-editing
en-keyword=Macrophage
kn-keyword=Macrophage
en-keyword=Chemoresistance
kn-keyword=Chemoresistance
en-keyword=Biomarker
kn-keyword=Biomarker
en-keyword=Colorectal cancer
kn-keyword=Colorectal cancer
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=2
article-no=
start-page=129
end-page=134
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202504
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A Case of Retinitis Pigmentosa Diagnosed with Severe Anterior Capsule Contraction after Cataract Surgery
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=A 66-year-old woman presented with significant anterior capsule contraction and intraocular lens dislocation in both eyes 4 months after cataract surgery. Postoperative examinations such as fluorescein angiography, Goldmann perimetry, and electroretinography revealed retinitis pigmentosa (RP). Patients with significant anterior capsule contraction after cataract surgery should be closely examined because RP may be a contributing factor.
en-copyright=
kn-copyright=

en-aut-name=TsujiAkihiro
en-aut-sei=Tsuji
en-aut-mei=Akihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ShiodeYusuke
en-aut-sei=Shiode
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KimuraShuhei
en-aut-sei=Kimura
en-aut-mei=Shuhei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=HosokawaMio
en-aut-sei=Hosokawa
en-aut-mei=Mio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MatobaRyo
en-aut-sei=Matoba
en-aut-mei=Ryo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MoritaTetsuro
en-aut-sei=Morita
en-aut-mei=Tetsuro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TakahashiKosuke
en-aut-sei=Takahashi
en-aut-mei=Kosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=MorizaneYuki
en-aut-sei=Morizane
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Fukuyama City Hospital, Fukuyama City
kn-affil=

affil-num=8
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=retinitis pigmentosa
kn-keyword=retinitis pigmentosa
en-keyword=intraocular lens
kn-keyword=intraocular lens
en-keyword=anterior capsule contraction
kn-keyword=anterior capsule contraction
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=2
article-no=
start-page=81
end-page=92
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202504
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Clinical Outcomes of Neoadjuvant Paclitaxel/Cisplatin/Gemcitabine Compared with Gemcitabine/Cisplatin for Muscle-Invasive Bladder Cancer
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=We retrospectively evaluated the oncologic outcomes of paclitaxel, cisplatin, and gemcitabine (PCG) with those of gemcitabine and cisplatin (GC) as neoadjuvant chemotherapy in muscle-invasive bladder cancer (MIBC) patients. The primary outcome was efficacy: pathological complete response (pCR), ypT0N0; and pathological objective response (pOR), ypT0N0, ? ypT1N0, or ypT0N1. Secondary outcomes included overall survival (OS), recurrence-free survival (RFS), predictive factors for pOR, OS, and RFS, and hematologic adverse events (AEs). Among 113 patients treated (PCG, n=28; GC, n=85), similar pOR and pCR rates were achieved by the groups (pOR: PCG, 57.1% vs. GC, 49. 4%; p=0.52; pCR: PCG, 39.3% vs. GC, 29.4%; p=0.36). No significant differences were observed in OS (p=1.0) or RFS (p=0.20). Multivariate logistic regression analysis showed that hydronephrosis (odds ratio [OR] 0.32, 95%CI: 0.11-0.92) and clinical node-positive status (cN+) (OR 0.22, 95%CI: 0.050-0.99) were significantly associated with a decreased probability of pOR. On multivariate Cox regression analyses, pOR achievement was associated with improved OS (hazard ratio [HR] 0.23, 95%CI: 0.10-0.56) and RFS (HR 0.30, 95%CI: 0.13-0.67). There were no significant between-group differences in the incidence of grade ? 3 hematologic AEs or dose-reduction required, but the PCG group had a higher incidence of grade 4 neutropenia.
en-copyright=
kn-copyright=

en-aut-name=KawadaTatsushi
en-aut-sei=Kawada
en-aut-mei=Tatsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KobayashiYasuyuki
en-aut-sei=Kobayashi
en-aut-mei=Yasuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TsugawaTakuji
en-aut-sei=Tsugawa
en-aut-mei=Takuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TsuboiKazuma
en-aut-sei=Tsuboi
en-aut-mei=Kazuma
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KatayamaSatoshi
en-aut-sei=Katayama
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=IwataTakehiro
en-aut-sei=Iwata
en-aut-mei=Takehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=BekkuKensuke
en-aut-sei=Bekku
en-aut-mei=Kensuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KobayashiTomoko
en-aut-sei=Kobayashi
en-aut-mei=Tomoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=EdamuraKohei
en-aut-sei=Edamura
en-aut-mei=Kohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=EbaraShin
en-aut-sei=Ebara
en-aut-mei=Shin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=ArakiMotoo
en-aut-sei=Araki
en-aut-mei=Motoo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

affil-num=1
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Urology, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=5
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Department of Urology, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=11
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=urothelial carcinoma
kn-keyword=urothelial carcinoma
en-keyword=paclitaxel
kn-keyword=paclitaxel
en-keyword=cisplatin
kn-keyword=cisplatin
en-keyword=gemcitabine
kn-keyword=gemcitabine
en-keyword=neoadjuvant
kn-keyword=neoadjuvant
END

start-ver=1.4
cd-journal=joma
no-vol=88
cd-vols=
no-issue=
article-no=
start-page=11
end-page=27
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=1991
dt-pub=19911115
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Variations of Residential Groups in Okayama City, Japan
kn-title=地方都市における町内会の類型 ――岡山市の事例――
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=NOBEMASAO
en-aut-sei=NOBE
en-aut-mei=MASAO
kn-aut-name=野邊政雄
kn-aut-sei=野邊
kn-aut-mei=政雄
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=98
cd-vols=
no-issue=
article-no=
start-page=55
end-page=69
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=1995
dt-pub=19950315
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=A Research  Note on Okayama City, Japan
kn-title=岡山市についての研究ノート
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=NOBEMASAO
en-aut-sei=NOBE
en-aut-mei=MASAO
kn-aut-name=野邊政雄
kn-aut-sei=野邊
kn-aut-mei=政雄
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=108
cd-vols=
no-issue=
article-no=
start-page=141
end-page=152
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=1998
dt-pub=19980715
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=A Research Note on Takahashi City, Japan
kn-title=高梁市についての研究ノート
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=NOBEMasao
en-aut-sei=NOBE
en-aut-mei=Masao
kn-aut-name=野邊政雄
kn-aut-sei=野邊
kn-aut-mei=政雄
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Department of Social Studies Education, Faculty of Education, Okayama University
kn-affil=岡山大学教育学部社会科教室
en-keyword=高梁市 (Takahashi City)
kn-keyword=高梁市 (Takahashi City)
en-keyword=人口動態 (Population Decrease and Migration of Population)
kn-keyword=人口動態 (Population Decrease and Migration of Population)
en-keyword=人口の空間構造 (Spatial Distribution of Population)
kn-keyword=人口の空間構造 (Spatial Distribution of Population)
en-keyword=就業者の構成 (Workforce Structure)
kn-keyword=就業者の構成 (Workforce Structure)
END

start-ver=1.4
cd-journal=joma
no-vol=112
cd-vols=
no-issue=
article-no=
start-page=57
end-page=78
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=1999
dt-pub=19991115
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Elderly Women's Personal Networks and Subjective Well-being in Takahashi City, Japan: Initial Findings
kn-title=「高梁市高齢女性のパーソナル・ネットワークと 主観的幸福感調査」の基礎分析
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=　筆者は，平成9年から平成10年にかけて高齢女性を対象に岡山県高梁市において集団加入やパーソナル・ネットワークに関する調査を実施した。本稿では，この調査の概要を説明し，単純集計表を提示した。そして，このデータを用いて，高梁市への流入過程，身体的健康，身体的活動能力，モラール，生活満足度，各種の集団への加入，町内会などがおこなう活動への参加，パーソナル・ネットワークについて検討をおこなった。さて，高梁市は都市部（＝市街地）と農村部からなりたっているが，都市部と農村部で暮らす高齢女性の違いについても考察した。
en-copyright=
kn-copyright=

en-aut-name=NOBEMasao
en-aut-sei=NOBE
en-aut-mei=Masao
kn-aut-name=野邊政雄
kn-aut-sei=野邊
kn-aut-mei=政雄
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Department of Social Studies Education, Faculty of Education, Okayama University
kn-affil=岡山大学教育学部社会科教育講座
en-keyword=高齢女性
kn-keyword=高齢女性
en-keyword=パーソナル・ネットワーク
kn-keyword=パーソナル・ネットワーク
en-keyword=主観的幸福感
kn-keyword=主観的幸福感
en-keyword=集団加入
kn-keyword=集団加入
END

start-ver=1.4
cd-journal=joma
no-vol=113
cd-vols=
no-issue=
article-no=
start-page=69
end-page=85
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2000
dt-pub=20000315
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=The Life Styles of Elderly Women in the Highlands of Takahashi City, Japan
kn-title=高梁市の高原部に住む高齢女性の暮らし
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=　本稿では，まず，過疎化と高齢化が岡山県高梁市を構成する各地区でどのくらい進行しているかを国勢調査のデータによって明らかにした。次に，箪者が1999年4月から5月にかけて高梁市で聞き取り調査をおこなったが，この調査によって収集した事例のうちから4つの事例を提示した。これを検討することによって，同市の高原部に住む高齢女性がどのような暮らしをしているかを明らかにした。
en-copyright=
kn-copyright=

en-aut-name=NOBEMasao
en-aut-sei=NOBE
en-aut-mei=Masao
kn-aut-name=野邊政雄
kn-aut-sei=野邊
kn-aut-mei=政雄
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Department of Social Studies Education, Faculty of Education, Okayama University
kn-affil=岡山大学教育学部社会科教育講座
en-keyword=高梁市
kn-keyword=高梁市
en-keyword=吉備高原
kn-keyword=吉備高原
en-keyword=高齢女性
kn-keyword=高齢女性
en-keyword=過疎化
kn-keyword=過疎化
en-keyword=高齢化
kn-keyword=高齢化
END

start-ver=1.4
cd-journal=joma
no-vol=114
cd-vols=
no-issue=
article-no=
start-page=47
end-page=57
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2000
dt-pub=20000717
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=The Life Styles of Solitary Elderly Women in the Highlands of Takahashi City, Japan
kn-title=高梁市の高原部に住む一人暮らしの高齢女性の生活
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=　筆者は2000年2月に高梁市の高原部に住む一人暮らしの高齢女性に聞き取り調査をおこなった。本稿では，収集した事例のうちから3つの事例を提示し，これを検討することによって，一人暮らしの高齢女性がどのような暮らしをしているかを明らかにした。
en-copyright=
kn-copyright=

en-aut-name=NOBEMasao
en-aut-sei=NOBE
en-aut-mei=Masao
kn-aut-name=野邊政雄
kn-aut-sei=野邊
kn-aut-mei=政雄
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Department of Social Studies Education, Faculty of Education, Okayama University
kn-affil=岡山大学教育学部社会科教育講座
en-keyword=高梁市
kn-keyword=高梁市
en-keyword=吉備高原
kn-keyword=吉備高原
en-keyword=高齢女性
kn-keyword=高齢女性
en-keyword=過疎化
kn-keyword=過疎化
en-keyword=高齢化
kn-keyword=高齢化
END

start-ver=1.4
cd-journal=joma
no-vol=116
cd-vols=
no-issue=
article-no=
start-page=43
end-page=53
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2001
dt-pub=20010315
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=The Life Styles of Elderly Women in the Urban Areas of Takahashi City, Japan-Part 1
kn-title=高梁市の市街地に住む高齢女性の暮らし（その１)
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=　筆者は2000年10月から11月にかけて高梁市の市街地に住む高齢女性に聞き取り調査をおこなった。本稿では，収集した事例のうちから６つの事例を提示し，これを検討することによって，地方小都市の市街地に住む高齢女性がどのような暮らしをしているかを明らかにした。
en-copyright=
kn-copyright=

en-aut-name=NOBEMasao
en-aut-sei=NOBE
en-aut-mei=Masao
kn-aut-name=野邊政雄
kn-aut-sei=野邊
kn-aut-mei=政雄
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Department of Social Studies Education, Faculty of Education, Okayama University
kn-affil=岡山大学教育学部社会科教育講座
en-keyword=高梁市
kn-keyword=高梁市
en-keyword=市街地
kn-keyword=市街地
en-keyword=高齢女性
kn-keyword=高齢女性
en-keyword=高齢化
kn-keyword=高齢化
END

start-ver=1.4
cd-journal=joma
no-vol=117
cd-vols=
no-issue=
article-no=
start-page=35
end-page=41
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2001
dt-pub=20010715
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=The Life Styles of Elderly Women in the Urban Areas of Takahashi City, Japan-PartII
kn-title=高梁市の市街地に住む高齢女性の暮らし（その２）
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=　筆者は2000年10月から11月にかけて高梁市の市街地に住む高齢女性に聞き取り調査をおこなった。本稿では，収集した事例のうちから６つの事例を提示し，これを検討することによって，地方小都市の市街地に住む高齢女性がどのような暮らしをしているかを明らかにした。
en-copyright=
kn-copyright=

en-aut-name=NOBEMasao
en-aut-sei=NOBE
en-aut-mei=Masao
kn-aut-name=野邊政雄
kn-aut-sei=野邊
kn-aut-mei=政雄
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Department of Social Studies Education, Faculty of Education, Okayama University
kn-affil=岡山大学教育学部社会科教育講座
en-keyword=高梁市
kn-keyword=高梁市
en-keyword=市街地
kn-keyword=市街地
en-keyword=高齢女性
kn-keyword=高齢女性
en-keyword=高齢化
kn-keyword=高齢化
END

start-ver=1.4
cd-journal=joma
no-vol=118
cd-vols=
no-issue=
article-no=
start-page=31
end-page=37
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2001
dt-pub=20011115
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Basic Characteristics of Personal Networks of Elderly Women in a Small Japanese City
kn-title=地方小都市に住む高齢女性のパーソナル・ネットワークの基本的特徴
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=　筆者は1997年11月から1998年1月にかけて高梁市に住む高齢女性に面接調査をおこなった。本稿では，そのデータを分析することによって，�@パーソナル・ネットワークの規模，�Aその構成，�B性別と年齢での社会関係の同質性，�Cソーシャル・サポートの入手を検討した。
en-copyright=
kn-copyright=

en-aut-name=NOBEMasao
en-aut-sei=NOBE
en-aut-mei=Masao
kn-aut-name=野邊政雄
kn-aut-sei=野邊
kn-aut-mei=政雄
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Department of Social Studies Education, Faculty of Education, Okayama University
kn-affil=岡山大学教育学部社会科教育講座
en-keyword=高梁市
kn-keyword=高梁市
en-keyword=高齢女性
kn-keyword=高齢女性
en-keyword=パーソナル・ネットワーク
kn-keyword=パーソナル・ネットワーク
en-keyword=ソーシャル・サボート
kn-keyword=ソーシャル・サボート
END

start-ver=1.4
cd-journal=joma
no-vol=120
cd-vols=
no-issue=
article-no=
start-page=23
end-page=30
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2002
dt-pub=20020715
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=The effects of income on personal networks of elderly women in a small local city
kn-title=収入と地方小都市に住む高齢女性のパーソナル・ネットワーク
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=　地方小都市である岡山県高梁市で65歳以上80歳未満の高齢女性を対象に1997年から1998年にかけて調査をおこなった。本稿では，重回帰分析によってそのデータを分析し，収入が高齢女性のパーソナル・ネットワークに与える影響を分析した。そして，次の3点を明らかにした。�@収入が高い高齢女性ほど多くの親族関係と友人関係を組織し，家族の外で多くの社会関係を保持していた。しかし，収入は近隣関係数に影響を及ぽしてはいなかった。�A居住場所は栽族関係数と近隣関係数に有意な影響を及ぽしていたけれど，友人関係数には影響を与えてはいなかった。これは，フィッシャーの下位文化理論が地方小都市に住む高齢女性の友人関係には妥当しないことを示唆している。�B収入は，家族外の社会関係総数に最も強い影響力を持っていた。
en-copyright=
kn-copyright=

en-aut-name=NOBEMasao
en-aut-sei=NOBE
en-aut-mei=Masao
kn-aut-name=野邊政雄
kn-aut-sei=野邊
kn-aut-mei=政雄
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Department of Social Studies Education, Faculty of Education, Okayama University
kn-affil=岡山大学教育学部社会科教育講座
en-keyword=パーソナル・ネットワーク
kn-keyword=パーソナル・ネットワーク
en-keyword=高齢女性
kn-keyword=高齢女性
en-keyword=地方小都市
kn-keyword=地方小都市
en-keyword=下位文化理論
kn-keyword=下位文化理論
END

start-ver=1.4
cd-journal=joma
no-vol=121
cd-vols=
no-issue=
article-no=
start-page=207
end-page=214
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2002
dt-pub=20021115
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Basic Characteristics of Personal Networks of Elderly Women in a Small Japanese City
kn-title=メルボルンの住民の暮らし 一参与観察による研究一
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=　メルボルンに住むオーストラリア人の家庭でホームステイをおこない，その家族生活や交際を参与観察した。そして，次の2点を明らかにした。�@メルボルンでは，大人は1台ずつ車を持つことが一般的になってきた。外出にはたいてい車を使い，近所を歩くことが少なくなったから，近所の人々と知り合いになりにくくなった。そこで，近隣関係や近隣交際が乏しくなり，近所の人々と助けあうこともあまりなくなった。�A車を使って外出をするので，自由に行き来できる地理的範囲が広くなった。そのため，住民は広範囲に住む多くの人々の中から，気心があったり，利害や関心を共有する相手を自由に選んで友人関係を取り結び，そうした友人と交遊をしたり，生活の助け合いをおこなっている。
en-copyright=
kn-copyright=

en-aut-name=NOBEMasao
en-aut-sei=NOBE
en-aut-mei=Masao
kn-aut-name=野邊政雄
kn-aut-sei=野邊
kn-aut-mei=政雄
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Department of Social Studies Education, Faculty of Education, Okayama University
kn-affil=岡山大学教育学部社会科教育講座
en-keyword=メルボルン
kn-keyword=メルボルン
en-keyword=参与観察
kn-keyword=参与観察
en-keyword=パーソナル・ネットワーク
kn-keyword=パーソナル・ネットワーク
en-keyword=ソーシャル・サポート
kn-keyword=ソーシャル・サポート
END

start-ver=1.4
cd-journal=joma
no-vol=123
cd-vols=
no-issue=
article-no=
start-page=219
end-page=227
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2003
dt-pub=20030710
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=A Trend Analysis of Migration in a Small Local Japanese City
kn-title=地方小都市における人口の地理的移動の趨勢分析
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=　高梁市は，岡山県の中西部に位置する地方小都市である。本稿では，1965年，1975年，1985年，1995年，2000年における，高梁市の人口の地理的移動に関するデータを検討しその趨勢を明らかにした。
en-copyright=
kn-copyright=

en-aut-name=NOBEMasao
en-aut-sei=NOBE
en-aut-mei=Masao
kn-aut-name=野邊政雄
kn-aut-sei=野邊
kn-aut-mei=政雄
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Department of Social Studies Education, Faculty of Education, Okayama University
kn-affil=岡山大学教育学部社会科教育講座
en-keyword=地理的移動
kn-keyword=地理的移動
en-keyword=転入・転出
kn-keyword=転入・転出
en-keyword=純移動数
kn-keyword=純移動数
en-keyword=地方小都市
kn-keyword=地方小都市
END

start-ver=1.4
cd-journal=joma
no-vol=124
cd-vols=
no-issue=
article-no=
start-page=113
end-page=121
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2003
dt-pub=20031115
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=A Trend Analysis of Migration in Okayama City, Japan
kn-title=岡山市における人口の地理的移動の趨勢分析
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=　岡山市は，人口約63万人の地方中核都市である。本稿では，1965年，1975年，1985年，1995年，2000年における，岡山市のデータを検討し，人口の地理的移動の趨勢を明らかにした。さらに，岡山県の地方小都市である高梁市の地理的移動と比較をおこなった。
en-copyright=
kn-copyright=

en-aut-name=NOBEMasao
en-aut-sei=NOBE
en-aut-mei=Masao
kn-aut-name=野邊政雄
kn-aut-sei=野邊
kn-aut-mei=政雄
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Department of Social Studies Education, Faculty of Education, Okayama University
kn-affil=岡山大学教育学部社会科教育講座
en-keyword=地理的移動
kn-keyword=地理的移動
en-keyword=転入・転出
kn-keyword=転入・転出
en-keyword=純移動数
kn-keyword=純移動数
en-keyword=岡山市
kn-keyword=岡山市
END

start-ver=1.4
cd-journal=joma
no-vol=18
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=2025
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Clipping closure length is a crucial factor for delayed bleeding after endoscopic papillectomy: a retrospective multicenter cohort study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Bleeding is a serious and frequent adverse event that occurs during and after endoscopic papillectomy (EP). Previous studies have highlighted the effectiveness of preventive clipping closure of the resection site in preventing post-EP bleeding. However, the optimal length of closure remained unclear. <br>
Objectives: We aimed to clarify the optimal clipping length at the post-EP resection site to prevent delayed bleeding. <br>
Design: This study was a multicenter retrospective cohort study. <br>]
Methods: We retrospectively analyzed patients who were consecutively admitted to nine high-volume centers for EP between November 2003 and October 2023. The primary outcome was the frequency of delayed bleeding based on the closure length. The optimal closure length rate of the resected site to prevent delayed bleeding was determined using a receiver operating characteristic curve. Secondary outcomes were the incidence, treatment outcomes, and risk factors for post-EP delayed bleeding. <br>
Results: A total of 130 patients who underwent EP were analyzed. Delayed bleeding was observed in 22 (17%) patients, occurring more frequently in cases without clipping closure than in those with clipping closure (28% (13/47) vs 11% (9/83); p = 0.014). Among 83 patients who underwent clipping closure, delayed bleeding occurred more frequently with a closure length rate <65% than in those with a closure rate >= 65% (25% (5/20) vs 6% (4/63); p = 0.019). Multivariate analysis showed that a closure rate <65% was the risk factor for delayed bleeding (odds ratio, 6.3; 95% confidence interval, 1.2-33; p = 0.030) in cases with clipping. <br>
Conclusion: Clipping closure was effective in preventing delayed bleeding, and closure length rate >= 65% of the resected site significantly reduced post-EP delayed bleeding.
en-copyright=
kn-copyright=

en-aut-name=FujiiYuki
en-aut-sei=Fujii
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MatsumotoKazuyuki
en-aut-sei=Matsumoto
en-aut-mei=Kazuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=OchiKiyoaki
en-aut-sei=Ochi
en-aut-mei=Kiyoaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=HimeiHitomi
en-aut-sei=Himei
en-aut-mei=Hitomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SakakiharaIchiro
en-aut-sei=Sakakihara
en-aut-mei=Ichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=UetaEijiro
en-aut-sei=Ueta
en-aut-mei=Eijiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=ToyokawaTatsuya
en-aut-sei=Toyokawa
en-aut-mei=Tatsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=HaradaRyo
en-aut-sei=Harada
en-aut-mei=Ryo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=OgawaTaiji
en-aut-sei=Ogawa
en-aut-mei=Taiji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=TomodaTakeshi
en-aut-sei=Tomoda
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=KatoHironari
en-aut-sei=Kato
en-aut-mei=Hironari
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=SatoRyosuke
en-aut-sei=Sato
en-aut-mei=Ryosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=ObataTaisuke
en-aut-sei=Obata
en-aut-mei=Taisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=MatsumiAkihiro
en-aut-sei=Matsumi
en-aut-mei=Akihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=MiyamotoKazuya
en-aut-sei=Miyamoto
en-aut-mei=Kazuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=UchidaDaisuke
en-aut-sei=Uchida
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=HoriguchiShigeru
en-aut-sei=Horiguchi
en-aut-mei=Shigeru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=TsutsumiKoichiro
en-aut-sei=Tsutsumi
en-aut-mei=Koichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=OtsukaMotoyuki
en-aut-sei=Otsuka
en-aut-mei=Motoyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

affil-num=1
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Gastroenterology, Fukuyama City Hospital
kn-affil=

affil-num=4
en-affil=Department of Gastroenterology, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=5
en-affil=Department of Gastroenterology, Kagawa Prefectural Central Hospital
kn-affil=

affil-num=6
en-affil=Department of Gastroenterology, National Hospital Organization, Iwakuni Clinical Center
kn-affil=

affil-num=7
en-affil=Department of Gastroenterology, National Hospital Organization, Fukuyama Medical Center
kn-affil=

affil-num=8
en-affil=Department of Gastroenterology, Japanese Red Cross Okayama Hospital
kn-affil=

affil-num=9
en-affil=Department of Gastroenterology, Tsuyama Chuo Hospital
kn-affil=

affil-num=10
en-affil=Department of Gastroenterology, Okayama City Hospital
kn-affil=

affil-num=11
en-affil=Department of Gastroenterology, Okayama City Hospital
kn-affil=

affil-num=12
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=13
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=14
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=15
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=16
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=17
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=18
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=19
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=
en-keyword=clipping closure
kn-keyword=clipping closure
en-keyword=delayed bleeding
kn-keyword=delayed bleeding
en-keyword=endoscopic papillectomy
kn-keyword=endoscopic papillectomy
END

start-ver=1.4
cd-journal=joma
no-vol=15
cd-vols=
no-issue=
article-no=
start-page=235
end-page=249
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250328
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Practical Research on Nurturing the Next Generation of Classical Japanese Instrument Music That Connects the Local and the Global Community (1): Analysis of External Evaluations of the “Okayama International Classical Japanese Instruments Student Festival”
kn-title=地域社会とグローバルをつなぐ和楽器音楽次世代育成の実践研究（１）　「おかやま国際和楽器学生フェスティバル」外的評価の分析
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=　本稿では，「和楽器音楽及び教育の拠点づくりの実践研究」の一環として開催した「おかやま国際和楽器学生フェスティバル」の取り組みについて，その概要を報告するとともに，外的評価として「おかやま国際和楽器学生フェスティバルコンサート」終演後に実施した一般来場者対象の質問紙調査及びフェスティバルを参観した岡山県内の学校関係者対象の質問紙調査を取り上げ，意義と課題について検討した。<br>
　その結果，第一に音楽を通じた世代間や国際交流の喜びを感じ，和楽器の伝承と教育の重要性を強く意識する機会となったこと，第二に，和楽器が様々な国籍・年齢の学生に受容されていることを，来場者が客観視することで，自文化の価値の再認識につながったこと，第三に，フェスティバル全体としては，ワークショップが充実しており，様々な国籍・年齢の学生が同じステージで演奏する姿に対する評価が得られた点が明らかとなった。
en-copyright=
kn-copyright=

en-aut-name=HAYAKAWARinko
en-aut-sei=HAYAKAWA
en-aut-mei=Rinko
kn-aut-name=早川倫子
kn-aut-sei=早川
kn-aut-mei=倫子
aut-affil-num=1
ORCID=

en-aut-name=YAMAJIMiho
en-aut-sei=YAMAJI
en-aut-mei=Miho
kn-aut-name=山路みほ
kn-aut-sei=山路
kn-aut-mei=みほ
aut-affil-num=2
ORCID=

en-aut-name=TAKASUHiromi
en-aut-sei=TAKASU
en-aut-mei=Hiromi
kn-aut-name=��須裕美
kn-aut-sei=��須
kn-aut-mei=裕美
aut-affil-num=3
ORCID=

en-aut-name=BEPPUYuko
en-aut-sei=BEPPU
en-aut-mei=Yuko
kn-aut-name=別府祐子
kn-aut-sei=別府
kn-aut-mei=祐子
aut-affil-num=4
ORCID=

en-aut-name=HIGUCHIAki
en-aut-sei=HIGUCHI
en-aut-mei=Aki
kn-aut-name=樋口亜希
kn-aut-sei=樋口
kn-aut-mei=亜希
aut-affil-num=5
ORCID=

en-aut-name=NAKAMURAAi
en-aut-sei=NAKAMURA
en-aut-mei=Ai
kn-aut-name=中村愛
kn-aut-sei=中村
kn-aut-mei=愛
aut-affil-num=6
ORCID=

en-aut-name=SHIMIZUNaoko
en-aut-sei=SHIMIZU
en-aut-mei=Naoko
kn-aut-name=清水尚子
kn-aut-sei=清水
kn-aut-mei=尚子
aut-affil-num=7
ORCID=

en-aut-name=HANAKUSAYoko
en-aut-sei=HANAKUSA
en-aut-mei=Yoko
kn-aut-name=花草容子
kn-aut-sei=花草
kn-aut-mei=容子
aut-affil-num=8
ORCID=

en-aut-name=TAKESHITANoriko
en-aut-sei=TAKESHITA
en-aut-mei=Noriko
kn-aut-name=竹下則子
kn-aut-sei=竹下
kn-aut-mei=則子
aut-affil-num=9
ORCID=

en-aut-name=MIYOSHIKeiko
en-aut-sei=MIYOSHI
en-aut-mei=Keiko
kn-aut-name=三好啓子
kn-aut-sei=三好
kn-aut-mei=啓子
aut-affil-num=10
ORCID=

en-aut-name=TOSAChihiro
en-aut-sei=TOSA
en-aut-mei=Chihiro
kn-aut-name=土佐千紘
kn-aut-sei=土佐
kn-aut-mei=千紘
aut-affil-num=11
ORCID=

affil-num=1
en-affil=Okayama University
kn-affil=岡山大学学術研究院教育学域

affil-num=2
en-affil=Koto Player
kn-affil=箏曲演奏家・岡山大学非常勤講師

affil-num=3
en-affil=Okayama University
kn-affil=岡山大学学術研究院教育学域

affil-num=4
en-affil=Kurashiki City College
kn-affil=倉敷市立短期大学

affil-num=5
en-affil=Okayama Prefectural School for the Deaf
kn-affil=岡山県立岡山聾学校

affil-num=6
en-affil=Doctoral Student at the Joint Graduate School in Science of School Education Hyogo University of Teacher Education
kn-affil=兵庫教育大学大学院連合学校教育学研究科博士課程

affil-num=7
en-affil=Doctoral Student at the Joint Graduate School in Science of School Education Hyogo University of Teacher Education
kn-affil=兵庫教育大学大学院連合学校教育学研究科博士課程

affil-num=8
en-affil=Research Student at the Joint Graduate School in Science of School Education Hyogo University of Teacher Education
kn-affil=兵庫教育大学大学院連合学校教育学研究科研究生

affil-num=9
en-affil=Research Student at the Joint Graduate School in Science of School Education Hyogo University of Teacher Education
kn-affil=兵庫教育大学大学院連合学校教育学研究科研究生

affil-num=10
en-affil=Master’s Student at the Graduate School of Education in Okayama University
kn-affil=岡山大学大学院教育学研究科修士課程

affil-num=11
en-affil=Master’s Student at the Graduate School of Education in Okayama University
kn-affil=岡山大学大学院教育学研究科修士課程
en-keyword=和楽器音楽 (Classical Japanese instrument)
kn-keyword=和楽器音楽 (Classical Japanese instrument)
en-keyword=教育 (education)
kn-keyword=教育 (education)
en-keyword=次世代育成 (nurturing the next generation)
kn-keyword=次世代育成 (nurturing the next generation)
en-keyword=グローカル (glocal)
kn-keyword=グローカル (glocal)
en-keyword=質問紙調査 (questionnaire survey)
kn-keyword=質問紙調査 (questionnaire survey)
END

start-ver=1.4
cd-journal=joma
no-vol=56
cd-vols=
no-issue=3
article-no=
start-page=15
end-page=33
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250321
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Survival, Creation, and Disappearance of Manufacturing Firms in the First Stage of Regional Revitalization
kn-title=地方創生第１期における製造事業所の存続，発生，消失
en-subtitle=
kn-subtitle=
en-abstract=　In many local municipalities, in addition to revitalizing existing businesses and creating new businesses, attracting manufacturing plants remains an important policy for regional development. Today, unlike the attraction of heavy, large-scale industries during the period of high economic growth, there is a trend to attract companies by making the most of the region's advantages. Although the job creation effect has become smaller than in the past, many manufacturing industries remain positioned as core industries in the region. During the first period of regional revitalization, we identify what manufacturing firms have disappeared, withdrawn, appeared, or survived in what regions, and analyze the factors behind those.<br>
　Comparing manufacturing firms in 2014 and 2019, the average of value-added and the distribution of that shows that manufacturing firms that existed in both 2014 and 2019 had the highest labor productivity. The next highest was manufacturing firms that existed in 2019, and the lowest was manufacturing firms that existed in 2014 but did not exist in 2019. In addition, the results of the logit analysis suggest that manufacturing firms with high productivity and large size tend not to disappear, and that manufacturing firms with a high degree of urbanization tend to disappear. On the other hand, a regression analysis at the city/town/village level using industry concentration by industry and urban concentration measured by population size as explanatory variables showed a positive effect on the number of manufacturing firms that had been established.
kn-abstract=　地方に位置する多くの自治体においては，従来からある事業所の活性化や新規事業所の誕生に加えて，製造工場の誘致は地域振興にとっていまも重要な政策となっている。今日，高度経済成長期における重厚長大型の産業の誘致とは異なり，地域優位性をできるだけ活用した企業誘致の傾向になっている。雇用創出効果は昔に比べて小さくなっているとはいえ，製造業の多くにおいて，地域の基盤産業としての位置づけは残っている。第1期の地方創生の期間で，どのような地域において，どのような製造工場が消失，撤退や出現，存続しているのかを識別し，それらの要因を分析する。<br>
　2014年と2019年の事業所の比較において，付加価値生産性の平均と分布を見ると2014年，2019年ともに存在する事業所の労働生産性が最も高い。次いで高いのが2019年に存在する事業所で，最も低かったのが2014年には存在したが2019年には存在していない事業所であった。またロジット分析の結果から，生産性が高く事業所規模が大きいと消滅しない傾向があり，また都市化の程度が高いと消滅傾向にあることが推定された。他方，発生した製造事業所について，産業別に同業種集積と人口規模で測った都市集積を説明変数とした市町村単位の回帰分析からは正の効果が示された。
en-copyright=
kn-copyright=

en-aut-name=NakamuraRyohei
en-aut-sei=Nakamura
en-aut-mei=Ryohei
kn-aut-name=中村良平
kn-aut-sei=中村
kn-aut-mei=良平
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学
END

start-ver=1.4
cd-journal=joma
no-vol=188
cd-vols=
no-issue=
article-no=
start-page=67
end-page=76
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250228
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Music Education Practice Based on the Region: An Improvisation Workshop at a Public Elementary School in Tamano City, Okayama
kn-title=地域を見つめ直す音楽教育実践の検討 ― 岡山県玉野市内の公立小学校における即興演奏ワークショップを例に ―
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=　本研究は，地域の文化や遺産，環境を念頭に置いた創造的な音楽教育によって，県内の人口減少に起因する課題の改善を図ることを目的としている。同時に，その創作教育を通じて，児童の柔軟な創造力や多様性を認める意識を育むこともねらっている。本研究において実践した取組は，現代音楽的表現を取り入れた即興演奏ワークショップである。<br>
　本稿では2024 年に行った玉野市内の小学校におけるワークショップの内容を中心に論じる。本ワークショップは，児童が柔軟かつ多様な創作表現を実践する場となったが，児童と地域住民らがその地域の特色を認識する機会としては新たな課題を生んだ。地域と創造的音楽教育を結んだ研究は実例が少なく，模索の段階であるため，本ワークショップを省みた上で今後の改善に繋げたい。
en-copyright=
kn-copyright=

en-aut-name=OKAMOTOShinsuke
en-aut-sei=OKAMOTO
en-aut-mei=Shinsuke
kn-aut-name=岡本伸介
kn-aut-sei=岡本
kn-aut-mei=伸介
aut-affil-num=1
ORCID=

en-aut-name=MASUDAKenta
en-aut-sei=MASUDA
en-aut-mei=Kenta
kn-aut-name=増田建太
kn-aut-sei=増田
kn-aut-mei=建太
aut-affil-num=2
ORCID=

affil-num=1
en-affil=Faculty of Education, Okayama University
kn-affil=岡山大学学術研究院教育学域

affil-num=2
en-affil=Faculty of Education, University of Toyama
kn-affil=富山大学学術研究部教育学系
en-keyword=音楽教育
kn-keyword=音楽教育
en-keyword=地域教育
kn-keyword=地域教育
en-keyword=即興演奏
kn-keyword=即興演奏
en-keyword=作曲
kn-keyword=作曲
en-keyword=現代音楽
kn-keyword=現代音楽
END

start-ver=1.4
cd-journal=joma
no-vol=188
cd-vols=
no-issue=
article-no=
start-page=47
end-page=56
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250228
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Classical Japanese Instrument Music: Connecting Local Communities and the Global World (2) ?Developing ‘Intercultural Competence’ in Next Generation Cultural Exchange ?
kn-title=地域社会とグローバルをつなぐ和楽器音楽次世代育成の実践研究（２）― 国際文化交流における「異文化間能力」育成の可能性 ―
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=　本研究は，地域社会とグローバルをつなぐ和楽器音楽次世代育成の実践研究の一環として実施した「おかやま国際和楽器学生フェスティバル」について，「異文化間能力」育成の視点からその可能性について検討したものである。<br>
　国内の学生については，�@和楽器を介した繋がり／音楽的な協働，�A演奏の質に関する違いの認識，�B 海外の和楽器演奏者に対する認識の３点が，海外の学生については，�@表現スタイルや技術に関する違いの認識，�A和楽器音楽の本質の理解，�B演奏者としての学びと成長に対する意識の３点が，特徴として示された。「異文化間能力」の視点からは，国内外共に「文化的多様性」と「絶対的正統性の緩和」についての認識が認められ，柔軟で且つ寛容な和楽器との向き合い方が形成されていたことが明らかとなった。また「共感・協働のスキル」については，特に国内の学生に多く認められる結果となった。
en-copyright=
kn-copyright=

en-aut-name=HAYAKAWARinko
en-aut-sei=HAYAKAWA
en-aut-mei=Rinko
kn-aut-name=早川倫子
kn-aut-sei=早川
kn-aut-mei=倫子
aut-affil-num=1
ORCID=

en-aut-name=TAKASUHiromi
en-aut-sei=TAKASU
en-aut-mei=Hiromi
kn-aut-name=��須裕美
kn-aut-sei=��須
kn-aut-mei=裕美
aut-affil-num=2
ORCID=

en-aut-name=SHIMIZUNaoko
en-aut-sei=SHIMIZU
en-aut-mei=Naoko
kn-aut-name=清水尚子
kn-aut-sei=清水
kn-aut-mei=尚子
aut-affil-num=3
ORCID=

en-aut-name=YAMAJIMiho
en-aut-sei=YAMAJI
en-aut-mei=Miho
kn-aut-name=山路みほ
kn-aut-sei=山路
kn-aut-mei=みほ
aut-affil-num=4
ORCID=

en-aut-name=BEPPUYuko
en-aut-sei=BEPPU
en-aut-mei=Yuko
kn-aut-name=別府祐子
kn-aut-sei=別府
kn-aut-mei=祐子
aut-affil-num=5
ORCID=

en-aut-name=HIGUCHIAki
en-aut-sei=HIGUCHI
en-aut-mei=Aki
kn-aut-name=樋口亜希
kn-aut-sei=樋口
kn-aut-mei=亜希
aut-affil-num=6
ORCID=

en-aut-name=NAKAMURAAi
en-aut-sei=NAKAMURA
en-aut-mei=Ai
kn-aut-name=中村愛
kn-aut-sei=中村
kn-aut-mei=愛
aut-affil-num=7
ORCID=

en-aut-name=MIYOSHIKeiko
en-aut-sei=MIYOSHI
en-aut-mei=Keiko
kn-aut-name=三好啓子
kn-aut-sei=三好
kn-aut-mei=啓子
aut-affil-num=8
ORCID=

en-aut-name=TOSAChihiro
en-aut-sei=TOSA
en-aut-mei=Chihiro
kn-aut-name=土佐千紘
kn-aut-sei=土佐
kn-aut-mei=千紘
aut-affil-num=9
ORCID=

en-aut-name=HANAKUSAYoko
en-aut-sei=HANAKUSA
en-aut-mei=Yoko
kn-aut-name=花草容子
kn-aut-sei=花草
kn-aut-mei=容子
aut-affil-num=10
ORCID=

en-aut-name=TAKESHITANoriko
en-aut-sei=TAKESHITA
en-aut-mei=Noriko
kn-aut-name=竹下則子
kn-aut-sei=竹下
kn-aut-mei=則子
aut-affil-num=11
ORCID=

affil-num=1
en-affil=Faculty of Education, Okayama University
kn-affil=岡山大学学術研究院教育学域

affil-num=2
en-affil=Faculty of Education, Okayama University
kn-affil=岡山大学学術研究院教育学域

affil-num=3
en-affil=Doctoral Student at the Joint Graduate School in Science of School Education Hyogo University of Teacher Education (Okayama University)
kn-affil=兵庫教育大学大学院連合学校教育学研究科博士課程（岡山大学所属）

affil-num=4
en-affil=Koto Player
kn-affil=箏曲演奏家

affil-num=5
en-affil=Department of Early Childhood Education and Care, Kurashiki City College
kn-affil=倉敷短期大学保育学科

affil-num=6
en-affil=Okayama Prefectural School for the Deaf
kn-affil=岡山県立岡山聾学校

affil-num=7
en-affil=Doctoral Student at the Joint Graduate School in Science of School Education Hyogo University of Teacher Education (Okayama University)
kn-affil=兵庫教育大学大学院連合学校教育学研究科博士課程（岡山大学所属）

affil-num=8
en-affil=Master’s Student at the Graduate School of Education in Okayama University
kn-affil=岡山大学大学院教育学研究科修士課程

affil-num=9
en-affil=Master’s Student at the Graduate School of Education in Okayama University
kn-affil=岡山大学大学院教育学研究科修士課程

affil-num=10
en-affil=Research Student at the Joint Graduate School in Science of School Education Hyogo University of Teacher Education (Okayama University)
kn-affil=兵庫教育大学大学院連合学校教育学研究科研究生（岡山大学所属）

affil-num=11
en-affil=Biwako-Gakuin University
kn-affil=びわこ学院大学
en-keyword=和楽器音楽
kn-keyword=和楽器音楽
en-keyword=異文化間能力
kn-keyword=異文化間能力
en-keyword=グローバル
kn-keyword=グローバル
en-keyword=次世代育成
kn-keyword=次世代育成
en-keyword=質問紙調査
kn-keyword=質問紙調査
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=1990
dt-pub=1990
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Social Change and Social Participation in a Planned City : the Case of Canberra
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=NobeMasao
en-aut-sei=Nobe
en-aut-mei=Masao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=1
article-no=
start-page=9
end-page=19
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202502
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Gastrectomy Causes an Imbalance in the Trunk Muscles
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Muscle loss negatively affects gastrectomy prognosis. However, muscle loss is recognized as a systemic change, and individual muscle function is often overlooked. We investigated changes in the muscle volume of individual muscles after gastrectomy to identify clues for prognostic factors and optimal rehabilitation programs. Patients who underwent R0 gastrectomy for Stage I gastric cancer at our hospital from 2015 to 2021 were retrospectively selected to minimize the effects of malignancy and chemotherapy. Trunk muscle volume was measured by computed tomography to analyze body composition changes. Statistical analysis was performed to identify risk factors related to body composition changes. We compared the preoperative and 6-month postoperative conditions of 59 patients after gastrectomy. There was no difference in the psoas major muscle, a conventional surrogate marker of sarcopenia. There were significant decreases in the erector spinae (p=0.01) and lateral abdominal (p=0.01) muscles, and a significant increase in the rectus abdominis muscle (p=0.02). No significant correlation was found between these muscle changes and nutritional status. Body composition imbalance may serve as a new indicator of the general condition of patients after gastrectomy. Rehabilitation to correct this imbalance may improve prognosis after gastrectomy.
en-copyright=
kn-copyright=

en-aut-name=IkeyaNanami
en-aut-sei=Ikeya
en-aut-mei=Nanami
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=OkitaAtsushi
en-aut-sei=Okita
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HashidaShinsuke
en-aut-sei=Hashida
en-aut-mei=Shinsuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YamamotoSumiharu
en-aut-sei=Yamamoto
en-aut-mei=Sumiharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=IkedaHirokuni
en-aut-sei=Ikeda
en-aut-mei=Hirokuni
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TsukudaKazunori
en-aut-sei=Tsukuda
en-aut-mei=Kazunori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=ToyookaShinichi
en-aut-sei=Toyooka
en-aut-mei=Shinichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Surgery, Okayama City Hospital
kn-affil=

affil-num=3
en-affil=Department of Surgery, Okayama City Hospital
kn-affil=

affil-num=4
en-affil=Department of Surgery, Okayama City Hospital
kn-affil=

affil-num=5
en-affil=Department of Surgery, Okayama City Hospital
kn-affil=

affil-num=6
en-affil=Department of Surgery, Okayama City Hospital
kn-affil=

affil-num=7
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=sarcopenia
kn-keyword=sarcopenia
en-keyword=skeletal muscle
kn-keyword=skeletal muscle
en-keyword=gastric cancer
kn-keyword=gastric cancer
en-keyword=gastrectomy
kn-keyword=gastrectomy
en-keyword=erector spinae muscle
kn-keyword=erector spinae muscle
END

start-ver=1.4
cd-journal=joma
no-vol=69
cd-vols=
no-issue=1
article-no=
start-page=1
end-page=9
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250204
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Relationships between tilt angles of rectus muscles and positions of rectus muscle pulleys in patients with sagging eye syndrome
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Purpose To examine the relationship between the rectus muscle (RM) angle and RM pulley displacement in patients with sagging eye syndrome (SES) without myopia.<br>
Study design Retrospective cross-sectional case series.<br>
Methods High-resolution quasi-coronal magnetic resonance imaging (MRI) data from 20 orbits of ten Japanese patients with SES but without high myopia were analyzed. The patients had no abduction deficiency. The RM angles were measured between the major axes of the horizontal and vertical RMs relative to the vertical and horizontal planes, respectively. The positions of the RM pulleys relative to the center of the globe were analyzed as previously described.<br>
Results The mean age of the patients was 75.8 ± 4.5 years (standard deviation). The average axial length was 23.6 ± 0.6 mm. The lateral rectus (LR) muscle angle (22 ± 6°) had moderate negative correlations with the inferior displacement of the inferior rectus (IR), superior rectus (SR), and LR pulleys (r =? 0.63,? 0.45, and? 0.45, respectively); however, no change was observed in the medial rectus (MR) pulley (r =? 0.41). No correlations were found between the angles of the SR (4 ± 8°), IR (? 13 ± 8°), and MR (? 1 ± 6°) muscles and the positions of the RM pulleys.<br>
Conclusion Given the correlation between increased LR muscle angle and inferior displacement of adjacent RM pulleys in SES, the LR muscle angle may serve as a diagnostic clue, even when inferior displacement is not identifiable on MRI. Further confirmation in larger studies is warranted.
en-copyright=
kn-copyright=

en-aut-name=KonoReika
en-aut-sei=Kono
en-aut-mei=Reika
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HamasakiIchiro
en-aut-sei=Hamasaki
en-aut-mei=Ichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KishimotoFumiko
en-aut-sei=Kishimoto
en-aut-mei=Fumiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=ShibataKiyo
en-aut-sei=Shibata
en-aut-mei=Kiyo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MorisawaShin
en-aut-sei=Morisawa
en-aut-mei=Shin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MorizaneYuki
en-aut-sei=Morizane
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Division of Ophthalmology, Ibara City Hospital, Ibara City
kn-affil=

affil-num=4
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=
en-keyword=Orbital pulley
kn-keyword=Orbital pulley
en-keyword=Sagging eye syndrome
kn-keyword=Sagging eye syndrome
en-keyword=Distance esotropia
kn-keyword=Distance esotropia
en-keyword=Cyclovertical strabismus
kn-keyword=Cyclovertical strabismus
en-keyword=Aging
kn-keyword=Aging
END

start-ver=1.4
cd-journal=joma
no-vol=4
cd-vols=
no-issue=1
article-no=
start-page=e70062
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250202
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Trends in uptake of cancer screening among people with severe mental illness before and after the COVID-19 pandemic in Japan: A repeated cross-sectional study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Aim: The aim of this study was to investigate trends in cancer screening participation among people with severe mental illness (PSMI) from periods before and after the COVID-19 pandemic.<br>
Methods: In this repeated cross-sectional study, we used anonymized datasets on municipal cancer screening participation among PSMI in Okayama City. The data covered fiscal year (FY) 2018 to FY2022; we used the municipal cancer screening database and Medical Payment for Services and Supports for Persons with Disabilities. PSMI were defined as those with schizophrenia or related psychotic disorders (F20-29) or bipolar disorder (F30 or F31), identified using International Classification of Diseases, Tenth Revision, codes. The analysis included men and women aged 40-69 years for colorectal and lung cancer screening; men and women aged 50-69 years for gastric cancer screening; women aged 40-69 years for breast cancer screening; and women aged 20-69 years for cervical cancer screening. Municipal cancer screening rates among PSMI were calculated for each FY.<br>
Results: For all cancer types, cancer screening rates for PSMI in FY2020 (colorectal: 9.0%; lung: 11.6%; gastric: 4.9%; breast: 6.2%; and cervical: 6.1%) were lower than the rates in FY2019 (11.5%, 14.0%, 6.5%, 9.3%, and 8.3%, respectively). In FY2022, the rates (9.9%, 12.9%; 5.3%; 8.0%, and 6.9%, respectively) recovered, but remained low.<br>
Conclusion: This study showed that cancer screening rates among PSMI were very low, both before and after the COVID-19 pandemic. Efforts to encourage participation in cancer screening in this population are urgently needed.
en-copyright=
kn-copyright=

en-aut-name=YamadaYuto
en-aut-sei=Yamada
en-aut-mei=Yuto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=FujiwaraMasaki
en-aut-sei=Fujiwara
en-aut-mei=Masaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NakayaNaoki
en-aut-sei=Nakaya
en-aut-mei=Naoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=OtsukiKoji
en-aut-sei=Otsuki
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=ShimazuTaichi
en-aut-sei=Shimazu
en-aut-mei=Taichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=FujimoriMaiko
en-aut-sei=Fujimori
en-aut-mei=Maiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=HinotsuShiro
en-aut-sei=Hinotsu
en-aut-mei=Shiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=NagoshiKiwamu
en-aut-sei=Nagoshi
en-aut-mei=Kiwamu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=UchitomiYosuke
en-aut-sei=Uchitomi
en-aut-mei=Yosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=InagakiMasatoshi
en-aut-sei=Inagaki
en-aut-mei=Masatoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Neuropsychiatry, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Tohoku Medical Megabank Organization, Tohoku University
kn-affil=

affil-num=4
en-affil=Department of Psychiatry, Faculty of Medicine, Shimane University
kn-affil=

affil-num=5
en-affil=Division of Behavioral Sciences, National Cancer Center Institute for Cancer Control, National Cancer Center
kn-affil=

affil-num=6
en-affil=Division of Survivorship Research, National Cancer Center Institute for Cancer Control, National Cancer Center
kn-affil=

affil-num=7
en-affil=Department of Biostatistics and Data Management, Sapporo Medical University
kn-affil=

affil-num=8
en-affil=Department of Environmental Medicine and Public Health, Faculty of Medicine, Shimane University
kn-affil=

affil-num=9
en-affil=Department of Cancer Survivorship and Digital Medicine, The Jikei University School of Medicine
kn-affil=

affil-num=10
en-affil=Department of Psychiatry, Faculty of Medicine, Shimane University
kn-affil=
en-keyword=bipolar disorder
kn-keyword=bipolar disorder
en-keyword=cancer screening
kn-keyword=cancer screening
en-keyword=COVID-19
kn-keyword=COVID-19
en-keyword=healthcare disparities
kn-keyword=healthcare disparities
en-keyword=schizophrenia
kn-keyword=schizophrenia
END

start-ver=1.4
cd-journal=joma
no-vol=13
cd-vols=
no-issue=3
article-no=
start-page=198
end-page=200
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250108
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Long-Term Follow-Up of a Patient With SPG11
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=We present a case of a male patient with disease-causing variants in SPG11, a causative gene for autosomal recessive spastic paraplegia with a thin corpus callosum (ARHSP-TCC), as well as juvenile amyotrophic lateral sclerosis (ALS5) and Charcot?Marie?Tooth disease (CMT2X). A neurological examination at age 18 revealed dysarthria, muscle weakness in bilateral lower extremities, hyperreflexia in patellar reflex, hyporeflexia in Achilles reflex with an extensor plantar reflex, and intellectual disability. Magnetic resonance imaging revealed a thin corpus callosum and ears of the lynx sign. At the age of 26, weakness and muscle atrophy progressed. While no sensory disturbances were noted, there was a mild decrease in sensory nerve action potentials of the sural nerve over the 8?years between 18 and 26. Clinicians should be aware that SPG11 belongs to the same spectrum of disorders as ALS5 and CMT2X and presents various phenotypes depending on the stage of the disease.
en-copyright=
kn-copyright=

en-aut-name=OsakadaYosuke
en-aut-sei=Osakada
en-aut-mei=Yosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YunokiTaijun
en-aut-sei=Yunoki
en-aut-mei=Taijun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MatsuokaChika
en-aut-sei=Matsuoka
en-aut-mei=Chika
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=FukuiYusuke
en-aut-sei=Fukui
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TsunodaKeiichiro
en-aut-sei=Tsunoda
en-aut-mei=Keiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=DeguchiKentaro
en-aut-sei=Deguchi
en-aut-mei=Kentaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MoriharaRyuta
en-aut-sei=Morihara
en-aut-mei=Ryuta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=YamashitaToru
en-aut-sei=Yamashita
en-aut-mei=Toru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=IshiuraHiroyuki
en-aut-sei=Ishiura
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=5
en-affil=Department of Neurology, Tsuyama Chuo Hospital
kn-affil=

affil-num=6
en-affil=Department of Neurology, Okayama City Hospital
kn-affil=

affil-num=7
en-affil=Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=8
en-affil=Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=9
en-affil=Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=15
cd-vols=
no-issue=
article-no=
start-page=1439705
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20241211
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=HOMA-beta independently predicts survival in patients with advanced cancer on treatment with immune checkpoint inhibitors
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Although immune checkpoint inhibitors (ICIs) are effective cancer drugs, ICI-induced diabetes is a rare but a life-threatening adverse event for patients. The deleterious action of ICI on pancreatic beta-cell function is a concern. However, the influence of ICI on insulin synthesis and secretion in patients with cancer without diabetes remains unknown. <br>
Methods: This study included 87 patients diagnosed with advanced cancer. Glucose metabolism markers (HbA1c, HOMA-IR) and indicators of insulin secretory capacity (HOMA-beta, C-peptide) were prospectively evaluated in patients with ICI-treated cancers to determine their association with cancer prognosis. <br>
Results: Patients with overall survival (OS) >= 7 months had substantially higher HOMA-beta levels at baseline (p=0.008) and 1 month after ICI administration (p=0.006) compared to those with OS <7 months. The median OS was significantly longer in patients with HOMA-beta >= 64.24 (13 months, 95%CI: 5.849-20.151, 37 events) than in those with HOMA-beta < 64.24 (5 months, 95%CI: 3.280-6.720, 50 events) (p=0.013). Further, the median progression-free survival (PFS) was significantly longer in patients with HOMA-beta >= 66.43 (4 months, 95%CI: 3.073-4.927, 33 events) than in those with HOMA-beta < 66.43 (2 months, 95%CI: 1.410-2.590, 54 events) (p=0.025). Additionally, multivariable logistic regression analysis revealed that a HOMA-beta value >= 64.24 independently predicted longer OS in ICI-treated patients. <br>
Conclusions: Pre-ICI HOMA-beta level is linked to longer OS in ICI-treated patients. This connection is significant and shows that insulin secretory capacity may predict ICI efficacy.
en-copyright=
kn-copyright=

en-aut-name=WatanabeMayu
en-aut-sei=Watanabe
en-aut-mei=Mayu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=EguchiJun
en-aut-sei=Eguchi
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TakamotoAtsushi
en-aut-sei=Takamoto
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KanzakiHiromitsu
en-aut-sei=Kanzaki
en-aut-mei=Hiromitsu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=NodaYohei
en-aut-sei=Noda
en-aut-mei=Yohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KagawaSyunsuke
en-aut-sei=Kagawa
en-aut-mei=Syunsuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=WadaJun
en-aut-sei=Wada
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Urology, Fukuyama City Hospital
kn-affil=

affil-num=4
en-affil=Department of Internal Medicine, Tsuyama Chuo Hospital
kn-affil=

affil-num=5
en-affil=Department of Urology, Fukuyama City Hospital
kn-affil=

affil-num=6
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=anti-PD1 immune checkpoint inhibitors
kn-keyword=anti-PD1 immune checkpoint inhibitors
en-keyword= insulin secretory capacity
kn-keyword= insulin secretory capacity
en-keyword= cancer prognosis
kn-keyword= cancer prognosis
en-keyword= insulin secretion
kn-keyword= insulin secretion
en-keyword= glucose metabolism markers
kn-keyword= glucose metabolism markers
END

start-ver=1.4
cd-journal=joma
no-vol=103
cd-vols=
no-issue=50
article-no=
start-page=e40849
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20241213
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Relevance of oxidative stress for small intestinal injuries induced by nonsteroidal anti-inflammatory drugs: A multicenter prospective study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Several reports revealed that oxidative stress was involved in the mouse model of nonsteroidal anti-inflammatory drug (NSAIDs)-induced small intestinal mucosal injuries. Thus, we aimed to investigate in the prospective clinical study, that the relevance of oxidative stress balance in small intestinal mucosal injury in NSAIDs users. We prospectively included 60 patients who had been taking NSAIDs continuously for more than 3 months and exhibited obscure gastrointestinal bleeding (number UMIN 000011775). Small intestinal mucosal injuries were assessed by capsule endoscopy (CE), and reactive oxygen metabolites (d-ROMs) levels and oxidant capacity (OXY) adsorbent test were performed to investigate the relevance of oxidative stress balance. More than half of the patients (N = 32, 53%) had small intestinal mucosal injuries by CE, and 14 patients (24%) had ulcers. The incidence of ulcers was relatively higher in nonaspirin users. Serum OXY levels were significantly lower in the mucosal injury group (P = .02), and d-ROM levels were significantly higher in the ulcer group (P < .01). In aspirin users, d-ROM and OXY levels did not differ significantly with respect to mucosal injuries or ulcers. However, in nonaspirin users, OXY level was significantly lower in the mucosal injury group (P = .04), and d-ROM levels were significantly higher in the ulcer group (P = .02). Nonaspirin NSAIDs-induced intestinal mucosal injury is associated with antioxidant systems, resulting in increased oxidative stress.
en-copyright=
kn-copyright=

en-aut-name=BabaYuki
en-aut-sei=Baba
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KawanoSeiji
en-aut-sei=Kawano
en-aut-mei=Seiji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TakakiAkinobu
en-aut-sei=Takaki
en-aut-mei=Akinobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KonoYoshiyasu
en-aut-sei=Kono
en-aut-mei=Yoshiyasu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HoriiJoichiro
en-aut-sei=Horii
en-aut-mei=Joichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TakahashiSakuma
en-aut-sei=Takahashi
en-aut-mei=Sakuma
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KawaiDaisuke
en-aut-sei=Kawai
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KobayashiSayo
en-aut-sei=Kobayashi
en-aut-mei=Sayo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=OkadaHiroyuki
en-aut-sei=Okada
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Internal Medicine, Japanese Red Cross Himeji Hospital
kn-affil=

affil-num=2
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Gastroenterology, National Hospital Organization Fukuyama Medical Center
kn-affil=

affil-num=6
en-affil=Department of Gastroenterology, Kagawa Prefectural Central Hospital
kn-affil=

affil-num=7
en-affil=Department of Internal Medicine, Okayama Saiseikai General Hospital
kn-affil=

affil-num=8
en-affil=Department of Internal Medicine, Fukuyama City Hospital
kn-affil=

affil-num=9
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=capsule endoscopy
kn-keyword=capsule endoscopy
en-keyword=NSAIDs
kn-keyword=NSAIDs
en-keyword=oxidative stress
kn-keyword=oxidative stress
en-keyword=small intestinal mucosal injury
kn-keyword=small intestinal mucosal injury
END

start-ver=1.4
cd-journal=joma
no-vol=31
cd-vols=
no-issue=2
article-no=
start-page=102570
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20241202
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Epidemiology and clinical features of patients with tick bites in the Japanese spotted fever-endemic zone
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Purpose: This study aimed to clarify the epidemiology and clinical features of tick bites in a Japanese spotted fever (JSF)-endemic area.<br>
Method: The clinical records of patients with tick bites were retrospectively reviewed based on a survey conducted at Numakuma Hospital, Fukuyama City, Hiroshima, Japan, from 2016 to 2023. Data on basic characteristics, visit dates, residential address, exposure activities, tick-bite sites, and prophylactic antimicrobial prescriptions for each patient with tick bites were collected at the JSF hotspot hospital.<br>
Results: A total of 443 patients with tick bites visited the hospital, of which data on 305 cases (68.8 %) were reviewed. The median age of these patients was 71 years, with a higher proportion of women (63.0 %). One-third of the patients had a preceding history of working in fields, whereas two-thirds had entered mountains or agricultural fields. Nearly 90 % of the patients visited the hospital from April to August, and the most common bite sites were the lower extremities (45.1 %). Most patients (76.1 %) resided in the southern area of Numakuma Hospital. Nearly all patients were prescribed prophylactic antibiotics (minocycline in 87.8 % of cases), and none subsequently developed JSF.<br>
Conclusion: Continued surveillance of patients with tick bites is warranted to better understand changes in the clinical impact of tick-borne diseases.
en-copyright=
kn-copyright=

en-aut-name=FukushimaShinnosuke
en-aut-sei=Fukushima
en-aut-mei=Shinnosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SumidaTakaomi
en-aut-sei=Sumida
en-aut-mei=Takaomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KawamataOsamu
en-aut-sei=Kawamata
en-aut-mei=Osamu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=HidaniYoshimi
en-aut-sei=Hidani
en-aut-mei=Yoshimi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HagiyaHideharu
en-aut-sei=Hagiya
en-aut-mei=Hideharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

affil-num=1
en-affil=Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Numakuma Hospital
kn-affil=

affil-num=3
en-affil=Numakuma Hospital
kn-affil=

affil-num=4
en-affil=Numakuma Hospital
kn-affil=

affil-num=5
en-affil=Department of Infectious Diseases, Okayama University Hospital
kn-affil=
en-keyword=Global warming
kn-keyword=Global warming
en-keyword=Japanese spotted fever
kn-keyword=Japanese spotted fever
en-keyword=Tick bite
kn-keyword=Tick bite
en-keyword=Tick-borne diseases
kn-keyword=Tick-borne diseases
END

start-ver=1.4
cd-journal=joma
no-vol=4
cd-vols=
no-issue=
article-no=
start-page=274
end-page=280
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250325
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=About Dr. Kubota Jiro who lived in Kaminishigawa, Okayama City, and his son, Tsutomu
kn-title=上西川町の窪田次郎、そして勤のこと
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=YAMASHITAHiroshi
en-aut-sei=YAMASHITA
en-aut-mei=Hiroshi
kn-aut-name=山下洋
kn-aut-sei=山下
kn-aut-mei=洋
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=4
cd-vols=
no-issue=
article-no=
start-page=80
end-page=90
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250325
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=A brief study on the gun-teki sekai (social conditions in the district) of Asuwa district in Echizen province
kn-title=古代越前国足羽郡の「郡的世界」寸考
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=　Often discussed in recent years, the term gun-teki sekai refers to the social conditions of a district. In ancient Japanese local communities, there existed complex webs of historical rule and intertwined relationships between local clans that date back to before the establishment of the Ritsury? system. Gun-teki sekai is a term that refers to the reality of the control of the provincial and district systems, in which multiple powerful clans served as gunji , district governors under the Ritsury? system. Each gunji organized smaller clans below them to carry out administrative duties based on such relationships. Recent research is beginning to reveal the multipolar structure of the gun-teki sekai .<br>
　In this study, the author examines the gun-teki sekai through an analysis of the Asuwa district in Echizen province, which is rich in historical materials. As a result, the following four points became clear. First, it is highly likely that the powerful clans who served as district governors in the mid-Nara period were traditional clans with roots in the eastern part of the district. Second, the powerful clans who served as district deputy governors may have been an emerging power. Third, from an archaeological perspective, the eastern part of the district is the traditional area, while the dominance of the western part of the district developed after the establishment of the Ritsury? system. Fourth, in terms of clan distribution, the clans who served as district governors were distributed over the widest area, followed by those who served as district deputy governors.
en-copyright=
kn-copyright=

en-aut-name=WATANABEAtsunori
en-aut-sei=WATANABE
en-aut-mei=Atsunori
kn-aut-name=渡部敦寛
kn-aut-sei=渡部
kn-aut-mei=敦寛
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Chigasaki City Museum
kn-affil=
en-keyword=Gun-teki sekai
kn-keyword=Gun-teki sekai
en-keyword=gunji（district governors under the Ritsury? system)
kn-keyword=gunji（district governors under the Ritsury? system)
en-keyword=local powerful clans
kn-keyword=local powerful clans
en-keyword=clan distribution
kn-keyword=clan distribution
en-keyword=Asuwa district
kn-keyword=Asuwa district
en-keyword=Echizen province
kn-keyword=Echizen province
END

start-ver=1.4
cd-journal=joma
no-vol=45
cd-vols=
no-issue=1
article-no=
start-page=11
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=20230323
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Mutation and apoptosis are well-coordinated for protecting against DNA damage-inducing toxicity in Drosophila
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background Apoptotic cell death is an important survival system for multicellular organisms because it removes damaged cells. Mutation is also a survival method for dealing with damaged cells in multicellular and also unicellular organisms, when DNA lesions are not removed. However, to the best of our knowledge, no reports have comprehensively explored the direct relationship between apoptosis and somatic cell mutations induced by various mutagenic factors.<br>
Results Mutation was examined by the wing-spot test, which is used to detect somatic cell mutations, including chromosomal recombination. Apoptosis was observed in the wing discs by acridine orange staining in situ. After treatment with chemical mutagens, ultraviolet light (UV), and X-ray, both the apoptotic frequency and mutagenic activity increased in a dose-dependent manner at non-toxic doses. When we used DNA repair-deficient Drosophila strains, the correlation coefficient of the relationship between apoptosis and mutagenicity, differed from that of the wild-type. To explore how apoptosis affects the behavior of mutated cells, we determined the spot size, i.e., the number of mutated cells in a spot. In parallel with an increase in apoptosis, the spot size increased with MNU or X-ray treatment dose-dependently; however, this increase was not seen with UV irradiation. In addition, BrdU incorporation, an indicator of cell proliferation, in the wing discs was suppressed at 6 h, with peak at 12 h post-treatment with X-ray, and that it started to increase again at 24 h; however, this was not seen with UV irradiation.<br>
Conclusion Damage-induced apoptosis and mutation might be coordinated with each other, and the frequency of apoptosis and mutagenicity are balanced depending on the type of DNA damage. From the data of the spot size and BrdU incorporation, it is possible that mutated cells replace apoptotic cells due to their high frequency of cell division, resulting in enlargement of the spot size after MNU or X-ray treatment. We consider that the induction of mutation, apoptosis, and/or cell growth varies in multi-cellular organisms depending on the type of the mutagens, and that their balance and coordination have an important function to counter DNA damage for the survival of the organism.
en-copyright=
kn-copyright=

en-aut-name=Toyoshima-SasataniMegumi
en-aut-sei=Toyoshima-Sasatani
en-aut-mei=Megumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ImuraFumika
en-aut-sei=Imura
en-aut-mei=Fumika
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HamatakeYuko
en-aut-sei=Hamatake
en-aut-mei=Yuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=FukunagaAkihiro
en-aut-sei=Fukunaga
en-aut-mei=Akihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=NegishiTomoe
en-aut-sei=Negishi
en-aut-mei=Tomoe
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

affil-num=1
en-affil=Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=School of Nursing, Osaka City University
kn-affil=

affil-num=5
en-affil=Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=Drosophila
kn-keyword=Drosophila
en-keyword=Apoptosis
kn-keyword=Apoptosis
en-keyword=Mutation
kn-keyword=Mutation
en-keyword=Larval wing disc
kn-keyword=Larval wing disc
en-keyword=X-ray
kn-keyword=X-ray
en-keyword=Ultraviolet
kn-keyword=Ultraviolet
en-keyword=Alkylating agents
kn-keyword=Alkylating agents
en-keyword=Tobacco smoke
kn-keyword=Tobacco smoke
en-keyword=Acridine orange
kn-keyword=Acridine orange
en-keyword=BrdU
kn-keyword=BrdU
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=cmad074
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=20230719
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Effect of 2-week postpartum check-ups on screening positive for postpartum depression: a population-based cohort study using instrumental variable estimation in Japan
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Postpartum depression is experienced by approximately 10% of women and affects the health and development of their children. Although it is recommended that all mothers have the opportunity for early detection and intervention for postpartum depression, it is unclear whether early postpartum check-ups help to reduce postpartum depression.<br>
Objective: The aim of this study was to assess the effect of 2-week postpartum check-ups on screening positive for postpartum depression in Japan.<br>
Methods: This was a population-based cohort study that used the administrative database of Tsuyama, Japan. Participants were women who received postpartum home visits from a public health nurse in Tsuyama during the fiscal years 2017?2019. Data were obtained on participant’s attendance at a 2-week postpartum check-up and their responses on the Edinburgh Postpartum Depression Scale. Owing to the initiation of a publicly funded postpartum check-up programme, participants were pseudo-randomly assigned to receive/not receive a 2-week postpartum check-up. We conducted instrumental variable estimation to assess the causal effects of the check-up on screening positive for postpartum depression.<br>
Results: The characteristics of the 1,382 participants did not differ by fiscal year of childbirth. We found a 6.7% (95% confidence interval 2.2?11.2) reduction in the prevalence of screening positive for postpartum depression as an effect of 2-week postpartum check-ups among women received 1-month postpartum home visits.<br>
Conclusion: The results suggest that 2-week postpartum check-ups are effective in reducing the prevalence of screening positive for postpartum depression among 1-month postpartum women. Despite some limitations, early postpartum care could reduce postpartum depression.
en-copyright=
kn-copyright=

en-aut-name=NakamuraNaoko
en-aut-sei=Nakamura
en-aut-mei=Naoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MitsuhashiToshiharu
en-aut-sei=Mitsuhashi
en-aut-mei=Toshiharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NakashimaYasuko
en-aut-sei=Nakashima
en-aut-mei=Yasuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MatsumotoNaomi
en-aut-sei=Matsumoto
en-aut-mei=Naomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=YorifujiTakashi
en-aut-sei=Yorifuji
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

affil-num=1
en-affil=Department of Epidemiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Health Promotion Division, Tsuyama City Department of Children’s Health
kn-affil=

affil-num=4
en-affil=Department of Epidemiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Epidemiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=community health planning
kn-keyword=community health planning
en-keyword=diagnostic screening programmes
kn-keyword=diagnostic screening programmes
en-keyword=home visits
kn-keyword=home visits
en-keyword=postpartum depression
kn-keyword=postpartum depression
en-keyword=postnatal care
kn-keyword=postnatal care
en-keyword=quasi-experimental study
kn-keyword=quasi-experimental study
END

start-ver=1.4
cd-journal=joma
no-vol=25
cd-vols=
no-issue=1
article-no=
start-page=82
end-page=89
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20241212
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Impact of high blood pressure on the risk of mortality among Japanese people aged 65?years and older
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Aim: The purpose of this study is to investigate the impact of abnormal blood pressure on the risk of all-cause and cardiovascular mortality in a large cohort of older Japanese people aged ?65?years.<br>
Methods: This cohort study enrolled 54?760 participants from Okayama City aged ?65?years who underwent basic health checkups from April 2006 to March 2008. Based on blood pressure, the participants were divided into six categories, from C1 (lowest) to C6 (highest). To assess the association of blood pressure with all-cause and cardiovascular mortality, we used survival analysis to estimate hazard ratios (HRs) for all-cause mortality and subdistribution HRs (SHRs) for cardiovascular mortality on C3. We then repeated the analyses based on age groups (65?74?years, 75?84?years, and ?85?years).<br>
Results: The fully adjusted HRs for all-cause mortality, which included all individual potential confounders, were 1.11 (95% confidence interval [CI]: 1.04?1.19) for C5 and 1.23 (95% CI: 1.09?1.38) for C6, respectively. The fully adjusted SHRs for cardiovascular mortality were 1.11 (95% CI: 1.01?1.21) for C4, 1.19 (95% CI: 1.05?1.34) for C5, and 1.36 (95% CI: 1.09?1.70) for C6. In the age-stratification, an increased risk of hypotension was observed with older age. The HR for C1 was 1.28 (95% CI: 1.16?1.41) for ?85?years.<br>
Conclusions: Hypertension increased the risk of all-cause and cardiovascular mortality among those aged 65?74 and 75?84?years, but not among those aged ?85?years. Geriatr Gerontol Int 2024; ??: ?????.
en-copyright=
kn-copyright=

en-aut-name=AkagiShinsuke
en-aut-sei=Akagi
en-aut-mei=Shinsuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TakaoSoshi
en-aut-sei=Takao
en-aut-mei=Soshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MatsuoRumi
en-aut-sei=Matsuo
en-aut-mei=Rumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MatsumotoNaomi
en-aut-sei=Matsumoto
en-aut-mei=Naomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=YorifujiTakashi
en-aut-sei=Yorifuji
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

affil-num=1
en-affil=Department of Epidemiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Epidemiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Epidemiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Epidemiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=5
en-affil=Department of Epidemiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=all-cause mortality
kn-keyword=all-cause mortality
en-keyword=cardiovascular disease
kn-keyword=cardiovascular disease
en-keyword=hypertension
kn-keyword=hypertension
en-keyword=Japanese older adults
kn-keyword=Japanese older adults
en-keyword=survival analysis
kn-keyword=survival analysis
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20241216
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Trends in the growing impact of group A Streptococcus infection on public health after COVID-19 pandemic: a multicentral observational study in Okayama, Japan
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Purpose Following the COVID-19 pandemic, group A Streptococcus (GAS) infection has been surging worldwide. We aimed to compare the disease burden between notified cases of streptococcal toxic shock syndrome (STSS) and unreported GAS infections.<br>
Methods This is a multicentral observational study, retrospectively performed at seven hospitals in Okayama prefecture in Japan from January 2022, to June 2024. Clinical and microbiological data of patients with positive cultures of GAS were collected from the medical records. Primary outcomes were defined as rates of surgical procedures, intensive care unit (ICU) admission, and in-hospital mortality, which were compared among patients with locally-defined STSS, invasive GAS (iGAS), and non-iGAS infection.<br>
Results GAS was detected in 181 patients, with 154 active cases of GAS infection. The number of patients with GAS infection surged in late 2023. The most common source of infection was skin and soft tissue infections, accounting for 83 cases, including 15 cases of necrotizing fasciitis, and 12 cases (7.8%) were notified to public health authorities as STSS. Among the 25 unreported iGAS cases, 9 (36.0%) underwent surgical intervention, and 4 patients (16.0%) required ICU admission. The mortality rates in the unreported iGAS cases were comparable to those observed in the notified STSS.<br>
Conclusions We highlighted that the number of iGAS infections was twofold higher than that of notified STSS, with comparable mortality rate between these groups, indicating substantial underestimation of the true burden of iGAS. This epidemiological investigation has significant implications for enhancing infectious disease surveillance frameworks and public health policy development.
en-copyright=
kn-copyright=

en-aut-name=FukushimaShinnosuke
en-aut-sei=Fukushima
en-aut-mei=Shinnosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SaitoTakashi
en-aut-sei=Saito
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=IwamotoYoshitaka
en-aut-sei=Iwamoto
en-aut-mei=Yoshitaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TakeharaYuko
en-aut-sei=Takehara
en-aut-mei=Yuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=YamadaHaruto
en-aut-sei=Yamada
en-aut-mei=Haruto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=FujitaKoji
en-aut-sei=Fujita
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=YoshidaMasayo
en-aut-sei=Yoshida
en-aut-mei=Masayo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=NakanoYasuhiro
en-aut-sei=Nakano
en-aut-mei=Yasuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=HagiyaHideharu
en-aut-sei=Hagiya
en-aut-mei=Hideharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of General Medicine, NHO Okayama Medical Center
kn-affil=

affil-num=3
en-affil=Department of General Medicine, NHO Okayama Medical Center
kn-affil=

affil-num=4
en-affil=Department of Surgery, Okayama Saiseikai General Hospital
kn-affil=

affil-num=5
en-affil=Department of General Medicine, Okayama City Hospital
kn-affil=

affil-num=6
en-affil=Department of General Medicine and Infectious Diseases, Tsuyama Chuo Hospital
kn-affil=

affil-num=7
en-affil=Department of General Medicine, Okayama Kyoritsu Hospital
kn-affil=

affil-num=8
en-affil=Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Infectious Diseases, Okayama University Hospital
kn-affil=
en-keyword=Epidemiology
kn-keyword=Epidemiology
en-keyword=Group A Streptococcus
kn-keyword=Group A Streptococcus
en-keyword=Necrotizing fasciitis
kn-keyword=Necrotizing fasciitis
en-keyword=Streptococcal toxic shock syndrome
kn-keyword=Streptococcal toxic shock syndrome
en-keyword=Surveillance
kn-keyword=Surveillance
END

start-ver=1.4
cd-journal=joma
no-vol=77
cd-vols=
no-issue=
article-no=
start-page=1
end-page=13
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20241216
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Location characteristics of textile-related business establishments in major industrial cities in the Sanbi region
kn-title=三備地域の主要工業都市における繊維関連事業所の立地特性
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=KITAGAWAHirofumi
en-aut-sei=KITAGAWA
en-aut-mei=Hirofumi
kn-aut-name=北川博史
kn-aut-sei=北川
kn-aut-mei=博史
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=16
cd-vols=
no-issue=23
article-no=
start-page=4089
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20241206
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Frequency and Significance of Body Weight Loss During Immunochemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Limited data are available on the frequency and significance of body weight loss during cancer therapy. This study investigated the frequency of patients who experienced body weight loss during immune checkpoint inhibitor (ICI) plus chemotherapy for advanced non-small cell lung cancer (NSCLC) and the impact of weight loss on treatment outcomes. Methods: Using the clinical data of 370 patients with NSCLC who received a combination of ICI and chemotherapy at 13 institutions, this study investigated the frequency of body weight loss > 5% during treatment and determined the impact of body weight loss on patient outcomes. Results: Of the 370 included patients, 141 (38.1%) lost more than 5% of their body weight during ICI plus chemotherapy (WL group). The 2-month landmark analysis showed that patients who experienced body weight loss of >5% during treatment had worse overall survival (OS) and progression-free survival (PFS) than those who did not (OS 14.0 and 31.1 months in the WL non-WL groups, respectively, p < 0.001; PFS 6.8 and 10.9 months in the WL non-WL groups, respectively, p = 0.002). Furthermore, a negative impact of body weight loss on survival was observed even in those who had obesity (body mass index [BMI] >= 25.0) at the start of therapy (OS 12.8 and 25.4 months in the WL non-WL groups, respectively, p < 0.001; PFS 5.7 and 10.7 months in the WL non-WL groups, respectively, p = 0.038). Conclusions: In conclusion, weight loss of >5% during ICI plus chemotherapy negatively influenced patient outcomes. Further and broader studies should investigate the role of nutritional status, specifically weight change and nutritional support, in responsiveness to ICI plus chemotherapy.
en-copyright=
kn-copyright=

en-aut-name=TaokaMasataka
en-aut-sei=Taoka
en-aut-mei=Masataka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=IchiharaEiki
en-aut-sei=Ichihara
en-aut-mei=Eiki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YokoyamaToshihide
en-aut-sei=Yokoyama
en-aut-mei=Toshihide
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=InoueKoji
en-aut-sei=Inoue
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TamuraTomoki
en-aut-sei=Tamura
en-aut-mei=Tomoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=SatoAkiko
en-aut-sei=Sato
en-aut-mei=Akiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=OdaNaohiro
en-aut-sei=Oda
en-aut-mei=Naohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KanoHirohisa
en-aut-sei=Kano
en-aut-mei=Hirohisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=NakamuraKayo
en-aut-sei=Nakamura
en-aut-mei=Kayo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=KawaiHaruyuki
en-aut-sei=Kawai
en-aut-mei=Haruyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=InoueMasaaki
en-aut-sei=Inoue
en-aut-mei=Masaaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=OchiNobuaki
en-aut-sei=Ochi
en-aut-mei=Nobuaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=FujimotoNobukazu
en-aut-sei=Fujimoto
en-aut-mei=Nobukazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=IchikawaHirohisa
en-aut-sei=Ichikawa
en-aut-mei=Hirohisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=AndoChihiro
en-aut-sei=Ando
en-aut-mei=Chihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=OzeIsao
en-aut-sei=Oze
en-aut-mei=Isao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=KiuraKatsuyuki
en-aut-sei=Kiura
en-aut-mei=Katsuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=MaedaYoshinobu
en-aut-sei=Maeda
en-aut-mei=Yoshinobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=HottaKatsuyuki
en-aut-sei=Hotta
en-aut-mei=Katsuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

affil-num=1
en-affil=Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Center for Clinical Oncology, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Respiratory Medicine, Ohara Healthcare Foundation, Kurashiki Central Hospital
kn-affil=

affil-num=4
en-affil=Department of Respiratory Medicine, Ehime Prefectural Central Hospital
kn-affil=

affil-num=5
en-affil=Department of Respiratory Medicine, NHO Iwakuni Clinical Center
kn-affil=

affil-num=6
en-affil=Department of Internal Medicine, National Hospital Organization Okayama Medical Center
kn-affil=

affil-num=7
en-affil=Department of Respiratory Medicine, Fukuyama City Hospital
kn-affil=

affil-num=8
en-affil=Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital
kn-affil=

affil-num=9
en-affil=Department of Respiratory Medicine, Japanese Red Cross Himeji Hospital
kn-affil=

affil-num=10
en-affil=Department of Internal Medicine, Okayama Saiseikai General Hospital
kn-affil=

affil-num=11
en-affil=Department of Chest Surgery, Shimonoseki City Hospital
kn-affil=

affil-num=12
en-affil=Department of General Internal Medicine 4 , Kawasaki Medical School
kn-affil=

affil-num=13
en-affil=Department of Respiratory Medicine, Okayama Rosai Hospital
kn-affil=

affil-num=14
en-affil=Department of Respiratory Medicine, KKR Takamatsu Hospital
kn-affil=

affil-num=15
en-affil=Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital
kn-affil=

affil-num=16
en-affil=Division of Cancer Information and Control, Aichi Cancer Center Research Institute
kn-affil=

affil-num=17
en-affil=Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=18
en-affil=Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=19
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=
en-keyword=non-small cell lung cancer
kn-keyword=non-small cell lung cancer
en-keyword=body weight loss
kn-keyword=body weight loss
en-keyword=immune checkpoint inhibitors
kn-keyword=immune checkpoint inhibitors
en-keyword=chemotherapy
kn-keyword=chemotherapy
END

start-ver=1.4
cd-journal=joma
no-vol=12
cd-vols=
no-issue=
article-no=
start-page=1434800
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20241127
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Efficacy of extracting and preventively intervening late-stage older adults who are at high risk for spending high medical costs by using the health check-up system in Japan: a pilot study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Objectives: In Japan, the seven diseases (femur fracture, cerebral infarction, chronic renal failure, heart failure, dementia, pneumonia, and chronic obstructive pulmonary disease) are the top causes of inpatient medical costs among the late-stage older adults aged 75 years and over. This pilot study was conducted with the following two objectives; (1) to examine the proportion of risks of onset and severity of seven diseases among the late-stage older adults, and (2) to examine the efficacy of interventions focusing on the prevention of unplanned hospitalization. <br>
Methods: Participants were 45,233 older adults aged 75 and over living in Kure City, Japan. In addition to the government-mandated health checkup items, the Intervention group underwent additional risk screening tests included questionnaires, physical examinations, blood tests, and educational guidance by nurses. The efficacy of the intervention was examined whether there were differences in the number of hospitalizations, the use of emergency and critical care, and the incidence of hemodialysis induction between the Intervention and control groups (Usual Health Checkup group and No Health Checkup group) for the 2 years. <br>
Results: There were 485 participants in the Intervention group, 1,067 in the Usual Health Checkup group, and 43,712 in the No Health Checkup group. As the risks of seven diseases in the Intervention group, the largest proportion of deviations occurred for systolic blood pressure (63.3%), estimated salt intake (60.3%), and low-density lipoprotein cholesterol (51.5%). Estimated glomerular filtration rate deviated in 41.0%, N-terminal pro b-type natriuretic peptide in 37.9%. 7.5% scored <2 points on the Mini-Cog (c), and 9.1% performed the Timed Up and Go test in >12 s. The incidence of hospitalization due to any of the seven diseases was significantly higher in the No Health Checkup group (p < 0.001). There were no differences among the three groups in the use of emergency and critical care or the introduction of hemodialysis. <br>
Conclusion: This study revealed that additional health checkup tests and intervention methods could be prevented hospitalization among the adults of 75 years and older. It is necessary to make health checkups and follow-ups more accessible those are already available within the existing health system in Japan.
en-copyright=
kn-copyright=

en-aut-name=KazawaKana
en-aut-sei=Kazawa
en-aut-mei=Kana
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KawaiMadoka
en-aut-sei=Kawai
en-aut-mei=Madoka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MoriyamaMichiko
en-aut-sei=Moriyama
en-aut-mei=Michiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

affil-num=1
en-affil=Faculty of Health Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Division of Nursing Science, Graduate School of Biomedical and Health Sciences, Hiroshima University
kn-affil=

affil-num=3
en-affil=Division of Nursing Science, Graduate School of Biomedical and Health Sciences, Hiroshima University
kn-affil=
en-keyword=older adults
kn-keyword=older adults
en-keyword=health checkups
kn-keyword=health checkups
en-keyword=health risk
kn-keyword=health risk
en-keyword=hospitalization
kn-keyword=hospitalization
en-keyword=education
kn-keyword=education
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=6
article-no=
start-page=439
end-page=447
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202412
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Risk Factors for Gangrenous Cholecystitis and the Outcomes of Early Cholecystectomy: A Retrospective Study of a Single-Center City General Hospital
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Gangrenous cholecystitis (GC) is classified as moderate acute cholecystitis according to the Tokyo Guidelines from 2018 (TG18). We evaluated the risk factors for GC and the outcomes of early cholecystectomy. A total of 136 patients who underwent emergency cholecystectomy for acute cholecystitis were retrospectively analyzed; 58 of these patients (42.6%) were diagnosed with GC (GC group) based on our retrospective pathologic diagnosis. We comparatively evaluated the patient backgrounds and surgical outcomes between the GC group and non-GC group. The GC group was significantly older and included more hypertensive patients than the non-GC group. The GC group was prescribed more antibiotics as initial treatment than the non-GC group, and they had more days between onset and surgery. The preoperative white blood cell count and C-reactive protein values were significantly higher in the GC group than in the non-GC group, and these values were predictive factors for GC. Cholecystectomy required a longer operation time and caused greater blood loss in the GC group. The GC group also had longer hospitalization times than the non-GC group; however, no significant differences were observed in terms of postoperative complications. In conclusion, gangrenous changes should be assessed when diagnosing cholecystitis, and appropriate treatment, such as surgery or drainage, should be undertaken.
en-copyright=
kn-copyright=

en-aut-name=YamashitaMampei
en-aut-sei=Yamashita
en-aut-mei=Mampei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TanakaTakayuki
en-aut-sei=Tanaka
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=SumidaYorihisa
en-aut-sei=Sumida
en-aut-mei=Yorihisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YamazakiShoto
en-aut-sei=Yamazaki
en-aut-mei=Shoto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HaraYuki
en-aut-sei=Hara
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=FukudaAkiko
en-aut-sei=Fukuda
en-aut-mei=Akiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=HisanagaMakoto
en-aut-sei=Hisanaga
en-aut-mei=Makoto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=WakataKoki
en-aut-sei=Wakata
en-aut-mei=Koki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=ArakiMasato
en-aut-sei=Araki
en-aut-mei=Masato
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=EguchiSusumu
en-aut-sei=Eguchi
en-aut-mei=Susumu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Department of Surgery, Sasebo City General Hospital
kn-affil=

affil-num=2
en-affil=Department of Surgery, Sasebo City General Hospital
kn-affil=

affil-num=3
en-affil=Department of Surgery, Sasebo City General Hospital
kn-affil=

affil-num=4
en-affil=Department of Surgery, Sasebo City General Hospital
kn-affil=

affil-num=5
en-affil=Department of Surgery, Sasebo City General Hospital
kn-affil=

affil-num=6
en-affil=Department of Surgery, Sasebo City General Hospital
kn-affil=

affil-num=7
en-affil=Department of Surgery, Sasebo City General Hospital
kn-affil=

affil-num=8
en-affil=Department of Surgery, Sasebo City General Hospital
kn-affil=

affil-num=9
en-affil=Department of Surgery, Sasebo City General Hospital
kn-affil=

affil-num=10
en-affil=Department of Surgery, Nagasaki University Graduate School of Biomedical Science
kn-affil=
en-keyword=gangrenous
kn-keyword=gangrenous
en-keyword=cholecystitis
kn-keyword=cholecystitis
en-keyword=acute cholecystitis
kn-keyword=acute cholecystitis
en-keyword=laparoscopic cholecystectomy
kn-keyword=laparoscopic cholecystectomy
END

start-ver=1.4
cd-journal=joma
no-vol=13
cd-vols=
no-issue=22
article-no=
start-page=6870
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20241115
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=The Clinical Significance of Interstitial Pneumonia with Autoimmune Features in Cryptogenic Organizing Pneumonia: A Prospective Multicenter Observational Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: There are cases of idiopathic interstitial pneumonias (IIPs) that do not meet the diagnostic criteria for connective tissue disease but have clinical features suggestive of autoimmune process. Interstitial pneumonia with autoimmune features (IPAF) was recently proposed as a research concept for these patients. Although several prospective studies on IPAF have been conducted, its clinical significance in cryptogenic organizing pneumonia (COP) remains unclear. Methods: Patients aged >= 20 years with suspected COP were prospectively enrolled between June 2018 and December 2022. Among the enrolled patients, those diagnosed with COP based on computed tomography (CT) and bronchoalveolar lavage (BAL) findings were compared between the IPAF and non-IPAF groups. Results: A total of 56 patients were enrolled in this study. Of these, 30 were diagnosed with COP and included in the analysis. Clinical and serological features were positive in two and six patients, respectively. Each feature was exclusive, and eight patients (26.7%) were diagnosed with IPAF. There were no differences between the IPAF and non-IPAF groups in terms of clinical features, including BAL findings, laboratory data, CT findings, and clinical course. During the one-year follow-up period, the frequency of COP exacerbation did not differ between the IPAF and non-IPAF groups, and no cases of systemic autoimmune disease or death occurred in either group. Conclusions: The COP characteristics of the IPAF and non-IPAF groups are similar in all aspects, and distinguishing between the two groups may be of little significance.
en-copyright=
kn-copyright=

en-aut-name=HigoHisao
en-aut-sei=Higo
en-aut-mei=Hisao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=IchikawaHirohisa
en-aut-sei=Ichikawa
en-aut-mei=Hirohisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=ArakawaYukako
en-aut-sei=Arakawa
en-aut-mei=Yukako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MoriYoshihiro
en-aut-sei=Mori
en-aut-mei=Yoshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TamuraTomoki
en-aut-sei=Tamura
en-aut-mei=Tomoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KuyamaShoichi
en-aut-sei=Kuyama
en-aut-mei=Shoichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MatsumotoChiaki
en-aut-sei=Matsumoto
en-aut-mei=Chiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=SugimotoKeisuke
en-aut-sei=Sugimoto
en-aut-mei=Keisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=HamadaNoboru
en-aut-sei=Hamada
en-aut-mei=Noboru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=SuwakiToshimitsu
en-aut-sei=Suwaki
en-aut-mei=Toshimitsu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=ItanoJunko
en-aut-sei=Itano
en-aut-mei=Junko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=TanimotoYasushi
en-aut-sei=Tanimoto
en-aut-mei=Yasushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=SenooSatoru
en-aut-sei=Senoo
en-aut-mei=Satoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=TaniguchiAkihiko
en-aut-sei=Taniguchi
en-aut-mei=Akihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=InukaiYumi
en-aut-sei=Inukai
en-aut-mei=Yumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=AritaMachiko
en-aut-sei=Arita
en-aut-mei=Machiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=MakimotoSatoko
en-aut-sei=Makimoto
en-aut-mei=Satoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=KojimaKatsuhide
en-aut-sei=Kojima
en-aut-mei=Katsuhide
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=MatsushitaTakashi
en-aut-sei=Matsushita
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=MaedaYoshinobu
en-aut-sei=Maeda
en-aut-mei=Yoshinobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=MiyaharaNobuaki
en-aut-sei=Miyahara
en-aut-mei=Nobuaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

affil-num=1
en-affil=Department of Allergy and Respiratory Medicine, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Respiratory Medicine, KKR Takamatsu Hospital
kn-affil=

affil-num=3
en-affil=Department of Respiratory Medicine, KKR Takamatsu Hospital
kn-affil=

affil-num=4
en-affil=Department of Respiratory Medicine, KKR Takamatsu Hospital
kn-affil=

affil-num=5
en-affil=Department of Respiratory Medicine, National Hospital Organization Iwakuni Clinical Center
kn-affil=

affil-num=6
en-affil=Department of Respiratory Medicine, National Hospital Organization Iwakuni Clinical Center
kn-affil=

affil-num=7
en-affil=Department of Respiratory Medicine, Japanese Red Cross Kobe Hospital
kn-affil=

affil-num=8
en-affil=Department of Respiratory Medicine, Japanese Red Cross Kobe Hospital
kn-affil=

affil-num=9
en-affil=Department of Respiratory Medicine, Okayama City Hospital
kn-affil=

affil-num=10
en-affil=Department of Respiratory Medicine, Okayama City Hospital
kn-affil=

affil-num=11
en-affil=Department of Allergy and Respiratory Medicine, National Hospital Organization Minami-Okayama Medical Center
kn-affil=

affil-num=12
en-affil=Department of Allergy and Respiratory Medicine, National Hospital Organization Minami-Okayama Medical Center
kn-affil=

affil-num=13
en-affil=Department of Respiratory Medicine, Fukuyama Medical Center
kn-affil=

affil-num=14
en-affil=Department of Respiratory Medicine, Fukuyama Medical Center
kn-affil=

affil-num=15
en-affil=Department of Allergy and Respiratory Medicine, Okayama University Hospital
kn-affil=

affil-num=16
en-affil=Department of Respiratory Medicine, Kurashiki Central Hospital
kn-affil=

affil-num=17
en-affil=Department of Radiology, Okayama University Hospital
kn-affil=

affil-num=18
en-affil=Department of Radiology, Okayama University Hospital
kn-affil=

affil-num=19
en-affil=Department of Dermatology, Kanazawa University Graduate School of Medical Science
kn-affil=

affil-num=20
en-affil=Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=21
en-affil=Department of Allergy and Respiratory Medicine, Okayama University Hospital
kn-affil=
en-keyword=interstitial pneumonia with autoimmune features
kn-keyword=interstitial pneumonia with autoimmune features
en-keyword=cryptogenic organizing pneumonia
kn-keyword=cryptogenic organizing pneumonia
en-keyword=bronchoalveolar lavage
kn-keyword=bronchoalveolar lavage
en-keyword=prospective multicenter observational study
kn-keyword=prospective multicenter observational study
en-keyword=connective tissue disease
kn-keyword=connective tissue disease
END

start-ver=1.4
cd-journal=joma
no-vol=6
cd-vols=
no-issue=4
article-no=
start-page=463
end-page=469
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=2023
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Effectiveness of the Original COVID-19 Vaccine against COVID-19 Exacerbations during the Omicron Wave: A Population-based Study in Okayama, Japan
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Introduction: In Japan, approximately 97 million individuals have received their primary two doses of coronavirus disease 2019 (COVID-19) vaccine at the end of 2022. In this study, we aim to examine the effectiveness of the primary vaccines and compare its efficacy to booster vaccine shots in terms of preventing COVID-19 exacerbations during the Omicron-predominant period in Japan.<br>
Methods: For this analysis, we have collected all the confirmed COVID-19-positive cases from different medical institutions in Okayama City and have also utilized the information from the public Vaccination Record System. Taking the number of vaccinations into consideration, we then conducted a population-based study to assess the effectiveness of the two primary vaccine doses in preventing COVID-19 exacerbations during the Omicron waves. Our primary and secondary outcomes were COVID-19 exacerbations with respiratory failure (i.e., oxygen saturation on room air ? 93%, requiring supplemental oxygen), intensive care unit admission and/or mechanical ventilator requirement, or death, in accordance with the Japanese COVID-19 guidelines, and pneumonia during the course of COVID-19 infection, respectively.<br>
Results: In total, 95,329 COVID-19-positive individuals, aged 5 years and above, were included in this analysis (study period from January 1 to September 10, 2022). As per our findings, the effectiveness of the primary two doses against COVID-19 exacerbations compared with those who had never been vaccinated was 55.5% (95% confidential interval [CI]: 32.6-71.7), whereas it was higher after the third dose (76.9%; 95% CI: 66.7-84.0) and the fourth dose (75.7%; 95% CI: 58.8-85.7). Effectiveness was sustained for ? 5 months after the third vaccination, and preventive effectiveness was observed in individuals aged ? 65 years.<br>
Conclusions: As per the results of this study, we can conclude that the efficacy of the primary two doses of SARS-CoV-2 vaccine can be further strengthened in terms of preventing COVID-19 exacerbations by administering third and fourth booster vaccine shots. The additional bivalent vaccine is anticipated to further increase its efficacy against the Omicron strain, suggesting that individuals who have not received their booster shots yet should consider getting them to prevent COVID-19 exacerbations.
en-copyright=
kn-copyright=

en-aut-name=MatsumotoNaomi
en-aut-sei=Matsumoto
en-aut-mei=Naomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MitsuhashiToshiharu
en-aut-sei=Mitsuhashi
en-aut-mei=Toshiharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MatsuoRumi
en-aut-sei=Matsuo
en-aut-mei=Rumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KadowakiTomoka
en-aut-sei=Kadowaki
en-aut-mei=Tomoka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TakaoSoshi
en-aut-sei=Takao
en-aut-mei=Soshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=YorifujiTakashi
en-aut-sei=Yorifuji
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Department of Epidemiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=5
en-affil=Department of Epidemiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=6
en-affil=Department of Epidemiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=COVID-19
kn-keyword=COVID-19
en-keyword=Vaccine
kn-keyword=Vaccine
en-keyword=Omicron
kn-keyword=Omicron
en-keyword=Prevention
kn-keyword=Prevention
en-keyword=Pneumonia
kn-keyword=Pneumonia
END

start-ver=1.4
cd-journal=joma
no-vol=68
cd-vols=
no-issue=6
article-no=
start-page=641
end-page=650
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20241108
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Relationships among eye dimensions in magnetic resonance images by sex, age, and strabismus type in Japanese patients with acquired strabismus and high myopia
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Purpose To investigate the relationships among eye dimensions in magnetic resonance imaging (MRI) scans by sex, age, and strabismus type in Japanese patients with acquired strabismus and high myopia.<br>
Study design Retrospective clinical case series.<br>
Methods We included 58 eyes of 29 patients with acquired strabismus and high myopia (mean age ± standard deviation: 60.2 ± 14.7 years, axial length [AL]: 28.69 ± 2.12 mm). For all eyes, the equatorial diameter of the globe/AL ratio (EAR) and the globe/orbit volume ratio (GOR) were measured using MRI. EAR and GOR values were compared between the following groups: 9 men vs. 20 women; 8 younger (< 56 years) vs. 21 older (? 56 years) patients; and non-esotropia strabismus (NES: 7 patients) vs. esotropia (ET: 13 patients) vs. restrictive strabismus (RS: 9 patients) groups.<br>
Results Female patients had a smaller EAR (0.87 ± 0.07) and larger GOR (0.38 ± 0.04) than male patients (0.92 ± 0.05 and 0.35 ± 0.03, both P < 0.01). Older patients had a smaller EAR (0.87 ± 0.07) than younger ones (0.93 ± 0.04, P < 0.01), without significant differences in GOR. EAR (NES: 0.92 ± 0.06, ET: 0.86 ± 0.06, RS: 0.89 ± 0.09) significantly differed among the three strabismus groups (P = 0.02: post-hoc test: NES vs. ET, P = 0.02; NES vs. RS, P = 0.49; RS vs. ET, P = 0.67), but no significant differences in GOR were found (P = 0.12).<br>
Conclusions Among patients with acquired strabismus and high myopia, women, older patients, and those with esotropia exhibit a smaller EAR and longer sphere shape with AL as the major axis. The parameter EAR might be useful for evaluating the pathogenesis of strabismus associated with high myopia.
en-copyright=
kn-copyright=

en-aut-name=KonoReika
en-aut-sei=Kono
en-aut-mei=Reika
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HamasakiIchiro
en-aut-sei=Hamasaki
en-aut-mei=Ichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KishimotoFumiko
en-aut-sei=Kishimoto
en-aut-mei=Fumiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=ShimizuTakehiro
en-aut-sei=Shimizu
en-aut-mei=Takehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KindoHiroya
en-aut-sei=Kindo
en-aut-mei=Hiroya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=ShibataKiyo
en-aut-sei=Shibata
en-aut-mei=Kiyo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MorisawaShin
en-aut-sei=Morisawa
en-aut-mei=Shin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=MorizaneYuki
en-aut-sei=Morizane
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Division of Ophthalmology, Ibara City Hospital
kn-affil=

affil-num=4
en-affil=Division of Ophthalmology, Okayama City Hospital
kn-affil=

affil-num=5
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=
en-keyword=High myopia
kn-keyword=High myopia
en-keyword=Strabismus
kn-keyword=Strabismus
en-keyword=Eye dimensions
kn-keyword=Eye dimensions
en-keyword=Magnetic resonance imaging
kn-keyword=Magnetic resonance imaging
en-keyword=Esotropia
kn-keyword=Esotropia
END

start-ver=1.4
cd-journal=joma
no-vol=24
cd-vols=
no-issue=1
article-no=
start-page=366
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20241120
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=The required experience of open pancreaticoduodenectomy before becoming a specialist in hepatobiliary and pancreatic surgeons: a multicenter, cohort study of 334 open pancreaticoduodenectomies
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background Open pancreaticoduodenectomy (OPD) is an essential surgical procedure for expert hepato-biliary-pancreatic (HBP) surgeons. However, there is no standard for how many surgeries must be performed by a surgeon in training before they are considered to have enough experience to ensure surgical safety. <br>
Methods Cumulative Sum (CUSUM) analysis was performed using the surgical data of OPDs performed during the training period of board-certified expert surgeons of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. <br>
Results Fourteen HBP surgeons participated in this study and performed 334 OPDs during their training period. The median (interquartile range) values for operative time, blood loss, and length of hospital stay were 455 (397-519) minutes, 450 (234--716) ml, and 28 (21-38) days, respectively. CUSUM analysis showed inflection points at 20 surgeries performed for operative time. After 20 procedures, operative time was significantly shorter (461 min vs. 425 min, p = 0.021) and blood loss was significantly lower (470 ml vs. 340 ml, p = 0.038). No significant differences between within 20 and after 21 procedures were found in the complication rate (53% vs. 48%, p = 0.424) and rate of in-hospital deaths (1.5% vs.1.4%. p = 0.945). Up to 20 surgeries, PDAC and another malignant tumor had longer operative time than benign/low malignant diseases (486 min vs. 472 min vs. 429 min, p < 0.001), and higher blood loss (500 ml vs. 502 ml vs. 355 ml, p < 0.001). Mortality rate was higher at PDAC cases (5% vs. 0% vs. 0%, p = 0.01). After the 21 procedures, these outcomes were improved and no differences in by primary disease were observed. Multivariable analysis showed that within 20 surgeries were independent risk factors of longer operative time (HR2.6, p = 0.013) and higher blood loss (HR2.0, p = 0.049). <br>
Conclusions To stabilize the surgical outcome of OPD for malignant disease, at least 20 surgeries should be performed at a certified institution during surgeon training. Trial registrationClinical trial number: Not applicable.
en-copyright=
kn-copyright=

en-aut-name=FujiTomokazu
en-aut-sei=Fuji
en-aut-mei=Tomokazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=UmedaYuzo
en-aut-sei=Umeda
en-aut-mei=Yuzo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TakagiKosei
en-aut-sei=Takagi
en-aut-mei=Kosei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=HiokiMasayoshi
en-aut-sei=Hioki
en-aut-mei=Masayoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=YoshidaRyuichi
en-aut-sei=Yoshida
en-aut-mei=Ryuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=EndoYoshikatsu
en-aut-sei=Endo
en-aut-mei=Yoshikatsu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=YasuiKazuya
en-aut-sei=Yasui
en-aut-mei=Kazuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=NobuokaDaisuke
en-aut-sei=Nobuoka
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MitsuhashiToshiharu
en-aut-sei=Mitsuhashi
en-aut-mei=Toshiharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=FujiwaraToshiyoshi
en-aut-sei=Fujiwara
en-aut-mei=Toshiyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Department of Gastroenterological Surgery Dentistry, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Gastroenterological Surgery Dentistry, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Gastroenterological Surgery Dentistry, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Surgery, Fukuyama City Hospital
kn-affil=

affil-num=5
en-affil=Department of surgery, Hiroshima Citizens Hiroshima Citizens Hospital
kn-affil=

affil-num=6
en-affil=Department of Surgery, Japanese Red Cross Society Himeji Hospital
kn-affil=

affil-num=7
en-affil=Department of Gastroenterological Surgery Dentistry, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Gastroenterological Surgery, Kagawa Prefectural Central Hospital
kn-affil=

affil-num=9
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=

affil-num=10
en-affil=Department of Gastroenterological Surgery Dentistry, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=
en-keyword=Education
kn-keyword=Education
en-keyword=High-volume hospital
kn-keyword=High-volume hospital
en-keyword=Learning curve
kn-keyword=Learning curve
en-keyword=Pancreaticoduodenectomy
kn-keyword=Pancreaticoduodenectomy
END

start-ver=1.4
cd-journal=joma
no-vol=13
cd-vols=
no-issue=22
article-no=
start-page=e038137
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20241119
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Eight-Year Outcomes of Cardiosphere-Derived Cells in Single Ventricle Congenital Heart Disease
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Cardiosphere‐derived cell (CDC) infusion was associated with better clinical outcomes at 2?years in patients with single ventricle heart disease. The current study investigates time‐to‐event outcomes at 8?years.<br>
Methods and Results: This cohort enrolled patients with single ventricles who underwent stage 2 or stage 3 palliation from January 2011 to January 2015 at 8 centers in Japan. The primary outcomes were time‐dependent CDC treatment effects on death and late complications during 8?years of follow‐up, assessed by restricted mean survival time. Among 93 patients enrolled (mean age, 2.3±1.3?years; 56% men), 40 received CDC infusion. Overall survival for CDC‐treated versus control patients did not differ at 8?years (hazard ratio [HR], 0.60 [95% CI, 0.21?1.77]; P=0.35). Treatment effect had nonproportional hazards for death favoring CDCs at 4?years (restricted mean survival time difference +0.33?years [95% CI, 0.01?0.66]; P=0.043). In patients with heart failure with reduced ejection fraction, CDC treatment effect on survival was greater over 8?years (restricted mean survival time difference +1.58?years [95% CI, 0.05?3.12]; P=0.043). Compared with control participants, CDC‐treated patients showed lower incidences of late failure (HR, 0.45 [95% CI, 0.21?0.93]; P=0.027) and adverse events (subdistribution HR, 0.50 [95% CI, 0.27?0.94]; P=0.036) at 8?years.<br>
Conclusions: By 8?years, CDC infusion was associated with lower hazards of late failure and adverse events in single ventricle heart disease. CDC treatment effect on survival was notable by 4?years and showed a durable clinical benefit in patients with heart failure with reduced ejection fraction over 8?years.<br>
Registration: URL: https://www.clinicaltrials.gov; Unique identifiers: NCT01273857 and NCT01829750.
en-copyright=
kn-copyright=

en-aut-name=HiraiKenta
en-aut-sei=Hirai
en-aut-mei=Kenta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SawadaRyusuke
en-aut-sei=Sawada
en-aut-mei=Ryusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HayashiTomohiro
en-aut-sei=Hayashi
en-aut-mei=Tomohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=ArakiToru
en-aut-sei=Araki
en-aut-mei=Toru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=NakagawaNaomi
en-aut-sei=Nakagawa
en-aut-mei=Naomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KondoMaiko
en-aut-sei=Kondo
en-aut-mei=Maiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=YasudaKenji
en-aut-sei=Yasuda
en-aut-mei=Kenji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=HirataTakuya
en-aut-sei=Hirata
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=SatoTomoyuki
en-aut-sei=Sato
en-aut-mei=Tomoyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=NakatsukaYuki
en-aut-sei=Nakatsuka
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=YoshidaMichihiro
en-aut-sei=Yoshida
en-aut-mei=Michihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=KasaharaShingo
en-aut-sei=Kasahara
en-aut-mei=Shingo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=BabaKenji
en-aut-sei=Baba
en-aut-mei=Kenji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=OhHidemasa
en-aut-sei=Oh
en-aut-mei=Hidemasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=the TICAP/PERSEUS Study Group
en-aut-sei=the TICAP/PERSEUS Study Group
en-aut-mei=
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

affil-num=1
en-affil=Department of Pediatrics Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Pharmacology Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Pediatrics Kurashiki Central Hospital
kn-affil=

affil-num=4
en-affil=Department of Pediatrics National Hospital Organization Fukuyama Medical Center
kn-affil=

affil-num=5
en-affil=Department of Pediatric Cardiology Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=6
en-affil=Department of Pediatrics Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Pediatrics Shimane University Faculty of Medicine
kn-affil=

affil-num=8
en-affil=Department of Pediatrics Kyoto University Graduate School of Medicine
kn-affil=

affil-num=9
en-affil=Department of Pediatrics Jichi Medical University
kn-affil=

affil-num=10
en-affil=Department of Data Science, Center for Innovative Clinical Medicine Okayama University Hospital
kn-affil=

affil-num=11
en-affil=Department of Data Science, Center for Innovative Clinical Medicine Okayama University Hospital
kn-affil=

affil-num=12
en-affil=Department of Cardiovascular Surgery Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=13
en-affil=Department of Pediatrics Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=14
en-affil=Department of Regenerative Medicine, Center for Innovative Clinical Medicine Okayama University Hospital
kn-affil=

affil-num=15
en-affil=
kn-affil=
en-keyword=cardiosphere
kn-keyword=cardiosphere
en-keyword=heart failure
kn-keyword=heart failure
en-keyword=restricted mean survival time
kn-keyword=restricted mean survival time
en-keyword=single ventricle
kn-keyword=single ventricle
en-keyword=survival
kn-keyword=survival
END

start-ver=1.4
cd-journal=joma
no-vol=26
cd-vols=
no-issue=1
article-no=
start-page=198
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20241112
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Clinical practice pattern of Pneumocystis pneumonia prophylaxis in systemic lupus erythematosus: a cross-sectional study from lupus registry of nationwide institutions (LUNA)
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background Pneumocystis jirovecii pneumonia (PCP) is an opportunistic infection in patients undergoing immunosuppressive therapy, such as glucocorticoid (GC) medication, for systemic autoimmune diseases like systemic lupus erythematosus (SLE). Despite the confirmed effectiveness of PCP prophylaxis, its clinical administration, especially in conjunction with GC dosage, remains unclear. We aimed to describe the clinical practice of PCP prophylaxis in association with SLE in Japan, evaluate the relationship between GC dosage and PCP prophylaxis, and explore the practice patterns associated with PCP prophylaxis. <br>
Methods This cross-sectional study used data from the Lupus Registry of Nationwide Institutions in Japan from 2016 to 2021 and included patients diagnosed with SLE. Using descriptive statistics, multivariate analysis, and decision tree analysis, we examined the prevalence of PCP prophylaxis and its association with the GC dosage. <br>
Results Out of 1,460 patients, 21% underwent PCP prophylaxis. The frequency of prophylaxis decreased with a decrease in GC dosage. After adjusting for confounders, logistic regression revealed the odds ratio of PCP prophylaxis increased with higher prednisolone (PSL) doses: 3.7 for 5 <= PSL < 7.5 mg, 5.2 for 7.5 <= PSL < 10 mg, 9.0 for 10 <= PSL < 20 mg, and 43.1 for PSL >= 20 mg, using PSL < 5 mg as the reference. Decision tree analysis indicated that a PSL dosage of < 11 mg/day and immunosuppressant use were key determinants of PCP prophylaxis. <br>
Conclusion This study provides valuable insights into PCP prophylaxis practices in patients with SLE in Japan, underscoring the importance of GC dosage and concomitant immunosuppressant use.
en-copyright=
kn-copyright=

en-aut-name=OnishiTakahisa
en-aut-sei=Onishi
en-aut-mei=Takahisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SadaKen-Ei
en-aut-sei=Sada
en-aut-mei=Ken-Ei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HayashiKeigo
en-aut-sei=Hayashi
en-aut-mei=Keigo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MiyawakiYoshia
en-aut-sei=Miyawaki
en-aut-mei=Yoshia
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=YoshimiRyusuke
en-aut-sei=Yoshimi
en-aut-mei=Ryusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=ShimojimaYasuhiro
en-aut-sei=Shimojima
en-aut-mei=Yasuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=OhnoShigeru
en-aut-sei=Ohno
en-aut-mei=Shigeru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KajiyamaHiroshi
en-aut-sei=Kajiyama
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=IchinoseKunihiro
en-aut-sei=Ichinose
en-aut-mei=Kunihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=SatoShuzo
en-aut-sei=Sato
en-aut-mei=Shuzo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=FujiwaraMichio
en-aut-sei=Fujiwara
en-aut-mei=Michio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=YajimaNobuyuki
en-aut-sei=Yajima
en-aut-mei=Nobuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=KidaTakashi
en-aut-sei=Kida
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=MatsuoYusuke
en-aut-sei=Matsuo
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=NishimuraKeisuke
en-aut-sei=Nishimura
en-aut-mei=Keisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=YamaneTakashi
en-aut-sei=Yamane
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

affil-num=1
en-affil=Department of Rheumatology, Kakogawa Central City Hospital
kn-affil=

affil-num=2
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=

affil-num=3
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=

affil-num=4
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=

affil-num=5
en-affil=Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine
kn-affil=

affil-num=6
en-affil=Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine
kn-affil=

affil-num=7
en-affil=Center for Rheumatic Diseases, Yokohama City University Medical Center
kn-affil=

affil-num=8
en-affil=Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University
kn-affil=

affil-num=9
en-affil=Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences
kn-affil=

affil-num=10
en-affil=Department of Rheumatology, Fukushima Medical University School of Medicine
kn-affil=

affil-num=11
en-affil=Department of Rheumatology, Yokohama Rosai Hospital
kn-affil=

affil-num=12
en-affil=Division of Rheumatology, Department of Medicine, Showa University School of Medicine
kn-affil=

affil-num=13
en-affil=Infammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine
kn-affil=

affil-num=14
en-affil=Department of Rheumatology, Tokyo Kyosai Hospital
kn-affil=

affil-num=15
en-affil=Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine
kn-affil=

affil-num=16
en-affil=Department of Rheumatology, Kakogawa Central City Hospital
kn-affil=
en-keyword=Systemic lupus erythematosus
kn-keyword=Systemic lupus erythematosus
en-keyword=Pneumocystis jirovecii pneumonia
kn-keyword=Pneumocystis jirovecii pneumonia
en-keyword=Glucocorticoid
kn-keyword=Glucocorticoid
en-keyword=Immunosuppressant
kn-keyword=Immunosuppressant
en-keyword=Practice pattern
kn-keyword=Practice pattern
END

start-ver=1.4
cd-journal=joma
no-vol=26
cd-vols=
no-issue=1
article-no=
start-page=195
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20241111
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Association between discontinuity of care and patient trust in the usual rheumatologist among patients with systemic lupus erythematosus: a cross-sectional study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background Patient trust plays a central role in the patient-physician relationship. This study aimed to determine whether the number of outpatient visits with a covering rheumatologist is associated with patient trust in their usual rheumatologist.<br>
Methods Japanese adults with systemic lupus erythematosus (SLE) who met the 1997 revised classification criteria of the American College of Rheumatology and had outpatient visits with a covering rheumatologist in the past year were included.<br>
We used the 11-item Japanese version of the modified Trust in Physician Scale (range 0?100) to assess patient trust. A general linear model with cluster-robust variance estimation was used to evaluate the association between the number of outpatient visits with covering rheumatologists and the patient’s trust in their usual rheumatologist.<br>
Results Of the 515 enrolled participants, 421 patients with SLE were included in our analyses. Patients were divided into groups according to the number of outpatient visits with a covering rheumatologist in the past year as follows: no visits (59.9%; reference group), one to three visits (24.2%; low-frequency group), and four or more visits (15.9%; high-frequency group). The median Trust in Physician Scale score was 81.8 (interquartile range: 72.7?93.2). Both the low-frequency group (mean difference: -3.03; 95% confidence interval [CI] -5.93 to -0.80) and high-frequency group (mean difference: -4.17; 95% CI -7.77 to -0.58) exhibited lower trust in their usual rheumatologist.<br>
Conclusion This study revealed that the number of outpatient visits with a covering rheumatologist was associated with lower trust in a patient’s usual rheumatologist.
en-copyright=
kn-copyright=

en-aut-name=KatayamaYu
en-aut-sei=Katayama
en-aut-mei=Yu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MiyawakiYoshia
en-aut-sei=Miyawaki
en-aut-mei=Yoshia
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=ShidaharaKenta
en-aut-sei=Shidahara
en-aut-mei=Kenta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NawachiShoichi
en-aut-sei=Nawachi
en-aut-mei=Shoichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=AsanoYosuke
en-aut-sei=Asano
en-aut-mei=Yosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KatsuyamaEri
en-aut-sei=Katsuyama
en-aut-mei=Eri
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KatsuyamaTakayuki
en-aut-sei=Katsuyama
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=Takano-NarazakiMariko
en-aut-sei=Takano-Narazaki
en-aut-mei=Mariko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MatsumotoYoshinori
en-aut-sei=Matsumoto
en-aut-mei=Yoshinori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=OguroNao
en-aut-sei=Oguro
en-aut-mei=Nao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=YajimaNobuyuki
en-aut-sei=Yajima
en-aut-mei=Nobuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=IshikawaYuichi
en-aut-sei=Ishikawa
en-aut-mei=Yuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=SakuraiNatsuki
en-aut-sei=Sakurai
en-aut-mei=Natsuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=HidekawaChiharu
en-aut-sei=Hidekawa
en-aut-mei=Chiharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=YoshimiRyusuke
en-aut-sei=Yoshimi
en-aut-mei=Ryusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=OhnoShigeru
en-aut-sei=Ohno
en-aut-mei=Shigeru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=IchikawaTakanori
en-aut-sei=Ichikawa
en-aut-mei=Takanori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=KishidaDai
en-aut-sei=Kishida
en-aut-mei=Dai
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=ShimojimaYasuhiro
en-aut-sei=Shimojima
en-aut-mei=Yasuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=SadaKen-Ei
en-aut-sei=Sada
en-aut-mei=Ken-Ei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=WadaJun
en-aut-sei=Wada
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=ThomDavid H.
en-aut-sei=Thom
en-aut-mei=David H.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=KuritaNoriaki
en-aut-sei=Kurita
en-aut-mei=Noriaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

affil-num=1
en-affil=Department of Nephrology, Rheumatology, Endocrinology, and Metabolism, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Nephrology, Rheumatology, Endocrinology, and Metabolism, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Nephrology, Rheumatology, Endocrinology, and Metabolism, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Nephrology, Rheumatology, Endocrinology, and Metabolism, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Nephrology, Rheumatology, Endocrinology, and Metabolism, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Nephrology, Rheumatology, Endocrinology, and Metabolism, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Nephrology, Rheumatology, Endocrinology, and Metabolism, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Nephrology, Rheumatology, Endocrinology, and Metabolism, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Nephrology, Rheumatology, Endocrinology, and Metabolism, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Division of Rheumatology, Department of Medicine, Showa University School of Medicine
kn-affil=

affil-num=11
en-affil=Division of Rheumatology, Department of Medicine, Showa University School of Medicine
kn-affil=

affil-num=12
en-affil=The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health
kn-affil=

affil-num=13
en-affil=Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine
kn-affil=

affil-num=14
en-affil=Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine
kn-affil=

affil-num=15
en-affil=Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine
kn-affil=

affil-num=16
en-affil=Centre for Rheumatic Disease, Yokohama City University Medical Centre
kn-affil=

affil-num=17
en-affil=Department of Clinical Epidemiology, Graduate School of Medicine, Fukushima Medical University
kn-affil=

affil-num=18
en-affil=Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine
kn-affil=

affil-num=19
en-affil=Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine
kn-affil=

affil-num=20
en-affil=Department of Nephrology, Rheumatology, Endocrinology, and Metabolism, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=21
en-affil=Department of Nephrology, Rheumatology, Endocrinology, and Metabolism, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=22
en-affil=Department of Medicine, Stanford University School of Medicine
kn-affil=

affil-num=23
en-affil=Division of Rheumatology, Department of Medicine, Showa University School of Medicine
kn-affil=
en-keyword=Systemic lupus erythematosus
kn-keyword=Systemic lupus erythematosus
en-keyword=Patient-physician relationship
kn-keyword=Patient-physician relationship
en-keyword=Outpatient visits
kn-keyword=Outpatient visits
en-keyword=Patient trust
kn-keyword=Patient trust
en-keyword=Discontinuity of care
kn-keyword=Discontinuity of care
END

start-ver=1.4
cd-journal=joma
no-vol=106
cd-vols=
no-issue=5
article-no=
start-page=972
end-page=984
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202411
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Demonstrating drug efficacy in slowing kidney disease progression requires large clinical trials when targeting participants with an early stage of chronic kidney disease (CKD). In this randomized, parallel-group, open-labeled trial (CANPIONE study), we assessed the effect of the sodium-glucose cotransporter 2 (SGLT2) inhibitor canagliflozin using the individual’s change in estimated glomerular filtration rate (eGFR) slope before (pre-intervention slope) and during treatment (chronic slope). We randomly assigned (1:1) participants with type 2 diabetes, urinary albumin-to-creatinine ratio (UACR) of 50 to under 300 mg/g, and an eGFR of at least 45 ml/min/1.73m2 to receive canagliflozin or guideline-recommended treatment except for SGLT2 inhibitors (control). The first and second primary outcomes were the geometric mean percentage change from baseline in UACR and the change in eGFR slope, respectively. Of 98 randomized participants, 96 received at least one study treatment. The least-squares mean change from baseline in log-transformed geometric mean UACR was significantly greater in the canagliflozin group than the control group (between group-difference, ?30.8% (95% confidence interval ?42.6 to ?16.8). The between-group difference (canagliflozin group ? control group) of change in eGFR slope (chronic ? pre-intervention) was 4.4 (1.6 to 7.3) ml/min/1.73 m2 per year, which was more pronounced in participants with faster eGFR decline. In summary, canagliflozin reduced albuminuria and the participant-specific natural course of eGFR decline in participants with type 2 diabetes and microalbuminuria. Thus, the CANPIONE study suggests that the within-individual change in eGFR slope may be a novel approach to determine the kidney protective potential of new therapies in early stages of CKD.
en-copyright=
kn-copyright=

en-aut-name=MiyamotoSatoshi
en-aut-sei=Miyamoto
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HeerspinkHiddo J.L.
en-aut-sei=Heerspink
en-aut-mei=Hiddo J.L.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=de ZeeuwDick
en-aut-sei=de Zeeuw
en-aut-mei=Dick
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SakamotoKota
en-aut-sei=Sakamoto
en-aut-mei=Kota
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=YoshidaMichihiro
en-aut-sei=Yoshida
en-aut-mei=Michihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=ToyodaMasao
en-aut-sei=Toyoda
en-aut-mei=Masao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=SuzukiDaisuke
en-aut-sei=Suzuki
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=HatanakaTakashi
en-aut-sei=Hatanaka
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=NakamuraTohru
en-aut-sei=Nakamura
en-aut-mei=Tohru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=KameiShinji
en-aut-sei=Kamei
en-aut-mei=Shinji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=MuraoSatoshi
en-aut-sei=Murao
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=HidaKazuyuki
en-aut-sei=Hida
en-aut-mei=Kazuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=AndoShinichiro
en-aut-sei=Ando
en-aut-mei=Shinichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=AkaiHiroaki
en-aut-sei=Akai
en-aut-mei=Hiroaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=TakahashiYasushi
en-aut-sei=Takahashi
en-aut-mei=Yasushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=KitadaMunehiro
en-aut-sei=Kitada
en-aut-mei=Munehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=SuganoHisashi
en-aut-sei=Sugano
en-aut-mei=Hisashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=NunoueTomokazu
en-aut-sei=Nunoue
en-aut-mei=Tomokazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=NakamuraAkihiko
en-aut-sei=Nakamura
en-aut-mei=Akihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=SasakiMotofumi
en-aut-sei=Sasaki
en-aut-mei=Motofumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=NakatouTatsuaki
en-aut-sei=Nakatou
en-aut-mei=Tatsuaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=FujimotoKei
en-aut-sei=Fujimoto
en-aut-mei=Kei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=KawanamiDaiji
en-aut-sei=Kawanami
en-aut-mei=Daiji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=WadaTakashi
en-aut-sei=Wada
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=MiyatakeNobuyuki
en-aut-sei=Miyatake
en-aut-mei=Nobuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=KuramotoHiromi
en-aut-sei=Kuramoto
en-aut-mei=Hiromi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

en-aut-name=ShikataKenichi
en-aut-sei=Shikata
en-aut-mei=Kenichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=27
ORCID=

affil-num=1
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen
kn-affil=

affil-num=3
en-affil=Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen
kn-affil=

affil-num=4
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine
kn-affil=

affil-num=7
en-affil=Suzuki Diadetes Clinic
kn-affil=

affil-num=8
en-affil=Department of Diabetes and Endocrinology, National Hospital Organization Fukuyama Medical Center
kn-affil=

affil-num=9
en-affil=Diabetes Internal Medicine, Sumitomo Besshi Hospital
kn-affil=

affil-num=10
en-affil=Department of Diabetic Medicine, Kurashiki Central Hospital
kn-affil=

affil-num=11
en-affil=Department of Diabetes and Endocrinology, Takamatsu Hospital
kn-affil=

affil-num=12
en-affil=Department of Diabetology and Metabolism, National Hospital Organization Okayama Medical Center
kn-affil=

affil-num=13
en-affil=Department of Internal Medicine Diabetic Center, Okayama City Hospital
kn-affil=

affil-num=14
en-affil=Division of Diabetes and Metabolism, Faculty of Medicine, Tohoku Medical and Pharmaceutical University
kn-affil=

affil-num=15
en-affil=Department of Diabetes, Ochiai General Hospital
kn-affil=

affil-num=16
en-affil=Department of Diabetology and Endocrinology, Kanazawa Medical University
kn-affil=

affil-num=17
en-affil=Department of Diabetes and Endocrinology, Kochi Health Sciences Center
kn-affil=

affil-num=18
en-affil=Nunoue Clinic
kn-affil=

affil-num=19
en-affil=Internal Medicine, Osafune Clinic
kn-affil=

affil-num=20
en-affil=Department of Diabetes and Endocrinology, Matsue City Hospital
kn-affil=

affil-num=21
en-affil=Diabetes Center, Okayama Saiseikai General Hospital
kn-affil=

affil-num=22
en-affil=Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, The Jikei University Kashiwa Hospital
kn-affil=

affil-num=23
en-affil=Department of Endocrinology and Diabetes, Fukuoka University School of Medicine
kn-affil=

affil-num=24
en-affil=Department of Nephrology and Laboratory Medicine, Graduate School of Medical Sciences, Kanazawa University
kn-affil=

affil-num=25
en-affil=Department of Hygiene, Faculty of Medicine, Kagawa University
kn-affil=

affil-num=26
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=

affil-num=27
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=
en-keyword=canagliflozin
kn-keyword=canagliflozin
en-keyword=CANPIONE study
kn-keyword=CANPIONE study
en-keyword=chronic kidney disease microalbuminuria
kn-keyword=chronic kidney disease microalbuminuria
en-keyword=preintervention eGFR slope
kn-keyword=preintervention eGFR slope
en-keyword=sodium-glucose cotransporter 2 inhibitor
kn-keyword=sodium-glucose cotransporter 2 inhibitor
END

start-ver=1.4
cd-journal=joma
no-vol=63
cd-vols=
no-issue=19
article-no=
start-page=2655
end-page=2660
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20241001
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A Prompt Diagnosis and Treatment of a Case of Nuclear Protein of the Testis Carcinoma Characterized by a Bronchial Lesion and High Serum Alpha-fetoprotein Level Following Genomic Testing
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Nuclear protein of the testis carcinoma (NUTC) is a rare and aggressive malignancy. We herein report a case of NUTC in the lung characterized by a bronchial lesion and elevated alpha-fetoprotein levels. A 35-year-old Japanese man presented to our institution with suspected advanced lung cancer based on a histological examination. Subsequently, next-generation sequencing (NGS) yielded a positive BRD4-NUTM1 fusion. In addition, positive NUT immunostaining of the lung biopsy specimen confirmed NUTC in the lungs. Systemic chemotherapy and radiotherapy showed a temporary response, with decreased serum alpha-fetoprotein levels. We highlight this case of a prompt diagnosis by NGS of NUTC in a young individual with a rapidly progressing tumor.
en-copyright=
kn-copyright=

en-aut-name=MatsuuraHiroaki
en-aut-sei=Matsuura
en-aut-mei=Hiroaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MakimotoGo
en-aut-sei=Makimoto
en-aut-mei=Go
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=OdaNaohiro
en-aut-sei=Oda
en-aut-mei=Naohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NinomiyaKiichiro
en-aut-sei=Ninomiya
en-aut-mei=Kiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HigoHisao
en-aut-sei=Higo
en-aut-mei=Hisao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=FujiiMasanori
en-aut-sei=Fujii
en-aut-mei=Masanori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=RaiKammei
en-aut-sei=Rai
en-aut-mei=Kammei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=IchiharaEiki
en-aut-sei=Ichihara
en-aut-mei=Eiki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=OhashiKadoaki
en-aut-sei=Ohashi
en-aut-mei=Kadoaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=HottaKatsuyuki
en-aut-sei=Hotta
en-aut-mei=Katsuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=TabataMasahiro
en-aut-sei=Tabata
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=MaedaYoshinobu
en-aut-sei=Maeda
en-aut-mei=Yoshinobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

affil-num=1
en-affil=Department of Respiratory Medicine, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Respiratory Medicine, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Respiratory Medicine, Fukuyama City Hospital
kn-affil=

affil-num=4
en-affil=Center for Comprehensive Genomic Medicine, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of Respiratory Medicine, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Department of Respiratory Medicine, Okayama University Hospital
kn-affil=

affil-num=7
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=

affil-num=8
en-affil=Department of Respiratory Medicine, Okayama University Hospital
kn-affil=

affil-num=9
en-affil=Department of Respiratory Medicine, Okayama University Hospital
kn-affil=

affil-num=10
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=

affil-num=11
en-affil=Center for Clinical Oncology, Okayama University Hospital
kn-affil=

affil-num=12
en-affil=Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=
en-keyword=NUT carcinoma
kn-keyword=NUT carcinoma
en-keyword=BRD4-NUTM1
kn-keyword=BRD4-NUTM1
en-keyword=lung cancer
kn-keyword=lung cancer
en-keyword=alpha-fetoprotein (AFP)
kn-keyword=alpha-fetoprotein (AFP)
en-keyword=immune checkpoint inhibitor
kn-keyword=immune checkpoint inhibitor
END

start-ver=1.4
cd-journal=joma
no-vol=56
cd-vols=
no-issue=2
article-no=
start-page=41
end-page=71
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20241125
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Reproducing Self-organizing Agglomeration using Agent-based Model: ICT Establishments in Tokyo’s Special Wards
kn-title=エージェントベースモデルによる自己組織化的集積の再現：特別区におけるICT 事業所
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=　As a preliminary step to conducting a self-organizing simulation of the agglomeration and dispersion of the information and communications industry, we quantify the spatial agglomeration of the information and communications industry in Japan’s major cities. Using the town and district data from the Economic Census for Economic Activity, we attempted a spatial analysis of the information and communications industry in the Tokyo Special Wards as well as in Sapporo, Sendai, Hiroshima, and Fukuoka, which have regional central functions. As a result of detecting spatial autocorrelation in small areas within each city, hotspots indicating the agglomeration of information and communications industry offi ces were found in the city center of each city. At the same time, we were able to confi rm the impact of agglomeration economies, which are the premise of the self-organizing model, and confi rmed that the information and communications industry is an industry suitable for simulation of the self-organizing model.
　Krugman（1996）was the fi rst to model the self-organizing model in cities and clarifi ed the emergence principle of peripheral cities, but this was limited to numerical simulations. Later, Kumar et al.（2007）used actual data to show that Krugman’s self-organizing model could be applied to predict corporate agglomeration and dispersion. In this paper, we use an agent-based model to examine whether a self-organizing model is also effective in reproducing and predicting the concentration and dispersion of the information and communications industry in Japanese cities.
en-copyright=
kn-copyright=

en-aut-name=NakamuraRyohei
en-aut-sei=Nakamura
en-aut-mei=Ryohei
kn-aut-name=中村良平
kn-aut-sei=中村
kn-aut-mei=良平
aut-affil-num=1
ORCID=

en-aut-name=NagamuneTakeshi
en-aut-sei=Nagamune
en-aut-mei=Takeshi
kn-aut-name=長宗武司
kn-aut-sei=長宗
kn-aut-mei=武司
aut-affil-num=2
ORCID=

en-aut-name=HayashiSyusei
en-aut-sei=Hayashi
en-aut-mei=Syusei
kn-aut-name=林秀星
kn-aut-sei=林
kn-aut-mei=秀星
aut-affil-num=3
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学

affil-num=2
en-affil=
kn-affil=新見公立大学

affil-num=3
en-affil=
kn-affil=東北大学大学院
END

start-ver=1.4
cd-journal=joma
no-vol=56
cd-vols=
no-issue=2
article-no=
start-page=17
end-page=40
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20241125
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Achievements and Challenges of Student-led Regional Revitalization Activities over 10 Years: Practical Activities in the Mokake District of Setouchi City
kn-title=学生による地方創生活動10年の成果と課題―瀬戸内市裳掛地区での実践活動―
en-subtitle=
kn-subtitle=
en-abstract=　Among the officially recognized student clubs at Okayama University, there is a club called the“ Town Development Research Association” that engages in regional revitalization activities. The Okayama University student club “Town Development Research Association” started its activities in 2014. The purpose of these activities is to collaborate with the local residents in the Mokake district of Oku Town, Setouchi City, which faces issues of depopulation and declining population. This project is commonly known as the “Setouchi City Mokake District Revitalization Project.”
　Over the past ten years, students have carried out various activities while passing down practical activities from seniors to juniors. The main focus of these activities is to support the children of Mokake Elementary School, where the number of students is decreasing, in order to curb the decline in student numbers. Specific measures for this include “information dissemination by students,” “participation in countermeasures for abandoned farmland,” “creating bases through support for the regeneration of vacant houses,” “support for promoting migration and settlement,” “planning and managing local events,” and “watching over the children.” These activities aim to continuously support and revitalize the community.
　This paper reports on the achievements of these student activities, presenting them as a case study of “student-led regional revitalization activities” from the perspective of mutual benefits in terms of student learning and contributions to the community.
kn-abstract=　岡山大学の公認学生サークルのなかで地方創生活動を展開しているサークルに「まちづくり研究会」がある。岡山大学学生サークル「まちづくり研究会」は，2014年に活動を開始，その活動の目的は，過疎化人口減少の問題を抱える瀬戸内市邑久町虫明（おくちょうむしあけ）の裳掛（もかけ）地区をフィールドとした学生と地域住民による地方創生の協働活動であり，通称『瀬戸内市裳掛地区再生プロジェクト』と呼ばれている。
　この10年間，学生たちは先輩たちから後輩たちに実践活動をリレーしながら様々な活動を展開してきた。その主眼が，生徒数の減る裳掛小学校の子どもたちの支援活動を続けることで，生徒数の減少に歯止めをかけることである。そのための具体的な方策として，「学生による情報発信」，「耕作放棄地対策への参加」，「空き家の再生支援による拠点づくり」，「移住定住促進支援」，「地域催事への企画・運営支援」，「子どもたちの見守り」などの活動を実践しながら地域を元気にする応援を継続してきた。なお，掲載写真の使用許可は，活動の都度，地域の皆様（保護者を含む）や学生たちに確認・了解を得ている。
　本論では，この学生たちの活動の成果を紹介しながら，学生たちの学びと地域への貢献という互恵性の視座に立ち「学生による地域創生活動の実践事例研究」として報告する。
en-copyright=
kn-copyright=

en-aut-name=MimuraSatoshi
en-aut-sei=Mimura
en-aut-mei=Satoshi
kn-aut-name=三村聡
kn-aut-sei=三村
kn-aut-mei=聡
aut-affil-num=1
ORCID=

en-aut-name=TokooAkane
en-aut-sei=Tokoo
en-aut-mei=Akane
kn-aut-name=床尾あかね
kn-aut-sei=床尾
kn-aut-mei=あかね
aut-affil-num=2
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学地域共創本部

affil-num=2
en-affil=
kn-affil=岡山大学地域共創本部
en-keyword=少子化対策 (Countermeasures against declining birthrates)
kn-keyword=少子化対策 (Countermeasures against declining birthrates)
en-keyword=空き家の再生 (Revitalization of vacant houses)
kn-keyword=空き家の再生 (Revitalization of vacant houses)
en-keyword=移住・定住促進 (Promotion of migration and settlement)
kn-keyword=移住・定住促進 (Promotion of migration and settlement)
END

start-ver=1.4
cd-journal=joma
no-vol=14
cd-vols=
no-issue=1
article-no=
start-page=16337
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240716
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Effects of dapagliflozin on myoglobin efflux from cardiomyocyte during myocardial ischemia/reperfusion in anesthetized rats
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=It has been suggested that sodium-glucose cotransporter 2 (SGLT2) inhibitors have cardioprotective effects during myocardial ischemia/reperfusion (I/R) independent of glucose-lowering action. However, the effects of SGLT2 inhibitors on structural damage to cardiomyocytes in the ischemic region during I/R remain unknown. We applied a microdialysis technique to the heart of anesthetized rats and investigated the effects of an SGLT2 inhibitor, dapagliflozin, on myocardial interstitial myoglobin levels in the ischemic region during coronary occlusion followed by reperfusion. Dapagliflozin was administered systemically (40 mu g/body iv) or locally via a dialysis probe (100 mu M and 1 mM) 30 min before coronary occlusion. In the vehicle group, coronary occlusion increased the dialysate myoglobin concentration in the ischemic region. Reperfusion further increased the dialysate myoglobin concentration. Intravenous administration of dapagliflozin reduced dialysate myoglobin concentration during ischemia and at 0-15 min after reperfusion, but local administration (100 mu M and 1 mM) did not. Therefore, acute systemic administration of dapagliflozin prior to ischemia has cardioprotective effects on structural damage during I/R.
en-copyright=
kn-copyright=

en-aut-name=HayashidaTomohiro
en-aut-sei=Hayashida
en-aut-mei=Tomohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KurokoYosuke
en-aut-sei=Kuroko
en-aut-mei=Yosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=ShimizuShuji
en-aut-sei=Shimizu
en-aut-mei=Shuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=AkiyamaTsuyoshi
en-aut-sei=Akiyama
en-aut-mei=Tsuyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SuezawaTakanori
en-aut-sei=Suezawa
en-aut-mei=Takanori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KiokaYukio
en-aut-sei=Kioka
en-aut-mei=Yukio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KotaniYasuhiro
en-aut-sei=Kotani
en-aut-mei=Yasuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=ShishidoToshiaki
en-aut-sei=Shishido
en-aut-mei=Toshiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=KasaharaShingo
en-aut-sei=Kasahara
en-aut-mei=Shingo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Cardiovascular Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Cardiovascular Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences and Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Cardiovascular Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Cardiac Physiology, National Cerebral and Cardiovascular Center
kn-affil=

affil-num=5
en-affil=Department of Cardiovascular Surgery, Fukuyama City Hospital
kn-affil=

affil-num=6
en-affil=Department of Cardiovascular Surgery, Fukuyama City Hospital
kn-affil=

affil-num=7
en-affil=Department of Cardiovascular Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences and Okayama University Hospital
kn-affil=

affil-num=8
en-affil=Department of Research Promotion and Management, National Cerebral and Cardiovascular Center
kn-affil=

affil-num=9
en-affil=Department of Cardiovascular Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences and Okayama University Hospital
kn-affil=
en-keyword=Sodium-glucose-cotransporter 2 inhibitor
kn-keyword=Sodium-glucose-cotransporter 2 inhibitor
en-keyword=Dapagliflozin
kn-keyword=Dapagliflozin
en-keyword=Myocardial ischemia/reperfusion
kn-keyword=Myocardial ischemia/reperfusion
en-keyword=Cardiac microdialysis
kn-keyword=Cardiac microdialysis
en-keyword=Myoglobin
kn-keyword=Myoglobin
END

start-ver=1.4
cd-journal=joma
no-vol=11
cd-vols=
no-issue=4
article-no=
start-page=557
end-page=564
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20241019
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Clinical Significance of Prior Ramucirumab Use on the Effectiveness of Nivolumab as the Third-Line Regimen in Gastric Cancer: A Multicenter Retrospective Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background and Objective Because vascular endothelial growth factor inhibition has been suggested to improve immune cell function in the cancer microenvironment, we examined whether using ramucirumab (RAM) before nivolumab usage is more effective in advanced gastric cancer. <br>
Methods This was a multicenter retrospective observational study. We analyzed patients who received nivolumab monotherapy as the third-line regimen for unresectable advanced or recurrent gastric cancer between October 2017 and December 2022. They were divided into the RAM (RAM-treated) group and the non-RAM (non-treated) group according to the RAM usage in the second-line regimen. The primary outcome was to compare the overall survival after nivolumab administration in the third-line regimen between the RAM and non-RAM groups. <br>
Results Fifty-two patients were included in the present study: 42 patients in the RAM group and ten patients in the non-RAM group. The median overall survival was significantly longer in the RAM group than in the non-RAM group (8.5 months vs 6.9 months, p < 0.05). In the RAM group, patients without peritoneal metastasis had significantly better median overall survival than those with peritoneal metastasis (23.8 months vs 7.7 months, p = 0.0033). Multivariate Cox-proportional hazards analyses showed that the presence of peritoneal metastasis (hazard ratio, 2.4; 95% confidence interval 1.0-5.7) alone was significantly associated with overall survival in the RAM group. <br>
Conclusions The use of RAM prior to nivolumab monotherapy may contribute to prolonged survival in patients with gastric cancer, especially those without peritoneal metastasis.
en-copyright=
kn-copyright=

en-aut-name=ObayashiYuka
en-aut-sei=Obayashi
en-aut-mei=Yuka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HirataShoichiro
en-aut-sei=Hirata
en-aut-mei=Shoichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KonoYoshiyasu
en-aut-sei=Kono
en-aut-mei=Yoshiyasu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=AbeMakoto
en-aut-sei=Abe
en-aut-mei=Makoto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MiyaharaKoji
en-aut-sei=Miyahara
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NakagawaMasahiro
en-aut-sei=Nakagawa
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=IshidaMichihiro
en-aut-sei=Ishida
en-aut-mei=Michihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=ChodaYasuhiro
en-aut-sei=Choda
en-aut-mei=Yasuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=HamadaKenta
en-aut-sei=Hamada
en-aut-mei=Kenta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=IwamuroMasaya
en-aut-sei=Iwamuro
en-aut-mei=Masaya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=KawanoSeiji
en-aut-sei=Kawano
en-aut-mei=Seiji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=KawaharaYoshiro
en-aut-sei=Kawahara
en-aut-mei=Yoshiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=OtsukaMotoyuki
en-aut-sei=Otsuka
en-aut-mei=Motoyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

affil-num=1
en-affil=Department of Internal Medicine, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=2
en-affil=Department of Gastroenterology and Hepatology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Gastroenterology and Hepatology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Internal Medicine, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=5
en-affil=Department of Internal Medicine, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=6
en-affil=Department of Endoscopy, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=7
en-affil=Department of Surgery, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=8
en-affil=Department of Surgery, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=9
en-affil=Department of Practical Gastrointestinal Endoscopy, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=10
en-affil=Department of Gastroenterology, Okayama University Hospital
kn-affil=

affil-num=11
en-affil=Department of Gastroenterology, Okayama University Hospital
kn-affil=

affil-num=12
en-affil=Department of Practical Gastrointestinal Endoscopy, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=13
en-affil=Department of Gastroenterology and Hepatology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=5
article-no=
start-page=377
end-page=386
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202410
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Prognostic Efficacy of the Albumin Grade in Patients with Hepatocellular Carcinoma
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=We previously found that “albumin grade”, formerly called the “ALBS grade,” demonstrated significant capability for prognostic stratification in hepatocellular carcinoma (HCC) patients treated with lenvatinib. The purpose of the present study was to compare the performance of the albumin grade with that of the modified albumin-bilirubin (mALBI) grade in predicting overall survival of HCC patients with different BCLC stages and treatment types. We enrolled 7,645 Japanese patients newly diagnosed with HCC using the Akaike information criteria (AIC), likelihood ratio, and C-index in different Barcelona Clinic Liver Cancer (BCLC) stages and treatments. The albumin grade showed similar and slightly better performance than the mALBI grade for BCLC stage 0 and A and especially for patients who underwent curative surgery and ablation. In patients treated with transcatheter arterial chemoembolization, molecular targeted agents, and the best supportive care, the mALBI grade had better performance than the albumin grade. However, the differences of the indices were very small in all scenarios. Overall, the albumin grade was comparable in efficacy to the mALBI grade, showing particular benefit for patients with early-stage HCC.
en-copyright=
kn-copyright=

en-aut-name=HiranoYuichi
en-aut-sei=Hirano
en-aut-mei=Yuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NousoKazuhiro
en-aut-sei=Nouso
en-aut-mei=Kazuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KariyamaKazuya
en-aut-sei=Kariyama
en-aut-mei=Kazuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=HiraokaAtsushi
en-aut-sei=Hiraoka
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=ShiotaShohei
en-aut-sei=Shiota
en-aut-mei=Shohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=WakutaAkiko
en-aut-sei=Wakuta
en-aut-mei=Akiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=YasudaSatoshi
en-aut-sei=Yasuda
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=ToyodaHidenori
en-aut-sei=Toyoda
en-aut-mei=Hidenori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=TsujiKunihiko
en-aut-sei=Tsuji
en-aut-mei=Kunihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=HatanakaTakeshi
en-aut-sei=Hatanaka
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=KakizakiSatoru
en-aut-sei=Kakizaki
en-aut-mei=Satoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=NaganumaAtsushi
en-aut-sei=Naganuma
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=TadaToshifumi
en-aut-sei=Tada
en-aut-mei=Toshifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=ItobayashiEi
en-aut-sei=Itobayashi
en-aut-mei=Ei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=IshikawaToru
en-aut-sei=Ishikawa
en-aut-mei=Toru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=ShimadaNoritomo
en-aut-sei=Shimada
en-aut-mei=Noritomo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=TakaguchiKoichi
en-aut-sei=Takaguchi
en-aut-mei=Koichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=TsutsuiAkemi
en-aut-sei=Tsutsui
en-aut-mei=Akemi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=NaganoTakuya
en-aut-sei=Nagano
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=ImaiMichitaka
en-aut-sei=Imai
en-aut-mei=Michitaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=NakamuraShinichiro
en-aut-sei=Nakamura
en-aut-mei=Shinichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=KumadaTakashi
en-aut-sei=Kumada
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=Real-Life Practice Experts for HCC (RELPEC) Study Group in Japan
en-aut-sei=Real-Life Practice Experts for HCC (RELPEC) Study Group in Japan
en-aut-mei=
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

affil-num=1
en-affil=Department of Gastroenterology, Okayama City Hospital
kn-affil=

affil-num=2
en-affil=Department of Gastroenterology, Okayama City Hospital
kn-affil=

affil-num=3
en-affil=Department of Gastroenterology, Okayama City Hospital
kn-affil=

affil-num=4
en-affil=Gastroenterology Center, Ehime Prefectural Central Hospital
kn-affil=

affil-num=5
en-affil=Department of Gastroenterology, Okayama City Hospital
kn-affil=

affil-num=6
en-affil=Department of Gastroenterology, Okayama City Hospital
kn-affil=

affil-num=7
en-affil=Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital
kn-affil=

affil-num=8
en-affil=Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital
kn-affil=

affil-num=9
en-affil=Center of Gastroenterology, Teine Keijinkai Hospital
kn-affil=

affil-num=10
en-affil=Department of Gastroenterology, Saiseikai Maebashi Hospital
kn-affil=

affil-num=11
en-affil=Department of Clinical Research, NHO Takasaki General Medical Center
kn-affil=

affil-num=12
en-affil=Department of Gastroenterology, NHO Takasaki General Medical Center
kn-affil=

affil-num=13
en-affil=Department of Internal Medicine, Japanese Red Cross Society Himeji Hospital
kn-affil=

affil-num=14
en-affil=Department of Gastroenterology, Asahi General Hospital
kn-affil=

affil-num=15
en-affil=Department of Gastroenterology, Saiseikai Niigata Hospital
kn-affil=

affil-num=16
en-affil=Division of Gastroenterology and Hepatology, Otakanomori Hospital
kn-affil=

affil-num=17
en-affil=Department of Hepatology, Kagawa Prefectural Central Hospital
kn-affil=

affil-num=18
en-affil=Department of Hepatology, Kagawa Prefectural Central Hospital
kn-affil=

affil-num=19
en-affil=Department of Hepatology, Kagawa Prefectural Central Hospital
kn-affil=

affil-num=20
en-affil=Department of Gastroenterology, Niigata Cancer Center Hospital
kn-affil=

affil-num=21
en-affil=Department of Internal Medicine, Japanese Red Cross Society Himeji Hospital
kn-affil=

affil-num=22
en-affil=Department of Nursing, Gifu Kyoritsu University
kn-affil=

affil-num=23
en-affil=
kn-affil=
en-keyword=albumin grade
kn-keyword=albumin grade
en-keyword=hepatocellular carcinoma
kn-keyword=hepatocellular carcinoma
en-keyword=modified albumin-bilirubin grade
kn-keyword=modified albumin-bilirubin grade
END

start-ver=1.4
cd-journal=joma
no-vol=39
cd-vols=
no-issue=12
article-no=
start-page=2760
end-page=2766
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20241003
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Rates and risk factors of bleeding after gastric endoscopic submucosal dissection with continuous warfarin or 1‐day withdrawal of direct oral anticoagulants
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background and Aim: The 2017 Japanese guidelines recommend continuing warfarin therapy during the perioperative period or discontinuing direct oral anticoagulants (DOACs) only on the day of endoscopic submucosal dissection for early gastric cancer. However, their safety has not been sufficiently explored. This study aimed to validate this management method.<br>
Methods: This retrospective, multicenter study analyzed the characteristics and outcomes of patients who underwent gastric endoscopic submucosal dissection between July 2017 and June 2019. The patients were categorized according to the use of warfarin or DOACs.<br>
Results: Among the 62 eligible patients, 53 (85%) were male (median age, 76 years). Warfarin was used in 10 patients (16%) and DOACs in 52 patients (84%). Fourteen patients taking DOACs (27%) used concomitant antiplatelet agents, with seven patients (13%) continuing treatment at the time of the endoscopic procedure. No postprocedural bleeding occurred in patients receiving warfarin (0%), whereas 10 cases (19%) of bleeding occurred in patients receiving DOACs: rivaroxaban, 0% (0/22); dabigatran, 0% (0/2); edoxaban, 43% (6/14); and apixaban, 29% (4/14). The type of anticoagulant (P < 0.01) and continuation of antiplatelet therapy (P = 0.02) were risk factors for postprocedural bleeding in patients receiving DOACs. Intraprocedural bleeding requiring transfusion or symptomatic thromboembolic events were not reported.<br>
Conclusions: Continuous warfarin therapy is preferred. DOAC withdrawal 1 day before a procedure is associated with a high bleeding rate, which may differ for different types of anticoagulants. The continuation of antiplatelet medications in patients receiving DOACs carries a high risk of bleeding and is a future challenge.
en-copyright=
kn-copyright=

en-aut-name=HirataShoichiro
en-aut-sei=Hirata
en-aut-mei=Shoichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HamadaKenta
en-aut-sei=Hamada
en-aut-mei=Kenta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=IwamuroMasaya
en-aut-sei=Iwamuro
en-aut-mei=Masaya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MouriHirokazu
en-aut-sei=Mouri
en-aut-mei=Hirokazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MiyaharaKoji
en-aut-sei=Miyahara
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TsuzukiTakao
en-aut-sei=Tsuzuki
en-aut-mei=Takao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=YamauchiKenji
en-aut-sei=Yamauchi
en-aut-mei=Kenji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KobayashiSayo
en-aut-sei=Kobayashi
en-aut-mei=Sayo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=TakahashiSakuma
en-aut-sei=Takahashi
en-aut-mei=Sakuma
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=TakenakaRyuta
en-aut-sei=Takenaka
en-aut-mei=Ryuta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=HoriShinichiro
en-aut-sei=Hori
en-aut-mei=Shinichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=InoueMasafumi
en-aut-sei=Inoue
en-aut-mei=Masafumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=ToyokawaTatsuya
en-aut-sei=Toyokawa
en-aut-mei=Tatsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=NishimuraMamoru
en-aut-sei=Nishimura
en-aut-mei=Mamoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=IshiyamaShuhei
en-aut-sei=Ishiyama
en-aut-mei=Shuhei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=MiyaikeJiro
en-aut-sei=Miyaike
en-aut-mei=Jiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=KatoRyo
en-aut-sei=Kato
en-aut-mei=Ryo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=MatsubaraMinoru
en-aut-sei=Matsubara
en-aut-mei=Minoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=YunokiNaoko
en-aut-sei=Yunoki
en-aut-mei=Naoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=KanzakiHiromitsu
en-aut-sei=Kanzaki
en-aut-mei=Hiromitsu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=KawaharaYoshiro
en-aut-sei=Kawahara
en-aut-mei=Yoshiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=OkadaHiroyuki
en-aut-sei=Okada
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=IshikawaHideki
en-aut-sei=Ishikawa
en-aut-mei=Hideki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=OtsukaMotoyuki
en-aut-sei=Otsuka
en-aut-mei=Motoyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=Okayama Gut Study Group
en-aut-sei=Okayama Gut Study Group
en-aut-mei=
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

affil-num=1
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Practical Gastrointestinal Endoscopy, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Gastroenterology and Hepatology, Kurashiki Central Hospital
kn-affil=

affil-num=5
en-affil=Department of Internal Medicine, Hiroshima City Hospital
kn-affil=

affil-num=6
en-affil=Department of Gastroenterology, Japanese Red Cross Society Himeji Hospital
kn-affil=

affil-num=7
en-affil=Department of Gastroenterology, Mitoyo General Hospital
kn-affil=

affil-num=8
en-affil=Department of Internal Medicine, Fukuyama City Hospital
kn-affil=

affil-num=9
en-affil=Department of Gastroenterology, Kagawa Prefectural Central Hospital
kn-affil=

affil-num=10
en-affil=Department of Internal Medicine, Tsuyama Chuo Hospital
kn-affil=

affil-num=11
en-affil=Department of Gastroenterology, Japanese Red Cross Society Himeji Hospital
kn-affil=

affil-num=12
en-affil=Department of Gastroenterology, Japanese Red Cross Okayama Hospital
kn-affil=

affil-num=13
en-affil=Department of Gastroenterology, National Hospital Organization Fukuyama Medical Center
kn-affil=

affil-num=14
en-affil=Department of Internal Medicine, Okayama City Hospital
kn-affil=

affil-num=15
en-affil=Department of Internal Medicine, Okayama Saiseikai General Hospital
kn-affil=

affil-num=16
en-affil=Department of Internal Medicine, Saiseikai Imabari Hospital
kn-affil=

affil-num=17
en-affil=Department of Gastroenterology, National Hospital Organization Iwakuni Clinical Center
kn-affil=

affil-num=18
en-affil=Department of Internal Medicine, Sumitomo Besshi Hospital
kn-affil=

affil-num=19
en-affil=Department of Internal Medicine, Akaiwa Medical Association Hospital
kn-affil=

affil-num=20
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=21
en-affil=Department of Practical Gastrointestinal Endoscopy, Okayama University
kn-affil=

affil-num=22
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=23
en-affil=Department of Molecular-Targeting Prevention, Kyoto Prefectural University of Medicine
kn-affil=

affil-num=24
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=25
en-affil=
kn-affil=
en-keyword=direct oral anticoagulants
kn-keyword=direct oral anticoagulants
en-keyword=endoscopic submucosal dissection
kn-keyword=endoscopic submucosal dissection
en-keyword=gastric cancer
kn-keyword=gastric cancer
en-keyword=postprocedural bleeding
kn-keyword=postprocedural bleeding
en-keyword=warfarin
kn-keyword=warfarin
END

start-ver=1.4
cd-journal=joma
no-vol=64
cd-vols=
no-issue=10
article-no=
start-page=382
end-page=386
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=2024
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Important Notes for Preventing Entrapment of Distal Filter-based Embolic Protection Device in Carotid Artery Stenting
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Failure to retrieve a distal filter-based embolic protection device (EPD) is a potential complication of carotid artery stenting. This may be caused by trapping of the proximal marker of the EPD within the stent tip marker. Maintaining an adequate distance between the two can prevent this. We examined the behavior of several stent-filter-based EPD combinations, focusing on their propensity to become trapped or disengage in vitro. Four physicians subjectively rated the force required to result in trapping using a 5-point scale. Moreover, the force required to disengage trapped devices was evaluated. The Casper stent & horbar;Spider FX EPD combination was difficult to disengage when entrapment occurred, which suggested that this phenomenon tended to occur with this combination. The stent tip marker of the closed-cell stents advanced as they shortened, which may be a unique feature of closed-cell stents. Although trapping is uncommon, it can cause serious complications. To prevent these complications, device characteristics should be well understood before they are used in patients.
en-copyright=
kn-copyright=

en-aut-name=FUJITAJuntaro
en-aut-sei=FUJITA
en-aut-mei=Juntaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HIROTSUNENobuyuki
en-aut-sei=HIROTSUNE
en-aut-mei=Nobuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MATSUDAYuki
en-aut-sei=MATSUDA
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=HAMASAKIOsamu
en-aut-sei=HAMASAKI
en-aut-mei=Osamu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=FUKUDAShoichi
en-aut-sei=FUKUDA
en-aut-mei=Shoichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=OKADAYoshihiro
en-aut-sei=OKADA
en-aut-mei=Yoshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KOBASHIAiko
en-aut-sei=KOBASHI
en-aut-mei=Aiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=NISHIGAKIShohei
en-aut-sei=NISHIGAKI
en-aut-mei=Shohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MAKINOKeigo
en-aut-sei=MAKINO
en-aut-mei=Keigo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=TOMITAYusuke
en-aut-sei=TOMITA
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=KIDANINaoya
en-aut-sei=KIDANI
en-aut-mei=Naoya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=MURAOKAKenichiro
en-aut-sei=MURAOKA
en-aut-mei=Kenichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=NISHINOShigeki
en-aut-sei=NISHINO
en-aut-mei=Shigeki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

affil-num=1
en-affil=Department of Neurological Surgery, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Neurosurgery and Neuroendovascular Surgery, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=3
en-affil=Department of Neurosurgery, Miyoshi Central Hospital
kn-affil=

affil-num=4
en-affil= Department of Neurosurgery, Miyoshi Central Hospital
kn-affil=

affil-num=5
en-affil=Department of Neurosurgery and Neuroendovascular Surgery, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=6
en-affil=Department of Neurosurgery and Neuroendovascular Surgery, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=7
en-affil=Department of Neurosurgery and Neuroendovascular Surgery, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=8
en-affil=Department of Neurosurgery and Neuroendovascular Surgery, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=9
en-affil=Department of Neurosurgery and Neuroendovascular Surgery, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=10
en-affil=Department of Neurosurgery and Neuroendovascular Surgery, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=11
en-affil=Department of Neurosurgery and Neuroendovascular Surgery, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=12
en-affil=Department of Neurosurgery and Neuroendovascular Surgery, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=13
en-affil=Department of Neurosurgery and Neuroendovascular Surgery, Hiroshima City Hiroshima Citizens Hospital
kn-affil=
en-keyword=carotid artery stenting
kn-keyword=carotid artery stenting
en-keyword=distal filter-based embolic protection device
kn-keyword=distal filter-based embolic protection device
en-keyword=complication
kn-keyword=complication
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=4
article-no=
start-page=349
end-page=355
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202408
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Middle-Ear Salivary Gland Choristoma with Congenital, Single-Sided Hearing Loss
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Middle-ear salivary gland choristoma (SGCh) is a rare, benign tumor that causes conductive hearing loss owing to middle-ear morphological abnormalities. Early diagnosis is challenging, and surgical resection is indispensable for a definitive diagnosis. We report the case of a 3-year-old boy diagnosed with middle-ear SGCh during the follow-up period for left-sided hearing loss discovered at newborn hearing screening (NHS). Long-term follow-up after the NHS result, subsequent computed tomography/magnetic resonance imaging, and surgical resection led to its relatively early diagnosis and treatment.
en-copyright=
kn-copyright=

en-aut-name=TominagaYuichiro
en-aut-sei=Tominaga
en-aut-mei=Yuichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SugayaAkiko
en-aut-sei=Sugaya
en-aut-mei=Akiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KariyaShin
en-aut-sei=Kariya
en-aut-mei=Shin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=ShimizuAiko
en-aut-sei=Shimizu
en-aut-mei=Aiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KataokaYuko
en-aut-sei=Kataoka
en-aut-mei=Yuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=AndoMizuo
en-aut-sei=Ando
en-aut-mei=Mizuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Department of Otolaryngology, Head and Neck Surgery, Hiroshima City, Hiroshima Citizens Hospital
kn-affil=

affil-num=2
en-affil=Department of Otolaryngology, Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Otolaryngology, Head and Neck Surgery, Kawasaki Medical School Hospital
kn-affil=

affil-num=4
en-affil=Department of Otolaryngology, Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Otolaryngology, Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Otolaryngology, Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=middle-ear salivary gland choristoma
kn-keyword=middle-ear salivary gland choristoma
en-keyword=middle-ear morphological abnormalities
kn-keyword=middle-ear morphological abnormalities
en-keyword=newborn hearing screening
kn-keyword=newborn hearing screening
en-keyword=unilateral hearing loss
kn-keyword=unilateral hearing loss
en-keyword=surgical resection
kn-keyword=surgical resection
END

start-ver=1.4
cd-journal=joma
no-vol=42
cd-vols=
no-issue=21
article-no=
start-page=126156
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202408
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Kinetics of SARS-CoV-2 antibody titers after booster vaccinations during an Omicron surge in Japan
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Despite the emergence of SARS-CoV-2 variants and waning immunity after initial vaccination, data on antibody kinetics following booster doses, particularly those adapted to Omicron subvariants like XBB.1.5, remain limited. This study assesses the kinetics of anti-spike protein receptor-binding domain (S-RBD) IgG antibody titers post-booster vaccination in a Japanese population during the Omicron variant epidemic.<br>
Methods: A prospective cohort study was conducted in Bizen City, Japan, from November 2023 to January 2024. Participants included residents and workers aged ?18 years, with at least three COVID-19 vaccinations. Antibody levels were measured from venous blood samples. The study analyzed 424 participants and 821 antibody measurements, adjusting for variables such as age, sex, underlying conditions, and prior infection status. Mixed-effects models were employed to describe the kinetics of log-transformed S-RBD antibody titers.<br>
Results: The study found that S-RBD antibody titers declined over time but increased with the number of booster vaccinations, particularly those adapted to Omicron and its subvariant XBB.1.5 (Pfizer-BioNTech Omicron-compatible: 0.156, 95%CI ?0.032 to 0.344; Pfizer-BioNTech XBB-compatible: 0.226; 95%CI ?0.051 to 0.504; Moderna Omicron-compatible: 0.279, 95%CI 0.012 to 0.546; and Moderna XBB-compatible: 0.338, 95%CI ?0.052 to 0.728). Previously infected individuals maintained higher antibody titers, which declined more gradually compared to uninfected individuals (coefficient for interaction with time 0.006; 95%CI 0.001 to 0.011). Sensitivity analyses using Generalized Estimating Equations and interval-censored random intercept model confirmed the robustness of these findings.<br>
Conclusions: The study provides specific data on antibody kinetics post-booster vaccination, including the XBB.1.5-adapted vaccine, in a highly vaccinated Japanese population. The results highlight the importance of considering individual demographics and prior infection history in optimizing vaccination strategies.
en-copyright=
kn-copyright=

en-aut-name=MatsumotoNaomi
en-aut-sei=Matsumoto
en-aut-mei=Naomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SasakiAyako
en-aut-sei=Sasaki
en-aut-mei=Ayako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KadowakiTomoka
en-aut-sei=Kadowaki
en-aut-mei=Tomoka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MitsuhashiToshiharu
en-aut-sei=Mitsuhashi
en-aut-mei=Toshiharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TakaoSoshi
en-aut-sei=Takao
en-aut-mei=Soshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=YorifujiTakashi
en-aut-sei=Yorifuji
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Department of Epidemiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of Epidemiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=6
en-affil=Department of Epidemiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=SARS-CoV-2
kn-keyword=SARS-CoV-2
en-keyword=Vaccine
kn-keyword=Vaccine
en-keyword=Antibody
kn-keyword=Antibody
en-keyword=Mixed-effects model
kn-keyword=Mixed-effects model
en-keyword=Omicron
kn-keyword=Omicron
END

start-ver=1.4
cd-journal=joma
no-vol=6
cd-vols=
no-issue=4
article-no=
start-page=253
end-page=256
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=20230614
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A case of mucosal-associated lymphoid tissue lymphoma of the urachus
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Introduction: Urachus carcinoma is a rare malignancy with an aggressive potential and a poor prognosis, and evidence is limited for its diagnosis and treatment.<br>
Case presentation: A 75-year-old man underwent fluorodeoxyglucose positron emission tomography/computed tomography for staging prostate cancer, and a mass (standardized uptake value max 9.5) was observed on the outside of the urinary bladder dome. T2-weighted magnetic resonance imaging showed the urachus and a low-intensity tumor, which suggested a malignant tumor. We suspected urachal carcinoma and performed total resection of the urachus and partial cystectomy. Pathological examination revealed mucosa-associated lymphoid tissue lymphoma with cells positive for CD20 and negative for CD3, CD5, and cyclin D1. After the surgery, no recurrence has been observed for more than 2 years.<br>
Conclusion: We encountered an extremely rare case of mucosa-associated lymphoid tissue lymphoma of the urachus. Surgical resection of the tumor provided an accurate diagnosis and good disease control.
en-copyright=
kn-copyright=

en-aut-name=TsuboiKazuma
en-aut-sei=Tsuboi
en-aut-mei=Kazuma
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=BekkuKensuke
en-aut-sei=Bekku
en-aut-mei=Kensuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HaisaKohei
en-aut-sei=Haisa
en-aut-mei=Kohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KajiharaYuta
en-aut-sei=Kajihara
en-aut-mei=Yuta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TsugawaTakuji
en-aut-sei=Tsugawa
en-aut-mei=Takuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=InoueYosuke
en-aut-sei=Inoue
en-aut-mei=Yosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=SakoTomoko
en-aut-sei=Sako
en-aut-mei=Tomoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=MuraoWataru
en-aut-sei=Murao
en-aut-mei=Wataru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=EbaraShin
en-aut-sei=Ebara
en-aut-mei=Shin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Urology, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=2
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Urology, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=4
en-affil=Department of Urology, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=5
en-affil=Department of Urology, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=6
en-affil=Department of Urology, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=7
en-affil=Department of Urology, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=8
en-affil=Department of Urology, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=9
en-affil=Department of Urology, Hiroshima City Hiroshima Citizens Hospital
kn-affil=
en-keyword=bladder cancer
kn-keyword=bladder cancer
en-keyword=malignant lymphoma
kn-keyword=malignant lymphoma
en-keyword=MALT lymphoma
kn-keyword=MALT lymphoma
en-keyword=urachal cancer
kn-keyword=urachal cancer
en-keyword=urachal remnant
kn-keyword=urachal remnant
END

start-ver=1.4
cd-journal=joma
no-vol=25
cd-vols=
no-issue=15
article-no=
start-page=8370
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240731
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Increased Oxidative Stress and Decreased Citrulline in Blood Associated with Severe Novel Coronavirus Pneumonia in Adult Patients
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=This study investigated the correlation between oxidative stress and blood amino acids associated with nitric oxide metabolism in adult patients with coronavirus disease (COVID-19) pneumonia. Clinical data and serum samples were prospectively collected from 100 adult patients hospitalized for COVID-19 between July 2020 and August 2021. Patients with COVID-19 were categorized into three groups for analysis based on lung infiltrates, oxygen inhalation upon admission, and the initiation of oxygen therapy after admission. Blood data, oxidative stress-related biomarkers, and serum amino acid levels upon admission were compared in these groups. Patients with lung infiltrations requiring oxygen therapy upon admission or starting oxygen post-admission exhibited higher serum levels of hydroperoxides and lower levels of citrulline compared to the control group. No remarkable differences were observed in nitrite/nitrate, asymmetric dimethylarginine, and arginine levels. Serum citrulline levels correlated significantly with serum lactate dehydrogenase and C-reactive protein levels. A significant negative correlation was found between serum levels of citrulline and hydroperoxides. Levels of hydroperoxides decreased, and citrulline levels increased during the recovery period compared to admission. Patients with COVID-19 with extensive pneumonia or poor oxygenation showed increased oxidative stress and reduced citrulline levels in the blood compared to those with fewer pulmonary complications. These findings suggest that combined oxidative stress and abnormal citrulline metabolism may play a role in the pathogenesis of COVID-19 pneumonia.
en-copyright=
kn-copyright=

en-aut-name=TsugeMitsuru
en-aut-sei=Tsuge
en-aut-mei=Mitsuru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=IchiharaEiki
en-aut-sei=Ichihara
en-aut-mei=Eiki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HasegawaKou
en-aut-sei=Hasegawa
en-aut-mei=Kou
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KudoKenichiro
en-aut-sei=Kudo
en-aut-mei=Kenichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TanimotoYasushi
en-aut-sei=Tanimoto
en-aut-mei=Yasushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NousoKazuhiro
en-aut-sei=Nouso
en-aut-mei=Kazuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=OdaNaohiro
en-aut-sei=Oda
en-aut-mei=Naohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=MitsumuneSho
en-aut-sei=Mitsumune
en-aut-mei=Sho
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=KimuraGoro
en-aut-sei=Kimura
en-aut-mei=Goro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=YamadaHaruto
en-aut-sei=Yamada
en-aut-mei=Haruto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=TakataIchiro
en-aut-sei=Takata
en-aut-mei=Ichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=MitsuhashiToshiharu
en-aut-sei=Mitsuhashi
en-aut-mei=Toshiharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=TaniguchiAkihiko
en-aut-sei=Taniguchi
en-aut-mei=Akihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=TsukaharaKohei
en-aut-sei=Tsukahara
en-aut-mei=Kohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=AokageToshiyuki
en-aut-sei=Aokage
en-aut-mei=Toshiyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=HagiyaHideharu
en-aut-sei=Hagiya
en-aut-mei=Hideharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=ToyookaShinichi
en-aut-sei=Toyooka
en-aut-mei=Shinichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=TsukaharaHirokazu
en-aut-sei=Tsukahara
en-aut-mei=Hirokazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=MaedaYoshinobu
en-aut-sei=Maeda
en-aut-mei=Yoshinobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

affil-num=1
en-affil=Department of Pediatrics, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Allergy and Respiratory Medicine, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of General Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Respiratory Medicine, National Hospital Organization Minami-Okayama Medical Center
kn-affil=

affil-num=5
en-affil=Department of Allergy and Respiratory Medicine, National Hospital Organization Minami-Okayama Medical Center
kn-affil=

affil-num=6
en-affil=Department of Gastroenterology, Okayama City Hospital
kn-affil=

affil-num=7
en-affil=Department of Internal Medicine, Fukuyama City Hospital
kn-affil=

affil-num=8
en-affil=Department of Respiratory Medicine, National Hospital Organization Minami-Okayama Medical Center
kn-affil=

affil-num=9
en-affil=Department of Allergy and Respiratory Medicine, National Hospital Organization Minami-Okayama Medical Center
kn-affil=

affil-num=10
en-affil=Department of Infectious Disease, Okayama City Hospital
kn-affil=

affil-num=11
en-affil=Department of Internal Medicine, Fukuyama City Hospital
kn-affil=

affil-num=12
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=

affil-num=13
en-affil=Department of Allergy and Respiratory Medicine, Okayama University Hospital
kn-affil=

affil-num=14
en-affil=Department of Emergency, Critical Care and Disaster Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=15
en-affil=Department of Emergency, Critical Care and Disaster Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=16
en-affil=Department of General Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=17
en-affil=Department of General Thoracic Surgery and Breast and Endocrine Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=18
en-affil=Department of Pediatrics, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=19
en-affil=Department of Hematology, Oncology and Respiratory Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=novel coronavirus disease 2019
kn-keyword=novel coronavirus disease 2019
en-keyword=pneumonia
kn-keyword=pneumonia
en-keyword=hydroperoxide
kn-keyword=hydroperoxide
en-keyword=nitric oxide
kn-keyword=nitric oxide
en-keyword=reactive oxygen species
kn-keyword=reactive oxygen species
en-keyword=citrulline
kn-keyword=citrulline
en-keyword=arginine
kn-keyword=arginine
en-keyword=asymmetric dimethylarginine
kn-keyword=asymmetric dimethylarginine
END

start-ver=1.4
cd-journal=joma
no-vol=13
cd-vols=
no-issue=15
article-no=
start-page=4384
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240726
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Impact of Serum Indoxyl Sulfate on One-Year Adverse Events in Chronic Kidney Disease Patients with Heart Failure
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background/Objectives: Indoxyl sulfate, a uremic toxin, is associated with mortality and cardiovascular events in patients with chronic kidney disease (CKD). This study aimed to evaluate the prognostic implications of serum indoxyl sulfate levels in patients with heart failure and CKD. Methods and Results: This was a prospective multicenter observational study. Overall, 300 patients with chronic heart failure with a previous history of hospitalization and an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or less (CKD stage G3b to G5) without dialysis were analyzed. The primary outcome assessed in a time-to-event analysis from the measurement of indoxyl sulfate was a composite of all-cause death, hospitalization for heart failure, nonfatal myocardial infarction, and nonfatal stroke. Clinical events were followed-up to one year after indoxyl sulfate measurement. The median patient age was 75 years, and 57% of the patients were men. We divided the cohort into low and high indoxyl sulfate categories according to a median value of 9.63 mg/mL. The primary outcome occurred in 27 of 150 patients (18.0%) in the low indoxyl sulfate group and 27 of 150 patients (18.0%) in the high indoxyl sulfate group (hazard ratio, 1.00; 95% confidence interval, 0.58 to 1.70, p = 0.99). In the post hoc exploratory analyses, the results were consistent across age, sex, body mass index, left ventricular ejection fraction, eGFR, and N-terminal pro b-type natriuretic peptide. Conclusions: Among heart failure patients with CKD stages G3b to 5G, serum indoxyl sulfate concentrations were not significantly associated with the subsequent occurrence of cardiovascular events.
en-copyright=
kn-copyright=

en-aut-name=IwasakiKeiichiro
en-aut-sei=Iwasaki
en-aut-mei=Keiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MiyoshiToru
en-aut-sei=Miyoshi
en-aut-mei=Toru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=UrabeChikara
en-aut-sei=Urabe
en-aut-mei=Chikara
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SakuragiSatoru
en-aut-sei=Sakuragi
en-aut-mei=Satoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KawaiYusuke
en-aut-sei=Kawai
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=FukeSoichiro
en-aut-sei=Fuke
en-aut-mei=Soichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=DoiMasayuki
en-aut-sei=Doi
en-aut-mei=Masayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=TakaishiAtsushi
en-aut-sei=Takaishi
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=OkaTakefumi
en-aut-sei=Oka
en-aut-mei=Takefumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=TokunagaNaoto
en-aut-sei=Tokunaga
en-aut-mei=Naoto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=ItoHiroshi
en-aut-sei=Ito
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

affil-num=1
en-affil=Department of Cardiovascular Medicine, Okayama University Institute of Academic and Research, Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Cardiovascular Medicine, Okayama University Institute of Academic and Research, Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Cardiovascular Medicine, Okayama University Institute of Academic and Research, Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Cardiovascular Medicine, Iwakuni Clinical Center
kn-affil=

affil-num=5
en-affil=Department of Cardiovascular Medicine, Okayama City Hospital
kn-affil=

affil-num=6
en-affil=Department of Cardiovascular Medicine, Japanese Red Cross Okayama Hospital
kn-affil=

affil-num=7
en-affil=Department of Cardiology, Kagawa Prefectural Central Hospital
kn-affil=

affil-num=8
en-affil=Department of Cardiology, Mitoyo General Hospital
kn-affil=

affil-num=9
en-affil=Department of Cardiology, Tsuyama Chuo Hospital
kn-affil=

affil-num=10
en-affil=Department of Cardiology, Ibara City Hospital
kn-affil=

affil-num=11
en-affil=Department of General Internal Medicine 3, Kawasaki Medical School
kn-affil=
en-keyword=heart failure
kn-keyword=heart failure
en-keyword=chronic kidney disease
kn-keyword=chronic kidney disease
en-keyword=indoxyl sulfate
kn-keyword=indoxyl sulfate
END

start-ver=1.4
cd-journal=joma
no-vol=29
cd-vols=
no-issue=10
article-no=
start-page=1594
end-page=1601
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240713
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Re-administration of platinum-based chemotherapy for recurrent endometrial cancer: an ancillary analysis of the SGSG-012/GOTIC-004/Intergroup study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background We previously demonstrated the applicability of the concept of “platinum sensitivity” in recurrent endometrial cancer. Although immune checkpoint inhibitors have been widely incorporated into endometrial cancer treatment, the debate continues regarding treatment options in patients with recurrent endometrial cancer who have previously received platinum-based chemotherapy. In this study, we assessed the duration of response to secondary platinum-based treatment using pooled data from the SGSG-012/GOTIC-004/Intergroup study.<br>
Methods Among the 279 participants in the SGSG-012/GOTIC-004/Intergroup study wherein platinum-based chemotherapy was re-administered for managing recurrent endometrial cancer between January 2005 and December 2009, 130 (47%) responded to chemotherapy. We compared the relationship between platinum-free interval and duration of secondary platinum-based treatment using pooled data.<br>
Results In 40 patients (31%), the duration of response to secondary platinum-based treatment exceeded the platinum-free interval. The duration of response to secondary platinum-based treatment exceeded 12 months in 51 patients (39%) [platinum-free interval:?<?12 months, 14/48 (29%); 12?23 months, 18/43 (42%); 24?35 months, 8/19 (42%);???36 months, 11/20 (55%)]. In particular, in eight patients (6%), the duration of response to secondary platinum-based treatment exceeded 36 months [platinum-free interval:?<?12 months, 3/48 (6%); 12?23 months, 0/19 (0%); 24?35 months, 2/19 (11%);???36 months, 3/20 (15%)].<br>
Conclusions Re-administration of platinum-based chemotherapy for recurrent endometrial cancer may result in a long-term response exceeding the platinum-free interval in some patients. Even in the current situation, where immune checkpoint inhibitors have been introduced, re-administration of platinum-based chemotherapy is worth considering.
en-copyright=
kn-copyright=

en-aut-name=NagaoShoji
en-aut-sei=Nagao
en-aut-mei=Shoji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NishioShin
en-aut-sei=Nishio
en-aut-mei=Shin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TakeharaKazuhiro
en-aut-sei=Takehara
en-aut-mei=Kazuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SatoShinya
en-aut-sei=Sato
en-aut-mei=Shinya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SatohToyomi
en-aut-sei=Satoh
en-aut-mei=Toyomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=ShimadaMuneaki
en-aut-sei=Shimada
en-aut-mei=Muneaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=YamaguchiSatoshi
en-aut-sei=Yamaguchi
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=TanabeHiroshi
en-aut-sei=Tanabe
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=TakanoMasashi
en-aut-sei=Takano
en-aut-mei=Masashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=HorieKouji
en-aut-sei=Horie
en-aut-mei=Kouji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=TakeiYuji
en-aut-sei=Takei
en-aut-mei=Yuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=ImaiYuichi
en-aut-sei=Imai
en-aut-mei=Yuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=HibinoYumi
en-aut-sei=Hibino
en-aut-mei=Yumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=HasegawaKosei
en-aut-sei=Hasegawa
en-aut-mei=Kosei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=TakekumaMunetaka
en-aut-sei=Takekuma
en-aut-mei=Munetaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=NakamuraKazuto
en-aut-sei=Nakamura
en-aut-mei=Kazuto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=TakanoHirokuni
en-aut-sei=Takano
en-aut-mei=Hirokuni
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=FujiwaraKeiichi
en-aut-sei=Fujiwara
en-aut-mei=Keiichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=MasuyamaHisashi
en-aut-sei=Masuyama
en-aut-mei=Hisashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

affil-num=1
en-affil=Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Obstetrics and Gynecology, Kurume University School of Medicine
kn-affil=

affil-num=3
en-affil=Department of Gynecologic Oncology, NHO Shikoku Cancer Center
kn-affil=

affil-num=4
en-affil=Department of Obstetrics and Gynecology, Tottori University
kn-affil=

affil-num=5
en-affil=Department of Obstetrics and Gynecology, Institute of Medicine, University of Tsukuba
kn-affil=

affil-num=6
en-affil=Department of Gynecology, Tohoku University Hospital
kn-affil=

affil-num=7
en-affil=Department of Medical Oncology, Hyogo Cancer Center
kn-affil=

affil-num=8
en-affil=Department of Obstetrics and Gynecology, Jikei University School of Medicine
kn-affil=

affil-num=9
en-affil=Department of Obstetrics and Gynecology, National Defense Medical College
kn-affil=

affil-num=10
en-affil=Department of Gynecologic Oncology, Saitama Cancer Center
kn-affil=

affil-num=11
en-affil=Department of Obstetrics and Gynecology, Jichi Medical University
kn-affil=

affil-num=12
en-affil=Department of Obstetrics and Gynecology, Yokohama City University Hospital
kn-affil=

affil-num=13
en-affil=Department of Gynecologic Oncology, NHO Shikoku Cancer Center
kn-affil=

affil-num=14
en-affil=Department of Gynecologic Oncology, Saitama Medical University International Medical Center
kn-affil=

affil-num=15
en-affil=Department of Gynecology, Shizuoka Cancer Center
kn-affil=

affil-num=16
en-affil=Department of Gynecology, Gunma Prefectural Cancer Center
kn-affil=

affil-num=17
en-affil=Department of Obstetrics and Gynecology, Jikei University School of Medicine
kn-affil=

affil-num=18
en-affil=Department of Gynecologic Oncology, Saitama Medical University International Medical Center
kn-affil=

affil-num=19
en-affil=Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=Recurrent endometrial cancer
kn-keyword=Recurrent endometrial cancer
en-keyword=Re-administration of platinum-based chemotherapy
kn-keyword=Re-administration of platinum-based chemotherapy
en-keyword=Platinum-free interval
kn-keyword=Platinum-free interval
en-keyword=Secondary platinum response
kn-keyword=Secondary platinum response
END

start-ver=1.4
cd-journal=joma
no-vol=56
cd-vols=
no-issue=1
article-no=
start-page=1
end-page=28
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240724
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Firm Entry and Exit in the First Stage of Regional Vitalization: Revolving Door Economy or Creative Destruction
kn-title=地方創生第１期における企業の参入と撤退：回転ドア型経済か創造的破壊か
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=　The growth of the regional economy needs an economic metabolism in which high-productivity firms newly enter the market, while low-productivity firms exit the market, resulting in a shift in labor and other production factors. A“ revolving door” economy is an economy in which firms that enter the market have a short existence period, withdraw and enter the market repeatedly, and new entrants do not contribute to productivity improvement. This means that if new entrants are not sufficiently innovative compared to incumbents, even if the rate of entry into business rises, they will simply be replaced by firms whose productivity level has not changed much, and this will not lead to job creation or improving productivity. A contrasting concept is the replacement of firms by Schumpeter's “creative destruction.” The high level of technology and productivity of new firms entering the market drives inefficient incumbents out of the market. Looking at the statistics, there is a tendency for both large cities to have higher business entry and exit rates, but the difference between the entry and exit rates is greater in metropolitan areas. Although it depends on the regional characteristics, location competitiveness is generally higher in metropolitan areas, and there is a tendency for the turnover rate to be high or the survival period to be short. Before and after regional revitalization, we will examine whether or not there is a departure from the revolving door economy by industry and region, using economic census and TSR （Tokyo Shoko Research） data.
en-copyright=
kn-copyright=

en-aut-name=NakamuraRyohei
en-aut-sei=Nakamura
en-aut-mei=Ryohei
kn-aut-name=中村良平
kn-aut-sei=中村
kn-aut-mei=良平
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=60
cd-vols=
no-issue=3
article-no=
start-page=3934
end-page=3949
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240301
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Designing and Prototyping an Axial-Flux Machine Using Ferrite PM and Round Wire for Traction Applications: Comparison With a Radial-Flux Machine Using Nd-Fe-B PM and Rectangular Wire
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=This paper proposes a novel axial-flux permanent magnet machine (AFPM) employing ferrite permanent magnets (PMs) and round copper wire. The proposed AFPM adopts a novel rotor structure and uses tooth-tips with a suitable trapezoidal shape. These structures compensate for the low magnetomotive force of the round copper wire and ferrite PMs, achieving high performance at low cost. Additionally, compared with an off-the-shelf radial-flux permanent magnet machine (RFPM) using Nd-sintered PMs and rectangular copper wire, the proposed AFPM achieves the same output power and higher efficiency, despite using ferrite PMs and the round copper wire. Finally, a prototype of the proposed AFPM was manufactured and evaluated experimentally. The prototype achieved a high efficiency of over 95% across a wide operating area while maintaining required maximum torque, suggesting its potential for traction applications.
en-copyright=
kn-copyright=

en-aut-name=TsunataRen
en-aut-sei=Tsunata
en-aut-mei=Ren
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=IzumiyaKosuke
en-aut-sei=Izumiya
en-aut-mei=Kosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TakemotoMasatsugu
en-aut-sei=Takemoto
en-aut-mei=Masatsugu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=ImaiJun
en-aut-sei=Imai
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SaitoTatsuya
en-aut-sei=Saito
en-aut-mei=Tatsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=UenoTomoyuki
en-aut-sei=Ueno
en-aut-mei=Tomoyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Division of Industrial Innovation Sciences Graduate School of Natural Science and Technology, Okayama University
kn-affil=

affil-num=2
en-affil=Division of Industrial Innovation Sciences Graduate School of Natural Science and Technology, Okayama University
kn-affil=

affil-num=3
en-affil=Division of Industrial Innovation Sciences Graduate School of Natural Science and Technology, Okayama University
kn-affil=

affil-num=4
en-affil=Division of Industrial Innovation Sciences Graduate School of Natural Science and Technology, Okayama University
kn-affil=

affil-num=5
en-affil=Sumitomo Electric Industries Ltd.
kn-affil=

affil-num=6
en-affil=Sumitomo Electric Industries Ltd.
kn-affil=
en-keyword=Axial gap motor
kn-keyword=Axial gap motor
en-keyword=axial-flux machine
kn-keyword=axial-flux machine
en-keyword=carbon fiber rotor
kn-keyword=carbon fiber rotor
en-keyword=carbon fiber-reinforced plastic
kn-keyword=carbon fiber-reinforced plastic
en-keyword=city commuter
kn-keyword=city commuter
en-keyword=ferrite magnet
kn-keyword=ferrite magnet
en-keyword=flat copper wire
kn-keyword=flat copper wire
en-keyword=high circumferential speed
kn-keyword=high circumferential speed
en-keyword=radial-flux machine
kn-keyword=radial-flux machine
END

start-ver=1.4
cd-journal=joma
no-vol=49
cd-vols=
no-issue=4
article-no=
start-page=291
end-page=297
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240330
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Evaluation of the trend of set-up errors during the treatment period using set-up margin in prostate radiotherapy
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Accurate information on set-up error during radiotherapy is essential for determining the optimal number of treatments in hypofractionated radiotherapy for prostate cancer. This necessitates careful control by the radiotherapy staff to assess the patient's condition. This study aimed to develop an evaluation method of the temporal trends in a patient's specific prostate movement during treatment using image matching and margin values. This study included 65 patients who underwent prostate volumetric modulated arc therapy (mean treatment time, 87.2 s). Set-up errors were assessed using bone, inter-, and intra-fraction marker matching across 39 fractions. The set-up margin was determined by dividing the four periods into 39 fractions using Stroom's formula and correlation coefficient. The intra-fraction set-up error was biased in the anterior-superior (AS) direction during treatment. The temporal trend of set-up errors during radiotherapy slightly increased based on bone matching and inter-fraction marker matching, with a 1.6-mm difference in the set-up margin fractions 11 to 20. The correlation coefficient of the mean prostate movement during treatment significantly decreased in the superior-inferior direction, while remaining high in the left-right and anterior-posterior directions. Image matching contributed significantly to the improvement of set-up errors; however, careful attention is needed for prostate movement in the AS direction, particularly during short treatment times. Understanding the trend of set-up errors during the treatment period is essential in numerical information sharing on patient condition and evaluating the margins for tailored hypo-fractionated radiotherapy, considering the facility's image-guided radiation therapy technology.
en-copyright=
kn-copyright=

en-aut-name=SasakiHinako
en-aut-sei=Sasaki
en-aut-mei=Hinako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MorishitaTakumi
en-aut-sei=Morishita
en-aut-mei=Takumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=IrieNaho
en-aut-sei=Irie
en-aut-mei=Naho
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KojimaRena
en-aut-sei=Kojima
en-aut-mei=Rena
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KiriyamaTetsukazu
en-aut-sei=Kiriyama
en-aut-mei=Tetsukazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NakamotoAkira
en-aut-sei=Nakamoto
en-aut-mei=Akira
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NishiokaKunio
en-aut-sei=Nishioka
en-aut-mei=Kunio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=TakahashiShotaro
en-aut-sei=Takahashi
en-aut-mei=Shotaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=TanabeYoshinori
en-aut-sei=Tanabe
en-aut-mei=Yoshinori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Radiological Technology, Faculty of Health Sciences, Okayama University Medical School
kn-affil=

affil-num=2
en-affil=Department of Radiological Technology, Faculty of Health Sciences, Okayama University Medical School
kn-affil=

affil-num=3
en-affil=Department of Radiological Technology, Faculty of Health Sciences, Okayama University Medical School
kn-affil=

affil-num=4
en-affil=Department of Radiological Technology, Faculty of Health Sciences, Okayama University Medical School
kn-affil=

affil-num=5
en-affil=Department of Radiology, Uwajima City Hospital
kn-affil=

affil-num=6
en-affil=Department of Radiology, Tokuyama Central Hospital
kn-affil=

affil-num=7
en-affil=Department of Radiology, Tokuyama Central Hospital
kn-affil=

affil-num=8
en-affil=Department of Radiology, Tokuyama Central Hospital
kn-affil=

affil-num=9
en-affil=Department of Radiological Technology, Graduate School of Health Sciences, Okayama University
kn-affil=
en-keyword=Hypofractionated radiotherapy
kn-keyword=Hypofractionated radiotherapy
en-keyword=Image-guided radiation therapy
kn-keyword=Image-guided radiation therapy
en-keyword=Prostate cancer
kn-keyword=Prostate cancer
en-keyword=Prostate movement
kn-keyword=Prostate movement
en-keyword=Set-up margin
kn-keyword=Set-up margin
END

start-ver=1.4
cd-journal=joma
no-vol=11
cd-vols=
no-issue=
article-no=
start-page=1383309
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240606
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Late-onset renal variant Fabry disease with R112H mutation and mild increase in plasma globotriaosylsphingosine: a case report
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Fabry disease (FD) is an X-linked disorder resulting in a deficiency of alpha-galactosidase A (GLA) activity. The R112H mutation of GLA is relatively common in Japanese FD patients, characterized by a late-onset phenotype, almost normal to mild lyso-Gb3 elevation, and mild clinical symptoms, despite low GLA activity. This is due to the structural features of the R112H GLA protein. We herein report the case of a 42-year-old male patient with late-onset FD with a R112H mutation. The patient exhibited only renal involvement with no other organ damage and was successfully treated with galactosidase beta and subsequent migalastat for approximately 10 years. Especially, migalastat was clinically effective in normalizing plasma lyso-Gb3 levels and inhibiting the progression of renal damage associated with FD. Therefore, the use of migalastat in the FD patients with R112H mutation is highly recommended based on this case report.
en-copyright=
kn-copyright=

en-aut-name=TanakaKeiko
en-aut-sei=Tanaka
en-aut-mei=Keiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SugiyamaHitoshi
en-aut-sei=Sugiyama
en-aut-mei=Hitoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MorinagaHiroshi
en-aut-sei=Morinaga
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=OnishiAkifumi
en-aut-sei=Onishi
en-aut-mei=Akifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TanabeKatsuyuki
en-aut-sei=Tanabe
en-aut-mei=Katsuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=UchidaHaruhito A.
en-aut-sei=Uchida
en-aut-mei=Haruhito A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MaruyamaHiroki
en-aut-sei=Maruyama
en-aut-mei=Hiroki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=WadaJun
en-aut-sei=Wada
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Department of Nephrology,  Rheumatology, Endocrinology and Metabolism, Okayama University
kn-affil=

affil-num=2
en-affil=Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Department of Nephrology,  Rheumatology, Endocrinology and Metabolism, Okayama University
kn-affil=

affil-num=3
en-affil=Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Department of Nephrology,  Rheumatology, Endocrinology and Metabolism, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Nephrology, Fukuyama City  Hospital
kn-affil=

affil-num=5
en-affil=Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Department of Nephrology,  Rheumatology, Endocrinology and Metabolism, Okayama University
kn-affil=

affil-num=6
en-affil=Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Department of Nephrology,  Rheumatology, Endocrinology and Metabolism, Okayama University
kn-affil=

affil-num=7
en-affil=Department of Clinical Nephroscience, Niigata University Graduate  School of Medical and Dental Sciences
kn-affil=

affil-num=8
en-affil=Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Department of Nephrology,  Rheumatology, Endocrinology and Metabolism, Okayama University
kn-affil=
en-keyword=Fabry disease
kn-keyword=Fabry disease
en-keyword=R112H mutation
kn-keyword=R112H mutation
en-keyword=migalastat
kn-keyword=migalastat
en-keyword=proteinuria
kn-keyword=proteinuria
en-keyword=chronic kidney disease
kn-keyword=chronic kidney disease
END

start-ver=1.4
cd-journal=joma
no-vol=14
cd-vols=
no-issue=1
article-no=
start-page=9869
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240430
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Absolute lymphocyte count and neutrophil-to-lymphocyte ratio as predictors of CDK 4/6 inhibitor efficacy in advanced breast cancer
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) are the standard agents for treating patients with estrogen receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer (ER + HER2 - ABC). However, markers predicting the outcomes of CDK4/6i treatment have yet to be identified. This study was a single-center retrospective cohort study. We retrospectively evaluated 101 patients with ER + HER2 - ABC receiving CDK4/6i in combination with endocrine therapy at Fukuyama City Hospital between November 2017 and July 2021. We investigated the clinical outcomes and the safety of CDK4/6i treatment, and the absolute lymphocyte count (ALC) and neutrophil-to-lymphocyte ratio (NLR) as predictive markers for CDK4/6i. We defined the cut-off values as 1000/mu L for ALC and 3 for NLR, and divided into "low" and "high" groups, respectively. We evaluated 43 and 58 patients who received abemaciclib and palbociclib, respectively. Patients with high ALC and low NLR had significantly longer overall survival than those with low ALC and high NLR (high vs. low; ALC: HR 0.29; 95% CI 0.12-0.70; NLR: HR 2.94; 95% CI 1.21-7.13). There was no significant difference in efficacy between abemaciclib and palbociclib and both had good safety profiles. We demonstrated that ALC and NLR might predict the outcomes of CDK4/6i treatment in patients with ER + HER2 - ABC.
en-copyright=
kn-copyright=

en-aut-name=NakamotoShogo
en-aut-sei=Nakamoto
en-aut-mei=Shogo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ShienTadahiko
en-aut-sei=Shien
en-aut-mei=Tadahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=IwamotoTakayuki
en-aut-sei=Iwamoto
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KuboShinichiro
en-aut-sei=Kubo
en-aut-mei=Shinichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=YamamotoMari
en-aut-sei=Yamamoto
en-aut-mei=Mari
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=YamashitaTetsumasa
en-aut-sei=Yamashita
en-aut-mei=Tetsumasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KuwaharaChihiro
en-aut-sei=Kuwahara
en-aut-mei=Chihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=IkedaMasahiko
en-aut-sei=Ikeda
en-aut-mei=Masahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Breast and Thyroid Surgery, Fukuyama City Hospital
kn-affil=

affil-num=5
en-affil=Department of Breast and Thyroid Surgery, Fukuyama City Hospital
kn-affil=

affil-num=6
en-affil=Department of Breast and Thyroid Surgery, Fukuyama City Hospital
kn-affil=

affil-num=7
en-affil=Department of Breast and Thyroid Surgery, Fukuyama City Hospital
kn-affil=

affil-num=8
en-affil=Department of Breast and Thyroid Surgery, Fukuyama City Hospital
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=3
article-no=
start-page=295
end-page=300
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202406
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Calcification of a Hydrophilic Acrylic Intraocular Lens after Glaucoma Surgery
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=A Japanese woman in her 70s was referred to our hospital for the evaluation and treatment of high intraocular pressure (IOP) in her right eye. She had undergone bilateral cataract surgeries and the insertion of hydrophilic acrylic intraocular lenses (IOLs). We performed trabeculotomy and trabeculectomy to lower her right IOP; thereafter, a circular opacity was observed on the right eye’s IOL surface. We removed the right IOL because that eye’s vision had decreased due to IOL opacification. The analysis of the removed IOL revealed that the main opacity component was calcium phosphate. This is the first post-glaucoma-surgery IOL calcification case report.
en-copyright=
kn-copyright=

en-aut-name=OkamotoSara
en-aut-sei=Okamoto
en-aut-mei=Sara
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ShiodeYusuke
en-aut-sei=Shiode
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KimuraShuhei
en-aut-sei=Kimura
en-aut-mei=Shuhei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=HosokawaMio
en-aut-sei=Hosokawa
en-aut-mei=Mio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MatobaRyo
en-aut-sei=Matoba
en-aut-mei=Ryo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KanzakiYuki
en-aut-sei=Kanzaki
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KindoHiroya
en-aut-sei=Kindo
en-aut-mei=Hiroya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=MoritaTetsuro
en-aut-sei=Morita
en-aut-mei=Tetsuro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=TsujiAkihiro
en-aut-sei=Tsuji
en-aut-mei=Akihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=TakahashiKosuke
en-aut-sei=Takahashi
en-aut-mei=Kosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=MorizaneYuki
en-aut-sei=Morizane
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

affil-num=1
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Fukuyama City Hospital
kn-affil=

affil-num=10
en-affil=Fukuyama City Hospital
kn-affil=

affil-num=11
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=intraocular lens
kn-keyword=intraocular lens
en-keyword=IOL
kn-keyword=IOL
en-keyword=IOL calcification
kn-keyword=IOL calcification
en-keyword=hydrophilic acrylic IOL
kn-keyword=hydrophilic acrylic IOL
en-keyword=glaucoma surgery
kn-keyword=glaucoma surgery
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=3
article-no=
start-page=281
end-page=284
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202406
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Spontaneous Bilateral Pneumothorax in a Patient with Anorexia Nervosa: The Management of Prolonged Postoperative Air Leakage
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=A 24-year-old Japanese female with anorexia nervosa presented to our hospital for bilateral pneumothorax, and 12-Fr thoracostomy catheters were inserted into the bilateral pleural cavities. On hospital day 9, a thoracoscopic bullectomy was performed. However, air leakage relapsed on both sides on postoperative day 1. The air leakage on the right side was particularly persistent, and we switched the drainage to a Heimlich valve. Both lungs expanded gradually and the chest tube was removed on postoperative day 19. Passive pleural drainage might be an option for prolonged air leakage after a bullectomy in patients with anorexia nervosa.
en-copyright=
kn-copyright=

en-aut-name=OkadaKazuhiro
en-aut-sei=Okada
en-aut-mei=Kazuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MakiYuho
en-aut-sei=Maki
en-aut-mei=Yuho
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MatsubaraKei
en-aut-sei=Matsubara
en-aut-mei=Kei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=HiranoYutaka
en-aut-sei=Hirano
en-aut-mei=Yutaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=FujiwaraToshiya
en-aut-sei=Fujiwara
en-aut-mei=Toshiya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MatsuuraMotoki
en-aut-sei=Matsuura
en-aut-mei=Motoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Department of Thoracic Surgery, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=2
en-affil=Department of Thoracic Surgery, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=3
en-affil=Department of Thoracic Surgery, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=4
en-affil=Department of Thoracic Surgery, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=5
en-affil=Department of Thoracic Surgery, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=6
en-affil=Department of Thoracic Surgery, Hiroshima City Hiroshima Citizens Hospital
kn-affil=
en-keyword=spontaneous pneumothorax
kn-keyword=spontaneous pneumothorax
en-keyword=anorexia nervosa
kn-keyword=anorexia nervosa
en-keyword=Heimlich valve
kn-keyword=Heimlich valve
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=3
article-no=
start-page=259
end-page=270
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202406
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=The Role of the Lipid Profile and Oxidative Stress in Fatigue, Sleep Disorders and Cognitive Impairment in Patients with Multiple Sclerosis
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The aim of this study is to investigate the relationship of the lipid profile, dysfunctional high-density lipoprotein, ischaemia-modified albumin and thiol?disulfide homeostasis with cognitive impairment, fatigue and sleep disorders in patients with multiple sclerosis. The cognitive functions of patients were evaluated with the Brief International Cognitive Assessment for Multiple Sclerosis battery. Fatigue was evaluated with the Fatigue Severity Scale and the Fatigue Impact Scale. The Pittsburgh Sleep Quality Index and the Epworth Sleepiness Scale were used to assess patients’ sleep disturbance. Peripheral blood samples were collected, and lipid levels and myeloperoxidase and paraoxonase activity were measured. The myeloperoxidase/paraoxonase ratio, which indicates dysfunctional high-density lipoprotein, was calculated. Thiol?disulfide homeostasis and ischaemia-modified albumin were measured.<br>
We did not identify any relationship between dysfunctional high-density lipoprotein and the physical disability, cognitive decline, fatigue and sleep problems of multiple sclerosis. Thiol?disulfide homeostasis was associated with cognitive scores. The shift of the balance towards disulfide was accompanied by a decrease in cognitive scores. On the other hand, we did not detect any relationship between fatigue and sleep disorders and thiol?disulfide homeostasis. Our findings revealed a possible correlation between cognitive dysfunction and thiol?disulfide homeostasis in multiple sclerosis patients.
en-copyright=
kn-copyright=

en-aut-name=VuralGonul
en-aut-sei=Vural
en-aut-mei=Gonul
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=DemirEsra
en-aut-sei=Demir
en-aut-mei=Esra
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=GumusyaylaSadiye
en-aut-sei=Gumusyayla
en-aut-mei=Sadiye
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=ErenFunda
en-aut-sei=Eren
en-aut-mei=Funda
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=BarakliSerdar
en-aut-sei=Barakli
en-aut-mei=Serdar
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NeseliogluSalim
en-aut-sei=Neselioglu
en-aut-mei=Salim
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=ErelOzcan
en-aut-sei=Erel
en-aut-mei=Ozcan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Department of Neurology, Faculty of Medicine, Ankara Yildirim Beyazit University
kn-affil=

affil-num=2
en-affil=Department of Neurology, Ankara City Hospital
kn-affil=

affil-num=3
en-affil=Department of Neurology, Faculty of Medicine, Ankara Yildirim Beyazit University
kn-affil=

affil-num=4
en-affil=Department of Clinical Biochemistry, Ankara City Hospital
kn-affil=

affil-num=5
en-affil=Department of Neurology, Ankara City Hospital
kn-affil=

affil-num=6
en-affil=Department of Clinical Biochemistry, Ankara City Hospital
kn-affil=

affil-num=7
en-affil=Department of Clinical Biochemistry, Ankara City Hospital
kn-affil=
en-keyword=multiple sclerosis
kn-keyword=multiple sclerosis
en-keyword=dysfunctional HDL
kn-keyword=dysfunctional HDL
en-keyword=thiol?disulfide homeostasis
kn-keyword=thiol?disulfide homeostasis
en-keyword=cognitive decline
kn-keyword=cognitive decline
END

start-ver=1.4
cd-journal=joma
no-vol=12
cd-vols=
no-issue=3
article-no=
start-page=e004237
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202405
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Plasma angiotensin-converting enzyme 2 (ACE2) is a marker for renal outcome of diabetic kidney disease (DKD) (U-CARE study 3)
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Introduction ACE cleaves angiotensin I (Ang I) to angiotensin II (Ang II) inducing vasoconstriction via Ang II type 1 (AT1) receptor, while ACE2 cleaves Ang II to Ang (1-7) causing vasodilatation by acting on the Mas receptor. In diabetic kidney disease (DKD), it is still unclear whether plasma or urine ACE2 levels predict renal outcomes or not.<br>
Research design and methods Among 777 participants with diabetes enrolled in the Urinary biomarker for Continuous And Rapid progression of diabetic nEphropathy study, the 296 patients followed up for 9 years were investigated. Plasma and urinary ACE2 levels were measured by the ELISA. The primary end point was a composite of a decrease of estimated glomerular filtration rate (eGFR) by at least 30% from baseline or initiation of hemodialysis or peritoneal dialysis. The secondary end points were a 30% increase or a 30% decrease in albumin-to-creatinine ratio from baseline to 1 year.<br>
Results The cumulative incidence of the renal composite outcome was significantly higher in group 1 with lowest tertile of plasma ACE2 (p=0.040). Group 2 with middle and highest tertile was associated with better renal outcomes in the crude Cox regression model adjusted by age and sex (HR 0.56, 95% CI 0.31 to 0.99, p=0.047). Plasma ACE2 levels demonstrated a significant association with 30% decrease in ACR (OR 1.46, 95% CI 1.044 to 2.035, p=0.027) after adjusting for age, sex, systolic blood pressure, hemoglobin A1c, and eGFR.<br>
Conclusions Higher baseline plasma ACE2 levels in DKD were protective for development and progression of albuminuria and associated with fewer renal end points, suggesting plasma ACE2 may be used as a prognosis marker of DKD.Trial registration number UMIN000011525.
en-copyright=
kn-copyright=

en-aut-name=UenoAsami
en-aut-sei=Ueno
en-aut-mei=Asami
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=OnishiYasuhiro
en-aut-sei=Onishi
en-aut-mei=Yasuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MiseKoki
en-aut-sei=Mise
en-aut-mei=Koki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YamaguchiSatoshi
en-aut-sei=Yamaguchi
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KannoAyaka
en-aut-sei=Kanno
en-aut-mei=Ayaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NojimaIchiro
en-aut-sei=Nojima
en-aut-mei=Ichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=HiguchiChigusa
en-aut-sei=Higuchi
en-aut-mei=Chigusa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=UchidaHaruhito A.
en-aut-sei=Uchida
en-aut-mei=Haruhito A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=ShikataKenichi
en-aut-sei=Shikata
en-aut-mei=Kenichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=MiyamotoSatoshi
en-aut-sei=Miyamoto
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=NakatsukaAtsuko
en-aut-sei=Nakatsuka
en-aut-mei=Atsuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=EguchiJun
en-aut-sei=Eguchi
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=HidaKazuyuki
en-aut-sei=Hida
en-aut-mei=Kazuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=KatayamaAkihiro
en-aut-sei=Katayama
en-aut-mei=Akihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=WatanabeMayu
en-aut-sei=Watanabe
en-aut-mei=Mayu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=NakatoTatsuaki
en-aut-sei=Nakato
en-aut-mei=Tatsuaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=ToneAtsuhito
en-aut-sei=Tone
en-aut-mei=Atsuhito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=TeshigawaraSanae
en-aut-sei=Teshigawara
en-aut-mei=Sanae
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=MatsuokaTakashi
en-aut-sei=Matsuoka
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=KameiShinji
en-aut-sei=Kamei
en-aut-mei=Shinji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=MurakamiKazutoshi
en-aut-sei=Murakami
en-aut-mei=Kazutoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=ShimizuIkki
en-aut-sei=Shimizu
en-aut-mei=Ikki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=MiyashitaKatsuhito
en-aut-sei=Miyashita
en-aut-mei=Katsuhito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=AndoShinichiro
en-aut-sei=Ando
en-aut-mei=Shinichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=NunoueTomokazu
en-aut-sei=Nunoue
en-aut-mei=Tomokazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=WadaJun
en-aut-sei=Wada
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

affil-num=1
en-affil=Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=11
en-affil=Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=12
en-affil=Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=13
en-affil=Department of Diabetology and Metabolism, National Hospital Organization Okayama Medical Center
kn-affil=

affil-num=14
en-affil=Department of Diabetology and Metabolism, National Hospital Organization Okayama Medical Center
kn-affil=

affil-num=15
en-affil=Department of Diabetology and Metabolism, National Hospital Organization Okayama Medical Center
kn-affil=

affil-num=16
en-affil=Department of Internal Medicine, Okayama Saiseikai General Hospital
kn-affil=

affil-num=17
en-affil=Department of Internal Medicine, Okayama Saiseikai General Hospital
kn-affil=

affil-num=18
en-affil=Okayama Saiseikai General Hospital
kn-affil=

affil-num=19
en-affil=Department of Diabetic Medicine, Kurashiki Central Hospital
kn-affil=

affil-num=20
en-affil=Department of Diabetic Medicine, Kurashiki Central Hospital
kn-affil=

affil-num=21
en-affil=Department of Diabetic Medicine, Kurashiki Central Hospital
kn-affil=

affil-num=22
en-affil=Sakakibara Heart Institute of Okayama
kn-affil=

affil-num=23
en-affil=Japanese Red Cross Okayama Hospital
kn-affil=

affil-num=24
en-affil=Okayama City General Medical Center
kn-affil=

affil-num=25
en-affil=Nunoue Clinic
kn-affil=

affil-num=26
en-affil=Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=12
cd-vols=
no-issue=5
article-no=
start-page=877
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240427
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Isolation of Vibrio cholerae and Vibrio vulnificus from Estuarine Waters, and Genotyping of V. vulnificus Isolates Using Loop-Mediated Isothermal Amplification
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Bacteria in the genus Vibrio are ubiquitous in estuarine and coastal waters. Some species (including Vibrio cholerae and Vibrio vulnificus) are known human pathogens causing ailments like cholera, diarrhea, or septicemia. Notably, V. vulnificus can also cause a severe systemic infection (known as vibriosis) in eels raised in aquaculture facilities. Water samples were periodically collected from the estuary of the Asahi River, located in the southern part of Okayama City, Japan. These samples were directly plated onto CHROMagar Vibrio plates, and colonies displaying turquoise-blue coloration were selected. Thereafter, polymerase chain reaction was used to identify V. cholerae and V. vulnificus. A total of 30 V. cholerae strains and 194 V. vulnificus strains were isolated during the warm season when the water temperature (WT) was higher than 20 degrees C. Concurrently, an increase in coliforms was observed during this period. Notably, V. vulnificus has two genotypes, designated as genotype 1 and genotype 2. Genotype 1 is pathogenic to humans, while genotype 2 is pathogenic to both humans and eels. The loop-mediated isothermal amplification method was developed to rapidly determine genotypes at a low cost. Of the 194 strains isolated, 80 (41.2%) were identified as genotype 1 strains. Among the 41 strains isolated when the WTs were higher than 28 degrees C, 25 strains (61.0%) belonged to genotype 1. In contrast, of the 32 strains isolated when the WTs were lower than 24 degrees C, 27 strains (84.4%) belonged to genotype 2. These results suggest that the distribution of the two genotypes was influenced by WT.
en-copyright=
kn-copyright=

en-aut-name=MiyoshiShin-Ichi
en-aut-sei=Miyoshi
en-aut-mei=Shin-Ichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KurataMegumi
en-aut-sei=Kurata
en-aut-mei=Megumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HiroseRiho
en-aut-sei=Hirose
en-aut-mei=Riho
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YoshikawaMasaya
en-aut-sei=Yoshikawa
en-aut-mei=Masaya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=LiangYong
en-aut-sei=Liang
en-aut-mei=Yong
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=YamagishiYosuke
en-aut-sei=Yamagishi
en-aut-mei=Yosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MizunoTamaki
en-aut-sei=Mizuno
en-aut-mei=Tamaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=5
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=6
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=7
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=Vibrio cholerae
kn-keyword=Vibrio cholerae
en-keyword=Vibrio vulnificus
kn-keyword=Vibrio vulnificus
en-keyword=genotype
kn-keyword=genotype
en-keyword=LAMP
kn-keyword=LAMP
en-keyword=water temperature
kn-keyword=water temperature
END

start-ver=1.4
cd-journal=joma
no-vol=47
cd-vols=
no-issue=3
article-no=
start-page=1177
end-page=1189
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240516
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Evaluation of output factors of different radiotherapy planning systems using Exradin W2 plastic scintillator detector
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=This study aims to evaluate the output factors (OPF) of different radiation therapy planning systems (TPSs) using a plastic scintillator detector (PSD). The validation results for determining a practical field size for clinical use were verified. The implemented validation system was an Exradin W2 PSD. The focus was to validate the OPFs of the small irradiation fields of two modeled radiation TPSs using RayStation version 10.0.1 and Monaco version 5.51.10. The linear accelerator used for irradiation was a TrueBeam with three energies: 4, 6, and 10 MV. RayStation calculations showed that when the irradiation field size was reduced from 10?×?10 to 0.5?×?0.5 cm2, the results were within 2.0% of the measured values for all energies. Similarly, the values calculated using Monaco were within approximately 2.0% of the measured values for irradiation field sizes between 10?×?10 and 1.5?×?1.5 cm2 for all beam energies of interest. Thus, PSDs are effective validation tools for OPF calculations in TPS. A TPS modeled with the same source data has different minimum irradiation field sizes that can be calculated. These findings could aid in verification of equipment accuracy for treatment planning requiring highly accurate dose calculations and for third-party evaluation of OPF calculations for TPS.
en-copyright=
kn-copyright=

en-aut-name=AndoYasuharu
en-aut-sei=Ando
en-aut-mei=Yasuharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=OkadaMasahiro
en-aut-sei=Okada
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MatsumotoNatsuko
en-aut-sei=Matsumoto
en-aut-mei=Natsuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=IkuhiroKawasaki
en-aut-sei=Ikuhiro
en-aut-mei=Kawasaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=IshiharaSoichiro
en-aut-sei=Ishihara
en-aut-mei=Soichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KiriuHiroshi
en-aut-sei=Kiriu
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TanabeYoshinori
en-aut-sei=Tanabe
en-aut-mei=Yoshinori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Hiroshima City Hospital
kn-affil=

affil-num=2
en-affil=Hiroshima City North Medical Center Asa Citizens Hospital
kn-affil=

affil-num=3
en-affil=Hiroshima City North Medical Center Asa Citizens Hospital
kn-affil=

affil-num=4
en-affil=Hiroshima City North Medical Center Asa Citizens Hospital
kn-affil=

affil-num=5
en-affil=Hiroshima City Hospital
kn-affil=

affil-num=6
en-affil=Hiroshima City Hospital
kn-affil=

affil-num=7
en-affil=Department of Radiological Technology, Graduate School of Health Sciences, Okayama University
kn-affil=
en-keyword=Plastic scintillator
kn-keyword=Plastic scintillator
en-keyword=Radiation therapy
kn-keyword=Radiation therapy
en-keyword=Small irradiation field
kn-keyword=Small irradiation field
en-keyword=Output factor
kn-keyword=Output factor
END

start-ver=1.4
cd-journal=joma
no-vol=9
cd-vols=
no-issue=19
article-no=
start-page=21287
end-page=21297
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240501
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Superstructure of Fe5?xGeTe2 Determined by Te K-Edge Extended X-ray Absorption Fine Structure and Te Kα X-ray Fluorescence Holography
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The local structure of the two-dimensional van der Waals material, Fe5?xGeTe2, which exhibits unique structural/magnetic phase transitions, was investigated by Te K-edge extended X-ray absorption fine structure (EXAFS) and Te Kα X-ray fluorescence holography (XFH) over a wide temperature range. The formation of a trimer of Te atoms at low temperatures has been fully explored using these methods. An increase in the Te?Fe distance at approximately 150 K was suggested by EXAFS and presumably indicates the formation of a Te trimer. Moreover, XFH displayed clear atomic images of Te atoms. Additionally, the distance between the Te atoms shortened, as confirmed from the atomic images reconstructed from XFH, indicating the formation of a trimer of Te atoms, i.e., a charge-ordered (3??√×3??√)?30? superstructure. Furthermore, Te Kα XFH provided unambiguous atomic images of Fe atoms occupying the Fe1 site; the images were not clearly observed in the Ge Kα XFH that was previously reported because of the low occupancy of Fe and Ge atoms. In this study, EXAFS and XFH clearly showed the local structure around the Te atom; in particular, the formation of Te trimers caused by charge-ordered phase transitions was clearly confirmed. The charge-ordered phase transition is fully discussed based on the structural variation at low temperatures, as established from EXAFS and XFH.
en-copyright=
kn-copyright=

en-aut-name=EguchiRitsuko
en-aut-sei=Eguchi
en-aut-mei=Ritsuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SekharHalubai
en-aut-sei=Sekhar
en-aut-mei=Halubai
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KimuraKoji
en-aut-sei=Kimura
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MasaiHirokazu
en-aut-sei=Masai
en-aut-mei=Hirokazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HappoNaohisa
en-aut-sei=Happo
en-aut-mei=Naohisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=IkedaMitsuki
en-aut-sei=Ikeda
en-aut-mei=Mitsuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=YamamotoYuki
en-aut-sei=Yamamoto
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=UtsumiMasaki
en-aut-sei=Utsumi
en-aut-mei=Masaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=GotoHidenori
en-aut-sei=Goto
en-aut-mei=Hidenori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=TakabayashiYasuhiro
en-aut-sei=Takabayashi
en-aut-mei=Yasuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=TajiriHiroo
en-aut-sei=Tajiri
en-aut-mei=Hiroo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=HayashiKoichi
en-aut-sei=Hayashi
en-aut-mei=Koichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=KubozonoYoshihiro
en-aut-sei=Kubozono
en-aut-mei=Yoshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

affil-num=1
en-affil=Research Institute for Interdisciplinary Science, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Physical Science and Technology, Nagoya Institute of Technology
kn-affil=

affil-num=3
en-affil=Department of Physical Science and Technology, Nagoya Institute of Technology
kn-affil=

affil-num=4
en-affil=Department of Materials and Chemistry, National Institute of Advanced Industrial Science and Technology (AIST)
kn-affil=

affil-num=5
en-affil=Graduate School of Information Sciences, Hiroshima City University
kn-affil=

affil-num=6
en-affil=Research Institute for Interdisciplinary Science, Okayama University
kn-affil=

affil-num=7
en-affil=Research Institute for Interdisciplinary Science, Okayama University
kn-affil=

affil-num=8
en-affil=Research Institute for Interdisciplinary Science, Okayama University
kn-affil=

affil-num=9
en-affil=Research Institute for Interdisciplinary Science, Okayama University
kn-affil=

affil-num=10
en-affil=Department of Physical Science and Technology, Nagoya Institute of Technology
kn-affil=

affil-num=11
en-affil=Japan Synchrotron Radiation Research Institute (JASRI)
kn-affil=

affil-num=12
en-affil=Department of Physical Science and Technology, Nagoya Institute of Technology
kn-affil=

affil-num=13
en-affil=Research Institute for Interdisciplinary Science, Okayama University
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=202
cd-vols=
no-issue=3
article-no=
start-page=473
end-page=483
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=20230909
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Purpose Mammography screening has increased the detection of subcentimeter breast cancers. The prognosis for estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative T1a/bN0M0 breast cancers is excellent; however, the necessity of adjuvant endocrine therapy (ET) is uncertain.<br>
Methods We evaluated the effectiveness of adjuvant ET in patients with ER-positive and HER2-negative T1a/bN0M0 breast cancer who underwent surgery from 2008 to 2012. Standard ET was administrated after surgery. The primary endpoint was the cumulative incidence of distant metastasis. All statistical tests were 2-sided.<br>
Results Adjuvant ET was administered to 3991 (83%) of the 4758 eligible patients (1202 T1a [25.3%] and 3556 T1b [74.7%], diseases). The median follow-up period was 9.2 years. The 9-year cumulative incidence of distant metastasis was 1.5% with ET and 2.6% without ET (adjusted subdistribution hazard ratio [sHR], 0.54; 95% CI, 0.32?0.93). In multivariate analysis, the independent risk factors for distant metastasis were no history of ET, mastectomy, high-grade, and lymphatic invasion. The 9-year overall survival was 97.0% and 94.4% with and without ET, respectively (adjusted HR, 0.57; 95% CI, 0.39?0.83). In addition, adjuvant ET reduced the incidence of ipsilateral and contralateral breast cancer (9-year rates; 1.1% vs. 6.9%; sHR, 0.17, and 1.9% vs. 5.2%; sHR, 0.33).<br>
Conclusions The prognosis was favorable in patients with ER-positive and HER2-negative T1a/bN0M0 breast cancer. Furthermore, adjuvant ET reduced the incidence of distant metastasis with minimal absolute risk difference. These findings support considering the omission of adjuvant ET, especially for patients with low-grade and no lymphatic invasion disease.
en-copyright=
kn-copyright=

en-aut-name=SasadaShinsuke
en-aut-sei=Sasada
en-aut-mei=Shinsuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KondoNaoto
en-aut-sei=Kondo
en-aut-mei=Naoto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HashimotoHiroya
en-aut-sei=Hashimoto
en-aut-mei=Hiroya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TakahashiYuko
en-aut-sei=Takahashi
en-aut-mei=Yuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TerataKaori
en-aut-sei=Terata
en-aut-mei=Kaori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KidaKumiko
en-aut-sei=Kida
en-aut-mei=Kumiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=SagaraYasuaki
en-aut-sei=Sagara
en-aut-mei=Yasuaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=UenoTakayuki
en-aut-sei=Ueno
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=AnanKeisei
en-aut-sei=Anan
en-aut-mei=Keisei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=SutoAkihiko
en-aut-sei=Suto
en-aut-mei=Akihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=KanbayashiChizuko
en-aut-sei=Kanbayashi
en-aut-mei=Chizuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=TakahashiMina
en-aut-sei=Takahashi
en-aut-mei=Mina
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=NakamuraRikiya
en-aut-sei=Nakamura
en-aut-mei=Rikiya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=IshibaToshiyuki
en-aut-sei=Ishiba
en-aut-mei=Toshiyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=TsuneizumiMichiko
en-aut-sei=Tsuneizumi
en-aut-mei=Michiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=NishimuraSeiichiro
en-aut-sei=Nishimura
en-aut-mei=Seiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=NaitoYoichi
en-aut-sei=Naito
en-aut-mei=Yoichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=HaraFumikata
en-aut-sei=Hara
en-aut-mei=Fumikata
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=ShienTadahiko
en-aut-sei=Shien
en-aut-mei=Tadahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=IwataHiroji
en-aut-sei=Iwata
en-aut-mei=Hiroji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

affil-num=1
en-affil=Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University
kn-affil=

affil-num=2
en-affil=Department of Breast Surgery, Nagoya City University Graduate School of Medical Sciences
kn-affil=

affil-num=3
en-affil=Core Laboratory, Nagoya City University Graduate School of Medical Sciences
kn-affil=

affil-num=4
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of Breast and Endocrine Surgery, Akita University Hospital
kn-affil=

affil-num=6
en-affil=Department of Breast Surgical Oncology, St. Luke’s International Hospital
kn-affil=

affil-num=7
en-affil=Department of Breast and Thyroid Surgical Oncology, Social medical corporation Hakuaikai, Sagara Hospital
kn-affil=

affil-num=8
en-affil=Breast Oncology Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research
kn-affil=

affil-num=9
en-affil=Department of Surgery, Kitakyushu Municipal Medical Center
kn-affil=

affil-num=10
en-affil=Department of Breast Surgery, National Cancer Center Hospital
kn-affil=

affil-num=11
en-affil=Department of Breast Oncology, Niigata Cancer Center Hospital
kn-affil=

affil-num=12
en-affil=Department of Breast Oncology, National Hospital Organization Shikoku Cancer Center
kn-affil=

affil-num=13
en-affil=Department of Breast Surgery, Chiba Cancer Center
kn-affil=

affil-num=14
en-affil=Department of Breast Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital
kn-affil=

affil-num=15
en-affil=Department of Breast Surgery, Shizuoka General Hospital
kn-affil=

affil-num=16
en-affil=Department of Breast Surgery, Shizuoka Cancer Center Hospital
kn-affil=

affil-num=17
en-affil=Department of General Internal Medicine, National Cancer Center Hospital East
kn-affil=

affil-num=18
en-affil=Breast Oncology Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research
kn-affil=

affil-num=19
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=20
en-affil=Department of Breast Oncology, Aichi Cancer Center Hospital
kn-affil=
en-keyword=Breast cancer
kn-keyword=Breast cancer
en-keyword=T1a/b
kn-keyword=T1a/b
en-keyword=Endocrine therapy
kn-keyword=Endocrine therapy
en-keyword=Estrogen receptor
kn-keyword=Estrogen receptor
en-keyword=Prognosis
kn-keyword=Prognosis
END

start-ver=1.4
cd-journal=joma
no-vol=54
cd-vols=
no-issue=1
article-no=
start-page=31
end-page=37
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=20230914
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Efficacy and safety of olaparib, olaparib plus bevacizumab and niraparib maintenance treatment in Japanese patients with platinum-sensitive advanced ovarian cancer
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Objective: To investigate whether maintenance treatment could be safely and effectively performed with olaparib, olaparib plus bevacizumab and niraparib in platinum-sensitive advanced ovarian cancer at multiple institutions in Japan.<br>
Methods: We investigated progression-free survival and adverse events in 117 patients with platinum-sensitive advanced ovarian cancer treated with maintenance therapy.<br>
Results: The median progression-free survival of 117 patients was 20.1 months. Patients with germline BRCA pathogenic variants had a significantly better prognosis than the other groups (P < 0.001). Furthermore, in the multivariate analysis, stage IV (P = 0.016) and germline BRCA wild-type (P ? 0.001) were significantly associated with worse progression-free survival in patients with advanced ovarian cancer. Regarding adverse events, all three types of maintenance treatment were significantly worse than chemotherapy given before maintenance treatment with respect to renal function (olaparib, P = 0.037; olaparib plus bevacizumab, P < 0.001; and niraparib, P = 0.016).<br>
Conclusion: Maintenance treatment was performed effectively and safely. Renal function deterioration is likely to occur during maintenance treatment, and careful administration is important in platinum-sensitive advanced ovarian cancer.
en-copyright=
kn-copyright=

en-aut-name=NakamuraKeiichiro
en-aut-sei=Nakamura
en-aut-mei=Keiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MatsuokaHirofumi
en-aut-sei=Matsuoka
en-aut-mei=Hirofumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YorimitsuMasae
en-aut-sei=Yorimitsu
en-aut-mei=Masae
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=OgawaMariko
en-aut-sei=Ogawa
en-aut-mei=Mariko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KanemoriMiho
en-aut-sei=Kanemori
en-aut-mei=Miho
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=SueokaKotaro
en-aut-sei=Sueoka
en-aut-mei=Kotaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KozaiAyumi
en-aut-sei=Kozai
en-aut-mei=Ayumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=NakamuraHiroko
en-aut-sei=Nakamura
en-aut-mei=Hiroko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=HarumaTomoko
en-aut-sei=Haruma
en-aut-mei=Tomoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=ShiroyamaYuko
en-aut-sei=Shiroyama
en-aut-mei=Yuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=HayataYuu
en-aut-sei=Hayata
en-aut-mei=Yuu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=SugiiHirokazu
en-aut-sei=Sugii
en-aut-mei=Hirokazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=UedaAkiko
en-aut-sei=Ueda
en-aut-mei=Akiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=KuriharaShuichi
en-aut-sei=Kurihara
en-aut-mei=Shuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=UrayamaSaiko
en-aut-sei=Urayama
en-aut-mei=Saiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=ShimizuMiyuki
en-aut-sei=Shimizu
en-aut-mei=Miyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=MasuyamaHisashi
en-aut-sei=Masuyama
en-aut-mei=Hisashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

affil-num=1
en-affil=Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Obstetrics and Gynecology, City Hiroshima Citizens Hospital
kn-affil=

affil-num=4
en-affil=Department of Obstetrics and Gynecology, National Organization Fukuyama Medical Center
kn-affil=

affil-num=5
en-affil=Department of Obstetrics and Gynecology, Fukuyama City Hospital
kn-affil=

affil-num=6
en-affil=Department of Obstetrics and Gynecology, Yamaguchi University Graduate School of Medicine
kn-affil=

affil-num=7
en-affil=Department of Perinatology and Gynecology, Kagawa University Graduate School of Medicine
kn-affil=

affil-num=8
en-affil=Department of Obstetrics and Gynecology, National Hospital Organization KURE Medical Center and Chugoku Cancer Center
kn-affil=

affil-num=9
en-affil=Department of Obstetrics and Gynecology, Saiseikai General Hospital
kn-affil=

affil-num=10
en-affil=Department of Obstetrics and Gynecology, Prefectural Hospital
kn-affil=

affil-num=11
en-affil=Department of Obstetrics and Gynecology, Kagawa Prefectural Central Hospital
kn-affil=

affil-num=12
en-affil=Department of Obstetrics and Gynecology, National Hospital Organization Iwakuni Clinical Center
kn-affil=

affil-num=13
en-affil=Department of Obstetrics and Gynecology, Onomichi General Hospital
kn-affil=

affil-num=14
en-affil=Department of Obstetrics and Gynecology, Japanese Red Cross Matsuyama Hospital
kn-affil=

affil-num=15
en-affil=Department of Obstetrics and Gynecology, Higashi Hiroshima Medical Center
kn-affil=

affil-num=16
en-affil=Department of Obstetrics and Gynecology, Kagawa Rosai Hospital
kn-affil=

affil-num=17
en-affil=Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=olaparib
kn-keyword=olaparib
en-keyword=olaparib plus bevacizumab
kn-keyword=olaparib plus bevacizumab
en-keyword=niraparib
kn-keyword=niraparib
en-keyword=renal function
kn-keyword=renal function
END

start-ver=1.4
cd-journal=joma
no-vol=28
cd-vols=
no-issue=6
article-no=
start-page=804
end-page=815
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=20230504
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Neoadjuvant chemotherapy followed by interval debulking surgery for advanced epithelial ovarian cancer: GOTIC-019 study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Introduction Three randomized controlled trials have resulted in extremely extensive application of the strategy of using neoadjuvant chemotherapy (NAC) followed by interval debulking surgery (IDS) for patients with advanced epithelial ovarian cancer in Japan. This study aimed to evaluate the status and effectiveness of treatment strategies using NAC followed by IDS in Japanese clinical practice.<br>
Patients and methods We conducted a multi-institutional observational study of 940 women with Federation of Gynecology and Obstetrics (FIGO) stages III?IV epithelial ovarian cancer treated at one of nine centers between 2010 and 2015. Progression-free survival (PFS) and overall survival (OS) were compared between 486 propensity-score matched participants who underwent NAC followed by IDS and primary debulking surgery (PDS) followed by adjuvant chemotherapy.<br>
Results Patients with FIGO stage IIIC receiving NAC had a shorter OS (median OS: 48.1 vs. 68.2 months, hazard ratio [HR]: 1.34; 95% confidence interval [CI] 0.99?1.82, p?=?0.06) but not PFS (median PFS: 19.7 vs. 19.4 months, HR: 1.02; 95% CI: 0.80?1.31, p?=?0.88). However, patients with FIGO stage IV receiving NAC and PDS had comparable PFS (median PFS: 16.6 vs. 14.7 months, HR: 1.07 95% CI: 0.74?1.53, p?=?0.73) and OS (median PFS: 45.2 vs. 35.7 months, HR: 0.98; 95% CI: 0.65?1.47, p?=?0.93).<br>
Conclusions NAC followed by IDS did not improve survival. In patients with FIGO stage IIIC, NAC may be associated with a shorter OS.
en-copyright=
kn-copyright=

en-aut-name=NagaoShoji
en-aut-sei=Nagao
en-aut-mei=Shoji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TamuraJun
en-aut-sei=Tamura
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=ShibutaniTakashi
en-aut-sei=Shibutani
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MiwaMaiko
en-aut-sei=Miwa
en-aut-mei=Maiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KatoTomoyasu
en-aut-sei=Kato
en-aut-mei=Tomoyasu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=ShikamaAyumi
en-aut-sei=Shikama
en-aut-mei=Ayumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TakeiYuji
en-aut-sei=Takei
en-aut-mei=Yuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KamiyaNatsuko
en-aut-sei=Kamiya
en-aut-mei=Natsuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=InoueNaoki
en-aut-sei=Inoue
en-aut-mei=Naoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=NakamuraKazuto
en-aut-sei=Nakamura
en-aut-mei=Kazuto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=InoueAya
en-aut-sei=Inoue
en-aut-mei=Aya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=YamamotoKoji
en-aut-sei=Yamamoto
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=FujiwaraKeiichi
en-aut-sei=Fujiwara
en-aut-mei=Keiichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=SuzukiMitsuaki
en-aut-sei=Suzuki
en-aut-mei=Mitsuaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

affil-num=1
en-affil=Department of Obstetrics and Gynecology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Biostatistics, Yokohama City University School of Medicine
kn-affil=

affil-num=3
en-affil=Department of Gynecologic Oncology, Hyogo Cancer Center
kn-affil=

affil-num=4
en-affil=Department of Gynecologic Oncology, Saitama Medical University International Medical Center
kn-affil=

affil-num=5
en-affil=Department of Gynecologic Oncology, National Cancer Center Hospital
kn-affil=

affil-num=6
en-affil=Department of Obstetrics and Gynecology, Graduate School of Comprehensive Human Sciences, University of Tsukuba
kn-affil=

affil-num=7
en-affil=Department of Obstetrics and Gynecology, Jichi Medical University
kn-affil=

affil-num=8
en-affil=Department of Obstetrics and Gynecology, Yokohama City University School of Medicine
kn-affil=

affil-num=9
en-affil=Department of Obstetrics and Gynecology, Gunma University
kn-affil=

affil-num=10
en-affil=Department of Gynecologic Oncology, Gunma Prefectural Cancer Center
kn-affil=

affil-num=11
en-affil=Department of Obstetrics and Gynecology, Ehime University School of Medicine
kn-affil=

affil-num=12
en-affil=Department of Biostatistics, Yokohama City University School of Medicine
kn-affil=

affil-num=13
en-affil=Department of Gynecologic Oncology, Saitama Medical University International Medical Center
kn-affil=

affil-num=14
en-affil=Department of Obstetrics and Gynecology, Shin-Yurigaoka General Hospital
kn-affil=
en-keyword=Neoadjuvant chemotherapy
kn-keyword=Neoadjuvant chemotherapy
en-keyword=Epithelial ovarian cancer
kn-keyword=Epithelial ovarian cancer
en-keyword=Adjuvant chemotherapy
kn-keyword=Adjuvant chemotherapy
en-keyword=Interval debulking surgery
kn-keyword=Interval debulking surgery
en-keyword=Primary debulking surgery
kn-keyword=Primary debulking surgery
END

start-ver=1.4
cd-journal=joma
no-vol=14
cd-vols=
no-issue=1
article-no=
start-page=4953
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240229
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Long-term monitoring of gastric mucosa-associated lymphoid tissue lymphoma in patients with extra copies of the MALT1 gene
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The objective of this study was to clarify the long-term prognosis of patients with gastric mucosa-associated lymphoid tissue (MALT) lymphoma with additional copies of MALT1. In this multicenter retrospective study, we enrolled 145 patients with gastric MALT lymphoma who underwent fluorescence in situ hybridization (FISH) analysis to detect t(11;18) translocation. The patient cohort was divided into three groups: Group A (n?=?87), comprising individuals devoid of the t(11;18) translocation or extra MALT1 copies; Group B (n?=?27), encompassing patients characterized by the presence of the t(11;18) translocation; and Group C (n?=?31), including patients with extra MALT1 copies. The clinical outcomes in each cohort were collected. Over the course of a mean follow-up of 8.5?±?4.2 years, one patient died of progressive MALT lymphoma, while 15 patients died due to etiologies unrelated to lymphoma. The progression or relapse of MALT lymphoma was observed in 11 patients: three in Group A, two in Group B, and six in Group C. In Groups A, B, and C, the 10-year overall survival rates were 82.5%, 93.8%, and 86.4%, respectively, and the 10-year event-free survival rates were 96.1%, 96.0%, and 82.9%, respectively. The event-free survival rate in Group C was significantly lower than that in Group A. However, no differences were observed in the 10-year event-free survival rates among individuals limited to stage I or II1 disease (equivalent to excluding patients with stage IV disease in this study, as there were no patients with stage II2), with rates of 98.6%, 95.8%, and 92.3% for Groups A, B, and C, respectively. In conclusion, the presence of extra copies of MALT1 was identified as an inferior prognostic determinant of event-free survival. Consequently, trisomy/tetrasomy 18 may serve as an indicator of progression and refractoriness to therapeutic intervention in patients with gastric MALT lymphoma, particularly stage IV gastric MALT lymphoma.
en-copyright=
kn-copyright=

en-aut-name=IwamuroMasaya
en-aut-sei=Iwamuro
en-aut-mei=Masaya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TakenakaRyuta
en-aut-sei=Takenaka
en-aut-mei=Ryuta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MiyaharaKoji
en-aut-sei=Miyahara
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=OkanoueShotaro
en-aut-sei=Okanoue
en-aut-mei=Shotaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=YoshiokaMasao
en-aut-sei=Yoshioka
en-aut-mei=Masao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=SakaguchiChihiro
en-aut-sei=Sakaguchi
en-aut-mei=Chihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=YamamotoKumiko
en-aut-sei=Yamamoto
en-aut-mei=Kumiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KawaiYoshinari
en-aut-sei=Kawai
en-aut-mei=Yoshinari
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=ToyokawaTatsuya
en-aut-sei=Toyokawa
en-aut-mei=Tatsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=TanakaTakehiro
en-aut-sei=Tanaka
en-aut-mei=Takehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=OtsukaMotoyuki
en-aut-sei=Otsuka
en-aut-mei=Motoyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

affil-num=1
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine,  Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil= Department  of Internal Medicine, Tsuyama Chuo Hospital
kn-affil=

affil-num=3
en-affil=Department of Internal Medicine,  Hiroshima City Hospital
kn-affil=

affil-num=4
en-affil=Department of Gastroenterology, Mitoyo General  Hospital
kn-affil=

affil-num=5
en-affil=Department of Internal Medicine, Okayama Saiseikai General Hospital
kn-affil=

affil-num=6
en-affil=Department of Gastroenterology, Shikoku Cancer Center
kn-affil=

affil-num=7
en-affil=Department of Gastroenterology, Kagawa Prefectural Central Hospital
kn-affil=

affil-num=8
en-affil=Department of Gastroenterology, Onomichi Municipal Hospital
kn-affil=

affil-num=9
en-affil=Department  of Gastroenterology, Fukuyama Medical Center
kn-affil=

affil-num=10
en-affil=Department of Pathology,  Okayama University Hospital
kn-affil=

affil-num=11
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine,  Dentistry, and Pharmaceutical Sciences
kn-affil=
en-keyword=Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue
kn-keyword=Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue
en-keyword=Gastric neoplasms
kn-keyword=Gastric neoplasms
en-keyword=Esophagogastroduodenoscopy
kn-keyword=Esophagogastroduodenoscopy
en-keyword=t(11;18) translocation,
kn-keyword=t(11;18) translocation,
en-keyword=Trisomy 18
kn-keyword=Trisomy 18
END

start-ver=1.4
cd-journal=joma
no-vol=14
cd-vols=
no-issue=1
article-no=
start-page=4564
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240225
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Longitudinal antibody dynamics after COVID-19 vaccine boosters based on prior infection status and booster doses
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Global concern over COVID-19 vaccine distribution disparities highlights the need for strategic booster shots. We explored longitudinal antibody responses post-booster during the Omicron wave in a Japanese cohort, emphasizing prior infection and booster doses. This prospective cohort study included 1763 participants aged 18 years and older with at least three vaccine doses (7376 datapoints). Antibody levels were measured every 2 months. We modeled temporal declines in antibody levels after COVID-19 vaccine boosters according to prior infection status and booster doses using a Bayesian linear mixed-effects interval-censored model, considering age, sex, underlying conditions, and lifestyle. Prior infection enhanced post-booster immunity (posterior median 0.346, 95% credible interval [CrI] 0.335-0.355), maintaining antibody levels (posterior median 0.021; 95% CrI 0.019-0.023) over 1 year, in contrast to uninfected individuals whose levels had waned by 8 months post-vaccination. Each additional booster was correlated with higher baseline antibody levels and slower declines, comparing after the third dose. Female sex, older age, immunosuppressive status, and smoking history were associated with lower baseline post-vaccination antibodies, but not associated with decline rates except for older age in the main model. Prior infection status and tailored, efficient, personalized booster strategies are crucial, considering sex, age, health conditions, and lifestyle.
en-copyright=
kn-copyright=

en-aut-name=MatsumotoNaomi
en-aut-sei=Matsumoto
en-aut-mei=Naomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SasakiAyako
en-aut-sei=Sasaki
en-aut-mei=Ayako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KadowakiTomoka
en-aut-sei=Kadowaki
en-aut-mei=Tomoka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MitsuhashiToshiharu
en-aut-sei=Mitsuhashi
en-aut-mei=Toshiharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TakaoSoshi
en-aut-sei=Takao
en-aut-mei=Soshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=YorifujiTakashi
en-aut-sei=Yorifuji
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Department of Epidemiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Epidemiology, Graduate School of  Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Epidemiology, Graduate School of  Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Center for Innovative  Clinical Medicine, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of Epidemiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=6
en-affil=Department of Epidemiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=14
cd-vols=
no-issue=
article-no=
start-page=357
end-page=371
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240329
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Picture Book Materials to Support Infants to Understand Down Syndrome and Intellectual Disabilities
kn-title=幼児のダウン症・知的障害への理解を援助する絵本教材
en-subtitle=
kn-subtitle=
en-abstract=Picture books on Down syndrome and intellectual disabilities should be further improved, to understanding not only the disabilities but also the disabled and their parents and siblings through stories. Further more, caregivers need not only to read picture books to infants, but also to provide support such as approach and encouragement to deepen individual understanding of infants with disabilities. A picture book list developed in this study is intended to assist caregivers in selecting picture books and to provide guidance in understanding disabilities. Future issues are to examine the practical application of the list in childcare and to test its validity in cooperation with caregivers. In addition, because of the usefulness of education for understanding disabilities from early childhood, there is a need for more picture books on these topics for infants.
kn-abstract=　ダウン症や知的障害に関する絵本は，物語を通した障害の具体例の提示や感情表現など，障害そのものに対する理解にとどまらず，障害者やその保護者・兄弟の理解と支援につながる教材であり，より一層の充実が求められる。また，障害理解の教材としての絵本と幼児を媒介する保育者には，絵本を読み聞かせるだけでなく，保育現場の事例と照合させ，幼児に対する個別的な障害理解の深化を促す声掛けや働き掛けなどの援助が必要となる。本研究において作成された絵本リストは，保育者による絵本選択や障害理解教育を支援すると考えられる。今後の課題は，保育の現場実践での具体的運用と環境整備の検討及び，保育者と連携した妥当性の検証である。また，障害に関する絵本は，描写されるエピソードや使用される言葉や漢字表記等から児童期以降の子どもを想定したものが多いと考えられ，幼児期からの障害理解教育の有用性を踏まえ，幼児を対象とした絵本の増加が求められる。
en-copyright=
kn-copyright=

en-aut-name=ASANOYasumasa
en-aut-sei=ASANO
en-aut-mei=Yasumasa
kn-aut-name=浅野泰昌
kn-aut-sei=浅野
kn-aut-mei=泰昌
aut-affil-num=1
ORCID=

en-aut-name=YAMAGUCHI (NISHIOKA)Yuki
en-aut-sei=YAMAGUCHI (NISHIOKA)
en-aut-mei=Yuki
kn-aut-name=山口（西岡）由稀
kn-aut-sei=山口（西岡）
kn-aut-mei=由稀
aut-affil-num=2
ORCID=

en-aut-name=SETOYAMAYu
en-aut-sei=SETOYAMA
en-aut-mei=Yu
kn-aut-name=瀬戸山悠
kn-aut-sei=瀬戸山
kn-aut-mei=悠
aut-affil-num=3
ORCID=

en-aut-name=BABANoriko
en-aut-sei=BABA
en-aut-mei=Noriko
kn-aut-name=馬場訓子
kn-aut-sei=馬場
kn-aut-mei=訓子
aut-affil-num=4
ORCID=

affil-num=1
en-affil=Department of Early Childhood Education and Care，Kurashiki City College
kn-affil=倉敷市立短期大学保育学科

affil-num=2
en-affil=MINAN Certified Centers for Early Childhood Education and Care
kn-affil=御南認定こども園

affil-num=3
en-affil=Faculty of Childhood Education, Kurashiki Sakuyo University
kn-affil=くらしき作陽大学子ども教育学部

affil-num=4
en-affil=Faculty of Education, Okayama University
kn-affil=岡山大学学術研究院教育学域
en-keyword=幼児期 (Early Childhood)
kn-keyword=幼児期 (Early Childhood)
en-keyword=障害理解教育 (Education for understanding disabilities)
kn-keyword=障害理解教育 (Education for understanding disabilities)
en-keyword=ダウン症 (Down Syndrome)
kn-keyword=ダウン症 (Down Syndrome)
en-keyword=知的障害 (Intellectual Disabilities)
kn-keyword=知的障害 (Intellectual Disabilities)
en-keyword=絵本 (Picture Book)
kn-keyword=絵本 (Picture Book)
END

start-ver=1.4
cd-journal=joma
no-vol=14
cd-vols=
no-issue=
article-no=
start-page=341
end-page=355
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240329
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Picture Book Materials to Support Infants to Understand Developmental Disorders Subtitle
kn-title=幼児の発達障害への理解を援助する絵本教材
en-subtitle=
kn-subtitle=
en-abstract=Autism Spectrum Disorder（ASD）, Attention Deficit Hyperactivity Disorder（ADHD）, and Learning Disabilities（LD） are obscure for infants to understand, but picture books about these disabilities have recently increased, and are considered to be educational materials to understand these disabilities from early childhood. Picture books, that can clearly present disabilities and their characteristic behaviors through stories, offer various choices and support an understanding of disabilities in the real childcare. Also, many picture books for understanding disabilities describe the emotions of the family and can be used to deepen infants' understanding of their parents and siblings. On the other hand, the number of picture books about the environment and its improvement is small. An increase in the number of picture books on these topics is expected, and handmade picture book materials based on the real conditions w ould also be effective.
kn-abstract=　発達障害である自閉スペクトラム症・注意欠如多動症・学習障害は，幼児にとって難解であるが，これを取り上げる絵本は近年増加傾向にあり，幼児期からの障害理解に資する教材として考えられる。障害とその特徴的な行動について，物語を通して分かりやすく示すことができる視覚教材である絵本は，選択の幅も広く，保育現場の実態に適合した幼児の障害理解を支援する。また，障害児への支援においては，保護者・兄弟支援も重要であるが，障害理解絵本には家族の心情を描写するものも多く，保護者・兄弟に対する幼児の理解を深めることにも活用できると考えられる。一方，人的環境に関わる絵本の多様性に比べて，物的環境に関わるものやその改善について紹介されたものは少ないことが把握された。これらに関する絵本の増加が期待されると共に，実態に即した手作りの絵本教材も有効であると考えられる。
en-copyright=
kn-copyright=

en-aut-name=YAMAGUCHI (NISHIOKA)Yuki
en-aut-sei=YAMAGUCHI (NISHIOKA)
en-aut-mei=Yuki
kn-aut-name=山口（西岡）由稀
kn-aut-sei=山口（西岡）
kn-aut-mei=由稀
aut-affil-num=1
ORCID=

en-aut-name=ASANOYasumasa
en-aut-sei=ASANO
en-aut-mei=Yasumasa
kn-aut-name=浅野泰昌
kn-aut-sei=浅野
kn-aut-mei=泰昌
aut-affil-num=2
ORCID=

en-aut-name=SETOYAMAYu
en-aut-sei=SETOYAMA
en-aut-mei=Yu
kn-aut-name=瀬戸山悠
kn-aut-sei=瀬戸山
kn-aut-mei=悠
aut-affil-num=3
ORCID=

en-aut-name=BABANoriko
en-aut-sei=BABA
en-aut-mei=Noriko
kn-aut-name=馬場訓子
kn-aut-sei=馬場
kn-aut-mei=訓子
aut-affil-num=4
ORCID=

affil-num=1
en-affil=MINAN Certified Centers for Early Childhood Education and Care
kn-affil=御南認定こども園

affil-num=2
en-affil=Department of Early Childhood Education and Care，Kurashiki City College
kn-affil=倉敷市立短期大学保育学科

affil-num=3
en-affil=Faculty of Childhood Education, Kurashiki Sakuyo University
kn-affil=くらしき作陽大学子ども教育学部

affil-num=4
en-affil=Faculty of Education, Okayama University
kn-affil=岡山大学学術研究院教育学域
en-keyword=幼児期 (Early Childhood)
kn-keyword=幼児期 (Early Childhood)
en-keyword=自閉スペクトラム症 (Autism Spectrum Disorder（ASD）)
kn-keyword=自閉スペクトラム症 (Autism Spectrum Disorder（ASD）)
en-keyword=注意欠如多動症 (Attention Deficit Hyperactivity Disorder（ADHD）)
kn-keyword=注意欠如多動症 (Attention Deficit Hyperactivity Disorder（ADHD）)
en-keyword=学習障害 (Learning Disabilities（LD）)
kn-keyword=学習障害 (Learning Disabilities（LD）)
en-keyword=絵本 (Picture Books)
kn-keyword=絵本 (Picture Books)
END

start-ver=1.4
cd-journal=joma
no-vol=14
cd-vols=
no-issue=
article-no=
start-page=325
end-page=339
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240329
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Development and Potential of the Reggio Emilia Approach to Education in Japan ―Aspects of the Acceptance and Introduction Phases and Challenges in the Practical Application Phase―
kn-title=日本におけるレッジョ・エミリア教育の展開と可能性 ―受容・導入期の様相と実践期の課題―
en-subtitle=
kn-subtitle=
en-abstract=　As the Reggio Emilia approach is transitioning from the period of acceptance and introduction to the period of practical application in Japan, this paper discusses the issues and challenges that need to be addressed to gain a more profound and accurate understanding of this educational approach. First, it is necessary to accurately grasp the formative and educational principles behind the artistic development of children in the city of Reggio Emilia. Second, there is a need to create a system for training “atelieristas” who can study the foundations of early childhood education, research children’s formative expressions, and engage in art production and appreciation. Third, a fundamental shift in the philosophy of childcare is required, positioning “project” as a higher-level concept over the Japanese childcare philosophy of “play = learning.” Fourth, annual events must be carefully selected for childcare practices that value children’s autonomy. Fifth, it is essential to examine whether “documentation” can replace the conventional Japanese way of recording childcare. 
kn-abstract=　本論は，日本への受容・導入期から実践期に移行しつつあるレッジョ・エミリア教育に関して正しく理解を深めるためには，何が問題や課題になるかについて考察する。第１に，レッジョ・エミリア市の子どもの造形芸術の背景にある造形原理や教育原理を正しく把握する必要がある。第２に，幼児教育を基礎から学び，子どもの造形表現を研究し，美術制作と鑑賞に従事できる「アトリエリスタ」養成の仕組み作りが要請される。第３に，日本の保育理念である「遊び＝学び」の上位概念として「プロジェクト」を位置付け，根本的な保育理念の転換が求められる。第４に，子どもの主体性を大切にした保育実践のために，年間行事を精選しなければならない。第５に，これまでの日本の保育記録の仕方を「ドキュメンテーション」に代替できるかどうかの検討が不可欠である。
en-copyright=
kn-copyright=

en-aut-name=TAKAHASHIToshiyuki
en-aut-sei=TAKAHASHI
en-aut-mei=Toshiyuki
kn-aut-name=��橋敏之
kn-aut-sei=��橋
kn-aut-mei=敏之
aut-affil-num=1
ORCID=

en-aut-name=TAKAHASHIKei
en-aut-sei=TAKAHASHI
en-aut-mei=Kei
kn-aut-name=��橋慧
kn-aut-sei=��橋
kn-aut-mei=慧
aut-affil-num=2
ORCID=

en-aut-name=ODAKumiko
en-aut-sei=ODA
en-aut-mei=Kumiko
kn-aut-name=小田久美子
kn-aut-sei=小田
kn-aut-mei=久美子
aut-affil-num=3
ORCID=

affil-num=1
en-affil=Faculty of Education, Okayama University
kn-affil=岡山大学学術研究院教育学域

affil-num=2
en-affil=Faculty of Childhood Education, Kurashiki Sakuyo University
kn-affil=くらしき作陽大学子ども教育学部

affil-num=3
en-affil=Faculty of Human Life Sciences, Notre Dame Seishin University
kn-affil=ノートルダム清心女子大学人間生活学部
en-keyword=レッジョ・エミリア教育 (Reggio Emilia approach)
kn-keyword=レッジョ・エミリア教育 (Reggio Emilia approach)
en-keyword=芸術性の理解 (understanding artistry)
kn-keyword=芸術性の理解 (understanding artistry)
en-keyword=アトリエリスタの養成 (atelierista training)
kn-keyword=アトリエリスタの養成 (atelierista training)
en-keyword=プロジェクト (project)
kn-keyword=プロジェクト (project)
en-keyword=ドキュメンテーション (documentation)
kn-keyword=ドキュメンテーション (documentation)
END

start-ver=1.4
cd-journal=joma
no-vol=4
cd-vols=
no-issue=2
article-no=
start-page=274
end-page=296
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=20230403
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A Study of the Active Access-Point Configuration Algorithm under Channel Bonding to Dual IEEE 802.11n and 11ac Interfaces in an Elastic WLAN System for IoT Applications
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Currently, Internet of Things (IoT) has become common in various applications, including smart factories, smart cities, and smart homes. In them, wireless local-area networks (WLANs) are widely used due to their high-speed data transfer, flexible coverage ranges, and low costs. To enhance the performance, the WLAN configuration should be optimized in dense WLAN environments where multiple access points (APs) and hosts exist. Previously, we have studied the active AP configuration algorithm for dual interfaces using IEEE802.11n and 11ac protocols at each AP under non-channel bonding (non-CB). In this paper, we study the algorithm considering the channel bonding (CB) to enhance its capacity by bonding two channels together. To improve the throughput estimation accuracy of the algorithm, the reduction factor is introduced at contending hosts for the same AP. For evaluations, we conducted extensive experiments using the WIMENT simulator and the testbed system using Raspberry Pi 4B APs. The results show that the estimated throughput is well matched with the measured one, and the proposal achieves the higher throughput with a smaller number of active APs than the previous configurations.
en-copyright=
kn-copyright=

en-aut-name=RoySujan Chandra
en-aut-sei=Roy
en-aut-mei=Sujan Chandra
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=FunabikiNobuo
en-aut-sei=Funabiki
en-aut-mei=Nobuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=RahmanMd. Mahbubur
en-aut-sei=Rahman
en-aut-mei=Md. Mahbubur
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=WuBin
en-aut-sei=Wu
en-aut-mei=Bin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KuribayashiMinoru
en-aut-sei=Kuribayashi
en-aut-mei=Minoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KaoWen-Chung
en-aut-sei=Kao
en-aut-mei=Wen-Chung
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Graduate School of Natural Science and Technology, Okayama University
kn-affil=

affil-num=2
en-affil=Graduate School of Natural Science and Technology, Okayama University
kn-affil=

affil-num=3
en-affil=Department Electrical and Electronic Engineering, Jatiya Kabi Kazi Nazrul Islam University
kn-affil=

affil-num=4
en-affil=Graduate School of Natural Science and Technology, Okayama University
kn-affil=

affil-num=5
en-affil=Graduate School of Natural Science and Technology, Okayama University
kn-affil=

affil-num=6
en-affil=Department of Electrical Engineering, National Taiwan Normal University
kn-affil=
en-keyword=Internet of Things
kn-keyword=Internet of Things
en-keyword=WLAN
kn-keyword=WLAN
en-keyword=access-points configuration
kn-keyword=access-points configuration
en-keyword=dual interface
kn-keyword=dual interface
en-keyword=channel bonding
kn-keyword=channel bonding
en-keyword=WIMNET
kn-keyword=WIMNET
en-keyword=Raspberry Pi 4B
kn-keyword=Raspberry Pi 4B
en-keyword=IEEE802.11n
kn-keyword=IEEE802.11n
en-keyword=11ac
kn-keyword=11ac
END

start-ver=1.4
cd-journal=joma
no-vol=8
cd-vols=
no-issue=3
article-no=
start-page=374
end-page=382
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240222
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A multi-center, prospective, clinical study to evaluate the anti-reflux efficacy of laparoscopic double-flap technique (lD-FLAP Study)
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Double-flap technique (DFT) is a reconstruction procedure after proximal gastrectomy (PG). We previously reported a multi-center, retrospective study in which the incidence of reflux esophagitis (RE) (Los Angeles Classification ?Grade B [LA-B]) 1 year after surgery was 6.0%. There have been many reports, but all of them were retrospective. Thus, a multi-center, prospective study was conducted.<br>
Methods: Laparoscopic PG?+?DFT was performed for cT1N0 upper gastric cancer patients. The primary endpoint was the incidence of RE (?LA-B) 1 year after surgery. The planned sample size was 40, based on an estimated incidence of 6.0% and an upper threshold of 20%.<br>
Results: Forty patients were recruited, and 39, excluding one with conversion to total gastrectomy, received protocol treatment. Anastomotic leakage (Clavien?Dindo ?Grade III) was observed in one patient (2.6%). In 38 patients, excluding one case of postoperative mortality, RE (?LA-B) was observed in two patients (5.3%) 1 year after surgery, and the upper limit of the 95% confidence interval was 17.3%, lower than the 20% threshold. Anastomotic stricture requiring dilatation was observed in two patients (5.3%). One year after surgery, body weight change was 88.9?±?7.0%, and PNI <40 and CONUT ?5, indicating malnutrition, were observed in only one patient (2.6%) each. In the quality of life survey using the PGSAS-45 questionnaire, the esophageal reflux subscale score was 1.4?±?0.6, significantly better than the public data (2.0?±?1.0; p?=?0.001).<br>
Conclusion: Laparoscopic DFT showed anti-reflux efficacy. Taken together with the acceptable incidence of anastomotic stricture, DFT can be an option for reconstruction procedure after PG.
en-copyright=
kn-copyright=

en-aut-name=KurodaShinji
en-aut-sei=Kuroda
en-aut-mei=Shinji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=IshidaMichihiro
en-aut-sei=Ishida
en-aut-mei=Michihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=ChodaYasuhiro
en-aut-sei=Choda
en-aut-mei=Yasuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MuraokaAtsushi
en-aut-sei=Muraoka
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HatoShinji
en-aut-sei=Hato
en-aut-mei=Shinji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KagawaTetsuya
en-aut-sei=Kagawa
en-aut-mei=Tetsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TanakaNorimitsu
en-aut-sei=Tanaka
en-aut-mei=Norimitsu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=MitsuhashiToshiharu
en-aut-sei=Mitsuhashi
en-aut-mei=Toshiharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=KakiuchiYoshihiko
en-aut-sei=Kakiuchi
en-aut-mei=Yoshihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=KikuchiSatoru
en-aut-sei=Kikuchi
en-aut-mei=Satoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=NishizakiMasahiko
en-aut-sei=Nishizaki
en-aut-mei=Masahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=KagawaShunsuke
en-aut-sei=Kagawa
en-aut-mei=Shunsuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=FujiwaraToshiyoshi
en-aut-sei=Fujiwara
en-aut-mei=Toshiyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

affil-num=1
en-affil=Department of Gastroenterological  Surgery, Okayama University Graduate  School of Medicine, Dentistry and  Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Surgery, Hiroshima City  Hiroshima Citizens Hospital, Hiroshima
kn-affil=

affil-num=3
en-affil=Department of Surgery, Hiroshima City  Hiroshima Citizens Hospital, Hiroshima
kn-affil=

affil-num=4
en-affil=Department of Surgery, Kagawa Rosai  Hospital
kn-affil=

affil-num=5
en-affil=Department of Surgery, Shikoku Cancer  Center
kn-affil=

affil-num=6
en-affil=Department of Surgery, Shikoku Cancer  Center
kn-affil=

affil-num=7
en-affil=Department of Surgery, Kagawa  Prefectural Central Hospital
kn-affil=

affil-num=8
en-affil=Center for Innovative Clinical Medicine,  Okayama University Hospital
kn-affil=

affil-num=9
en-affil=Department of Gastroenterological  Surgery, Okayama University Graduate  School of Medicine, Dentistry and  Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Department of Gastroenterological  Surgery, Okayama University Graduate  School of Medicine, Dentistry and  Pharmaceutical Sciences
kn-affil=

affil-num=11
en-affil=Department of Surgery, Tsuyama Chuo  Hospital
kn-affil=

affil-num=12
en-affil=Department of Gastroenterological  Surgery, Okayama University Graduate  School of Medicine, Dentistry and  Pharmaceutical Sciences
kn-affil=

affil-num=13
en-affil=Department of Gastroenterological  Surgery, Okayama University Graduate  School of Medicine, Dentistry and  Pharmaceutical Sciences
kn-affil=
en-keyword=anti-reflux surgery
kn-keyword=anti-reflux surgery
en-keyword=double-flap technique
kn-keyword=double-flap technique
en-keyword=gastric cancer
kn-keyword=gastric cancer
en-keyword=Kamikawa procedure
kn-keyword=Kamikawa procedure
en-keyword=proximal gastrectomy
kn-keyword=proximal gastrectomy
END

start-ver=1.4
cd-journal=joma
no-vol=185
cd-vols=
no-issue=
article-no=
start-page=73
end-page=82
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240222
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Relationship between the Experience of Identity Swaying in Childcare Practice and Childcare Workers’ Efficacy
kn-title=保育実践におけるアイデンティティの揺らぎ体験と保育者効力感との関係
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=　This study aims to examine the relationship between childcare workers’ “experience of identity swaying” as described in their autobiographical memory and their occupation efficacy. First, the influence that stemmed from the experience of childcare workers’ swaying on their sense of efficacy is examined. The results showed that those who experienced identity swaying in their autobiographical memory had a remarkably higher sense of efficacy as childcare workers than those who didn’t. On the other hand, no difference was found in their sense of efficacy depending on the trigger of the identity swaying. The differences in childcare workers’ descriptions depending on the level of their sense of efficacy were then investigated the records of childcare workers with a high sense of occupation efficacy showed a higher level of ego involvement stays as a memory that can be utilized in the future. Closing the article, the authors examine future issues.
en-copyright=
kn-copyright=

en-aut-name=NISHIYAMAOsamu
en-aut-sei=NISHIYAMA
en-aut-mei=Osamu
kn-aut-name=西山修
kn-aut-sei=西山
kn-aut-mei=修
aut-affil-num=1
ORCID=

en-aut-name=WAKADAMika
en-aut-sei=WAKADA
en-aut-mei=Mika
kn-aut-name=若田美香
kn-aut-sei=若田
kn-aut-mei=美香
aut-affil-num=2
ORCID=

en-aut-name=BABANoriko
en-aut-sei=BABA
en-aut-mei=Noriko
kn-aut-name=馬場訓子
kn-aut-sei=馬場
kn-aut-mei=訓子
aut-affil-num=3
ORCID=

affil-num=1
en-affil=Faculty of Education, Okayama University
kn-affil=岡山大学学術研究院教育学域

affil-num=2
en-affil=Maniwa City Amanogawa Centers for Early Childhood Education and Care
kn-affil=真庭市立天の川こども園

affil-num=3
en-affil=Faculty of Education, Okayama University
kn-affil=岡山大学学術研究院教育学域
en-keyword=Childcare Practice
kn-keyword=Childcare Practice
en-keyword=Identity Swaying
kn-keyword=Identity Swaying
en-keyword=Autobiographical Memory
kn-keyword=Autobiographical Memory
en-keyword=Childcare Workers’ Efficacy
kn-keyword=Childcare Workers’ Efficacy
END

start-ver=1.4
cd-journal=joma
no-vol=150
cd-vols=
no-issue=2
article-no=
start-page=89
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240212
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Purpose Immune checkpoint inhibitors (ICIs) are ineffective against epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). This study aimed to investigate the clinical characteristics of patients who were treated or not treated with ICIs, and of those who benefit from immunotherapy in EGFR-mutant NSCLC.<br>
Methods We analyzed patients with unresectable stage III/IV or recurrent NSCLC harboring EGFR mutations using a prospective umbrella-type lung cancer registry (CS-Lung-003).<br>
Results A total of 303 patients who met the eligibility criteria were analyzed. The median age was 69 years; 116 patients were male, 289 had adenocarcinoma, 273 had major mutations, and 67 were treated with ICIs. The duration of EGFR-TKI treatment was longer in the Non-ICI group than in the ICI group (17.1 vs. 12.7 months, p?<?0.001). Patients who received ICIs for more than 6 months were categorized into the durable clinical benefit (DCB) group (24 patients), and those who received ICIs for less than 6 months into the Non-DCB group (43 patients). The overall survival in the DCB group exhibited longer than the Non-DCB group (69.3 vs. 47.1 months), and an equivalent compared to that in the Non-ICI group (69.3 vs. 68.9 months). Multivariate analysis for time to next treatment (TTNT) of ICIs showed that a poor PS was associated with a shorter TTNT [hazard ratio (HR) 3.309; p?<?0.001]. Patients who were treated with ICIs and chemotherapy combination were associated with a longer TTNT (HR 0.389; p?=?0.003). In addition, minor EGFR mutation was associated with a long TTNT (HR 0.450; p?=?0.046).<br>
Conclusion ICIs were administered to only 22% of patients with EGFR-mutated lung cancer, and they had shorter TTNT of EGFR-TKI compared to other patients. ICI treatment should be avoided in EGFR mutated lung cancer with poor PS but can be considered for lung cancer with EGFR minor mutations. Pathological biomarker to predict long-term responders to ICI are needed.<br>
en-copyright=
kn-copyright=

en-aut-name=KuribayashiTadahiro
en-aut-sei=Kuribayashi
en-aut-mei=Tadahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=OhashiKadoaki
en-aut-sei=Ohashi
en-aut-mei=Kadoaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NishiiKazuya
en-aut-sei=Nishii
en-aut-mei=Kazuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NinomiyaKiichiro
en-aut-sei=Ninomiya
en-aut-mei=Kiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TsubataYukari
en-aut-sei=Tsubata
en-aut-mei=Yukari
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=IshikawaNobuhisa
en-aut-sei=Ishikawa
en-aut-mei=Nobuhisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KodaniMasahiro
en-aut-sei=Kodani
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KanajiNobuhiro
en-aut-sei=Kanaji
en-aut-mei=Nobuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=YamasakiMasahiro
en-aut-sei=Yamasaki
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=FujitakaKazunori
en-aut-sei=Fujitaka
en-aut-mei=Kazunori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=KuyamaShoichi
en-aut-sei=Kuyama
en-aut-mei=Shoichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=TakigawaNagio
en-aut-sei=Takigawa
en-aut-mei=Nagio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=FujimotoNobukazu
en-aut-sei=Fujimoto
en-aut-mei=Nobukazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=KubotaTetsuya
en-aut-sei=Kubota
en-aut-mei=Tetsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=InoueMasaaki
en-aut-sei=Inoue
en-aut-mei=Masaaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=FujiwaraKeiichi
en-aut-sei=Fujiwara
en-aut-mei=Keiichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=HaritaShingo
en-aut-sei=Harita
en-aut-mei=Shingo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=TakataIchiro
en-aut-sei=Takata
en-aut-mei=Ichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=TakadaKenji
en-aut-sei=Takada
en-aut-mei=Kenji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=OkawaSachi
en-aut-sei=Okawa
en-aut-mei=Sachi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=KiuraKatsuyuki
en-aut-sei=Kiura
en-aut-mei=Katsuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=HottaKatsuyuki
en-aut-sei=Hotta
en-aut-mei=Katsuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

affil-num=1
en-affil=Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Allergy and Respiratory Medicine, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Allergy and Respiratory Medicine, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of Internal Medicine, Division of Medical Oncology and Respiratory Medicine, Faculty of Medicine, Shimane University
kn-affil=

affil-num=6
en-affil=Department of Respiratory Medicine, Hiroshima Prefectural Hospital
kn-affil=

affil-num=7
en-affil=Division of Respiratory Medicine and Rheumatology, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University
kn-affil=

affil-num=8
en-affil=Department of Internal Medicine, Division of Hematology, Rheumatology, and Respiratory Medicine, Faculty of Medicine, Kagawa University
kn-affil=

affil-num=9
en-affil=Department of Respiratory Medicine, Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital
kn-affil=

affil-num=10
en-affil=Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences
kn-affil=

affil-num=11
en-affil=Department of Respiratory Medicine, National Hospital Organization Iwakuni Clinical Center
kn-affil=

affil-num=12
en-affil=Department of Internal Medicine 4, Kawasaki Medical School
kn-affil=

affil-num=13
en-affil=Department of Medical Oncology, Okayama Rosai Hospital
kn-affil=

affil-num=14
en-affil=Department of Respiratory Medicine and Allergology, Kochi University Hospital
kn-affil=

affil-num=15
en-affil=Department of Chest Surgery, Shimonoseki City Hospital
kn-affil=

affil-num=16
en-affil=Department of Respiratory Medicine, NHO Okayama Medical Center
kn-affil=

affil-num=17
en-affil=Department of Internal Medicine, Okayama Saiseikai General Hospital
kn-affil=

affil-num=18
en-affil=Internal Medicine, Fukuyama City Hospital
kn-affil=

affil-num=19
en-affil=Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=20
en-affil=Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=21
en-affil=Department of Allergy and Respiratory Medicine, Okayama University Hospital
kn-affil=

affil-num=22
en-affil=Department of Allergy and Respiratory Medicine, Okayama University Hospital
kn-affil=
en-keyword=EGFR
kn-keyword=EGFR
en-keyword=EGFR-TKI
kn-keyword=EGFR-TKI
en-keyword=Lung cancer
kn-keyword=Lung cancer
en-keyword=Immune checkpoint inhibitors
kn-keyword=Immune checkpoint inhibitors
en-keyword=Performance status
kn-keyword=Performance status
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=1
article-no=
start-page=29
end-page=36
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202402
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Regression of Necrotic Lesions after Methotrexate Withdrawal in Patients with Methotrexate-Associated Lymphoproliferative Disorders: A Retrospective CT Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=This retrospective study investigated whether necrotic lesions detected on a computed tomography (CT) scan are more regressive than non-necrotic lesions after methotrexate withdrawal in patients pathologically diagnosed with methotrexate-associated lymphoproliferative disorders (MTX-LPD). In total, 89 lesions extracted from 24 patients on CT scans were included in the analysis. All patients had been evaluated for the presence of necrosis within lesions via CT scan upon first suspicion of MTX-LPD (baseline CT scan). The percentage lesion size reduction between the baseline and initial follow-up CT scan was calculated. The association between necrosis within lesions and size changes was estimated via linear regression analyses using both crude and adjusted models. Necrosis was significantly more common in extranodal lesions (27 out of 30 lesions, 90%) than in nodal lesions (9 out of 59 lesions, 15%, p<0.001). In the crude model, the regression of necrotic lesions was 58.5% greater than that of non-necrotic lesions; the difference was statistically significant (p<0.001). Additionally, the longest diameter of necrotic lesions at the baseline CT scan was significantly greater than that of non-necrotic lesions (p<0.001). Based on the adjusted model, necrotic lesions showed 49.3% greater regression than non-necrotic lesions (p=0.017). Necrosis detected on a CT scan was found to be an independent predictor of regression after MTX withdrawal in patients with MTX-LPD.
en-copyright=
kn-copyright=

en-aut-name=KitayamaTakahiro
en-aut-sei=Kitayama
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TanakaTakashi
en-aut-sei=Tanaka
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KanieYuichiro
en-aut-sei=Kanie
en-aut-mei=Yuichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MarukawaYohei
en-aut-sei=Marukawa
en-aut-mei=Yohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KojimaKatsuhide
en-aut-sei=Kojima
en-aut-mei=Katsuhide
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TanakaTakehiro
en-aut-sei=Tanaka
en-aut-mei=Takehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TakaoSoshi
en-aut-sei=Takao
en-aut-mei=Soshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=HirakiTakao
en-aut-sei=Hiraki
en-aut-mei=Takao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Radiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Radiology, Okayama City Hospital
kn-affil=

affil-num=3
en-affil=Department of Radiology, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Radiology, Okayama Saiseikai General Hospital
kn-affil=

affil-num=5
en-affil=Department of Radiology, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Department of Pathology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=7
en-affil=Department of Epidemiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=8
en-affil=Department of Radiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=methotrexate
kn-keyword=methotrexate
en-keyword=lymphoproliferative disorder
kn-keyword=lymphoproliferative disorder
en-keyword=computed tomography
kn-keyword=computed tomography
en-keyword=necrosis
kn-keyword=necrosis
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=1
article-no=
start-page=15
end-page=20
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202402
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Lung Oligometastasis of Breast Cancer: Prospective Cohort Study of Treatment Strategies (SBP-06)
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=While local treatment of metastases is considered to be unrelated to prognosis, previous studies have suggested that local treatment of isolated lung metastases may have positive prognostic impact. We designed this prospective cohort study to investigate the clinical situation and its outcomes. We enrolled patients with fewer than 3 lung nodules suspected of being oligometastases after curative breast cancer surgery. Treatments, including local and systemic therapy, were selected by the physician and patient in consultation. The primary outcome was overall survival (OS); secondary outcomes were the efficacy and the safety of the surgery for lung oligometastases. Between May 2015 and May 2019, 14 patients were enrolled. Resection of lung nodules (metastasectomy) was performed in 11 (78.6%) of 14 patients, and one of these cases was diagnosed as primary lung cancer. Metastasectomies were all performed employing video-assisted thoracic surgery (VATS) without perioperative complications. Systemic therapies were administered to all patients except one. The respective 3-year and 5-year OS rates of patients with lung oligometastases were 91.6% and 81.5%, respectively. Progression occurred in 6 patients: 3 of the 10 with metastasectomy and all 3 without this surgical procedure. Lung metastasectomy was worthwhile as a diagnostic evaluation and may provide long-term benefit in some patients.
en-copyright=
kn-copyright=

en-aut-name=MaedaReina
en-aut-sei=Maeda
en-aut-mei=Reina
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ShienTadahiko
en-aut-sei=Shien
en-aut-mei=Tadahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TakahashiMina
en-aut-sei=Takahashi
en-aut-mei=Mina
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KawadaKengo
en-aut-sei=Kawada
en-aut-mei=Kengo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KajiwaraYukiko
en-aut-sei=Kajiwara
en-aut-mei=Yukiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KuboShinichiro
en-aut-sei=Kubo
en-aut-mei=Shinichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TakabatakeDaisuke
en-aut-sei=Takabatake
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=OhtaniShoichiro
en-aut-sei=Ohtani
en-aut-mei=Shoichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MatsuokaKinya
en-aut-sei=Matsuoka
en-aut-mei=Kinya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=HikinoHajime
en-aut-sei=Hikino
en-aut-mei=Hajime
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=OgasawaraYutaka
en-aut-sei=Ogasawara
en-aut-mei=Yutaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=TairaNaruto
en-aut-sei=Taira
en-aut-mei=Naruto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=OsumiShozo
en-aut-sei=Osumi
en-aut-mei=Shozo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=IkedaMasahiko
en-aut-sei=Ikeda
en-aut-mei=Masahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=DoiharaHiroyoshi
en-aut-sei=Doihara
en-aut-mei=Hiroyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

affil-num=1
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Breast Oncology, NHO Shikoku Cancer Center
kn-affil=

affil-num=4
en-affil=Department of Breast and Endocrine Surgery, Kagawa Prefectural Central Hospital
kn-affil=

affil-num=5
en-affil=Department of Breast Surgery, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=6
en-affil=Department of Breast and Thyroid Surgery, Fukuyama City Hospital
kn-affil=

affil-num=7
en-affil=Department of Breast Surgery, Kochi Health Sciences Center
kn-affil=

affil-num=8
en-affil=Department of Breast Surgery, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=9
en-affil=Department of Breast and Thyroid Surgery, Ehime Prefectural Central Hospital
kn-affil=

affil-num=10
en-affil=Department of Breast Surgery, Matsue Red Cross Hospital
kn-affil=

affil-num=11
en-affil=Department of Breast and Endocrine Surgery, Kagawa Prefectural Central Hospital
kn-affil=

affil-num=12
en-affil=Department of Breast and Thyroid Surgery, Kawasaki Medical School
kn-affil=

affil-num=13
en-affil=Department of Breast Oncology, NHO Shikoku Cancer Center
kn-affil=

affil-num=14
en-affil=Department of Breast and Thyroid Surgery, Fukuyama City Hospital
kn-affil=

affil-num=15
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=
en-keyword=oligometastasis
kn-keyword=oligometastasis
en-keyword=breast cancer
kn-keyword=breast cancer
en-keyword=lung
kn-keyword=lung
en-keyword=metastasectomy
kn-keyword=metastasectomy
END

start-ver=1.4
cd-journal=joma
no-vol=14
cd-vols=
no-issue=1
article-no=
start-page=2202
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240125
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Endoscopic and clinical features of gastric emphysema
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Gastric emphysema is characterized by the presence of intramural gas in the stomach without bacterial infection. Due to its rarity, most reports on gastric emphysema have been limited to single-case studies, and this condition's clinical and endoscopic features have not been thoroughly investigated. In this study, we analyzed 45 patients with gastric emphysema from 10 institutions and examined their characteristics, endoscopic features, and outcomes. The mean age at diagnosis of gastric emphysema in our study population (35 males and 10 females) was 68.6 years (range, 14-95 years). The top five underlying conditions associated with gastric emphysema were the placement of a nasogastric tube (26.7%), diabetes mellitus (20.0%), post-percutaneous endoscopic gastrostomy (17.8%), malignant neoplasms (17.8%), and renal failure (15.6%). Among the 45 patients, 42 were managed conservatively with fasting and administration of proton pump inhibitors. Unfortunately, seven patients died within 30 days of diagnosis, and 35 patients experienced favorable recoveries. The resolution of gastric emphysema was confirmed in 30 patients through computed tomography (CT) scans, with a mean duration of 17.1 +/- 34.9 days (mean +/- standard deviation [SD], range: 1-180 days) from the time of diagnosis to the disappearance of the gastric intramural gas. There were no instances of recurrence. Endoscopic evaluation was possible in 18 patients and revealed that gastric emphysema presented with features such as redness, erosion, coarse mucosa, and ulcers, with fewer mucosal injuries on the anterior wall (72.2%), a clear demarcation between areas of mucosal injury and intact mucosa (61.1%), and predominantly longitudinal mucosal injuries on the stomach folds (50.0%). This study is the first English-language report to analyze endoscopic findings in patients with gastric emphysema.
en-copyright=
kn-copyright=

en-aut-name=IwamuroMasaya
en-aut-sei=Iwamuro
en-aut-mei=Masaya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TakenakaRyuta
en-aut-sei=Takenaka
en-aut-mei=Ryuta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=ToyokawaTatsuya
en-aut-sei=Toyokawa
en-aut-mei=Tatsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KitaMasahide
en-aut-sei=Kita
en-aut-mei=Masahide
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TsuzukiTakao
en-aut-sei=Tsuzuki
en-aut-mei=Takao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=YoshiokaMasao
en-aut-sei=Yoshioka
en-aut-mei=Masao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=GotodaTatsuhiro
en-aut-sei=Gotoda
en-aut-mei=Tatsuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=OkanoueShotaro
en-aut-sei=Okanoue
en-aut-mei=Shotaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MatsubaraMinoru
en-aut-sei=Matsubara
en-aut-mei=Minoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=SakaguchiChihiro
en-aut-sei=Sakaguchi
en-aut-mei=Chihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=OtsukaMotoyuki
en-aut-sei=Otsuka
en-aut-mei=Motoyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

affil-num=1
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry,  and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Internal  Medicine, Tsuyama Chuo Hospital
kn-affil=

affil-num=3
en-affil=Department of  Gastroenterology, National Hospital Organization Fukuyama Medical Center
kn-affil=

affil-num=4
en-affil=Department of Internal Medicine, Okayama City Hospital
kn-affil=

affil-num=5
en-affil=Department of Internal Medicine, Japanese Red Cross  Society Himeji Hospital
kn-affil=

affil-num=6
en-affil=Department of Internal Medicine,  Okayama Saiseikai General Hospital
kn-affil=

affil-num=7
en-affil=Department of  Gastroenterology and Hepatology, Kurashiki Central Hospital
kn-affil=

affil-num=8
en-affil=Department of Gastroenterology, Mitoyo General Hospital
kn-affil=

affil-num=9
en-affil=Department of Gastroenterology, Sumitomo Besshi Hospital
kn-affil=

affil-num=10
en-affil=Department of Endoscopy, National Hospital Organization Shikoku Cancer Center
kn-affil=

affil-num=11
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry,  and Pharmaceutical Sciences
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=56
cd-vols=
no-issue=
article-no=
start-page=53
end-page=72
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=20231228
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Regional Measures to Maintain Public Transportation in Mountainous Areas―A Case Study of Mimasaka City, Okayama Prefecture―
kn-title=中山間地域における公共交通維持に係る地域的対応―岡山県美作市を例に―
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=KATAOKAKatsumi
en-aut-sei=KATAOKA
en-aut-mei=Katsumi
kn-aut-name=片岡克巳
kn-aut-sei=片岡
kn-aut-mei=克巳
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学大学院社会文化科学研究科
END

start-ver=1.4
cd-journal=joma
no-vol=10
cd-vols=
no-issue=1
article-no=
start-page=e914
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=20231226
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Clinical parameter-guided initial resuscitation in adult patients with septic shock: A systematic review and network meta-analysis
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Aim: To identify the most useful tissue perfusion parameter for initial resuscitation in sepsis/septic shock adults using a network meta-analysis.<br>
Methods: We searched major databases until December 2022 for randomized trials comparing four tissue perfusion parameters or against usual care. The primary outcome was short-term mortality up to 90?days. The Confidence in Network Meta-Analysis web application was used to assess the quality of evidence.<br>
Results: Seventeen trials were identified. Lactate-guided therapy (risk ratios, 0.59; 95% confidence intervals [0.45?0.76]; high certainty) and capillary refill time-guided therapy (risk ratios, 0.53; 95% confidence intervals [0.33?0.86]; high certainty) were significantly associated with lower short-term mortality compared with usual care, whereas central venous oxygen saturation-guided therapy (risk ratio, 1.50; 95% confidence intervals [1.16?1.94]; moderate certainty) increased the risk of short-term mortality compared with lactate-guided therapy.<br>
Conclusions: Lactate or capillary refill time-guided initial resuscitation for sepsis/septic shock patients may decrease short-term mortality. More research is essential to personalize and optimize treatment strategies for septic shock resuscitation.
en-copyright=
kn-copyright=

en-aut-name=YumotoTetsuya
en-aut-sei=Yumoto
en-aut-mei=Tetsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KuribaraTomoki
en-aut-sei=Kuribara
en-aut-mei=Tomoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YamadaKohei
en-aut-sei=Yamada
en-aut-mei=Kohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SatoTakehito
en-aut-sei=Sato
en-aut-mei=Takehito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KobaShigeru
en-aut-sei=Koba
en-aut-mei=Shigeru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TetsuharaKenichi
en-aut-sei=Tetsuhara
en-aut-mei=Kenichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KashiuraMasahiro
en-aut-sei=Kashiura
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=SakurayaMasaaki
en-aut-sei=Sakuraya
en-aut-mei=Masaaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Emergency, Critical Care,  and Disaster Medicine, Faculty of Medicine,  Dentistry, and Pharmaceutical Sciences,  Okayama University
kn-affil=

affil-num=2
en-affil=School of Nursing, Sapporo City University
kn-affil=

affil-num=3
en-affil=Department of Traumatology and Critical  Care Medicine, National Defense Medical  College Hospital
kn-affil=

affil-num=4
en-affil=Department of Anesthesiology, Nagoya  University Hospital
kn-affil=

affil-num=5
en-affil=Department of Critical Care Medicine,  Nerima Hikarigaoka Hospital
kn-affil=

affil-num=6
en-affil=Department of Critical Care Medicine,  Fukuoka Children's Hospital
kn-affil=

affil-num=7
en-affil=Department of Emergency and Critical Care  Medicine, Saitama Medical Center, Jichi  Medical University
kn-affil=

affil-num=8
en-affil=Department of Emergency and Intensive Care  Medicine, JA Hiroshima General Hospital
kn-affil=
en-keyword=capillary refill timecarbon dioxide gapcentral venous oxygen saturationlactatenetwork meta-analysissepsisseptic shock
kn-keyword=capillary refill timecarbon dioxide gapcentral venous oxygen saturationlactatenetwork meta-analysissepsisseptic shock
END

start-ver=1.4
cd-journal=joma
no-vol=7
cd-vols=
no-issue=24
article-no=
start-page=7459
end-page=7470
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=20231214
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Distribution and clinical impact of molecular subtypes with dark zone signature of DLBCL in a Japanese real-world study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The distribution and clinical impact of cell-of-origin (COO) subtypes of diffuse large B-cell lymphoma (DLBCL) outside Western countries remain unknown. Recent literature also suggests that there is an additional COO subtype associated with the germinal center dark zone (DZ) that warrants wider validation to generalize clinical relevance. Here, we assembled a cohort of Japanese patients with untreated DLBCL and determined the refined COO subtypes, which include the DZ signature (DZsig), using the NanoString DLBCL90 assay. To compare the distribution and clinical characteristics of the molecular subtypes, we used a data set from the cohort of British Columbia Cancer (BCC) (n = 804). Through the 1050 patient samples on which DLBCL90 assay was successfully performed in our cohort, 35%, 45%, and 6% of patients were identified to have germinal center B-cell?like (GCB) DLBCL, activated B-cell?like (ABC) DLBCL, and DZsig-positive (DZsigpos) DLBCL, respectively, with the highest prevalence of ABC-DLBCL, differing significantly from the BCC result (P < .001). GCB-DLBCL, ABC-DLBCL, and DZsigpos-DLBCL were associated with 2-year overall survival rates of 88%, 75%, and 66%, respectively (P < .0001), with patients with DZsigpos-DLBCL having the poorest prognosis. In contrast, GCB-DLBCL without DZsig showed excellent outcomes after rituximab-containing immunochemotherapy. DZsigpos-DLBCL was associated with the significant enrichment of tumors with CD10 expression, concurrent MYC/BCL2 expression, and depletion of microenvironmental components (all, P < .05). These results provide evidence of the distinct distribution of clinically relevant molecular subtypes in Japanese DLBCL and that refined COO, as measured by the DLBCL90 assay, is a robust prognostic biomarker that is consistent across geographical areas.
en-copyright=
kn-copyright=

en-aut-name=UrataTomohiro
en-aut-sei=Urata
en-aut-mei=Tomohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NaoiYusuke
en-aut-sei=Naoi
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=JiangAixiang
en-aut-sei=Jiang
en-aut-mei=Aixiang
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=BoyleMerrill
en-aut-sei=Boyle
en-aut-mei=Merrill
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SunamiKazutaka
en-aut-sei=Sunami
en-aut-mei=Kazutaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=ImaiToshi
en-aut-sei=Imai
en-aut-mei=Toshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NawaYuichiro
en-aut-sei=Nawa
en-aut-mei=Yuichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=HiramatsuYasushi
en-aut-sei=Hiramatsu
en-aut-mei=Yasushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=YamamotoKazuhiko
en-aut-sei=Yamamoto
en-aut-mei=Kazuhiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=FujiiSoichiro
en-aut-sei=Fujii
en-aut-mei=Soichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=YoshidaIsao
en-aut-sei=Yoshida
en-aut-mei=Isao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=YanoTomofumi
en-aut-sei=Yano
en-aut-mei=Tomofumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=ChijimatsuRyota
en-aut-sei=Chijimatsu
en-aut-mei=Ryota
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=MurakamiHiroyuki
en-aut-sei=Murakami
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=IkeuchiKazuhiro
en-aut-sei=Ikeuchi
en-aut-mei=Kazuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=KobayashiHiroki
en-aut-sei=Kobayashi
en-aut-mei=Hiroki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=TaniKatsuma
en-aut-sei=Tani
en-aut-mei=Katsuma
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=UjiieHideki
en-aut-sei=Ujiie
en-aut-mei=Hideki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=InoueHirofumi
en-aut-sei=Inoue
en-aut-mei=Hirofumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=TomidaShuta
en-aut-sei=Tomida
en-aut-mei=Shuta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=YamamotoAkira
en-aut-sei=Yamamoto
en-aut-mei=Akira
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=KondoTakumi
en-aut-sei=Kondo
en-aut-mei=Takumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=FujiwaraHideaki
en-aut-sei=Fujiwara
en-aut-mei=Hideaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=AsadaNoboru
en-aut-sei=Asada
en-aut-mei=Noboru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=NishimoriHisakazu
en-aut-sei=Nishimori
en-aut-mei=Hisakazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=FujiiKeiko
en-aut-sei=Fujii
en-aut-mei=Keiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

en-aut-name=FujiiNobuharu
en-aut-sei=Fujii
en-aut-mei=Nobuharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=27
ORCID=

en-aut-name=MatsuokaKen-ichi
en-aut-sei=Matsuoka
en-aut-mei=Ken-ichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=28
ORCID=

en-aut-name=SawadaKeisuke
en-aut-sei=Sawada
en-aut-mei=Keisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=29
ORCID=

en-aut-name=MomoseShuji
en-aut-sei=Momose
en-aut-mei=Shuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=30
ORCID=

en-aut-name=TamaruJun-ichi
en-aut-sei=Tamaru
en-aut-mei=Jun-ichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=31
ORCID=

en-aut-name=NishikoriAsami
en-aut-sei=Nishikori
en-aut-mei=Asami
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=32
ORCID=

en-aut-name=SatoYasuharu
en-aut-sei=Sato
en-aut-mei=Yasuharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=33
ORCID=

en-aut-name=YoshinoTadashi
en-aut-sei=Yoshino
en-aut-mei=Tadashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=34
ORCID=

en-aut-name=MaedaYoshinobu
en-aut-sei=Maeda
en-aut-mei=Yoshinobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=35
ORCID=

en-aut-name=ScottDavid W.
en-aut-sei=Scott
en-aut-mei=David W.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=36
ORCID=

en-aut-name=EnnishiDaisuke
en-aut-sei=Ennishi
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=37
ORCID=

affil-num=1
en-affil=Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=British Columbia Cancer, Centre for Lymphoid Cancer
kn-affil=

affil-num=4
en-affil=British Columbia Cancer, Centre for Lymphoid Cancer
kn-affil=

affil-num=5
en-affil=Department of Hematology, NHO Okayama Medical Center
kn-affil=

affil-num=6
en-affil=Department of Hematology and Blood Transfusion, Kochi Health Sciences Center
kn-affil=

affil-num=7
en-affil=Division of Hematology, Ehime Prefectural Central Hospital
kn-affil=

affil-num=8
en-affil=Department of Hematology and Oncology, Japanese Red Cross Society Himeji Hospital
kn-affil=

affil-num=9
en-affil=Department of Hematology and Oncology, Okayama City Hospital
kn-affil=

affil-num=10
en-affil=Department of Hematology, Japanese Red Cross Okayama Hospital
kn-affil=

affil-num=11
en-affil=Department of Hematologic Oncology, NHO Shikoku Cancer Center
kn-affil=

affil-num=12
en-affil=Department of Internal Medicine, Okayama Rosai Hospital
kn-affil=

affil-num=13
en-affil=Center for Comprehensive Genomic Medicine, Okayama University Hospital
kn-affil=

affil-num=14
en-affil=Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=15
en-affil=Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=16
en-affil=Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=17
en-affil=Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=18
en-affil=Center for Comprehensive Genomic Medicine, Okayama University Hospital
kn-affil=

affil-num=19
en-affil=Clinical Genomic Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science
kn-affil=

affil-num=20
en-affil=Center for Comprehensive Genomic Medicine, Okayama University Hospital
kn-affil=

affil-num=21
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=22
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=23
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=24
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=25
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=26
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=27
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=28
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=29
en-affil=Department of Pathology, Saitama Medical Center, Saitama Medical University
kn-affil=

affil-num=30
en-affil=Department of Pathology, Saitama Medical Center, Saitama Medical University
kn-affil=

affil-num=31
en-affil=Department of Pathology, Saitama Medical Center, Saitama Medical University
kn-affil=

affil-num=32
en-affil=Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences
kn-affil=

affil-num=33
en-affil=Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences
kn-affil=

affil-num=34
en-affil=Department of Pathology, Okayama University
kn-affil=

affil-num=35
en-affil=Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=36
en-affil=British Columbia Cancer, Centre for Lymphoid Cancer
kn-affil=

affil-num=37
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=15
cd-vols=
no-issue=
article-no=
start-page=100418
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=20230930
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Collapse-related traumatic intracranial hemorrhage following out-of-hospital cardiac arrest: A multicenter retrospective cohort study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Sudden loss of consciousness as a result of cardiac arrest can cause severe traumatic head injury. Collapse-related traumatic intracranial hemorrhage (CRTIH) following out-of-hospital cardiac arrest (OHCA) may be linked to poor neurological outcomes; however, there is a paucity of data on this entity. This study aimed to investigate the frequency, characteristics, and outcomes of CRTIH following OHCA.<br>
Methods: Adult patients treated post-OHCA at 5 intensive care units who had head computed tomography (CT) scans were included in the study. CRTIH following OHCA was defined as a traumatic intracranial injury from collapse due to sudden loss of consciousness associated with OHCA. Patients with and without CRTIH were compared. The primary outcome assessed was the frequency of CRTIH following OHCA. Additionally, the clinical features, management, and consequences of CRTIH were analyzed descriptively.<br>
Results: CRTIH following OHCA was observed in 8 of 345 enrolled patients (2.3%). CRTIH was more frequent after collapse outside the home, from a standing position, or due to cardiac arrest with a cardiac etiology. Intracranial hematoma expansion on follow up CT was seen in 2 patients; both received anticoagulant therapy, and one required surgical evacuation. Three patients (37.5%) with CRTIH had favorable neurological outcomes 28 days after collapse.<br>
Conclusions: Despite its rare occurrence, physicians should pay special attention to CRTIH following OHCA during the post-resuscitation care period. Larger prospective studies are warranted to provide a more explicit picture of this clinical condition.
en-copyright=
kn-copyright=

en-aut-name=InoueFumiya
en-aut-sei=Inoue
en-aut-mei=Fumiya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HongoTakashi
en-aut-sei=Hongo
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=IchibaToshihisa
en-aut-sei=Ichiba
en-aut-mei=Toshihisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=OtaniTakayuki
en-aut-sei=Otani
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=NaitoHiroshi
en-aut-sei=Naito
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KosakiYoshinori
en-aut-sei=Kosaki
en-aut-mei=Yoshinori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MurakamiYuya
en-aut-sei=Murakami
en-aut-mei=Yuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=IidaAtsuyoshi
en-aut-sei=Iida
en-aut-mei=Atsuyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=YumotoTetsuya
en-aut-sei=Yumoto
en-aut-mei=Tetsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=NaitoHiromichi
en-aut-sei=Naito
en-aut-mei=Hiromichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=NakaoAtsunori
en-aut-sei=Nakao
en-aut-mei=Atsunori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

affil-num=1
en-affil=Department of Emergency Medicine, Hiroshima City Hospital
kn-affil=

affil-num=2
en-affil=Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Emergency Medicine, Hiroshima City Hospital
kn-affil=

affil-num=4
en-affil=Department of Emergency Medicine, Hiroshima City Hospital
kn-affil=

affil-num=5
en-affil=Department of Emergency Medicine, Hiroshima City Hospital
kn-affil=

affil-num=6
en-affil=Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=11
en-affil=Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=
en-keyword=Cardiac arrest
kn-keyword=Cardiac arrest
en-keyword=Computed tomography
kn-keyword=Computed tomography
en-keyword=Craniocerebral trauma
kn-keyword=Craniocerebral trauma
en-keyword=Intracranial hemorrhage
kn-keyword=Intracranial hemorrhage
en-keyword=Out-of-hospital cardiac arrest
kn-keyword=Out-of-hospital cardiac arrest
END

start-ver=1.4
cd-journal=joma
no-vol=15
cd-vols=
no-issue=11
article-no=
start-page=e49273
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=20231123
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Risk Factors for Anterior Skull Base Injury in Endoscopic Sinus Surgery
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Objectives<br>
This retrospective study aimed to investigate the relationships between the Keros classification, the Gera classification, the vertical height of the posterior ethmoid roof (ER), and anterior ethmoidal artery (AEA) types in Japanese patients.<br>
Methods<br>
We investigated the computed tomography (CT) slices of paranasal sinuses (120 sides) of 60 patients; measured the cribriform plate (CP) depth, lateral lamella CP angle (LLCPA), and vertical height of the lateral ER from the hard palate (LERHP) at the coronal plane of the posterior ethmoidal artery (PEA); and reviewed the AEA types, whether floating or non-floating.<br>
Results<br>
CP depth was positively correlated with LLCPA (r=0.63; p<0.01) and the height of LERHP (r=0.19; p<0.05). The height of the LERHP in females was significantly lower than that in males. With increased CP depth, floating AEAs became prevalent (p<0.001).<br>
Conclusion<br>
In females, low height of the posterior ethmoid sinus roof, where cerebrospinal fluid (CSF) leaks occurred while penetrating the basal lamella, often existed; the heights positively correlated with the Keros classification in Japanese patients. The Keros and Gera classifications, AEA type, and posterior ER height do not individually constitute a complete risk assessment but may correlate, preventing major complications, such as CSF leak and orbital hemorrhage.
en-copyright=
kn-copyright=

en-aut-name=MakiharaSeiichiro
en-aut-sei=Makihara
en-aut-mei=Seiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=UraguchiKensuke
en-aut-sei=Uraguchi
en-aut-mei=Kensuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NaitoTomoyuki
en-aut-sei=Naito
en-aut-mei=Tomoyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=ShimizuAiko
en-aut-sei=Shimizu
en-aut-mei=Aiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MuraiAya
en-aut-sei=Murai
en-aut-mei=Aya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=HigakiTakaya
en-aut-sei=Higaki
en-aut-mei=Takaya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NodaYohei
en-aut-sei=Noda
en-aut-mei=Yohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KariyaShin
en-aut-sei=Kariya
en-aut-mei=Shin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=OkanoMitsuhiro
en-aut-sei=Okano
en-aut-mei=Mitsuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=AndoMizuo
en-aut-sei=Ando
en-aut-mei=Mizuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Otolaryngology-Head and Neck Surgery, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Otolaryngology-Head and Neck Surgery, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Otolaryngology-Head and Neck Surgery, Kagawa Rosai Hospital
kn-affil=

affil-num=4
en-affil=Otolaryngology-Head and Neck Surgery, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Otolaryngology-Head and Neck Surgery, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Otolaryngology-Head and Neck Surgery, Okayama University Hospital
kn-affil=

affil-num=7
en-affil=Otolaryngology-Head and Neck Surgery, Fukuyama City Hospital
kn-affil=

affil-num=8
en-affil=Otolaryngology, Kawasaki Medical School
kn-affil=

affil-num=9
en-affil=Otolaryngology, School of Medicine, International University of Health and Welfare
kn-affil=

affil-num=10
en-affil=Otolaryngology-Head and Neck Surgery, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=posterior ethmoid roof
kn-keyword=posterior ethmoid roof
en-keyword=cerebrospinal fluid leak
kn-keyword=cerebrospinal fluid leak
en-keyword=anterior ethmoidal artery
kn-keyword=anterior ethmoidal artery
en-keyword=gera classification
kn-keyword=gera classification
en-keyword=keros classification
kn-keyword=keros classification
END

start-ver=1.4
cd-journal=joma
no-vol=3
cd-vols=
no-issue=
article-no=
start-page=315
end-page=316
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240325
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=OKADO Masakatsu, OKADA Tomohiro, KAWAUCHI Atsushi, KAWANISHI Hidemichi, and TAKAOKA Hiroyuki (Eds.). Connecting the history of 'survival': Ten years after the Earthquake, from the intersection of 'City of Memory' and 'New Town'
kn-title=大門正克・岡田知弘・川内淳史・河西英通・高岡裕之編『「生存」の歴史をつなぐ：震災10年、「記憶のまち」と「新たなまち」の交差から』
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=IMAZUKatsunori
en-aut-sei=IMAZU
en-aut-mei=Katsunori
kn-aut-name=今津勝紀
kn-aut-sei=今津
kn-aut-mei=勝紀
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学
END

start-ver=1.4
cd-journal=joma
no-vol=3
cd-vols=
no-issue=
article-no=
start-page=119
end-page=133
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240325
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Damage caused by the torrential rain in western Japan in 2018 and the reconstruction of local culture: The case of Kogakud? in Az?, ?zu City, Ehime Prefecture
kn-title=活動紹介　西日本豪雨による被災と地域文化の再構築―愛媛県大洲市阿蔵の古学堂の事例を中心に―
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=TOKIWAIMorimichi
en-aut-sei=TOKIWAI
en-aut-mei=Morimichi
kn-aut-name=常磐井守道
kn-aut-sei=常磐井
kn-aut-mei=守道
aut-affil-num=1
ORCID=

en-aut-name=SHIRAISHINaohiro
en-aut-sei=SHIRAISHI
en-aut-mei=Naohiro
kn-aut-name=白石尚寛
kn-aut-sei=白石
kn-aut-mei=尚寛
aut-affil-num=2
ORCID=

en-aut-name=OMOTOTakahisa
en-aut-sei=OMOTO
en-aut-mei=Takahisa
kn-aut-name=大本敬久
kn-aut-sei=大本
kn-aut-mei=敬久
aut-affil-num=3
ORCID=

affil-num=1
en-affil=
kn-affil=大洲古学堂保存会

affil-num=2
en-affil=
kn-affil=大洲市立博物館

affil-num=3
en-affil=
kn-affil=愛媛県歴史文化博物館
END

start-ver=1.4
cd-journal=joma
no-vol=3
cd-vols=
no-issue=
article-no=
start-page=60
end-page=66
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240325
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=The formation of sandbanks and regional transformation in the Late Medieval period
kn-title=中洲の形成と中世後期の地域変容
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The purpose of this paper is to clarify how a harbor city established in a sandbank inlet transformed a local area. In the Later Medieval period, the harbor city of Nakamura was established in the lower part of the Chikusa river. In the late 15th century, the Ei?ji temple of J?do Shinsh? Buddhism was constructed in the harbor city of Nakamura. Nakamura used Sagoshinosh? as a local name. In the 16th century, the harbor city of Kariya on the west coast of the Chikusa river also used the local name of Sagoshinosh?. In the early modern period, villages to the west of the mouth of the Chikusa river came to use the local name of Sagoshinosh?. While the local name of the west coastal area of the Chikusa river mouth had been Ak?nosh?, it changed to Sagoshinosh?. Areas where local names may have changed also include Shikatanosh? and Mikuriyanosh? elsewhere in the Later Medieval period.
en-copyright=
kn-copyright=

en-aut-name=YATAToshifumi
en-aut-sei=YATA
en-aut-mei=Toshifumi
kn-aut-name=矢田俊文
kn-aut-sei=矢田
kn-aut-mei=俊文
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Niigata University, Humanities and Social Sciences
kn-affil=
en-keyword=sandbank
kn-keyword=sandbank
en-keyword=the Chikusa river
kn-keyword=the Chikusa river
en-keyword=harbor city
kn-keyword=harbor city
en-keyword=temple of J?do Shinsh? Buddhism
kn-keyword=temple of J?do Shinsh? Buddhism
en-keyword=local names
kn-keyword=local names
END

start-ver=1.4
cd-journal=joma
no-vol=3
cd-vols=
no-issue=
article-no=
start-page=41
end-page=54
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240325
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=The inflow of Bizen Sue ware into the palace capital in the first half of the Asuka period
kn-title=飛鳥時代前半における備前産須恵器の宮都流入過程
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=In this paper, we attempt to reconstruct the process by which Bizen Sue ware flowed into the palace capital in the early 7th century, the first half of the Asuka period. Among the large lids collected from the Sazarashi Nakaike Kiln in Setouchi City, Okayama Prefecture, we found one that closely resembles the lids unearthed in the southern part of the Nara Basin, the Asuka Fujiwara area, and it is now clear that Sue ware was supplied to the capital from the Bizen area in the eastern part of Okayama Prefecture. The supply of Sue ware from the Bizen area to the Asuka Fujiwara area may date back to the first half of the Asuka period. It has been suggested that the supply of Sue ware to the imperial capital became active in the latter half of the Asuka period, but the results of this paper clarify that the Bizen area was supplying Sue ware to the palace capital before such large-scale supply began. It is highly likely that the supply of Sue ware to the palace capital in the first half of the Asuka period became the basis for the mass supply seen in the latter half.
en-copyright=
kn-copyright=

en-aut-name=KIMURAOsamu
en-aut-sei=KIMURA
en-aut-mei=Osamu
kn-aut-name=木村理
kn-aut-sei=木村
kn-aut-mei=理
aut-affil-num=1
ORCID=

en-aut-name=BABAMasakazu
en-aut-sei=BABA
en-aut-mei=Masakazu
kn-aut-name=馬場昌一
kn-aut-sei=馬場
kn-aut-mei=昌一
aut-affil-num=2
ORCID=

en-aut-name=MORIKAWAMinoru
en-aut-sei=MORIKAWA
en-aut-mei=Minoru
kn-aut-name=森川実
kn-aut-sei=森川
kn-aut-mei=実
aut-affil-num=3
ORCID=

affil-num=1
en-affil=Okayama University, Research Institute for the Dynamics of Civilization
kn-affil=

affil-num=2
en-affil=Sabukaze pottery center
kn-affil=

affil-num=3
en-affil=Nara National Research Institute for Cultural Properties
kn-affil=
en-keyword=Asuka period
kn-keyword=Asuka period
en-keyword=ancient Bizen Sue ware
kn-keyword=ancient Bizen Sue ware
en-keyword=supply of Sue ware to the imperial capital
kn-keyword=supply of Sue ware to the imperial capital
en-keyword=production and circulation
kn-keyword=production and circulation
END

start-ver=1.4
cd-journal=joma
no-vol=77
cd-vols=
no-issue=6
article-no=
start-page=607
end-page=612
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=202312
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Fine Particulate Matter and Diabetes Prevalence in Okayama, Japan
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Many studies have shown an association between long-term exposure to particulate matter having an aerodynamic diameter of 2.5 μm or less (PM2.5) and diabetes mellitus (DM), but few studies have focused on Asian subjects. We thus examined the association between long-term exposure to PM2.5 and DM prevalence in Okayama City, Japan. We included 76,591 participants who had received basic health checkups in 2006 and 2007. We assigned the census-level modeled PM2.5 data from 2006 and 2007 to each participant and defined DM using treatment status and the blood testing. PM2.5 was associated with DM prevalence, and the prevalence ratio (95% confidence interval) was 1.10 (1.00-1.20) following each interquartile range increase (2.1 μg/m3) in PM2.5. This finding is consistent with previous results and suggests that long-term exposure to PM2.5 is associated with an increased prevalence of DM in Okayama City, Japan, where the PM2.5 level is lower than in other cities in Asian countries.
en-copyright=
kn-copyright=

en-aut-name=TaniYasunari
en-aut-sei=Tani
en-aut-mei=Yasunari
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KashimaSaori
en-aut-sei=Kashima
en-aut-mei=Saori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MitsuhashiToshiharu
en-aut-sei=Mitsuhashi
en-aut-mei=Toshiharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SuzukiEtsuji
en-aut-sei=Suzuki
en-aut-mei=Etsuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TakaoSoshi
en-aut-sei=Takao
en-aut-mei=Soshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=YorifujiTakashi
en-aut-sei=Yorifuji
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Department of Epidemiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Environmental Health Sciences Laboratory, Graduate School of Advanced Science and Engineering, Center for the Planetary Health and Innovation Science, The IDEC Institute, Hiroshima University
kn-affil=

affil-num=3
en-affil=Center for Innovate Clinical Medicine, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Epidemiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Epidemiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Epidemiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=air pollution
kn-keyword=air pollution
en-keyword=diabetes mellitus
kn-keyword=diabetes mellitus
en-keyword=epidemiology
kn-keyword=epidemiology
en-keyword=glycosylated hemoglobin
kn-keyword=glycosylated hemoglobin
en-keyword=particulate matter
kn-keyword=particulate matter
END

start-ver=1.4
cd-journal=joma
no-vol=77
cd-vols=
no-issue=6
article-no=
start-page=577
end-page=587
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=202312
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Japanese Nursing Staff’s Knowledge and Attitude toward Bereavement Care for Couples with Miscarriage/Stillbirth and Its Associated Factors
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Bereavement care is conducted to meet the emotional needs of grieving couples who are devastated by the experience of a miscarriage or stillbirth. From January to April 2022, we distributed a questionnaire that assessed the knowledge and attitudes of Japanese nursing staff (nurses and midwives) in Japan’s Chugoku-Shikoku region toward bereavement care for couples with miscarriage/stillbirth. The 370 survey respondents’ answers revealed that the nursing staff’s knowledge regarding recurrent pregnancy loss and subsequent bereavement care was insufficient. About 41.1% and 64.1% of the respondents had received school and on-the-job education in bereavement care, respectively, and 79.2% expressed willingness to provide such care. Our analyses revealed that the following factors were associated with the nursing staff’s knowledge level: parent status, age, reproductive history, midwifery license, work experience and environment, and on-the-job education. The following were correlated with the staff’s willingness to provide bereavement care: work environment, midwifery license, bereavement care knowledge, and on-the-job education. Together our findings indicate that education plays a significant role in equipping caregivers to provide effective bereavement care for couples who have experienced a miscarriage or stillbirth.
en-copyright=
kn-copyright=

en-aut-name=LiuSiyu
en-aut-sei=Liu
en-aut-mei=Siyu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=AthurupanaRukmali
en-aut-sei=Athurupana
en-aut-mei=Rukmali
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HanHongmei
en-aut-sei=Han
en-aut-mei=Hongmei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YangTiti
en-aut-sei=Yang
en-aut-mei=Titi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=NakatsukaMikiya
en-aut-sei=Nakatsuka
en-aut-mei=Mikiya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

affil-num=1
en-affil=Graduate School of Health Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Graduate School of Health Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Graduate School of Health Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Graduate School of Medicine, Density and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=5
en-affil=Graduate School of Health Sciences, Okayama University
kn-affil=
en-keyword=midwife
kn-keyword=midwife
en-keyword=nurse
kn-keyword=nurse
en-keyword=miscarriage
kn-keyword=miscarriage
en-keyword=bereavement
kn-keyword=bereavement
en-keyword=knowledge
kn-keyword=knowledge
END

start-ver=1.4
cd-journal=joma
no-vol=77
cd-vols=
no-issue=6
article-no=
start-page=567
end-page=575
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=202312
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Review of a Series of Surveys on Adverse Reactions to the COVID-19 mRNA-1273 Vaccine at Okayama University
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=This paper presents the results of a series of surveys conducted from July 2021 to March 2023 to investigate the post-vaccination adverse reactions to the mRNA-1273 (Moderna) vaccine among faculty, staff, and students at Okayama University. These studies complement the official surveys conducted by the Ministry of Health, Labour and Welfare (MHLW) and provide a more representative picture of adverse reactions in the general population including large numbers of healthy young people. Pain, swelling, redness at the injection site, fever, headache, and malaise were the main adverse reactions reported. The proportion of adverse reactions was generally higher after the second vaccination and decreased with each additional vaccination. No statistically significant differences in the adverse reactions were found for males and females and those with/without a history of allergy, but a lower proportion of fever was observed in older participants and those with underlying medical conditions. We also evaluated the association between adverse reactions and antibody titers after the third vaccination and found no significant differences in antibody levels one month after vaccination. This series of studies highlights the importance of conducting surveys in diverse populations to provide a more representative picture of post-vaccination adverse reactions during a pandemic.
en-copyright=
kn-copyright=

en-aut-name=MatsumotoNaomi
en-aut-sei=Matsumoto
en-aut-mei=Naomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HiguchiChigusa
en-aut-sei=Higuchi
en-aut-mei=Chigusa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MiyajiChikara
en-aut-sei=Miyaji
en-aut-mei=Chikara
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MitsuhashiToshiharu
en-aut-sei=Mitsuhashi
en-aut-mei=Toshiharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HagiyaHideharu
en-aut-sei=Hagiya
en-aut-mei=Hideharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TakaoSoshi
en-aut-sei=Takao
en-aut-mei=Soshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=YorifujiTakashi
en-aut-sei=Yorifuji
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Department of Epidemiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Okayama University Health Service Center
kn-affil=

affil-num=3
en-affil=Okayama University Health Service Center
kn-affil=

affil-num=4
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of Infectious Diseases, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Department of Epidemiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=7
en-affil=Department of Epidemiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=coronavirus disease 2019
kn-keyword=coronavirus disease 2019
en-keyword=adverse reactions
kn-keyword=adverse reactions
en-keyword=mRNA vaccine
kn-keyword=mRNA vaccine
en-keyword=antibody titers
kn-keyword=antibody titers
en-keyword=young adults
kn-keyword=young adults
END

start-ver=1.4
cd-journal=joma
no-vol=184
cd-vols=
no-issue=
article-no=
start-page=77
end-page=94
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=20231124
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Examination of Common Teaching Materials for Singing in Elementary School Music Classes from the Viewpoint of Children
kn-title=児童の立場から見た小学校音楽科における歌唱共通教材の検討
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=　本研究は，小学校歌唱共通教材に対する児童が抱いている印象の調査及び，児童の音楽的嗜好の調査，併せて音楽教員の歌唱共通教材に対する捉え方も調査することにより，小学校音楽科における歌唱共通教材の新しい選定基準について検討するものである。<br>
　児童の調査では，小学校5・6 年生を対象として実施し，歌唱共通教材に対する印象，教科書への掲載希望曲について調べた。また，音楽専科教員にも，歌唱共通教材についてインタビュー調査を行った。調査・分析から，今を生きる子どもにふさわしい曲について，以下５点の特徴が見出された。�@メロディーがよい，�A明るくリズミカルな曲調，�B景色が浮かび，季節感のある曲，�C歌詞のわかりやすさ，�D詩やことばに共感できることである。また，児童は自身の嗜好をもとに曲の特徴を捉える力を有しており，それ故，自分でお気に入りの曲を見つけていることがわかった。従って，歌唱共通教材にも，主体的に曲選択の自由性をもたせ，子どもの嗜好に寄り添った選曲が必要である。
en-copyright=
kn-copyright=

en-aut-name=MUSHIAKIMasako
en-aut-sei=MUSHIAKI
en-aut-mei=Masako
kn-aut-name=虫明眞砂子
kn-aut-sei=虫明
kn-aut-mei=眞砂子
aut-affil-num=1
ORCID=

en-aut-name=KISHIMOTOMiu
en-aut-sei=KISHIMOTO
en-aut-mei=Miu
kn-aut-name=岸本未有
kn-aut-sei=岸本
kn-aut-mei=未有
aut-affil-num=2
ORCID=

affil-num=1
en-affil=Faculty of Education, Okayama University
kn-affil=岡山大学学術研究院教育学域

affil-num=2
en-affil=Okayama City Higashiyama Junior High School
kn-affil=岡山市立東山中学校
en-keyword=歌唱共通教材
kn-keyword=歌唱共通教材
en-keyword=唱歌
kn-keyword=唱歌
en-keyword=教師
kn-keyword=教師
en-keyword=子どもの嗜好
kn-keyword=子どもの嗜好
en-keyword=印象調査
kn-keyword=印象調査
END